<SEC-DOCUMENT>0001714899-19-000043.txt : 20190806
<SEC-HEADER>0001714899-19-000043.hdr.sgml : 20190806
<ACCEPTANCE-DATETIME>20190806165409
ACCESSION NUMBER:		0001714899-19-000043
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190806
DATE AS OF CHANGE:		20190806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		191002855

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8548

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dnli-20190630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2017 Workiva--><!--r:8011caee-abc0-437e-96e5-962907bf5aea,g:892d10ab-e474-4c56-aa84-e84b6d701647,d:0a61eb73047948a5877cfb90a2644d70--><html xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dnli="http://www.denalitherapeutics.com/20190630"><head><meta http-equiv="Content-Type" content="text/html"></meta>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGFibGU6OWQ0ODVlN2QzNDAwNGNmMGEwOWU5YmYxMWM0YmNhZWMvdGFibGVyYW5nZTo5ZDQ4NWU3ZDM0MDA0Y2YwYTA5ZTliZjExYzRiY2FlY18xMi0xLTEtMS0w_336e435f-db69-4db2-8604-0514e189f9b0">2019</ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGFibGU6OWQ0ODVlN2QzNDAwNGNmMGEwOWU5YmYxMWM0YmNhZWMvdGFibGVyYW5nZTo5ZDQ4NWU3ZDM0MDA0Y2YwYTA5ZTliZjExYzRiY2FlY18xMy0xLTEtMS0w_163b6021-5c25-4210-91f6-a49c9547bf4e">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGFibGU6OWQ0ODVlN2QzNDAwNGNmMGEwOWU5YmYxMWM0YmNhZWMvdGFibGVyYW5nZTo5ZDQ4NWU3ZDM0MDA0Y2YwYTA5ZTliZjExYzRiY2FlY18xNC0xLTEtMS0w_00fdc4e4-c9f6-4593-8815-72c12a1828fd">false</ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGV4dHJlZ2lvbjo1MGZmY2Q5MjcxMGU0MzQzOTQ0NmY1M2IzZWJhZmFhOF85Ng_f5574897-b88b-41d6-9e71-90393f994eef">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGV4dHJlZ2lvbjo1MGZmY2Q5MjcxMGU0MzQzOTQ0NmY1M2IzZWJhZmFhOF85NQ_1ccadd3f-30cd-412b-9f94-e332eacdaf58">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMi0xLTEtMS0w_5a1ce9c6-dc94-4455-9bf0-ee23b0b7bc8c">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMi0zLTEtMS0w_c186d26e-087d-4c62-a266-e0b88424358d">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMy0xLTEtMS0w_42c3d512-30fa-4a4b-8f3d-602075e6a65b">40,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMy0zLTEtMS0w_490c43af-b32f-4b83-a8f8-dd01f470062e">40,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNC0xLTEtMS0w_7c97def0-a7c3-4c3e-91fc-292e9e6f0791">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNC0zLTEtMS0w_5f79195b-67ef-4937-8eaa-15310d07ed94">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNS0xLTEtMS0w_814db2ca-436b-4004-a1de-64edaac49f87">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNS0zLTEtMS0w_fbdf2eb4-f453-486f-b966-79bca5a6e213">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOC0xLTEtMS0w_13a687e3-5ac9-433d-9ecb-2127e3fa2a07">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOC0zLTEtMS0w_2909b5c4-31eb-4f81-9d64-1da26a04256b">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOS0xLTEtMS0w_79453393-0a0e-461a-9ee8-d59870a3ca3d">400,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOS0zLTEtMS0w_4839c7a1-94e3-435a-acb8-96d32440c3c1">400,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTAtMS0xLTEtMA_2ec4c31b-795d-429a-a7d5-57cead3a3512">95,656,896</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTAtMy0xLTEtMA_37c9cbfe-9f00-4512-b5ea-82b3cefd0a75">94,662,435</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTEtMS0xLTEtMA_b199afbb-3b0d-4d14-b277-50546066c114">95,656,896</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTEtMy0xLTEtMA_4d78b9fc-81ca-4f09-8e92-928e2234d407">94,662,435</ix:nonFraction><ix:nonNumeric contextRef="iecff526c59e7452aafbe14147f3cc250_D20171201-20171231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTIzMQ_89106c99-db8f-42c3-9be0-ac8e95402417">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="iedf7537799d4426a9667a6f97c5239eb_D20150501-20150531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjIwNQ_7426f688-b493-4e9a-8e34-f30a5275909d">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630" name="dnli:PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjE5Ng_40ff6178-4587-42fe-8169-938e295fadf9">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS0xLTEtMS0w_297fdf1e-71ba-4856-a7b3-1a3f4759e826">&#8212;</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS0zLTEtMS0w_83a7f4cc-1b0f-4d45-9caf-d1a84c726398">&#8212;</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS01LTEtMS0w_a010da65-4a88-4fde-a8d2-eff822b11732">&#8212;</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS03LTEtMS0w_35a114dd-6e1a-48e5-ad1f-393db1012916">&#8212;</ix:nonFraction><ix:nonNumeric contextRef="if14c6b440b8f48a9838c5d9fcdb9c515_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy0xLTEtMS01NjQw_fe6fdb89-8d97-4e81-a92a-21e3ff764c97">5.50</ix:nonNumeric><ix:nonNumeric contextRef="i5c6b993b5bde429e9a7fba5ab9832fca_D20180401-20180630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy0zLTEtMS01NjQz_ca6563a6-e8d3-4a39-9ba6-d24aa1c87551">5.50</ix:nonNumeric><ix:nonNumeric contextRef="i3d126a8dcd56440998101048ca785846_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy01LTEtMS0w_ae4869de-aa71-4954-86e9-8e62fb0431e6">5.50</ix:nonNumeric><ix:nonNumeric contextRef="i275b58f10ba74daeae1286217a8a4e5d_D20180101-20180630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy03LTEtMS01NjA4_6a601b13-b269-4a07-a50b-1412c1e749a9">5.50</ix:nonNumeric><ix:nonNumeric contextRef="i24c9b655a8e8443a87f7a3e134f345ba_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC0xLTEtMS01NjQw_f33c7499-9aa5-434e-a3bf-8a80b1f843d5">6.08</ix:nonNumeric><ix:nonNumeric contextRef="ia04b255ecd884d8e9200605be79d6280_D20180401-20180630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC0zLTEtMS01NjQ0_7c603eed-a4c8-41a1-a4a3-1ce9e8692da6">6.08</ix:nonNumeric><ix:nonNumeric contextRef="iedf8f1f2f33e4108b9baf4e4d8091e2a_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC01LTEtMS0w_93765f45-0df3-47d7-8ef0-087e0d3edaa8">6.08</ix:nonNumeric><ix:nonNumeric contextRef="i237c5ee93e0b4218a0aca4f2977365cf_D20180101-20180630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC03LTEtMS01NjA4_89708f6b-1053-46f9-9b0a-215d2dc30032">6.08</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi0xLTEtMS0w_61abcd29-f79a-4d77-97d0-dce00846224d">66.9</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi0zLTEtMS0w_bdbc3cd0-c0c8-4ffd-ae86-8b902dc40e69">80.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi01LTEtMS0w_a39c1e78-e633-4922-aa23-028663ebaf99">66.9</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi03LTEtMS0w_7c8a9080-b766-448b-aa15-4bc9f3ee5db0">80.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy0xLTEtMS0w_3094245f-57fd-4404-9fe2-b4e30e791fda">77.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy0zLTEtMS0w_c4a02566-f0d9-45c2-8ad2-d9f24686e7ec">85.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy01LTEtMS0w_13fb03ee-9cb7-4fab-82ed-b1440da45acd">77.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy03LTEtMS0w_db6f9e12-a033-444a-bcdb-f7465dd50786">87.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS0xLTEtMS0w_be5f0c57-c9a0-4cc0-8ab4-adbc1427cde4">2.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS0zLTEtMS0w_3f94851e-59ac-44d0-b090-14a92218b135">2.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS01LTEtMS0w_607ffe03-8214-42a8-9fc1-e2b6ff34aa9c">2.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS03LTEtMS0w_af59f524-1bff-4cac-9658-4ddf1a086cca">2.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtMS0xLTEtMA_deffeca3-9045-4263-a254-caa1c97b1858">2.3</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtMy0xLTEtMA_98d145e4-35a3-4385-b1c1-d4f2018611c2">2.9</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtNS0xLTEtMA_7ba3d8f9-8477-4481-b4b1-4ad676c1ff65">2.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtNy0xLTEtMA_9b6461ce-7304-4281-b81f-538c5aa6ead0">2.9</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="dnli-20190630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie6858c183ded4c66a5c4cae5464a8c49_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if15afa2e1e5d465bbf364f085370272d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb687f8433d24be0ac5335c8c79c0494_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8beed483e6423490b503483915e4f2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5344b99e882d4934943a39b1eb4887b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51bc7132b78422f88cfdae7c0aacebd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722034f7c8044775b8f4e39ab11f9044_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48efc218d04b44c5bd998761d74d0369_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i023b35c87938433a989302ec87e7ab6c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b99abb30444402e9dd33c0c70fe40f9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42701eeb1e1c4a17b979e71633036f02_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if166a88ab9ee4dda853e8603cb29e805_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35e501f47d4427fbd9b62dc2c00e2dc_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71648051f8714218b99562e835fa904b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db11cdb9fdc4fda8887c70798fe0bb4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b1265cc2294fccb8fee9c3f57ef5ad_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d14f1d11c174d03b34f14d15c06d0e4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf0c5c2b81f14b2ba8bf900712c881a8_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e066377dcf4dd1909aa3b352723c01_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fbad4386a8427d8c6f6a3d5a7374ac_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f9d4a6b28cc473c805fb4ad62ae184b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412e26418ded47729bc5c01e358338bc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i654d7777e96c48528ad08a99690746d9_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie023db07ba2245d89a07be32e19c8699_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie57571f426694fe089fe9cb5f12584ce_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00aa4b8cda04136b378e14fb7af25df_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3637006edc4480da3b4668dd1f931c1_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7131d5c68734000965acd7cf27ca3a6_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b047174d458400c8d2c9e6554f436c6_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de42ac379c3456094525bb4ad42c025_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25146bfdcf2a47919d391a395b32bece_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if624bfc7618444aaaee3b88445cdcd15_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41e9af92e2b4bce9bf0ea68da08021d_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae5650d2914b4b4a8c62050aaaa3c4a7_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib74065ebcb8745068d2741baeaf0b579_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f972032aeb2409db70c5438d495f50e_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61e2d55e75b47bf9f99395f341b50b6_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b1ab5fa47f47a3a75b2baeb7eb3662_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823adbb4c4d94559b833efb563159c96_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dnli:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="contract"><xbrli:measure>dnli:contract</xbrli:measure></xbrli:unit><xbrli:context id="i6abc0c7c5a6f4e6ea981285f7ae4c287_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b119c34dd944daa20fa4eaaa3d2ced_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8c6e58df014428922e55023f630ade_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534bf8602525455db76397bb865e573f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i351b20a5b439409598aa2bedf197448c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d35607870c64688827351e700854bef_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77531d54e5404598a5078438c8677b65_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564db519a26f4cb8a0fb1d4e669911f2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039ece834d1c4019baf20e251e2da235_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db3561ea15848dab72e9c69da84ebf7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i394557b4e90043e2a2085e2207e5f704_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia647cd1b2d9a45278c18b341c2434e5f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7a9a68ed1e4b98bf5fcf82a0334cc8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646027daed3e4e16b08888af3c67909c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac821d5ca4ca49dc813f6db1babf4665_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7fb855d6104424da5e93287267c6ac0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f2152514a74f9691322d7bb19989c8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2188c27fed024d2d9d5cec962236ec1c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01b372be06641fcb73d69acee794292_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee33812b6d5f432a938b1e20a417c276_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32984200dcc845b2a45fea17a3812a06_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id738d34d6e8e4df2b2e0892ca8583817_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81ed0dc4a654555b4dfaf4dcc554425_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36129c3c0fb4ec89ee0b9be9bbc5bff_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i748d5ac449c24510a0986355b63cb280_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib33f0957ce474dd592ca5b6c23e5ef19_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a6c38d032f484a9b67307311107bd7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8323e729c3744b6984ff8264d437b124_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f0f26e09b64eacb441ec24cd77394c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3042590e499441eac62f97939bd16f4_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc97570e5b24fa1a75addc5f860af72_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if168f11e35b14d38bce3e5890ebba5d9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1069dc0cad4a3ea5572938e4106e4c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8389b77f46614b0baac4260fdedf92b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75c93d80020f42b0ba67cdc0e3a25b2a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aee8333029a4f6c8e7f1247f704004a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c9e6e09b474edc8ac0da0e91d2dd01_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c0452366984f519dbceb86cfc31faf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie776c9afea3243b2848d752347f688f4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c75b127ec34f38865969acc6d34c86_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220e6c77c75d4bfa83017f0736091135_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79715623139e4d188ee2ddfaff3f8843_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8717aa8b6241c5a643413d64130b63_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993e3d3eb54f4a728171781129ded3bc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i334c9164544d47ed90f823053546feae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cd710ca1ca48d0bc2fb6d628a11664_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48ac7d1c4324712a1e1298222a87945_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae0df8b808c43f280dc28bec5cb444d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73851e2673146dcb0a9e092ab545074_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2699ac9a6b4a4f988e31180fb9faa2e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife73f39b1eae47ee85a5a9584ee232ae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27601e3031d1415087e9519936e0588a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4803624bc1af45deb9ea98f47e4bef89_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e4decf7be84439945e9ce2850dc451_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d2b210ee09411c9fa11bbd2deba373_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b7162b4cdf45099ea769306a7bc7ba_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e221499c55d4599a35ccd9f1aba1e74_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb76427e3334f2b8e9ec593be008827_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a911ac92d6942418c24d25c2c06cc32_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b8017f6aa641f5a8ba1117e78c4395_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30bc951a4ed74f0ea630f8070210ce78_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i080696e2011c4cebb6a89ccdbaa3ee8d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fdf1cc314e547498192214867642863_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41ba916828a4459913741d70d7bc3fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i372598dc17214865814f1254ebfb5161_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7640f25a11a54310893f0d59b851a625_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ac2039e8dc42bead781da7dcf42fd1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497df5ae51894ba7a5a6422af04376bf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe03351931fd4b02bcbdf4d454a976b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec24689629b54d34951dd76fb613749b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia035bfff287e4ca591f2a341c56b6b2d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c31645a10044e59139a51722cc253f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a14322869be4b658cd4cde6e287c652_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica751d3b16db4f8ea312582a7139852b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c65238201f2438099ea08259947cf04_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdfa55cc0574d5b9693592150a1b134_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae5e02b2d6aa49058387f1cea12b93b3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e2a799afac4657bf2990fa9faac6e4_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic132aa6373a64c79b5f996854ca9bc8c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c25e606153542d88af272a7ffac8a0e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1434d14831d0404caa8e13694f7f25be_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a0f1d286ed4f01b14d389eca094eda_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1014a17a2a46eba10d842ec1fccd9b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b6982078fb47e882b2de8e34ef5adb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e891a3823f24de4a4f4b99b41087154_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9124e0422c4ff1b46cd042394237b5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivative_instrument"><xbrli:measure>dnli:derivative_instrument</xbrli:measure></xbrli:unit><xbrli:context id="ia14c2927959544239a3d263ec3dda43e_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48082d8a3fa74a8c95c2264e9a347d42_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardEurosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i234d3a677c614b128ac23ca5c79da8dc_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardBritishPoundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="id1232cc1f5524033b330344d942beb81_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardSwissFrancsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i8674d4a62e2a492fa95fdbeefacd0bad_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9f18818b52f4aeabfbf7dbbb4aba705_D20160801-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d1fcfacd0d4b0db994f652d3301667_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647555a3917440f38eef6a6989f68269_D20160824-20160824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">dnli:ExerciseOfBuyoutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-24</xbrli:startDate><xbrli:endDate>2016-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2148ac99ab3d4a618499bc77ee8d8c62_D20180530-20180530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">dnli:ExerciseOfBuyoutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-30</xbrli:startDate><xbrli:endDate>2018-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i958b3c7abe6a45a592e44305c54c7fb4_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ca5f46b88d4457b2266e87e2008a2a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98115cad708471ebe459199e2f80f46_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5e0ab57a754c6a92c0fdd5ab774b2d_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c7d3db28004ce59eb812568e573405_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975bd76e0cd24e4c801c23d18da1297b_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib519012f763b4591aa20a39b32e7dd07_D20160824-20160824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-24</xbrli:startDate><xbrli:endDate>2016-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-20</xbrli:startDate><xbrli:endDate>2018-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c733524c4364bb1abc239f59033a6be_I20181120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cac8973f2034a84af0e4eb2891e8341_I20181120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:CNSProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec92903cf114ddf965cde15c398dded_I20181120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:PeripheralProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i507009778f314351bad25199f392e188_I20181029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e6fd6fd17d48a7a5c80813484b128b_I20181029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:DenaliMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb8f5ce74fd4b1b890b44970091705b_D20181001-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2052c42ed02b4803ac262cf9409d6d92_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain xsi:nil="true"></us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02f20c18d7e4a85a122b3bb744dc9bb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain xsi:nil="true"></us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c76dce5aed14afdbce822ee27041a9f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba03e85f7755476dbbc016d142e2579a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41156f6db385494f9b24bd04dcc38e24_D20181001-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb617794c10c4d4ba7d9d482b9cd58bc_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-23</xbrli:startDate><xbrli:endDate>2018-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic542e2b47d374ba59c6ab567374c8c94_D20180103-20180103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-03</xbrli:startDate><xbrli:endDate>2018-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>dnli:program</xbrli:measure></xbrli:unit><xbrli:context id="ia22967129e234978a541856d93c716a7_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="targets"><xbrli:measure>dnli:targets</xbrli:measure></xbrli:unit><xbrli:context id="ia53bec4ac3404ce2b6767a4da564148f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1aebd881a6473d8f034dc7cd3ba883_D20180103-20180103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-03</xbrli:startDate><xbrli:endDate>2018-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5ea44d386548708e70442d3abb3e3c_I20180103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id111363c81ee4dffbaa484859d2e9554_I20180103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-23</xbrli:startDate><xbrli:endDate>2018-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifadb9641e1d64862836bde0c518e5c56_I20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i506ba94099c0474082d55a807783f8de_D20180101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b83a26513784d7ba644b0159e2fcac2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327284cdcb314428b0f05baf0584c173_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2bdbc9872a42678f000e70d3eb04e1_D20180101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121aa99f2d3f4692bdd510f9652ac846_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ece0b562fb24861a00cc1837d3ba44d_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb48aaf3a1cf4e36903d0037ad367e4c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec13fd38f514239afa935809142d525_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f1e0b6d51d423fab44d10992a22439_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0a29ec79a2640e5a067988c35bbf456_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa172b849b9451881f587516f825b58_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6d26112ff24d9ab029f080a339e130_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973a1b238c6743cf8760ffc6932c3a7e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1affd54d523b488da0673a88c0036970_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e589b4bde248369e6e024a7f4abb85_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7fab35ed3247c4a11fd24731d5db87_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c1aab124cf41eab4654a55ce7d0456_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff05dbaad9645c284a3cedd8231323a_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d0ffc88019497f86735d349075b74c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97dc1f800de421eb8179a2c93529853_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if131cb24360a4f85bb336dd0ab7af8b9_D20160617-20160617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-17</xbrli:startDate><xbrli:endDate>2016-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7842b7854c410c9c6bb0e061d46cec_D20160601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c69c189be94bfc9380598800c85b4c_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fe92c33d98463bba6b004929024cfa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff9d49b979f434281543ef489df6e3c_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0036869090d6435dba566fa93d050600_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i0dd82aee18cf4b4d91431b4b49ef0bdb_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0de68e60891642eca083500a43ec45ec_I20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id56b451693a4495eaac87af0665021d3_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2634280b279f4601af826b4c8125dd23_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c4f0ef14eb44cd94cfc60e492db814_I20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8dc4dba49b4160b31e6e823e1ae788_D20180502-20180502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">dnli:LandlordFundedTenantImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6adb2eb42e59415094e9c0d4ffb38967_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:NewPremisesSubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293b5b178de44724a3a09c4a2268ccae_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcee909d65844bdd8691aaef6db01445_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195078f2e63c4ec69a1f3aed2a49cca6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a3e9667de048f9be4f3e9b194a89da_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380397739fb3409c84068db1cde52240_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3fd410c4ab04f2a98010ca624256620_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1a63d9fd9048e9b346a1bb1e5b53be_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d6c473afb5460780db3507a8b37630_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0427708156c3454cb4eb96e9b7ea3878_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc1cd06135f47ebb307c315c07c68a8_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecff526c59e7452aafbe14147f3cc250_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a76c5b5b6e4f3f9cd6493d2dba156f_I20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0e4017eafa4b21a497bff216646578_D20150501-20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf7537799d4426a9667a6f97c5239eb_D20150501-20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d03abee79c4854acb028d0eef7bf6b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieea49b8c39144a13b75a300520691ead_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52074d4e46047fdb42400ddf9179e83_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifceb656364a74a0da5c6b45c4e52919b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3fe6755fa445a7b223008c32301c1a_D20150801-20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4cc341fdaab4fb1baca8e685795587f_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id498dc8dfd914e4ca6892bfb92be83bd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef8038c831e4d59a9459cb27f4f1ec8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1c8f46d9a3426091ee2103297afede_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89660bd12204c74b680b13055456d71_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8980df381840e981e39e869a8ad187_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a1246830c7445e9ce63b86b50115b5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33146e3241854f64a4965054ea62ee6c_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71431700ff4c41c698876f5248f1b209_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33aae1a9291846d08a77fafcbb0fd48f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58d3dfd7fcb4f99a54807dfac3b6669_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1f6b3468396492fb70d28ad0e7f8b98_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b4ec6e313c422fb982eb70ccc6089b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2e60ed90c84ab2b33750989f3caf7b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c40a2236074822a36030b30b61a38c_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b68413bf0b9461591e8c59a2ccb9464_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362003e4d15e477299173e68bb66528d_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f2e8ea17014067925b92520d7e19bf_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4633b220bff4b1ea513d03256f027b0_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05bfa152469e4c2a8509fcde1cfa0f93_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieffd6c376be94ea4a96216622c548e7f_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if979d5313f0948369e6c21ef7aec9f23_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14c6b440b8f48a9838c5d9fcdb9c515_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c6b993b5bde429e9a7fba5ab9832fca_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d126a8dcd56440998101048ca785846_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275b58f10ba74daeae1286217a8a4e5d_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24c9b655a8e8443a87f7a3e134f345ba_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04b255ecd884d8e9200605be79d6280_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf8f1f2f33e4108b9baf4e4d8091e2a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237c5ee93e0b4218a0aca4f2977365cf_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b682f4a3a5c487695cf4824ecff6284_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8afd96134f0548538b390aa584b11fbd_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd6c4f1d91440f7aab878612276cb59_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9cdfc6602e4cbcbb2d61b338e5e9d1_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000b38f6d8874a1ba6da55900807e8e1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c2ef2c49884bb4b4428fbe8e81d56e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b5ff74e3d147f392767ecdbd341aa2_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7196f17f798b440fb5034d6f6a84eb2e_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d5f8a792ce41f6b36480b7307d2e65_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99aa73c5353433e959eff9dba13f059_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e55800d90541c4b977630444bbdbd0_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd2245025b2447a92a8217ee5cde65c_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-bottom:2pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:2pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:12pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.513661%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:8pt;margin-bottom:2pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV84Nw_b34ef696-0eb9-4909-b41b-a0d6d8d02130">10-Q</ix:nonNumeric></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.513661%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:0.1%;"></td><td style="width:1.415301%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:94.584699%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MmU0ZjA5MTU0NGFkNDQwMjhlZTZkMjU1NWViZDQ3MWEvdGFibGVyYW5nZToyZTRmMDkxNTQ0YWQ0NDAyOGVlNmQyNTU1ZWJkNDcxYV8wLTAtMS0xLTU3NDI_a1b279fa-7e57-4331-a322-6c8602c60c9c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES&#160;EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8xMzc_d7d92a4e-8f5d-47f7-b2f4-47bfcf2cb487">June 30, 2019</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:0.1%;"></td><td style="width:1.415301%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:94.584699%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6ODM1YTQ5ZWNmNjg3NDQ1MDhiN2MxY2ZkNDZjNzlkMDMvdGFibGVyYW5nZTo4MzVhNDllY2Y2ODc0NDUwOGI3YzFjZmQ0NmM3OWQwM18wLTAtMS0xLTU3NDY_8d031b4f-7a66-481a-9bf3-aec96c564f15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;margin-bottom:2pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">For the transition period from&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">&#160;to&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-bottom:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNDg1_fe496df3-b887-43fc-b744-405d47348fbb">001-38311</ix:nonNumeric></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.513661%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNTk_b4c08ccb-b281-4f1b-8b07-47f0f0ae04f9">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.513661%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.743169%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:40.622951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.530055%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.846995%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8wLTAtMS0xLTU3NTI_fc6b6bd1-1faa-4618-9fcf-6b5e1216700a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8wLTItMS0xLTU3NTI_65b8ad7b-6523-4938-a0a5-fad5d86c442f">46-3872213</ix:nonNumeric>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTE5_2e5d63c2-3608-42e8-bc18-bfdff28485c1">161 Oyster Point Blvd</ix:nonNumeric>.</span></div><div style="text-align:center;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTM0_67ebe106-60b2-41de-95b6-3f09ec136181">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTM4_cc159594-544a-4023-abff-0d28dd2b371e">CA</ix:nonNumeric>, <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTQ1_13282dc9-8aa4-4edc-947e-d8a74ace74f3">94080</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices and zip code)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNDkw_a7f77db4-85b4-4cc3-b193-5fabd94a6213">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTAw_7134be4d-b439-4267-a019-1eab1cb7540d">866-8548</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">_______________________________________</span></div><div style="text-indent:18pt;margin-top:4pt;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:38.437158%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.491803%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.071038%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MjQ0NWM0ZmFhNDlhNDE5Y2ExODU4NmY5ZGM4MDE5ZGIvdGFibGVyYW5nZToyNDQ1YzRmYWE0OWE0MTljYTE4NTg2ZjlkYzgwMTlkYl8xLTAtMS0xLTgxNDc_f7c6feaf-22c8-4ae2-b71a-6ee73616b9c1">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MjQ0NWM0ZmFhNDlhNDE5Y2ExODU4NmY5ZGM4MDE5ZGIvdGFibGVyYW5nZToyNDQ1YzRmYWE0OWE0MTljYTE4NTg2ZjlkYzgwMTlkYl8xLTEtMS0xLTgxNDc_f740d099-c4a1-4307-baff-ba421ce9ae62">DNLI</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MjQ0NWM0ZmFhNDlhNDE5Y2ExODU4NmY5ZGM4MDE5ZGIvdGFibGVyYW5nZToyNDQ1YzRmYWE0OWE0MTljYTE4NTg2ZjlkYzgwMTlkYl8xLTItMS0xLTgxNDk_0945c449-901e-4c6e-acd0-4f7e9cedc72c">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTA1_7a600c8a-befb-42b3-a53b-85ad91944690">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings';font-size:9pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;margin-top:4pt;margin-bottom:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">(&#167;232.405 of this chapter) during t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">he preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTEw_2b5443a4-d05f-42b7-9ea0-0fc62c0bbb7a">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings';font-size:9pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;margin-top:4pt;margin-bottom:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:15.486339%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:56.469945%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.765027%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.278689%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6YjNjM2M1M2YzNGExNDZjZjhhMjc4NDcyZDM4NTI5ZmQvdGFibGVyYW5nZTpiM2MzYzUzZjM0YTE0NmNmOGEyNzg0NzJkMzg1MjlmZF8xLTItMS0xLTU3NzE_7b7244d0-17f6-4ec2-9978-1695a4791b36">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6YjNjM2M1M2YzNGExNDZjZjhhMjc4NDcyZDM4NTI5ZmQvdGFibGVyYW5nZTpiM2MzYzUzZjM0YTE0NmNmOGEyNzg0NzJkMzg1MjlmZF8zLTMtMS0xLTU3NzU_ecc9d675-1325-437d-8aab-def464097365">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6YjNjM2M1M2YzNGExNDZjZjhhMjc4NDcyZDM4NTI5ZmQvdGFibGVyYW5nZTpiM2MzYzUzZjM0YTE0NmNmOGEyNzg0NzJkMzg1MjlmZF81LTMtMS0xLTU3Nzg_f539ee58-e650-4b9a-84cb-3ed32fbd0a24">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt;margin-top:4pt;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTE3_c18a04c0-f655-43c3-b86f-eb606ad719a2">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt;margin-top:4pt;margin-bottom:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTE2_e9773661-af34-4f23-941f-81f0164a80fa">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings';font-size:9pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:18pt;margin-top:4pt;margin-bottom:4pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">The number of outstanding shares of the registrant&#8217;s common stock as of July&#160;31, 2019 w</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">as <ix:nonFraction unitRef="shares" contextRef="ie6858c183ded4c66a5c4cae5464a8c49_I20190731" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yMDA5_1a1fd019-00e4-4e7f-bdd5-1adf737a83fb">95,841,615</ix:nonFraction>.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_7"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:36pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="text-indent:25pt;text-align:center;"><span><br/></span></div><div style="text-indent:25pt;text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:7.134615%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:79.570513%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.294872%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Page</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;1.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">Financial Statements</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13"> (</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;2.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">28</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;3.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">42</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;4.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">43</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_106">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;1.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_109">44</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;1A.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_112">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_112">44</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;2.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_133">101</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;3.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_136">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_136">102</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;4.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_139">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_139">102</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;5.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_142">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_142">102</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Item&#160;6.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_145">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_145">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_148">Signatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_148">104</a></span></div></td></tr></table></div><div style="text-indent:27pt;margin-top:5pt;margin-bottom:5pt;"><span><br/></span></div><div id="i_0_10"></div><div style="text-align:center;margin-top:12pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="i_0_13"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1.&#160;  FINANCIAL STATEMENTS</span></div><div id="i_0_16"></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share amounts)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:63.865385%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666667%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.666667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMy0xLTEtMS0w_3305bfd3-00e7-43ef-9a81-0e77f6c5f393">62,936</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMy0zLTEtMS0w_ffb51c88-1758-4ed8-b0a6-99fa3fe9d5e0">77,123</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNC0xLTEtMS0w_c0571dc6-6abf-44e4-bf80-1f4b3e95a67d">415,667</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNC0zLTEtMS0w_8dc6ee09-ad46-4b72-a2f1-73433efa7d52">387,174</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNS0xLTEtMS0w_fa9e7369-062b-4649-b8f7-1e45658eb108">17,378</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNS0zLTEtMS0w_a5f01c3e-74ff-4d2d-97c7-eb105d409378">16,539</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:31pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNi0xLTEtMS0w_b19eb6cd-1483-4dfa-a7ed-cbc5324ce68e">495,981</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNi0zLTEtMS0w_196c5a16-7798-47f0-b2c7-bb71cb920d00">480,836</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNy0xLTEtMS0w_e3288a77-b370-4fab-97e5-7122da38dffd">55,832</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNy0zLTEtMS0w_e4c6c50d-89f9-44f3-be09-3dea5b956c42">147,881</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfOC0xLTEtMS0w_62b5e0cd-de1b-4350-a05b-a982a8048938">47,195</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfOC0zLTEtMS0w_26b95d29-f54a-4d55-891d-7b9054972855">25,162</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfOS0xLTEtMS0w_46583d91-add1-4556-85e1-0364012f2b0b">34,647</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTAtMS0xLTEtMA_50dfc09d-57f0-4036-a8ac-f40ff1d76730">3,949</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTAtMy0xLTEtMA_f8fff112-95bc-40b0-88dc-eab55afc5131">8,105</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTEtMS0xLTEtMA_8d39813b-476f-4db1-a4da-a02b16357b98">637,604</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTEtMy0xLTEtMA_eeea7464-50c0-4cd6-a2e1-568a4a8678e8">661,984</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders' equity </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTQtMS0xLTEtMA_13d3dcf7-a498-4ea6-8a8f-e9ec6b5846b5">3,931</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTQtMy0xLTEtMA_5c0013d8-8589-48a6-8158-5d18d21dabf1">1,891</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTUtMS0xLTEtMA_df155444-e355-4d51-80e1-9142c15eceab">13,793</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTUtMy0xLTEtMA_ca110a27-3168-485b-9de3-2ef8afd6efca">8,520</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTYtMS0xLTEtMA_e47725e6-9185-44f4-9693-f0bb7c92be62">4,092</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTYtMy0xLTEtMA_a3d4054c-4422-431c-bf78-4b2d09b4a810">9,952</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTctMS0xLTEtMA_70cf551b-1910-4a8a-afd9-cfcb180c41b0">22,598</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTctMy0xLTEtMA_a0970aaf-9e55-46ab-ac3a-1f2b4367c7fa">11,427</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTgtMS0xLTEtMA_b8f4bec9-7fe7-484c-a3cb-4f529efc7851">2,135</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTgtMy0xLTEtMA_7afeb8bd-f8cb-4b79-90bb-8d602096883d">996</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:31pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTktMS0xLTEtMA_404657f6-bb01-47b2-9409-4fc907cec0f2">46,549</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTktMy0xLTEtMA_386e1993-539b-4310-92fe-be70b03e4aab">32,786</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities, less current portion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjAtMS0xLTEtMA_1b8a11eb-734f-4c1d-a9ec-92abec07d44a">44,563</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjAtMy0xLTEtMA_3e618d55-1a99-4bb0-82de-ff365d8d3b53">57,350</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, less current portion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjEtMS0xLTEtMA_1c011e58-55ac-4d32-9b04-3bf3900f2406">70,911</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent, less current portion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjItMy0xLTEtMA_eb87e274-2654-4a62-8bb4-8dfd577fa0f5">24,532</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjMtMS0xLTEtMA_cf43ff41-bda1-44e9-92d0-34d0d30b2c16">408</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjMtMy0xLTEtMA_40f1f356-afe5-4155-95ea-e722249a7c0c">471</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjQtMS0xLTEtMA_1577e81d-26c2-4228-8d27-0ff983664266">162,431</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjQtMy0xLTEtMA_3dea6c5f-3f68-486f-83c9-1de0cd60ccb7">115,139</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjUtMS0xLTEtMA_6e71afaa-5d61-4f86-8b4e-c1118321442b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjUtMy0xLTEtMA_b9519d55-4f53-49a9-90bd-444506df9631"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjctMS0xLTEtMA_c54496f0-4e3b-40df-a9b9-7f59282865dc">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjctMy0xLTEtMA_801d8fed-7804-49ab-83b8-e68d274de15e">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 95,656,896 shares and 94,662,435 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjgtMS0xLTEtMA_4851548c-7440-4ff1-b2e2-fb2ca2a57fb2">1,283</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjgtMy0xLTEtMA_65f7da44-53e0-430d-943e-5f7e363bb30c">1,273</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjktMS0xLTEtMA_3230e611-fafb-4459-b5cd-0b9f7733355c">798,277</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjktMy0xLTEtMA_9b78af62-736f-4408-bd6d-5e83fb5f5f87">774,158</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzAtMS0xLTEtMA_267be9c0-db92-45af-a52b-a3724c17e922">879</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzAtMy0xLTEtMA_8be65cd1-c39a-4777-96d6-32e7a297e237">649</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzEtMS0xLTEtMA_2b5ef3dd-7175-4b98-9a4e-04b9a48a00fd">325,266</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzEtMy0xLTEtMA_abc2a8c6-72ad-40a3-8e35-752646cbab38">227,937</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:31pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzItMS0xLTEtMA_c86ec445-1ff1-43a1-85d4-d0936dbea966">475,173</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzItMy0xLTEtMA_21a73f65-e8c8-4f73-8a65-cf664727d706">546,845</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzMtMS0xLTEtMA_1c550a1e-91d9-4545-9f20-92d1c62e6673">637,604</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzMtMy0xLTEtMA_59a24f0f-66b5-440a-9db9-b194d5df5420">661,984</ix:nonFraction>&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div id="i_0_22"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share amounts)</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:46.237179%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.339744%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.339744%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.339744%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.339744%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi0xLTEtMS0w_8b9bb41d-98f8-4be7-bbef-b777ae33fa04">4,197</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi0zLTEtMS0w_22ee099a-2d90-4f01-bd17-2e056cab51f3">1,648</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi01LTEtMS01NA_f6a37be5-b1a4-49cc-8bdf-46c34b949efe">8,402</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi03LTEtMS01NA_d86c1410-04e6-4af2-8706-157c23ebdb72">2,289</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC0xLTEtMS0w_d649e410-9fbf-40c2-bb34-120619240d69">51,884</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC0zLTEtMS0w_a18ada1d-24e8-4fd9-a910-969d4fcad063">52,134</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC01LTEtMS01NA_9271cc1c-ab79-4dd8-8b7c-687379e1c630">89,287</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC03LTEtMS01NA_b223e69c-c33b-4898-bbdb-057a2482f68a">72,953</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS0xLTEtMS0w_69ecd225-97fc-47e1-9be1-b2bd4d333100">15,076</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS0zLTEtMS0w_d28edafb-4932-42b9-8099-b60988c11b9e">6,896</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS01LTEtMS01NA_5653b2fa-af96-4f87-987c-29aecb0bd17a">24,386</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS03LTEtMS01NA_79dd060a-cfd3-4267-a4c2-39b1678fd18b">12,466</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:37pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi0xLTEtMS0w_5e8b9637-5ea3-42d5-9411-5832f9381a24">66,960</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi0zLTEtMS0w_b96ae723-752a-4895-befc-b3b367d3fcc6">59,030</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi01LTEtMS01NA_958bc10b-40e9-48b2-8b91-85e55b55b875">113,673</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi03LTEtMS01NA_cec6feea-6f66-4e80-8443-4be0769d15fa">85,419</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy0xLTEtMS0w_e2637aed-395a-46c2-aad5-e5648a555aca">62,763</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy0zLTEtMS0w_44fcf69f-0a72-45a9-a0bf-6784f30469c9">57,382</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy01LTEtMS01NA_b3cf2a9f-218b-4bc1-bc36-5b94ca1950dd">105,271</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy03LTEtMS01NA_aad1777d-0f97-4f99-aced-157ddae02914">83,130</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC0xLTEtMS0w_c9373382-e04f-4aee-a53c-ef2cc6086431">4,113</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC0zLTEtMS0w_c3bf5460-2086-4880-b772-43a3c4404d7f">2,658</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC01LTEtMS01NA_63e75ff5-003f-46ee-aae9-5f7af9fe5bba">7,629</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC03LTEtMS01NA_808de4e8-0afc-4763-be49-430923e9a609">4,728</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0xLTEtMS0zMTg3_fed2c989-03de-414d-b943-169413cd58f6">58,650</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0zLTEtMS0zMTg3_92388a9b-b582-411f-8fac-3906bfce73f6">54,724</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS01LTEtMS0zMTkw_891d6720-c523-4e5a-ae61-7cb4b36187fc">97,642</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS03LTEtMS0zMTkw_27c3cede-c5d4-4631-8a7b-5b03636b5dd1">78,402</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtMS0xLTEtMzE4Nw_d1260926-c033-45f0-9ff3-3d2b0cac744f">313</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtMy0xLTEtMzE4Nw_79a160e5-9dba-46bb-970e-c572cdeeb42b">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtNS0xLTEtMzE5MA_2c5b2db6-3dcb-4fee-ae13-744369dccbe0">313</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtNy0xLTEtMzE5MA_c5003aef-bd09-477a-875a-6841dd939d88">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0xLTEtMS0w_314b9cb2-1928-44f5-97c7-9aae23fdc0e3">58,337</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0zLTEtMS0w_46a325a9-3e0d-413e-b664-d78eac4a699a">54,724</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS01LTEtMS01NA_0692f8d7-fe81-40bd-a9ba-ccbc0f4f12f3">97,329</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS03LTEtMS01NA_96070413-0bb0-4dd4-bc7e-80218673d2d5">78,402</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:29.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Net unrealized income (loss) on marketable securities, net of tax</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtMS0xLTEtMA_5d2c245c-f9e3-4eab-8d86-3f47aadc29b0">547</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtMy0xLTEtMA_00ef8c60-9779-4df1-b572-f366223435f5">206</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtNS0xLTEtNTg_5bcee414-620e-4c10-afcc-56ac007848f3">1,528</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtNy0xLTEtNTg_096ae999-90a5-42a9-9899-860e462414cc">1,125</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItMS0xLTEtMA_c7a4282b-5ebf-4944-970e-be9d0c02ca3f">57,790</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItMy0xLTEtMA_0d160463-bfc8-40ac-accb-9610838525a9">54,930</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItNS0xLTEtNTg_47555f4f-f5fe-4743-9e61-12ff82d33588">95,801</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItNy0xLTEtNTg_ca90e85c-c314-4287-8201-37fb710003aa">79,527</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtMS0xLTEtMA_260d8d33-c26d-46e4-be8a-d772d3576dff">0.61</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtMy0xLTEtMA_67a4be54-963a-471b-82fc-7ddcd3d28b59">0.59</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtNS0xLTEtNjE_ba581149-7780-4123-a85f-05a53accf75a">1.02</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtNy0xLTEtNjE_5f05a402-5206-41fc-8a18-2d37e27bf9a9">0.86</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:29.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Weighted average number of shares outstanding, basic and diluted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtMS0xLTEtMA_cc47e454-3ce5-4ffe-af63-93e7b3e7cc23">95,495,497</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtMy0xLTEtMA_caecf6f6-3681-460c-b921-651245282aac">92,899,524</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtNS0xLTEtNjE_a7568623-8385-44c8-9a7b-4925d7bd774f">95,241,412</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtNy0xLTEtNjE_004fd99f-6e7d-4cab-ac36-e9a077e8498c">91,239,274</ix:nonFraction>&#160;</span></td></tr></table></div><div style="text-indent:4.5pt;text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-indent:4.5pt;text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:27pt;text-align:center;"><span><br/></span></div><div id="i_0_25"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share amounts)</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:28.448718%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.455128%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.852564%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441026%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.096154%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441026%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942308%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441026%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.019231%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441026%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icb687f8433d24be0ac5335c8c79c0494_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi02LTEtMS0w_53fcdfbc-92d9-43e5-89c1-1515bd3bc53e">94,662,435</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb687f8433d24be0ac5335c8c79c0494_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi04LTEtMS0w_4b40a88e-147e-45d1-9b88-93403d08c0b9">1,273</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b8beed483e6423490b503483915e4f2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xMC0xLTEtMA_3a38288a-61d3-47e0-a7a8-74c40c09c8db">774,158</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5344b99e882d4934943a39b1eb4887b1_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xMi0xLTEtMA_8d2c2616-2307-49dc-8d85-36a776f93b6f">649</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie51bc7132b78422f88cfdae7c0aacebd_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xNC0xLTEtMA_024083c8-4b39-4a29-978a-22f125b9cb8a">227,937</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xNi0xLTEtMA_1595041f-f2b2-43f4-b2d2-e0c53949fbaf">546,845</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuances under equity incentive plans</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy02LTEtMS0w_ab377028-3aa8-4220-b039-43f2c4954cdc">547,124</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="-3" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy04LTEtMS0w_6fb3a5ac-27c7-4605-ab6f-0790aae31310">5</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy0xMC0xLTEtMA_cb04d341-19b6-4cdf-8d29-0dbf480555aa">3,472</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy0xNi0xLTEtMA_aabb7c48-5244-47d1-aaf0-02fa13309c59">3,477</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Vesting of early exercised common stock</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC02LTEtMS0w_c35a6748-9844-408f-8671-ec9e4ce127ce">93,752</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC04LTEtMS0w_d8ec19e4-26c5-4c3c-a1f9-e5e75c27f4df">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC0xMC0xLTEtMA_97939740-9471-4e5a-886d-4e46b41f8a85">62</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC0xNi0xLTEtMA_73666f97-e815-4be4-a378-b988991fc711">64</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of restricted stock awards</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS02LTEtMS0w_ddcb0f80-a762-4071-9d6d-30bd8e542f45">353,585</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS04LTEtMS0w_8455c64f-1c75-43ea-9504-a6d22661c897">3</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS0xMC0xLTEtMA_4fbd9801-2451-4159-9fac-7302a91ca87a">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS0xNi0xLTEtMA_20233681-ff03-4792-a9f0-2ca7abff133b">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNi0xMC0xLTEtMA_4f328b3d-717e-41e1-9497-0e7d9b15ca6e">20,588</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNi0xNi0xLTEtMA_214797e0-d957-408e-a173-3f281891548b">20,588</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i722034f7c8044775b8f4e39ab11f9044_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNy0xNC0xLTEtMA_7204f9d9-9522-4081-a2a4-f6e78be3841b">97,329</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNy0xNi0xLTEtMA_1e799865-4bfd-405f-afa8-2782899d014e">97,329</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48efc218d04b44c5bd998761d74d0369_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOC0xMi0xLTEtMA_4ff0ae6f-2edc-4351-bb32-1dbc8ffb48e5">1,528</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOC0xNi0xLTEtMA_4d69ab8f-9a1b-4856-8d44-f6f03be295a4">1,528</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS02LTEtMS0w_8c85d5dd-da6c-4692-8497-fb74fb3d1f07">95,656,896</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS04LTEtMS0w_2c2cd7cd-d151-42be-b056-64f4d98b6910">1,283</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i023b35c87938433a989302ec87e7ab6c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xMC0xLTEtMA_46089924-0e8c-4f08-bafe-5b6445b34465">798,277</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b99abb30444402e9dd33c0c70fe40f9_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xMi0xLTEtMA_a21306e5-1c5a-4f11-9632-bfc9b81b91c0">879</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42701eeb1e1c4a17b979e71633036f02_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xNC0xLTEtMA_42b1c9e0-9e9a-4e7d-b61d-9badc9e0321f">325,266</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xNi0xLTEtMA_2dd3b588-ecb4-4c7d-b889-b213c9e6d48b">475,173</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if166a88ab9ee4dda853e8603cb29e805_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtNi0xLTEtNzgzNw_c387f304-c638-452d-9ea5-0cadf6507fa3">95,257,705</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if166a88ab9ee4dda853e8603cb29e805_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtOC0xLTEtNzgzNw_3d669640-b2a2-4dda-9e72-a522b1a8b655">1,279</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie35e501f47d4427fbd9b62dc2c00e2dc_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTAtMS0xLTc4Mzc_2c4169b1-45f3-4c26-8606-1139912b9889">781,966</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71648051f8714218b99562e835fa904b_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTItMS0xLTc4Mzc_ed0d70fe-3d77-446e-a11a-c8f3a02bb7ca">332</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3db11cdb9fdc4fda8887c70798fe0bb4_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTQtMS0xLTc4Mzc_d38a0c2b-6318-4129-bb8a-df36ca190d4d">266,929</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8b1265cc2294fccb8fee9c3f57ef5ad_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTYtMS0xLTc4Mzc_3611e6d5-c085-433a-ab1d-65e87be74838">516,648</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuances under equity incentive plans</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItNi0xLTEtNzgzNw_c4b955f3-3ba8-4abd-b67a-849527043436">347,621</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630" decimals="-3" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItOC0xLTEtNzgzNw_fdd31940-b03b-4259-8f29-30d9972c8e65">3</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTAtMS0xLTc4Mzc_a019ceda-e440-4d8a-a3fd-b520185a94d9">2,566</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTYtMS0xLTc4Mzc_95a4da91-815e-462a-9a10-b33b1f543d51">2,569</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Vesting of early exercised common stock</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtNi0xLTEtNzgzNw_1f44bf61-35ad-4ad2-98b0-1c61bd289fbc">46,878</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtOC0xLTEtNzgzNw_226429c1-14e7-4fa0-bb0b-4833fe7a42a4">1</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTAtMS0xLTc4Mzc_05b72dbe-05de-4433-b855-9913f5a72ba6">31</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTYtMS0xLTc4Mzc_beff51ab-f54e-418b-b13a-aee06d064fa0">32</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of restricted stock awards</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtNi0xLTEtNzgzNw_928ea822-0919-489f-9d79-885adb0abe8f">4,692</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtMTYtMS0xLTc4Mzc_59b8bee0-8a71-4329-8c87-862a7fbab070">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTAtMS0xLTc4Mzc_e19c3d59-d7e7-4fc7-93c3-11f3f1f802f4">13,714</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTYtMS0xLTc4Mzc_eca3b06a-830c-4d24-b723-9843de17c2f5">13,714</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9d14f1d11c174d03b34f14d15c06d0e4_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTQtMS0xLTc4Mzc_d5f59e65-1026-4c43-9d80-084378e1caa1">58,337</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTYtMS0xLTc4Mzc_9e687c0b-0813-49db-9f78-cf365fc3ae32">58,337</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idf0c5c2b81f14b2ba8bf900712c881a8_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTItMS0xLTc4Mzc_e7ad3196-d244-411d-9518-4ab723275689">547</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTYtMS0xLTc4Mzc_c28ffc93-447e-47df-8c94-eb82cadf30e5">547</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtNi0xLTEtNzgzNw_c4a076a0-16b3-4e7c-bab0-3098ec821cff">95,656,896</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtOC0xLTEtNzgzNw_08dd6800-e56c-41b0-af8f-fbd28caaa7b8">1,283</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i023b35c87938433a989302ec87e7ab6c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTAtMS0xLTc4Mzc_1205b920-292f-4c36-859e-a02fbdeb1fdd">798,277</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b99abb30444402e9dd33c0c70fe40f9_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTItMS0xLTc4Mzc_579388e9-fd69-4b2a-be0b-1235fe932ed3">879</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42701eeb1e1c4a17b979e71633036f02_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTQtMS0xLTc4Mzc_04f52711-76d0-4a31-8df9-0ccf7ca6c2fe">325,266</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTYtMS0xLTc4Mzc_d2a3f9bc-ac9e-4eb2-ae04-02d2c32f5e9c">475,173</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i59e066377dcf4dd1909aa3b352723c01_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItNi0xLTEtMA_54dec306-bf34-481b-9f37-d6588a7254b4">87,480,362</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59e066377dcf4dd1909aa3b352723c01_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItOC0xLTEtMA_8609d59f-6ede-4c87-9396-1d0d7110a6d7">1,201</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3fbad4386a8427d8c6f6a3d5a7374ac_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTAtMS0xLTA_79041e73-b67a-45c7-9774-e582850d3c4e">656,660</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9f9d4a6b28cc473c805fb4ad62ae184b_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTItMS0xLTA_2ca7f922-196a-456f-89e0-584a440e9de9">368</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412e26418ded47729bc5c01e358338bc_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTQtMS0xLTA_21327445-4769-4e7d-b5d5-48b2b8bd23f4">191,697</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i654d7777e96c48528ad08a99690746d9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTYtMS0xLTA_dec55c54-aa0b-452f-9099-b78da868c1f2">465,796</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:23.98pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock in connection with the Takeda Collaboration Agreement</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesCollaborationAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtNi0xLTEtMA_e6e2f601-b7d1-47dc-8727-939f7c3fc9bf">4,214,559</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="-3" name="dnli:StockIssuedDuringPeriodValueCollaborationAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtOC0xLTEtMA_41a6227e-8684-4c72-959b-42949f7b9fc4">42</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueCollaborationAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTAtMS0xLTA_59dd25a3-8c3b-4b65-b48c-de589fef479a">94,364</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueCollaborationAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTYtMS0xLTA_4c3cd2a5-745e-4018-a1f0-1bfdcb0e63ee">94,406</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances under equity incentive plans</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtNi0xLTEtMA_092c9a87-c4f1-46e1-aab5-1df8a5cdb6e3">360,409</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="-3" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtOC0xLTEtMA_820a498c-cc32-4fce-a45e-a6bcd1a1d75f">3</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtMTAtMS0xLTA_4a257fec-9184-4c9e-8cfa-6a043415b6cc">1,649</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtMTYtMS0xLTA_bb414279-3eee-4b9c-a8c0-f6dfb0d390f5">1,652</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of early exercised common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtNi0xLTEtMA_d1b97f09-326b-4759-8723-10d04d47e9ff">140,624</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtOC0xLTEtMA_87b7258e-8f8d-4e5f-b375-97e2cc5da1d1">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTAtMS0xLTA_02ff7927-7f5b-4f6e-9cc9-e19b1fb22e1b">308</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTYtMS0xLTA_97692523-18de-471c-b94f-a3293dd44b05">310</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of restricted stock awards</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtNi0xLTEtMA_f23a9da6-c5c4-4d50-b098-ffdb38fd3149">1,125,791</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtOC0xLTEtMA_fb8508ee-5266-477d-80f9-d5acebeed487">11</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTAtMS0xLTA_9eed5fe0-37b4-46b4-81a1-d6b9ae5fb335">11</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTYtMS0xLTA_965a09bb-4733-4bc9-ab0e-4c59810256fb">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTAtMS0xLTA_0deb8909-ae5d-4463-a487-2f009b6136fe">7,635</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTYtMS0xLTA_14590d30-3bbb-4aa3-8407-e26adaa7de43">7,635</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie023db07ba2245d89a07be32e19c8699_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTQtMS0xLTA_768b22ca-8405-4856-9082-e0949af852dc">78,402</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTYtMS0xLTA_7f525d33-bf48-4cf1-95cc-c021a86573da">78,402</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie57571f426694fe089fe9cb5f12584ce_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTktMTItMS0xLTA_546b2915-5a8e-4a3a-a00a-36ff31a9f688">1,125</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTktMTYtMS0xLTA_f788536a-5621-4d90-b7a2-7a5f038acb3b">1,125</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtNi0xLTEtMA_7449d8b0-38e5-4c82-9e05-203cfb556ec9">93,321,745</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtOC0xLTEtMA_001d3137-884e-4463-984b-b2a2ef98fa47">1,259</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3637006edc4480da3b4668dd1f931c1_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTAtMS0xLTA_ea468d46-8946-450e-9b0b-3ea0c9372370">760,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7131d5c68734000965acd7cf27ca3a6_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTItMS0xLTA_3916ecf6-eb7b-44fb-9df9-608a08c41cff">1,493</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b047174d458400c8d2c9e6554f436c6_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTQtMS0xLTA_b576f69b-fc7f-4d0d-99da-cac314f6beec">270,099</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTYtMS0xLTA_86cc0f97-531f-4e1d-a757-e7c76910265f">490,272</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i25146bfdcf2a47919d391a395b32bece_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtNi0xLTEtNzgxNw_72e6902d-3c63-47f8-82d3-a210b7cde209">92,588,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25146bfdcf2a47919d391a395b32bece_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtOC0xLTEtNzgxNw_28be50a8-d4c7-4f90-84d3-ab51640051b1">1,252</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if624bfc7618444aaaee3b88445cdcd15_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTAtMS0xLTc4MTc_57681dc5-2482-4c7b-865d-a176bf386f9b">754,438</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib41e9af92e2b4bce9bf0ea68da08021d_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTItMS0xLTc4MTc_7322f7cd-f768-4104-96c1-dfdbea390319">1,287</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iae5650d2914b4b4a8c62050aaaa3c4a7_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTQtMS0xLTc4MTc_ee343899-ad9d-4c99-a57f-ad9a972b4f8a">215,375</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib74065ebcb8745068d2741baeaf0b579_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTYtMS0xLTc4MTc_374a0338-2be7-42b6-af16-b9dc47d4dc55">539,028</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances under equity incentive plans</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItNi0xLTEtNzgxNw_f9f3ebc2-014e-4f1a-b31b-97c214fe9626">278,674</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630" decimals="-3" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItOC0xLTEtNzgxNw_7f145a28-be85-4bd9-9a4b-7cf1b51df799">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItMTAtMS0xLTc4MTc_27852d7e-f99b-453f-8e0d-4aa8b94aa54f">1,431</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:StockIssuedDuringPeriodValueEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItMTYtMS0xLTc4MTc_0a13e13c-0302-4339-bd0e-f4c2b8c11629">1,433</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of early exercised common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtNi0xLTEtNzgxNw_c8054765-69c7-40fd-ac5f-56d650b06872">46,875</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtOC0xLTEtNzgxNw_339f8dd3-168f-4f02-8746-07bad05d38e7">1</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtMTAtMS0xLTc4MTc_401b6d00-e01d-4ee3-89c7-f2c111736052">30</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtMTYtMS0xLTc4MTc_9c35d411-f882-495f-a124-f03f58ee77f2">31</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of restricted stock awards</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtNi0xLTEtNzgxNw_7c09e638-32cb-4f7c-b141-a5350643b062">407,207</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtOC0xLTEtNzgxNw_32ffd2d0-5755-4b10-962d-cf9ff38ee3d5">4</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtMTAtMS0xLTc4MTc_7ba218fd-e7d3-465f-9356-9ddf4f25a3fa">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtMTYtMS0xLTc4MTc_f94b8604-09cf-444d-9058-4bac6fb076e8">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzUtMTAtMS0xLTc4MTc_96e7c83b-a7c0-4110-b3b0-d99e22dbc483">4,710</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzUtMTYtMS0xLTc4MTc_a1348dad-a8ee-4f5c-ad93-0a24205a7406">4,710</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9f972032aeb2409db70c5438d495f50e_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzYtMTQtMS0xLTc4MTc_af697b1d-64d7-4062-b02b-1d2d002f44d2">54,724</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzYtMTYtMS0xLTc4MTc_561fda68-b1a4-4cc5-b19f-60a6ca6eaec0">54,724</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie61e2d55e75b47bf9f99395f341b50b6_D20180401-20180630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzctMTItMS0xLTc4MTc_b9a541dc-1977-40cf-8c6e-92a57d19a3de">206</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzctMTYtMS0xLTc4MTc_ed7005f0-f5d8-445a-b6d4-c19b21c24fae">206</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtNi0xLTEtNzgxNw_fb9d1aca-3326-488c-9026-0c5df49b3bb6">93,321,745</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtOC0xLTEtNzgxNw_2c23a0b4-2bf3-47cb-8fd0-6dadf19151f3">1,259</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3637006edc4480da3b4668dd1f931c1_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTAtMS0xLTc4MTc_ca975660-c7ea-4868-99c3-521cd0f47465">760,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7131d5c68734000965acd7cf27ca3a6_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTItMS0xLTc4MTc_9a526d6c-9068-483b-b4a4-f1034b2c2a0c">1,493</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b047174d458400c8d2c9e6554f436c6_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTQtMS0xLTc4MTc_76f74828-1e8d-4e2f-a46d-03230a9d4111">270,099</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTYtMS0xLTc4MTc_76680dc0-2ed6-4680-979d-126b0a03af1a">490,272</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div id="i_0_28"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:71.557692%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMy0xLTEtMS0w_33eabb43-1aad-4d9c-a2a4-84d3081d648f">97,329</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMy0zLTEtMS0w_38dd63ea-d47c-47e6-989f-0a44cc2440f9">78,402</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNS0xLTEtMS0w_1f2f2bd0-d497-40bd-8245-3f83dd07e8d5">4,046</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNS0zLTEtMS0w_c37b254e-0d71-4269-8346-652eede5e69c">2,709</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock&#8211;based compensation expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNi0xLTEtMS0w_0e24879b-a7fe-4f5e-a303-7c8d9e9f6913">20,588</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNi0zLTEtMS0w_8781c333-814c-4b12-8de2-dcd8bbcfa206">7,635</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net amortization of discounts on marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNy0xLTEtMS0w_05e6f91d-2d25-4903-aa0b-e3d98b12e055">2,734</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNy0zLTEtMS0w_2fdc7409-fe14-43de-bdbf-3979fe096550">1,092</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash rent expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOC0xLTEtMS0w_b32f5a59-df6e-4193-aa18-367f2b2acd5a">1,740</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="dnli:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOC0zLTEtMS0w_d34ac394-11d0-4510-8249-312a77a1a022">1,339</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on disposal of property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOS0xLTEtMS0w_18c42e0a-57dc-4bb4-80c8-f4dd3c99399e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOS0zLTEtMS0w_afee10db-ceab-41bc-b387-7812e4e6c425">36</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-cash items</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTAtMS0xLTEtNDY2OA_1e29a7a7-bbbd-4916-b8c0-bffff70a34e7">313</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTAtMy0xLTEtNDY3Mg_bd0da5ff-7e15-4244-a9b6-53b3865e873d">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTEtMS0xLTEtMA_edd3e313-d68c-4a01-85a0-018e0371b56c">2,704</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTEtMy0xLTEtMA_5277198f-1878-4355-8f61-3dcb3bbeff4f">1,718</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTItMS0xLTEtMA_7f736d54-8ef7-4d8f-93f2-b1588d711bff">1,303</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTItMy0xLTEtMA_3b06fd68-5df9-47ab-a2af-913d2a790b26">7,094</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued and other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTMtMS0xLTEtMA_885afb3c-9859-4a71-9d7a-088b35a66c1b">1,887</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTMtMy0xLTEtMA_a750d148-d477-4924-a761-edaad97df562">1,403</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTQtMS0xLTEtMA_4b4829ad-6fb3-447f-8a84-209cd7b2fb06">1,616</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTQtMy0xLTEtMA_feae9243-f41e-471c-bf13-d9679072798d">58,305</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:37pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTYtMS0xLTEtMA_d96e6a6d-ff60-4fe4-8271-534dc66cd41c">73,498</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTYtMy0xLTEtMA_435ed359-1e9e-497c-8036-bb0665a3e8e7">8,247</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Investing activities</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTgtMS0xLTEtMA_cde55b87-d118-4c3f-93ec-aebf7a28cb39">144,029</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTgtMy0xLTEtMA_effaa207-dffa-4429-b292-d4cb828359d3">361,686</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTktMS0xLTEtMA_3620a007-6a71-47e0-945b-a711f851b292">12,299</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTktMy0xLTEtMA_f08cffe2-2cb4-4997-bf80-7d3f9e0651eb">1,109</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjAtMS0xLTEtMA_ed8454c8-6062-4a93-ac78-4747e451bcab">212,162</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjAtMy0xLTEtMA_b2a40168-4a99-4d26-b613-6996da7d1e41">92,049</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:37pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjEtMS0xLTEtMA_ad88ea95-b33d-4001-873a-24e74e1f8e94">55,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjEtMy0xLTEtMA_c11e8831-35e0-4170-bd91-e813a9d6b5b2">270,746</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Payments of issuance costs related to issuance of common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjMtMS0xLTEtMA_0a6c6517-5552-4cad-adff-76ebd5519d49">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjMtMy0xLTEtMA_08009e53-dd58-442f-b991-42bea9e858b5">1,342</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Payments of issuance costs related to issuance of preferred stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73b1ab5fa47f47a3a75b2baeb7eb3662_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjQtMS0xLTEtMA_8afaff86-08f4-4693-827f-c94c67e33bd6">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i823adbb4c4d94559b833efb563159c96_D20180101-20180630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjQtMy0xLTEtMA_d48616dc-d199-4b42-a8cd-29923c982a46">44</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in connection with the Takeda Collaboration Agreement</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="dnli:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjUtMS0xLTEtMA_65292da5-71a1-4e31-95fb-27d306d59b65">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="dnli:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjUtMy0xLTEtMA_8a82676f-caa8-4248-8341-2fa27b9447be">94,406</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of awards under equity incentive plans</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjYtMS0xLTEtMA_86434ca0-f0a4-4777-a788-551d8054b8fd">3,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjYtMy0xLTEtMA_e5a9d3ee-4c30-497b-86e0-ed9e18ae7703">1,651</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:37pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjctMS0xLTEtMA_edfa5338-a141-4c58-9d30-7adbc043940c">3,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjctMy0xLTEtMA_a818ce25-741c-4f00-813e-e2a948dd724f">94,671</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjgtMS0xLTEtMA_87b4029d-0fd6-430d-9926-922cbb5efbcc">14,187</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjgtMy0xLTEtMA_22826eaf-1b4a-4de2-ada3-4156c4bb153e">184,322</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjktMS0xLTEtMA_d3ca9950-3e15-4105-8678-0cd816672fae">78,623</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i654d7777e96c48528ad08a99690746d9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjktMy0xLTEtMA_b2e48a13-c070-4701-8b5c-431b0ec78c3a">218,910</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzAtMS0xLTEtMA_25c340ef-5e32-4d2e-bf33-373a3c3f6169">64,436</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzAtMy0xLTEtMA_e01bf782-2ae5-4d73-912f-a03d086eee36">34,588</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Supplemental disclosures of cash flow information</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Tenant improvements provided by the landlord</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="dnli:NoncashTenantImprovementsPaidByLandlord" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzItMS0xLTEtMA_e335d120-938c-45be-a26a-245dff41f494">11,341</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="dnli:NoncashTenantImprovementsPaidByLandlord" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzItMy0xLTEtMA_e4d13842-f2db-42d3-bf6c-85c11828a125">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment purchases accrued but not yet paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzMtMS0xLTEtMA_17292027-4d4f-4b8c-bf62-9f76d1e93887">2,162</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzMtMy0xLTEtMA_e63a62d2-3164-4b73-8905-80afd6b4461d">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div id="i_0_31"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i_0_34"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">1.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4Njk_252abbeb-2d28-4bab-8e08-3f68bee854a2" continuedAt="i511455b1b6f5492d9a0112fe23b22a9a" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i511455b1b6f5492d9a0112fe23b22a9a" continuedAt="i864590769bc84bb483cb53e44f97aff8"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NjY_837b6815-66b9-4e77-9187-ac0e83b6c157" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Organization and Description of Business</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali Therapeutics Inc. ("Denali" or the &#8220;Company&#8221;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzQ_06749192-ef3f-48a0-84a5-e2968d625936" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">as filed with the Securities and Exchange Commission on March&#160;12, 2019 (the "2018 Annual Report on Form 10-K"). The condensed consolidated Balance Sheet as of December 31, 2018 was derived from the audited annual consolidated financial statements as of the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended&#160;June 30, 2019, except as discussed below in the sections titled Leases and Recently Adopted Accounting Standards, there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2018 Annual Report on Form 10-K. For further information with regard to the Company&#8217;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#8217;s Consolidated Financial Statements included in the 2018 Annual Report on Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzM_9a10fb82-f676-438a-8056-b3b22eeff7c4" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated on consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i864590769bc84bb483cb53e44f97aff8" continuedAt="i3b25febf688041b98af1e6f03b9c929d"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4Njc_98068d7c-d651-4126-9c15-339c74f06714" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the condensed consolidated financial position and statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzA_85965ae2-cb4b-43e5-90b0-872cdec7a7f2" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of June 30, 2019 and December 31, 2018, the Company had&#160;no&#160;off-balance&#160;sheet&#160;concentrations of credit risk.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzU_c8ab617b-907b-42bc-a292-5fa75e5ff44d" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has <ix:nonFraction unitRef="segment" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfNjU4MA_f5f688f5-45bf-41c1-8bcf-3aca200ed2d5">one</ix:nonFraction> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzY_96c287e7-fabf-4506-8179-04acc9bf738b" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s restricted cash consists of the letter of credit for the Company&#8217;s headquarters building lease, and is included&#160;within other&#160;non-current&#160;assets&#160;on the accompanying condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i3b25febf688041b98af1e6f03b9c929d" continuedAt="ia25de2ea0f6143ee97aab0242e0a18e7"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4Njg_05ecce1c-09df-4062-9708-9f824f846847" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Derivatives and Hedging Activities</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its derivative instruments as either assets or liabilities on the condensed consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through Interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzE_98561fa4-2fd5-4026-9304-cae58307d1ff" continuedAt="idb1b945b1e934fcd850d90ce21eadb52" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company adopted Accounting Standards Update ("ASU") No. 2016-02, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> as of January 1, 2019. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#8220;ROU&#8221;) asset an</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">d operating lease liability is recognized for identified operating leases in the condensed consolidated balance sheet. </span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent the Company&#8217;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate (&#8220;IBR&#8221;) on the date of lease commencement, or the rate implicit in the lease, if known.  The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.</span></div></ix:nonNumeric><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="idb1b945b1e934fcd850d90ce21eadb52">Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NjM_6910dc6f-f07c-4a17-b5c0-a8070871b43c" continuedAt="i2a3e527087824061bea742f2aed722f0" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License and Collaboration Revenue</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#8220;ASC&#160;808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &#160;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. </span></div></ix:nonNumeric></ix:continuation><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="ia25de2ea0f6143ee97aab0242e0a18e7" continuedAt="i0aab231320a7499d9e481a88135d129b"><ix:continuation id="i2a3e527087824061bea742f2aed722f0"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company's consolidated balance sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span></div></ix:continuation></ix:continuation><div style="margin-top:18pt;margin-bottom:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i0aab231320a7499d9e481a88135d129b"><div style="margin-top:18pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTIwOTQ2Mjc5MjcwNDg_9976302a-c686-4e2d-aaa2-f0eab2940407" continuedAt="i80319fc4f9d24362ba2b786dfd094229" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i80319fc4f9d24362ba2b786dfd094229">Intraperiod tax allocation rules require allocation of the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. A related tax benefit is then recorded in continuing operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NjQ_b742684c-7a39-4287-bede-345e6145f58e" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss per Share</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzI_94303327-3d14-4524-8288-375caf1bfb8a" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which supersedes the guidance in former ASC 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, C</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">odification Improvements to Topic 842, Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, in December 2018 through ASU 2018-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Narrow-Scope Improvements for Lessors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and in March 2019 through ASU 2019-01 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Codification Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and is required to be adopted using a modified retrospective approach.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has adopted this standard as of January 1, 2019, applying the optional transition method such that it is not required to adjust prior period presentations. ASU 2016-02 has impacted the Company&#8217;s condensed consolidated balance sheet as the Company has certain operating lease arrangements for which the Company is the lessee and one operating lease arrangement for which the Company is the lessor. The Company has <ix:nonFraction unitRef="contract" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="dnli:LesseeFinanceLeaseNumberOfContracts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTczMDM_3f7e1464-ad2a-44d3-beb2-55719ebe77c1">no</ix:nonFraction> financing leases. Management has elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The impact of adoption of the standard is that the Company as of January 1, 2019 recognized a ROU asset of $<ix:nonFraction unitRef="usd" contextRef="i6abc0c7c5a6f4e6ea981285f7ae4c287_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc2MzA_3c5a73d7-13ab-437c-b06c-f7121c05e350">46.1</ix:nonFraction> million and operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i6abc0c7c5a6f4e6ea981285f7ae4c287_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc2ODA_c124cf4b-5578-4c6e-b403-b64379596330">71.3</ix:nonFraction> million. The standard did not have a material impact on the Company&#8217;s condensed consolidated statements of operations and comprehensive loss and stockholders' equity.</span></div></ix:nonNumeric></ix:continuation><div id="i_0_37"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">2.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RleHRyZWdpb246YmI0NzZiMDI4ZTEyNDY3MWFhNTQ0OTNhOGJiNWFkNTlfNjg2_478d56de-c847-4b84-bae2-49e0c6915d12" continuedAt="i1a58d0b24051498b8ff1968892a35647" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i1a58d0b24051498b8ff1968892a35647" continuedAt="i6cad3c1e37384fb586434c7b1ec73381"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RleHRyZWdpb246YmI0NzZiMDI4ZTEyNDY3MWFhNTQ0OTNhOGJiNWFkNTlfNjg3_f912d882-82a0-44b1-acb7-680e72536a3f" escape="true"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.314103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.378205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.262821%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0b119c34dd944daa20fa4eaaa3d2ced_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC0xLTEtMS0w_42b2622c-1a08-4b4b-9071-9f0e6844e024">36,180</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc8c6e58df014428922e55023f630ade_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC0zLTEtMS0w_32cff8b4-6970-40c4-b35b-86a514b44e57">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i534bf8602525455db76397bb865e573f_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC01LTEtMS0w_f9ad521d-0b92-4a80-93b7-359e2a288d4d">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i351b20a5b439409598aa2bedf197448c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC03LTEtMS0w_7611959d-8519-4d4f-9bcf-8801f9463464">36,180</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d35607870c64688827351e700854bef_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC0xLTEtMS0w_85ee162c-36a6-47a0-ab4c-6b8ae3c3d678">273,103</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77531d54e5404598a5078438c8677b65_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC0zLTEtMS0w_9eea64e4-dd3f-46dd-91b0-8aa93e1ffff5">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i564db519a26f4cb8a0fb1d4e669911f2_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC01LTEtMS0w_423cae1a-c32b-426b-94cb-98ad46db7941">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i039ece834d1c4019baf20e251e2da235_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC03LTEtMS0w_e6dbbf79-c887-4882-8ec1-e1070bf98364">273,103</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7db3561ea15848dab72e9c69da84ebf7_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS0xLTEtMS0w_f5a4ce68-4c5d-4df3-be76-2b63d4870206">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i394557b4e90043e2a2085e2207e5f704_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS0zLTEtMS0w_0a7ad614-ec40-477e-baac-b41d657bbe59">28,957</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia647cd1b2d9a45278c18b341c2434e5f_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS01LTEtMS0w_8a83c990-0b59-4c38-8842-ab03d5f1e4f3">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied7a9a68ed1e4b98bf5fcf82a0334cc8_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS03LTEtMS0w_43da67bc-355f-439d-834e-026ca7b50cbc">28,957</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i646027daed3e4e16b08888af3c67909c_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtMS0xLTEtMA_01e0ddf7-4f29-4cd3-b907-6d0c56ef8b5c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac821d5ca4ca49dc813f6db1babf4665_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtMy0xLTEtMA_e53ef57e-f224-4468-91a6-2e1c10a69076">78,950</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7fb855d6104424da5e93287267c6ac0_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtNS0xLTEtMA_ad2bf43e-104b-4eec-8efe-3d5e0a79ddfc">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3f2152514a74f9691322d7bb19989c8_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtNy0xLTEtMA_6115aba5-1068-4504-87f9-a02f3841d0e8">78,950</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2188c27fed024d2d9d5cec962236ec1c_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtMS0xLTEtMA_a5bc72f1-f4a7-492c-827a-6ea1d159985c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if01b372be06641fcb73d69acee794292_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtMy0xLTEtMA_866593a4-cfec-4963-856c-ef876419c1cc">34,657</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee33812b6d5f432a938b1e20a417c276_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtNS0xLTEtMA_59c6c5b3-9e89-4b29-be9a-018739074e10">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i32984200dcc845b2a45fea17a3812a06_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtNy0xLTEtMA_a4b20b7a-3eaf-489f-b554-35ee1a099557">34,657</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id738d34d6e8e4df2b2e0892ca8583817_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtMS0xLTEtMA_b00fa0da-3a2e-44bd-bace-b04b0b7de9fd">45,794</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie81ed0dc4a654555b4dfaf4dcc554425_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtMy0xLTEtMA_09ae61d1-82f3-4718-9639-f296c24b806b">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia36129c3c0fb4ec89ee0b9be9bbc5bff_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtNS0xLTEtMA_5efac356-7cea-438e-8171-d37983e34ef5">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i748d5ac449c24510a0986355b63cb280_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtNy0xLTEtMA_cd1d7653-2abf-4e23-8154-5966dc382460">45,794</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib33f0957ce474dd592ca5b6c23e5ef19_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtMS0xLTEtMA_f25521ce-8f50-4d51-a14c-9eeb90a06076">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16a6c38d032f484a9b67307311107bd7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtMy0xLTEtMA_cb7e218b-3c25-4716-ac59-d9b41de6589c">10,038</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8323e729c3744b6984ff8264d437b124_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtNS0xLTEtMA_64c94e64-c77f-44b7-9c13-9b61dad335b0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76f0f26e09b64eacb441ec24cd77394c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtNy0xLTEtMA_35891614-c4d3-425d-adc4-47a262fc0003">10,038</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtMS0xLTEtMA_901d9f98-b6d6-464f-b17d-de2b6b3a2632">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3042590e499441eac62f97939bd16f4_I20190630" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtMy0xLTEtMA_9c91d948-5704-4fd9-8351-04328f165bff">16</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtNS0xLTEtMA_2559d510-fa25-4bb4-adcb-09312d621603">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtNy0xLTEtMA_c81c3a7a-0bba-4240-a800-f167ff808c3a">16</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctMS0xLTEtMA_3578c665-4430-417e-8f58-0410459f56d7">355,077</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3042590e499441eac62f97939bd16f4_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctMy0xLTEtMA_8dbe41d7-bfa2-453e-ad36-406bde9b05ff">152,618</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctNS0xLTEtMA_2bb3e8ee-e5f7-419d-ac55-25bfdf2a8087">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctNy0xLTEtMA_152ee7a8-cbb9-428c-ab97-97f13e1fcb87">507,695</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktMS0xLTEtMA_dc9309bc-0bf7-4495-aeb4-7247b90fbdbf">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3042590e499441eac62f97939bd16f4_I20190630" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktMy0xLTEtMA_0ab1fdd1-2f28-4139-9580-6c129646b31d">155</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktNS0xLTEtMA_e4722ea9-eb3f-4ed4-8784-4dea7a0f8fda">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktNy0xLTEtMA_7bbefe50-76f6-4a55-a236-20fc4940ac4d">155</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtMS0xLTEtMA_46a99f9f-15f3-47be-9150-7b241a7edcbb">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3042590e499441eac62f97939bd16f4_I20190630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtMy0xLTEtMA_23066985-a1d9-43ad-8b9c-8d0c552ee3cc">155</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtNS0xLTEtMA_5ef5c911-045b-42bc-95f3-f7515c875ff1">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtNy0xLTEtMA_465c2db3-580a-4e35-8abc-6e71aa82e669">155</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.153846%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.980769%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if168f11e35b14d38bce3e5890ebba5d9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC0xLTEtMS0w_6638b284-f1db-47e6-8410-1128c98ea9a3">42,225</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad1069dc0cad4a3ea5572938e4106e4c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC0zLTEtMS0w_f0245fa7-a690-41f6-b23f-42ec15a3b692">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8389b77f46614b0baac4260fdedf92b2_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC01LTEtMS0w_59fe913a-bb84-4db3-847c-bf5f5347a025">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75c93d80020f42b0ba67cdc0e3a25b2a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC03LTEtMS0w_03083b38-c66d-443c-bc90-b52e8bcce3fd">42,225</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2aee8333029a4f6c8e7f1247f704004a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS0xLTEtMS0w_9ff0231c-8786-4f61-a664-8cb84d299fe9">1,499</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5c9e6e09b474edc8ac0da0e91d2dd01_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS0zLTEtMS0w_94321488-227d-4190-8f68-fe2dc275cf59">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57c0452366984f519dbceb86cfc31faf_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS01LTEtMS0w_12c1111b-04e7-4b1c-a6e1-95b81ed73737">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie776c9afea3243b2848d752347f688f4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS03LTEtMS0w_912556e2-ec4b-46b1-aad9-d8085dd0263d">1,499</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9c75b127ec34f38865969acc6d34c86_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi0xLTEtMS0w_64c7a9bc-6086-4ba9-89eb-7aeab5568c0f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i220e6c77c75d4bfa83017f0736091135_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi0zLTEtMS0w_1d0770b2-db37-4677-b60d-7016a8a6a2b1">9,979</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79715623139e4d188ee2ddfaff3f8843_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi01LTEtMS0w_60a30b56-5db4-4be8-b85a-5f50370c85e0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d8717aa8b6241c5a643413d64130b63_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi03LTEtMS0w_74f78568-97c5-47ea-9555-1564773f7534">9,979</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i993e3d3eb54f4a728171781129ded3bc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC0xLTEtMS0w_5c414e1f-0d67-40dd-b22e-f00326d5a39d">219,754</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i334c9164544d47ed90f823053546feae_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC0zLTEtMS0w_45f20235-e041-430a-b166-0558cbd8ac7f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58cd710ca1ca48d0bc2fb6d628a11664_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC01LTEtMS0w_d57555b2-2d10-4bb2-be94-1e9aba3a01e5">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic48ac7d1c4324712a1e1298222a87945_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC03LTEtMS0w_f8020ae6-a46f-4db3-aeb4-12dc4909c30e">219,754</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ae0df8b808c43f280dc28bec5cb444d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS0xLTEtMS0w_819fc9c1-232a-4a9c-8ea8-b9029ed5a070">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id73851e2673146dcb0a9e092ab545074_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS0zLTEtMS0w_c7ab6f04-6893-4b4f-9aff-9a606961ac51">73,151</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2699ac9a6b4a4f988e31180fb9faa2e0_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS01LTEtMS0w_49d392b4-fd79-4e6d-be5b-3c0e78569aba">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife73f39b1eae47ee85a5a9584ee232ae_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS03LTEtMS0w_3bc2bc40-bbef-4803-a105-3aa1aee21c90">73,151</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27601e3031d1415087e9519936e0588a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtMS0xLTEtMA_a15508da-3cb6-480e-ba17-b2bbdf946c96">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4803624bc1af45deb9ea98f47e4bef89_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtMy0xLTEtMA_831b04e2-9619-444a-aa64-2eff0543111c">71,675</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46e4decf7be84439945e9ce2850dc451_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtNS0xLTEtMA_ace7c7af-86cb-4b19-b467-bd7fc7b5d107">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1d2b210ee09411c9fa11bbd2deba373_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtNy0xLTEtMA_c09eba34-8ec6-490c-87f1-6685d950958f">71,675</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66b7162b4cdf45099ea769306a7bc7ba_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtMS0xLTEtMA_213ae9ec-acfb-418c-a357-ce984b4e603f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e221499c55d4599a35ccd9f1aba1e74_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtMy0xLTEtMA_99566290-a696-443b-809a-f1b05c5c67de">22,594</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadb76427e3334f2b8e9ec593be008827_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtNS0xLTEtMA_4c304aff-6b5e-4b0c-919a-4e2ab1823565">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a911ac92d6942418c24d25c2c06cc32_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtNy0xLTEtMA_c880149b-35ea-4e8f-8644-c03804251c11">22,594</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74b8017f6aa641f5a8ba1117e78c4395_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtMS0xLTEtMA_73aaa875-2ffa-4ba2-952a-9fe06c502311">117,131</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30bc951a4ed74f0ea630f8070210ce78_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtMy0xLTEtMA_b820bc4e-b68c-44ac-8808-6cf45284b134">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i080696e2011c4cebb6a89ccdbaa3ee8d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtNS0xLTEtMA_aec31140-51c7-46d6-b28f-23c353b2236c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fdf1cc314e547498192214867642863_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtNy0xLTEtMA_92c07288-ec13-4697-a165-713e3a9a7c9e">117,131</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie41ba916828a4459913741d70d7bc3fb_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtMS0xLTEtMA_c3f7336e-c9c4-40b5-ab15-01e6757d159a">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i372598dc17214865814f1254ebfb5161_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtMy0xLTEtMA_01e2a380-5c8e-4636-95a5-cc916cab5d68">1,977</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7640f25a11a54310893f0d59b851a625_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtNS0xLTEtMA_8e16b19e-17fa-4ca9-bf9c-bab34ce84d32">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6ac2039e8dc42bead781da7dcf42fd1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtNy0xLTEtMA_b07c60bf-2eda-479b-9f00-3c5d1fc461a8">1,977</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i497df5ae51894ba7a5a6422af04376bf_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtMS0xLTEtMA_d561aa08-e639-4fe9-9c09-3934bb940d1f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe03351931fd4b02bcbdf4d454a976b2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtMy0xLTEtMA_3bb3aa95-c64f-49dd-ada4-343c3c15a0f2">28,773</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec24689629b54d34951dd76fb613749b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtNS0xLTEtMA_dda71645-3211-417d-b4fa-8f14db98f3fd">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia035bfff287e4ca591f2a341c56b6b2d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtNy0xLTEtMA_ba81ec8d-800b-468a-bf2a-d64942907783">28,773</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49c31645a10044e59139a51722cc253f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtMS0xLTEtMA_ab7b3aac-7d2c-4843-86f5-a19c6a5cc6c0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtMy0xLTEtMA_1a40207c-c749-4399-b6ca-b91a4e7c6b9c">14</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtNS0xLTEtMA_0f2f58a7-2eb3-42c0-a13d-b0d03ef07e0f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtNy0xLTEtMA_495ba125-a099-435d-9958-7c47188ce21b">14</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49c31645a10044e59139a51722cc253f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctMS0xLTEtMA_7130af0a-e40d-444b-bce6-03484eb6ea36">380,609</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctMy0xLTEtMA_bad90b94-ec2a-4a83-ac12-5463c85de5a4">208,163</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctNS0xLTEtMA_cfbe38a8-5c14-44c6-be1f-745c4c64ce45">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctNy0xLTEtMA_16635dbe-8153-4e08-8d81-3446029699a0">588,772</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49c31645a10044e59139a51722cc253f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktMS0xLTEtMA_9599ecbc-c101-45b7-a791-2d1ca1f29a67">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktMy0xLTEtMA_1705b66f-30be-4a6d-82dc-5b7eae6178a2">182</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktNS0xLTEtMA_bc3fea6e-285f-4b74-9ede-116cdd87fb98">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktNy0xLTEtMA_c0e62fc7-636f-4acc-8d76-31e973da5bc5">182</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49c31645a10044e59139a51722cc253f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtMS0xLTEtMA_cf9bde24-acdd-43c0-ac7d-a48995e3c989">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtMy0xLTEtMA_8344757b-99e3-4fb7-bafe-ff9987ec406d">182</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtNS0xLTEtMA_f663514d-a7f3-4d8c-950b-35e7739f9923">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtNy0xLTEtMA_9839a812-8f29-43c5-82b7-011f158d332b">182</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div></ix:continuation><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6cad3c1e37384fb586434c7b1ec73381">There were no transfers of assets or liabilities between the fair value measurement levels during the three and six months ended June 30, 2019 or 2018.</ix:continuation></span></div><div id="i_0_40"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">3.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5NQ_6c6682d2-6fc3-42b5-9652-a9aaf75fd3ce" continuedAt="i67a763e4f24343a8b2b1d1f1c2c5114e" escape="true">Cash and Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i67a763e4f24343a8b2b1d1f1c2c5114e" continuedAt="i7b3c9965d89e47bd8f69557df1b976df"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Cash, cash equivalents and restricted cash</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5Nw_cc66dac2-541f-4c45-9543-72b75030cf24" escape="true"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5Ng_254dd8b8-1125-489b-b7c7-13b57bd1378d" escape="true"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:55.852564%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.461538%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.461538%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.621795%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMS0xLTEtMS0w_55fbdcaa-9444-469a-aefb-9a595d5a4db5">62,936</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMS0zLTEtMS0w_bf7fa7de-70a8-45ff-bb00-b5faee8da6c1">77,123</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMS01LTEtMS0w_8b2d8b90-63a3-4fa2-a7dc-b8207d2e4a02">33,088</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted cash included within other non-current assets</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMi0xLTEtMS0w_7dd882ba-16e4-4974-ac4e-1df098dff063">1,500</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMi0zLTEtMS0w_51003b71-2a1b-4394-bb18-d6f863c6a1b3">1,500</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMi01LTEtMS0w_b1471517-6410-404d-97c4-65e52f3a85ea">1,500</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMy0xLTEtMS0w_30255582-61ba-4b27-a2d0-3c2b7428101a">64,436</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMy0zLTEtMS0w_e8731619-87b4-4092-b7d5-2901136ff016">78,623</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMy01LTEtMS0w_4bb240c3-754d-4b82-aa12-ef4acd8571d7">34,588</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Marketable securities</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">All marketable securities were considered&#160;available-for-sale&#160;at June 30, 2019 and December 31, 2018. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as discussed in Note 2, "Fair Value Measurements". <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMjc0ODc3OTA3NDg5MQ_82784743-0ae3-4fc2-a044-0a3a83767c3a" continuedAt="i43ee91ae8ade4142b998e16a5583f73b" escape="true">The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="i43ee91ae8ade4142b998e16a5583f73b" continuedAt="i365f59be9b524db585ac71de523c1591"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.153846%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.980769%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c65238201f2438099ea08259947cf04_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy0xLTEtMS0w_85db90ef-2bf7-4320-bb7d-00f18f008d7e">272,540</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c65238201f2438099ea08259947cf04_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy0zLTEtMS0w_f9685af6-97e1-4eee-8d9e-5db887073232">568</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6c65238201f2438099ea08259947cf04_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy01LTEtMS0w_54b4219a-379e-42c7-9f0a-bf237199fc0b">5</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c65238201f2438099ea08259947cf04_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy03LTEtMS0w_a80cba2b-3ff6-4770-9d54-334b00c3a0f0">273,103</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC0xLTEtMS0w_7f736c2b-d7d2-402b-80ba-e2e9be7f8c63">28,960</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC0zLTEtMS0w_f13b4653-cfb2-4b15-810e-d59fdc56237e">7</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC01LTEtMS0w_79f6b965-2d37-49bf-9904-98219d97536b">10</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC03LTEtMS0w_7596fc7a-88bd-4515-81ac-ffd5f8cc4e29">28,957</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS0xLTEtMS0w_4b50f338-3337-4017-a094-644e5b919bbe">78,842</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS0zLTEtMS0w_aaa8e2da-cd8a-46d6-809e-4a414daf0fe7">122</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS01LTEtMS0w_36b65eb6-7565-47f2-b46b-9d2296adc951">14</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS03LTEtMS0w_805dc90c-750d-447d-80b9-74c18c6184b6">78,950</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Commercial paper</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi0xLTEtMS0w_00848fe8-9ff8-49f6-b6ea-87de151b1fd0">34,657</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi0zLTEtMS0w_2dc87873-428c-4f56-ad3c-656fcb760ecc">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi01LTEtMS0w_b7fd316d-ec51-41a8-996d-006274b68fa6">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi03LTEtMS0w_6051a8d8-4b5c-479e-a45d-7c82f320a219">34,657</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total short-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy0xLTEtMS0w_221d3e04-c0e5-4a94-8263-34e654be211b">414,999</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy0zLTEtMS0w_41dab404-63b4-480f-854a-7254ed8ca62a">697</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy01LTEtMS0w_29a0b9bb-30ee-47c7-87ab-5bf6ead4fafe">29</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy03LTEtMS0w_f98f1fab-b155-4bd7-ba5a-a4afbde5bb90">415,667</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS0xLTEtMS0w_bfdb8322-65e8-497e-b4a5-4e563d9d7a66">45,339</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS0zLTEtMS0w_b814ec1a-4c9d-40bc-86a8-b3ba0c815d9b">455</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS01LTEtMS0w_0349810d-a79b-4d6c-9bf9-21d8025c7bde">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS03LTEtMS0w_83dca02a-cca6-45d1-a2c8-629efc55565b">45,794</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtMS0xLTEtMA_c50beee0-5018-4f0c-914b-1527422a2673">9,968</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtMy0xLTEtMA_9b2ec697-841b-402a-83e9-3fbcc9b63673">70</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtNS0xLTEtMA_77a665b3-2c2d-4d38-a552-310f7f05a2cc">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtNy0xLTEtMA_472bf4fd-1457-40b6-8cae-bbdbe815978c">10,038</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total long-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtMS0xLTEtMA_a10cee99-6c60-4fd1-9e46-444bae133d4d">55,307</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtMy0xLTEtMA_898ac515-278a-413c-91d0-67c75ed6b586">525</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtNS0xLTEtMA_6835c06c-3052-4e74-ad55-019c4f10af29">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtNy0xLTEtMA_abfaf3f2-69fa-42a0-ab00-b2ed6c2b1fb3">55,832</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItMS0xLTEtMA_67e6a76e-84ea-4e54-a74d-f17c32171f84">470,306</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItMy0xLTEtMA_513e659b-932f-4890-ac29-a797ff485eee">1,222</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItNS0xLTEtMA_31306ff7-f73b-4008-a8d0-87b156c690f4">29</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItNy0xLTEtMA_3fc46cbe-e0c3-44f7-acf0-30c8d1441705">471,499</ix:nonFraction>&#160;</span></td></tr></table></ix:continuation></div></ix:continuation><div style="text-indent:27pt;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i7b3c9965d89e47bd8f69557df1b976df"><div style="margin-top:10pt;"><ix:continuation id="i365f59be9b524db585ac71de523c1591"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.314103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy0xLTEtMS0w_113dabca-8692-4623-a161-efbe70c34f18">220,081</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy0zLTEtMS0w_e8c33ac9-869d-497c-b68a-1c5c0af0f3ec">29</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy01LTEtMS0w_acf91c91-dac6-4c46-9989-600efc752890">356</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy03LTEtMS0w_372287c8-962a-4b17-b0b6-4cbd69dbefad">219,754</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC0xLTEtMS0w_a9c55985-41d4-48f8-bac8-ce115991d7ff">73,373</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC0zLTEtMS0w_53acf7db-ac14-417a-aa68-af2bfb208c9c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC01LTEtMS0w_001b249e-6e8d-4278-875a-eec77698bfa8">222</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC03LTEtMS0w_9552ff0f-0587-4882-87a2-ee57be150297">73,151</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS0xLTEtMS0w_6e39d1ad-45d2-4b4f-8f52-3d8bf2333e69">71,940</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS0zLTEtMS0w_ec3ef4e1-a5bf-44c4-a860-d240fca37d86">1</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS01LTEtMS0w_35546ae6-37f8-48cc-bcad-3ba6328e23e9">266</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS03LTEtMS0w_a30a66ad-fc53-45b7-848b-8ef1a264e715">71,675</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Commercial paper</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi0xLTEtMS0w_710f046c-364b-464b-8457-7f0a65c4ade7">22,594</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi0zLTEtMS0w_ab467d0d-adaa-47a2-bc2e-2341c1e50895">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi01LTEtMS0w_d07ddf8b-1ff2-4cf3-aa10-73b5d43e32f0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi03LTEtMS0w_46d97af2-2fd1-47d7-9776-65d74603c016">22,594</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total short-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy0xLTEtMS0w_a4249bc9-9113-4e17-9082-c497d62d95de">387,988</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy0zLTEtMS0w_8fb593a0-8d99-4bbf-81ed-54f089435d24">30</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy01LTEtMS0w_8b361888-a340-437e-94d2-132cc4ac75ed">844</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy03LTEtMS0w_ec0d4851-d63e-409e-8604-5ab1eb6752b3">387,174</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS0xLTEtMS0w_6a77baff-da5d-47a6-97d9-11b44d7ccc4f">116,878</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS0zLTEtMS0w_141be4b2-3111-457e-becb-112825e14358">329</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS01LTEtMS0w_fb3b94a4-cb79-4a9c-a976-f4c243908744">76</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS03LTEtMS0w_f389601a-0915-492e-bcf6-94b0d9c79282">117,131</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtMS0xLTEtMA_8fc9d451-a49a-456b-9077-7852afabc217">1,975</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtMy0xLTEtMA_b902396c-fd97-4ee7-beb2-8636ccbc6a65">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtNS0xLTEtMA_2713e8bd-01ee-4085-b3d7-18ce79ceaa75">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtNy0xLTEtMA_25b24000-2936-418f-b1f9-8426639553fa">1,977</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtMS0xLTEtMA_8592e77e-4f27-48ba-95cf-287f77b8b772">28,864</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtMy0xLTEtMA_2830f588-d6d9-4c78-9a6d-4577a1eaba0a">8</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtNS0xLTEtMA_e71665bb-bcd2-4b50-9cb2-e4b1f83fd0ed">99</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtNy0xLTEtMA_b571e5ee-41ca-4ac3-a056-e14bcce631c5">28,773</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total long-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItMS0xLTEtMA_77aa674a-332d-43bc-a14c-79376a7633f3">147,717</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItMy0xLTEtMA_47e39a8a-2ae2-4304-aeec-5bf2f2b65828">339</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItNS0xLTEtMA_b6acd21f-1a4a-4188-968e-eb6c2afdceef">175</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItNy0xLTEtMA_99f1085d-9c1f-483e-98c2-3c44883acd10">147,881</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtMS0xLTEtMA_de7d4fed-96dc-4f7c-b00a-3ef5a0831f77">535,705</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtMy0xLTEtMA_1e392147-e5ac-48a6-ac6b-eb66f8dda299">369</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtNS0xLTEtMA_f66855d5-a4c8-4738-ae91-b50da47392c4">1,019</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtNy0xLTEtMA_503963c2-9150-4a31-a6fb-386e1052fa51">535,055</ix:nonFraction>&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, some of the Company&#8217;s marketable securities were in an unrealized loss position. At each balance sheet date, the Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been <ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_6cb0046b-5e16-4325-89f3-4c0760131782"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_a77e2d74-abbd-47da-a8a0-8f3d65a29511"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_cd53ba3e-83d1-430a-9fe3-4ab2a6f07573"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_e5f6ee0c-9023-4a51-afd0-6132dc853ce7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> recognition of any other-than-temporary impairment in the three and six months ended June 30, 2019 and 2018. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than twelve months or the loss is not material.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company recorded unrealized gains on marketable securities in other comprehensive income during the three and six months ended June 30, 2019. There were <ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_6cb0046b-5e16-4325-89f3-4c0760131782"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_a77e2d74-abbd-47da-a8a0-8f3d65a29511"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_cd53ba3e-83d1-430a-9fe3-4ab2a6f07573"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_e5f6ee0c-9023-4a51-afd0-6132dc853ce7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> unrealized gains in other comprehensive income during the three and six months ended June 30, 2018. As a result, the Company recorded a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MDk5Nw_9b73fb63-8bb9-4900-bc7d-19e0920f1352"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MDk5Nw_c3057153-9fe7-428f-bab1-a00f15d2aebd">0.3</ix:nonFraction></ix:nonFraction> million for the three and six months ended June 30, 2019 on the condensed consolidated statements of operations and a corresponding tax charge in other comprehensive income of $<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTA5OTUxMTYzMzI1OQ_487a0c86-cf37-404d-acd3-9ccf39e017bc"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTA5OTUxMTYzMzI1OQ_fcba34b5-6bae-4fb2-ae0f-c9fb9979a6ff">0.3</ix:nonFraction></ix:nonFraction> million. There was <ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTY0OTI2NzQ0NjIxNw_79a160e5-9dba-46bb-970e-c572cdeeb42b">no</ix:nonFraction> tax benefit recorded for the three and six months ended June 30, 2018 on the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">All of the Company&#8217;s marketable securities have an effective maturity of less than <ix:nonNumeric contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5Mw_8929dda8-b836-4a11-a7a1-708881106903">two years</ix:nonNumeric>.</span></div></ix:continuation><div id="i_0_43"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">4.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTg2Nw_fd9b7a07-77fe-410c-8e49-bd4cdc7b5cb5" continuedAt="i5ba6b39e0b9d456aa4541d053b46121f" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i5ba6b39e0b9d456aa4541d053b46121f" continuedAt="id4642e496e174116806f9512ee89bbe2"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Exchange Rate Exposure</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted cash flows being denominated in currencies other than the U.S. dollar, primarily the Euro, British Pound, and Swiss Franc. The derivative instruments the Company uses to hedge this exposure are not designated as cash flow hedges, and as a result, changes in their fair value are recorded in Interest and other income, net, on the Company's condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates and take into consideration the current creditworthiness of the counterparties. Information regarding the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations is provided below. The Company did <ix:nonFraction unitRef="derivative_instrument" contextRef="ia14c2927959544239a3d263ec3dda43e_I20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA2Mg_ef2f572c-fc25-4f63-af35-353765884a5f">no</ix:nonFraction>t have foreign currency exchange contracts prior to June 2018.</span></div></ix:continuation><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="id4642e496e174116806f9512ee89bbe2"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTg2OA_03fc62b6-e012-4ce5-b678-db56a2f1dd31" continuedAt="icf97fe80a5d2447f916b13e570d8eb7a" escape="true"><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s forward foreign currency exchange contracts outstanding as of June 30, 2019 (notional amounts in thousands):</span></div><div style="margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"></td><td style="width:31.868379%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.385233%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.916533%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.422151%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Aggregate Notional</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Amount in Foreign Currency</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Euros </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="derivative_instrument" contextRef="i48082d8a3fa74a8c95c2264e9a347d42_I20190630" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMS0yLTEtMS0w_a9d30404-3eb5-4a83-94f9-a3f416c4b6c1">19</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="eur" contextRef="i48082d8a3fa74a8c95c2264e9a347d42_I20190630" decimals="-3" format="ixt:numdotdecimal" name="invest:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMS00LTEtMS0w_ecc41a39-7db9-490e-b7b1-94fd329433bf">2,776</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - May 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">British Pounds </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="derivative_instrument" contextRef="i234d3a677c614b128ac23ca5c79da8dc_I20190630" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMi0yLTEtMS0w_8cfce1b8-c434-4600-af81-1148bdb261f9">21</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="gbp" contextRef="i234d3a677c614b128ac23ca5c79da8dc_I20190630" decimals="-3" format="ixt:numdotdecimal" name="invest:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMi00LTEtMS0w_67f875f3-386b-4879-8e36-a15e75f17d6b">3,181</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - May 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Swiss Francs </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="derivative_instrument" contextRef="id1232cc1f5524033b330344d942beb81_I20190630" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMy0yLTEtMS0w_c3bba764-d384-4042-b771-3947349218ef">18</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="chf" contextRef="id1232cc1f5524033b330344d942beb81_I20190630" decimals="-3" name="invest:DerivativeNotionalAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMy00LTEtMS0w_2f4465b9-729b-4b35-8e34-66dd10540249">703</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - Feb 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="derivative_instrument" contextRef="i8674d4a62e2a492fa95fdbeefacd0bad_I20190630" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfNC0yLTEtMS0w_fa623cdf-4773-483a-b57d-da5f5b88e960">58</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">_________________________________________________</span></div></ix:nonNumeric><div style="text-indent:-36pt;padding-left:36pt;margin-top:4pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"><ix:continuation id="icf97fe80a5d2447f916b13e570d8eb7a" continuedAt="i70dc10dcd5a44bc79f1c2d9ba2c82574">(1) &#160;</ix:continuation></sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;"><ix:continuation id="i70dc10dcd5a44bc79f1c2d9ba2c82574">The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts</ix:continuation>.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The derivative liability balance of $<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTkzNg_0df75e44-8631-4159-b29f-0325ce722992"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTkzNg_936bc926-3f3f-4fd3-8803-45f9cd1349d2">0.2</ix:nonFraction></ix:nonFraction> million is recorded in Other current liabilities on the condensed consolidated balance sheet as of both June 30, 2019 and December 31, 2018. The derivative asset balance of $<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTU3Mw_b8691318-1f84-4637-94b2-5dcf078275b3">15,682</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTk2MQ_887c3c42-3d0b-4f04-8bef-72b4b119671e">13,669</ix:nonFraction> is recorded in Prepaid assets and other current assets on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. The net loss associated with the Company's derivative instruments of $<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTY2Mw_55eaedaf-a949-44b2-811e-a03558fdd400">7,320</ix:nonFraction> and gain of $<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTc1NA_4b0522f2-eb6f-4cdf-8432-b02f08a74e7d">11,967</ix:nonFraction> is recognized in Interest and other income, net on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2019, respectively, and a net loss of $<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTY3Nw_6563f497-489c-4048-94c5-bc7047a2cb40"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTY3Nw_6b8754e1-ea3a-40fc-bc3f-c3641b56ca4d">31,952</ix:nonFraction></ix:nonFraction> was recognized in Interest and other income, net on the condensed consolidated statement of operations and comprehensive loss for both the three and six months ended June 30, 2018.</span></div></ix:continuation><div id="i_0_46"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">5.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dnli:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfNDIzNg_820a83ed-1eef-4133-b6b7-c5c54dc65645" continuedAt="i551a1e90a4104eb487f51100a3b5290a" escape="true">Acquisition</ix:nonNumeric></span></div><ix:continuation id="i551a1e90a4104eb487f51100a3b5290a" continuedAt="i622b7a664a834a688568cac8a8f2e092"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August 2016, the Company entered into a License and Collaboration Agreement (&#8220;F-star Collaboration Agreement&#8221;) with&#160;F-star&#160;Gamma Limited (&#8220;F-star Gamma&#8221;),&#160;F-star&#160;Biotechnologische Forschungs-Und Entwicklungsges M.B.H ("F-star GmbH") and&#160;F-star&#160;Biotechnology Limited ("F-star Ltd") (collectively,&#160;&#8220;F-star&#8221;) to leverage&#160;F-star&#8217;s&#160;modular antibody technology and the Company&#8217;s expertise in the development of therapies for neurodegenerative diseases. Under the F-star Collaboration Agreement, the Company has made payments to F-star totaling $<ix:nonFraction unitRef="usd" contextRef="ib9f18818b52f4aeabfbf7dbbb4aba705_D20160801-20180531" decimals="-5" format="ixt:numdotdecimal" name="dnli:CollaborativeArrangementPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfODI0NjMzNzIyMDQ1NA_ded3bbb8-feee-4400-b1e1-41a98fa46083">11.5</ix:nonFraction>&#160;million. In connection with the entry into the F-star Collaboration Agreement, the Company also purchased an option for an upfront option fee of $<ix:nonFraction unitRef="usd" contextRef="i55d1fcfacd0d4b0db994f652d3301667_D20160801-20160831" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontOptionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfNTk5_c3530b3b-64db-40b3-9261-48b09696f3cf">0.5</ix:nonFraction> million (the&#160;&#8220;buy-out-option&#8221;),&#160;to acquire all of the outstanding shares of&#160;F-star&#160;Gamma pursuant to a&#160;pre-negotiated&#160;buy-out&#160;option agreement (the &#8220;Option Agreement&#8221;).</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company exercised the Option Agreement and entered into a Share Purchase Agreement (the &#8220;Purchase&#160;Agreement&#8221;) with the shareholders of&#160;F-star&#160;Gamma and Shareholder Representative Services LLC, pursuant to which the Company acquired all of the outstanding shares of&#160;F-star&#160;Gamma (the &#8220;Acquisition&#8221;).</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As a result of the Acquisition,&#160;F-star&#160;Gamma became a wholly-owned subsidiary of the Company and the Company changed the entity&#8217;s name to Denali BBB Holding Limited. In addition, the Company became a direct licensee of certain intellectual property of&#160;F-star&#160;Ltd by way of the Company&#8217;s assumption of&#160;F-star&#160;Gamma&#8217;s license agreement with&#160;F-star&#160;Ltd, dated August&#160;24, 2016, (the&#160;&#8220;F-star&#160;Gamma License&#8221;). The Company made initial exercise payments under the&#160;Purchase Agreement and the&#160;F-star&#160;Gamma License, in the aggregate, of $<ix:nonFraction unitRef="usd" contextRef="i647555a3917440f38eef6a6989f68269_D20160824-20160824" decimals="-5" format="ixt:numdotdecimal" name="dnli:InitialOptionExercisePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzg0ODI5MDcwMjQ1NA_5a1bf3c6-1e88-40e1-b098-bf725d8e026b">17.8</ix:nonFraction> million. In addition, the Company is required to make future contingent payments, to F-star Ltd and the former shareholders of F-star Gamma, up to a maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i2148ac99ab3d4a618499bc77ee8d8c62_D20180530-20180530" decimals="-5" format="ixt:numdotdecimal" name="dnli:ContingentPaymentsUponAchievementOfMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTg0Mw_a1e1416b-2c03-46d8-adea-cbe5fe016750">447.0</ix:nonFraction> million in the aggregate upon the achievement of certain defined preclinical, clinical, regulatory and commercial milestones. The amount of the contingent payments will vary based on whether&#160;F-star&#160;delivers an Fcab&#160;(constant&#160;Fc-domains&#160;with antigen-binding activity) that meets&#160;pre-defined&#160;criteria and whether the Fcab has been identified solely by the Company or solely by&#160;F-star&#160;or jointly by the Company and&#160;F-star. In June 2019, the Company made a payment of $<ix:nonFraction unitRef="usd" contextRef="i958b3c7abe6a45a592e44305c54c7fb4_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:ContingentConsiderationPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTY0OTI2NzQ1NDkwNQ_085fc884-a623-4920-b32b-c5c9a937c959">1.5</ix:nonFraction> million to F-star Ltd upon the achievement of a specified preclinical milestone in the Company's ETV:IDS program.</span></div></ix:continuation><div style="text-indent:27pt;margin-bottom:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i622b7a664a834a688568cac8a8f2e092" continuedAt="i736eb6988f7042c089cfe8cfdcb5bb90">The Company concluded that the assets acquired and liabilities assumed upon the exercise of the Option Agreement did not meet the accounting definition of a business, and as such, the acquisition was accounted for as an asset purchase. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i51ca5f46b88d4457b2266e87e2008a2a_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:AssetAcquisitionContingentConsiderationAmountRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfODI0NjMzNzIyMDQzNg_c30088e8-4cce-4dac-9c5b-3ed0b8a83fd8"><ix:nonFraction unitRef="usd" contextRef="ib98115cad708471ebe459199e2f80f46_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:AssetAcquisitionContingentConsiderationAmountRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfODI0NjMzNzIyMDQzNg_fdb36b95-3b11-4f3d-80ad-b2ed6daa4ce0">1.5</ix:nonFraction></ix:nonFraction> million of contingent consideration as research and development expense during the three and six months ended June 30, 2019 and $<ix:nonFraction unitRef="usd" contextRef="i6f5e0ab57a754c6a92c0fdd5ab774b2d_D20180101-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzM2Nw_20144f92-503b-44d9-a648-d3bda18339fe"><ix:nonFraction unitRef="usd" contextRef="i02c7d3db28004ce59eb812568e573405_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzM2Nw_246e4455-701c-421d-86ca-deffae94a9d1">18.3</ix:nonFraction></ix:nonFraction>&#160;million of upfront consideration as research and development expense in the three and six months ended June 30, 2018. As the transaction was accounted for as an asset purchase rather than a business combination, the Company did <ix:nonFraction unitRef="usd" contextRef="i975bd76e0cd24e4c801c23d18da1297b_D20180531-20180531" decimals="-5" format="ixt-sec:numwordsen" name="dnli:AssetAcquisitionContingentConsiderationAmountRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzU2MA_12b6b431-6e28-4011-a6fc-cd071fda48eb">no</ix:nonFraction>t recognize any contingent consideration on the acquisition date. Further future contingent consideration is expected to be recognized in research and development expense as incurred.</ix:continuation></span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i736eb6988f7042c089cfe8cfdcb5bb90">Under the F-star Collaboration Agreement, the Company is responsible for certain research costs incurred by F-star Ltd in conducting activities under an agreed development plan for each Fcab, for up to <ix:nonNumeric contextRef="ib519012f763b4591aa20a39b32e7dd07_D20160824-20160824" format="ixt-sec:durmonth" name="dnli:MaximumDevelopmentPlanPeriodForResearchCosts" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzkxNQ_4ce3ba4f-86ec-4fdc-9db7-f6106091b3ad">24</ix:nonNumeric> months after the target Fcab is accepted. The Company's responsibility for research costs under the first development plan related to an Fcab that targets the transferrin receptor was completed during the year ended December 31, 2018. The responsibility for costs under the second development plan related to an undisclosed Fcab target commenced in February 2019. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i51ca5f46b88d4457b2266e87e2008a2a_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfNDA3NA_2bea5fa9-ca95-4ef3-bab6-7cc3e9759329">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib98115cad708471ebe459199e2f80f46_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTA5OTUxMTYzMjM1Mw_95e91d73-80e9-43fc-9b06-38e8471e28ce">0.5</ix:nonFraction>&#160;million in research and development expense related to the funding of&#160;F-star&#160;Ltd activities under these development plans during the three and six months ended June 30, 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i02c7d3db28004ce59eb812568e573405_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTA5OTUxMTYzMjM4Mg_17955c7d-ec2d-45f3-8dfb-a50f3c7e2cf7">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6f5e0ab57a754c6a92c0fdd5ab774b2d_D20180101-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTA5OTUxMTYzMjQyOQ_1a5e6788-e1c8-49f8-9732-4070b2239299">0.5</ix:nonFraction> million for the three and six months ended June 30, 2018, respectively.</ix:continuation> </span></div><div id="i_0_49"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">6.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE2MDE_6cb709a9-1933-4233-ab92-a44baec8a0eb" continuedAt="i930a282f1a994561b88906060e115c12" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i930a282f1a994561b88906060e115c12" continuedAt="id83adb290f1d4e9b85f80006c1b29b9f"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi") pursuant to which certain small molecule RIPK1 inhibitors contributed by Sanofi and by Denali will be developed and commercialized. The Sanofi Collaboration Agreement became effective in November 2018, at which time Sanofi paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNTMx_c648fa77-7948-4a09-82ca-9c27f1825d64">125.0</ix:nonFraction> million. Under the Sanofi Collaboration Agreement, Denali is eligible to receive milestone payments from Sanofi up to approximately $<ix:nonFraction unitRef="usd" contextRef="i5c733524c4364bb1abc239f59033a6be_I20181120" decimals="-8" format="ixt:numdotdecimal" name="dnli:AggregateClinicalRegulatoryAndSalesMilestonePayment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNjU4_5e89ab33-6f54-418e-b332-90dceff470a1">1.1</ix:nonFraction> billion upon achievement of certain clinical, regulatory and sales milestone events. Such milestone payments include $<ix:nonFraction unitRef="usd" contextRef="i9cac8973f2034a84af0e4eb2891e8341_I20181120" decimals="-5" format="ixt:numdotdecimal" name="dnli:ClinicalAndRegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzcw_e8321d3f-e472-4089-8275-888cb13cda42">600.0</ix:nonFraction> million in clinical and regulatory milestone payments for CNS Products and $<ix:nonFraction unitRef="usd" contextRef="iaec92903cf114ddf965cde15c398dded_I20181120" decimals="-5" format="ixt:numdotdecimal" name="dnli:ClinicalRegulatoryAndCommercialMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODQw_40000986-4494-41ee-bc47-0c635db2acac">495.0</ix:nonFraction> million in clinical, regulatory and commercial milestone payments for Peripheral Products, as defined in the Sanofi Collaboration Agreement. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali will share profits and losses equally with Sanofi for CNS Products sold in the United States and China, and receive variable royalties on net sales for CNS Products sold outside of the United States and China and for Peripheral Products sold worldwide.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali and Sanofi will jointly develop CNS Products pursuant to a global development plan. The Company will be responsible, at its own cost, for conducting Phase 1 and Phase 2 trials for CNS Products in Alzheimer&#8217;s disease and any activities required to support such clinical trials and specific for Alzheimer&#8217;s disease. Denali is conducting, at Sanofi&#8217;s cost, a Phase 1b trial for the lead CNS penetrant RIPK1 inhibitor, DNL747, in ALS. Sanofi is responsible, at its cost, for all other Phase 1 and Phase 2 trials for CNS Products, including for multiple sclerosis. Sanofi will lead the conduct of all Phase 3 and later stage development trials for CNS Products, with Sanofi and Denali funding <ix:nonFraction unitRef="number" contextRef="i507009778f314351bad25199f392e188_I20181029" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE2MQ_2341193e-37d2-496b-8ec3-9826f81909c4">70</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i06e6fd6fd17d48a7a5c80813484b128b_I20181029" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE2OA_c37c691d-1a64-475f-a806-6025d070bb45">30</ix:nonFraction>% of such costs, respectively. Sanofi will also lead the commercialization activities globally for CNS Products, subject to certain options that Denali has to conduct co-commercialization activities with respect to each CNS Product in the United States and China. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Sanofi will be responsible, at its cost, for conducting activities relating to the development and commercialization of all Peripheral Products. Denali will be entitled to receive tiered royalties in the low- to mid- teen percentages on net sales of Peripheral Products.</span></div></ix:continuation><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="id83adb290f1d4e9b85f80006c1b29b9f" continuedAt="ibd93d4f133004b1f93af18d0b129e767"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company identified the following distinct performance obligations associated with the Sanofi Collaboration Agreement upon inception: the CNS program license, the Peripheral program license, the Phase 1 and Phase 2 trials for CNS Products for Alzheimer&#8217;s disease ("Alzheimer's Disease Services"), and the Phase 1b trial for DNL747 for ALS and associated activities ("Retained Activities"). </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company believes that the Sanofi Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements. The Company also believes that Sanofi meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for three of the performance obligations identified at inception, but does not meet the definition of a customer for the Alzheimer's Disease Services. Further, Sanofi does not meet the definition of a customer for all Phase 3 and later stage development trials for CNS Products led by Sanofi for which Denali will fund <ix:nonFraction unitRef="number" contextRef="i06e6fd6fd17d48a7a5c80813484b128b_I20181029" decimals="INF" name="dnli:CollaborativeAgreementFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNTI5Nw_c37c691d-1a64-475f-a806-6025d070bb45">30</ix:nonFraction>% of total costs. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the Alzheimer's Disease Services, the guidance in ASC 606 should be analogized for the recognition, measurement and reporting of this performance obligation, and for the cost sharing provisions, the Company determined that the guidance in ASC 730, Research and Development should be applied. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The transaction price at inception included upfront fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNTg5Mw_c648fa77-7948-4a09-82ca-9c27f1825d64">125.0</ix:nonFraction> million. All potential future milestones and other payments were considered constrained at the inception of the Sanofi Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. The transaction price increased by $<ix:nonFraction unitRef="usd" contextRef="i3cb8f5ce74fd4b1b890b44970091705b_D20181001-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:CollaborationAgreementTransactionPriceIncrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNjE4Nw_2bbbc986-e217-40a1-80c7-ebe5421f9d1e">9.1</ix:nonFraction> million from inception through June 30, 2019 as amounts due for costs incurred related to the Retained Activities were no longer constrained. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The respective standalone value for each of the performance obligations has been determined by applying the SSP method and the transaction price allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery or the provision of services.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company used an adjusted market assessment approach to estimate the selling price for the program licenses, and an expected cost plus margin approach for estimating the Alzheimer&#8217;s Disease Services and the Retained Activities. The program licenses and existing know-how were delivered on the effective date of the Sanofi Collaboration Agreement. The Alzheimer&#8217;s Disease Services and the Retained Activities are expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, revenue will be recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Sanofi. For the Retained Activities, revenue will be recognized over time using the output method, based on amounts invoiced to Sanofi, since this is believed to directly correlate to the value of the services performed.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A contract liability of $<ix:nonFraction unitRef="usd" contextRef="i2052c42ed02b4803ac262cf9409d6d92_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzU3NA_b79c32ba-2758-4543-9490-74e16c032a45">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if02f20c18d7e4a85a122b3bb744dc9bb_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzU4MQ_89cc6c33-8c99-4415-9d75-2a3b388643ba">3.9</ix:nonFraction>&#160;million was recorded on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. These contract liabilities relate to the portion of the Alzheimer's Disease Services performance obligation yet to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. There was a receivable of $<ix:nonFraction unitRef="usd" contextRef="i8c76dce5aed14afdbce822ee27041a9f_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzkyMw_ac2f949a-8c8b-47ee-b466-03b71969665e">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba03e85f7755476dbbc016d142e2579a_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzkzMA_e59fc8af-449a-446a-b419-a85dfd7851b4">2.3</ix:nonFraction> million at June 30, 2019 and December 31, 2018, respectively, associated with the Sanofi Collaboration Agreement. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In assessing the Sanofi Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Managem</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">ent applies judgment in determining the separate performance obligations, in estimating the selling price, in determining when control was transferred to Sanofi for the licenses, and in estimating total future costs when using the input method.  </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Through June 30, 2019, Denali has <ix:nonFraction unitRef="usd" contextRef="i3cb8f5ce74fd4b1b890b44970091705b_D20181001-20190630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODQzNw_b376c583-eb21-465b-8305-28e43a9c52a5">no</ix:nonFraction>t recognized any milestones and has <ix:nonFraction unitRef="usd" contextRef="i41156f6db385494f9b24bd04dcc38e24_D20181001-20190630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODQ3Mw_1e19a44c-2028-44a5-b898-4b1e15cf3fde">no</ix:nonFraction>t recorded any product sales recorded under the Sanofi Collaboration Agreement. In July 2019, Sanofi received regulatory approval for the commencement of a DNL758 Phase 1 clinical trial in healthy volunteers. The trial commenced and triggered a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ieb617794c10c4d4ba7d9d482b9cd58bc_D20190801-20190831" decimals="-3" format="ixt:numdotdecimal" name="dnli:ClinicalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODI0NjMzNzI1NzA2MA_98724453-bf0b-4763-bb9e-9cdc37f3121e">10.0</ix:nonFraction> million, which the Company expects to receive in August 2019.</span></div></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="ibd93d4f133004b1f93af18d0b129e767" continuedAt="ia1e88e14c2664d7a860d26dbf5f7604d"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Takeda </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company granted Takeda an option to develop and commercialize, jointly with the Company, certain biologic products that are enabled by Denali's blood-brain barrier ("BBB") delivery technology and intended for the treatment of neurodegenerative disorders. The programs were Denali&#8217;s ATV:BACE1/Tau and ATV:TREM2 programs, as well as a third identified discovery stage program.&#160;The Takeda Collaboration Agreement became effective in February 2018, at which time Takeda paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzE0NjgyNTYyOTIwMw_03267a27-182b-4a47-bf83-a7e5570b67a9">40.0</ix:nonFraction> million. Takeda may pay up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic542e2b47d374ba59c6ab567374c8c94_D20180103-20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzE0NjgyNTYyOTIxOQ_e3518499-ef16-43a9-84fb-420feb86903f">25.0</ix:nonFraction> million with respect to each of the <ix:nonFraction unitRef="program" contextRef="ia22967129e234978a541856d93c716a7_I20180228" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5OTUxMTY3NzQzNA_82cd259e-c3c1-46f0-b3b3-a9e9d2e9c7b7">three</ix:nonFraction> programs directed to a target and based upon the achievement of certain preclinical milestone events, up to $<ix:nonFraction unitRef="usd" contextRef="ic542e2b47d374ba59c6ab567374c8c94_D20180103-20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregatePreclinicalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzE0NjgyNTYyOTI0NA_6d11f1be-b810-49f0-b956-06dd795592d3">75.0</ix:nonFraction> million in total, $<ix:nonFraction unitRef="usd" contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODI0NjMzNzI1NzAzOQ_f74b12ed-669a-4a0d-b0e9-1d3d18b4663f">5.0</ix:nonFraction> million of which was paid upon the Takeda Collaboration Agreement becoming effective. In February 2019, the agreement was amended to replace ATV:BACE1/Tau with ATV:Tau. The amendment did not have a material impact to the condensed consolidated financial statements.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the Takeda Collaboration Agreement and unless otherwise agreed jointly between both parties, Denali will be responsible, at its cost, for conducting activities relating to&#160;pre-IND&#160;development of biologic products directed to the <ix:nonFraction unitRef="targets" contextRef="ia53bec4ac3404ce2b6767a4da564148f_I20190630" decimals="INF" format="ixt-sec:numwordsen" name="dnli:NumberOfTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY0OTI2NzQ5MTUzNg_2339a6ed-29e6-4457-9266-a5bec7c0bdd0">three</ix:nonFraction> identified targets and enabled by its BBB delivery technology targeting TfR during the applicable research period. The period through which the option can be exercised continues for each target until the first biologic product directed to the relevant target is&#160;IND-ready&#160;or approximately <ix:nonNumeric contextRef="i3f1aebd881a6473d8f034dc7cd3ba883_D20180103-20180103" format="ixt-sec:durwordsen" name="dnli:TargetOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfOTk2Mw_a4ab649a-ff67-49d6-91a3-42e8b1fea5db">five years</ix:nonNumeric> after selection of the target, whichever is earlier.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If Takeda exercises its option with respect to a particular target, then Takeda will have the right to develop and commercialize, jointly with the Company, a specified number of biologic products enabled by its BBB delivery technology that were developed during the research period and which are directed to the relevant target. The Company will grant to Takeda a&#160;co-exclusive&#160;license under the intellectual property the Company controls related to those biologic products.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Takeda is obligated to pay Denali a $<ix:nonFraction unitRef="usd" contextRef="ibc5ea44d386548708e70442d3abb3e3c_I20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:OptionFeesPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5MjE_449e6191-3452-49d8-ac97-ce3647454216">5.0</ix:nonFraction> million option fee for each target for which Takeda exercises its option, up to $<ix:nonFraction unitRef="usd" contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregateOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5OTY_f600644f-cbf9-442a-bc1a-f9bd6779904f">15.0</ix:nonFraction> million in total.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, Takeda may be obligated to pay Denali up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregateDevelopmentMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTEwODM_2cc5af8a-b835-4f06-8975-5cc3f346cdcb">707.5</ix:nonFraction> million upon achievement of certain clinical and regulatory milestone events if Takeda exercises its option for all three collaboration programs. Takeda may also be obligated to pay Denali up to $<ix:nonFraction unitRef="usd" contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:CommercialMilestonesPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTEyNzM_e0c7b16c-e148-4fdf-a5fe-936b3d640499">75.0</ix:nonFraction> million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103" decimals="-5" format="ixt:numdotdecimal" name="dnli:AggregateCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTEzNjk_14d30069-e998-4491-8646-55273821aab7">225.0</ix:nonFraction> million if one biologic product from each program achieves this milestone.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If Takeda exercises its option for a particular target, Denali and Takeda will share equally the development and commercialization costs, and, if applicable, the profits, for each collaboration program.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Takeda Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with Takeda on January&#160;3, 2018, pursuant to which Takeda purchased <ix:nonFraction unitRef="shares" contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTYyNTQ_cca28b4f-54e6-40c4-b2ee-a4fbe082a924">4,214,559</ix:nonFraction> shares of Denali&#8217;s common stock (the "Shares") for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTYzMzk_58157af3-93ec-4320-a19f-9a32e382ccb7">110.0</ix:nonFraction> million. The sale of the Shares closed on February&#160;23, 2018. The fair market value of the common stock sold to Takeda was $<ix:nonFraction unitRef="usd" contextRef="ifadb9641e1d64862836bde0c518e5c56_I20180223" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY0NDE_0c5e3a19-9d23-46ec-b22c-7c6845127148">94.4</ix:nonFraction> million, based on the closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifadb9641e1d64862836bde0c518e5c56_I20180223" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY0ODE_f818e3ff-07a8-4938-8ade-0bfd4a692e8e">22.40</ix:nonFraction> on the date of issuance, resulting in&#160;a $<ix:nonFraction unitRef="usd" contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY1MjQ_dd38fcf9-5f72-4a42-90dd-91e32e71b4eb">15.6</ix:nonFraction> million premium paid to the Company above the fair value of the Company's common stock which was credited to contract liability in the Company's condensed consolidated balance sheet.&#160; </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company believes that the Takeda Collaboration Agreement is a collaboration arrangement as defined in ASC&#160;808,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;Further, during the research period, the Company believes that the arrangement is a contract with a customer as defined in ASC 606,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue From Contracts With Customers.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> The Takeda Collaboration Agreement and the Stock Purchase Agreement are being accounted for as one arrangement because they were entered into at the same time with interrelated financial terms.</span></div></ix:continuation><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="ia1e88e14c2664d7a860d26dbf5f7604d" continuedAt="i371237faf4b844848d8b8079f85c3bbf"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company identified performance obligations during the research period consisting of the license, the development options, and joint steering committee ("JSC") participation together with the research services for each collaboration program. The license rights, JSC involvement, option and research services are considered to be a single performance obligation for each program since the research services are highly interrelated with the option and JSC involvement and will significantly modify the license. The performance obligations under each of the <ix:nonFraction unitRef="program" contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5OTUxMTY3NjgwNg_30208087-7157-43c2-9b95-a8539f91bfa3">three</ix:nonFraction> programs are separate since the activities and risks under the programs are distinct. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has determined that all other goods or services which are contingent upon Takeda exercising its option for each program are not considered performance obligations at the inception of the Takeda Collaboration Agreement.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The transaction price at inception included fixed consideration consisting of the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgxNjU_03267a27-182b-4a47-bf83-a7e5570b67a9">40.0</ix:nonFraction> million, the $<ix:nonFraction unitRef="usd" contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgxNzM_dd38fcf9-5f72-4a42-90dd-91e32e71b4eb">15.6</ix:nonFraction> million premium on the sale of common stock, and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">first preclinical milestone payment of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgyNjA_f74b12ed-669a-4a0d-b0e9-1d3d18b4663f">5.0</ix:nonFraction> million. It also included variable consideration of $<ix:nonFraction unitRef="usd" contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:VariableConsiderationFutureConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgzMDc_d515446c-46fd-49eb-9bdd-a91ded60c8bc">26.0</ix:nonFraction> million relating to future milestones that were not constrained. The amount of variable consideration was estimated using the most likely amount method. A total of $<ix:nonFraction unitRef="usd" contextRef="i506ba94099c0474082d55a807783f8de_D20180101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMzg0ODI5MDc0MzMxMw_a21c2a14-208b-4dc8-8624-7c561fb579bb">15.0</ix:nonFraction> million in preclinical milestone payments has been received under the Takeda Collaboration Agreement from inception through June 30, 2019.  </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The remaining $<ix:nonFraction unitRef="usd" contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223" decimals="-5" format="ixt:numdotdecimal" name="dnli:ConstrainedVariableConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTg3ODM_8d939eed-dca4-4871-a0b9-15cd42203d4f">44.0</ix:nonFraction> million of preclinical milestones were considered constrained at the inception of the Takeda Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. Additionally, cost and profit sharing income, and the development and commercial milestones as outlined above, have not been considered given Takeda has not exercised its options for the development and commercial phases for any program. There was no change in the transaction price from inception through June 30, 2019. This will be reassessed at each reporting period. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The transaction price has been ascribed in its entirety to the <ix:nonFraction unitRef="program" contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTk0NDE_30208087-7157-43c2-9b95-a8539f91bfa3">three</ix:nonFraction> performance obligations identified in the research term of the Takeda Collaboration Agreement.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue is recognized when, or as, the Company satisfies its performance obligations by transferring the promised services to Takeda. Revenue will be recognized over time using the input method, based on costs incurred to perform the research services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda. There were no material changes in estimates during the three and six months ended June 30, 2019.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A contract liability of $<ix:nonFraction unitRef="usd" contextRef="ia53bec4ac3404ce2b6767a4da564148f_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTk5ODc_304b722c-d9ff-41d9-b734-c9d99107e8f1">63.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b83a26513784d7ba644b0159e2fcac2_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTk5OTQ_41777996-1b4b-46bf-ae55-71893a020ce7">64.9</ix:nonFraction> million was recorded on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. These contract liabilities relate to the <ix:nonFraction unitRef="program" contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223" decimals="INF" format="ixt-sec:numwordsen" name="dnli:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjAxMDQ_30208087-7157-43c2-9b95-a8539f91bfa3">three</ix:nonFraction> performance obligations identified, with such amounts to be recognized over the estimated period of the pre-IND research services, which is expected to be several years. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue recognized relating to future milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i327284cdcb314428b0f05baf0584c173_D20190101-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjAzNTM_0f8f1087-3c37-46cc-aa32-5efe7b3172f1">1.5</ix:nonFraction>&#160;million, which the Company concluded is probable that a significant reversal in the amount recognized will not occur, is presented net in the contract liability on the condensed consolidated balance sheet. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In assessing the Takeda Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Management applies judgment in determining the separate performance obligations in the research period, estimating variable consideration, and estimating total future costs when using the input method.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Through June 30, 2019, Denali has recognized $<ix:nonFraction unitRef="usd" contextRef="i506ba94099c0474082d55a807783f8de_D20180101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjA5NTE_a21c2a14-208b-4dc8-8624-7c561fb579bb">15.0</ix:nonFraction> million in milestones from Takeda and has <ix:nonFraction unitRef="usd" contextRef="i7c2bdbc9872a42678f000e70d3eb04e1_D20180101-20190630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjA5ODg_66605543-a4f1-4311-b1b5-b44de59bcaa5">no</ix:nonFraction>t recorded any product sales under the Takeda Collaboration Agreement. There was <ix:nonFraction unitRef="usd" contextRef="ia53bec4ac3404ce2b6767a4da564148f_I20190630" decimals="-5" format="ixt-sec:numwordsen" name="dnli:PreclinicalMilestonePaymentEarnedNotYetReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjEwNzE_a09f062e-8ba1-440b-9f0d-320c6bfdfe63">no</ix:nonFraction> receivable as of June 30, 2019, and a receivable of $<ix:nonFraction unitRef="usd" contextRef="i2b83a26513784d7ba644b0159e2fcac2_I20181231" decimals="-5" format="ixt:numdotdecimal" name="dnli:PreclinicalMilestonePaymentEarnedNotYetReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjExMTU_048676c5-9b94-44c5-9457-16f7c69536de">5.0</ix:nonFraction> million as of December 31, 2018, related to the Takeda Collaboration Agreement.  </span></div></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i371237faf4b844848d8b8079f85c3bbf" continuedAt="i05c00f6f15994d908a25abb98c6ecdcb"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Revenue</span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE1OTk_32f0a767-458b-4a15-94c5-127107043f05" continuedAt="i56795eea1996472cbad9dcf62129ad62" escape="true"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:37.583333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.583333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441026%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441026%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583333%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Takeda Collaboration Agreement</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i121aa99f2d3f4692bdd510f9652ac846_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi0xLTEtMS0w_8133c67e-ee5d-43a2-8314-390089ae5c92">740</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ece0b562fb24861a00cc1837d3ba44d_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi0zLTEtMS0w_c25c6b3b-e2ca-482b-bbe5-51ff497efa21">1,648</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb48aaf3a1cf4e36903d0037ad367e4c_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi01LTEtMS0zODY_d3c10636-78c3-4af7-9e87-37bfe3252d81">1,422</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ec13fd38f514239afa935809142d525_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi03LTEtMS0zOTc_e7221c16-ec89-4fc8-b40a-69b976344547">2,289</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Alzheimer's Disease Services</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93f1e0b6d51d423fab44d10992a22439_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC0xLTEtMS0w_01e4d623-51bf-4352-ab63-d8cda9babb91">99</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0a29ec79a2640e5a067988c35bbf456_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC0zLTEtMS0w_5fe3f542-ba43-4433-a82e-e18d36dcb294">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieaa172b849b9451881f587516f825b58_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC01LTEtMS0zODY_02c74b21-3b20-4bb1-bdc7-17e490b25fe6">193</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b6d26112ff24d9ab029f080a339e130_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC03LTEtMS0zOTk_5b12acf0-03bd-45d3-b874-fa00d79b41c4">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Retained Activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i973a1b238c6743cf8760ffc6932c3a7e_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS0xLTEtMS0w_efcfe2c2-6062-4365-afeb-0e55d37d1b8d">3,358</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1affd54d523b488da0673a88c0036970_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS0zLTEtMS0w_28d76d70-91ac-4250-8aed-f8acc11ba5c8">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50e589b4bde248369e6e024a7f4abb85_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS01LTEtMS0zODY_933e14df-a691-4f61-b492-ed7523e88084">6,787</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f7fab35ed3247c4a11fd24731d5db87_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS03LTEtMS0zOTk_51488a8c-d4dd-4bc8-804d-1c3cc17af43d">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Sanofi Collaboration Revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86c1aab124cf41eab4654a55ce7d0456_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi0xLTEtMS0w_ec7b9f48-1251-4a4b-a293-8089561e5a73">3,457</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ff05dbaad9645c284a3cedd8231323a_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi0zLTEtMS0w_3a4ae0d3-c3a6-4165-9f8f-14cab86bc253">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02d0ffc88019497f86735d349075b74c_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi01LTEtMS0zODY_fee72fc6-58d6-49db-86ee-baf96da31b93">6,980</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib97dc1f800de421eb8179a2c93529853_D20180101-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi03LTEtMS0zOTk_87e61061-98f9-409c-998c-b2190c95b255">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Collaboration Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy0xLTEtMS0w_4859ce9e-8303-4563-ae6b-b5ebae365c84">4,197</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy0zLTEtMS0w_d39c0fae-d99d-43c3-9ebf-f7e62f9195a4">1,648</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy01LTEtMS0zODY_fbcd3fe4-799f-4855-8989-1e6b64fcf838">8,402</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy03LTEtMS0zOTk_a8c62f15-cb3a-4af9-9962-d7890298f721">2,289</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">_________________________________________________</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:-18pt;padding-left:18pt;margin-top:3pt;margin-bottom:10pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"><ix:continuation id="i05c00f6f15994d908a25abb98c6ecdcb" continuedAt="i335a6f822aa54f6d86cbbc7891fad0e5"><ix:continuation id="i56795eea1996472cbad9dcf62129ad62" continuedAt="i578a1eced9694c13aa1316a762d6113a">(1)</ix:continuation></ix:continuation></sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;"><ix:continuation id="i335a6f822aa54f6d86cbbc7891fad0e5"><ix:continuation id="i578a1eced9694c13aa1316a762d6113a">Amounts for the three and six months ended June 30, 2019 and the three months ended June 30, 2018 represent revenue recognized during the period that was included in the contract liability balance at the beginning of the period. There was <ix:nonFraction unitRef="usd" contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE1MzM_4d73bdd9-fc0d-4c8b-8b7f-90d4d920de01">no</ix:nonFraction> deferred revenue at the beginning of the period for the six months ended June 30, 2018.</ix:continuation></ix:continuation>  </span></div><div id="i_0_55"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">7. &#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="dnli:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMzc3Nw_6aaaa30b-ba97-401d-944a-255217ea31e6" continuedAt="i66a003cf7e384406b0234dcdc5db6c1d" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="i66a003cf7e384406b0234dcdc5db6c1d" continuedAt="ic17e0d077f4b41589233507dc5eed962"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Genentech</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (&#8220;Genentech&#8221;). The agreement gives the Company access to Genentech&#8217;s LRRK2 inhibitor small molecule program for Parkinson&#8217;s disease. Under the agreement, Genentech granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under Genentech&#8217;s rights to certain patents and patent applications directed to small molecule compounds which bind to and inhibit LRRK2 and (ii)&#160;a&#160;non-exclusive,&#160;worldwide, sublicensable license to certain related&#160;know-how,&#160;in each case, to develop and commercialize certain compounds and licensed products incorporating any such compound. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company may owe Genentech milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="if131cb24360a4f85bb336dd0ab7af8b9_D20160617-20160617" decimals="-5" format="ixt:numdotdecimal" name="dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTMwNQ_7eea2c35-af63-4012-b847-304cbcc7a5fb">315.0</ix:nonFraction> million in the aggregate, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages.</span></div></ix:continuation><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic17e0d077f4b41589233507dc5eed962">To date, the Company has paid Genentech an upfront fee, a technology transfer fee and a clinical milestone payment totaling $<ix:nonFraction unitRef="usd" contextRef="ief7842b7854c410c9c6bb0e061d46cec_D20160601-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfNjU5NzA2OTc3ODY4NA_d926a2cc-1b42-4ccb-bf40-1fe5dcd2115a">12.5</ix:nonFraction>&#160;million in the aggregate, all of which were recorded as research and development expense as incurred. <ix:nonFraction unitRef="usd" contextRef="i38c69c189be94bfc9380598800c85b4c_D20180401-20180630" decimals="-5" format="ixt-sec:numwordsen" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_0f6e007f-f2c1-474a-a54f-417889d7a9e6"><ix:nonFraction unitRef="usd" contextRef="ia9fe92c33d98463bba6b004929024cfa_D20190401-20190630" decimals="-5" format="ixt-sec:numwordsen" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_6f1b321f-48db-46eb-aa17-9564b4f382d5"><ix:nonFraction unitRef="usd" contextRef="i6ff9d49b979f434281543ef489df6e3c_D20180101-20180630" decimals="-5" format="ixt-sec:numwordsen" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_bfc06eb7-4ce3-4ace-85f3-4e9547eb37b0"><ix:nonFraction unitRef="usd" contextRef="i0036869090d6435dba566fa93d050600_D20190101-20190630" decimals="-5" format="ixt-sec:numwordsen" name="dnli:UpfrontFeesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_c8c7fa00-4cec-4223-9096-34f98c16cb32">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> amounts were recorded in the three and six months ended June 30, 2019 and 2018.</ix:continuation> </span></div><div id="i_0_58"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">8.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0NA_a43be5f1-8ada-4f53-8a3c-c9cc425b775b" continuedAt="i70283ec9d1b54d5298d84453f45cf756" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i70283ec9d1b54d5298d84453f45cf756" continuedAt="i9502cab96ace49ba9c8e5e5c10e7e6c7"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lease Obligations</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In May 2018, the Company entered into an amendment to its operating lease for its former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand its headquarters to <ix:nonFraction unitRef="sqft" contextRef="i0dd82aee18cf4b4d91431b4b49ef0bdb_D20180502-20180502" decimals="-1" format="ixt:numdotdecimal" name="dnli:OperatingLeasesAreaUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfODIx_b04841d4-06b9-4f9f-9775-c197cb252719">148,020</ix:nonFraction> rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of <ix:nonNumeric contextRef="i0de68e60891642eca083500a43ec45ec_I20180502" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfOTc1_d3763b39-d513-4a22-b7a2-23d5792ea6c7">ten years</ix:nonNumeric> from the legal commencement date, which was April&#160;1, 2019 when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which the Company was deemed to have obtained control over the property. The Company has an option to extend the lease term for a period of <ix:nonNumeric contextRef="i0de68e60891642eca083500a43ec45ec_I20180502" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTI4OQ_c0251af7-7f68-43fa-80a0-b1235689fa81">ten years</ix:nonNumeric> by giving the landlord written notice of the election to exercise the option at least <ix:nonNumeric contextRef="id56b451693a4495eaac87af0665021d3_D20180502-20180502" format="ixt-sec:durwordsen" name="dnli:LesseeOperatingLeaseRenewalNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTM3OA_e205a88d-c96f-4683-ac46-c129ce6111d3">nine months</ix:nonNumeric>, but not more than <ix:nonNumeric contextRef="i2634280b279f4601af826b4c8125dd23_D20180502-20180502" format="ixt-sec:durwordsen" name="dnli:LesseeOperatingLeaseRenewalNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0NQ_73b8dc20-be01-430f-8de3-253b7fe1d64f">twelve months</ix:nonNumeric>, prior to the expiration of the Headquarters Lease Amendment lease term. The Company did not believe this renewal was reasonably certain at lease inception.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $<ix:nonFraction unitRef="usd" contextRef="ic2c4f0ef14eb44cd94cfc60e492db814_I20180502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTc0Mg_d26c0308-2e15-4607-9d44-c2e92921f0bc">25.9</ix:nonFraction> million, which was fully utilized, of which $<ix:nonFraction unitRef="usd" contextRef="i9f8dc4dba49b4160b31e6e823e1ae788_D20180502-20180502" decimals="-5" format="ixt:numdotdecimal" name="dnli:TenantImprovementAllowanceRepayableAsRent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ1NzA1Ng_9c663e27-9e58-4c86-8878-28709c86bcf2">4.4</ix:nonFraction> million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the condensed consolidated balance sheet as of June 30, 2019. The Company is also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As of June 30, 2019, the carrying value of the ROU asset was $<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjMwMA_9a39f4aa-20ef-4b5b-920d-259930d5ac50">34.6</ix:nonFraction> million. The related current and non-current liabilities as of June 30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjQzNg_5cff89d4-fd61-4fc6-8bb1-31a98d92b414">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjQ0Mw_cfe68fff-591d-4185-a7f5-bd4d75c4c554">70.9</ix:nonFraction> million, respectively. The current and non-current lease liabilities are included in Other current liabilities and Operating lease liability, less current portion, respectively, in the Condensed Consolidated Balance Sheet.  </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Management was required to exercise judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for the Headquarters Lease Amendment, the discount rate used to determine the measurement of the lease liability. The discount rate used was <ix:nonFraction unitRef="number" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjkwMw_01a46361-d304-4629-9c0b-f7c4bee99216">9.0</ix:nonFraction>%, which was management&#8217;s estimate of the Company&#8217;s incremental borrowing rate since the rate implicit in the lease was not known. To estimate the Company&#8217;s incremental borrowing rate, management considered observable debt yields of comparable market instruments, as well as benchmarks within the Headquarters Lease Amendment that may be indicative of the rate implicit in the lease. </span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Total operating lease costs, including variable and short term lease costs, were $<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTI2Nw_9071b409-5500-4d2d-9f18-740199e30dfe">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTI4MQ_0dce60a8-0131-4c6b-8eda-60223ef2ab95">4.8</ix:nonFraction> million for the three and six months ended June 30, 2019, respectively. Rent expense excluding amortization of leasehold improvements was $<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwOTk0OQ_1540082f-d0fb-4334-b3cd-978c86c42d89">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwOTk1Mg_35cc9f37-616c-4333-90cd-092f51d733c4">1.3</ix:nonFraction> million for the three and six months ended June 30, 2018, respectively.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2019, the weighted average remaining lease term is <ix:nonNumeric contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNDMzMw_114bcaec-6a18-4d81-a9ad-84ddb6025664">9.8</ix:nonNumeric> years and the weighted average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNDQzMw_0771cdc4-a62a-4a7d-a90e-3830961d5f79">9.0</ix:nonFraction>%. Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNDUyNg_821ee9c2-2d4f-426d-959f-ba9eaa4e091f">1.9</ix:nonFraction> million and was included in Net cash used in operating activities in our condensed consolidated statements of cash flows.</span></div></ix:continuation><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i9502cab96ace49ba9c8e5e5c10e7e6c7" continuedAt="i741e5a8f061b456f9cd026fe8056c4eb"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0Mg_4aae8a02-c918-42b4-a775-ec512b4995ee" escape="true"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of June 30, 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:27.967949%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.262821%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.769231%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (six months)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfMS0yLTEtMS0w_20042649-e513-41fd-9bbd-2f8bc49b8fd2">3,642</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfMi0yLTEtMS0w_f1e267c4-3157-4980-9047-50ec4a6ad0ac">9,767</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfMy0yLTEtMS0w_81925417-c227-4c07-b5f1-aac58adfcc2c">10,386</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNC0yLTEtMS0w_ee7beed2-f521-4237-a29c-79bbf5b0f6b3">10,726</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNS0yLTEtMS0w_76f94952-bfb6-49a6-ae43-e3a84b073099">11,078</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and later</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNi0yLTEtMS0w_e5026d8c-5f04-45db-8598-4460652b1717">65,494</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNy0yLTEtMS0w_f0902c93-648c-40eb-9683-baaad2b9a5f3">111,093</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfOC0yLTEtMS0w_6d8939a7-99f6-4149-8152-a9212d9ac7fb">38,217</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfOS0yLTEtMS0w_4a90f0b4-6561-4c0c-accc-a6e5a7c1772f">72,876</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") to sublease approximately <ix:nonFraction unitRef="sqft" contextRef="i6adb2eb42e59415094e9c0d4ffb38967_I20181031" decimals="0" format="ixt:numdotdecimal" name="dnli:OperatingLeasesSubleaseNetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzIzNQ_d5ceb8be-fb3c-436f-b540-3ad2a2f5b421">36,835</ix:nonFraction> rentable square feet of space in its New Premises. The Sublease Agreement has a term of <ix:nonNumeric contextRef="i6adb2eb42e59415094e9c0d4ffb38967_I20181031" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzMyNg_68f8c5ba-e6db-48d5-bef8-80ab7ef591f4">five years</ix:nonNumeric> from the commencement date of April&#160;12, 2019 and provides for the Company to receive monthly base rent amounts escalating over the term of the lease. The Company  also passes through a portion of the operating expenses for the New Premises to the sublessee, such as taxes and insurance, which are treated as variable sublease income. Total sublease income for the three and six months ended June 30, 2019, including rent and variable costs, was $<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY4Mw_6c41cd73-d4de-478d-a2c5-a57296d1ae83"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY4Mw_c529a086-d12f-4f00-98f0-432273934959">0.8</ix:nonFraction></ix:nonFraction> million. There was <ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY5Nw_21cb2e11-bbc2-459b-9ae8-a461857b635d"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY5Nw_7085be2a-c427-46f1-adbd-b34312e9bb75">no</ix:nonFraction></ix:nonFraction> sublease income for the three and six months ended June 30, 2018.</span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0Mw_843bfcad-13e5-43f2-89b8-13aebcdd64ca" escape="true"><div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table details the future undiscounted cash inflows relating to the Company's sublease as of June 30, 2019 (in thousands):</span></div><div style="margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:27.967949%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.262821%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.769231%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (six months)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfMS0yLTEtMS0w_1236afea-048d-4076-b20c-15c81a5d7fd5">1,392</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfMi0yLTEtMS0w_50315afd-6f51-4598-a7e3-ad13a788790d">2,842</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfMy0yLTEtMS0w_4ff8a602-5735-47eb-b4e9-545288a643bf">2,925</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNC0yLTEtMS0w_62a3af84-d5d7-49f2-8060-55345a0804d1">3,009</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNS0yLTEtMS0w_89a8e176-44fc-4447-8f39-bf3409d2f8ee">3,096</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and later</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNi0yLTEtMS0w_377ee13d-f603-47f8-b243-860039c40efe">876</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted sublease receipts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNy0yLTEtMS0w_834583c5-fedd-4448-8e4b-0640a451f991">14,140</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i741e5a8f061b456f9cd026fe8056c4eb" continuedAt="i72d7f4aacfaf4f48819222af076a996d"><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnification</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company&#8217;s balance sheet, statements of comprehensive loss, or statements of cash flows.</span></div><div style="margin-top:18pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commitments</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (&#8220;DMSA&#8221;) with Lonza Sales AG (&#8220;Lonza&#8221;) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the DMSA will expire on September&#160;6, 2022.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 and December 31, 2018, the Company had non-cancellable purchase orders for biological product development and manufacturing costs totaling $<ix:nonFraction unitRef="usd" contextRef="i293b5b178de44724a3a09c4a2268ccae_I20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PurchaseOrderExecuted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjgwNQ_475423fc-65ad-4f6c-8646-d5a2f8a9242f">25.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifcee909d65844bdd8691aaef6db01445_I20181231" decimals="-5" format="ixt:numdotdecimal" name="dnli:PurchaseOrderExecuted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjgxMg_c0280fcf-6edf-4a68-a87c-c56186fc99da">24.7</ix:nonFraction> million respectively. The activities under these purchase orders are expected to be completed by November 2024. As of June 30, 2019 and December 31, 2018, the Company had total non-refundable purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i293b5b178de44724a3a09c4a2268ccae_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcxNzc4Ng_d5111879-3331-4845-840c-d3a0bdd49f4d">10.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifcee909d65844bdd8691aaef6db01445_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcxNzc5Mw_39b5e633-fa33-4f17-9b52-6b1ed71e333a">14.0</ix:nonFraction> million, respectively, under the DMSA.</span></div></ix:continuation><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i72d7f4aacfaf4f48819222af076a996d">During the three months ended June 30, 2019 and 2018, the Company incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i195078f2e63c4ec69a1f3aed2a49cca6_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsIncurredDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjk3Ng_ff020f9e-960c-4b9c-904e-6f3b88b21315">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i65a3e9667de048f9be4f3e9b194a89da_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsIncurredDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjk4Mw_48f4537a-f48f-44c7-bd44-ce276db312bd">1.1</ix:nonFraction>&#160;million, respectively, and made payments of $<ix:nonFraction unitRef="usd" contextRef="i195078f2e63c4ec69a1f3aed2a49cca6_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PaymentsForManufacturingCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzAyMg_19f74934-3af1-4a63-9237-52607aed7a00">3.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i65a3e9667de048f9be4f3e9b194a89da_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PaymentsForManufacturingCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzAyOQ_0462bcd2-3946-4393-9b23-c9680507ac5e">0.6</ix:nonFraction> million, respectively, for the development and manufacturing services rendered under the DMSA. During the six months ended June 30, 2019 and 2018, the Company incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i380397739fb3409c84068db1cde52240_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsIncurredDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTY5OQ_ee1e81d3-b780-4360-a8af-1ed57a1ea871">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3fd410c4ab04f2a98010ca624256620_D20180101-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsIncurredDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTcwNg_6d62319b-827d-47e4-8c4f-efc5a2bd7484">1.2</ix:nonFraction> million, respectively, and made payments of $<ix:nonFraction unitRef="usd" contextRef="i380397739fb3409c84068db1cde52240_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PaymentsForManufacturingCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTc0Nw_ef14397a-7b06-4326-82b4-644061a62812">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3fd410c4ab04f2a98010ca624256620_D20180101-20180630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PaymentsForManufacturingCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTc1NA_2f0ca506-5390-43ba-8904-0b76a441a0c9">0.7</ix:nonFraction> million, respectively, for the development and manufacturing services rendered under the DMSA.</ix:continuation> </span></div><div id="i_0_64"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">9.&#160;<ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNTE_70d6d941-9c73-4831-98bc-c6530a37380c" continuedAt="ia8d7099ddda34be6838aa35a4c83356c" escape="true">Stock-Based Awards</ix:nonNumeric></span></div><ix:continuation id="ia8d7099ddda34be6838aa35a4c83356c" continuedAt="icc92ba04659646939d55132c86adae8f"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2017 Equity Incentive Plan</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which initially reserved approximately <ix:nonFraction unitRef="shares" contextRef="i7d1a63d9fd9048e9b346a1bb1e5b53be_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTgy_884b149c-683f-4115-93a9-0833272889ca">6.4</ix:nonFraction>&#160;million shares of common stock for the issuance of stock options,&#160;restricted stock and other stock awards, to employees,&#160;non-employee&#160;directors, and consultants under terms and provisions established by the Board of Directors and approved by the stockholders. The 2017 Plan provides that the number of shares reserved and available for issuance under the 2017 Plan will automatically increase each January 1, beginning on January 1, 2019, by the least of (i) <ix:nonFraction unitRef="shares" contextRef="i7d1a63d9fd9048e9b346a1bb1e5b53be_I20171231" decimals="INF" format="ixt:numdotdecimal" name="dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjIz_077cef6d-78c8-43c2-a698-1f29a569613e">10.0</ix:nonFraction> million shares, (ii) <ix:nonFraction unitRef="number" contextRef="ie3d6c473afb5460780db3507a8b37630_D20171201-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjM5_bf5b492a-1fd2-47d8-ae57-26f670e47ac2">5</ix:nonFraction>% of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the administrator of the 2017 Plan. In January 2019, common stock available for issuance under the 2017 Plan was increased by approximately <ix:nonFraction unitRef="shares" contextRef="i0427708156c3454cb4eb96e9b7ea3878_I20190131" decimals="INF" format="ixt:numdotdecimal" name="dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTE1_f6dbec31-ba38-48ac-aa1d-d58f799b38e9">4.8</ix:nonFraction> million shares as a result of this automatic increase provision.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Awards granted under the 2017 Plan expire no later than&#160;<ix:nonNumeric contextRef="i1fc1cd06135f47ebb307c315c07c68a8_D20171201-20171231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAyNQ_a9d2494f-6fec-4dfa-ac5a-74e015496c4a">ten years</ix:nonNumeric> from the date of grant. For stock options, the option price shall not be less than&#160;<ix:nonFraction unitRef="number" contextRef="iecff526c59e7452aafbe14147f3cc250_D20171201-20171231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTExMQ_b2a7ee17-4b57-47ae-b0f4-a8657c6825de">100</ix:nonFraction>%&#160;of the estimated fair value of the Company's common stock on the day of grant. Options granted typically vest over a&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTIzMQ_89106c99-db8f-42c3-9be0-ac8e95402417">four</span>-year period but may be granted with different vesting terms. </span></div></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="icc92ba04659646939d55132c86adae8f" continuedAt="ieac08edb26274d7ba87bb96ab8d1c223"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2015 Stock Incentive Plan</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;In May 2015, the Company adopted the 2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;), which as amended, reserved approximately <ix:nonFraction unitRef="shares" contextRef="i32a76c5b5b6e4f3f9cd6493d2dba156f_I20150531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTQ0Nw_7e575ea1-b637-4ba8-9d92-6042e6a10564">8.3</ix:nonFraction> million shares of common stock for the issuance of stock options, restricted stock and other stock awards, to employees,&#160;non-employee&#160;directors, and consultants under terms and provisions established by the Board of Directors and approved by the stockholders. Awards granted under the 2015 Plan expire no later than&#160;<ix:nonNumeric contextRef="i5e0e4017eafa4b21a497bff216646578_D20150501-20150531" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTc1OA_d6d6e1be-e245-4052-b4bf-991a25c198b6">ten years</ix:nonNumeric> from the date of grant. For stock options, the option price shall not b</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">e less than&#160;<ix:nonFraction unitRef="number" contextRef="iedf7537799d4426a9667a6f97c5239eb_D20150501-20150531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTg0NA_a758c259-d307-4b2e-b739-aad17cfb1f37">100</ix:nonFraction>%&#160;of the estimated fair value of the Company's common stock on the day of grant. Options granted typically vest over a&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjIwNQ_7426f688-b493-4e9a-8e34-f30a5275909d">four</span>-year period but may be granted with different vesting terms. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon adoption of the 2017 Plan, <ix:nonFraction unitRef="shares" contextRef="i82d03abee79c4854acb028d0eef7bf6b_I20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjMwMw_3b1b4eaf-ffec-4f7d-bbb6-8facbc261dec">no</ix:nonFraction> new awards or grants are permitted under the 2015 Plan, and the approximately <ix:nonFraction unitRef="shares" contextRef="ieea49b8c39144a13b75a300520691ead_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjM4NA_abdd4c6f-9ec6-4460-97ed-f6fcc9410685">0.2</ix:nonFraction> million shares that were then unissued and available for future award under the 2015 Plan became available under the 2017 Plan. The 2015 Plan will continue to govern restricted stock awards and option awards previously granted thereunder.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 there were approximately <ix:nonFraction unitRef="shares" contextRef="if52074d4e46047fdb42400ddf9179e83_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjY1Mg_5b95be6a-4df9-4dc9-aa17-633b4b26353e">3.7</ix:nonFraction>&#160;million shares available for the Company to grant under the 2017 Plan. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:27pt;"><span><br/></span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNDg_9fe7ad69-cb40-45bc-b48d-e1c8a6fe28e5" escape="true"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes option award activity under the 2017 Plan and the 2015 Plan:&#160;</span></div><div style="margin-top:10pt;margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:42.391026%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.301282%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.301282%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.301282%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.301282%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Weighted- </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Average</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Exercise&#160;Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Weighted- </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Average</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">remaining</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">contractual</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">life (years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Aggregate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Intrinsic</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS0xLTEtMS0w_7c3784cd-58d8-484a-8700-3d372a330bf8">9,612,652</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS0zLTEtMS0w_e08e24a7-5ad6-4bfc-9d17-4735e7ac184a">10.49</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ifceb656364a74a0da5c6b45c4e52919b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS01LTEtMS0w_7ebf941d-e42c-42c7-97c6-1420a7f6573a">8.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS03LTEtMS0w_69a7cec8-05b9-492b-bcbf-965d84c7c4ca">97,804</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMi0xLTEtMS0w_14883dbc-a5ea-4dbc-ba8e-283ccdc160b2">3,296,335</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMi0zLTEtMS0w_654fd219-6d42-4095-88d2-e0a9cc898afc">18.58</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMy0xLTEtMS0w_3aafd493-3b60-410d-bceb-2f0cc92573f2">465,281</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMy0zLTEtMS0w_37f7de7a-776c-4a07-9504-7f5ceb7337fd">4.62</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNC0xLTEtMS0w_ab9a1fa3-ef04-4d05-aba2-925755d6599f">447,374</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNC0zLTEtMS0w_036a2aff-304e-4b59-a5cb-4836ca0f933b">16.30</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS0xLTEtMS0w_7e997376-60fd-411d-a8bd-8733d468f2da">11,996,332</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS0zLTEtMS0w_88113b04-5a79-4e9a-bce7-0153aab96c5b">12.72</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS01LTEtMS0w_c9364d05-2b47-423e-8e30-4663d316b52f">8.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS03LTEtMS0w_7c0d041c-1088-4974-a68c-9acc9b73d34f">96,434</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi0xLTEtMS0w_5841f7f9-01c4-4ec8-9257-ee4593dae3a7">10,251,600</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi0zLTEtMS0w_09950949-dee9-48f4-8cf0-02f418e733de">14.77</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi01LTEtMS0w_9402cf51-ebbb-472f-921a-c7d9d5925d2d">8.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi03LTEtMS0w_11773d0f-29f8-4c1f-ad7b-67a58e6dcbcc">61,400</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy0xLTEtMS0w_33f53774-5ad3-404d-988d-2215158e45e2">3,228,421</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy0zLTEtMS0w_bf6f293f-1b51-42d1-b528-14c334f79af5">10.17</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy01LTEtMS0w_414f45fb-936a-48a0-bb40-1652c533b942">7.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy03LTEtMS0w_4e3853da-8874-4d3a-82ef-766cbc9402f7">34,173</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Aggregate intrinsic value represents the difference between the Company&#8217;s estimated fair value of its common stock and the exercise price of outstanding options. The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzA1MQ_28603328-e006-4a2e-9343-a5fc36175140">5.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MjkzMA_2047fc0e-5d12-4fd3-9b96-51f9a4148bf3">8.4</ix:nonFraction>&#160;million for the three and six months ended June 30, 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1Mjg5Ng_fce5317f-f0e4-49bf-b82a-ed1b21d3be05">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MjkzNQ_aa61c1c9-d9d3-442c-8cfb-edb0cd7f7873">4.7</ix:nonFraction>&#160;million for the three and six months ended June 30, 2018, respectively. During the three and six months ended June 30, 2019, the weighted-average grant date fair value of the vested options was $<ix:nonFraction unitRef="usdPerShare" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzE5Mg_222bf54c-fb74-44a7-99f4-62ef5eb07932">9.35</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzAyNw_6269b98d-fb69-40b4-a1e7-9e40508fe8cc">10.80</ix:nonFraction> per share, respectively. During the three and six months ended June 30, 2018, the weighted-average grant-date fair value of the vested options was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzE5OQ_8ad91e25-b808-41c7-bec0-71c6b47bb288">2.83</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzIwMQ_e3cdca82-7359-450b-a449-e8cf3ac6807a">2.87</ix:nonFraction> per share, respectively. The weighted-average grant date fair value of all options granted during the three and six months ended June 30, 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzMyMQ_1f5371d5-3cd0-446b-b276-58a62cff3946">13.16</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzI5OA_18d25557-f70d-403c-bcd3-b20bc3d7191e">11.92</ix:nonFraction> per share, respectively. The weighted-average grant date fair value of all options granted during the three and six months ended June 30, 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzMyOA_c34532ca-bed3-42e0-8ea7-8475203e4859">13.37</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzQ1NA_b888b5dd-d573-4ed3-a366-e7c179409fc3">15.90</ix:nonFraction> per share, respectively. </span></div></ix:continuation><div style="text-indent:27pt;"><span><br/></span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="ieac08edb26274d7ba87bb96ab8d1c223" continuedAt="i4b979d3b59ae4b0db0cd8dd121a81ee5"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options Granted to Employees with Service-Based Vesting</span></div><div style="text-indent:27pt;"><span><br/></span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjc0ODc3OTA5MTQxMw_b5cf856f-3df1-4483-8d8d-2417198e074a" escape="true"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:26.365385%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.307692%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.307692%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.307692%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.307692%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;5.50 - 6.08 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Volatility</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;66.9% - 77.8% </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">80.0% - 85.6%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">66.9% - 77.8%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">80.0% - 87.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2.0% - 2.3% </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.7% - 2.9%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0% - 2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.6% - 2.9%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Dividend yield</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS0xLTEtMS0w_297fdf1e-71ba-4856-a7b3-1a3f4759e826">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS0zLTEtMS0w_83a7f4cc-1b0f-4d45-9caf-d1a84c726398">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS01LTEtMS0w_a010da65-4a88-4fde-a8d2-eff822b11732">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS03LTEtMS0w_35a114dd-6e1a-48e5-ad1f-393db1012916">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the&#160;mid-point&#160;between the vesting date and the end of the contractual term).</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.  The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividend:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company has <ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Dividends" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjA0NQ_e8caf010-8815-4798-a507-44668a47b51e">no</ix:nonFraction>t paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was <ix:nonFraction unitRef="number" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDY4NQ_9bfe8627-604f-44d7-b085-54f7d18409c9">zero</ix:nonFraction>.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Performance and Market Contingent Stock Options Granted to Employees</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August and November 2015, the Board of Directors granted approximately <ix:nonFraction unitRef="shares" contextRef="i3f3fe6755fa445a7b223008c32301c1a_D20150801-20150831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDgzMw_f7e6acf8-24d2-40e3-a6a1-4cad74d3c26a">1.6</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="if4cc341fdaab4fb1baca8e685795587f_D20151101-20151130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDg0MA_58c2c22a-11e2-4b58-9072-4ee8a86458a3">0.1</ix:nonFraction> million shares of performance- and market- contingent awards to members of the senior management team, respectively. These awards have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if4cc341fdaab4fb1baca8e685795587f_D20151101-20151130" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDk5MQ_d9313f18-60a1-4824-90d9-43ad9bb894ce"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f3fe6755fa445a7b223008c32301c1a_D20150801-20150831" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDk5MQ_fdd3aee5-f324-4636-a065-2a80d39d79c7">0.68</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These awards have two separate market triggers for vesting based upon either (i)&#160;the successful achievement of stepped target closing prices on a national securities exchange for <ix:nonNumeric contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630" format="ixt-sec:durday" name="dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNTE4NQ_e0db0834-7abd-469e-b7d7-46d6adba9bb7">90</ix:nonNumeric> consecutive trading days later than <ix:nonNumeric contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630" format="ixt-sec:durday" name="dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNTIyNA_9fb7ce13-4ad2-4ae2-a0ae-cb750b32fc74">180</ix:nonNumeric> days after the Company&#8217;s initial public offering for its common stock, or (ii)&#160;stepped target prices for a change in control transaction. In the event that neither of these market triggers are achieved by the specified timelines, such awards will terminate with respect to that portion of the shares. The expense recognized associated with these performance- and market- contingent awards is $<ix:nonFraction unitRef="usd" contextRef="id498dc8dfd914e4ca6892bfb92be83bd_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PerformanceAndMarketShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA2NA_6cc0e06b-c277-4ead-a599-d68fbcf31303"><ix:nonFraction unitRef="usd" contextRef="i8ef8038c831e4d59a9459cb27f4f1ec8_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PerformanceAndMarketShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA2NA_7226a640-7a8c-469f-9522-7941d1a03aea">4.8</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifb1c8f46d9a3426091ee2103297afede_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PerformanceAndMarketShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA3MQ_6359bcc5-4039-455f-a270-4b1820aaded2"><ix:nonFraction unitRef="usd" contextRef="ib89660bd12204c74b680b13055456d71_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PerformanceAndMarketShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA3MQ_cd3fef4d-058e-4246-b8b1-b49f7d9eb1bd">0.4</ix:nonFraction></ix:nonFraction> million of general and administrative and research and development expense, respectively, for the three and six months ended June 30, 2019. The remaining expense to be recognized for these awards, using the accelerated attribution method, is $<ix:nonFraction unitRef="usd" contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="dnli:PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzg0ODI5MDcxODQyNQ_f3d7ca2c-d77a-4285-85ce-4ff23315b8ef">0.8</ix:nonFraction>&#160;million which will be recognized over the remaining derived service period of approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjE5Ng_40ff6178-4587-42fe-8169-938e295fadf9">one</span> year.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company used a lattice model with a Monte Carlo simulation to value these stock options. This valuation methodology utilized the estimated fair value of the Company&#8217;s common stock on grant date and several key assumptions, including expected volatility of the Company&#8217;s stock price based on comparable public companies, risk-free rates of return and expected dividend yield.</span></div></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i4b979d3b59ae4b0db0cd8dd121a81ee5" continuedAt="i3ab45b0c52bc4a3588040d753edf6ddf"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options Granted to&#160;Non-Employees&#160;with Service-Based Vesting Valuation Assumptions</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation related to stock options granted to&#160;non-employees&#160;is recognized as the stock options are earned. Prior to the adoption of ASU 2018-07 during the third quarter of 2018, the unvested options granted to non-employees were revalued using the Company's estimate of fair value on each reporting date. Subsequent to the adoption of ASU 2018-07, existing stock options granted to non-employees are no longer revalued, and the estimated fair value of new stock options granted to non-employees is calculated on the date of grant and not remeasured, similar to stock options granted to employees. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Activity</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the 2017 Plan, the Company may grant restricted stock awards ("RSAs"), which represent restricted shares of issued common stock for which the recipient's rights in the stock are restricted until the shares are vested, and restricted stock units ("RSUs"), which represent a commitment to issue shares of common stock in the future upon vesting. The fair value of restricted stock underlying the RSAs and RSUs is determined based on the closing market price of the Company's common stock on the date of grant.</span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNTQ_82a0c2d0-d73b-413e-835a-3c5752381fda" escape="true"><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Aggregated information regarding RSAs and RSUs granted under the Plan for the six months ended June 30, 2019 is summarized below:</span></div><div style="margin-top:10pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:62.903846%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.147436%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.147436%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Share Awards &amp; Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value at Date of Grant per Share</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4b8980df381840e981e39e869a8ad187_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMS0xLTEtMS0w_20171844-ec07-4657-92e6-bfdedd01ed7b">503,243</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b8980df381840e981e39e869a8ad187_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMS0zLTEtMS0w_08bc4c46-e217-4ab9-8599-47012e84ea85">4.86</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMi0xLTEtMS0w_134ff4c5-1ba9-481a-8b2c-f489e88fd674">494,984</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMi0zLTEtMS0w_4f5c815c-ca46-4cd1-b3a2-f30e6b94d403">19.09</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and released</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMy0xLTEtMS0w_08a07453-67e2-4110-b9c3-067906695f1f">353,585</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMy0zLTEtMS0w_6952e719-b9f6-4892-b7bb-17e74447a1a2">0.17</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNC0xLTEtMS0w_197c3ca3-654b-448b-ac50-ba721fb635ab">34,639</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNC0zLTEtMS0w_f3bc8b0b-6c2a-4b63-b3d4-6461709fa01b">21.31</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6a1246830c7445e9ce63b86b50115b5_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNS0xLTEtMS0w_e0680112-7dea-40d0-9584-c139145f54cc">610,003</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6a1246830c7445e9ce63b86b50115b5_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNS0zLTEtMS0w_e433a932-4a69-479b-84cf-566b4eead36a">18.44</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected to vest - June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6a1246830c7445e9ce63b86b50115b5_I20190630" decimals="INF" format="ixt:numdotdecimal" name="dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNi0xLTEtMS0w_a8b40d66-63ec-4a63-b62a-efbc5cd5667d">610,003</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630" decimals="2" name="dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNi0zLTEtMS0w_566059a8-5f32-4ca6-b1f9-20aaf039f97f">18.44</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company adopted the 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;), which initially reserved </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfODQ2Mg_84ab336c-ae42-43d9-85fd-52bfd7a20219">1.0</ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> shares of common stock for employee purchases under terms and provisions established by the Board of Directors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The 2017 ESPP provides that the number of shares reserved and available for issuance under the 2017 ESPP will automatically increase each January 1, beginning on January 1, 2019, by the least of (i) <ix:nonFraction unitRef="shares" contextRef="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231" decimals="INF" format="ixt:numdotdecimal" name="dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfODc1NQ_38a964f0-83f1-40fe-9873-e97daa8e36b4">2.0</ix:nonFraction> million shares, (ii) <ix:nonFraction unitRef="number" contextRef="i33146e3241854f64a4965054ea62ee6c_D20171201-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfODc3MQ_95d8dcd3-1633-4280-a464-fc6f5a67ea6e">1</ix:nonFraction>% of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the administrator of the 2017 Plan. In January 2019, common stock available for issuance under the 2017 ESPP was increased by approximately <ix:nonFraction unitRef="shares" contextRef="i71431700ff4c41c698876f5248f1b209_I20190131" decimals="INF" format="ixt:numdotdecimal" name="dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTA0Nw_22115274-508d-43b9-8f6f-26ed7abd9ac2">1.0</ix:nonFraction> million shares as a result of this automatic increase provision.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the 2017 ESPP, employees may purchase common stock through payroll deductions at a price equal to&#160;<ix:nonFraction unitRef="number" contextRef="i33146e3241854f64a4965054ea62ee6c_D20171201-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTIxMg_361022d3-91d7-48d7-9c63-9790183fad72">85</ix:nonFraction>%&#160;of the lower of the fair market value of common stock on the first trading day of each offering period or on the exercise date. The 2017 ESPP provides for consecutive, overlapping 12-month offering periods. The offering periods are scheduled to start on the first trading day on or after May 31 or November 30 of each year. Contributions under the 2017 ESPP are limited to a maximum of&#160;<ix:nonFraction unitRef="number" contextRef="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTYwMg_92940351-4eec-4ac0-be08-2ef7ae11b86a">15</ix:nonFraction>%&#160;of an employee's eligible compensation. During the three and six months ended June 30, 2019 and 2018, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="i33aae1a9291846d08a77fafcbb0fd48f_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_3f1556f6-5b2f-4bc6-9a56-4c870d3d8a40"><ix:nonFraction unitRef="shares" contextRef="ic58d3dfd7fcb4f99a54807dfac3b6669_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_516950ab-64af-40d3-a40e-bb2f4b6df0bc"><ix:nonFraction unitRef="shares" contextRef="if1f6b3468396492fb70d28ad0e7f8b98_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_d6348119-a570-403b-bb08-abce88936cba"><ix:nonFraction unitRef="shares" contextRef="ie1b4ec6e313c422fb982eb70ccc6089b_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_e02da434-aa7a-41fd-a3a5-80d8e3613b9e">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> shares of common stock were issued under the 2017 ESPP.</span></div></ix:continuation><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><ix:continuation id="i3ab45b0c52bc4a3588040d753edf6ddf"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNTI_b25fd2e4-ed78-4ed4-8285-baaf38400d7c" escape="true"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s results of operations include expenses relating to stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:39.185897%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.102564%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.102564%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.102564%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.102564%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d2e60ed90c84ab2b33750989f3caf7b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi0xLTEtMS0w_8b39bf0c-a2d0-4f84-bdf3-6b50594c4ed5">5,295</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81c40a2236074822a36030b30b61a38c_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi0zLTEtMS0w_986c9305-24e6-466c-98e0-718eb15edb8c">2,586</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b68413bf0b9461591e8c59a2ccb9464_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi01LTEtMS0w_0260f2a8-3d49-4b24-bfe1-0be253ffcd51">9,277</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i362003e4d15e477299173e68bb66528d_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi03LTEtMS0w_66ad1103-694b-446d-8ad8-60bff4366ec7">4,272</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0f2e8ea17014067925b92520d7e19bf_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy0xLTEtMS0w_4a514d0f-e856-40da-aac0-aae77bb4efea">8,419</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4633b220bff4b1ea513d03256f027b0_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy0zLTEtMS0w_afd287f3-31b3-4f3e-8777-7b9b4deb702c">2,124</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05bfa152469e4c2a8509fcde1cfa0f93_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy01LTEtMS0w_bcc40aff-3f01-48c4-9904-b734bec35e25">11,311</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieffd6c376be94ea4a96216622c548e7f_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy03LTEtMS0w_c11aa3ff-8711-41bb-8ad2-4655991ed2c2">3,363</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC0xLTEtMS0w_41aa2eea-86e4-4c5f-b594-3747da3e0e53">13,714</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC0zLTEtMS0w_ba9375c1-c73a-4474-9dc0-d6ab518a15c4">4,710</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC01LTEtMS0w_a27e5403-befa-4299-9a64-35f23717fcbb">20,588</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC03LTEtMS0w_fd173296-2e3e-4811-82e8-7fa4eb8baafd">7,635</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, total unamortized stock-based compensation expense related to employee and non-employee awards was $<ix:nonFraction unitRef="usd" contextRef="if979d5313f0948369e6c21ef7aec9f23_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAwMjc_380a9527-f636-4a90-a54d-58d5e98d378b">86.7</ix:nonFraction> million. The weighted-average periods over which such stock-based compensation expense will be recognized is approximately <ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNDU_724ef4fc-3a05-4884-9e08-d89b7782fecd">3.0</ix:nonNumeric> years.</span></div></ix:continuation><div id="i_0_70"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">10.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RleHRyZWdpb246MGU2OGFmNGE2NWJhNDZjOWFhZmY2ZmYyY2FjNjI0NDVfNDI5_96bae61e-4a1f-4553-8e46-76e681cf002a" continuedAt="ib6f1261f4b224a8cb039396ad1cf8b97" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="ib6f1261f4b224a8cb039396ad1cf8b97"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. </span></div><div style="text-indent:25pt;"><span><br/></span></div><ix:nonNumeric contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RleHRyZWdpb246MGU2OGFmNGE2NWJhNDZjOWFhZmY2ZmYyY2FjNjI0NDVfNDI4_77b32f8b-700f-4dd4-a039-3912c35bb299" escape="true"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:53.288462%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.596154%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.314103%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three and Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options issued and outstanding and ESPP shares issuable</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b682f4a3a5c487695cf4824ecff6284_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0xLTEtMS0w_b81a9781-4bc6-4a90-af19-a038b4780aa6"><ix:nonFraction unitRef="shares" contextRef="i8afd96134f0548538b390aa584b11fbd_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0xLTEtMS0w_eaca3301-d01b-446e-a53a-90dea4263b76">12,214,029</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0fd6c4f1d91440f7aab878612276cb59_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0zLTEtMS0w_2af62eb3-289b-4c21-8c0f-ce0b24628e45"><ix:nonFraction unitRef="shares" contextRef="i7f9cdfc6602e4cbcbb2d61b338e5e9d1_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0zLTEtMS0w_da5c08fb-5e7d-44a6-be32-50d0ae7cd3b4">9,264,644</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted shares subject to future vesting</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i000b38f6d8874a1ba6da55900807e8e1_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0xLTEtMS0w_ce1dfcd7-66d9-40a6-b643-590f17fafa66"><ix:nonFraction unitRef="shares" contextRef="ie3c2ef2c49884bb4b4428fbe8e81d56e_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0xLTEtMS0w_d1e3cb74-5289-462e-820e-5c0d161b1dc7">610,003</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8b5ff74e3d147f392767ecdbd341aa2_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0zLTEtMS0w_03fa2ecc-8971-4dc9-9824-f0e2e2395d89"><ix:nonFraction unitRef="shares" contextRef="i7196f17f798b440fb5034d6f6a84eb2e_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0zLTEtMS0w_f2431c5d-5573-41da-af24-518a50515fab">1,167,997</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Early exercised common stock subject to future vesting</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie5d5f8a792ce41f6b36480b7307d2e65_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0xLTEtMS0w_62afc513-0d35-41f7-abd5-482184dbf17f"><ix:nonFraction unitRef="shares" contextRef="id99aa73c5353433e959eff9dba13f059_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0xLTEtMS0w_c28e12f2-28a7-4af3-a639-dfdbf68764f4">41,672</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i97e55800d90541c4b977630444bbdbd0_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0zLTEtMS0w_9b4bec7d-3fe5-4a32-b1c5-03420ed3a40c"><ix:nonFraction unitRef="shares" contextRef="iecd2245025b2447a92a8217ee5cde65c_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0zLTEtMS0w_c3204cb0-b050-482c-ba35-2104481a6909">229,172</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0xLTEtMS0w_3594d1a8-156d-47ce-8658-6319fb509aee"><ix:nonFraction unitRef="shares" contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0xLTEtMS0w_74e2b293-7813-4452-909b-b28b553dad2d">12,865,704</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0zLTEtMS0w_84c41f15-c526-4fb1-bf10-1913030f5e8e"><ix:nonFraction unitRef="shares" contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0zLTEtMS0w_8f206f25-8721-44a5-a56a-a865a011c3c6">10,661,813</ix:nonFraction></ix:nonFraction>&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_73"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i_0_76"></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events coul</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">d differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled &#8220;Risk Factors&#8221; included in this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the success, cost and timing of our development activities, preclinical studies and clinical trials, including the enrollment in such trials, and in particular the development of our blood-brain barrier (&#8220;BBB&#8221;) platform technology, core programs and biomarkers;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the extent to which any dosing limitations that we have been subject to, and/or may be subject to in the future, may affect the success of our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the impact of preclinical findings on our ability to achieve exposures of our product candidates that allow us to explore a robust pharmacodynamic range of these candidates in humans;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the expected potential benefits and potential revenue resulting from strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the timing or likelihood of regulatory filings and approvals;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the terms and conditions of licenses granted to us and our ability to license and/or acquire additional intellectual property relating to our product candidates and BBB platform technology;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our current and potential future product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">future agreements with third parties in connection with the commercialization of our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the rate and degree of market acceptance of our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">existing regulations and regulatory developments in the United States and foreign countries; </span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">potential claims relating to our intellectual property and third-party intellectual property;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our potential plans and ability to develop our own manufacturing facilities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the pricing and reimbursement of our product candidates, if approved and commercialized;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the success of competing products or platform technologies that are or may become available;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our ability to attract and retain key managerial, scientific and medical personnel;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our ability to enhance operational, financial and information management systems;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our financial performance; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in &#8220;Risk Factors&#8221;. In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section entitled &#8220;Risk Factors&#8221; included in Part II, Item 1A and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We qualify all of the forward-looking statements in this Quarterly Report on Form 10-Q by these cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our goal is to discover and develop therapeutics to defeat degeneration.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our strategy is guided by three overarching principles:</span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt;">Genetic Pathway Potential</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">: We select our therapeutic targets and disease pathways based on genes that, when mutated, cause, or are major risk factors for, neurodegenerative diseases. We refer to these genes as degenogenes;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt;">Engineering Brain Delivery</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">: We engineer our product candidates to cross the BBB and act directly in the brain; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt;">Biomarker-Driven Development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">: We discover, develop and utilize biomarkers to select the right patient population and demonstrate target engagement, pathway engagement and impact on disease progression of our product candidates.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are developing a broad portfolio of targeted therapeutic candidates for neurodegenerative diseases. Our programs are at different stages of clinical and preclinical development, including three programs in clinical studies.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our three clinical programs are our leucine-rich repeat kinase 2 ("LRRK2") inhibitor program to address Parkinson&#8217;s disease, our receptor interacting serine/threonine protein kinase 1 ("RIPK1") inhibitor program to address neurodegenerative Alzheimer&#8217;s disease and amyotrophic lateral sclerosis ("ALS"), and a second RIPK1 inhibitor that our partner Sanofi is developing to address peripheral diseases such as rheumatoid arthritis. The two most advanced product candidates in our LRRK2 program, DNL201 and DNL151, are potent, selective and brain-penetrant small molecule LRRK2 inhibitor product candidates for Parkinson&#8217;s disease. DNL201 is currently in a Phase 1b clinical study in Parkinson&#8217;s disease patients with and without the genetic LRRK2 mutation. DNL151 is currently in a Phase 1 clinical trial in healthy volunteers in the Netherlands. The most advanced product candidate in our RIPK1 inhibitor program, DNL747, is a potent, selective and brain-penetrant small molecule RIPK1 inhibitor product candidate and is currently in Phase 1b clinical studies in ALS and Alzheimer's disease patients. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">DNL758 is a small molecule RIPK1 inhibitor that is not designed to cross the blood-brain barrier. DNL758 is being developed by our partner Sanofi in several non-neurological indications and is currently in Phase 1. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have also developed a proprietary BBB platform technology, our transport vehicle ("TV"), which is designed to effectively transport antibodies (antibody transport vehicle ("ATV")) and enzymes (enzyme transport vehicle ("ETV")) across the BBB. This technology is designed to engage specific BBB transport receptors, which are ubiquitously expressed in brain capillaries and facilitate transport of proteins into the brain. We are currently optimizing and broadening this platform technology. We plan to have multiple product candidates that utilize our ATV or ETV platforms enter clinical development in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">2020 and 2021, including iduronate 2-sulfatase (&#8220;IDS").</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To complement our internal capabilities, we have entered into arrangements with biopharmaceutical companies, patient-focused data companies, numerous leading academic institutions and foundations to gain access to new product candidates, enable and accelerate the development of our existing programs and deepen our scientific understanding of certain areas of biology. We rely on third-party contract manufacturers to manufacture and supply our preclinical and clinical materials to be used during the development of our product candidates. We currently do not need commercial manufacturing capacity.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Since we commenced operations in May 2015, we have devoted substantially all of our resources to discovering, acquiring and developing product candidates, building our BBB platform technology and assembling our core capabilities in understanding neurodegenerative disease pathways.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Key operational and financing milestones in 2019 to date include:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">In December 2018, we confirmed that the first preclinical milestone was met for the third program under the Takeda Collaboration Agreement, triggering a milestone payment of $5.0 million, which we received in February 2019;</span></div><div style="text-indent:4.5pt;padding-left:13.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">In January 2019, we announced, in collaboration with our partner Sanofi, the first patient dosed in our Phase 1b study of DNL747 in ALS patients, and in February 2019, we announced the first patient dosed in our Phase 1b study of DNL747 in Alzheimer's disease patients;</span></div><div style="text-indent:4.5pt;padding-left:13.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">In February 2019, DNL310 (ETV:IDS), which we are developing to treat mucopolysaccharidosis type II ("MPS II") or Hunter Syndrome patients, was granted orphan drug designation and rare pediatric disease designation by the FDA. DNL310 utilizes our proprietary enzyme transport vehicle (ETV) designed to bring IDS across the blood-brain barrier and into the brain. A Phase 1/2 clinical study of DNL310 in Hunter Syndrome patients is planned for this program in mid 2020;</span></div><div style="text-indent:4.5pt;padding-left:13.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">In April 2019, we completed our move to our new headquarters location; </span></div><div style="padding-left:13.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">In June 2019, we presented the progress of DNL343, a therapeutic candidate designed to inhibit the formation of stress granules by activating EIF2B. Stress granule formation is present in many neurodegenerative diseases, including ALS and Frontotemporal Dementia ("FTD"). We plan to commence dosing in a Phase 1 clinical study in healthy volunteers for this program in the first half of 2020; and</span></div><div style="text-indent:4.5pt;padding-left:13.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">In July 2019, our partner Sanofi commenced dosing of our partnered small molecule RIPK1 inhibitor, DNL758, in a Phase 1 clinical study in healthy volunteers. This triggered a milestone payment of $10.0 million, which we expect to receive in August 2019.</span></div><div style="text-indent:27pt;padding-left:49pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We do not have any products approved for sale and have not generated any product revenue since our inception. We have funded our operations primarily from the issuance and sale of convertible preferred stock, and the proceeds from our IPO and payments received from our collaboration agreements with Takeda and Sanofi.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant operating losses to date and expect to continue to incur operating losses for the foreseeable future. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses wer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">e $58.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$97.3 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">three and six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> June 30, 2019 and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$54.7 million, respectively, and $78.4 million for the three and six months ended June 30, 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, respectively.  As of June 30, 2019, we had an accumulated deficit o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">f $325.3 million. We e</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">xpect to continue to incur significant expenses and operating losses as we advance our LRRK2 and RIPK1 programs through patient trials; initiate first-in-human trials for our ETV:IDS and EIF2B programs, broaden and improve our BBB platform technology; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel.</span></div><div id="i_0_79"></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Components of Operating Results </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Revenue</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. All revenue recognized to date has been collaboration revenue from our collaboration agreements with Takeda and Sanofi.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In the future, we will continue to recognize revenue from the Takeda Collaboration Agreement and Sanofi Collaboration Agreement and may generate revenue from product sales or milestones, royalties and cost reimbursement from other collaboration agreements, strategic alliances and licensing arrangements. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year as a result of the timing and amount of license fees, milestones, reimbursement of costs incurred and other payments and product sales, to the extent any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Research and development activities account for a significant portion of our operating expenses. We record research and development expenses as incurred. Research and development expenses incurred by us for the discovery and development of our product candidates and BBB platform technology include:</span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">external research and development expenses, including:</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">expenses incurred under arrangements with third parties, such as contract research organizations ("CROs"), preclinical testing organizations, contract manufacturing organizations ("CMOs"), academic and non-profit institutions and consultants;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;text-align:center;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">expenses to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;text-align:center;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">fees related to our license and collaboration agreements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;text-align:center;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">personnel related expenses, including salaries, benefits and non-cash stock-based compensation expense; and</span></div><div style="text-indent:-13.5pt;padding-left:27pt;text-align:center;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A portion of our research and development expenses are direct external expenses, which we track on a program-specific basis once a program has commenced late-stage IND-enabling studies.</span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Program expenses include expenses associated with our most advanced product candidates and the discovery and development of backup or next-generation molecules. We also track external expenses associated with our BBB platform technology. These expenses include those incurred by us relating to our Takeda Collaboration Agreement and Sanofi Collaboration Agreement. All external costs associated with earlier stage programs, or that benefit the entire portfolio, are tracked as a group. We do not track personnel or other operating expenses incurred for our research and development programs on a program-specific basis. These expenses primarily relate to salaries and benefits, stock-based compensation, facility expenses including depreciation and lab consumables.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:</span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to add and retain key research and development personnel;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to establish an appropriate safety profile with IND-enabling toxicology studies;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our successful enrollment in and completion of clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our molecules;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates if and when approved;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the continued acceptable safety profiles of the product candidates following approval.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. We expect our research and development expenses to increase at least over the next several years as we continue to implement our business strategy, advance our current programs, expand our research and development efforts, seek regulatory approvals for any product candidates that successfully complete clinical trials, access and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses include personnel-related expenses, such as salaries, benefits, travel and non-cash stock-based compensation expense, expenses for outside professional services and allocated expenses. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expenses related to our office and research and development facility not otherwise included in research and development expenses. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase our administrative headcount as we advance our product candidates through clinical development, which will also likely require us to increase our general and administrative expenses.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest and Other Income, Net </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, consists pr</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">imarily of interest income and investment income earned on our cash, cash equivalents, and marketable securities, unrealized gains and losses on foreign currency hedges, and sublease income.</span></div><div id="i_0_82"></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">three and six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> June 30, 2019 and 2018 </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following tables set forth the significant components of our results of operations (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:43.352564%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.921795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.897436%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.364103%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Collaboration revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,197&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,648&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,549&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">51,884&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">52,134&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(250)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">15,076&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,896&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,180&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:60pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total operating expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">66,960&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">59,030&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,930&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Loss from operations</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(62,763)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(57,382)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(5,381)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Interest and other income, net</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,113&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,658&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,455&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">313&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">313&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(58,337)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(54,724)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,613)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">__________________________________________________</span></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">* &#160;Percentage is not meaningful.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:43.352564%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.921795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.897436%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.364103%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Collaboration revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,402&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,289&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,113&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">267&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">89,287&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">72,953&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16,334&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">24,386&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,466&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,920&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">96&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:60pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total operating expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">113,673&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">85,419&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,254&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Loss from operations</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(105,271)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(83,130)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(22,141)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Interest and other income, net</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,629&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,728&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,901&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">313&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">313&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(97,329)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(78,402)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,927)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">__________________________________________________</span></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">* &#160;Percentage is not meaningful.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Revenue.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Collaboration revenue was&#160;$4.2 million and $8.4 million&#160;for the three and six months ended June 30, 2019, respectively, and $1.6&#160;million and $2.3&#160;million for the three and six months ended June 30, 2018, respectively.&#160;The increase in the three months ended June 30, 2019 compared to the three months ended June 30, 2018 was due to $3.5 million of revenue recognized under our Sanofi Collaboration Agreement, partially offset by a decrease in revenue recognized under the Takeda Collaboration Agreement of $0.9 million. The increase in the six months ended June 30, 2019 compared to the six months ended June 30, 2018 was due to $7.0 million of revenue recognized under our Sanofi Collaboration Agreement, partially offset by a decrease in revenue recognized under the Takeda Collaboration Agreement of $0.9 million. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ses.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses were $51.9 million and $89.3 million for the three and six months ended June 30, 2019, compared to $52.1 million and $73.0 million for the three and six months ended June 30, 2018.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our research and development expenses by program and category (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:45.916667%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.921795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820513%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">LRRK2 program external expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,454&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,039&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,616&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,247&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">RIPK1 program external expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,613&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,094&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,813&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,947&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">ETV program external expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,756&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,486&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,041&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,936&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other BBB program external expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,740&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,010&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,456&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,006&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">BBB platform external expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">447&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">27,546&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">785&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,197&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Other external research and development expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,533&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,200&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,996&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,304&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Personnel-related expenses</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">&#160;(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">15,915&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,358&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">17,098&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Other unallocated research and development expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,426&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,401&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">15,590&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,218&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-12pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">51,884&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">52,134&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">89,287&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">72,953&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">__________________________________________________</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:3pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt;">Personnel-related expenses include stock-based compensation expense of $5.3 million and $9.3 million for the three and six months ended June 30, 2019, respectively, and $2.6 million and $4.3 million for the three and six months ended June 30, 2018, respectively, reflecting increases of $2.7 million and $5.0 million, respectively. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The decrease in total research and development expenses of $0.3 million for the three months ended June 30, 2019 compared to the three months ended June 30, 2018 was primarily attributable to a $27.1 million decrease in BBB platform associated expenses, the majority of which related to expenses associated with the nomination of two additional Fcab targets under the F-star Collaboration Agreement, and the acquisition of F-star Gamma Limited in May 2018. This decrease was offset by increases in external expenses related to our portfolio and platform technology, including an increase of $5.4 million in LRRK2 program external expenses, an increase of $3.3&#160;million in ETV program external expenses, an increase of $2.7 million in other BBB program external expenses, and an increase of $0.5 million in RIPK1 program external expenses. Further there was a $6.6 million increase in personnel-related expenses, consisting of a $3.9 million increase in salaries and related expenses attributable to an increase in our research and development headcount, and a $2.7 million increase in stock-based compensation expense primarily attributable to new equity award grants and certain performance and market-based awards, a $4.3 million increase in other external research and development expenses to support our growing pipeline, and an increase in other unallocated research and development expenses of $4.0 million, which was primarily due to an increase in facilities related expenses of $3.1 million resulting from increased rent expense associated with the new headquarters lease.  </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The increase in total research and development expenses of $16.3 million for the six months ended June 30, 2019 compared to the six months ended June 30, 2018 was primarily attributable to a $11.8 million increase in personnel-related expenses, consisting of a $6.8 million increase in salaries and related expenses attributable to an increase in our research and development headcount, and a $5.0 million increase in stock-based compensation expense primarily attributable to new equity award grants and certain performance and market-based awards. Further, there were increases in external expenses related to our portfolio and platform technology, including an increase of $6.4 million in LRRK2 program external expenses, an increase of $6.1 million in ETV program external expenses, an increase of $4.5 million in other BBB program external expenses, and an increase of $1.9 million in RIPK1 program external expenses. There was also an increase in other unallocated research and development expenses of $7.4 million, which was primarily due to an increase in facilities related expenses of $6.0 million resulting from increased rent expense associated with the new headquarters lease, and a $5.7 million increase in other external research and development expenses to support our growing pipeline. These increases were partially offset by a $27.5 million decrease in BBB platform associated expenses, the majority of which related to expense associated with the nomination of two additional Fcab targets under the F-star Collaboration Agreement, and the acquisition of F-star Gamma Limited in May 2018.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. General and administrative expenses were $15.1 million for the three months ended June 30, 2019 compared to $6.9 million for the three months ended June 30, 2018. The increase of approximately $8.2&#160;million was primarily attributable to a $7.0 million increase in personnel-related expenses, including non-cash stock-based compensation, driven primarily by higher headcount and stock-based compensation expense associated with new equity award grants and certain performance and market-based awards. Additionally, there was a $0.6&#160;million increase in facilities related expenses, including increased rent expense associated with the new headquarters lease, and a $0.2 million increase in legal expenses and other professional services to support our growing operations, with the remainder of the difference relating to other miscellaneous costs such as insurance and taxes.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses were $24.4 million for the six months ended June 30, 2019 compared to $12.5 million for the six months ended June 30, 2018. The</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">increase of approximately $11.9 million was primarily attributable to a $9.3&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">increase in personnel-related expenses, including non-cash stock-based compensation, driven primarily by higher headcount and stock-based compensation expense associated with new equity award grants and certain performance and market-based awards. Additionally, there was a $1.3&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">increase in facilities related expenses, including increased rent expense associated with the new headquarters lease, and a $0.5&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">increase in legal expenses and other professional services to support our growing operations, with the remainder of the difference relating to other miscellaneous costs such as insurance and taxes.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest and other income, net.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;Interest and other income, net was $4.1 million for the three months ended June 30, 2019 compared to $2.7 million for the three months ended June 30, 2018. The increase of $1.4 million reflects increased interest rates on marketable securities in our portfolio for the three months ended June 30, 2019, as well as $0.8 million of sublease income received in the three months ended June 30, 2019. There was no sublease income for the three months ended June 30, 2018.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net was $7.6 million for the six months ended June 30, 2019 compared to $4.7 million for the six months ended June 30, 2018. The increase of</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$2.9 million reflects that the average marketable securities balance was higher in the period, and reflects increased interest rates on marketable securities in our portfolio for the six months ended June 30, 2019. Further, there was $0.8 million of sublease income received in the six months ended June 30, 2019 but no sublease income for the six months ended June 30, 2018.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income tax benefit. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Income tax benefit was $0.3 million for the three and six months ended June 30, 2019 due to the tax benefit associated with unrealized gain on marketable securities in other comprehensive income. There was no income tax benefit for the three and six months ended June 30, 2018.</span></div><div id="i_0_85"></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sources of Liquidity</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have funded our operations primarily from the issuance and sale of convertible preferred stock, proceeds from our IPO and payments received from our collaboration agreements with Takeda and Sanofi. We received&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$264.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;from our IPO in December 2017. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Takeda Collaboration Agreement, we have received $55.0 million related to upfront and milestone payments through </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. Further, under the associated Purchase Agreement we received </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$110.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in February 2018 for the sale and issuance of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">4,214,559</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> shares of our common stock.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Sanofi Collaboration Agreement, we received an upfront payment of $125.0 million in November 2018, and we received further payments of $5.8 million for performance of Retained Activities through June&#160;30, 2019.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019, we had cash, cash equivalents and marketable securities in the amount of</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$534.4 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future Funding Requirements</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To date, we have not generated any product revenue. We do not expect to generate any product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, either will occur.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we expand our research and development activities and continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. Further, we expect general and administrative expenses to increase as we continue to incur additional costs associated with operating as a public company. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Until we can generate a sufficient amount of revenue from the commercialization of our product candidates or from our existing collaboration agreements, or future agreements with other third parties, if ever, we expect to finance our future cash needs through public or private equity or debt financings. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. Any of the foregoing could significantly harm our business, financial condition and prospects.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have incurred significant losses and negative cash flows from operations. We have an accumulated deficit of $325.3 million through June 30, 2019. We expect to incur substantial additional losses in the future as we conduct and expand our research and development activities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund our projected operations through at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing and progress of preclinical and clinical development activities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the progress of the development efforts of third parties with whom we have entered into license and collaboration agreements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to maintain our current research and development programs and to establish new research and development, license or collaboration arrangements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability and success in securing manufacturing relationships with third parties or, in the future, in establishing and operating a manufacturing facility;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the costs involved in prosecuting, defending and enforcing patent claims and other intellectual property claims;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the cost and timing of regulatory approvals;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our efforts to enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the costs and ongoing investments to in-license and/or acquire additional technologies.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:55.951070%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.642202%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.642202%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(73,498)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(8,247)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55,834&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(270,746)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,477&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">94,671&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(14,187)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(184,322)</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Used In Operating Activities </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, cash used in operating activities was $73.5 million, which consisted of a net loss of $97.3 million, adjusted by non-cash expenses primarily related to stock-based compensation, depreciation, and non-cash rent expenses, partially offset by net amortization of premiums and discounts on marketable securities. Cash used in operating activities was also driven by changes in our operating assets and liabilities.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2018, cash used in operating activities was $8.2 million, which consisted of a net loss of $78.4 million, adjusted by non-cash expenses related to stock-based compensation and depreciation expenses, partially offset by net amortization of premiums and discounts on marketable securities. Cash used in operating activities was also driven by changes in our operating assets and liabilities primarily due to an increase of $58.3 million in the contract liability related to the Takeda Collaboration Agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Provided By (Used In) Investing Activities </span></div><div><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, cash provided by investing activities was $55.8 million, which consisted of $212.2 million in proceeds from the maturity of marketable securities, partially offset by $144.0 million of purchases of marketable securities and $12.3 million of capital expenditures to purchase property and equipment.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2018, cash used in investing activities was $270.7 million, which consisted of $361.7 million of purchases of marketable securities and $1.1 million of capital expenditures to purchase property and equipment, partially offset by $92.0 million in proceeds from the maturity of marketable securities.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Provided By Financing Activities </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, cash provided by financing activities was $3.5 million, which consisted entirely of proceeds from the exercise of options to purchase common stock and issuance of ESPP shares. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, cash provided by financing activities was </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$94.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">which consisted of the $94.4 million market value of the 4,214,559 shares of common stock issued to Takeda in February 2018 under the Stock Purchase Agreement, and $1.7 million of proceeds from the exercise of common stock options. These amounts were partially offset by $1.4 million for payments of issuance costs related to the issuance of common and preferred stock.</span></div><div id="i_0_88"></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have not entered into any off-balance sheet arrangements. Prior to our acquisition of all of the outstanding shares of F-star Gamma, our F-star Collaboration Agreement represented a variable interest in a variable interest entity, or VIE, F-star Gamma. However, we did not consolidate F-star Gamma in our consolidated financial statements because we had determined that we were not considered to be its primary beneficiary.</span></div><div id="i_0_91"></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commitments</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In May 2018, we entered into an amendment to our headquarters lease (the "Headquarters Lease Amendment") to relocate and expand our headquarters to 148,020 rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of ten years from the legal commencement date, which was April&#160;1, 2019 when the building was ready for occupancy. We have an option to extend the lease term for a period of ten years by giving the landlord written notice of the election to exercise the option at least nine months, but not more than twelve months, prior to the expiration of the Headquarters Lease Amendment lease term. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provides a tenant improvement allowance of up to $25.9 million, of which $4.4 million will be repaid to the landlord in the form of additional monthly rent. We are also required to pay the operating expenses for the New Premises, such as taxes and insurance.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Effective September 2017, we entered into a Development and Manufacturing Services Agreement, as amended ("DMSA") with Lonza Sales AG ("Lonza") for the development and manufacture of biologic products. Under the DMSA, we will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of our antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. Unless earlier terminated, the DMSA will expire on September&#160;6, 2022. </span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 and December 31, 2018, we had non-cancellable purchase orders for biological product development and manufacturing costs totaling $25.1 million and $24.7 million respectively. The activities under these purchase orders are expected to be completed by November 2024. As of June 30, 2019 and December 31, 2018, we had total non-refundable purchase commitments of $10.3 million and $14.0 million, respectively, under the DMSA.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2019 and 2018, we incurred costs of $3.1&#160;million and $1.1&#160;million, respectively, and made payments of $3.9&#160;million and $0.6 million, respectively, for the development and manufacturing services rendered under the DMSA. During the six months ended June 30, 2019 and 2018, we incurred costs of $6.7 million and $1.2 million, respectively, and made payments of $6.5 million and $0.7 million, respectively, for the development and manufacturing services rendered under the DMSA. </span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Other than those detailed above, there have been no other material changes from the contractual obligations and commitments previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March&#160;12, 2019.</span></div><div id="i_0_94"></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Other than the updated leases accounting policy included below, there have been no material changes to our critical accounting policies and estimates during the six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">March&#160;12, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Leases</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We make a determination as to whether an arrangement is a lease at inception. We recognize a right-of-use (&#8220;ROU&#8221;) asset and operating lease liability for identified operating leases in the condensed consolidated balance sheets. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease ROU assets and liabilities at commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, we use our incremental borrowing rate (&#8220;IBR&#8221;) on the date of lease commencement, or the rate implicit in the lease, if known.  We do not assume renewals in our determination of the lease term unless the renewals are deemed to be reasonably assured at lease inception.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We do not include leases with an initial term of 12 months or less on the balance sheet, unless they include an option to purchase the underlying asset which is reasonably certain of exercise. We recognize lease expenses on a straight-line basis over the lease term. We have leases with lease and non-lease components, which we have elected to account for as a single lease component. </span></div><div id="i_0_97"></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:27pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Except as described in Note 1 to the condensed consolidated financial statements under the headings &#8220;Recently Issued Accounting Pronouncements&#8221; and "Recently Adopted Accounting Pronouncements", there have been no new accounting pronouncements or changes to accounting pronouncements during the&#160;six months ended&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, as compared to the recent accounting pronouncements described in our&#160;Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March&#160;12, 2019, that are of significance or potential significance to us.</span></div><div id="i_0_100"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3. &#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate and foreign currency sensitivities.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Interest Rate Sensitivity</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and marketable securities of $534.4 million as of June 30, 2019, which consisted primarily of money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income securities.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, according to our board-approved investment policy. Our investments are subject to interest rate risk and could fall in value if market interest rates increase. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Sensitivity</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The majority of our transactions occur in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily the Euro, British Pound, and Swiss Franc, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities primarily associated with a limited number of preclinical and clinical activities. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We seek to mitigate the impact of changes in currency exchange rates on cash flows from certain foreign currency denominated operating expenses by entering into forward foreign currency exchange contracts. Generally, the market risks of these contracts are offset by the corresponding gains and losses on the transactions being hedged.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the effects of changes in foreign currency exchange rates. The counterparties to these forward foreign currency exchange contracts are creditworthy multinational commercial banks, which minimizes the risk of counterparty nonperformance. We regularly review our hedging program and may, as part of this review, make changes to the program.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, we had open forward foreign currency exchange contracts with notional amounts of $8.1 million. A hypothetical 10% strengthening in foreign currency compared with the U.S. dollar at June 30, 2019 would have resulted in an increase in the value received over the remaining life of these contracts of approximately $0.8 million and, if realized, would positively affect earnings during the remaining life of the contracts. This analysis does not consider the impact of the hypothetical changes in foreign currency rates would have on the forecasted transactions that these foreign currency sensitive instruments were designated to offset.</span></div><div id="i_0_103"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. &#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i_0_106"></div><div style="text-align:center;margin-top:18pt;"><span><br/></span></div><div style="text-align:center;margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="i_0_109"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS </span></div><div style="text-indent:27pt;text-align:center;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i_0_112"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A. &#160;RISK FACTORS </span></div><div style="margin-top:2pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in t</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">his Quarterly Report on Form 10-Q, incl</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">uding our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. The risk factors set forth below are substantially the same as the risk factors included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#160;12, 2019.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business, Financial Condition and Capital Requirements</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are in the early stages of clinical drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are an early clinical-stage biopharmaceutical company with a very limited operating history, focused on developing therapeutics for neurodegenerative diseases, including Alzheimer&#8217;s disease, Parkinson&#8217;s disease and amyotrophic lateral sclerosis ("ALS"). We commenced operations in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">May 2015</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, have no products approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> and involves a substantial degree of risk. We are in Phase 1 clinical trials for our LRRK2 and RIPK1 programs and have not initiated clinical trials for any of our other current product candidates. To date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidat</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">es, manufactured a commercial scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant net losses since our inception, including net losses of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$58.3 million and $97.3 million for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, respectively, and $54.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$78.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">three and six months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> June 30, 2018,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">respectively. As of June 30, 2019, we had an accumulated deficit of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$325.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have invested significant financial resources in research and development activities, including for our preclinical and clinical product candidates and our BBB platform technology. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur significant expenses and increasingly higher operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">continue our research and discovery activities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">progress our current and any future product candidates through preclinical and clinical development;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">initiate and conduct additional preclinical, clinical or other studies for our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">work with our contract manufacturers to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">change or add additional contract manufacturers or suppliers;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">seek regulatory approvals and marketing authorizations for our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">acquire or in-license product candidates, intellectual property and technologies;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">make milestone, royalty or other payments due under any license or collaboration agreements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">obtain, maintain, protect and enforce our intellectual property portfolio, including intellectual property obtained through license agreements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">attract, hire and retain qualified personnel;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">experience any delays or encounter other issues related to our operations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">meet the requirements and demands of being a public company; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">defend against any product liability claims or other lawsuits related to our products.</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have never generated any revenue from product sales, and we may never generate product revenue or be profitable.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We have no products approved for commercial sale and have not generated any revenue from product sales. To obtain revenue from the sales of our product candidates that are significant or large enough to achieve pr</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">ofitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing and marketing therapies with significant commercial success.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our ability to generate revenue and achieve profitability depends significantly on many factors, including:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">successfully completing research and preclinical and clinical development of our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">developing a sustainable and scalable manufacturing process for our product candidates, including those that utilize our BBB platform technology, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;text-align:center;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">identifying, assessing, acquiring and/or developing new product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">obtaining adequate reimbursement for our product candidates from payors;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">obtaining market acceptance of our product candidates as viable treatment options;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">addressing any competing technological and market developments;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">attracting, hiring and retaining qualified personnel.</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the U.S. Food and Drug Administration, or FDA, or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#8217; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts.</span></div><div style="text-indent:27pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as significant as we anticipate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may adversely affect our viability.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to obtain additional financing, we may be unable to complete the development and, if approved, commercialization of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our operations have required substantial amounts of cash since inception. To date, we have financed our operations primarily through the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">issuance and sale of convertible preferred stock, the proceeds from our initial public offering ("IPO") and cash proceeds under our Takeda Collaboration Agreement and Sanofi Collaboration Agreement. We are currently advancing three product candidates, DNL201, DNL151 and DNL747, through clinical development and have several other product candidates in preclinical development, as well as early-stage research projects. Developing our product candidates is expensive, and we expect to continue to spend substa</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">ntial amounts as we fund our early-stage research projects, continue preclinical development of our seed programs and, in particular, advance our core programs through preclinical development and clinical trials. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, we had $534.4 million in cash, cash equivalents and marketable securities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our projected operations through at least the next 12 months. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to be available to fund our operations is based on assumptions that may be proved inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We will require additional capital for the further development and, if approved, commercialization of our product candidates. Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, growth prospects and cause the price of our common stock to decline.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We designate certain programs as core programs and others as seed programs. Together, these programs require significant capital investment.  Our programs are at various stages of research, discovery, preclinical and early clinical development.  We seek to maintain a process of prioritization and resource allocation to maintain an optimal balance between aggressively advancing lead programs and ensuring replenishment of our portfolio.  We regularly review the designation of each program as core or seed, and terminate those programs which do not meet our development criteria, which we have done a number of times in the past.  </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Due to the significant resources required for the development of our programs, we must focus our programs on specific diseases and disease pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases, our business, financial condition, results of operations and growth prospects could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</span></div><div id="i_0_115"></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and development of biopharmaceutical products is inherently risky.&#160;We are heavily dependent on the successful development of our BBB platform technology and the product candidates currently in our core programs, which are in the early stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are at an early stage of development of the product candidates currently in our programs and are further developing our BBB platform technology. To date, we have invested substantially all of our efforts and financial resources to identify, acquire intellectual property for, and develop our BBB platform technology and our programs, including conducting preclinical studies and early-stage clinical trials in our core programs, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our product candidates may not successfully complete preclinical studies or clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our drug delivery platform technology designed to deliver large molecule therapeutics across the BBB may not be clinically viable;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our competitors may develop platform technologies to deliver large molecule therapeutics across the BBB that render our platform technology obsolete or less attractive;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the product candidates and BBB platform technology that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the product candidates and BBB platform technology that we develop may be covered by third parties&#8217; patents or other intellectual property or exclusive rights;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We may not be successful in our efforts to further develop our BBB platform technology and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have never completed a clinical development program. In the past two years, we have discontinued the development of certain molecules prior to completion of preclinical development because we did not believe they </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">met our criteria for potential clinical success. We currently have one product candidate, DNL201, in a Phase 1b clinical study in Parkinson's disease patients with and without the genetic LRRK2 mutation, one product candidate, DNL747, in Phase 1b clinical studies in ALS and Alzheimer's disease patients, and one product candidate, DNL151, in a Phase 1 clinical trial in healthy volunteers. None of our product candidates have advanced into late-stage development or a pivotal clinical trial and it may be years before any such trial is initiated, if at all. Further, we canno</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">t be certain that any of our product candidates will be successful in clinical trials. For instance, in 2016, we initiated a Phase 1 clinical trial in a former RIPK1 inhibitor product candidate, DNL104, which we subsequently discontinued based on liver test abnormalities in some clinical trial healthy volunteer participants. We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates successfully complete clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the European Union, or EU, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or partners will conduct these activities or do so within the time frame we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue, business, financial condition, results of operations and growth prospects could be negatively affected.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or other diseases, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">One of our strategies is to identify and pursue clinical development of additional product candidates. We curren</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">tly have several programs </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">in the research, discovery and preclinical stages of development. Identifying, developing, obtaining regulatory approval and commercializing additional product candidates for the treatment of neurodegenerative diseases will require substantial additional funding and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our product candidates are based on new approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have focused our research and development efforts on addressing neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are few effective therapeutic options available for patients with Alzheimer&#8217;s disease, Parkinson&#8217;s disease, ALS and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our BBB platform technology and our product candidates for treating neurodegenerative diseases. Developing and, if approved, commercializing our product candidates for treatment of neurodegenerative diseases subjects us to a number of challenges, including engineering product candidates to cross the BBB to enable optimal concentration of the therapeutic in the brain and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our approach to the treatment of neurodegenerative diseases aims to identify and select targets with a genetic link to neurodegenerative diseases, identify and develop molecules that engage the intended target, identify and develop biomarkers, which are biological molecules found in blood, other bodily fluids or tissues that are signs of a normal or abnormal process or of a condition or disease, to select the right patient population and demonstrate target engagement, pathway engagement and impact on disease progression of our molecules, and engineer our molecules to cross the BBB and act directly in the brain. This strategy may not prove to be successful. We may not be able to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our molecules. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to novel treatments.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an investigational new drug application, or IND, or a clinical trial application, or CTA, will result in the FDA or European Medicines Agency, or EMA, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">inability to generate sufficient preclinical, toxicology, or other&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;or&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vitro</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;data to support the initiation or continuation of clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in confirming target engagement, patient selection or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in reaching a consensus with regulatory agencies on study design;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in identifying, recruiting and training suitable clinical investigators;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or study sites; developments on trials conducted by competitors for related technology that raises FDA or EMA concerns about risk to patients of the technology broadly; or if the FDA or EMA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in identifying, recruiting and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">difficulty collaborating with patient groups and investigators;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure by our CROs, other third parties, or us to adhere to clinical trial requirements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current good clinical practices ("cGCPs") requirements, or applicable EMA or other regulatory guidelines in other countries;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the cost of clinical trials of our product candidates being greater than we anticipate;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">transfer of manufacturing processes from our academic collaborators to larger-scale facilities operated by a CMO or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our most advanced LRRK2 product candidate, DNL201, is in a Phase 1b clinical study in Parkinson's disease patients with and without the genetic LRRK2 mutation. This program was previously subject to a partial clinical hold due to preclinical toxicity data. The partial clinical hold was removed in December 2017 based on additional clinical and preclinical data provided to the FDA. Our other clinical stage programs are DNL747, which is in Phase 1b clinical studies in ALS and Alzheimer's disease patients, and DNL151 which is in a Phase 1 clinical trial in healthy volunteers. In the nonclinical safety studies for DNL201, DNL747 and DNL151, toxicities were observed at high doses in rat and/or cynomolgus monkey above doses and exposures that will be tested in the clinic. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We cannot assure you that DNL201, DNL747 and DNL151 or our other product candidates will not be subject to new, partial or full clinical holds in the future.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, such as we did for DNL104, which could adversely affect our business.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the size and nature of the patient population;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the proximity of patients to a trial site;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the design of the trial;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to obtain and maintain patient consents; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the risk that patients enrolled in clinical trials will not complete such trials, for any reason.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Open-label extension studies may also extend the timing and increase the cost of clinical development substantially. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including Alzheimer&#8217;s disease, Parkinson&#8217;s disease and ALS. Companies that we are aware are developing therapeutics in the neurodegenerative disease area include large companies with significant financial resources, such as AbbVie, AstraZeneca, Biogen, Celgene, Eli Lilly, GlaxoSmithKline, Johnson&#160;&amp; Johnson, Novartis, Roche, Sanofi and Takeda. In addition to competition from other companies targeting neurodegenerative indications, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. See &#8220;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The manufacture of our product candidates, particularly those that utilize our BBB platform technology, is complex and we may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The processes involved in manufacturing our drug and biological product candidates, particularly those that utilize our BBB platform technology, are complex, expensive, highly-regulated and subject to multiple risks. Additionally, the manufacture of biologics involves complex processes, including developing cells or cell systems to produce the biologic, growing large quantities of such cells, and harvesting and purifying the biologic produced by them. As a result, the cost to manufacture a biologic is generally far higher than traditional small molecule chemical compounds, and the biologics manufacturing process is less reliable and is difficult to reproduce. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in small and large quantities. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risks would apply to our internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including complying with current good manufacturing practices ("cGMPs"), on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Factors that may inhibit our efforts to commercialize any approved product on our own include:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the potential and perceived advantages compared to alternative treatments;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the ability to offer our products for sale at competitive prices;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the ability to offer appropriate patient access programs, such as co-pay assistance;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the extent to which physicians recommend our products to their patients;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">convenience and ease of dosing and administration compared to alternative treatments;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the clinical indications for which the product candidate is approved by FDA, EMA or other regulatory agencies;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a product&#8217;s approved labeling;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">restrictions on how the product is distributed;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing of market introduction of competitive products;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">publicity concerning our products or competing products and treatments;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the strength of marketing and distribution support;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">sufficient third-party coverage or reimbursement; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the prevalence and severity of any side effects.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The regulations that govern marketing approvals, pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs, or VA, hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any of our product candidates that are small molecules obtain regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic copy of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application, or NDA, under section&#160;505(b)(2) that references the FDA&#8217;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and reviewing) of an ANDA or 505(b)(2) NDA. These include, subject to certain exceptions, the period during which an FDA-approved drug is subject to orphan drug exclusivity. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in the ANDA a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Accordingly, if any of our small molecule product candidates are approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products, respectively. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected. See &#8220;Risks Related to Our Intellectual Property.&#8221;</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our biologic, or large molecule, product candidates for which we intend to seek approval may face competition sooner than anticipated.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, our large molecule product candidates may face competition from biosimilar products. In the United States, our large molecule product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the biologics license application, or BLA, pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our large molecule product candidates.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We believe that any of our large molecule product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get it on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If competitors are able to obtain marketing approval for biosimilars referencing our large molecule product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">decreased or interrupted demand for our products;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">injury to our reputation;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">initiation of investigations by regulators;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">costs to defend the related litigation;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a diversion of management&#8217;s time and our resources;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">substantial monetary awards to trial participants or patients;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">loss of revenue;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">exhaustion of any available insurance and our capital resources;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the inability to commercialize any product candidate; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a decline in our share price.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div id="i_0_118"></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The time required to obtain approval by the FDA, EMA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Moreover, the FDA, EMA or other regulatory authorities may fail to approve companion diagnostics that we contemplate using with our therapeutic product candidates. We have not submitted for, or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, EMA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our most advanced product candidates, DNL201, DNL747 and DNL151 are currently our only clinical stage product candidates. DNL201 and DNL</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">747 progressed to Phase 1b trials in patients in 2018, and DNL151 is in a Phase 1 clinical trial in healthy volunteers. In trials to date, all three molecules have been well tolerated. Adverse events and other side effects may result from higher dosing, repeated dosing and/or longer-term exposure to DNL201, DNL747 and/or DNL151 and could lead to delays and/or termination of the development of these product candidates.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In 2016, we initiated a Phase 1 clinical trial in a former RIPK1 inhibitor product candidate, DNL104, which we subsequently discontinued based on liver function test abnormalities in some clinical trial healthy volunteer participants.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our license agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">regulatory authorities may withdraw approvals of such product and cause us to recall our product;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">regulatory authorities may require additional warnings on the label;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements, such as boxed warning on the packaging, to assure safe use;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">we could be sued and held liable for harm caused to patients; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our reputation may suffer.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations, and growth prospects.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may in the future conduct clinical trials for our product candidates outside the United&#160;States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We may in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive requirements imposed by the FDA, EMA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA or marketing authorization application, or MAA. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">issue warning letters that would result in adverse publicity;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">impose civil or criminal penalties;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">suspend or withdraw regulatory approvals;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">suspend any of our ongoing clinical trials;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">seize or detain products; and/or</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">require a product recall.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We plan to seek orphan drug designation for some product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. In June 2019, the FDA granted orphan drug designation for our DNL310 program in Hunter syndrome. We plan to seek orphan drug designations for some other product candidates and may be unable to obtain such designations.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other NDA or BLA applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even though DNL310 has been granted orphan drug designation and even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Affordable Care Act, or ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals&#160;enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Recent changes in the U.S. administration could lead to repeal of or changes in some or all of the ACA, and complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be difficult to predict its full impact and influence on our business.</span></div><div style="text-indent:27pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year, which went into effect in&#160;2013, and will remain in effect through 2025 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to receive or set a price that we believe is fair for our products;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the level of taxes that we are required to pay; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the availability of capital.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities; provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which impose criminal and civil penalties, including through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">A wide variety of provincial, state, national, and international laws and regulations apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. These data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. For example, the European Union General Data Protection Regulation, or GDPR, which became fully effective on May 25, 2018, imposes stringent data protection requirements and provides for penalties for noncompliance of up to the greater of &#8364;20 million or four percent of worldwide annual revenues.&#160; Additionally, California recently enacted legislation, the California Consumer Privacy Act, or CCPA, that will, among other things, require covered companies to provide new disclosures to California consumers, and afford such consumers new abilities to opt-out of certain sales of personal information, when it goes into effect on January 1, 2020.  The CCPA was amended in September 2018, and it is unclear whether further modifications will be made to this legislation or how it will be interpreted.  The GDPR, CCPA and many other laws and regulations relating to privacy and data protection are still being tested in courts, and they are subject to new and differing interpretations by courts and regulatory officials.&#160; We are working to comply with the GDPR, CCPA and other privacy and data protection laws and regulations that apply to us, and we anticipate needing to devote significant additional resources to complying with these laws and regulations.&#160; It is possible that the GDPR, CCPA or other laws and regulations relating to privacy and data protection may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices.&#160; </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our actual or perceived failure to adequately comply with applicable laws and regulations relating to privacy and data protection, or to protect personal data and other data we process or maintain, could result in regulatory fines, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, any of which could materially affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or SEC, and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, in the future once we enter a commercialization phase, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations.  Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue.  Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, we may be fined or other penalties could be imposed, including a denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or technologies targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any limitation on our ability to export or sell access to our products would likely adversely affect our business.</span></div><div id="i_0_121"></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We anticipate seeking third-party collaborators for the research, development, and commercialization of certain of the product candidates we may develop. For example, we have collaborations with F-star, Takeda, Sanofi and others, to further our development of product candidates and to enhance our research efforts directed to better understanding neurodegenerative diseases. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies and academic institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Collaborations involving our research programs, or any product candidates we may develop, pose the following risks to us:</span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may own or co-own intellectual property covering our product candidates or research programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research programs;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may control certain interactions with regulatory authorities, which may impact on our ability to obtain and maintain regulatory approval of our products candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may restrict us from researching, developing or commercializing certain products or technologies without their involvement;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how or intellectual property of the collaborator relating to our products, product candidates or research programs;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">If our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our collaborations with them, we may not be able to develop or commercialize product candidates as planned;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully control and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies, including our BBB platform technology;&#160;and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished, or terminated.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this &#8220;Risk Factors&#8221; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain time frames. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We contract with third parties for the manufacture of materials for our research programs and preclinical studies and expect to continue to do so for clinical trials and for commercialization of any product candidates that we may develop. This reliance on third parties may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We do not have any manufacturing facilities. We currently rely on third-party manufacturers for the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials and for commercial supply of any product candidates that we may develop.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We may be unable to establish any further agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the possible breach of the manufacturing agreement by the third party;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the inability to produce required volume in a timely manner and to quality standards.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for any of our product candidates. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We rely on third-party suppliers for the raw materials required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></div><div id="i_0_124"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to obtain and maintain patent protection for any product candidates we develop or for our BBB platform technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our BBB platform technology and any proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by in-licensing intellectual property and filing patent applications in the United States and abroad relating to our BBB platform technology, core programs and product candidates, as well as other technologies that are important to our business. Given that the development of our technology and product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of our technology and product candidates is also at an early stage.&#160;For example, as of June 30, 2019, we do not own or in-license any issued patents in the United States directed to the composition of matter of any of the antibodies or enzymes that we have thus far developed using our BBB platform technology. In addition, we do not own or in-license any issued United States patents covering the composition of matter of the Fc domain portion of our BBB platform technology that binds to transferrin receptor, or any issued United States patents that cover the composition of matter of antibodies or enzymes being developed in our TREM2, aSyn, Tau or IDS core programs.&#160;We have filed or intend to file patent applications on these aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents.&#160;Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our BBB platform technology, core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such BBB platform technology, core programs, product candidates and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology.&#160;Any failure to obtain or maintain patent protection with respect to our BBB platform technology, core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our BBB platform technology, product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether our BBB platform technology, product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#160;review, or interference proceedings or other similar proceedings challenging our owned or licensed patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in-licensed patent rights, allow third parties to commercialize our BBB platform technology, product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our owned or in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our BBB platform technology, product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. For example, we currently, and may in the future, co-own certain patents and patent applications relating to our BBB platform technology with F-star. In addition, certain of our licensors co-own the patents and patent applications we in-license with other third parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements.  If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our rights to develop and commercialize our BBB platform technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our BBB platform technology and product candidates. For example, in June 2016, we entered into a license agreement with Genentech pursuant to which we received an exclusive license to certain of Genentech&#8217;s intellectual property relating to our LRRK2 program, including our DNL201 and DNL151 product candidates.  </span></div><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our agreements with F-star and other license agreements may not provide exclusive rights to use certain licensed intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. For example, F-star retains the right to use itself, and to license to others, its modular antibody technology for any purpose other than the targets and antibodies which we have agreed with F-star would or may be exclusively available to us. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that also utilizes technology that we have in-licensed.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, subject to the terms of any such license agreements, we do not have the right to control the preparation, filing, prosecution and maintenance, and we may not have the right to control the enforcement, and defense of patents and patent applications covering the technology that we license from third parties. For example, under our agreements with F-star and Genentech, the licensors control prosecution and, in the case of F-star and in specified circumstances, enforcement of certain of the patents and patent applications licensed to us. Also, under our agreement with Sanofi, they control prosecution, and in specified circumstances, enforcement of certain of the patents and patent applications licensed to them. We cannot be certain that our in-licensed or out-licensed patents and patent applications that are controlled by our licensors or licensees will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors or licensees fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize our BBB platform technology and any of our product candidates that are subject of such licensed rights could be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, our license to certain intellectual property owned by Genentech is subject to certain research rights Genentech granted to third parties prior to our license agreement. In addition, certain of our in-licensed intellectual property relating to RIPK1 was funded in part by the U.S. government. As a result, the U.S. government may have certain rights to such intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="text-indent:27pt;margin-top:10pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have entered into license agreements with third parties and may need to obtain additional licenses from others to advance our research or allow commercialization of product candidates we may develop or our BBB platform technology. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates or continue to utilize our existing BBB platform technology, which could harm our business, financial condition, results of operations and growth prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our BBB platform technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, each of our license agreements, and we expect our future agreements, will impose various development, diligence, commercialization, and other obligations on us. Certain of our license agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates or of our current BBB platform technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the priority of invention of patented technology.</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting, and defending patents on our BBB platform technology, product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file&#160;a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our BBB platform technology, product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#160;review, and derivation proceedin</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">gs. Although the evidentiary standards in USPTO proceedings compared to United States federal courts is supposed to follow the same legal standards set in recent federal court rulings, we cannot guarantee that the USPTO will not use a different evidentiary standard, or that the USPTO judges will not view facts differently than a federal court judge or jury might view facts, to invalidate a patent claim, and a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issued patents covering our BBB platform technology, product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our BBB platform technology, product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable or raise a defense to infringement. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of subject matter eligibility for patenting, novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Grounds for defenses to infringement include statutory exemptions to patent infringement for uses related to submitting information to regulatory authorities to seek certain regulatory approvals. Third parties may raise claims challenging the validity or enforceability of our owned or in-licensed patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our BBB platform technology, product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that a judge or jury wouldn't find that our patent claims laws of nature or are otherwise ineligible for patenting, or there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our BBB platform technology, product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our BBB platform technology, product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our BBB platform technology, product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition to seeking patents for our BBB platform technology, product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, necessary rights to our BBB platform technology, product candidates or other technologies.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We currently have rights to intellectual property, through licenses from third parties, to identify and develop our BBB platform technology and product candidates. Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field of neurodegeneration and BBB technology and may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain BBB technologies that we are evaluating for use with our current or future product candidates. In addition, with respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest to such patents. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our current or future product candidates and our BBB platform technology. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our licensors, competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our BBB platform technology, product candidates and other technologies.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The field of discovering treatments for neurodegenerative diseases, especially using BBB technology, is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, there may be significant intellectual property litigation and proceedings relating to our owned and in-licensed, and other third-party intellectual property and proprietary rights in the future.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on our licensors&#8217; and our collaborators&#8217; ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist relating to BBB technology and in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our BBB platform technology, product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot assure you that our BBB platform technology, product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our BBB platform technology, product candidates, and other technologies might assert are infringed by our current or future BBB platform technology, product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our BBB platform technology, product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our BBB platform technology, product candidates or other technologies, could be found to be infringed by our BBB platform technology, product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our BBB platform technology, product candidates or other technologies may infringe.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our BBB platform technology, product candidates or other technologies infringes upon these patents. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our BBB platform technology, product candidates or other technologies. In this case, the holders of such patents may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our BBB platform technology, product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing BBB platform technology, product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our BBB platform technology, product candidates or other technologies, which could harm our business significantly.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations or growth prospects.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our owned and in-licensed patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual property rights do not necessarily address all potential threats.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may not develop additional proprietary technologies that are patentable;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the patents of others may harm our business; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may choose not to file&#160;a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div id="i_0_127"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Operations</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr.&#160;Ryan Watts, and our scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We conduct our operations at our facility in South San Francisco, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region, and doing so may be costly and difficult.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of all of these individuals or the lives of any of our other employees. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, we had over</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> 230 emplo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">yees, all of whom were full-time. As our development plans and strategies develop, and as we transition into operating as a public company, we must add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">identifying, recruiting, integrating, retaining, and motivating additional employees;</span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties;</span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">expanding our operational, financial and management controls, reporting systems, and procedures; and</span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-9pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">managing increasing operational and managerial complexity.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. Our ability to successfully manage our expected growth is uncertain given the fact that all of our executive officers have joined us since February&#160;2015. This lack of long-term experience working together as a company may adversely impact our senior management team&#8217;s ability to effectively manage our business and growth.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">92</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have engaged in and may in the future engage in acquisitions or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We have in the past engaged in acquisitions and strategic partnerships, and we may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. For instance, in January 2018 we entered into the Takeda Collaboration Agreement, as amended in February 2019, and in connection therewith we issued and sold to Takeda 4,214,559 shares of our common stock for an aggregate purchase price of $110.0 million in February 2018.  On May&#160;30, 2018, we exercised our buy-out option in connection with the F-star Collaboration Agreement and entered into a Purchase Agreement pursuant to which we acquired all of the outstanding shares of F-star Gamma.  Further, on October&#160;29, 2018, we entered into the Sanofi Collaboration Agreement. Any acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">increased operating expenses and cash requirements;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the assumption of indebtedness or contingent liabilities;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the issuance of our equity securities which would result in dilution to our stockholders;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer other breakdowns, cyberattacks or information security breaches</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">that could compromise the confidentiality, integrity, and availability of such systems and data, and affect our reputation</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">93</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering and/or other means. Although to our knowledge we have not experienced any such material system failure or security breach to date, if a breakdown, cyberattack or other information security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, including data related to our personnel, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of systems that could adversely affect our business and operations and/or result in the loss or disclosure of critical or sensitive data, which could result in financial, legal, business or reputational harm to us.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our operations, and those of our third-party research institution collaborators, CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">All of our operations including our corporate headquarters are located in a single facility in South San Francisco, California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business is subject to economic, political, regulatory and other risks associated with international operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">94</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">differing and changing regulatory requirements in non-U.S. countries;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in non-U.S. currency exchange rates and currency controls;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">negative consequences from changes in tax laws;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">potential liability under the FCPA, UK Bribery Act or comparable foreign laws; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2018, we had federal net operating loss carryforwards of approximately $118.6 million, and federal research and development tax credit carryforwards of approximately $7.5 million which will begin to expire in 2035. Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50-percentage-point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. As a result of our initial public offering ("IPO"), in December 2017 and private placements and other transactions that have occurred since our incorporation, we may have experienced such an ownership change. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.</span></div><div id="i_0_130"></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">95</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The trading price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this report, these factors include:&#160;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the success of existing or new competitive products or technologies;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">commencement or termination of collaborations for our product development and research programs;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure to achieve development, regulatory or commercialization milestones under our collaborations;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure or discontinuation of any of our product development and research programs;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure to develop our BBB platform technology;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">regulatory or legal developments in the United States and other countries;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the recruitment or departure of key personnel;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the results of our efforts to develop additional product candidates or products;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">announcement or expectation of additional financing efforts;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">sales of our common stock by us, our insiders, or other stockholders;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in the structure of healthcare payment systems;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">market conditions in the pharmaceutical and biotechnology sectors; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">96</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">general economic, industry, and market conditions.</span></div><div style="text-indent:27pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of any such lawsuits could be costly and divert the time and attention of our management and harm our operating results, regardless of the merits of such a claim.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock and trading volume could decline.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.  On March 12, 2019, we filed a shelf registration statement on Form S-3 (File No. 333-230232) with the Securities and Exchange Commission, which became effective upon filing. The shelf registration allows us to sell, from time to time, an unspecified number of shares of common stock; shares of preferred stock; debt securities; warrants to purchase shares of common stock, preferred stock, or other securities; purchase contracts; and units representing two or more of the foregoing securities.  Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially own shares representing more than 50.0% of our outstanding common stock. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">97</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; the date we qualify as a "large accelerated filer," with at least $700 million of equity securities held by non-affiliates; the issuance, in any three-year period, by us of more than $1.0 billion in non-convertible debt securities; and the last day of the fiscal year ending after the fifth anniversary of our initial public offering, or December 31, 2022. References herein to "emerging growth company" are intended to have the meaning associated with it in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&#160;404 of the&#160;Sarbanes-Oxley&#160;Act of 2002, or SOX Section&#160;404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, are be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has been and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices, including maintaining an effective system of internal controls over financial reporting.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As a public company, and particularly after we are no longer an emerging growth company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. The SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of NASDAQ, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to continue to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">98</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to SOX Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed time frame or at all, that our internal control over financial reporting is effective as required by SOX Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to maintain effective internal controls, our business, financial position and results of operations and growth prospects could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As a public company, we are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act, including the requirements of SOX Section&#160;404, which require annual management assessments of the effectiveness of our internal control over financial reporting. However, our auditors will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to SOX Section&#160;404 until we are no longer an emerging growth company if we continue to take advantage of the exemptions available to us through the JOBS Act.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position, results of operations and growth prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have not paid and do not expect to pay any dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have never paid cash dividends on our common stock and do not anticipate that we will pay any dividends in the foreseeable future. We currently intend to retain our future earnings, if any, to maintain and expand our existing operations. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Delaware law and provisions in our charter documents might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">99</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock.&#160;Among other things, our charter documents:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">provide that our directors may only be removed for cause;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">eliminate cumulative voting in the election of directors;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">authorize our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">prohibit stockholders from calling a special meeting of stockholders;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">authorize our board of directors, by a majority vote, to amend the bylaws; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware, or DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15.0% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">100</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">any derivative action or proceeding brought on our behalf;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">any action asserting a claim of breach of fiduciary duty;</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws; and</span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (such provision, the "Federal Forum Provision").  However, as previously disclosed in our Current Report on Form 8-K filed with the SEC on January 4, 2019, in light of the decision issued by the Delaware Court of Chancery in Matthew Sciabacucchi v. Matthew B. Salzberg et al., C.A. No. 2017-0931-JTL (Del. Ch.), finding that provisions such as the Federal Forum Provision are not valid under Delaware law, we do not intend to enforce the Federal Forum provision unless and until such time that Court of Chancery, or the Delaware Supreme Court, determines that such a provision is valid under Delaware law.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div id="i_0_133"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Recent Sales of Unregistered Securities</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Use of Proceeds from Registered Securities</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On December&#160;7, 2017, our Registration Statement on Form S-1 (File No. 333-221522) was declared effective by the SEC for our initial public offering of common stock.  We started trading on The NASDAQ Global Select Market on December&#160;8, 2017, and the transaction formally closed on December 12, 2017.  In connection with the initial public offering, we sold an aggregate of 15,972,221 shares of common stock, including 2,083,333 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $18.00 per share. The aggregate offering price for shares sold in the offering was $287.5 million. The joint book-running managers for the initial public offering were Goldman, Sachs&#160;&amp; Co. LLC, Morgan Stanley&#160;&amp; Co. LLC, and J.P. Morgan Securities LLC. After deducting underwriting discounts, commissions and offering expenses paid or payable by us of approximately $23.2 million, the net proceeds from the offering were approximately $264.3 million. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on December&#160;8, 2017 pursuant to Rule 424(b)(4). We invested the funds received in short-term, interest-bearing investment-grade securities and government securities.</span></div><div style="margin-top:18pt;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">101</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Issuer Purchases of Equity Securities</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Not applicable. </span></div><div id="i_0_136"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160; DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-indent:25pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i_0_139"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="text-indent:25pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i_0_142"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 5. OTHER INFORMATION</span></div><div style="text-indent:25pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i_0_145"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:2pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">102</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">ITEM 6.&#160;EXHIBITS</span></div><div style="margin-top:2pt;"><span><br/></span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT INDEX</span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"></td><td style="width:7.149278%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.635634%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.260032%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.717496%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.828250%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.396469%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Exhibit</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:100%;">Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">File No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Filing Date</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit311q22019.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit312q22019.htm">Certification of Chief Financial </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit312q22019.htm">Officer</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit312q22019.htm"> pursuant to Section 302 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit321q22019.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">32.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit322q22019.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Incline XBRL document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:0.1%;"></td><td style="width:1.685897%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:94.314103%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">*</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Denali Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">#</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Portions of this exhibit have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.</span></td></tr></table></div><div style="text-indent:27pt;text-align:center;"><span><br/></span></div><div><span><br/></span></div><div id="i_0_148"></div><div style="text-align:center;margin-top:2pt;"><span><br/></span></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">103</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:30pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:4.250000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.198718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.717949%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.647436%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.185897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">DENALI THERAPEUTICS INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Ryan J. Watts</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Ryan J. Watts, Ph.D.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Steve E. Krognes</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Steve E. Krognes</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;padding-left:261pt;"><span><br/></span></div><div style="text-indent:27pt;padding-left:261pt;"><span><br/></span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">104</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311q22019.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:54pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">I, Ryan J. Watts, Ph.D., certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">I have reviewed this Quarterly Report on Form 10-Q of Denali Therapeutics Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;  </font></div><div style="text-indent:-18pt;padding-left:76.5pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:76.5pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:76.5pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:76.5pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:76.5pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:76.5pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August&#160;6, 2019</font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:36.301282%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.032051%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.666667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; Ryan J. Watts</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:100%;">Ryan J. Watts, Ph.D.</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:100%;">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312q22019.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:54pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">I, Steve E. Krognes, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">I have reviewed this Quarterly Report on Form 10-Q of Denali Therapeutics Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;  </font></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:9pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.  </font></div><div style="margin-top:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August&#160;6, 2019</font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.198718%;"><tr><td style="width:1.0%;"></td><td style="width:31.602585%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.294023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.103393%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:3pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; Steve E. Krognes</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:100%;">Steve E. Krognes</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Treasurer</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321q22019.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:27pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Ryan J. Watts, Ph.D., President and Chief Executive Officer of Denali Therapeutics Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2019, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:144%;">Date&#58; August&#160;6, 2019</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"></td><td style="width:6.988764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.252006%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.759230%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Ryan J. Watts</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Ryan J. Watts, Ph.D.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322q22019.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:27pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Steve E. Krognes, Chief Financial Officer and Treasurer of Denali Therapeutics Inc. (the &#8220;Company&#8221;), hereby certify that&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2019, to which this Certification is attached as Exhibit 32.2 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:144%;">Date&#58; August&#160;6, 2019</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"></td><td style="width:6.988764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.252006%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.759230%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Steve E. Krognes</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Steve E. Krognes</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer and Treasurer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:36pt;margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>dnli-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:8011caee-abc0-437e-96e5-962907bf5aea,g:892d10ab-e474-4c56-aa84-e84b6d701647-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:dnli="http://www.denalitherapeutics.com/20190630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20190630">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xs:element id="dnli_StockIssuedDuringPeriodValueCollaborationAgreement" abstract="false" name="StockIssuedDuringPeriodValueCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ClinicalRegulatoryAndCommercialMilestonePayment" abstract="false" name="ClinicalRegulatoryAndCommercialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AggregatePreclinicalMilestonePayment" abstract="false" name="AggregatePreclinicalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_InitialOptionExercisePayments" abstract="false" name="InitialOptionExercisePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" abstract="false" name="AggregateClinicalRegulatoryAndSalesMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" abstract="false" name="PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_PerformanceAndMarketContingentStockOptionsMember" abstract="true" name="PerformanceAndMarketContingentStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" abstract="true" name="EarlyExercisedCommonStockSubjectToFutureVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_EmployeeAndNonEmployeeStockOptionMember" abstract="true" name="EmployeeAndNonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_AggregateDevelopmentMilestonePayment" abstract="false" name="AggregateDevelopmentMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_TargetOptionPeriod" abstract="false" name="TargetOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_TenantImprovementAllowanceRepayableAsRent" abstract="false" name="TenantImprovementAllowanceRepayableAsRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" abstract="false" name="SaleOfStockConsiderationPremiumReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_UpfrontOptionFee" abstract="false" name="UpfrontOptionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AlzheimersDiseaseServicesMember" abstract="true" name="AlzheimersDiseaseServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" abstract="false" name="ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" abstract="false" name="StockIssuedDuringPeriodSharesCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dnli_AssetAcquisitionContingentConsiderationAmountRecognized" abstract="false" name="AssetAcquisitionContingentConsiderationAmountRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AggregateOptionExerciseFee" abstract="false" name="AggregateOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" abstract="true" name="SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_PreclinicalMilestonePaymentPerProgram" abstract="false" name="PreclinicalMilestonePaymentPerProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_HeadquartersLeaseMember" abstract="true" name="HeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_UpfrontFeesPaid" abstract="false" name="UpfrontFeesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_PeripheralProductMember" abstract="true" name="PeripheralProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_PurchaseOrderExecuted" abstract="false" name="PurchaseOrderExecuted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_OperatingLeasesAreaUnderLease" abstract="false" name="OperatingLeasesAreaUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="dnli_LesseeFinanceLeaseNumberOfContracts" abstract="false" name="LesseeFinanceLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" abstract="false" name="OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dnli_VariableConsiderationFutureConsideration" abstract="false" name="VariableConsiderationFutureConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CollaborationAgreementTransactionPriceIncrease" abstract="false" name="CollaborationAgreementTransactionPriceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" abstract="false" name="StockIssuedDuringPeriodSharesEquityIncentivePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" abstract="false" name="PreclinicalMilestonePaymentEarnedNotYetReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_DMSAMember" abstract="true" name="DMSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_AssetAcquisitionTextBlock" abstract="false" name="AssetAcquisitionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dnli_CommercialMilestonesPerProgram" abstract="false" name="CommercialMilestonesPerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_TakedaCollaborationAgreementMember" abstract="true" name="TakedaCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_NumberOfTargets" abstract="false" name="NumberOfTargets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_NumberOfPrograms" abstract="false" name="NumberOfPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" abstract="false" name="PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_PaymentsForManufacturingCost" abstract="false" name="PaymentsForManufacturingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_OptionFeesPerProgram" abstract="false" name="OptionFeesPerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_AggregateCommercialMilestones" abstract="false" name="AggregateCommercialMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_TwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_DenaliMember" abstract="true" name="DenaliMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_CollaborativeArrangementPayment" abstract="false" name="CollaborativeArrangementPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" abstract="false" name="LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_NewPremisesSubleaseAgreementMember" abstract="true" name="NewPremisesSubleaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SanofiCollaborationAgreementMember" abstract="true" name="SanofiCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_LesseeOperatingLeaseRenewalNoticePeriod" abstract="false" name="LesseeOperatingLeaseRenewalNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_OperatingLeasesSubleaseNetRentableArea" abstract="false" name="OperatingLeasesSubleaseNetRentableArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="dnli_CollaborativeAgreementFundedPercentage" abstract="false" name="CollaborativeAgreementFundedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" abstract="false" name="IncreaseDecreaseInNonCashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ShortTermMarketableSecuritiesMember" abstract="true" name="ShortTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" abstract="true" name="CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="dnli_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_GenentechIncMember" abstract="true" name="GenentechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dnli_RevenueNumberOfPerformanceObligations" abstract="false" name="RevenueNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dnli_ConstrainedVariableConsideration" abstract="false" name="ConstrainedVariableConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ContingentConsiderationPayment" abstract="false" name="ContingentConsiderationPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ForeignExchangeForwardSwissFrancsMember" abstract="true" name="ForeignExchangeForwardSwissFrancsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_RestrictedSharesSubjectToFutureVestingMember" abstract="true" name="RestrictedSharesSubjectToFutureVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_RetainedActivitiesMember" abstract="true" name="RetainedActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_NoncashTenantImprovementsPaidByLandlord" abstract="false" name="NoncashTenantImprovementsPaidByLandlord" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ForeignExchangeForwardEurosMember" abstract="true" name="ForeignExchangeForwardEurosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ClinicalMilestonePayment" abstract="false" name="ClinicalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_LandlordFundedTenantImprovementsMember" abstract="true" name="LandlordFundedTenantImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ExerciseOfBuyoutOptionMember" abstract="true" name="ExerciseOfBuyoutOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_MaximumDevelopmentPlanPeriodForResearchCosts" abstract="false" name="MaximumDevelopmentPlanPeriodForResearchCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dnli_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ForeignExchangeForwardBritishPoundsMember" abstract="true" name="ForeignExchangeForwardBritishPoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_ContingentPaymentsUponAchievementOfMilestones" abstract="false" name="ContingentPaymentsUponAchievementOfMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" abstract="false" name="StockIssuedDuringPeriodValueEquityIncentivePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_PreclinicalMilestonePaymentReceived" abstract="false" name="PreclinicalMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_ClinicalAndRegulatoryMilestonePayment" abstract="false" name="ClinicalAndRegulatoryMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dnli_CNSProductMember" abstract="true" name="CNSProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dnli_PerformanceAndMarketShareBasedCompensation" abstract="false" name="PerformanceAndMarketShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403401 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements">
        <link:definition>2104102 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails">
        <link:definition>2406402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecurities" roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecurities">
        <link:definition>2107103 - Disclosure - Cash and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesTables" roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Cash and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails">
        <link:definition>2409403 - Disclosure - Cash and Marketable Securities - Schedule of Restricted Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails">
        <link:definition>2410404 - Disclosure - Cash and Marketable Securities - Summary of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails">
        <link:definition>2411405 - Disclosure - Cash and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments">
        <link:definition>2112104 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2313303 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails">
        <link:definition>2414406 - Disclosure - Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://www.denalitherapeutics.com/role/Acquisition">
        <link:definition>2115105 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDetails" roleURI="http://www.denalitherapeutics.com/role/AcquisitionDetails">
        <link:definition>2416407 - Disclosure - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements">
        <link:definition>2117106 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables">
        <link:definition>2318304 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSanofiDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails">
        <link:definition>2419408 - Disclosure - Collaboration Agreements - Sanofi (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSanofiPerformanceObligationDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails">
        <link:definition>2420409 - Disclosure - Collaboration Agreements - Sanofi Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails">
        <link:definition>2421410 - Disclosure - Collaboration Agreements - Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSummaryofCollaborationRevenueDetails" roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails">
        <link:definition>2422411 - Disclosure - Collaboration Agreements - Summary of Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements">
        <link:definition>2123107 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails">
        <link:definition>2424412 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>2125108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2326305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2427413 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2428414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2428414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails">
        <link:definition>2429415 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwards" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards">
        <link:definition>2130109 - Disclosure - Stock-Based Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsTables" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables">
        <link:definition>2331306 - Disclosure - Stock-Based Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsNarrativeDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails">
        <link:definition>2432416 - Disclosure - Stock-Based Awards - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofStockOptionActivityDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails">
        <link:definition>2433417 - Disclosure - Stock-Based Awards - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails">
        <link:definition>2434418 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofRestrictedStockActivityDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails">
        <link:definition>2435419 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>2436420 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare">
        <link:definition>2137110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables">
        <link:definition>2338307 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails">
        <link:definition>2439421 - Disclosure - Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>dnli-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:8011caee-abc0-437e-96e5-962907bf5aea,g:892d10ab-e474-4c56-aa84-e84b6d701647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dnli-20190630.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_55a78073-b442-4f9b-a30c-4c548a7dd418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0a2537b3-4ebc-478c-be25-b16e7349640a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_55a78073-b442-4f9b-a30c-4c548a7dd418" xlink:to="loc_us-gaap_PreferredStockValue_0a2537b3-4ebc-478c-be25-b16e7349640a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b81e05b2-1905-4f98-a028-f5f6ece0806e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_55a78073-b442-4f9b-a30c-4c548a7dd418" xlink:to="loc_us-gaap_CommonStockValue_b81e05b2-1905-4f98-a028-f5f6ece0806e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6aeb4727-ec52-47b9-aee3-c5ae38b6bf44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_55a78073-b442-4f9b-a30c-4c548a7dd418" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6aeb4727-ec52-47b9-aee3-c5ae38b6bf44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697dd84a-7afc-4d0d-bc39-eb1568615a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_55a78073-b442-4f9b-a30c-4c548a7dd418" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_697dd84a-7afc-4d0d-bc39-eb1568615a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fc1ffba-df32-4879-9bbc-0536ad62b5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_55a78073-b442-4f9b-a30c-4c548a7dd418" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fc1ffba-df32-4879-9bbc-0536ad62b5c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb505a63-932e-4e30-ba79-01a7d3616b43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_73709885-8996-4dda-810f-8b6ecf072cce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb505a63-932e-4e30-ba79-01a7d3616b43" xlink:to="loc_us-gaap_AccountsPayableCurrent_73709885-8996-4dda-810f-8b6ecf072cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7ffaa8a3-dfcb-4657-8c50-9ee97a821a99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb505a63-932e-4e30-ba79-01a7d3616b43" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7ffaa8a3-dfcb-4657-8c50-9ee97a821a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a287f78b-0384-4dee-ac13-351fd22b0fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb505a63-932e-4e30-ba79-01a7d3616b43" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a287f78b-0384-4dee-ac13-351fd22b0fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2afb8f60-0ecb-4fe1-a9ce-ac6a3206ec36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb505a63-932e-4e30-ba79-01a7d3616b43" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2afb8f60-0ecb-4fe1-a9ce-ac6a3206ec36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_27391c61-4bbe-4015-94d4-a03647cb16de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb505a63-932e-4e30-ba79-01a7d3616b43" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_27391c61-4bbe-4015-94d4-a03647cb16de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b8453af-5d5b-4acb-a1bd-4680489c4a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5e5481f1-2c1d-4d40-8e63-6e2f84e5459a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b8453af-5d5b-4acb-a1bd-4680489c4a2f" xlink:to="loc_us-gaap_Liabilities_5e5481f1-2c1d-4d40-8e63-6e2f84e5459a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d886978-710b-4e39-9791-b37efa64f553" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b8453af-5d5b-4acb-a1bd-4680489c4a2f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d886978-710b-4e39-9791-b37efa64f553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc6cf47c-76a1-402b-861f-a01173ca1abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b8453af-5d5b-4acb-a1bd-4680489c4a2f" xlink:to="loc_us-gaap_StockholdersEquity_dc6cf47c-76a1-402b-861f-a01173ca1abd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a0addb8c-3808-4197-92c0-df944b0b4648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0af5dc5c-cb32-4d72-a5b2-b8f30d0fa22b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a0addb8c-3808-4197-92c0-df944b0b4648" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0af5dc5c-cb32-4d72-a5b2-b8f30d0fa22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d5876a5d-5b4d-4401-8511-adb17ebe6c70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a0addb8c-3808-4197-92c0-df944b0b4648" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d5876a5d-5b4d-4401-8511-adb17ebe6c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6c9558-cddc-455b-8208-cefaee047b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a0addb8c-3808-4197-92c0-df944b0b4648" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6c9558-cddc-455b-8208-cefaee047b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c35616d9-4aa2-42b7-b3a1-031825834ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9a1b888-6a70-4074-a1b8-0248cf68cf99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c35616d9-4aa2-42b7-b3a1-031825834ccc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9a1b888-6a70-4074-a1b8-0248cf68cf99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a0ce86eb-badc-4102-8156-a52779c54b77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c35616d9-4aa2-42b7-b3a1-031825834ccc" xlink:to="loc_us-gaap_AssetsCurrent_a0ce86eb-badc-4102-8156-a52779c54b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_de9ff014-46e6-407e-951c-5296a3f6b116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c35616d9-4aa2-42b7-b3a1-031825834ccc" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_de9ff014-46e6-407e-951c-5296a3f6b116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c016f011-0621-4d43-950f-6bdf72466781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c35616d9-4aa2-42b7-b3a1-031825834ccc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c016f011-0621-4d43-950f-6bdf72466781" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e62b4e3d-384f-4aba-a119-040a7440e447" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c35616d9-4aa2-42b7-b3a1-031825834ccc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e62b4e3d-384f-4aba-a119-040a7440e447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_15b1eb11-b551-4b47-aa8d-b888938280d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3fc3a835-cb84-4d8d-8fcb-b6fa3b0f2f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15b1eb11-b551-4b47-aa8d-b888938280d2" xlink:to="loc_us-gaap_LiabilitiesCurrent_3fc3a835-cb84-4d8d-8fcb-b6fa3b0f2f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_61c16d40-ab4f-490c-be78-0fbde90661fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15b1eb11-b551-4b47-aa8d-b888938280d2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_61c16d40-ab4f-490c-be78-0fbde90661fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_60a086b9-3b01-4d56-ae46-a43fe98810b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15b1eb11-b551-4b47-aa8d-b888938280d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_60a086b9-3b01-4d56-ae46-a43fe98810b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5e1aec84-16be-4bc1-84b4-ad3c2aab5e76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15b1eb11-b551-4b47-aa8d-b888938280d2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5e1aec84-16be-4bc1-84b4-ad3c2aab5e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_11aafe41-4a60-49fc-9871-8c6a483d4976" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15b1eb11-b551-4b47-aa8d-b888938280d2" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_11aafe41-4a60-49fc-9871-8c6a483d4976" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6e0118f8-3c28-46e4-863e-3e6cf5448b53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44378486-72e9-46ce-baba-c59d6dcb26cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e0118f8-3c28-46e4-863e-3e6cf5448b53" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44378486-72e9-46ce-baba-c59d6dcb26cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f7a59ed3-45c9-4468-b3b7-bd3f56c869c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e0118f8-3c28-46e4-863e-3e6cf5448b53" xlink:to="loc_us-gaap_OperatingExpenses_f7a59ed3-45c9-4468-b3b7-bd3f56c869c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b50a3ff3-85de-4982-9075-a68ca815ea0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aff61716-d365-4905-a9e4-2619ffcdbf02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b50a3ff3-85de-4982-9075-a68ca815ea0c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aff61716-d365-4905-a9e4-2619ffcdbf02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_952eaa05-6f86-4e75-bd6b-3fc8c9c53351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b50a3ff3-85de-4982-9075-a68ca815ea0c" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_952eaa05-6f86-4e75-bd6b-3fc8c9c53351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_552c2c6f-6696-4859-8baf-efb3a43af196" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20bb7212-2cf0-4d69-be7d-7919263e85b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_552c2c6f-6696-4859-8baf-efb3a43af196" xlink:to="loc_us-gaap_OperatingIncomeLoss_20bb7212-2cf0-4d69-be7d-7919263e85b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_82058f7e-e42a-4fa1-9b44-9d432ba483fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_552c2c6f-6696-4859-8baf-efb3a43af196" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_82058f7e-e42a-4fa1-9b44-9d432ba483fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_543862ce-53c8-4781-ab40-1e441e9c445d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_adf6aa72-efc7-467d-a666-b69aa6b26fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_543862ce-53c8-4781-ab40-1e441e9c445d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_adf6aa72-efc7-467d-a666-b69aa6b26fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f5620a69-adfc-4159-b431-01e7e3c961c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_543862ce-53c8-4781-ab40-1e441e9c445d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f5620a69-adfc-4159-b431-01e7e3c961c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_57a0d2bc-f1b0-4ade-881f-71affbf4d77e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3cc849f8-d0a3-450e-966c-1aca82980367" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_57a0d2bc-f1b0-4ade-881f-71affbf4d77e" xlink:to="loc_us-gaap_NetIncomeLoss_3cc849f8-d0a3-450e-966c-1aca82980367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_131cc885-bdf1-4d25-bce6-6d7852ad0a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_57a0d2bc-f1b0-4ade-881f-71affbf4d77e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_131cc885-bdf1-4d25-bce6-6d7852ad0a0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dnli-20190630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dnli-20190630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1bd736b1-52b9-4713-a547-5b99c572d6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_NetIncomeLoss_1bd736b1-52b9-4713-a547-5b99c572d6d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_63c6b5fe-a691-4133-9ff2-a2b919836522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_63c6b5fe-a691-4133-9ff2-a2b919836522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fc6c9714-6776-4e8d-8f13-f2aed274a27d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_ShareBasedCompensation_fc6c9714-6776-4e8d-8f13-f2aed274a27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_585bb294-6bde-42e7-b14f-a3a5a0b74e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_585bb294-6bde-42e7-b14f-a3a5a0b74e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7e0bae89-e13d-442f-973c-d1bea9460a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7e0bae89-e13d-442f-973c-d1bea9460a8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c8a71770-5c91-4bbe-9423-40f743a06504" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c8a71770-5c91-4bbe-9423-40f743a06504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a5525f39-ddf0-4726-9e57-bbfa4b07c722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a5525f39-ddf0-4726-9e57-bbfa4b07c722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d7ca374f-4228-4a5f-a7bb-73712d3d9408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d7ca374f-4228-4a5f-a7bb-73712d3d9408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInDeferredRent_3d14d6ce-0e74-4bf9-8a3d-233617364c0b" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_dnli_IncreaseDecreaseInDeferredRent_3d14d6ce-0e74-4bf9-8a3d-233617364c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9252d7e3-6500-4cc6-bace-f5e8c363ae0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9252d7e3-6500-4cc6-bace-f5e8c363ae0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_440ec58d-f178-402e-9051-514fb982a855" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_440ec58d-f178-402e-9051-514fb982a855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_11b4c63f-89f7-49d5-bfdc-6e85a4518c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b003c1c0-bcdf-4762-8aeb-ec870c21b851" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_11b4c63f-89f7-49d5-bfdc-6e85a4518c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57a349e6-0b57-4907-aa5e-a6fd38004334" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1249c02b-7a8e-418a-8778-de234694f07a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57a349e6-0b57-4907-aa5e-a6fd38004334" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1249c02b-7a8e-418a-8778-de234694f07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_eb5f9ddb-08cd-445b-9522-1a502dba6b21" xlink:href="dnli-20190630.xsd#dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57a349e6-0b57-4907-aa5e-a6fd38004334" xlink:to="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_eb5f9ddb-08cd-445b-9522-1a502dba6b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_13b540ed-795c-4a7e-a72e-ebcffce59063" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57a349e6-0b57-4907-aa5e-a6fd38004334" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_13b540ed-795c-4a7e-a72e-ebcffce59063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_772c58c4-f04e-482f-8c20-b2b5c255958e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a1a7654-daae-4a10-b54b-a92f1f629143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_772c58c4-f04e-482f-8c20-b2b5c255958e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a1a7654-daae-4a10-b54b-a92f1f629143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ca46473-0ca9-4134-897c-06b112f774c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_772c58c4-f04e-482f-8c20-b2b5c255958e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ca46473-0ca9-4134-897c-06b112f774c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_872ea470-0722-433e-b43e-bb56a863039b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_772c58c4-f04e-482f-8c20-b2b5c255958e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_872ea470-0722-433e-b43e-bb56a863039b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8ad13e6-7496-4a1b-80c2-147f6fcfcbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9000caf6-3e8d-4e41-8599-ca0e9ac2656f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8ad13e6-7496-4a1b-80c2-147f6fcfcbe6" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9000caf6-3e8d-4e41-8599-ca0e9ac2656f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77b8050d-834d-4c80-b00a-39727ab011f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8ad13e6-7496-4a1b-80c2-147f6fcfcbe6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77b8050d-834d-4c80-b00a-39727ab011f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ab6b63b5-2d09-405d-8704-fb10027b7f09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8ad13e6-7496-4a1b-80c2-147f6fcfcbe6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ab6b63b5-2d09-405d-8704-fb10027b7f09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_bf0be8f6-4a34-4f45-b21a-d448bab4cf82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b7233701-4480-4d9a-a52d-9f74ad466917" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_bf0be8f6-4a34-4f45-b21a-d448bab4cf82" xlink:to="loc_us-gaap_DerivativeLiabilities_b7233701-4480-4d9a-a52d-9f74ad466917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_82bb301c-3fa5-408f-b175-a91c652cac4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d59064a-d1d1-4236-9bcc-bbe38a4e240f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_82bb301c-3fa5-408f-b175-a91c652cac4b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d59064a-d1d1-4236-9bcc-bbe38a4e240f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0327421e-55e0-48f8-982b-416b5ea1a023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_82bb301c-3fa5-408f-b175-a91c652cac4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0327421e-55e0-48f8-982b-416b5ea1a023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4b35747c-2266-413b-8eb4-13d73a7c8dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_82bb301c-3fa5-408f-b175-a91c652cac4b" xlink:to="loc_us-gaap_DerivativeAssets_4b35747c-2266-413b-8eb4-13d73a7c8dc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecurities" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b6d66ce-5dea-4bf3-bf13-3f82322ab70e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d81476f-bf18-4211-8da3-3c534800ea04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b6d66ce-5dea-4bf3-bf13-3f82322ab70e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d81476f-bf18-4211-8da3-3c534800ea04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_55fba961-4fad-4d81-be5e-a931aba42f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b6d66ce-5dea-4bf3-bf13-3f82322ab70e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_55fba961-4fad-4d81-be5e-a931aba42f76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c23a08e-8ff5-4296-9941-a747562ef016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c51c533c-8868-4da4-a23c-7f8e521f5e22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c23a08e-8ff5-4296-9941-a747562ef016" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c51c533c-8868-4da4-a23c-7f8e521f5e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b649fc27-255b-4f9f-ae50-ae6fa451175d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c23a08e-8ff5-4296-9941-a747562ef016" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b649fc27-255b-4f9f-ae50-ae6fa451175d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_88f8674a-44f4-40a4-9589-840c85086f79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c23a08e-8ff5-4296-9941-a747562ef016" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_88f8674a-44f4-40a4-9589-840c85086f79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Acquisition" xlink:type="simple" xlink:href="dnli-20190630.xsd#Acquisition"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/Acquisition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/AcquisitionDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#AcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/AcquisitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSanofiDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSanofiPerformanceObligationDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsTakedaDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSummaryofCollaborationRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="simple" xlink:href="dnli-20190630.xsd#LicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#LicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0835dab0-be03-4d1e-aae6-f72f7dd9fceb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0835dab0-be03-4d1e-aae6-f72f7dd9fceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_1381948f-22e0-4c67-a3db-d6be9f481925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_1381948f-22e0-4c67-a3db-d6be9f481925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_549c2b3a-09af-4ccf-8c61-f8b98e1de122" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_549c2b3a-09af-4ccf-8c61-f8b98e1de122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_fad45915-66a9-47a0-92e7-3329686917a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_fad45915-66a9-47a0-92e7-3329686917a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_6b199fdd-2e05-49d5-8024-c0512369b6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_6b199fdd-2e05-49d5-8024-c0512369b6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_213fb778-0dfc-4fcd-9a79-c53d95638ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10aa016f-a3b0-410f-b537-20d51613fff7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_213fb778-0dfc-4fcd-9a79-c53d95638ac9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_53a52aa5-4a65-4c60-a070-ece09ff62c29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_34a570be-1c68-4eb6-b8c4-9c8b70d8a20a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_53a52aa5-4a65-4c60-a070-ece09ff62c29" xlink:to="loc_us-gaap_OperatingLeaseLiability_34a570be-1c68-4eb6-b8c4-9c8b70d8a20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b3a8534-393f-4c25-bd7e-256dab05173b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_53a52aa5-4a65-4c60-a070-ece09ff62c29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b3a8534-393f-4c25-bd7e-256dab05173b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_e02dfda0-a3a9-4124-a6b0-64d18c361a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_e02dfda0-a3a9-4124-a6b0-64d18c361a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_2c331599-465c-43a3-891a-145f327e4df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_2c331599-465c-43a3-891a-145f327e4df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_270b7810-bded-4754-84e6-d53965cc2aba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_270b7810-bded-4754-84e6-d53965cc2aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_719133fb-5368-47c4-a602-94d0fd45a1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_719133fb-5368-47c4-a602-94d0fd45a1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_25837a24-2728-41cb-ac0f-0293eb892607" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_25837a24-2728-41cb-ac0f-0293eb892607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b589f876-0b3c-4ec5-bcfc-328843e5f045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7f190edc-24f0-4dfb-9942-e2e79fe759cb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b589f876-0b3c-4ec5-bcfc-328843e5f045" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwards"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>dnli-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:8011caee-abc0-437e-96e5-962907bf5aea,g:892d10ab-e474-4c56-aa84-e84b6d701647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dnli-20190630.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="extended" id="i03889eb8962640cdab581f45e7fe3862_bd6e9562-e690-4ca0-9263-f0df4b18d981"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="ia340b641f1304fb681a0f0cd421da304_7ff0d662-cd86-439e-a979-4e25237def5b"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i64cebdd40d414feab3a3f812755da32d_d29f625e-571d-4dd9-990b-339bcce8818f"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ibfa8a921a05c4ccf9769a68afb7ce5ce_af77cd1e-56f4-4233-89c7-b6f719fefa6c"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dnli-20190630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i4d48639314bb4a4caa57c56f9254c265_235a3757-62ae-4c37-8e76-ed2e7e586733">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f0495158-2be9-4649-a9b7-16b975165b69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0495158-2be9-4649-a9b7-16b975165b69" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87a764e0-f099-4d39-a72b-5fb6dc234c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87a764e0-f099-4d39-a72b-5fb6dc234c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a177abb5-36e1-4e71-8a95-87c84bbc0d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockholdersEquity_a177abb5-36e1-4e71-8a95-87c84bbc0d1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_914d4d7f-8a28-424b-a27d-4a0efe5e2914" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_914d4d7f-8a28-424b-a27d-4a0efe5e2914" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_867d9b05-311f-4eb6-b64f-70e7f20d79f5" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodValueEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_867d9b05-311f-4eb6-b64f-70e7f20d79f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54150210-1ab3-4cf1-967b-8831a296d75c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54150210-1ab3-4cf1-967b-8831a296d75c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7ada4286-5fb5-4a7b-9afb-bfffccec8e07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7ada4286-5fb5-4a7b-9afb-bfffccec8e07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d5ebc3ad-07f1-4b60-b108-4f238e4c721f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d5ebc3ad-07f1-4b60-b108-4f238e4c721f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_427d9157-5e25-4e5d-8292-af0cbe57d065" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_427d9157-5e25-4e5d-8292-af0cbe57d065" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23bda36b-7d4a-4fc9-8ff8-c06b4af13fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23bda36b-7d4a-4fc9-8ff8-c06b4af13fdf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6c7b9e6-d065-4d28-8701-dc16896849cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_NetIncomeLoss_e6c7b9e6-d065-4d28-8701-dc16896849cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_33d64677-a0bd-4df7-89d6-daa66035a700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_33d64677-a0bd-4df7-89d6-daa66035a700" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_7b3377e8-901f-4dfe-a338-f7e169ffddc3" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_7b3377e8-901f-4dfe-a338-f7e169ffddc3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_9f9d2e80-baef-425d-b139-b13fce1a68b0" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_9f9d2e80-baef-425d-b139-b13fce1a68b0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec560ce0-a0f3-4130-b91c-6d782432aaed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_077c5a06-a469-46af-88d9-d41aa3e379e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f0495158-2be9-4649-a9b7-16b975165b69" xlink:to="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_112a2f64-d67e-446a-b06d-065daad4b9bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:to="loc_us-gaap_EquityComponentDomain_112a2f64-d67e-446a-b06d-065daad4b9bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:to="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_78da9133-7998-45f3-82a3-6d1d09baddd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_CommonStockMember_78da9133-7998-45f3-82a3-6d1d09baddd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ad51378b-1735-4572-bf00-b050fc269dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ad51378b-1735-4572-bf00-b050fc269dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e43f6481-885a-480b-8e1b-388d83beed12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e43f6481-885a-480b-8e1b-388d83beed12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9cf45035-7cc0-4438-913b-059a06545736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_RetainedEarningsMember_9cf45035-7cc0-4438-913b-059a06545736" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dnli-20190630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="id52f9ee7eb114a61a8606e4eb93119b6_44110b4a-a3db-49bf-82e6-b2ac0479ae9c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4e74e5f-6022-43f8-950b-89f1846c183b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_NetIncomeLoss_f4e74e5f-6022-43f8-950b-89f1846c183b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_abecd621-d070-4ffa-ab20-ec441e3920f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_abecd621-d070-4ffa-ab20-ec441e3920f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b5bacb8b-c47f-4f05-9cc8-6ad23b8c5525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_ShareBasedCompensation_b5bacb8b-c47f-4f05-9cc8-6ad23b8c5525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f0126d32-b204-4525-9da4-6143ad8afb89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f0126d32-b204-4525-9da4-6143ad8afb89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_a2421c18-718f-4bc1-a810-3e67a1cf1965" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_a2421c18-718f-4bc1-a810-3e67a1cf1965" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInDeferredRent_3cf4ea51-e52a-4be1-95fd-05d9aa91080c" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInDeferredRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_dnli_IncreaseDecreaseInDeferredRent_3cf4ea51-e52a-4be1-95fd-05d9aa91080c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0ae676e3-8123-4b61-aee3-326406ac9663" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0ae676e3-8123-4b61-aee3-326406ac9663" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e3b993b7-bafc-43dc-991c-a1b5bc13ceaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e3b993b7-bafc-43dc-991c-a1b5bc13ceaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_edb33c69-5f1e-4c7c-885c-ed4f5790e5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_edb33c69-5f1e-4c7c-885c-ed4f5790e5a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ffc4c28-896a-4e32-b53e-52a8436a19ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ffc4c28-896a-4e32-b53e-52a8436a19ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e7a1b8f8-6b96-491a-8f75-80f5cc548b91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e7a1b8f8-6b96-491a-8f75-80f5cc548b91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_773391e9-cb74-4375-aef0-985cccb2fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_773391e9-cb74-4375-aef0-985cccb2fbb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f346d71e-d523-4a8f-b9e4-f29bd724cc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f346d71e-d523-4a8f-b9e4-f29bd724cc6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5c76729c-9988-4cc1-9f57-ecb492d7571a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5c76729c-9988-4cc1-9f57-ecb492d7571a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d3e298dc-c1e3-4264-a0de-e3a2e95488db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d3e298dc-c1e3-4264-a0de-e3a2e95488db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_43a80501-be55-485e-b835-e0837440fa50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_43a80501-be55-485e-b835-e0837440fa50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38bf645d-e014-48af-a3b5-850eebb5e63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38bf645d-e014-48af-a3b5-850eebb5e63b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a7921383-33ab-4004-9794-ee70a811fe6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a7921383-33ab-4004-9794-ee70a811fe6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_328a659d-a7da-40b4-8378-cea88a291d29" xlink:href="dnli-20190630.xsd#dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_328a659d-a7da-40b4-8378-cea88a291d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_62aeb9fa-f6f4-4cb3-b1f5-f61febbb428a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_62aeb9fa-f6f4-4cb3-b1f5-f61febbb428a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2a90674-b023-40fb-ab83-10235f8ff95c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2a90674-b023-40fb-ab83-10235f8ff95c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_27ec6798-dc49-44dc-b8a1-643ab5b32489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_27ec6798-dc49-44dc-b8a1-643ab5b32489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49b954f4-cab7-4e8b-a28e-b61a965e292b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49b954f4-cab7-4e8b-a28e-b61a965e292b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64972274-285f-4768-be39-31d783972234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NoncashTenantImprovementsPaidByLandlord_ddb01e2f-d952-42bc-b027-04304c2c02cd" xlink:href="dnli-20190630.xsd#dnli_NoncashTenantImprovementsPaidByLandlord"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:to="loc_dnli_NoncashTenantImprovementsPaidByLandlord_ddb01e2f-d952-42bc-b027-04304c2c02cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a152e8a-5c78-4f4a-9540-c351ef665778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a152e8a-5c78-4f4a-9540-c351ef665778" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b764996-2f45-4b91-9ef4-82cd094b119d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:to="loc_us-gaap_EquityComponentDomain_2b764996-2f45-4b91-9ef4-82cd094b119d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:to="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_47c71c2e-1b52-435a-96d1-a778ae8155a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:to="loc_us-gaap_CommonStockMember_47c71c2e-1b52-435a-96d1-a778ae8155a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d197c047-9187-45cd-aafd-2373675567be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:to="loc_us-gaap_PreferredStockMember_d197c047-9187-45cd-aafd-2373675567be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended" id="ie2befbdf9a8d444bb51b671eb96a6d86_eb0d794c-55ce-400e-8550-33b8db35e702"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i716c528238614c82884f680e38c9135b_03070066-6334-405e-b7b0-ca20fc4e08ab"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i8aa15fabd7cb491ca6e1ea528d89b016_d18d1bda-89e1-4123-9322-a70bc049e2aa">
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:href="dnli-20190630.xsd#dnli_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_346bac12-7e36-4055-b74d-c1a866d951e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_346bac12-7e36-4055-b74d-c1a866d951e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeFinanceLeaseNumberOfContracts_2162bf1b-c1dd-4e5d-8bbe-4940975ac0f7" xlink:href="dnli-20190630.xsd#dnli_LesseeFinanceLeaseNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_dnli_LesseeFinanceLeaseNumberOfContracts_2162bf1b-c1dd-4e5d-8bbe-4940975ac0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e20ad86-95f1-4f13-be50-c3473619f3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e20ad86-95f1-4f13-be50-c3473619f3fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6175dc94-7442-44df-beb6-f3f8f8877537" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_us-gaap_OperatingLeaseLiability_6175dc94-7442-44df-beb6-f3f8f8877537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:href="dnli-20190630.xsd#dnli_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_50e0b30e-0647-4886-86af-80240805da1e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_50e0b30e-0647-4886-86af-80240805da1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f2d25d85-9bca-4a99-94e6-0042e873c689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f2d25d85-9bca-4a99-94e6-0042e873c689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_39eef942-7b0d-43b3-be3a-10eae0ebd758" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f2d25d85-9bca-4a99-94e6-0042e873c689" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_39eef942-7b0d-43b3-be3a-10eae0ebd758" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="extended" id="i2da7c51223ea45b48095e151956b5c54_c0d7fa03-aa5a-4559-94c4-8df8b054d5f4"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i22bd791f8b524f359a9e2df6aee2f3d2_c28c3c5c-3a28-4e5b-ba40-a362645071a4"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i05655ab253df48918e2f84ccebe83296_a303c315-4374-4dba-aa93-6da738541eaf">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a56e5dcc-7802-48f2-bc95-ce15bcdb3952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a56e5dcc-7802-48f2-bc95-ce15bcdb3952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_632415ba-e445-4dfd-be4f-9991f01c5e58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_632415ba-e445-4dfd-be4f-9991f01c5e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_771ba98c-e872-4adf-b3e8-523eca90f96e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_DerivativeAssets_771ba98c-e872-4adf-b3e8-523eca90f96e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_13ed81b5-73c2-45ed-b9d1-0fbe08d437ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_13ed81b5-73c2-45ed-b9d1-0fbe08d437ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_481fe568-c186-44a8-bb2e-656346f0531a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_DerivativeLiabilities_481fe568-c186-44a8-bb2e-656346f0531a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_35a38923-7233-403b-a290-8f488ec73556" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_35a38923-7233-403b-a290-8f488ec73556" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7db4612f-51da-41bf-a255-406b22948a8e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7db4612f-51da-41bf-a255-406b22948a8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_691a544b-534b-49ca-99c6-5a1dfef19cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_691a544b-534b-49ca-99c6-5a1dfef19cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c0786d88-dd11-4a8c-b9b3-196c18bbb7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c0786d88-dd11-4a8c-b9b3-196c18bbb7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_66c7e0e3-aa5d-443c-94df-2474541b7b99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_66c7e0e3-aa5d-443c-94df-2474541b7b99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_65765dc0-b798-4113-850a-0add81cf4bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_65765dc0-b798-4113-850a-0add81cf4bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermInvestmentsMember_e1b468e8-4486-491b-9d8d-fd0fdc458b36" xlink:href="dnli-20190630.xsd#dnli_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:to="loc_dnli_LongTermInvestmentsMember_e1b468e8-4486-491b-9d8d-fd0fdc458b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ca67063b-4804-4545-abd8-0dcdb4f88349_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ca67063b-4804-4545-abd8-0dcdb4f88349_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0ca1e1ad-d51e-4403-9ed9-f2bd2136698e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0ca1e1ad-d51e-4403-9ed9-f2bd2136698e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8b4c4c3a-f5df-4cb7-832f-a6abb672fcb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8b4c4c3a-f5df-4cb7-832f-a6abb672fcb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_edd156f0-fb32-4901-973e-bc3372c40805" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:to="loc_us-gaap_CommercialPaperMember_edd156f0-fb32-4901-973e-bc3372c40805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3844071-3047-4f40-bc0a-2d272bef7281_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3844071-3047-4f40-bc0a-2d272bef7281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b806dea6-01a8-4360-817b-7ff72162885c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b806dea6-01a8-4360-817b-7ff72162885c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a49106c1-406c-470b-a4a9-395487d2b0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a49106c1-406c-470b-a4a9-395487d2b0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1bca7836-402e-42a4-90e5-0c734e029677" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1bca7836-402e-42a4-90e5-0c734e029677" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_293bbb6d-411b-4d5d-8f80-5636157f3ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_CommercialPaperMember_293bbb6d-411b-4d5d-8f80-5636157f3ae4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecurities" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecurities" xlink:type="extended" id="i58ef24ddcb9e4800bc92fdf896e7a7ba_20ffed17-8f28-4dcb-8f0d-f1d999e72782"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables" xlink:type="extended" id="ia077269ecd024e82a1cc329a59f4d632_60656043-18e7-4e38-84da-b2f92fec7d20"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="extended" id="ib2988949ae834990a45fe39ac1d64ead_804b0d85-146b-426e-80c9-99080348536e"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i7f640d9ef38741d49c0a5ef7e3efd354_847c33d2-d738-4a66-b54a-9b927db12512">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9eb596c5-513e-4754-84b2-edb61343fd67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9eb596c5-513e-4754-84b2-edb61343fd67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_909739a5-d84c-4ec1-914b-8cbcb8cdc373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_909739a5-d84c-4ec1-914b-8cbcb8cdc373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef5bfff0-1480-4d43-aca7-4fdc821d47da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef5bfff0-1480-4d43-aca7-4fdc821d47da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3358e651-93b8-4ebb-a3d1-9b1154c244af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3358e651-93b8-4ebb-a3d1-9b1154c244af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:to="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_18e35fa7-814a-4774-b3a5-b83c9a1e1c43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_18e35fa7-814a-4774-b3a5-b83c9a1e1c43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShortTermMarketableSecuritiesMember_bdd62394-08e1-4d81-aeb5-d42ea0e3f6cd" xlink:href="dnli-20190630.xsd#dnli_ShortTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:to="loc_dnli_ShortTermMarketableSecuritiesMember_bdd62394-08e1-4d81-aeb5-d42ea0e3f6cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermMarketableSecuritiesMember_c5f81f48-646c-4ac3-a8c0-dec1f5e29417" xlink:href="dnli-20190630.xsd#dnli_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:to="loc_dnli_LongTermMarketableSecuritiesMember_c5f81f48-646c-4ac3-a8c0-dec1f5e29417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61b00ecd-f4d2-4d48-bd76-d4d3624817a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61b00ecd-f4d2-4d48-bd76-d4d3624817a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0efb490f-bdd9-46d2-9836-32efb553aaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0efb490f-bdd9-46d2-9836-32efb553aaf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fdb77ea6-c835-4055-8c56-24d146ef93c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fdb77ea6-c835-4055-8c56-24d146ef93c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_208a53f0-78ab-4bee-95b1-331911854db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_208a53f0-78ab-4bee-95b1-331911854db5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_4c3f577e-cfc9-4fdf-8e5b-19fe668b12db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_4c3f577e-cfc9-4fdf-8e5b-19fe668b12db" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails" xlink:type="extended" id="i8ad7a8d14e8340a78e14a7aaa75c0086_01d46a35-be4f-4d47-a2cc-72d5b79a572c"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="extended" id="ia80a2eb75c69416f9bf770e87512bb15_1909f48c-dd27-4aa4-97de-50bc7d171b47"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended" id="ie67d4c6dc0fb4c2b863a90810db449b5_9c7c0ed2-5c04-42e4-ba3d-256482c4fe19"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended" id="icee358a0db184240818bfb7b62068d05_9eaea5f2-3fd1-4932-a25d-e8e0ffd2e377">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_634f7d9a-a7bd-45b8-b922-b69844539853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_634f7d9a-a7bd-45b8-b922-b69844539853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_invest_DerivativeNotionalAmount_a65c58fe-c6b0-4a68-99b9-8c1360b21cc8" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_invest_DerivativeNotionalAmount_a65c58fe-c6b0-4a68-99b9-8c1360b21cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6b5026d2-91f9-4bd7-86d7-59d95f818c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeLiabilities_6b5026d2-91f9-4bd7-86d7-59d95f818c0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_5c4449a9-19c3-4cf5-a9ba-43798ca8b216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeAssets_5c4449a9-19c3-4cf5-a9ba-43798ca8b216" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_90b8232b-0ff7-42e4-b375-95a85fb0a833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_90b8232b-0ff7-42e4-b375-95a85fb0a833" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5162a559-9312-4c73-8aa0-72dc41c7b9dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5162a559-9312-4c73-8aa0-72dc41c7b9dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardEurosMember_64f2eb74-9510-4cde-9729-78cfc9cc98a9" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardEurosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_dnli_ForeignExchangeForwardEurosMember_64f2eb74-9510-4cde-9729-78cfc9cc98a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardBritishPoundsMember_cab53192-5520-4e27-85ae-ab7134e0964b" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardBritishPoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_dnli_ForeignExchangeForwardBritishPoundsMember_cab53192-5520-4e27-85ae-ab7134e0964b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardSwissFrancsMember_b2fe3b75-4840-4485-9ae1-cffc59331dfe" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardSwissFrancsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_dnli_ForeignExchangeForwardSwissFrancsMember_b2fe3b75-4840-4485-9ae1-cffc59331dfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7fadf102-38a5-42b9-9c21-6e5d0d59bd83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7fadf102-38a5-42b9-9c21-6e5d0d59bd83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:to="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ecb6458c-b7ba-4752-929b-49802c6622e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:to="loc_us-gaap_HedgingDesignationDomain_ecb6458c-b7ba-4752-929b-49802c6622e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ea5f6ece-5e10-4ad5-9265-19482391c344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:to="loc_us-gaap_HedgingDesignationDomain_ea5f6ece-5e10-4ad5-9265-19482391c344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d5f7f8e5-3681-4e86-957b-ec67b6bc67e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ea5f6ece-5e10-4ad5-9265-19482391c344" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d5f7f8e5-3681-4e86-957b-ec67b6bc67e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Acquisition" xlink:type="simple" xlink:href="dnli-20190630.xsd#Acquisition"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/Acquisition" xlink:type="extended" id="i35d18f142d6e4f969fecd2af123d84ca_6c27c30d-cd24-45ab-a922-af0530c1a9b0"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/AcquisitionDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#AcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/AcquisitionDetails" xlink:type="extended" id="icfff19ccbc44475d8a121f97845841bf_11c41a18-ad10-4a56-b780-94b94b41f0b6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementPayment_fa6f3a72-710a-456d-8439-e7129384c316" xlink:href="dnli-20190630.xsd#dnli_CollaborativeArrangementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_CollaborativeArrangementPayment_fa6f3a72-710a-456d-8439-e7129384c316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontOptionFee_97ea4208-d3d5-4239-8c53-1b397e766591" xlink:href="dnli-20190630.xsd#dnli_UpfrontOptionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_UpfrontOptionFee_97ea4208-d3d5-4239-8c53-1b397e766591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_InitialOptionExercisePayments_2ebe7b42-58e1-4a8f-b15d-3794934937f0" xlink:href="dnli-20190630.xsd#dnli_InitialOptionExercisePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_InitialOptionExercisePayments_2ebe7b42-58e1-4a8f-b15d-3794934937f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContingentPaymentsUponAchievementOfMilestones_38369186-80f4-48b5-b259-a2231b4355f5" xlink:href="dnli-20190630.xsd#dnli_ContingentPaymentsUponAchievementOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_ContingentPaymentsUponAchievementOfMilestones_38369186-80f4-48b5-b259-a2231b4355f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContingentConsiderationPayment_0179556f-6048-40fb-804c-860c179408e7" xlink:href="dnli-20190630.xsd#dnli_ContingentConsiderationPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_ContingentConsiderationPayment_0179556f-6048-40fb-804c-860c179408e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3f0728ff-1cb5-4543-86e2-e78ae83c8660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3f0728ff-1cb5-4543-86e2-e78ae83c8660" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_08b13da0-9dd4-4015-a586-e56b5ea2f04b" xlink:href="dnli-20190630.xsd#dnli_AssetAcquisitionContingentConsiderationAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_08b13da0-9dd4-4015-a586-e56b5ea2f04b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_25d1adc9-afe0-403b-97cd-60aeb14f2e0c" xlink:href="dnli-20190630.xsd#dnli_MaximumDevelopmentPlanPeriodForResearchCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_25d1adc9-afe0-403b-97cd-60aeb14f2e0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0a601dcb-5790-4cde-bdab-ec68ac20e609" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0a601dcb-5790-4cde-bdab-ec68ac20e609" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:to="loc_us-gaap_ProjectMember_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fe289f27-d0d2-439f-a40a-ed0a8321f5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:to="loc_us-gaap_ProjectMember_fe289f27-d0d2-439f-a40a-ed0a8321f5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_16842b1d-a839-4fdb-a0b3-e3b2186947c5" xlink:href="dnli-20190630.xsd#dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_fe289f27-d0d2-439f-a40a-ed0a8321f5c2" xlink:to="loc_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_16842b1d-a839-4fdb-a0b3-e3b2186947c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00958dac-8af5-49f4-ae1e-649f76c7a2a1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:to="loc_srt_RangeMember_00958dac-8af5-49f4-ae1e-649f76c7a2a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5826908-dedf-49d7-9565-1bdd813d47bd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:to="loc_srt_RangeMember_d5826908-dedf-49d7-9565-1bdd813d47bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d58d2844-7de8-4536-8cef-72409f9d6b98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5826908-dedf-49d7-9565-1bdd813d47bd" xlink:to="loc_srt_MaximumMember_d58d2844-7de8-4536-8cef-72409f9d6b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f8353954-7944-4638-ba5d-31cb3005103e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f8353954-7944-4638-ba5d-31cb3005103e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f678de7c-93de-415d-af70-96b807fa81d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f678de7c-93de-415d-af70-96b807fa81d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ExerciseOfBuyoutOptionMember_6d84f7e6-8b5f-41f3-9e64-2929c63a9b44" xlink:href="dnli-20190630.xsd#dnli_ExerciseOfBuyoutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f678de7c-93de-415d-af70-96b807fa81d3" xlink:to="loc_dnli_ExerciseOfBuyoutOptionMember_6d84f7e6-8b5f-41f3-9e64-2929c63a9b44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="extended" id="i813cf81cfc574d988fc1b1b91286c55f_82cd6e5c-711f-42a6-a719-4a1b05fcb654"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended" id="ia19f09fe395e4733ac65738fabd8ff4d_1f6cdd82-2681-479c-b569-f79297740791"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="extended" id="ifbd4563ad0494578af1afe3eb07dad32_92c307a1-fca7-4452-9240-f3881728cc5c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_895e6d84-5eb5-428f-8a04-efadefa1a57a" xlink:href="dnli-20190630.xsd#dnli_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_UpfrontPayments_895e6d84-5eb5-428f-8a04-efadefa1a57a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_25d4db9d-04e1-40d0-b348-02e11030d042" xlink:href="dnli-20190630.xsd#dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_25d4db9d-04e1-40d0-b348-02e11030d042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalAndRegulatoryMilestonePayment_7d7f7f09-7a4c-4e36-a869-30c7769377c9" xlink:href="dnli-20190630.xsd#dnli_ClinicalAndRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_ClinicalAndRegulatoryMilestonePayment_7d7f7f09-7a4c-4e36-a869-30c7769377c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_0a166bf2-d59a-467c-ad86-1cb9d93c8ca7" xlink:href="dnli-20190630.xsd#dnli_ClinicalRegulatoryAndCommercialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_0a166bf2-d59a-467c-ad86-1cb9d93c8ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage_e51c3667-3b45-408e-be82-5968a9d2baea" xlink:href="dnli-20190630.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_CollaborativeAgreementFundedPercentage_e51c3667-3b45-408e-be82-5968a9d2baea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncrease_d7c02d28-4328-4807-a184-2e72a8f3a019" xlink:href="dnli-20190630.xsd#dnli_CollaborationAgreementTransactionPriceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncrease_d7c02d28-4328-4807-a184-2e72a8f3a019" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_50032ff2-72dd-4244-b554-0480ae16fed9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_AccountsReceivableNet_50032ff2-72dd-4244-b554-0480ae16fed9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMilestonePayment_519cca5b-1b64-4c4b-952d-a559cacb1866" xlink:href="dnli-20190630.xsd#dnli_ClinicalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_ClinicalMilestonePayment_519cca5b-1b64-4c4b-952d-a559cacb1866" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1c3aebd3-85d9-449d-8606-7e8b75359754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1c3aebd3-85d9-449d-8606-7e8b75359754" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b0bb0da-bc93-48be-b31e-3256b2affebb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b0bb0da-bc93-48be-b31e-3256b2affebb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f1152df-0b1e-4d11-94a3-b283146a7021_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f1152df-0b1e-4d11-94a3-b283146a7021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89fda59f-df94-4feb-b9e0-e6683a27b519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89fda59f-df94-4feb-b9e0-e6683a27b519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6a817aa6-1341-4d6a-a269-e92336baefe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89fda59f-df94-4feb-b9e0-e6683a27b519" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6a817aa6-1341-4d6a-a269-e92336baefe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31303d9c-76a9-4c3d-b13c-f360b1340da2_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31303d9c-76a9-4c3d-b13c-f360b1340da2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember_3201ac16-6975-4ab0-85bb-02856bf0c7ba" xlink:href="dnli-20190630.xsd#dnli_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:to="loc_dnli_SanofiMember_3201ac16-6975-4ab0-85bb-02856bf0c7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DenaliMember_8b6fa471-fe2c-4c0e-89a9-5f479da793ae" xlink:href="dnli-20190630.xsd#dnli_DenaliMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:to="loc_dnli_DenaliMember_8b6fa471-fe2c-4c0e-89a9-5f479da793ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6627f562-ee36-476f-9186-b949eebab392_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:to="loc_srt_ProductsAndServicesDomain_6627f562-ee36-476f-9186-b949eebab392_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:to="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CNSProductMember_809bf2fc-03eb-4078-a306-9aa712911ffd" xlink:href="dnli-20190630.xsd#dnli_CNSProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:to="loc_dnli_CNSProductMember_809bf2fc-03eb-4078-a306-9aa712911ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PeripheralProductMember_209608cf-a9d0-4b21-a31a-81f8a235a2e1" xlink:href="dnli-20190630.xsd#dnli_PeripheralProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:to="loc_dnli_PeripheralProductMember_209608cf-a9d0-4b21-a31a-81f8a235a2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6ab58978-dc20-4088-8c4a-5b4d3855a5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:to="loc_us-gaap_ProductMember_6ab58978-dc20-4088-8c4a-5b4d3855a5ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_23d61b6c-7a99-43f0-89d5-41cac55dac1d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_23d61b6c-7a99-43f0-89d5-41cac55dac1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_690dc425-9b55-4bc4-b3ba-d141714caacf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_690dc425-9b55-4bc4-b3ba-d141714caacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4e42e15e-66c3-40f3-b31e-c8c38a13ab84" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_690dc425-9b55-4bc4-b3ba-d141714caacf" xlink:to="loc_srt_ScenarioForecastMember_4e42e15e-66c3-40f3-b31e-c8c38a13ab84" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSanofiPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="extended" id="i2fa345a7496a453b8369d752a69b054c_2bdc5fa8-5aee-472f-973c-6cbb180b3fbf">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4af6a28c-c25f-4d06-8d4f-1c6e882bdd2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3589ffbf-ae2e-4fa7-8c79-f6f0b4f811a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4af6a28c-c25f-4d06-8d4f-1c6e882bdd2f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3589ffbf-ae2e-4fa7-8c79-f6f0b4f811a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4af6a28c-c25f-4d06-8d4f-1c6e882bdd2f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:to="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec1649c2-2fd6-46bf-bd64-15f18cd3b829_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:to="loc_srt_ProductsAndServicesDomain_ec1649c2-2fd6-46bf-bd64-15f18cd3b829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2791865-fb31-4251-a0ab-84123d660f07" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:to="loc_srt_ProductsAndServicesDomain_e2791865-fb31-4251-a0ab-84123d660f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_07051289-bf39-404e-bcaa-717216a26caa" xlink:href="dnli-20190630.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2791865-fb31-4251-a0ab-84123d660f07" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_07051289-bf39-404e-bcaa-717216a26caa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b0e335a3-dde8-456c-af1a-373c19d3d266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b0e335a3-dde8-456c-af1a-373c19d3d266" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="extended" id="i2de4739f9f644c6aada4c8150d78bc0c_a8902ac5-7434-4a0f-bdf0-6246be9e6135">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_1f35c909-8631-4804-9ec1-f64c16cb3b4f" xlink:href="dnli-20190630.xsd#dnli_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_UpfrontPayments_1f35c909-8631-4804-9ec1-f64c16cb3b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentPerProgram_bd6011f3-2265-43c5-868a-bab7ef9187a6" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_PreclinicalMilestonePaymentPerProgram_bd6011f3-2265-43c5-868a-bab7ef9187a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfPrograms_379dd01e-b2db-4637-9b69-cf6f22af0a38" xlink:href="dnli-20190630.xsd#dnli_NumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_NumberOfPrograms_379dd01e-b2db-4637-9b69-cf6f22af0a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregatePreclinicalMilestonePayment_871ae8a7-5b79-459d-8e1e-47190efa04dd" xlink:href="dnli-20190630.xsd#dnli_AggregatePreclinicalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregatePreclinicalMilestonePayment_871ae8a7-5b79-459d-8e1e-47190efa04dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentReceived_b45703b4-82fd-4f99-a70c-4a9ae6e912ba" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_PreclinicalMilestonePaymentReceived_b45703b4-82fd-4f99-a70c-4a9ae6e912ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfTargets_09631efd-c3f5-4475-b3e9-beef290d4d95" xlink:href="dnli-20190630.xsd#dnli_NumberOfTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_NumberOfTargets_09631efd-c3f5-4475-b3e9-beef290d4d95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TargetOptionPeriod_eb5e836b-668d-431a-ac97-e0b9398507ac" xlink:href="dnli-20190630.xsd#dnli_TargetOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_TargetOptionPeriod_eb5e836b-668d-431a-ac97-e0b9398507ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionFeesPerProgram_77b26eb8-284a-4364-8764-53cecaea020d" xlink:href="dnli-20190630.xsd#dnli_OptionFeesPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_OptionFeesPerProgram_77b26eb8-284a-4364-8764-53cecaea020d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateOptionExerciseFee_5bbb058c-8223-40dc-867b-a8dafa87ca78" xlink:href="dnli-20190630.xsd#dnli_AggregateOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregateOptionExerciseFee_5bbb058c-8223-40dc-867b-a8dafa87ca78" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentMilestonePayment_43396552-a73c-43ee-a977-caf5ea21c3f3" xlink:href="dnli-20190630.xsd#dnli_AggregateDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregateDevelopmentMilestonePayment_43396552-a73c-43ee-a977-caf5ea21c3f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonesPerProgram_6b9e94dc-35b0-4013-916a-768bcf09ca78" xlink:href="dnli-20190630.xsd#dnli_CommercialMilestonesPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_CommercialMilestonesPerProgram_6b9e94dc-35b0-4013-916a-768bcf09ca78" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateCommercialMilestones_79d30a18-319e-4e01-88c2-03fb047855f5" xlink:href="dnli-20190630.xsd#dnli_AggregateCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregateCommercialMilestones_79d30a18-319e-4e01-88c2-03fb047855f5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_933cfbb3-250b-4459-936b-78bd66309c31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_933cfbb3-250b-4459-936b-78bd66309c31" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_870380e5-9a71-4c51-bae4-f79bae2e34e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_870380e5-9a71-4c51-bae4-f79bae2e34e5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_80010e7f-e6e5-4860-a2dd-11ef589820af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_80010e7f-e6e5-4860-a2dd-11ef589820af" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5d2f8243-7014-402f-a145-80462ddd5ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5d2f8243-7014-402f-a145-80462ddd5ad8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_ad26b625-0e97-4abb-93e2-1a2c38bcb9c9" xlink:href="dnli-20190630.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_ad26b625-0e97-4abb-93e2-1a2c38bcb9c9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_VariableConsiderationFutureConsideration_4c6e65da-79f0-4d27-9a93-564fcbebf56d" xlink:href="dnli-20190630.xsd#dnli_VariableConsiderationFutureConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_VariableConsiderationFutureConsideration_4c6e65da-79f0-4d27-9a93-564fcbebf56d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_f17fe5db-23e3-4eb2-b71d-54df3f77ca72" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentEarnedNotYetReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_f17fe5db-23e3-4eb2-b71d-54df3f77ca72" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ConstrainedVariableConsideration_51021dc0-23da-4418-8ade-bf895becbaef" xlink:href="dnli-20190630.xsd#dnli_ConstrainedVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_ConstrainedVariableConsideration_51021dc0-23da-4418-8ade-bf895becbaef" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RevenueNumberOfPerformanceObligations_ef79afc2-4f5f-482b-b990-bdf0f2a8353e" xlink:href="dnli-20190630.xsd#dnli_RevenueNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_RevenueNumberOfPerformanceObligations_ef79afc2-4f5f-482b-b990-bdf0f2a8353e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cfd01858-43ec-404c-a2a7-69f512cb4c72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cfd01858-43ec-404c-a2a7-69f512cb4c72" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_216a2df5-8e0f-4a5f-8b49-7813384d2008" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_216a2df5-8e0f-4a5f-8b49-7813384d2008" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_6b6b9bf6-5bc2-4288-ba0c-25d37256b55e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_6b6b9bf6-5bc2-4288-ba0c-25d37256b55e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eff90f7f-b71d-4aa2-ba15-3bd3e415bc5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eff90f7f-b71d-4aa2-ba15-3bd3e415bc5f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4a2919-4646-42fc-b262-702399beaf6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4a2919-4646-42fc-b262-702399beaf6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84c21d9b-38bc-4651-837a-6400e21d3781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84c21d9b-38bc-4651-837a-6400e21d3781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_45b9d996-17c1-4436-bc1e-b4f7311b6b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84c21d9b-38bc-4651-837a-6400e21d3781" xlink:to="loc_us-gaap_CollaborativeArrangementMember_45b9d996-17c1-4436-bc1e-b4f7311b6b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f9fec2d-8118-4081-85e5-8499713b028d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:to="loc_srt_RangeMember_6f9fec2d-8118-4081-85e5-8499713b028d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64116949-fb04-469f-8c4c-0dc3a9191e76" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:to="loc_srt_RangeMember_64116949-fb04-469f-8c4c-0dc3a9191e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_451023d2-3a7b-44ab-a896-807aaf9e911b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64116949-fb04-469f-8c4c-0dc3a9191e76" xlink:to="loc_srt_MaximumMember_451023d2-3a7b-44ab-a896-807aaf9e911b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_74886e0d-ea5d-4d8f-afd0-494591097a0a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_74886e0d-ea5d-4d8f-afd0-494591097a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8b5b174-7379-4bd6-affb-6565b184d90b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8b5b174-7379-4bd6-affb-6565b184d90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember_dbeddf4b-3c89-4946-9abc-36f834ad3449" xlink:href="dnli-20190630.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8b5b174-7379-4bd6-affb-6565b184d90b" xlink:to="loc_dnli_SharePurchaseAgreementMember_dbeddf4b-3c89-4946-9abc-36f834ad3449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d19874a2-adce-4707-902d-feacef11f962" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d19874a2-adce-4707-902d-feacef11f962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_0d20199a-d881-4fc2-8c24-488962fe12c8" xlink:href="dnli-20190630.xsd#dnli_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d19874a2-adce-4707-902d-feacef11f962" xlink:to="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_0d20199a-d881-4fc2-8c24-488962fe12c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27c7f543-cd3c-4280-8a16-5a9709d8befe_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:to="loc_srt_ProductsAndServicesDomain_27c7f543-cd3c-4280-8a16-5a9709d8befe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a12b2957-c094-40a5-a087-6c9575073a50" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:to="loc_srt_ProductsAndServicesDomain_a12b2957-c094-40a5-a087-6c9575073a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a8fba550-11f4-496b-bfc9-140d5648a284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a12b2957-c094-40a5-a087-6c9575073a50" xlink:to="loc_us-gaap_ProductMember_a8fba550-11f4-496b-bfc9-140d5648a284" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSummaryofCollaborationRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="extended" id="iecb8840b8c7f4481937f91ffa694a80f_d9b2ff79-db3f-4183-9fc6-cbdcec1d07af">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298e83b-1376-4917-b210-52b3c21daa68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298e83b-1376-4917-b210-52b3c21daa68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_0faabda5-9310-45cf-859b-7541a10fd41d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:to="loc_us-gaap_DeferredRevenue_0faabda5-9310-45cf-859b-7541a10fd41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72890ce4-6213-4808-a7cb-103489d00c1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72890ce4-6213-4808-a7cb-103489d00c1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaCollaborationAgreementMember_b1cd6dae-9575-42b5-b665-d3c4e9bf6a47" xlink:href="dnli-20190630.xsd#dnli_TakedaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:to="loc_dnli_TakedaCollaborationAgreementMember_b1cd6dae-9575-42b5-b665-d3c4e9bf6a47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiCollaborationAgreementMember_3d1fc980-5641-45ce-9ee4-e2159284d7bc" xlink:href="dnli-20190630.xsd#dnli_SanofiCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:to="loc_dnli_SanofiCollaborationAgreementMember_3d1fc980-5641-45ce-9ee4-e2159284d7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:to="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:to="loc_srt_ProductsAndServicesDomain_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:to="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_d28fb278-8d8d-4f9b-8cb7-001eb1a1e7ef" xlink:href="dnli-20190630.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_d28fb278-8d8d-4f9b-8cb7-001eb1a1e7ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember_45a22f00-001c-4dd7-a48d-481eaf4ed6db" xlink:href="dnli-20190630.xsd#dnli_RetainedActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:to="loc_dnli_RetainedActivitiesMember_45a22f00-001c-4dd7-a48d-481eaf4ed6db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="simple" xlink:href="dnli-20190630.xsd#LicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="extended" id="i34a9ef9fd290416fa11962c0148121d1_b850bc14-bb41-4928-b2a9-7a7b099a08c6"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails" xlink:type="extended" id="i5a689d5ea5934ece96dd9f1ecb697417_988eb209-e0a7-4096-adfc-8c1e1b39b2a1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_812cd8b7-ab19-47ad-92ed-457329619607" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:to="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_812cd8b7-ab19-47ad-92ed-457329619607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontFeesPaid_13d2b0cd-c088-438b-8a02-3c8c7a3ff8d1" xlink:href="dnli-20190630.xsd#dnli_UpfrontFeesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:to="loc_dnli_UpfrontFeesPaid_13d2b0cd-c088-438b-8a02-3c8c7a3ff8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c68c97d-5316-48b4-9e80-d2c4d1994701_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c68c97d-5316-48b4-9e80-d2c4d1994701_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bc7020-82d7-46c2-9918-5e5335b3368a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bc7020-82d7-46c2-9918-5e5335b3368a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMember_849e936c-184e-4f0e-8676-562926e072b1" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bc7020-82d7-46c2-9918-5e5335b3368a" xlink:to="loc_dnli_LicenseAgreementMember_849e936c-184e-4f0e-8676-562926e072b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56d4888b-ed62-48f4-861e-858f49ee2c05_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:to="loc_srt_RangeMember_56d4888b-ed62-48f4-861e-858f49ee2c05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57c6332f-70a2-4584-b6ae-8c4752a67554" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:to="loc_srt_RangeMember_57c6332f-70a2-4584-b6ae-8c4752a67554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_39b88773-76b6-4808-809e-69cf416831c2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57c6332f-70a2-4584-b6ae-8c4752a67554" xlink:to="loc_srt_MaximumMember_39b88773-76b6-4808-809e-69cf416831c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38d6f790-ee51-48da-9ce6-42cfa6dedfb9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38d6f790-ee51-48da-9ce6-42cfa6dedfb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69acdff6-1382-4dbc-b008-00b5dd39baeb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69acdff6-1382-4dbc-b008-00b5dd39baeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_GenentechIncMember_854e99dd-8b4e-46f4-8000-648951fbf071" xlink:href="dnli-20190630.xsd#dnli_GenentechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69acdff6-1382-4dbc-b008-00b5dd39baeb" xlink:to="loc_dnli_GenentechIncMember_854e99dd-8b4e-46f4-8000-648951fbf071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a02a5f36-42bb-4dde-8030-de97ca3711ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a02a5f36-42bb-4dde-8030-de97ca3711ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c9b94ccb-8f7e-4dcb-a635-dbdc316171e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c9b94ccb-8f7e-4dcb-a635-dbdc316171e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f3dc1e6-c8c9-4a35-8e40-dd6805d368c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c9b94ccb-8f7e-4dcb-a635-dbdc316171e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f3dc1e6-c8c9-4a35-8e40-dd6805d368c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended" id="i13d2e1bbee004dfd8c9ef782f3060186_9d608d72-1127-4415-915f-374cd907b733"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i80e789abf37b4ae6a7fd903e11d8a14f_8b123456-823b-4fc6-9f2b-5c1ed505da45"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i9f144dd80ecb47a590f61d477f96aa37_62ec7e5d-3e62-4425-abbe-16aa781c466e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesAreaUnderLease_a07e454e-6f15-4867-9688-ebde7833de2b" xlink:href="dnli-20190630.xsd#dnli_OperatingLeasesAreaUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_OperatingLeasesAreaUnderLease_a07e454e-6f15-4867-9688-ebde7833de2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f25356cb-0129-4316-8ea9-188746a253dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f25356cb-0129-4316-8ea9-188746a253dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TenantImprovementAllowanceRepayableAsRent_e2c29d13-9ffe-4a9a-8fa7-ab3c5748d6b1" xlink:href="dnli-20190630.xsd#dnli_TenantImprovementAllowanceRepayableAsRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_TenantImprovementAllowanceRepayableAsRent_e2c29d13-9ffe-4a9a-8fa7-ab3c5748d6b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad9aed2b-321c-45b9-b4cb-853bd28e2c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad9aed2b-321c-45b9-b4cb-853bd28e2c0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_ba6e52b0-3cff-4545-8184-864094a40f20" xlink:href="dnli-20190630.xsd#dnli_LesseeOperatingLeaseRenewalNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_ba6e52b0-3cff-4545-8184-864094a40f20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_3e92fa3b-3fb9-40f7-a6f2-d8debf58bdd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_3e92fa3b-3fb9-40f7-a6f2-d8debf58bdd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f3d289c-fe01-4e0f-afaf-518b5b5ef7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f3d289c-fe01-4e0f-afaf-518b5b5ef7b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6e8fefdb-1ce8-40ed-8217-f0255d9e74b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6e8fefdb-1ce8-40ed-8217-f0255d9e74b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ece280ae-8e42-4a7b-903a-ccd0e7f45133" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ece280ae-8e42-4a7b-903a-ccd0e7f45133" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_6871e4ed-882d-400f-884c-a68cd6684b51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_6871e4ed-882d-400f-884c-a68cd6684b51" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c92505be-b64f-4d22-9f16-90c2ecdd15f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LeaseCost_c92505be-b64f-4d22-9f16-90c2ecdd15f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_5c881f1d-b836-486d-8e18-f410d1ce396f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_5c881f1d-b836-486d-8e18-f410d1ce396f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a778a61b-11fa-446c-9cf5-d03785a09891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a778a61b-11fa-446c-9cf5-d03785a09891" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9953753e-b793-4791-af5b-c49f1ca82db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9953753e-b793-4791-af5b-c49f1ca82db6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3579cb3b-50d3-4efe-a284-a23019556469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeasePayments_3579cb3b-50d3-4efe-a284-a23019556469" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesSubleaseNetRentableArea_5acb64f6-f6f9-4d9a-8c81-3d5b95788b9e" xlink:href="dnli-20190630.xsd#dnli_OperatingLeasesSubleaseNetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_OperatingLeasesSubleaseNetRentableArea_5acb64f6-f6f9-4d9a-8c81-3d5b95788b9e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_d6cbae31-8fbd-428d-b8dd-9337659359c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_d6cbae31-8fbd-428d-b8dd-9337659359c0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_e28ca5cc-1d58-4072-8406-26551f4d124e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_e28ca5cc-1d58-4072-8406-26551f4d124e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PurchaseOrderExecuted_0b9aab6e-b42b-4725-8e4b-603ee4905da5" xlink:href="dnli-20190630.xsd#dnli_PurchaseOrderExecuted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_PurchaseOrderExecuted_0b9aab6e-b42b-4725-8e4b-603ee4905da5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsIncurredDevelopmentCosts_9e2a7106-d4eb-45ff-8b49-08904cdd89e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsIncurredDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_CostsIncurredDevelopmentCosts_9e2a7106-d4eb-45ff-8b49-08904cdd89e8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PaymentsForManufacturingCost_a867e539-5da8-4fec-9156-6881cc088e74" xlink:href="dnli-20190630.xsd#dnli_PaymentsForManufacturingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_PaymentsForManufacturingCost_a867e539-5da8-4fec-9156-6881cc088e74" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_075bcbc4-a440-4540-8d6d-6fe452ef2271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_PurchaseObligation_075bcbc4-a440-4540-8d6d-6fe452ef2271" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1274fd8-785e-44bc-bdb3-2e301a95b6ba_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:to="loc_srt_RangeMember_b1274fd8-785e-44bc-bdb3-2e301a95b6ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:to="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d7e27f79-c34e-4004-ad49-b57d50a58fc8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:to="loc_srt_MinimumMember_d7e27f79-c34e-4004-ad49-b57d50a58fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a59f359c-7f55-4378-873c-307ecdb24e40" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:to="loc_srt_MaximumMember_a59f359c-7f55-4378-873c-307ecdb24e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d776e7d1-70a1-4dab-a0a0-6c0beef1e294_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d776e7d1-70a1-4dab-a0a0-6c0beef1e294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_677997cb-3d8d-419b-a8a3-01f9d3fdc1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_677997cb-3d8d-419b-a8a3-01f9d3fdc1b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DMSAMember_d9f24cb0-1059-4685-983d-bb6e2a120fd9" xlink:href="dnli-20190630.xsd#dnli_DMSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_677997cb-3d8d-419b-a8a3-01f9d3fdc1b1" xlink:to="loc_dnli_DMSAMember_d9f24cb0-1059-4685-983d-bb6e2a120fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_1ba29a80-f76d-4173-887d-22a3b60590a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_1ba29a80-f76d-4173-887d-22a3b60590a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_286b152f-c0b2-4a2f-9448-4880a6435ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_286b152f-c0b2-4a2f-9448-4880a6435ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LandlordFundedTenantImprovementsMember_1333a3e9-2520-4bf1-8263-d3e1e6856b0c" xlink:href="dnli-20190630.xsd#dnli_LandlordFundedTenantImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_286b152f-c0b2-4a2f-9448-4880a6435ab5" xlink:to="loc_dnli_LandlordFundedTenantImprovementsMember_1333a3e9-2520-4bf1-8263-d3e1e6856b0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_4b900d06-23c4-468a-800e-35109d05e986_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_4b900d06-23c4-468a-800e-35109d05e986_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_HeadquartersLeaseMember_a97c47ab-a20e-41bb-a607-354aa4d03954" xlink:href="dnli-20190630.xsd#dnli_HeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:to="loc_dnli_HeadquartersLeaseMember_a97c47ab-a20e-41bb-a607-354aa4d03954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NewPremisesSubleaseAgreementMember_35e0dfe6-b32b-481e-b252-2503fa03d95b" xlink:href="dnli-20190630.xsd#dnli_NewPremisesSubleaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:to="loc_dnli_NewPremisesSubleaseAgreementMember_35e0dfe6-b32b-481e-b252-2503fa03d95b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="ica37410278f540a1919e93fc1f5eaeb1_3b6a728e-7e79-42dd-b10f-0aa2c8771278"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="extended" id="i53e91640b1134a0f815dd8aa6e478d9b_3eaea2b9-29e6-488d-b4b4-49cc4995db04"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwards"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="extended" id="i125acdbfb530440493ff1295fb78c3d3_651d6e27-a057-4ddf-9aed-7cb1f1233edb"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="extended" id="i1d593c1e80c349bc925fba6c2c1e5a51_44e1a0aa-8d81-4b1e-95fb-83f8d8ed67a4"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails" xlink:type="extended" id="i82ccc95f2f434fc5a347f6ed8f45f12d_4e7696d8-e648-4f74-86c0-85ef96a8cd35">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59a66254-79ed-44fb-b4f8-32b29cb0109a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59a66254-79ed-44fb-b4f8-32b29cb0109a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_9279994b-2aa8-486b-919c-203e065b5f0b" xlink:href="dnli-20190630.xsd#dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_9279994b-2aa8-486b-919c-203e065b5f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5ab4f27d-acbf-404c-ae94-2a87f9056b90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5ab4f27d-acbf-404c-ae94-2a87f9056b90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_934d42ea-8349-4147-997c-7a07df474520" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_934d42ea-8349-4147-997c-7a07df474520" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1a624c18-9c75-41c4-8de4-241ed8538668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1a624c18-9c75-41c4-8de4-241ed8538668" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58d9d783-e9ed-4b69-977d-57d45db2345a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58d9d783-e9ed-4b69-977d-57d45db2345a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aa60979c-2f46-4c4b-bc1e-27715f3170fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aa60979c-2f46-4c4b-bc1e-27715f3170fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7e745ee1-6222-4fde-92f8-3ad6b760d7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7e745ee1-6222-4fde-92f8-3ad6b760d7b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56131511-6161-457d-ac0d-c7df7c7cb8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56131511-6161-457d-ac0d-c7df7c7cb8d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_139d234e-9361-498d-b1fb-487f64a92724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_139d234e-9361-498d-b1fb-487f64a92724" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3aacb410-b4af-4e1f-8a73-50e3943f5ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3aacb410-b4af-4e1f-8a73-50e3943f5ddc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8f501f98-5032-4c88-90bf-691a10c3bbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_Dividends_8f501f98-5032-4c88-90bf-691a10c3bbfc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_843acc93-916b-4b98-88e5-87c9b64845b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_843acc93-916b-4b98-88e5-87c9b64845b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_7c980e2c-0c7a-4ad5-ba77-8b936277ea79" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_7c980e2c-0c7a-4ad5-ba77-8b936277ea79" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_e746d41d-63af-4136-8faa-419d4129c24f" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_e746d41d-63af-4136-8faa-419d4129c24f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensation_1bc0c203-ec51-41fb-9f7b-c5780e1ae8b0" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_PerformanceAndMarketShareBasedCompensation_1bc0c203-ec51-41fb-9f7b-c5780e1ae8b0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_ae6f895e-9760-4f70-bc06-828eb11a003d" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_ae6f895e-9760-4f70-bc06-828eb11a003d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_70433745-9a35-4af3-8690-2e70a6ea35d3" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_70433745-9a35-4af3-8690-2e70a6ea35d3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2d19b80-687a-4137-87f5-e851345b8560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2d19b80-687a-4137-87f5-e851345b8560" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_916190fd-723b-432c-85df-376e2e273161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_916190fd-723b-432c-85df-376e2e273161" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac51164d-2145-4374-978d-3796887986ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac51164d-2145-4374-978d-3796887986ee" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_04a4d228-8b88-4879-a704-8cef3e51374d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_04a4d228-8b88-4879-a704-8cef3e51374d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ee7fe7d3-94ff-4c8d-a7f0-8bb64515592e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ee7fe7d3-94ff-4c8d-a7f0-8bb64515592e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6aa9ec1f-b7fb-43ee-ba88-1b60aab4b6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6aa9ec1f-b7fb-43ee-ba88-1b60aab4b6b5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a13adce-7da4-4968-aed3-1c68213850d4_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:to="loc_srt_RangeMember_2a13adce-7da4-4968-aed3-1c68213850d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:to="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ceeb65fc-52a0-4f00-a216-c97acb1b10c9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:to="loc_srt_MaximumMember_ceeb65fc-52a0-4f00-a216-c97acb1b10c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bee1caf5-91cb-4c2d-85e2-836f282fe253" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:to="loc_srt_MinimumMember_bee1caf5-91cb-4c2d-85e2-836f282fe253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be08a7b6-be09-4639-9f3a-e588bc55d157_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:to="loc_us-gaap_PlanNameDomain_be08a7b6-be09-4639-9f3a-e588bc55d157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:to="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandSeventeenEquityIncentivePlanMember_20bd38b2-29d6-458b-8196-88e51d1e485a" xlink:href="dnli-20190630.xsd#dnli_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:to="loc_dnli_TwoThousandSeventeenEquityIncentivePlanMember_20bd38b2-29d6-458b-8196-88e51d1e485a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandFifteenEquityIncentivePlanMember_dde7fbf2-e2d4-4c0f-a3ff-fdcbfd757e3b" xlink:href="dnli-20190630.xsd#dnli_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:to="loc_dnli_TwoThousandFifteenEquityIncentivePlanMember_dde7fbf2-e2d4-4c0f-a3ff-fdcbfd757e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_61cd0454-1bff-4618-8e5a-7565273f48df" xlink:href="dnli-20190630.xsd#dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:to="loc_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_61cd0454-1bff-4618-8e5a-7565273f48df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d613d0d5-4f4f-46e0-b082-fa38b4990782_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d613d0d5-4f4f-46e0-b082-fa38b4990782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketContingentStockOptionsMember_de90fd3a-cc2d-4c76-bfc9-b44700bd50d5" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketContingentStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_dnli_PerformanceAndMarketContingentStockOptionsMember_de90fd3a-cc2d-4c76-bfc9-b44700bd50d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5897ceb5-0e6d-4a09-813e-f7a2b63d1f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_us-gaap_RestrictedStockMember_5897ceb5-0e6d-4a09-813e-f7a2b63d1f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_0ab823a8-4a30-45bd-b02f-53f52c33c8d3" xlink:href="dnli-20190630.xsd#dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_0ab823a8-4a30-45bd-b02f-53f52c33c8d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_837ead91-30b3-4144-aaf7-26cee85ce962" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_837ead91-30b3-4144-aaf7-26cee85ce962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d78ddc23-76a2-471f-95e9-8113ca9b3faf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d78ddc23-76a2-471f-95e9-8113ca9b3faf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1a10882-5c30-49ce-8439-f106936bd9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1a10882-5c30-49ce-8439-f106936bd9e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22927e27-264b-41fb-9cc2-ff5975480762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22927e27-264b-41fb-9cc2-ff5975480762" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="extended" id="i03181030ac9b48798e187c645d3eb35e_005051ba-91ed-44da-a0c3-f77f9884e2f8"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="extended" id="i737adba01f47479eb0c384b71d00cff7_4b0c8b5d-6f10-4cbf-a00a-5cb1cfbd9aaa">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cc774088-941a-4ed4-a0b2-b4451562ce89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cc774088-941a-4ed4-a0b2-b4451562ce89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_789e30aa-30d0-4818-8747-a5f5071deead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_789e30aa-30d0-4818-8747-a5f5071deead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_cb9d9e26-f15e-4f39-990e-15fa1adbe971" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_cb9d9e26-f15e-4f39-990e-15fa1adbe971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1c31113d-67ec-4706-846c-682ffa2b68bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1c31113d-67ec-4706-846c-682ffa2b68bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f9b4f57-0e2a-42a3-8d0e-8dc4792b42cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f9b4f57-0e2a-42a3-8d0e-8dc4792b42cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_83ee204f-124d-4e84-a7a7-9d6865498b71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_83ee204f-124d-4e84-a7a7-9d6865498b71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:to="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_173defec-0f2c-4da0-abe4-52785c183b27_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:to="loc_srt_RangeMember_173defec-0f2c-4da0-abe4-52785c183b27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:to="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f791fe99-13b5-431a-9724-2252a7109642" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:to="loc_srt_MinimumMember_f791fe99-13b5-431a-9724-2252a7109642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be5041ac-c73d-48db-a44a-a74e0f36707d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:to="loc_srt_MaximumMember_be5041ac-c73d-48db-a44a-a74e0f36707d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="i7a84d5179b514d4987fd102f45b7d250_64711297-21ca-4d44-aa66-117bd160b967">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ee53bfa-1197-46c5-9d0a-b1ad003948ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ee53bfa-1197-46c5-9d0a-b1ad003948ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bcab891f-4c04-4997-b097-fd2c40b90677" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bcab891f-4c04-4997-b097-fd2c40b90677" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37d6a1d4-bcab-4e53-89d2-60a7c8f413b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37d6a1d4-bcab-4e53-89d2-60a7c8f413b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a7be8c8c-be94-4c5d-8809-a266f9a54ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a7be8c8c-be94-4c5d-8809-a266f9a54ea7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ebd9f5d-5d18-4ea1-9dae-05ac54c93f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_45bc5e01-92ab-4ae3-867b-7fdfe2d0cfb3" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_45bc5e01-92ab-4ae3-867b-7fdfe2d0cfb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_18ffb016-c6c3-4972-aafa-358a01b39ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_18ffb016-c6c3-4972-aafa-358a01b39ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0f04b189-dd73-478e-8832-7888421f8b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0f04b189-dd73-478e-8832-7888421f8b0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cc72346f-75e0-42d4-8df7-056d59b7eea0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cc72346f-75e0-42d4-8df7-056d59b7eea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4d5133ce-8aac-4d01-9ef6-01931db5e833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4d5133ce-8aac-4d01-9ef6-01931db5e833" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_62916209-c804-45da-9404-6fcb67c48229" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_85f96926-8412-4e44-be8d-d1cdbfe0992e" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_85f96926-8412-4e44-be8d-d1cdbfe0992e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:to="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741f4c7b-112d-449a-8cbe-700180db899c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741f4c7b-112d-449a-8cbe-700180db899c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_032c7fc7-7f05-4de5-91ac-95ab66ab8f79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741f4c7b-112d-449a-8cbe-700180db899c" xlink:to="loc_us-gaap_RestrictedStockMember_032c7fc7-7f05-4de5-91ac-95ab66ab8f79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended" id="ie4612d1f7d0a4468ad8e5568d9a37ace_cb757827-4860-4d76-af41-e15ba24a26f5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a919b3b7-8eda-42f6-ac91-aa434a2e7ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ebef931c-13a2-408d-a9c5-ebf017628e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a919b3b7-8eda-42f6-ac91-aa434a2e7ab4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ebef931c-13a2-408d-a9c5-ebf017628e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a919b3b7-8eda-42f6-ac91-aa434a2e7ab4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4491c206-078a-4da2-983f-9324a2e4bb6a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4491c206-078a-4da2-983f-9324a2e4bb6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8916a70-2f35-4710-9dc9-e78d570d3c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8916a70-2f35-4710-9dc9-e78d570d3c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd34958e-a35f-408b-82f3-1586cef2158e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd34958e-a35f-408b-82f3-1586cef2158e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="extended" id="ic933a68b24bc4424ae32666cafa427cb_3634d53c-68ab-4edc-83cb-3ff2938efa7b"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="extended" id="i1c72aebfeedd420a9bd8f671cb892dff_eb5b2d8e-2474-471e-91c0-92303905c725"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="extended" id="i5a1a07aa067c4f7b852fdb5048b0ec32_6a93c00c-864d-4364-bed9-c223f2b4e716">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d2cdd01-aed3-412f-8f01-479c6e838da0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_951d4da7-bb32-4b65-8227-0c2028b670d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d2cdd01-aed3-412f-8f01-479c6e838da0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_951d4da7-bb32-4b65-8227-0c2028b670d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d2cdd01-aed3-412f-8f01-479c6e838da0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e81331c-d5b2-43b4-96a7-211a72382875_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e81331c-d5b2-43b4-96a7-211a72382875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_d0b79613-f160-4b95-a504-15bd33851930" xlink:href="dnli-20190630.xsd#dnli_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:to="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_d0b79613-f160-4b95-a504-15bd33851930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_0b079081-16d5-4828-9a50-2ff643a9ef18" xlink:href="dnli-20190630.xsd#dnli_RestrictedSharesSubjectToFutureVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:to="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_0b079081-16d5-4828-9a50-2ff643a9ef18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_624ea6a5-c509-4df0-a7af-c42153c10399" xlink:href="dnli-20190630.xsd#dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:to="loc_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_624ea6a5-c509-4df0-a7af-c42153c10399" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>dnli-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:8011caee-abc0-437e-96e5-962907bf5aea,g:892d10ab-e474-4c56-aa84-e84b6d701647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_37ca7455-d646-4939-a76d-4a93ead694ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee contribution to ESPP, percent of base compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_33b75058-fb1a-4d10-bcb2-b91524f4ff1e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_afe0463c-d5af-4f3c-bfc5-e620620663e3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of option price of estimated fair value on grant date</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3555e5a6-1cb2-43fe-8d09-13d6d2dcaba6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5fe0944a-bf87-467e-89ed-6447579f4ad6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2af73249-b9e2-4d12-b566-02f0709b991e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateCommercialMilestones_13c188df-ee26-414b-89ed-984fc62249e0_terseLabel_en-US" xlink:label="lab_dnli_AggregateCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of biologic product from each program</link:label>
    <link:label id="lab_dnli_AggregateCommercialMilestones_label_en-US" xlink:label="lab_dnli_AggregateCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Commercial Milestones</link:label>
    <link:label id="lab_dnli_AggregateCommercialMilestones_documentation_en-US" xlink:label="lab_dnli_AggregateCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate commercial milestones if one biologic product from each program achieves the milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateCommercialMilestones" xlink:href="dnli-20190630.xsd#dnli_AggregateCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateCommercialMilestones" xlink:to="lab_dnli_AggregateCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9e70cb55-8e0e-4de0-98a0-b74c75a36418_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a945d3d-a3a6-40b1-8953-75f6f61a3a30_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ad61b923-4e09-4fc7-a4b7-c9dfc04dd919_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_333872b9-0f24-4341-896c-e78cab0cb6cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f8eb93d1-ce82-4747-8523-ed2d22a7eb8f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized stock- based compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d9df920-9636-4e14-b9b0-c136f905fc2f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_2cd875ac-b65d-4081-9a13-7c35c78a2cef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary impairment</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0a85b07b-9f42-4303-b0e2-16accf3e4e7a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4609ea26-8596-4208-bc63-e7e920135da4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e19717a9-daf3-4f5c-8d24-6720986fafc8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4e42ffdc-17f8-4ada-a103-0b5f787e1cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3e661bfe-c677-4de7-8d07-fea7d5f10800_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_820fd01d-f381-4db7-bf26-2d0beb6b758c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_fb5d422c-a7be-461b-9cc7-6e5447924f5c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ForeignExchangeForwardBritishPoundsMember_9b207baa-74ec-43f9-b585-b1906c483d8f_terseLabel_en-US" xlink:label="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Pounds</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardBritishPoundsMember_label_en-US" xlink:label="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - British Pounds [Member]</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardBritishPoundsMember_documentation_en-US" xlink:label="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - British Pounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardBritishPoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:to="lab_dnli_ForeignExchangeForwardBritishPoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OperatingLeasesSubleaseNetRentableArea_5b3022e3-7314-4cf6-88bd-dc4053a9b3ce_terseLabel_en-US" xlink:label="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentable square feet</link:label>
    <link:label id="lab_dnli_OperatingLeasesSubleaseNetRentableArea_label_en-US" xlink:label="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease, Net Rentable Area</link:label>
    <link:label id="lab_dnli_OperatingLeasesSubleaseNetRentableArea_documentation_en-US" xlink:label="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease, Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:href="dnli-20190630.xsd#dnli_OperatingLeasesSubleaseNetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:to="lab_dnli_OperatingLeasesSubleaseNetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_e25b5e3c-871f-461e-b3d0-b18ae0ec7fe5_terseLabel_en-US" xlink:label="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, regulatory and commercial milestone payments</link:label>
    <link:label id="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_label_en-US" xlink:label="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone Payment</link:label>
    <link:label id="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_documentation_en-US" xlink:label="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalRegulatoryAndCommercialMilestonePayment" xlink:href="dnli-20190630.xsd#dnli_ClinicalRegulatoryAndCommercialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ClinicalRegulatoryAndCommercialMilestonePayment" xlink:to="lab_dnli_ClinicalRegulatoryAndCommercialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_01da2918-70db-467e-9931-255f32391ae1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liability fair value measurements</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6451130f-612f-4bd9-baef-1490923f8a7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_779cc413-fae1-4ec4-8729-39f73301eaa4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_34cfe700-aae4-4892-a9e9-1ab46e938645_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f104e254-3d16-4402-8019-a7ef8e40feef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_50e6db11-2278-4587-a6b0-e984b704de4c_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d4e220ce-305c-40f9-a852-4d888bfb4e2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2cb68e42-0792-4a1e-b4ac-80213a1b3340_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise&#160;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_180c64d4-ed0b-452f-8a07-d0a7d7c6dce9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23e83a37-4193-49fb-a773-0f317be7a42f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_96a9b5cb-12a8-4e72-aeb7-ee8d5705a2ed_terseLabel_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting trigger, number of days after IPO</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_label_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Days After Initial Public Offering</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_documentation_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Days After Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" xlink:to="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ae5da88e-6957-4679-bc15-543efef7a7e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c04f0e1b-b681-431c-be02-40875daf5c58_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_fc731408-f739-413b-bd0d-9245466a5030_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain (loss) on derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LandlordFundedTenantImprovementsMember_b1c71d66-10f4-4fc1-95c6-1704825c859a_terseLabel_en-US" xlink:label="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord Funded Tenant Improvements</link:label>
    <link:label id="lab_dnli_LandlordFundedTenantImprovementsMember_label_en-US" xlink:label="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord Funded Tenant Improvements [Member]</link:label>
    <link:label id="lab_dnli_LandlordFundedTenantImprovementsMember_documentation_en-US" xlink:label="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord funded tenant improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LandlordFundedTenantImprovementsMember" xlink:href="dnli-20190630.xsd#dnli_LandlordFundedTenantImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LandlordFundedTenantImprovementsMember" xlink:to="lab_dnli_LandlordFundedTenantImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6768ac2d-f038-4b5f-90e2-319b97c04948_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c87ed6bd-6695-41c5-8465-74c9a79fe2ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b027391-331e-44eb-88e4-598fa229d9a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_03320f18-f6e7-4bd9-81f1-da9c173c0589_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_875542e1-0a36-46e2-866e-c7884a2cdb36_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_43eea5bf-e5f5-43df-8487-84c3d45bfbfd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_00a854c7-6a7a-42ab-b47b-8558d0d2e792_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_99acf04d-50eb-43c8-b510-5d2315770f63_terseLabel_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested and expected to vest (usd per share)</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_label_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Expected To Vest</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_documentation_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value expected to vest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:to="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_bfd7f826-85c9-4862-88b6-c8677807e9f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e65f2750-ae5c-4349-b245-3572f3a2d20b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Issued and Outstanding and ESPP Shares Issuable and Outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2b648bce-3bf2-4869-b33f-5960efc37fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60b5bd96-b839-4909-a151-4da752ab16af_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c330354b-8b2f-4b0c-9e28-a194bd154a50_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9b4cc616-0cf1-4c67-bffa-3096de24f3ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_b1c5c28e-9a50-4fc7-8026-5a8238717a2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_520b84fe-c19c-4fc1-b42a-ab13002bd603_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateOptionExerciseFee_7f55e4bb-199c-4529-b068-a7f044526375_terseLabel_en-US" xlink:label="lab_dnli_AggregateOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated option exercise fee</link:label>
    <link:label id="lab_dnli_AggregateOptionExerciseFee_label_en-US" xlink:label="lab_dnli_AggregateOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Option Exercise Fee</link:label>
    <link:label id="lab_dnli_AggregateOptionExerciseFee_documentation_en-US" xlink:label="lab_dnli_AggregateOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate option exercise fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateOptionExerciseFee" xlink:href="dnli-20190630.xsd#dnli_AggregateOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateOptionExerciseFee" xlink:to="lab_dnli_AggregateOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7f6d5a5e-4653-4630-809d-51af7859e84a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_cb2aae97-8b5a-4472-9c9e-ed0a9ca34b97_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2fbde525-2f1d-4b63-97a9-56c59201dab8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9d41387-ec23-4269-a97b-114983d0feb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_5a99eb35-f8c0-416e-bd7a-7ccc401a041c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_5dc9154a-2444-4272-ad61-f4efcfe343e1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f23fdf07-ef3b-471d-846e-a6b3cece6801_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_186ae53f-00fa-4a46-8405-1b61460b9dc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate (as a percentage)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8809e408-7d52-421c-88b1-6758bf676469_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a84e483d-5f45-43f3-a6da-15cbc58c5e4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_9e8a8b42-1b4a-4248-900c-ad066d956406_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5d52ae26-b3d8-46c7-8a53-303a4a168c29_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TakedaCollaborationAgreementMember_3d2c68d4-6ee7-4f32-9149-98d3f4cd49b8_terseLabel_en-US" xlink:label="lab_dnli_TakedaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Collaboration Agreement</link:label>
    <link:label id="lab_dnli_TakedaCollaborationAgreementMember_label_en-US" xlink:label="lab_dnli_TakedaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dnli_TakedaCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dnli_TakedaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaCollaborationAgreementMember" xlink:href="dnli-20190630.xsd#dnli_TakedaCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TakedaCollaborationAgreementMember" xlink:to="lab_dnli_TakedaCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LongTermMarketableSecuritiesMember_33d8ddce-7ac3-45a3-9be8-323e0b25dd7e_terseLabel_en-US" xlink:label="lab_dnli_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities:</link:label>
    <link:label id="lab_dnli_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_dnli_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_dnli_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_dnli_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermMarketableSecuritiesMember" xlink:href="dnli-20190630.xsd#dnli_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LongTermMarketableSecuritiesMember" xlink:to="lab_dnli_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4f88ce3c-64e9-4d2a-87d5-26888e2a4755_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included within other non-current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentReceived_23302207-226c-4fd9-bad6-18c31e92dc2d_terseLabel_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payment received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentReceived_label_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentReceived_documentation_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentReceived" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PreclinicalMilestonePaymentReceived" xlink:to="lab_dnli_PreclinicalMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbb0501d-7c6f-428f-a899-eb5b5a6e43f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_47190a90-d7ec-4d79-ab0f-7114b874b0df_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_20ecb00c-101e-40ba-83b0-e4d60e5b2cd8_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_24f0f941-39e4-4e2f-86ce-efd43dc17f1a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4c9d3701-6f85-4184-bed6-705dfdc86766_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation cost recognized</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_71687590-6eae-46c4-ad44-8ebe05518f4a_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c187215e-1ede-48e4-9aae-6b640e0ae117_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_551d57c8-e930-4a30-8a02-3112116baf90_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease term</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06b55cd2-73d1-4e7d-a93a-e25c91279b04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f0372271-67f4-4cf8-b898-ee9a1b22b140_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cf0908e-a486-4e55-a24a-b28eab9efa22_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_invest_DerivativeNotionalAmount_3f28eb0f-7627-4c5d-b2af-cfd2d6aa4ee7_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Notional Amount in Foreign Currency</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_invest_DerivativeNotionalAmount" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount" xlink:to="lab_invest_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_9250f354-06b7-4416-a5ff-c5c360ac3b5d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_88a44a49-6248-4c0f-b298-b54c6e4ab4fb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_21cb6971-06c2-43d6-bc84-8f88dd2df950_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a5ea8209-ea4c-4b45-b774-c593f5541c0f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_e46f91f8-9227-46ca-b5fe-df09cb666ff1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset - foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_189a025a-ed2d-4738-b658-53b54cb7485c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_aaae420c-b3bf-49b1-81f9-657d15f1578c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_714fdfda-d152-4fa5-900e-7e5061b840cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NewPremisesSubleaseAgreementMember_9376aecc-8afe-4b8e-ae34-71b3fb88e04a_terseLabel_en-US" xlink:label="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Premises Sublease Agreement</link:label>
    <link:label id="lab_dnli_NewPremisesSubleaseAgreementMember_label_en-US" xlink:label="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Premises Sublease Agreement [Member]</link:label>
    <link:label id="lab_dnli_NewPremisesSubleaseAgreementMember_documentation_en-US" xlink:label="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Premises Sublease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NewPremisesSubleaseAgreementMember" xlink:href="dnli-20190630.xsd#dnli_NewPremisesSubleaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NewPremisesSubleaseAgreementMember" xlink:to="lab_dnli_NewPremisesSubleaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_b915350d-a26a-41b1-8c32-962add3e9a1c_terseLabel_en-US" xlink:label="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration recognized</link:label>
    <link:label id="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_label_en-US" xlink:label="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Amount Recognized</link:label>
    <link:label id="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_documentation_en-US" xlink:label="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Amount Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AssetAcquisitionContingentConsiderationAmountRecognized" xlink:href="dnli-20190630.xsd#dnli_AssetAcquisitionContingentConsiderationAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AssetAcquisitionContingentConsiderationAmountRecognized" xlink:to="lab_dnli_AssetAcquisitionContingentConsiderationAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_00fd6fb1-88d2-4563-8320-c3f52eab7a2d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fafb1d19-26ff-40e6-8191-4ca798123986_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OptionFeesPerProgram_17887f6b-0151-4541-ac01-71e07c7112fd_terseLabel_en-US" xlink:label="lab_dnli_OptionFeesPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee</link:label>
    <link:label id="lab_dnli_OptionFeesPerProgram_label_en-US" xlink:label="lab_dnli_OptionFeesPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Fees Per Program</link:label>
    <link:label id="lab_dnli_OptionFeesPerProgram_documentation_en-US" xlink:label="lab_dnli_OptionFeesPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fees per program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionFeesPerProgram" xlink:href="dnli-20190630.xsd#dnli_OptionFeesPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OptionFeesPerProgram" xlink:to="lab_dnli_OptionFeesPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_f4df5e1b-9165-47e6-ad06-18c4efe4e5f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective maturity (less than)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4a637921-634a-4c17-90e1-77ca9c8ff20a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6176d015-8763-4dd9-9e5e-dba7cf9d3e6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember_3c551af9-6e55-4438-a769-f76584ec5fa1_terseLabel_en-US" xlink:label="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda pharmaceutical company limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="dnli-20190630.xsd#dnli_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_dnli_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_408443bf-8fd6-4b9c-95b1-88942755ae40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_0ef78b4b-fb78-4e44-b2f4-393f9743f8fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a1131ad9-f40a-462f-bfe7-f6fc26b47865_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3e78a9b5-f03c-4d14-8b3d-12131a0bc68a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_8da9814c-5348-4a4e-a2ff-85f9da62724e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, less current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_81da2506-b240-445a-853d-d2ce3a9ebce4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e0fd3c89-737b-42b0-91a1-212b4d987a2c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NoncashTenantImprovementsPaidByLandlord_ca8204d3-bdc3-4606-a4b6-6df84974a0d0_terseLabel_en-US" xlink:label="lab_dnli_NoncashTenantImprovementsPaidByLandlord" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements provided by the landlord</link:label>
    <link:label id="lab_dnli_NoncashTenantImprovementsPaidByLandlord_label_en-US" xlink:label="lab_dnli_NoncashTenantImprovementsPaidByLandlord" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Tenant Improvements Paid By Landlord</link:label>
    <link:label id="lab_dnli_NoncashTenantImprovementsPaidByLandlord_documentation_en-US" xlink:label="lab_dnli_NoncashTenantImprovementsPaidByLandlord" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Tenant Improvements Paid By Landlord</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NoncashTenantImprovementsPaidByLandlord" xlink:href="dnli-20190630.xsd#dnli_NoncashTenantImprovementsPaidByLandlord"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NoncashTenantImprovementsPaidByLandlord" xlink:to="lab_dnli_NoncashTenantImprovementsPaidByLandlord" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c6e603d-8c06-43db-8131-c553aa97913d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RevenueNumberOfPerformanceObligations_133407db-b8a8-4606-b55c-e5fe50999f0f_terseLabel_en-US" xlink:label="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_dnli_RevenueNumberOfPerformanceObligations_label_en-US" xlink:label="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:label id="lab_dnli_RevenueNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RevenueNumberOfPerformanceObligations" xlink:href="dnli-20190630.xsd#dnli_RevenueNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RevenueNumberOfPerformanceObligations" xlink:to="lab_dnli_RevenueNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_74e73752-7aa3-4194-b9d7-df426baedc70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_4f108d85-11c8-42c6-a2b3-74ad030e82cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase discounted rate for employees</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_9640de76-bd66-4da4-aa81-69917579a5bf_terseLabel_en-US" xlink:label="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on sale of common stock</link:label>
    <link:label id="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_label_en-US" xlink:label="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Premium Received On Transaction</link:label>
    <link:label id="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_documentation_en-US" xlink:label="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration premium received on transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:href="dnli-20190630.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:to="lab_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94cdb8c8-7d7b-41b5-a912-ac2362001015_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fd0f266b-1979-44f2-aeb0-931a3d9504c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PurchaseOrderExecuted_c854960f-eba6-49e3-8814-318ef6864752_terseLabel_en-US" xlink:label="lab_dnli_PurchaseOrderExecuted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase order executed</link:label>
    <link:label id="lab_dnli_PurchaseOrderExecuted_label_en-US" xlink:label="lab_dnli_PurchaseOrderExecuted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Order Executed</link:label>
    <link:label id="lab_dnli_PurchaseOrderExecuted_documentation_en-US" xlink:label="lab_dnli_PurchaseOrderExecuted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase order executed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PurchaseOrderExecuted" xlink:href="dnli-20190630.xsd#dnli_PurchaseOrderExecuted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PurchaseOrderExecuted" xlink:to="lab_dnli_PurchaseOrderExecuted" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_d9edf28a-7fa6-404e-86b4-e997cbac7c95_terseLabel_en-US" xlink:label="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised common stock subject to future vesting</link:label>
    <link:label id="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_label_en-US" xlink:label="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised common stock subject to future vesting [Member]</link:label>
    <link:label id="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_documentation_en-US" xlink:label="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised common stock subject to future vesting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:href="dnli-20190630.xsd#dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:to="lab_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cd68cf19-4279-4912-a6fa-b24b40925d35_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal option term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_8c126f7e-eb02-4d45-98cf-d5cb3a438cd6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9faa2ad4-ac80-48ce-829e-98a6263af476_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ClinicalAndRegulatoryMilestonePayment_3711ce8f-7edd-4662-9958-2dc06b3ea054_terseLabel_en-US" xlink:label="lab_dnli_ClinicalAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and regulatory milestone payments</link:label>
    <link:label id="lab_dnli_ClinicalAndRegulatoryMilestonePayment_label_en-US" xlink:label="lab_dnli_ClinicalAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestone Payment</link:label>
    <link:label id="lab_dnli_ClinicalAndRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_dnli_ClinicalAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalAndRegulatoryMilestonePayment" xlink:href="dnli-20190630.xsd#dnli_ClinicalAndRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ClinicalAndRegulatoryMilestonePayment" xlink:to="lab_dnli_ClinicalAndRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_b6883395-5c91-47c0-a06f-d1f52050d784_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a2b31df7-c20d-4f7a-a870-b52a75f7e1f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax charge in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f0bccb7-002f-44e1-a851-14481405be4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_80eb8609-2576-4503-a2fe-dfbc450087eb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c6d67b74-60c3-4cf5-b854-54b636a34d4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8242e0bd-b3ba-4ff9-b5dd-e11f6130522f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_60f04175-d5df-4666-9e3a-19a9add5f352_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6252f9f5-11d2-42bb-afb7-89d01d6b90ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0e15a69f-e508-4f8d-902f-61aec287adfc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_71970a43-0f4b-4b67-89c9-cc45400a22dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_aec43b4b-e936-478d-af20-2ad79f36cb13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_3254facf-c067-4796-a877-173135ef8660_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_VariableConsiderationFutureConsideration_eabcdecc-70bc-4580-9636-a410a5820165_terseLabel_en-US" xlink:label="lab_dnli_VariableConsiderationFutureConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration relating to future milestones</link:label>
    <link:label id="lab_dnli_VariableConsiderationFutureConsideration_label_en-US" xlink:label="lab_dnli_VariableConsiderationFutureConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Consideration Future Consideration</link:label>
    <link:label id="lab_dnli_VariableConsiderationFutureConsideration_documentation_en-US" xlink:label="lab_dnli_VariableConsiderationFutureConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration relating to future milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_VariableConsiderationFutureConsideration" xlink:href="dnli-20190630.xsd#dnli_VariableConsiderationFutureConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_VariableConsiderationFutureConsideration" xlink:to="lab_dnli_VariableConsiderationFutureConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncrease_b54ccbbb-d08e-4adf-bc6c-c1b89dd9bf7c_terseLabel_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in transaction price</link:label>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncrease_label_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price, Increase</link:label>
    <link:label id="lab_dnli_CollaborationAgreementTransactionPriceIncrease_documentation_en-US" xlink:label="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:href="dnli-20190630.xsd#dnli_CollaborationAgreementTransactionPriceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:to="lab_dnli_CollaborationAgreementTransactionPriceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e8ebebf6-a57e-4b9b-939a-5c93baecca70_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued and Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3806de89-a58a-4cff-90fa-379e1a5ae8ca_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_50f8290d-5a3a-4f33-b846-0568334616fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a87ef6b9-6553-430a-bb02-49cfc8cf49df_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_532d3ed5-6958-40eb-8d42-7c21c746579e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5a5a24a7-e38b-4dc5-a3e5-60067404e527_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_5897a90c-8a53-4d29-a0ee-6857b5cabc81_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0fd148f8-8298-45d2-a065-345e3dc80229_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_3848f2a4-620e-45c5-8c8b-85dc338df821_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b94765ac-d0d2-4b0e-8da2-ebcf9644ec66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd4e4a5-7df7-43c2-a0cd-02719e2642e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_186e8ba2-5dba-46bf-abcb-d411bf7fc9cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b21fa452-694d-4798-b44f-a4aa52b576de_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AlzheimersDiseaseServicesMember_e353c12b-0224-4015-b162-58fa148d52b7_terseLabel_en-US" xlink:label="lab_dnli_AlzheimersDiseaseServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alzheimer's Disease Services</link:label>
    <link:label id="lab_dnli_AlzheimersDiseaseServicesMember_label_en-US" xlink:label="lab_dnli_AlzheimersDiseaseServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alzheimer's Disease Services [Member]</link:label>
    <link:label id="lab_dnli_AlzheimersDiseaseServicesMember_documentation_en-US" xlink:label="lab_dnli_AlzheimersDiseaseServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alzheimer's Disease Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember" xlink:href="dnli-20190630.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AlzheimersDiseaseServicesMember" xlink:to="lab_dnli_AlzheimersDiseaseServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75dfdb90-4287-4ff8-913d-f219403864a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of option (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ForeignExchangeForwardSwissFrancsMember_32942f70-7260-4e82-910e-17205e8b2688_terseLabel_en-US" xlink:label="lab_dnli_ForeignExchangeForwardSwissFrancsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss Francs</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardSwissFrancsMember_label_en-US" xlink:label="lab_dnli_ForeignExchangeForwardSwissFrancsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - Swiss Francs [Member]</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardSwissFrancsMember_documentation_en-US" xlink:label="lab_dnli_ForeignExchangeForwardSwissFrancsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - Swiss Francs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardSwissFrancsMember" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardSwissFrancsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ForeignExchangeForwardSwissFrancsMember" xlink:to="lab_dnli_ForeignExchangeForwardSwissFrancsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_189c30e9-14a5-4119-916b-c9fb8addd063_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Awards &amp; Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c95e7de1-5b0f-4d67-9a27-05bcbc798760_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fce64ace-7438-4afa-903a-a1b34f5d9f2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_909f3535-30fb-480c-a063-901732112ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock&#8211;based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_65fac848-539f-4dd8-8492-0846397a698e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c45c0a8b-ca27-4549-8781-7bb965e3d6f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f26ab135-1a8d-44b1-9548-b3e4b6d3c6a3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OperatingLeasesAreaUnderLease_d9b07d83-08ce-491b-b858-6ac5d320cd1f_terseLabel_en-US" xlink:label="lab_dnli_OperatingLeasesAreaUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area under lease</link:label>
    <link:label id="lab_dnli_OperatingLeasesAreaUnderLease_label_en-US" xlink:label="lab_dnli_OperatingLeasesAreaUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Under Lease</link:label>
    <link:label id="lab_dnli_OperatingLeasesAreaUnderLease_documentation_en-US" xlink:label="lab_dnli_OperatingLeasesAreaUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases area under lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesAreaUnderLease" xlink:href="dnli-20190630.xsd#dnli_OperatingLeasesAreaUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OperatingLeasesAreaUnderLease" xlink:to="lab_dnli_OperatingLeasesAreaUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_70625daf-ad24-414b-a8a5-656e599aef90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9514df25-fc24-4145-98d4-b013b32867e0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_27b930ab-4aef-48d9-849a-3717926f6f1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1eaad132-6fc1-4eba-a585-7b6e9622ce1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value at Date of Grant per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ee5e52f6-29ef-4f84-9140-6054e2a89d22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_47cf28e2-a5f0-42fb-8a0f-8bf6471d67b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_c2355e2b-31ac-4c06-a5de-dec087ba8623_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2b8e0f17-ec99-4ef2-ac1e-86911cfad863_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_db042d11-e7fb-42a8-9b61-d3159fe1c14b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregatePreclinicalMilestonePayment_e6abd461-3ac8-40cb-8c2a-3cf3b6703c3b_terseLabel_en-US" xlink:label="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate payments due upon achievement of certain preclinical milestone events</link:label>
    <link:label id="lab_dnli_AggregatePreclinicalMilestonePayment_label_en-US" xlink:label="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Preclinical Milestone Payment</link:label>
    <link:label id="lab_dnli_AggregatePreclinicalMilestonePayment_documentation_en-US" xlink:label="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate payments due upon achievement of certain preclinical milestone events.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregatePreclinicalMilestonePayment" xlink:href="dnli-20190630.xsd#dnli_AggregatePreclinicalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregatePreclinicalMilestonePayment" xlink:to="lab_dnli_AggregatePreclinicalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87ff7049-c7fe-4a08-9b4d-aec3945ec5e9_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_bdf49c93-7092-47fa-b201-66aca69f3609_terseLabel_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation cost not recognized</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_documentation_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and market share based compensation cost not yet recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" xlink:to="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7f6706b6-a1af-4ff0-8cb7-c214f7b04f27_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_11793d7b-635a-43cd-9f07-a5cc6a78c1c4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_b6df4285-e8a3-40a6-b1c1-20f595a5612a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4df7ab95-189a-4596-acc5-e79ceccd3c57_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_65cd4107-b576-445c-9a92-18dc9ab7a16d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_25111700-62b6-437d-9974-ea3584e403b0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CommercialMilestonesPerProgram_a66b7f9c-9340-4aa8-902e-a14a66458e5d_terseLabel_en-US" xlink:label="lab_dnli_CommercialMilestonesPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments per biologic product upon achievement of a certain sales-based milestone</link:label>
    <link:label id="lab_dnli_CommercialMilestonesPerProgram_label_en-US" xlink:label="lab_dnli_CommercialMilestonesPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones Per Program</link:label>
    <link:label id="lab_dnli_CommercialMilestonesPerProgram_documentation_en-US" xlink:label="lab_dnli_CommercialMilestonesPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones per program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonesPerProgram" xlink:href="dnli-20190630.xsd#dnli_CommercialMilestonesPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CommercialMilestonesPerProgram" xlink:to="lab_dnli_CommercialMilestonesPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TargetOptionPeriod_e861f3b2-1ce1-424d-9354-359c63d2aa67_terseLabel_en-US" xlink:label="lab_dnli_TargetOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target option period</link:label>
    <link:label id="lab_dnli_TargetOptionPeriod_label_en-US" xlink:label="lab_dnli_TargetOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Option Period</link:label>
    <link:label id="lab_dnli_TargetOptionPeriod_documentation_en-US" xlink:label="lab_dnli_TargetOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TargetOptionPeriod" xlink:href="dnli-20190630.xsd#dnli_TargetOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TargetOptionPeriod" xlink:to="lab_dnli_TargetOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_41bfc2e8-9730-4372-b730-edf075138cc9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RestrictedSharesSubjectToFutureVestingMember_2303485b-c69c-4649-9035-3a480b494990_terseLabel_en-US" xlink:label="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares subject to future vesting</link:label>
    <link:label id="lab_dnli_RestrictedSharesSubjectToFutureVestingMember_label_en-US" xlink:label="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares subject to future vesting [Member]</link:label>
    <link:label id="lab_dnli_RestrictedSharesSubjectToFutureVestingMember_documentation_en-US" xlink:label="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares subject to future vesting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:href="dnli-20190630.xsd#dnli_RestrictedSharesSubjectToFutureVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:to="lab_dnli_RestrictedSharesSubjectToFutureVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_18fa3232-c389-4178-a761-43bd6b614ff7_terseLabel_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payment earned not yet received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_label_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Earned Not Yet Received</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_documentation_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Earned Not Yet Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentEarnedNotYetReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:to="lab_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_568315ca-b461-4815-a6d3-af81fab4b97d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0980a88d-c558-4786-9bfb-efd8e3700dda_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_UpfrontPayments_6a12e6a7-a4d8-4e5c-b97e-7388a1a16a78_terseLabel_en-US" xlink:label="lab_dnli_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_dnli_UpfrontPayments_label_en-US" xlink:label="lab_dnli_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments</link:label>
    <link:label id="lab_dnli_UpfrontPayments_documentation_en-US" xlink:label="lab_dnli_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments" xlink:href="dnli-20190630.xsd#dnli_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_UpfrontPayments" xlink:to="lab_dnli_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e7d5fde9-2766-45a4-8d51-3461192be4d7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_5ec7f1de-791e-4df1-ba7c-480b6711e6a9_terseLabel_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Takeda Collaboration Agreement</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_label_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Collaboration Agreement</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_documentation_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:to="lab_dnli_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_748fb474-a7dd-45c6-93ad-759f002bf998_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fe750d98-6008-4045-b4fc-b44031b13370_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_acd12ac5-550d-423e-b78b-b12a9d57ceeb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f5bb7901-76f8-4185-8e72-508e12e1b925_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of issuance costs related to issuance of stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_76b43af4-b58b-4717-aca0-577d69ae2c16_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_85d2a508-721e-4e7a-8a63-623200446860_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5ecd3fa0-9192-43a4-8201-99effde52058_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7953ed80-69f7-4f25-b227-0451e062a5fa_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_444723a4-feab-4943-a527-daba07ea26c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e059eb6e-8d80-4f99-8691-be050d584d5c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0870b27e-9bda-4512-9616-adc60d9f24d7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_576237f9-8517-4aa5-956c-76580ac4dab8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_7703c977-83f7-4830-af15-eeaed5ae56a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate (as a percentage)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a9ae23a8-74a9-4c7d-96e8-7ebbc5af713d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_7cff1ffb-0fd7-4a69-b7f1-f1bfa3c97d79_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of specified clinical and regulatory milestones</link:label>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_label_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payment Upon Achievement Of Clinical And Regulatory Milestones</link:label>
    <link:label id="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement milestone payment upon achievement of clinical and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:to="lab_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_45417d22-26b2-4972-8b0d-b1c9792c4484_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_HeadquartersLeaseMember_c8d90cb7-d8fd-4cc4-95b8-9c7bb1c0a9b1_terseLabel_en-US" xlink:label="lab_dnli_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease</link:label>
    <link:label id="lab_dnli_HeadquartersLeaseMember_label_en-US" xlink:label="lab_dnli_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:label id="lab_dnli_HeadquartersLeaseMember_documentation_en-US" xlink:label="lab_dnli_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_HeadquartersLeaseMember" xlink:href="dnli-20190630.xsd#dnli_HeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_HeadquartersLeaseMember" xlink:to="lab_dnli_HeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_4d7d6235-28e9-46af-897c-da6d1858f34c_terseLabel_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_label_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Equity Incentive Plan</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_documentation_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodValueEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:to="lab_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a8bb2d92-b21d-4035-95a6-5bb822195d90_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_bcfd47ab-f7be-43b5-9cc4-3fb107881e92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ClinicalMilestonePayment_214abb03-49d3-4794-b485-0008fac03cdd_verboseLabel_en-US" xlink:label="lab_dnli_ClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_dnli_ClinicalMilestonePayment_label_en-US" xlink:label="lab_dnli_ClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestone Payment</link:label>
    <link:label id="lab_dnli_ClinicalMilestonePayment_documentation_en-US" xlink:label="lab_dnli_ClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMilestonePayment" xlink:href="dnli-20190630.xsd#dnli_ClinicalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ClinicalMilestonePayment" xlink:to="lab_dnli_ClinicalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AssetAcquisitionTextBlock_408c63f9-a383-4bca-9c6b-c93cbe7e9b7d_terseLabel_en-US" xlink:label="lab_dnli_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_dnli_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_dnli_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:label id="lab_dnli_AssetAcquisitionTextBlock_documentation_en-US" xlink:label="lab_dnli_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AssetAcquisitionTextBlock" xlink:href="dnli-20190630.xsd#dnli_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AssetAcquisitionTextBlock" xlink:to="lab_dnli_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bbcb7190-380d-48df-b785-0567e75421c0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7dc005f7-5696-4ab3-b831-e857182de397_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2b523717-0733-437a-8f18-00be32f9859a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_5104dc50-699d-4e92-92cc-ea8165c32898_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_InitialOptionExercisePayments_d3c91094-6df0-41ab-a7a9-bf4d02dc2d4d_terseLabel_en-US" xlink:label="lab_dnli_InitialOptionExercisePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial option exercise payments</link:label>
    <link:label id="lab_dnli_InitialOptionExercisePayments_label_en-US" xlink:label="lab_dnli_InitialOptionExercisePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial option exercise payments</link:label>
    <link:label id="lab_dnli_InitialOptionExercisePayments_documentation_en-US" xlink:label="lab_dnli_InitialOptionExercisePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial option exercise payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_InitialOptionExercisePayments" xlink:href="dnli-20190630.xsd#dnli_InitialOptionExercisePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_InitialOptionExercisePayments" xlink:to="lab_dnli_InitialOptionExercisePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_cc74e2df-8cc2-4d36-986f-8e4e65c06112_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized income (loss) on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_DenaliMember_a186bfb5-41ca-4177-92a6-e09f72a0f760_terseLabel_en-US" xlink:label="lab_dnli_DenaliMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali</link:label>
    <link:label id="lab_dnli_DenaliMember_label_en-US" xlink:label="lab_dnli_DenaliMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali [Member]</link:label>
    <link:label id="lab_dnli_DenaliMember_documentation_en-US" xlink:label="lab_dnli_DenaliMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DenaliMember" xlink:href="dnli-20190630.xsd#dnli_DenaliMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_DenaliMember" xlink:to="lab_dnli_DenaliMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3b1934e5-680b-49e0-83b8-ab8bac2c8c9a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_0f120752-2da6-4ecf-9bd6-4635cdbcdabd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_95ce9ab1-7a83-49c9-8063-f36dbf922bed_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95e286a5-1ae7-40d2-8ff8-2275a74ebb67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_144c5331-63f2-4763-b497-20c762f884e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_8a4c874f-baef-4f3a-b73f-6e993805d849_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_be2aed17-0555-450b-a28b-e0f583175e0a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementMember_d245e112-1313-4cea-b2d0-6fec84bd02ff_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_dnli_LicenseAgreementMember_label_en-US" xlink:label="lab_dnli_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_dnli_LicenseAgreementMember_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMember" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementMember" xlink:to="lab_dnli_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain_840ba68f-211e-459c-b0e2-fd56ee65b378_terseLabel_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement, Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain_label_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement, Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_6fc0d6ba-1d81-4e6f-a91e-9c15d3c4afe4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_39acf288-0d21-4249-ab85-528f4ca39c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_72cb2a74-4184-4547-9406-31d861e9af0c_terseLabel_en-US" xlink:label="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" xlink:href="dnli-20190630.xsd#dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" xlink:to="lab_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_41190881-a5e4-4312-9fd9-2b560c344655_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_a9ecadd8-3b23-4dcf-a584-0a4691944c8a_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a5e95d06-2f73-42e1-97e8-ee5a3b4778a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f47a988c-dc0c-454f-bab0-890eb5008a8e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_773d1240-a1c2-46aa-a13c-3dd85b491cb9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_ca2d99c7-ad7c-4dcc-ad97-d348467955cd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f66380fe-747e-4be0-9712-9d6f3875f398_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_1d8c2be5-592c-44ad-bc2c-d3673ffa373e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_397803b6-83b0-4697-8c31-8757187f97bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Forward Foreign Currency Exchange Purchase Contracts Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_345cd99a-db3f-4988-a628-152249bc18ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a3bc1839-6b7c-4517-b34b-c3b89e5eb5fb_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e0335b92-a099-41a1-97f2-b8362f54bab4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64632092-fdbd-44bb-ac93-0729ea1d283d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_836c116a-43b9-457a-bd2f-6b7ba9791ca4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_ae54b20b-4514-4426-9b63-39cc2b839dc6_terseLabel_en-US" xlink:label="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_label_en-US" xlink:label="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Non-Cash Operating Lease Expense</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Non-Cash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:to="lab_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_9f7b6eba-120a-4e51-a2ed-982c14aa2dc7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_3d5c620c-fba4-4579-932f-9936f4b40699_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_848b33c5-e1fb-4c89-b697-9025058ec558_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ff8e9c94-086a-449c-a5cb-be1dc50bd6e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a370851-9b5c-4218-bc10-ea1a747d3048_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_78e09ac5-44a6-4fa0-b28b-f41e94573f1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of awards under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_7694398c-efce-472f-8140-790e83d7ec56_terseLabel_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans (in shares)</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_label_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Equity Incentive Plan</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_documentation_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:to="lab_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c31824e3-3638-4509-bf15-300c9f8125dd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_89fd6ce9-e22b-4f08-a5dc-d8de6831fa22_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_cde3fe4c-6dac-4455-a873-1b52556f37bf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_95f82c8e-2547-43aa-a888-a16d00803297_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones recognized</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0a65ded5-8825-48e3-952f-ede0a1f4147a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember_269ef290-8939-4569-9f1b-eb316f4ed011_terseLabel_en-US" xlink:label="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="dnli-20190630.xsd#dnli_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_dnli_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_181fbdb9-07b9-4415-8a3b-4b5787b0ad1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensation_f66ba992-8d2e-4f21-aa73-d1d5f45aeb13_terseLabel_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and market-contingent awards expense</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensation_label_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance And Market Share Based Compensation</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensation_documentation_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance And Market Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensation" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PerformanceAndMarketShareBasedCompensation" xlink:to="lab_dnli_PerformanceAndMarketShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea9f0507-d627-4bda-8878-d81641e7ccd9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a862c109-554b-4101-91a9-e038180837e4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_bd1102c0-3f3d-4e82-bfc1-fccc6f57360d_terseLabel_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting trigger, number of consecutive trading days</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" xlink:to="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_34a42e91-5725-4db7-844c-b1242bcf00af_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5f20c93d-f273-4865-8523-22b34cc86637_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29d5bb64-ecbc-4c74-b464-42c3978c2e73_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c23d3ab1-7670-4b1e-80ae-a9824822b6cf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_79f7032f-f101-4849-95ca-d1648cfe96d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember_308cc4c8-03eb-43ab-a818-218dc14cc7dc_terseLabel_en-US" xlink:label="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Stock Incentive Plan</link:label>
    <link:label id="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fifteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandFifteenEquityIncentivePlanMember" xlink:href="dnli-20190630.xsd#dnli_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_dnli_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SignificantAccountingPoliciesLineItems_6d759a09-8ea3-4311-bed8-26e8e4b3e285_terseLabel_en-US" xlink:label="lab_dnli_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dnli_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_dnli_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dnli_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_dnli_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SignificantAccountingPoliciesLineItems" xlink:href="dnli-20190630.xsd#dnli_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems" xlink:to="lab_dnli_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_94e399a1-f618-476f-88be-6c73929dd501_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0fcf84b9-e31b-40ff-85b2-a9d56ec69d85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2484947d-04d8-45dc-8332-0a95b71d3924_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a9ad7148-ec60-483e-8749-968b969498c4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_41cf9eb4-cbf8-4c1a-9767-96e7a32dc171_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e1488450-6194-4667-855e-d329241fd6bc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsIncurredDevelopmentCosts_14b9984e-b990-4b7c-b600-7c573bd92d83_terseLabel_en-US" xlink:label="lab_us-gaap_CostsIncurredDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_CostsIncurredDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_CostsIncurredDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Incurred, Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsIncurredDevelopmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsIncurredDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsIncurredDevelopmentCosts" xlink:to="lab_us-gaap_CostsIncurredDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_672e4e62-5fb9-4139-beb0-6ea4e486cc55_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3104499f-b6f4-47cf-a65e-5bd5a0a670fa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_0c6a42e8-ad18-4e4f-a224-f49e1a6de775_terseLabel_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a7d14eca-0435-49e1-bb1e-7b7212be3410_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_423b9bf5-a576-4a56-b0df-f8c730037012_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_25f44a39-61e7-40a4-b62f-24c0a3204fef_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset fair value measurements</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_7d8dcfe6-6db9-423a-80a3-ff1e3acb76b2_terseLabel_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with Takeda Collaboration Agreement (in shares)</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_label_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Collaboration Agreement</link:label>
    <link:label id="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_documentation_en-US" xlink:label="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:to="lab_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_5e5d7f68-7a30-4454-94e2-79a46fa944cd_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and later</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ade6237b-ca00-4f9b-9c7b-08fd875419b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9970a51f-5180-4f38-806c-718235eefce2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_fc527c1b-7793-4d7f-90b7-b662f7bbd243_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 (six months)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_IncreaseDecreaseInDeferredRent_ba3efd29-b059-4d0c-acc9-3a9a5cb4a52f_terseLabel_en-US" xlink:label="lab_dnli_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_dnli_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Deferred Rent</link:label>
    <link:label id="lab_dnli_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_dnli_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) of deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInDeferredRent" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_IncreaseDecreaseInDeferredRent" xlink:to="lab_dnli_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b0a58594-3e92-4b47-afef-3a350419d097_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_feb1600b-80c4-4e69-bc46-90dbb3b5eb08_terseLabel_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of recognition</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_label_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized Period Of Recognition</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_documentation_en-US" xlink:label="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized Period Of Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" xlink:to="lab_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_de787a27-1e49-4788-8471-504489d5025e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f394d047-caf7-4ed6-937e-e9d4e6c8ee94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e476ab3d-b8ad-42ae-8b4d-fc910f2c5583_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_23333127-a6a5-45b0-9613-bc6b4a5be971_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_bb62622f-4d33-4828-89bd-72f443f741c1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ded9f0b4-cfce-4a64-94f7-710a080b19c2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e9a7f59c-aa11-4770-8b18-504e149b64a7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases accrued but not yet paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fd3230fb-e917-4f92-a2ac-11a655655881_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_437f2eb1-81d7-4e2f-a655-cfd9689022fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_70b3b070-c735-40d7-80a1-35f1b2d82be8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_490bba98-590c-47ca-801a-dad55cafce80_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_90440f92-3e8f-44ed-9ca7-05e7f4259c3f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 95,656,896 shares and 94,662,435 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_abe8b5d3-6721-4bf2-a79f-2433c8b6d1c6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SanofiCollaborationAgreementMember_8c159e05-a754-4467-a942-785434612cc2_terseLabel_en-US" xlink:label="lab_dnli_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement</link:label>
    <link:label id="lab_dnli_SanofiCollaborationAgreementMember_label_en-US" xlink:label="lab_dnli_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dnli_SanofiCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dnli_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiCollaborationAgreementMember" xlink:href="dnli-20190630.xsd#dnli_SanofiCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SanofiCollaborationAgreementMember" xlink:to="lab_dnli_SanofiCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ac4eed1c-c244-4eba-8583-8c9928d5edf4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_68108837-b312-45d0-833e-d7cd6fdd6145_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SignificantAccountingPoliciesTable_d5fc9d3f-53b4-4a0a-9550-2eb5f397dfe2_terseLabel_en-US" xlink:label="lab_dnli_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dnli_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_dnli_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dnli_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_dnli_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SignificantAccountingPoliciesTable" xlink:href="dnli-20190630.xsd#dnli_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SignificantAccountingPoliciesTable" xlink:to="lab_dnli_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_45e50208-e9d7-423c-bc17-71071ed85123_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_30ebf5df-2d93-471a-93f7-6e945dced7c9_terseLabel_en-US" xlink:label="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development plan period for research costs</link:label>
    <link:label id="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_label_en-US" xlink:label="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development plan period for research costs</link:label>
    <link:label id="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_documentation_en-US" xlink:label="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development plan period for research costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MaximumDevelopmentPlanPeriodForResearchCosts" xlink:href="dnli-20190630.xsd#dnli_MaximumDevelopmentPlanPeriodForResearchCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_MaximumDevelopmentPlanPeriodForResearchCosts" xlink:to="lab_dnli_MaximumDevelopmentPlanPeriodForResearchCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_28de5599-815d-458d-a657-bd806f2af64c_terseLabel_en-US" xlink:label="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares allowable under the plan (in shares)</link:label>
    <link:label id="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="dnli-20190630.xsd#dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_747b9519-cb4c-4e1e-ac66-96f8c22582fa_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentPerProgram_0525723e-9040-4eb6-9f36-a48b978f1449_terseLabel_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical milestone payments per program</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentPerProgram_label_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Milestone Payment Per Program</link:label>
    <link:label id="lab_dnli_PreclinicalMilestonePaymentPerProgram_documentation_en-US" xlink:label="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments due upon achievement of certain preclinical milestone events per program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentPerProgram" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PreclinicalMilestonePaymentPerProgram" xlink:to="lab_dnli_PreclinicalMilestonePaymentPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ee18e382-2323-448d-8c0e-235953547e47_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1358527d-a30e-46f0-a444-fffe49dc8633_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_ef0757ce-653b-4839-bb14-0524c6e2b438_terseLabel_en-US" xlink:label="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Transferred As Available For Issuance From 2015 Plan to 2017 Plan</link:label>
    <link:label id="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_label_en-US" xlink:label="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Transferred As Available For Issuance From Two Thousand Fifteen Plan to Two Thousand Seventeen Plan [Member]</link:label>
    <link:label id="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_documentation_en-US" xlink:label="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares transferred as available for issuance from the 2015 plan to the 2017 plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" xlink:href="dnli-20190630.xsd#dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" xlink:to="lab_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_74cd1cab-b8ef-4b2c-8968-d1e7603e82f1_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity, Receivable</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7cecefae-217e-4796-a2f2-a58c128b35d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3c2bea18-9fc8-4700-885c-8a37c3430d1d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ffff9fd6-1ee4-415c-8190-80d9640c3712_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_2aebe1ee-0b42-4f7d-b2e0-f94a4ad0f4ff_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_b0f816ef-7600-44b5-afc1-eb6e12775d01_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_10cb20a9-b9db-4311-a7eb-e9d6c8daeff0_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0afe5bba-ea28-46f6-9024-e1bb9e208933_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_GenentechIncMember_8c3994c7-6556-4238-ac73-48c14e3640f8_terseLabel_en-US" xlink:label="lab_dnli_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc</link:label>
    <link:label id="lab_dnli_GenentechIncMember_label_en-US" xlink:label="lab_dnli_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc [Member]</link:label>
    <link:label id="lab_dnli_GenentechIncMember_documentation_en-US" xlink:label="lab_dnli_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_GenentechIncMember" xlink:href="dnli-20190630.xsd#dnli_GenentechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_GenentechIncMember" xlink:to="lab_dnli_GenentechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_f3f1a3b8-8dc3-448e-a4d9-ca2db0705178_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7ee1c31b-8ca3-4e24-8b31-ee2955b29bb8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_0caa2cea-c0e7-4647-bb68-a2370fc57e3f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and later</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3c63df86-f8d3-4ee9-8c21-4d41d949c825_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b234d416-ef44-442a-97b8-054118d8285a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0b412780-0c54-48c3-bdd7-f96d6fa2d334_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ec5e2372-9464-4858-b9ad-da8e6a80855b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3cc0065a-59a6-41f3-9e3b-fb1535fa5158_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_fd483c89-89ab-4c73-a291-f2561bcc7412_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c1ff2039-4b6b-4023-a27d-90dbf4de45f8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LesseeFinanceLeaseNumberOfContracts_526b0123-52a6-4596-bdb7-37a2cc43b2df_terseLabel_en-US" xlink:label="lab_dnli_LesseeFinanceLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financing leases</link:label>
    <link:label id="lab_dnli_LesseeFinanceLeaseNumberOfContracts_label_en-US" xlink:label="lab_dnli_LesseeFinanceLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Number Of Contracts</link:label>
    <link:label id="lab_dnli_LesseeFinanceLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_dnli_LesseeFinanceLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeFinanceLeaseNumberOfContracts" xlink:href="dnli-20190630.xsd#dnli_LesseeFinanceLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LesseeFinanceLeaseNumberOfContracts" xlink:to="lab_dnli_LesseeFinanceLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7c726074-50c3-49ee-823e-0d34d714ae18_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ac1a0c98-41b8-49af-8b30-0da7b10e7157_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2c0001e3-f2fa-4b3b-9ffb-a48abfecb248_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2bf52e84-b3f1-4252-8f03-80a44a5361a4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_807d511e-b4bf-453f-b6b0-e1445822974a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_be3937f8-35bc-41bb-8b03-5c6287bc0605_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2bb3cf21-4e6b-44e8-b4e0-2579fa249798_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a9a29edc-0f13-44cb-975e-fc287b24f9e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity, Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_784df5e9-2f36-4a9a-9dc4-9e8775c17a21_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_01322500-b9cd-46e4-ac96-55c98f3f5138_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_UpfrontOptionFee_c7426d51-092e-4283-b168-94d3caab4c12_terseLabel_en-US" xlink:label="lab_dnli_UpfrontOptionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront option fee</link:label>
    <link:label id="lab_dnli_UpfrontOptionFee_label_en-US" xlink:label="lab_dnli_UpfrontOptionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Option Fee</link:label>
    <link:label id="lab_dnli_UpfrontOptionFee_documentation_en-US" xlink:label="lab_dnli_UpfrontOptionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront option fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontOptionFee" xlink:href="dnli-20190630.xsd#dnli_UpfrontOptionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_UpfrontOptionFee" xlink:to="lab_dnli_UpfrontOptionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9632cd7a-06ba-4160-8c9a-18ad674515f4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0b5ead8b-fbfa-4a5f-bd20-138a0736b8ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LicenseAgreementTextBlock_48400a1d-9700-4777-a255-b145bbc653f5_terseLabel_en-US" xlink:label="lab_dnli_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_dnli_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_dnli_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_dnli_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_dnli_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementTextBlock" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LicenseAgreementTextBlock" xlink:to="lab_dnli_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_cacf24f5-746d-4ca4-b5db-038810874964_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateDevelopmentMilestonePayment_d5fc3934-cc67-485d-a1a7-a785f4413515_terseLabel_en-US" xlink:label="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate payments due upon achievement of certain clinical and regulatory milestone events</link:label>
    <link:label id="lab_dnli_AggregateDevelopmentMilestonePayment_label_en-US" xlink:label="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Development Milestone Payment</link:label>
    <link:label id="lab_dnli_AggregateDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate development milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentMilestonePayment" xlink:href="dnli-20190630.xsd#dnli_AggregateDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateDevelopmentMilestonePayment" xlink:to="lab_dnli_AggregateDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_46f6cf49-eac7-418c-9a2e-85074f3cc6b4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ccae8fef-c66d-41ea-a18c-30d116e4b9ac_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_5e0abc4a-c002-4abb-8fa0-59d2b91cbdb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a26edd42-f94a-49d6-9c61-8323bf307ecd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a093d2ca-11a2-4299-b299-33ceba6160b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SanofiMember_9ee5db54-8587-499a-a424-7af9a45d7b58_terseLabel_en-US" xlink:label="lab_dnli_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_dnli_SanofiMember_label_en-US" xlink:label="lab_dnli_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_dnli_SanofiMember_documentation_en-US" xlink:label="lab_dnli_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember" xlink:href="dnli-20190630.xsd#dnli_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SanofiMember" xlink:to="lab_dnli_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_12f40bb2-baba-4eb2-9386-5c86853b9bd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b7a42c61-b941-41a6-8bc4-4fa429d1530e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ca5f1ce-4466-420a-a9df-1b05b27e39a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cf3e1df4-5d9e-4ec0-bbea-ae0ee8380d36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ed86e43f-3f1a-41ed-9c71-5c750d6ea78a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assumptions Used for Estimating the Fair Value of Stock Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f4620a3a-305a-410d-8e05-619947abcc67_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4131855e-d153-466b-8b47-8287919799e6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_fb944d5a-ff5d-492b-9fb3-7555848043f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PaymentsForManufacturingCost_b7d2d285-2bbf-49f6-b5b8-4db1710b292e_terseLabel_en-US" xlink:label="lab_dnli_PaymentsForManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for development and manufacturing services</link:label>
    <link:label id="lab_dnli_PaymentsForManufacturingCost_label_en-US" xlink:label="lab_dnli_PaymentsForManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Manufacturing Cost</link:label>
    <link:label id="lab_dnli_PaymentsForManufacturingCost_documentation_en-US" xlink:label="lab_dnli_PaymentsForManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for manufacturing cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PaymentsForManufacturingCost" xlink:href="dnli-20190630.xsd#dnli_PaymentsForManufacturingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PaymentsForManufacturingCost" xlink:to="lab_dnli_PaymentsForManufacturingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ExerciseOfBuyoutOptionMember_4b6c04cd-a098-4181-b85e-9140479fd5f1_terseLabel_en-US" xlink:label="lab_dnli_ExerciseOfBuyoutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of buy-out option</link:label>
    <link:label id="lab_dnli_ExerciseOfBuyoutOptionMember_label_en-US" xlink:label="lab_dnli_ExerciseOfBuyoutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of buy-out option [Member]</link:label>
    <link:label id="lab_dnli_ExerciseOfBuyoutOptionMember_documentation_en-US" xlink:label="lab_dnli_ExerciseOfBuyoutOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of buy-out option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ExerciseOfBuyoutOptionMember" xlink:href="dnli-20190630.xsd#dnli_ExerciseOfBuyoutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ExerciseOfBuyoutOptionMember" xlink:to="lab_dnli_ExerciseOfBuyoutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_RetainedActivitiesMember_1d692b41-a3f7-4883-bf68-c5c591778266_terseLabel_en-US" xlink:label="lab_dnli_RetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Activities</link:label>
    <link:label id="lab_dnli_RetainedActivitiesMember_label_en-US" xlink:label="lab_dnli_RetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Activities [Member]</link:label>
    <link:label id="lab_dnli_RetainedActivitiesMember_documentation_en-US" xlink:label="lab_dnli_RetainedActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember" xlink:href="dnli-20190630.xsd#dnli_RetainedActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_RetainedActivitiesMember" xlink:to="lab_dnli_RetainedActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_1b08ae00-2b9e-4da3-8aac-52a55bb7c5e6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability - foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_fc021383-e6d6-4b93-ac39-f7dbf6fff8a1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis_741be5fa-57c3-4492-903d-ebb20a2f80cd_terseLabel_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</link:label>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis_label_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c44fd31e-38f1-4d84-9329-c46cd42b362d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ShortTermMarketableSecuritiesMember_adaa437e-03ce-4802-9f29-afa29b7f9e44_terseLabel_en-US" xlink:label="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities:</link:label>
    <link:label id="lab_dnli_ShortTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Securities [Member]</link:label>
    <link:label id="lab_dnli_ShortTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShortTermMarketableSecuritiesMember" xlink:href="dnli-20190630.xsd#dnli_ShortTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ShortTermMarketableSecuritiesMember" xlink:to="lab_dnli_ShortTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_31804ec4-2ead-48e5-a44c-5528413c35f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_aaee040c-0095-4d5e-9cf3-2c34c6d48a0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e27bb41c-bc2d-4aef-b746-69bcd1ff4402_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c036270b-89ba-44c8-9474-846091b1bee7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8fa9aeba-3f02-42d7-99ba-30ed2a04969b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5ccd3696-a4fd-49b4-91d4-abbeaee08041_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementPayment_8dd780f5-f568-4566-a594-7fdca276995b_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementPayment_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementPayment_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementPayment" xlink:href="dnli-20190630.xsd#dnli_CollaborativeArrangementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementPayment" xlink:to="lab_dnli_CollaborativeArrangementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0e3b9dc4-1c44-49d1-b793-4d4cb683cf0f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e33a701-91c7-4321-8529-791622906dc3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ConstrainedVariableConsideration_38d48a27-b7bd-4c7f-b15a-671cd116a0bd_terseLabel_en-US" xlink:label="lab_dnli_ConstrainedVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining preclinical milestones, cost and profit sharing income, and the development and commercial milestones</link:label>
    <link:label id="lab_dnli_ConstrainedVariableConsideration_label_en-US" xlink:label="lab_dnli_ConstrainedVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constrained Variable Consideration</link:label>
    <link:label id="lab_dnli_ConstrainedVariableConsideration_documentation_en-US" xlink:label="lab_dnli_ConstrainedVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constrained variable consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ConstrainedVariableConsideration" xlink:href="dnli-20190630.xsd#dnli_ConstrainedVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ConstrainedVariableConsideration" xlink:to="lab_dnli_ConstrainedVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b511eb5-dbf8-41ac-a2b3-d4a4843a9435_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f849d921-4822-46af-b25b-48cfe4618d80_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_84575396-4737-4eb2-a927-67b101489a46_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ContingentConsiderationPayment_77a1b02a-19c0-406a-abd1-147826655e55_terseLabel_en-US" xlink:label="lab_dnli_ContingentConsiderationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payment</link:label>
    <link:label id="lab_dnli_ContingentConsiderationPayment_label_en-US" xlink:label="lab_dnli_ContingentConsiderationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Payment</link:label>
    <link:label id="lab_dnli_ContingentConsiderationPayment_documentation_en-US" xlink:label="lab_dnli_ContingentConsiderationPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContingentConsiderationPayment" xlink:href="dnli-20190630.xsd#dnli_ContingentConsiderationPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ContingentConsiderationPayment" xlink:to="lab_dnli_ContingentConsiderationPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_73788657-d39f-43e6-bd5a-44ce0264db89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeAgreementFundedPercentage_6fb81b8c-d2b0-49f0-9b1d-ca5dd83982dc_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded percentage</link:label>
    <link:label id="lab_dnli_CollaborativeAgreementFundedPercentage_label_en-US" xlink:label="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funded Percentage</link:label>
    <link:label id="lab_dnli_CollaborativeAgreementFundedPercentage_documentation_en-US" xlink:label="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funded Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage" xlink:href="dnli-20190630.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeAgreementFundedPercentage" xlink:to="lab_dnli_CollaborativeAgreementFundedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_617f96eb-7319-4bf7-9c05-f538df607b71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16ba0f77-486f-40ec-9f52-170596704d1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_658e55b0-a1f4-4b76-b6d3-2a551eab2cc0_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f137525f-3a8d-4ffb-9189-b9cfec6904cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2eee57b9-be18-41f0-aa81-c5c125949e32_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PerformanceAndMarketContingentStockOptionsMember_b44c1dcc-1737-4a8f-8135-0321346181b3_terseLabel_en-US" xlink:label="lab_dnli_PerformanceAndMarketContingentStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and Market Contingent Stock Options</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketContingentStockOptionsMember_label_en-US" xlink:label="lab_dnli_PerformanceAndMarketContingentStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance And Market Contingent Stock Options [Member]</link:label>
    <link:label id="lab_dnli_PerformanceAndMarketContingentStockOptionsMember_documentation_en-US" xlink:label="lab_dnli_PerformanceAndMarketContingentStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and market contingent stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketContingentStockOptionsMember" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketContingentStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PerformanceAndMarketContingentStockOptionsMember" xlink:to="lab_dnli_PerformanceAndMarketContingentStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0de241fb-6f38-4982-9857-7cb32e629801_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ad130a90-3714-4e85-a834-16124b77e405_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_6a729b6e-e6d6-408d-b22f-f8c9b346775f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_EmployeeAndNonEmployeeStockOptionMember_a30347eb-477c-4a7c-b9f7-11a5831cad41_terseLabel_en-US" xlink:label="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding and ESPP shares issuable</link:label>
    <link:label id="lab_dnli_EmployeeAndNonEmployeeStockOptionMember_label_en-US" xlink:label="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_dnli_EmployeeAndNonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:href="dnli-20190630.xsd#dnli_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:to="lab_dnli_EmployeeAndNonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9c9e36e2-eda4-480b-8b9c-346c56f7ba7b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3207e232-0d69-4b95-b49e-8da2fe8713d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_598a964d-bde2-4e8a-bc85-741fa17fbc3d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3e1f72fd-a4b7-4400-8348-69b940b34c89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_31e72e54-4278-4242-aa24-2d1f612e790a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c9ff1e4f-5228-4483-b6c9-829b6aee5a1a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_adfb3c9e-f628-4ae5-b680-afca6b6fb05c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7b819ea9-45dd-4b61-87c9-2599d4b2a445_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NumberOfTargets_68b6636e-6d77-4fb3-9ae1-c081a0960876_terseLabel_en-US" xlink:label="lab_dnli_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets</link:label>
    <link:label id="lab_dnli_NumberOfTargets_label_en-US" xlink:label="lab_dnli_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targets</link:label>
    <link:label id="lab_dnli_NumberOfTargets_documentation_en-US" xlink:label="lab_dnli_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfTargets" xlink:href="dnli-20190630.xsd#dnli_NumberOfTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NumberOfTargets" xlink:to="lab_dnli_NumberOfTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_TenantImprovementAllowanceRepayableAsRent_b5509804-c368-4651-a9a9-e14e6ea8428c_terseLabel_en-US" xlink:label="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance repayable in rent</link:label>
    <link:label id="lab_dnli_TenantImprovementAllowanceRepayableAsRent_label_en-US" xlink:label="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Repayable As Rent</link:label>
    <link:label id="lab_dnli_TenantImprovementAllowanceRepayableAsRent_documentation_en-US" xlink:label="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of tenant improvement allowance repayable to landlord in future rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:href="dnli-20190630.xsd#dnli_TenantImprovementAllowanceRepayableAsRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:to="lab_dnli_TenantImprovementAllowanceRepayableAsRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c5ed3c1a-38d1-4674-9a34-6a21101faa65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_fa926a83-b6dc-4a40-9e55-b35fe30e3472_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_3dd38599-5623-4f55-a4b2-3e6597193a0c_terseLabel_en-US" xlink:label="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_label_en-US" xlink:label="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma [Member]</link:label>
    <link:label id="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_documentation_en-US" xlink:label="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" xlink:href="dnli-20190630.xsd#dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" xlink:to="lab_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_68724dd3-49a6-4e1f-9ae1-7de7d65a6638_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_199e24d5-0c9c-4377-b618-a19e811d3756_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e11635d7-b020-4afb-9335-6c2cebb905e3_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f2898d58-f05c-4d6b-bd02-daa3fffd41cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a70efc27-08fe-4102-9d78-cf3029c05e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_76ff4a0b-0beb-4672-b35e-1fc628596d99_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod_fe10a165-d3d6-485c-9570-be01c49e14aa_terseLabel_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal notice period</link:label>
    <link:label id="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod_label_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Notice Period</link:label>
    <link:label id="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod_documentation_en-US" xlink:label="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:href="dnli-20190630.xsd#dnli_LesseeOperatingLeaseRenewalNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:to="lab_dnli_LesseeOperatingLeaseRenewalNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_815f3226-c757-40f0-91fb-34cabd807e40_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_ecf462b4-aaaf-41a0-ae6e-433fe42804f4_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted sublease receipts</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_DMSAMember_3295953b-3f08-4659-bf1a-6d28e0cf0dde_terseLabel_en-US" xlink:label="lab_dnli_DMSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMSA</link:label>
    <link:label id="lab_dnli_DMSAMember_label_en-US" xlink:label="lab_dnli_DMSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMSA [Member]</link:label>
    <link:label id="lab_dnli_DMSAMember_documentation_en-US" xlink:label="lab_dnli_DMSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMSA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DMSAMember" xlink:href="dnli-20190630.xsd#dnli_DMSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_DMSAMember" xlink:to="lab_dnli_DMSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_065d69d4-0f02-4133-a63b-27411235a0c7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_fd2887bf-cf25-4229-ae38-e3d6a822ab9b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_df5d3f4d-702a-4266-bd32-6297fed9e770_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_715ccd8d-5950-4ac3-80b9-b58b0937cb1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, unvested, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b6b34710-faf0-432c-944c-06cfc4d72426_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, unvested, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac55ade7-e5d9-4a75-81d1-c9973a0bc32b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a2f9c11-cff4-4719-8316-b8a37e681b20_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_CNSProductMember_e5c707c4-edbe-4f10-a1ae-cd77b0fdae56_terseLabel_en-US" xlink:label="lab_dnli_CNSProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CNS Product</link:label>
    <link:label id="lab_dnli_CNSProductMember_label_en-US" xlink:label="lab_dnli_CNSProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CNS Product [Member]</link:label>
    <link:label id="lab_dnli_CNSProductMember_documentation_en-US" xlink:label="lab_dnli_CNSProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CNS Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CNSProductMember" xlink:href="dnli-20190630.xsd#dnli_CNSProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_CNSProductMember" xlink:to="lab_dnli_CNSProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ContingentPaymentsUponAchievementOfMilestones_66ddc7ea-00f4-4f9e-b311-8c133e2cad67_terseLabel_en-US" xlink:label="lab_dnli_ContingentPaymentsUponAchievementOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon the achievement of milestones</link:label>
    <link:label id="lab_dnli_ContingentPaymentsUponAchievementOfMilestones_label_en-US" xlink:label="lab_dnli_ContingentPaymentsUponAchievementOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of milestones</link:label>
    <link:label id="lab_dnli_ContingentPaymentsUponAchievementOfMilestones_documentation_en-US" xlink:label="lab_dnli_ContingentPaymentsUponAchievementOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon the achievement of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContingentPaymentsUponAchievementOfMilestones" xlink:href="dnli-20190630.xsd#dnli_ContingentPaymentsUponAchievementOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ContingentPaymentsUponAchievementOfMilestones" xlink:to="lab_dnli_ContingentPaymentsUponAchievementOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d77fcec7-f812-4104-857f-bbabb29d8b52_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_UpfrontFeesPaid_1d7860ea-4897-4e26-8cde-fc7468be59e5_terseLabel_en-US" xlink:label="lab_dnli_UpfrontFeesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee paid</link:label>
    <link:label id="lab_dnli_UpfrontFeesPaid_label_en-US" xlink:label="lab_dnli_UpfrontFeesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Fees Paid</link:label>
    <link:label id="lab_dnli_UpfrontFeesPaid_documentation_en-US" xlink:label="lab_dnli_UpfrontFeesPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontFeesPaid" xlink:href="dnli-20190630.xsd#dnli_UpfrontFeesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_UpfrontFeesPaid" xlink:to="lab_dnli_UpfrontFeesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_5de529ce-2d9f-41f6-b623-49cca73ee4c1_terseLabel_en-US" xlink:label="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of certain clinical, regulatory and sales milestone events</link:label>
    <link:label id="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_label_en-US" xlink:label="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Clinical Regulatory And Sales Milestone Payment</link:label>
    <link:label id="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_documentation_en-US" xlink:label="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Clinical Regulatory And Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:href="dnli-20190630.xsd#dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:to="lab_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ade56f6c-8ea1-48cd-a73f-836bbbe988d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fa3055fb-1694-48e4-a749-11c0e80007c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 (six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_SharePurchaseAgreementMember_812c4104-84d5-4daf-be36-6b8fe6db175e_terseLabel_en-US" xlink:label="lab_dnli_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_dnli_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_dnli_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_dnli_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_dnli_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember" xlink:href="dnli-20190630.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_SharePurchaseAgreementMember" xlink:to="lab_dnli_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_be3c2ca6-5d46-4c9d-82be-8c1980840069_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f16205c-6185-40e2-aeb6-9232701f306a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_847c3f4e-8fc4-4fc9-a3ba-c9ce397ee80f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_09bdc7d3-f25d-4de2-89be-666ccfe6fdb8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e2b8c8de-9af3-422d-b907-4665d6067e88_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_53b5ca2e-57e5-444d-aa1d-e48fe59f2eb9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_e0b08f9e-275e-4bbc-a3ce-24fae2cbdbeb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7eb0cbb1-de60-46de-b150-e2a37c0316fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f05364aa-5e51-4515-9235-26f8d8dbdc5e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_e32bd390-1e38-4464-869d-b0c29d28d7ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6939a847-c24b-4b83-a4e9-e922a6c6980c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_LongTermInvestmentsMember_06121bdc-199f-4b16-abfc-3ceb7f7bae1a_terseLabel_en-US" xlink:label="lab_dnli_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities:</link:label>
    <link:label id="lab_dnli_LongTermInvestmentsMember_label_en-US" xlink:label="lab_dnli_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_dnli_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_dnli_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermInvestmentsMember" xlink:href="dnli-20190630.xsd#dnli_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_LongTermInvestmentsMember" xlink:to="lab_dnli_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_601ec930-dc0d-4092-90b4-80ceb768a6ea_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4cb9cf78-95fe-4ee9-a004-c49033bb1733_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_17d325c2-d469-43a1-ac50-df66ca7322cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1e15c396-7ce0-4f4e-99f2-8ab29fc7be74_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_PeripheralProductMember_d09dbe6c-893d-4682-9610-cb99db67087d_terseLabel_en-US" xlink:label="lab_dnli_PeripheralProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peripheral Product</link:label>
    <link:label id="lab_dnli_PeripheralProductMember_label_en-US" xlink:label="lab_dnli_PeripheralProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peripheral Product [Member]</link:label>
    <link:label id="lab_dnli_PeripheralProductMember_documentation_en-US" xlink:label="lab_dnli_PeripheralProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peripheral Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PeripheralProductMember" xlink:href="dnli-20190630.xsd#dnli_PeripheralProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_PeripheralProductMember" xlink:to="lab_dnli_PeripheralProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_79709958-da8d-455e-990e-1560aee2f1f3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9e3ebcfa-2476-444e-b737-780e41826521_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Collaboration Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_142635d6-1392-4514-8931-6b62a67541e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_5e853e5b-9b1e-4624-9667-d254d8c446f6_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_8ad1c391-857b-4fc0-83e6-4f29b1525d0d_terseLabel_en-US" xlink:label="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Takeda Collaboration Agreement</link:label>
    <link:label id="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_label_en-US" xlink:label="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement</link:label>
    <link:label id="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_documentation_en-US" xlink:label="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" xlink:href="dnli-20190630.xsd#dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" xlink:to="lab_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f70f28cd-c02f-4cbf-86cd-8ca5605c3b81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9c584be3-cbe6-4d10-a1fb-2fe654705bd1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_f1a83cba-f16e-4f63-8a73-7671266899c7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_ForeignExchangeForwardEurosMember_89a35676-dcac-42e1-bc41-ea8b35ce0b5d_terseLabel_en-US" xlink:label="lab_dnli_ForeignExchangeForwardEurosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euros</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardEurosMember_label_en-US" xlink:label="lab_dnli_ForeignExchangeForwardEurosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - Euros [Member]</link:label>
    <link:label id="lab_dnli_ForeignExchangeForwardEurosMember_documentation_en-US" xlink:label="lab_dnli_ForeignExchangeForwardEurosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward - Euros [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardEurosMember" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardEurosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_ForeignExchangeForwardEurosMember" xlink:to="lab_dnli_ForeignExchangeForwardEurosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_NumberOfPrograms_8de27a54-55f1-46ff-93bd-2b981092a441_terseLabel_en-US" xlink:label="lab_dnli_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_dnli_NumberOfPrograms_label_en-US" xlink:label="lab_dnli_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs</link:label>
    <link:label id="lab_dnli_NumberOfPrograms_documentation_en-US" xlink:label="lab_dnli_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfPrograms" xlink:href="dnli-20190630.xsd#dnli_NumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_NumberOfPrograms" xlink:to="lab_dnli_NumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f48f196c-e9bc-451a-8abb-c2d22aa1153a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_8a08439e-0839-4fdd-8ec1-e67879ba6833_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_dcf796d8-e4e3-48fd-86d2-422ee511b685_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_931bca84-6ce0-47cf-8424-c55edad57ab4_terseLabel_en-US" xlink:label="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_label_en-US" xlink:label="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business, Policy [Policy Text Block]</link:label>
    <link:label id="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and description of business, policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:href="dnli-20190630.xsd#dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:to="lab_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_aaa1b06a-6194-464d-98db-290a1d7be9b8_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_39b59221-783b-4228-a3ea-7e2d69f237d8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0cffd94c-4710-4d16-b011-72a5ad8c6eea_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>dnli-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:8011caee-abc0-437e-96e5-962907bf5aea,g:892d10ab-e474-4c56-aa84-e84b6d701647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dnli-20190630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ab0e32b2-a258-409b-b78c-dc887a880239" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityRegistrantName_ab0e32b2-a258-409b-b78c-dc887a880239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_66dcbe0c-7f87-47c3-8529-f06af827eee0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_66dcbe0c-7f87-47c3-8529-f06af827eee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_77e33bda-fb90-4d6e-96ac-94215b328ead" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityAddressPostalZipCode_77e33bda-fb90-4d6e-96ac-94215b328ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7c7f2977-3084-4a70-b07c-55c60a698bbe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityAddressCityOrTown_7c7f2977-3084-4a70-b07c-55c60a698bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f6b5d6fc-8607-46b6-8775-63cdff004dda" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityAddressStateOrProvince_f6b5d6fc-8607-46b6-8775-63cdff004dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_003d9fa4-e6c6-4c38-8cb8-818e9a61b793" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityAddressAddressLine1_003d9fa4-e6c6-4c38-8cb8-818e9a61b793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0ccede94-ad9a-4840-88d5-a9dceac4b16b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_CityAreaCode_0ccede94-ad9a-4840-88d5-a9dceac4b16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7da072f6-6e8b-494c-aa95-ded0e373ad92" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityFileNumber_7da072f6-6e8b-494c-aa95-ded0e373ad92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_576a9d68-a2e6-4f8a-81ca-285c8b70fe73" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_DocumentTransitionReport_576a9d68-a2e6-4f8a-81ca-285c8b70fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_243ead5f-45b5-49e1-8ad5-cb3f9b322757" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_DocumentQuarterlyReport_243ead5f-45b5-49e1-8ad5-cb3f9b322757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dbf044a0-8ecb-4814-9283-a41e07837bc0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityCentralIndexKey_dbf044a0-8ecb-4814-9283-a41e07837bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_18ef1ce2-d1f4-417c-b785-7cd67ae38315" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityInteractiveDataCurrent_18ef1ce2-d1f4-417c-b785-7cd67ae38315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f3e12276-0f53-4f70-83b6-cc0ca0ea1d17" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityCurrentReportingStatus_f3e12276-0f53-4f70-83b6-cc0ca0ea1d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5d23fa35-8428-4fd1-9f42-8b22f9a933d6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_LocalPhoneNumber_5d23fa35-8428-4fd1-9f42-8b22f9a933d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_02c36227-9ded-4764-a7a6-32fafc5f9a67" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_TradingSymbol_02c36227-9ded-4764-a7a6-32fafc5f9a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1e7c6a0a-199f-4c98-b421-3bcf3d90705d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1e7c6a0a-199f-4c98-b421-3bcf3d90705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_54c0b742-7b77-41a3-9247-362b5145898a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_Security12bTitle_54c0b742-7b77-41a3-9247-362b5145898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_117d21ce-d4c0-49d1-9534-9d3851dbe358" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_SecurityExchangeName_117d21ce-d4c0-49d1-9534-9d3851dbe358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5edfa330-7cbd-49ce-a5cc-c13633f8eb06" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_CurrentFiscalYearEndDate_5edfa330-7cbd-49ce-a5cc-c13633f8eb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_178c2f48-eafa-4237-bb19-cbb3bca30912" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityFilerCategory_178c2f48-eafa-4237-bb19-cbb3bca30912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_babea6b3-e466-41ae-a5ed-5dab16bf511e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_DocumentType_babea6b3-e466-41ae-a5ed-5dab16bf511e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3c62e872-bea1-4373-b283-cda70dcd29ab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_DocumentPeriodEndDate_3c62e872-bea1-4373-b283-cda70dcd29ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_18358e96-b17b-490f-8176-d09a33882c9e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_DocumentFiscalYearFocus_18358e96-b17b-490f-8176-d09a33882c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e839b85b-17d7-4c7a-8731-cfbf51e3c5f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e839b85b-17d7-4c7a-8731-cfbf51e3c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1771a34c-326a-4f6c-950c-073891c09a84" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_AmendmentFlag_1771a34c-326a-4f6c-950c-073891c09a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_119ea2d1-5305-41f7-a4b1-bae4620b7037" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_119ea2d1-5305-41f7-a4b1-bae4620b7037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_1d04f96b-1d63-4615-af9d-2d14d76f5509" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityExTransitionPeriod_1d04f96b-1d63-4615-af9d-2d14d76f5509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_622bf81c-7159-4e42-84f3-e3ab0f58e07b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntitySmallBusiness_622bf81c-7159-4e42-84f3-e3ab0f58e07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_be85c27e-d815-4570-855f-69ee3ded54be" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityShellCompany_be85c27e-d815-4570-855f-69ee3ded54be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9a0fa579-07fc-440a-a796-323d6996b050" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c443fcf1-5397-4eb5-87d6-7d7b2f45c5e0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9a0fa579-07fc-440a-a796-323d6996b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0c869c2-9f1a-4ab6-b021-d3c48626a30c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0c869c2-9f1a-4ab6-b021-d3c48626a30c" xlink:to="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61e2ad9a-45d0-48c7-aeac-596535fd0160" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61e2ad9a-45d0-48c7-aeac-596535fd0160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0d42b54-0a66-4ad6-a96b-4587324a7d74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61e2ad9a-45d0-48c7-aeac-596535fd0160" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0d42b54-0a66-4ad6-a96b-4587324a7d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_a26bfcd3-9900-4473-b7fe-7ea675007b42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61e2ad9a-45d0-48c7-aeac-596535fd0160" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_a26bfcd3-9900-4473-b7fe-7ea675007b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9a3a7cf0-6076-4b12-9eea-b82ff23d3f34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61e2ad9a-45d0-48c7-aeac-596535fd0160" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9a3a7cf0-6076-4b12-9eea-b82ff23d3f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4325ca70-db9a-414f-a659-c7b491124a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61e2ad9a-45d0-48c7-aeac-596535fd0160" xlink:to="loc_us-gaap_AssetsCurrent_4325ca70-db9a-414f-a659-c7b491124a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_4462ad50-6b3b-4f4f-bc1d-e882aea2712d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_4462ad50-6b3b-4f4f-bc1d-e882aea2712d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b9452899-3cbd-49aa-9d6b-9b2caeba3d32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b9452899-3cbd-49aa-9d6b-9b2caeba3d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_de21f0a2-1fb6-4f1b-b88e-4d4918ed15a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_de21f0a2-1fb6-4f1b-b88e-4d4918ed15a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_66a5fbd2-bd92-47d1-af50-87e225f18d94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_66a5fbd2-bd92-47d1-af50-87e225f18d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cad173de-2376-4ef7-9d69-2d58342c41d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b07e72d0-f0c7-4309-83c5-9a8cf8d79456" xlink:to="loc_us-gaap_Assets_cad173de-2376-4ef7-9d69-2d58342c41d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0c869c2-9f1a-4ab6-b021-d3c48626a30c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_97c3fd6d-6d69-4d59-a395-0e93374ffe6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:to="loc_us-gaap_AccountsPayableCurrent_97c3fd6d-6d69-4d59-a395-0e93374ffe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_43068937-3bc2-4950-b253-f23169d0426c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_43068937-3bc2-4950-b253-f23169d0426c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a114526-f184-4c98-95ad-82f333ce2ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a114526-f184-4c98-95ad-82f333ce2ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_195889b9-c28f-491f-8df4-988e96375d71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_195889b9-c28f-491f-8df4-988e96375d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e09c94da-032b-49a2-8307-547feb66b5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e09c94da-032b-49a2-8307-547feb66b5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c4b8bf7-2090-4e86-8cf1-c8058406456a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7c777eab-806b-4479-ade5-72858c341745" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c4b8bf7-2090-4e86-8cf1-c8058406456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_72e84247-8598-4b54-9c63-6dedb6e93696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_72e84247-8598-4b54-9c63-6dedb6e93696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d2b36a2f-12f1-448f-8f4f-1f2556fe8d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d2b36a2f-12f1-448f-8f4f-1f2556fe8d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_b197620e-52ee-42c1-9022-282fbd5305e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_b197620e-52ee-42c1-9022-282fbd5305e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4435e51d-709e-4201-95c5-a24dd0c1b736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4435e51d-709e-4201-95c5-a24dd0c1b736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_379a06b3-68f9-45bf-9467-26f5490c23e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_Liabilities_379a06b3-68f9-45bf-9467-26f5490c23e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_eff1b652-3b76-4a5b-b062-ca195093cc27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_eff1b652-3b76-4a5b-b062-ca195093cc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fde30be4-ef32-4c7c-85ea-b47ae1226a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:to="loc_us-gaap_PreferredStockValue_fde30be4-ef32-4c7c-85ea-b47ae1226a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_10a9ba24-3a8a-40d8-a623-871404196ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:to="loc_us-gaap_CommonStockValue_10a9ba24-3a8a-40d8-a623-871404196ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_40a95c40-3ef5-4ead-a969-c2b8f714bb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_40a95c40-3ef5-4ead-a969-c2b8f714bb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bc6c1fff-ea00-4c19-8766-774e4cbf7f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bc6c1fff-ea00-4c19-8766-774e4cbf7f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf91f911-1f75-4c9b-bfa8-822ef74bf631" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf91f911-1f75-4c9b-bfa8-822ef74bf631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e440f7e-2481-43bc-b6d8-6765531a5872" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ccc9502-b2aa-44a2-b09b-e85ef51bffd4" xlink:to="loc_us-gaap_StockholdersEquity_7e440f7e-2481-43bc-b6d8-6765531a5872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8280f336-6009-4e63-8ee3-80f5b8498d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3f47788-0dd6-4a39-9efc-6c0aa816c8e5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8280f336-6009-4e63-8ee3-80f5b8498d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7e4133a7-0c12-4827-9e2f-3c38ce21eb89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7e4133a7-0c12-4827-9e2f-3c38ce21eb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d0283a91-4c78-4c10-85a2-64e2ba9b298b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d0283a91-4c78-4c10-85a2-64e2ba9b298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b42a13e1-b04f-45c9-9eb2-0edc3d060081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b42a13e1-b04f-45c9-9eb2-0edc3d060081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0724eae4-8e4a-4189-b666-e3a4735b8779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0724eae4-8e4a-4189-b666-e3a4735b8779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_172cb468-ae59-4c14-9d41-daab6a872b53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_172cb468-ae59-4c14-9d41-daab6a872b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c31c7114-5d9c-4e07-9671-6b3215a6837b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c31c7114-5d9c-4e07-9671-6b3215a6837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_80ad1b2b-93fc-4c07-985f-719bb61b462b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_CommonStockSharesIssued_80ad1b2b-93fc-4c07-985f-719bb61b462b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_656eec93-0c2e-4ca9-bb72-82ee2456d618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ca4f3b5-ebd7-4f88-8a96-430e60c1b831" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_656eec93-0c2e-4ca9-bb72-82ee2456d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dnli-20190630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_488f8654-af6d-4302-b08e-2070f8ceb393" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_488f8654-af6d-4302-b08e-2070f8ceb393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_036e9d92-b451-41f5-a836-b43bc39bff4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_OperatingExpensesAbstract_036e9d92-b451-41f5-a836-b43bc39bff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0259fd76-1184-48b5-a187-7be924c30b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_036e9d92-b451-41f5-a836-b43bc39bff4f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0259fd76-1184-48b5-a187-7be924c30b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3b378dc1-580e-49c0-afd2-85f31b249236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_036e9d92-b451-41f5-a836-b43bc39bff4f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3b378dc1-580e-49c0-afd2-85f31b249236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2a5ec889-4b1d-42b3-a755-060a5d5bc0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_036e9d92-b451-41f5-a836-b43bc39bff4f" xlink:to="loc_us-gaap_OperatingExpenses_2a5ec889-4b1d-42b3-a755-060a5d5bc0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b01ef9da-89c7-4d76-b95c-89d8db596ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_OperatingIncomeLoss_b01ef9da-89c7-4d76-b95c-89d8db596ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d893a7a1-09d8-49de-8977-8ffb65c0a2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d893a7a1-09d8-49de-8977-8ffb65c0a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_dd1ca1c2-49a6-4dc5-8fd8-1d9ea188816a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_dd1ca1c2-49a6-4dc5-8fd8-1d9ea188816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1eb7bf2d-463d-432a-bc6e-7710eae888b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1eb7bf2d-463d-432a-bc6e-7710eae888b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f934802e-f799-4ed3-981e-d60c80b34b67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_NetIncomeLoss_f934802e-f799-4ed3-981e-d60c80b34b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_9f7fc17a-254f-4087-9691-d45e696d596c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_9f7fc17a-254f-4087-9691-d45e696d596c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3809d569-cfff-4c59-a0d5-764996204b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_9f7fc17a-254f-4087-9691-d45e696d596c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3809d569-cfff-4c59-a0d5-764996204b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a8bc3f31-ae43-4ffb-a465-8b6cc291cdac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a8bc3f31-ae43-4ffb-a465-8b6cc291cdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7bc349bc-54b6-4779-87e7-10647b95369b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_7bc349bc-54b6-4779-87e7-10647b95369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_378c7b28-a34a-487a-a37b-6fcc33c4bfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_64e9bded-7923-49bb-b432-78aac3b15f66" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_378c7b28-a34a-487a-a37b-6fcc33c4bfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dnli-20190630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7576e989-471f-4725-9f64-3613d25b2fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7576e989-471f-4725-9f64-3613d25b2fbb" xlink:to="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_112a2f64-d67e-446a-b06d-065daad4b9bc" xlink:to="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_78da9133-7998-45f3-82a3-6d1d09baddd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_CommonStockMember_78da9133-7998-45f3-82a3-6d1d09baddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ad51378b-1735-4572-bf00-b050fc269dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ad51378b-1735-4572-bf00-b050fc269dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e43f6481-885a-480b-8e1b-388d83beed12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e43f6481-885a-480b-8e1b-388d83beed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9cf45035-7cc0-4438-913b-059a06545736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc53fa08-b0c9-4300-b74a-775042945f7a" xlink:to="loc_us-gaap_RetainedEarningsMember_9cf45035-7cc0-4438-913b-059a06545736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f0495158-2be9-4649-a9b7-16b975165b69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94b40c84-bdc0-4d6a-a7a4-00fa4e6ae4b2" xlink:to="loc_us-gaap_StatementLineItems_f0495158-2be9-4649-a9b7-16b975165b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0495158-2be9-4649-a9b7-16b975165b69" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87a764e0-f099-4d39-a72b-5fb6dc234c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87a764e0-f099-4d39-a72b-5fb6dc234c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a177abb5-36e1-4e71-8a95-87c84bbc0d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockholdersEquity_a177abb5-36e1-4e71-8a95-87c84bbc0d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_914d4d7f-8a28-424b-a27d-4a0efe5e2914" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan_914d4d7f-8a28-424b-a27d-4a0efe5e2914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_867d9b05-311f-4eb6-b64f-70e7f20d79f5" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodValueEquityIncentivePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan_867d9b05-311f-4eb6-b64f-70e7f20d79f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54150210-1ab3-4cf1-967b-8831a296d75c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54150210-1ab3-4cf1-967b-8831a296d75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7ada4286-5fb5-4a7b-9afb-bfffccec8e07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7ada4286-5fb5-4a7b-9afb-bfffccec8e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d5ebc3ad-07f1-4b60-b108-4f238e4c721f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d5ebc3ad-07f1-4b60-b108-4f238e4c721f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_427d9157-5e25-4e5d-8292-af0cbe57d065" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_427d9157-5e25-4e5d-8292-af0cbe57d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23bda36b-7d4a-4fc9-8ff8-c06b4af13fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23bda36b-7d4a-4fc9-8ff8-c06b4af13fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6c7b9e6-d065-4d28-8701-dc16896849cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_NetIncomeLoss_e6c7b9e6-d065-4d28-8701-dc16896849cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_33d64677-a0bd-4df7-89d6-daa66035a700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_33d64677-a0bd-4df7-89d6-daa66035a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_7b3377e8-901f-4dfe-a338-f7e169ffddc3" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement_7b3377e8-901f-4dfe-a338-f7e169ffddc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_9f9d2e80-baef-425d-b139-b13fce1a68b0" xlink:href="dnli-20190630.xsd#dnli_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_dnli_StockIssuedDuringPeriodValueCollaborationAgreement_9f9d2e80-baef-425d-b139-b13fce1a68b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec560ce0-a0f3-4130-b91c-6d782432aaed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ec560ce0-a0f3-4130-b91c-6d782432aaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_077c5a06-a469-46af-88d9-d41aa3e379e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d283bc77-732c-44ed-94cc-76022c9b997b" xlink:to="loc_us-gaap_StockholdersEquity_077c5a06-a469-46af-88d9-d41aa3e379e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dnli-20190630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_516803e6-557a-4ed4-b955-e74791a7d055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_516803e6-557a-4ed4-b955-e74791a7d055" xlink:to="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2b764996-2f45-4b91-9ef4-82cd094b119d" xlink:to="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_47c71c2e-1b52-435a-96d1-a778ae8155a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:to="loc_us-gaap_CommonStockMember_47c71c2e-1b52-435a-96d1-a778ae8155a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d197c047-9187-45cd-aafd-2373675567be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1df01aa5-c00a-4720-a8fa-8d9236e4cdbc" xlink:to="loc_us-gaap_PreferredStockMember_d197c047-9187-45cd-aafd-2373675567be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e5ff9009-cec8-4305-baea-dd295620bbe1" xlink:to="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4e74e5f-6022-43f8-950b-89f1846c183b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_NetIncomeLoss_f4e74e5f-6022-43f8-950b-89f1846c183b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_abecd621-d070-4ffa-ab20-ec441e3920f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_abecd621-d070-4ffa-ab20-ec441e3920f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b5bacb8b-c47f-4f05-9cc8-6ad23b8c5525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_ShareBasedCompensation_b5bacb8b-c47f-4f05-9cc8-6ad23b8c5525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f0126d32-b204-4525-9da4-6143ad8afb89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f0126d32-b204-4525-9da4-6143ad8afb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_a2421c18-718f-4bc1-a810-3e67a1cf1965" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense_a2421c18-718f-4bc1-a810-3e67a1cf1965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_IncreaseDecreaseInDeferredRent_3cf4ea51-e52a-4be1-95fd-05d9aa91080c" xlink:href="dnli-20190630.xsd#dnli_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_dnli_IncreaseDecreaseInDeferredRent_3cf4ea51-e52a-4be1-95fd-05d9aa91080c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0ae676e3-8123-4b61-aee3-326406ac9663" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0ae676e3-8123-4b61-aee3-326406ac9663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e3b993b7-bafc-43dc-991c-a1b5bc13ceaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a7c7007-c9e4-4725-86b0-b3f5e4d27817" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e3b993b7-bafc-43dc-991c-a1b5bc13ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_edb33c69-5f1e-4c7c-885c-ed4f5790e5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_edb33c69-5f1e-4c7c-885c-ed4f5790e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ffc4c28-896a-4e32-b53e-52a8436a19ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ffc4c28-896a-4e32-b53e-52a8436a19ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e7a1b8f8-6b96-491a-8f75-80f5cc548b91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e7a1b8f8-6b96-491a-8f75-80f5cc548b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_773391e9-cb74-4375-aef0-985cccb2fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df841c2-be2a-4b38-b918-cce5310c5bea" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_773391e9-cb74-4375-aef0-985cccb2fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f346d71e-d523-4a8f-b9e4-f29bd724cc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_38898fe1-c1e8-4e68-9463-65e997bc25b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f346d71e-d523-4a8f-b9e4-f29bd724cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5c76729c-9988-4cc1-9f57-ecb492d7571a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5c76729c-9988-4cc1-9f57-ecb492d7571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d3e298dc-c1e3-4264-a0de-e3a2e95488db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d3e298dc-c1e3-4264-a0de-e3a2e95488db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_43a80501-be55-485e-b835-e0837440fa50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_43a80501-be55-485e-b835-e0837440fa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38bf645d-e014-48af-a3b5-850eebb5e63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50f1ff47-2101-40a1-bc5a-7e0f10de2696" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38bf645d-e014-48af-a3b5-850eebb5e63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a7921383-33ab-4004-9794-ee70a811fe6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a7921383-33ab-4004-9794-ee70a811fe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_328a659d-a7da-40b4-8378-cea88a291d29" xlink:href="dnli-20190630.xsd#dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement_328a659d-a7da-40b4-8378-cea88a291d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_62aeb9fa-f6f4-4cb3-b1f5-f61febbb428a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_62aeb9fa-f6f4-4cb3-b1f5-f61febbb428a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2a90674-b023-40fb-ab83-10235f8ff95c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4dfdf534-d654-4820-b28c-6bc04713e593" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2a90674-b023-40fb-ab83-10235f8ff95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_27ec6798-dc49-44dc-b8a1-643ab5b32489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_27ec6798-dc49-44dc-b8a1-643ab5b32489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49b954f4-cab7-4e8b-a28e-b61a965e292b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49b954f4-cab7-4e8b-a28e-b61a965e292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64972274-285f-4768-be39-31d783972234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64972274-285f-4768-be39-31d783972234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4eb6236b-a1c5-4f33-95df-b9ed2cdcc23c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NoncashTenantImprovementsPaidByLandlord_ddb01e2f-d952-42bc-b027-04304c2c02cd" xlink:href="dnli-20190630.xsd#dnli_NoncashTenantImprovementsPaidByLandlord"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:to="loc_dnli_NoncashTenantImprovementsPaidByLandlord_ddb01e2f-d952-42bc-b027-04304c2c02cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a152e8a-5c78-4f4a-9540-c351ef665778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4965bc0-d259-4820-8ed0-60559407b1d9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a152e8a-5c78-4f4a-9540-c351ef665778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_98594c69-ea87-4597-b469-5d7d66a6eedc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d1e557eb-e3d7-4c4b-8155-e84020053930" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98594c69-ea87-4597-b469-5d7d66a6eedc" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d1e557eb-e3d7-4c4b-8155-e84020053930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_5a454425-4b11-4040-8982-4c09c3e47195" xlink:href="dnli-20190630.xsd#dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock_5a454425-4b11-4040-8982-4c09c3e47195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a1492959-bfe1-4660-b725-4858b02069f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a1492959-bfe1-4660-b725-4858b02069f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2601118f-176a-46da-977e-3336cf9377fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2601118f-176a-46da-977e-3336cf9377fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d6751e16-945f-4651-a497-62847797a192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_UseOfEstimates_d6751e16-945f-4651-a497-62847797a192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_319d826a-384a-4538-a60a-86b868541f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_319d826a-384a-4538-a60a-86b868541f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_234a5c1e-8c51-43a8-830e-0aed4834c21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_234a5c1e-8c51-43a8-830e-0aed4834c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f2617c6d-19ef-4e12-9fab-b24400c1d7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f2617c6d-19ef-4e12-9fab-b24400c1d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_ac3edf05-6f9f-40e3-9c1b-cf87d15ec7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_ac3edf05-6f9f-40e3-9c1b-cf87d15ec7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_455a718d-445c-44a4-a2d5-daa09ceaaebb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_455a718d-445c-44a4-a2d5-daa09ceaaebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0779a7af-c8ad-46af-b5f0-a782c646f74a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0779a7af-c8ad-46af-b5f0-a782c646f74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b5d2785d-b7bc-47a9-b3fe-e89c4e53d886" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b5d2785d-b7bc-47a9-b3fe-e89c4e53d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c0b3e189-1ff3-4aec-b714-437c2bf1e1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c0b3e189-1ff3-4aec-b714-437c2bf1e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c97384f-6639-40e0-9177-73ec9d27f033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a756e7d1-23d7-43e4-bacf-67015b53279f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c97384f-6639-40e0-9177-73ec9d27f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_50161138-50ce-432e-8cad-489dde60f533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:href="dnli-20190630.xsd#dnli_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50161138-50ce-432e-8cad-489dde60f533" xlink:to="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f2d25d85-9bca-4a99-94e6-0042e873c689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_50e0b30e-0647-4886-86af-80240805da1e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f2d25d85-9bca-4a99-94e6-0042e873c689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_39eef942-7b0d-43b3-be3a-10eae0ebd758" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f2d25d85-9bca-4a99-94e6-0042e873c689" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_39eef942-7b0d-43b3-be3a-10eae0ebd758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:href="dnli-20190630.xsd#dnli_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_SignificantAccountingPoliciesTable_33c34ef8-befb-4f66-a4ea-4ee7cc20a715" xlink:to="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_346bac12-7e36-4055-b74d-c1a866d951e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_346bac12-7e36-4055-b74d-c1a866d951e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeFinanceLeaseNumberOfContracts_2162bf1b-c1dd-4e5d-8bbe-4940975ac0f7" xlink:href="dnli-20190630.xsd#dnli_LesseeFinanceLeaseNumberOfContracts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_dnli_LesseeFinanceLeaseNumberOfContracts_2162bf1b-c1dd-4e5d-8bbe-4940975ac0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e20ad86-95f1-4f13-be50-c3473619f3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e20ad86-95f1-4f13-be50-c3473619f3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6175dc94-7442-44df-beb6-f3f8f8877537" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dnli_SignificantAccountingPoliciesLineItems_982bed36-1f57-48de-a62b-630d0b5f7d9f" xlink:to="loc_us-gaap_OperatingLeaseLiability_6175dc94-7442-44df-beb6-f3f8f8877537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e2c2999-e555-438f-935c-ddd022d0aa75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8720ecc3-60d8-4b90-9a0a-b21936b5fca3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e2c2999-e555-438f-935c-ddd022d0aa75" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8720ecc3-60d8-4b90-9a0a-b21936b5fca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9340ee5d-fcfe-4bbe-9278-facdfeb5152f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fa99ae47-07e6-4d76-9d56-082d9efde7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9340ee5d-fcfe-4bbe-9278-facdfeb5152f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fa99ae47-07e6-4d76-9d56-082d9efde7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5b85186-2a7c-4c09-955a-67f15773cfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5b85186-2a7c-4c09-955a-67f15773cfb7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7db4612f-51da-41bf-a255-406b22948a8e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_691a544b-534b-49ca-99c6-5a1dfef19cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_691a544b-534b-49ca-99c6-5a1dfef19cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c0786d88-dd11-4a8c-b9b3-196c18bbb7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c0786d88-dd11-4a8c-b9b3-196c18bbb7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_66c7e0e3-aa5d-443c-94df-2474541b7b99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9912699-62cc-4ddf-bcd4-5df7d0d9f86a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_66c7e0e3-aa5d-443c-94df-2474541b7b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f4fef8d7-1cc4-41a0-84b9-df94de54a7dc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_65765dc0-b798-4113-850a-0add81cf4bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_65765dc0-b798-4113-850a-0add81cf4bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermInvestmentsMember_e1b468e8-4486-491b-9d8d-fd0fdc458b36" xlink:href="dnli-20190630.xsd#dnli_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b553178-62bf-49ba-8d3f-e6a65a6eff86" xlink:to="loc_dnli_LongTermInvestmentsMember_e1b468e8-4486-491b-9d8d-fd0fdc458b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ca67063b-4804-4545-abd8-0dcdb4f88349" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0ca1e1ad-d51e-4403-9ed9-f2bd2136698e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0ca1e1ad-d51e-4403-9ed9-f2bd2136698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8b4c4c3a-f5df-4cb7-832f-a6abb672fcb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8b4c4c3a-f5df-4cb7-832f-a6abb672fcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_edd156f0-fb32-4901-973e-bc3372c40805" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2371ce56-4239-420a-a73a-4c95cc047781" xlink:to="loc_us-gaap_CommercialPaperMember_edd156f0-fb32-4901-973e-bc3372c40805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e3844071-3047-4f40-bc0a-2d272bef7281" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b806dea6-01a8-4360-817b-7ff72162885c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b806dea6-01a8-4360-817b-7ff72162885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a49106c1-406c-470b-a4a9-395487d2b0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a49106c1-406c-470b-a4a9-395487d2b0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1bca7836-402e-42a4-90e5-0c734e029677" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1bca7836-402e-42a4-90e5-0c734e029677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_293bbb6d-411b-4d5d-8f80-5636157f3ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b17ce85-0f59-4547-bad2-a32faa214b82" xlink:to="loc_us-gaap_CommercialPaperMember_293bbb6d-411b-4d5d-8f80-5636157f3ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_254736ab-ef9f-4c94-8a5e-476c9202ba44" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a56e5dcc-7802-48f2-bc95-ce15bcdb3952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a56e5dcc-7802-48f2-bc95-ce15bcdb3952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_632415ba-e445-4dfd-be4f-9991f01c5e58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_632415ba-e445-4dfd-be4f-9991f01c5e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_771ba98c-e872-4adf-b3e8-523eca90f96e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_DerivativeAssets_771ba98c-e872-4adf-b3e8-523eca90f96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_13ed81b5-73c2-45ed-b9d1-0fbe08d437ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_13ed81b5-73c2-45ed-b9d1-0fbe08d437ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_481fe568-c186-44a8-bb2e-656346f0531a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_DerivativeLiabilities_481fe568-c186-44a8-bb2e-656346f0531a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_35a38923-7233-403b-a290-8f488ec73556" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d2e24630-66aa-4648-bd88-9d96a3c634bb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_35a38923-7233-403b-a290-8f488ec73556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecurities" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0a401317-0443-41e7-b9d7-fb7e29c66fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_44a1b260-afdc-42e3-a7e5-ab8fc0e9df56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0a401317-0443-41e7-b9d7-fb7e29c66fcd" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_44a1b260-afdc-42e3-a7e5-ab8fc0e9df56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_eed0c370-1ef1-483e-a295-09f64feab502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1772c541-c952-4fb8-85d6-bace5816f86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_eed0c370-1ef1-483e-a295-09f64feab502" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1772c541-c952-4fb8-85d6-bace5816f86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1ce32d46-4109-4a1a-bd2f-ca7ef052263e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_eed0c370-1ef1-483e-a295-09f64feab502" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1ce32d46-4109-4a1a-bd2f-ca7ef052263e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_03876c08-65f4-42e7-b190-575a2a8d56ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_eed0c370-1ef1-483e-a295-09f64feab502" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_03876c08-65f4-42e7-b190-575a2a8d56ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_4ee6086e-610f-4738-b54a-a62dae638693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_214010e9-b0ae-43df-95ce-8bbbd913b83c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4ee6086e-610f-4738-b54a-a62dae638693" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_214010e9-b0ae-43df-95ce-8bbbd913b83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2fcfb477-6a8b-4774-8e8e-bfbecd272e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4ee6086e-610f-4738-b54a-a62dae638693" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2fcfb477-6a8b-4774-8e8e-bfbecd272e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae40ab17-2b8e-4c79-9592-283a9ad37a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4ee6086e-610f-4738-b54a-a62dae638693" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae40ab17-2b8e-4c79-9592-283a9ad37a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_4649dc8b-36ac-4557-8024-1d900b01a5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4649dc8b-36ac-4557-8024-1d900b01a5e4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:to="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_18e35fa7-814a-4774-b3a5-b83c9a1e1c43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShortTermMarketableSecuritiesMember_bdd62394-08e1-4d81-aeb5-d42ea0e3f6cd" xlink:href="dnli-20190630.xsd#dnli_ShortTermMarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:to="loc_dnli_ShortTermMarketableSecuritiesMember_bdd62394-08e1-4d81-aeb5-d42ea0e3f6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LongTermMarketableSecuritiesMember_c5f81f48-646c-4ac3-a8c0-dec1f5e29417" xlink:href="dnli-20190630.xsd#dnli_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fde84902-f085-4726-9046-6c1912112c1d" xlink:to="loc_dnli_LongTermMarketableSecuritiesMember_c5f81f48-646c-4ac3-a8c0-dec1f5e29417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_61b00ecd-f4d2-4d48-bd76-d4d3624817a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0efb490f-bdd9-46d2-9836-32efb553aaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0efb490f-bdd9-46d2-9836-32efb553aaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fdb77ea6-c835-4055-8c56-24d146ef93c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fdb77ea6-c835-4055-8c56-24d146ef93c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_208a53f0-78ab-4bee-95b1-331911854db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_208a53f0-78ab-4bee-95b1-331911854db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_4c3f577e-cfc9-4fdf-8e5b-19fe668b12db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01b9e6ae-c3b5-446a-b131-e564a558f21d" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_4c3f577e-cfc9-4fdf-8e5b-19fe668b12db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_46293531-5292-448e-8314-02386f29b0f3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9eb596c5-513e-4754-84b2-edb61343fd67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9eb596c5-513e-4754-84b2-edb61343fd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_909739a5-d84c-4ec1-914b-8cbcb8cdc373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_909739a5-d84c-4ec1-914b-8cbcb8cdc373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef5bfff0-1480-4d43-aca7-4fdc821d47da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef5bfff0-1480-4d43-aca7-4fdc821d47da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3358e651-93b8-4ebb-a3d1-9b1154c244af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98f706f6-3d14-4015-8ca5-06bdd176387a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3358e651-93b8-4ebb-a3d1-9b1154c244af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CashandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_fef0dc33-c06d-41f7-8060-4757d20ded4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_11d360f8-e35c-4609-84f1-863f0b282c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fef0dc33-c06d-41f7-8060-4757d20ded4b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_11d360f8-e35c-4609-84f1-863f0b282c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_45a9d1af-379c-4878-90c6-3c5a764cd369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fef0dc33-c06d-41f7-8060-4757d20ded4b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_45a9d1af-379c-4878-90c6-3c5a764cd369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b70e1043-3f82-4f93-8583-b60a1039c595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fef0dc33-c06d-41f7-8060-4757d20ded4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b70e1043-3f82-4f93-8583-b60a1039c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_04e80e6e-3847-4908-8901-0268341400ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fef0dc33-c06d-41f7-8060-4757d20ded4b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_04e80e6e-3847-4908-8901-0268341400ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a46a4a02-378b-4737-9b2e-523db392e9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5f60cbe7-c3f1-4e4a-91b6-01017debac97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a46a4a02-378b-4737-9b2e-523db392e9bf" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5f60cbe7-c3f1-4e4a-91b6-01017debac97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f7dde78c-ae2b-4f39-975f-672ba713b8b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_83e98057-7825-452e-a622-5520d664e9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f7dde78c-ae2b-4f39-975f-672ba713b8b2" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_83e98057-7825-452e-a622-5520d664e9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dc9a6dae-79b8-4441-9afd-f12bc0586144" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dc9a6dae-79b8-4441-9afd-f12bc0586144" xlink:to="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5162a559-9312-4c73-8aa0-72dc41c7b9dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardEurosMember_64f2eb74-9510-4cde-9729-78cfc9cc98a9" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardEurosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_dnli_ForeignExchangeForwardEurosMember_64f2eb74-9510-4cde-9729-78cfc9cc98a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardBritishPoundsMember_cab53192-5520-4e27-85ae-ab7134e0964b" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardBritishPoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_dnli_ForeignExchangeForwardBritishPoundsMember_cab53192-5520-4e27-85ae-ab7134e0964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ForeignExchangeForwardSwissFrancsMember_b2fe3b75-4840-4485-9ae1-cffc59331dfe" xlink:href="dnli-20190630.xsd#dnli_ForeignExchangeForwardSwissFrancsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_dnli_ForeignExchangeForwardSwissFrancsMember_b2fe3b75-4840-4485-9ae1-cffc59331dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7fadf102-38a5-42b9-9c21-6e5d0d59bd83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cdac4628-6283-4a85-baa7-490286d63081" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7fadf102-38a5-42b9-9c21-6e5d0d59bd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:to="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ea5f6ece-5e10-4ad5-9265-19482391c344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ecb6458c-b7ba-4752-929b-49802c6622e8" xlink:to="loc_us-gaap_HedgingDesignationDomain_ea5f6ece-5e10-4ad5-9265-19482391c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d5f7f8e5-3681-4e86-957b-ec67b6bc67e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ea5f6ece-5e10-4ad5-9265-19482391c344" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d5f7f8e5-3681-4e86-957b-ec67b6bc67e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_946fc910-8bba-4e9d-87d7-2470717d8ad7" xlink:to="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_634f7d9a-a7bd-45b8-b922-b69844539853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_634f7d9a-a7bd-45b8-b922-b69844539853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_invest_DerivativeNotionalAmount_a65c58fe-c6b0-4a68-99b9-8c1360b21cc8" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_invest_DerivativeNotionalAmount_a65c58fe-c6b0-4a68-99b9-8c1360b21cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6b5026d2-91f9-4bd7-86d7-59d95f818c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeLiabilities_6b5026d2-91f9-4bd7-86d7-59d95f818c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_5c4449a9-19c3-4cf5-a9ba-43798ca8b216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeAssets_5c4449a9-19c3-4cf5-a9ba-43798ca8b216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_90b8232b-0ff7-42e4-b375-95a85fb0a833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_38b5eff8-0f39-4fc9-9f21-06afbbc41a61" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_90b8232b-0ff7-42e4-b375-95a85fb0a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Acquisition" xlink:type="simple" xlink:href="dnli-20190630.xsd#Acquisition"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_628ce014-451b-44f6-91cd-ea86bbee3e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AssetAcquisitionTextBlock_f70ffee4-f238-419c-96ce-22e173654cde" xlink:href="dnli-20190630.xsd#dnli_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_628ce014-451b-44f6-91cd-ea86bbee3e62" xlink:to="loc_dnli_AssetAcquisitionTextBlock_f70ffee4-f238-419c-96ce-22e173654cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/AcquisitionDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#AcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/AcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fce833cd-0261-4310-a5ea-d0f48ebb440e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fce833cd-0261-4310-a5ea-d0f48ebb440e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fe289f27-d0d2-439f-a40a-ed0a8321f5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0a85efd-63bd-47d4-bd21-07fe6ce15cd2" xlink:to="loc_us-gaap_ProjectMember_fe289f27-d0d2-439f-a40a-ed0a8321f5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_16842b1d-a839-4fdb-a0b3-e3b2186947c5" xlink:href="dnli-20190630.xsd#dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_fe289f27-d0d2-439f-a40a-ed0a8321f5c2" xlink:to="loc_dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember_16842b1d-a839-4fdb-a0b3-e3b2186947c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5826908-dedf-49d7-9565-1bdd813d47bd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00958dac-8af5-49f4-ae1e-649f76c7a2a1" xlink:to="loc_srt_RangeMember_d5826908-dedf-49d7-9565-1bdd813d47bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d58d2844-7de8-4536-8cef-72409f9d6b98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5826908-dedf-49d7-9565-1bdd813d47bd" xlink:to="loc_srt_MaximumMember_d58d2844-7de8-4536-8cef-72409f9d6b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f678de7c-93de-415d-af70-96b807fa81d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_f8353954-7944-4638-ba5d-31cb3005103e" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f678de7c-93de-415d-af70-96b807fa81d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ExerciseOfBuyoutOptionMember_6d84f7e6-8b5f-41f3-9e64-2929c63a9b44" xlink:href="dnli-20190630.xsd#dnli_ExerciseOfBuyoutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_f678de7c-93de-415d-af70-96b807fa81d3" xlink:to="loc_dnli_ExerciseOfBuyoutOptionMember_6d84f7e6-8b5f-41f3-9e64-2929c63a9b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8b479605-e47e-4816-836a-40fbbe1175ca" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeArrangementPayment_fa6f3a72-710a-456d-8439-e7129384c316" xlink:href="dnli-20190630.xsd#dnli_CollaborativeArrangementPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_CollaborativeArrangementPayment_fa6f3a72-710a-456d-8439-e7129384c316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontOptionFee_97ea4208-d3d5-4239-8c53-1b397e766591" xlink:href="dnli-20190630.xsd#dnli_UpfrontOptionFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_UpfrontOptionFee_97ea4208-d3d5-4239-8c53-1b397e766591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_InitialOptionExercisePayments_2ebe7b42-58e1-4a8f-b15d-3794934937f0" xlink:href="dnli-20190630.xsd#dnli_InitialOptionExercisePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_InitialOptionExercisePayments_2ebe7b42-58e1-4a8f-b15d-3794934937f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContingentPaymentsUponAchievementOfMilestones_38369186-80f4-48b5-b259-a2231b4355f5" xlink:href="dnli-20190630.xsd#dnli_ContingentPaymentsUponAchievementOfMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_ContingentPaymentsUponAchievementOfMilestones_38369186-80f4-48b5-b259-a2231b4355f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ContingentConsiderationPayment_0179556f-6048-40fb-804c-860c179408e7" xlink:href="dnli-20190630.xsd#dnli_ContingentConsiderationPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_ContingentConsiderationPayment_0179556f-6048-40fb-804c-860c179408e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3f0728ff-1cb5-4543-86e2-e78ae83c8660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3f0728ff-1cb5-4543-86e2-e78ae83c8660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_08b13da0-9dd4-4015-a586-e56b5ea2f04b" xlink:href="dnli-20190630.xsd#dnli_AssetAcquisitionContingentConsiderationAmountRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_AssetAcquisitionContingentConsiderationAmountRecognized_08b13da0-9dd4-4015-a586-e56b5ea2f04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_25d1adc9-afe0-403b-97cd-60aeb14f2e0c" xlink:href="dnli-20190630.xsd#dnli_MaximumDevelopmentPlanPeriodForResearchCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_dnli_MaximumDevelopmentPlanPeriodForResearchCosts_25d1adc9-afe0-403b-97cd-60aeb14f2e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0a601dcb-5790-4cde-bdab-ec68ac20e609" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdac9e2b-92e8-44b1-948b-030b1df4f250" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0a601dcb-5790-4cde-bdab-ec68ac20e609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8397436b-00ec-4786-9ff8-7b91391adaed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6aa08ca3-36ae-49ee-882f-5f2b7028056d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8397436b-00ec-4786-9ff8-7b91391adaed" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6aa08ca3-36ae-49ee-882f-5f2b7028056d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42c684b6-adce-4d89-9ce1-0e8003647513" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2dc0fcea-2c25-4032-9bb3-4e64dced51a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42c684b6-adce-4d89-9ce1-0e8003647513" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2dc0fcea-2c25-4032-9bb3-4e64dced51a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4495796-96a1-4ca7-87c2-12686e19e58d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4495796-96a1-4ca7-87c2-12686e19e58d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89fda59f-df94-4feb-b9e0-e6683a27b519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f1152df-0b1e-4d11-94a3-b283146a7021" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89fda59f-df94-4feb-b9e0-e6683a27b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6a817aa6-1341-4d6a-a269-e92336baefe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89fda59f-df94-4feb-b9e0-e6683a27b519" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6a817aa6-1341-4d6a-a269-e92336baefe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_31303d9c-76a9-4c3d-b13c-f360b1340da2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiMember_3201ac16-6975-4ab0-85bb-02856bf0c7ba" xlink:href="dnli-20190630.xsd#dnli_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:to="loc_dnli_SanofiMember_3201ac16-6975-4ab0-85bb-02856bf0c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DenaliMember_8b6fa471-fe2c-4c0e-89a9-5f479da793ae" xlink:href="dnli-20190630.xsd#dnli_DenaliMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf03d1d7-e0b5-4579-9dbd-1cfe714be67b" xlink:to="loc_dnli_DenaliMember_8b6fa471-fe2c-4c0e-89a9-5f479da793ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6627f562-ee36-476f-9186-b949eebab392" xlink:to="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CNSProductMember_809bf2fc-03eb-4078-a306-9aa712911ffd" xlink:href="dnli-20190630.xsd#dnli_CNSProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:to="loc_dnli_CNSProductMember_809bf2fc-03eb-4078-a306-9aa712911ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PeripheralProductMember_209608cf-a9d0-4b21-a31a-81f8a235a2e1" xlink:href="dnli-20190630.xsd#dnli_PeripheralProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:to="loc_dnli_PeripheralProductMember_209608cf-a9d0-4b21-a31a-81f8a235a2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6ab58978-dc20-4088-8c4a-5b4d3855a5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0119b46d-ec89-438b-9a47-e6cf34566c8e" xlink:to="loc_us-gaap_ProductMember_6ab58978-dc20-4088-8c4a-5b4d3855a5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_690dc425-9b55-4bc4-b3ba-d141714caacf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_23d61b6c-7a99-43f0-89d5-41cac55dac1d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_690dc425-9b55-4bc4-b3ba-d141714caacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4e42e15e-66c3-40f3-b31e-c8c38a13ab84" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_690dc425-9b55-4bc4-b3ba-d141714caacf" xlink:to="loc_srt_ScenarioForecastMember_4e42e15e-66c3-40f3-b31e-c8c38a13ab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5538c1ec-8770-4827-a5e9-25b4c00f7187" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_895e6d84-5eb5-428f-8a04-efadefa1a57a" xlink:href="dnli-20190630.xsd#dnli_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_UpfrontPayments_895e6d84-5eb5-428f-8a04-efadefa1a57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_25d4db9d-04e1-40d0-b348-02e11030d042" xlink:href="dnli-20190630.xsd#dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment_25d4db9d-04e1-40d0-b348-02e11030d042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalAndRegulatoryMilestonePayment_7d7f7f09-7a4c-4e36-a869-30c7769377c9" xlink:href="dnli-20190630.xsd#dnli_ClinicalAndRegulatoryMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_ClinicalAndRegulatoryMilestonePayment_7d7f7f09-7a4c-4e36-a869-30c7769377c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_0a166bf2-d59a-467c-ad86-1cb9d93c8ca7" xlink:href="dnli-20190630.xsd#dnli_ClinicalRegulatoryAndCommercialMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_ClinicalRegulatoryAndCommercialMilestonePayment_0a166bf2-d59a-467c-ad86-1cb9d93c8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborativeAgreementFundedPercentage_e51c3667-3b45-408e-be82-5968a9d2baea" xlink:href="dnli-20190630.xsd#dnli_CollaborativeAgreementFundedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_CollaborativeAgreementFundedPercentage_e51c3667-3b45-408e-be82-5968a9d2baea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CollaborationAgreementTransactionPriceIncrease_d7c02d28-4328-4807-a184-2e72a8f3a019" xlink:href="dnli-20190630.xsd#dnli_CollaborationAgreementTransactionPriceIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_CollaborationAgreementTransactionPriceIncrease_d7c02d28-4328-4807-a184-2e72a8f3a019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_50032ff2-72dd-4244-b554-0480ae16fed9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_AccountsReceivableNet_50032ff2-72dd-4244-b554-0480ae16fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ClinicalMilestonePayment_519cca5b-1b64-4c4b-952d-a559cacb1866" xlink:href="dnli-20190630.xsd#dnli_ClinicalMilestonePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_dnli_ClinicalMilestonePayment_519cca5b-1b64-4c4b-952d-a559cacb1866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1c3aebd3-85d9-449d-8606-7e8b75359754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1c3aebd3-85d9-449d-8606-7e8b75359754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b0bb0da-bc93-48be-b31e-3256b2affebb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44dcf772-2dbe-43bf-952b-69e7361e204c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b0bb0da-bc93-48be-b31e-3256b2affebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSanofiPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5bb530dc-a15c-449f-9792-f99a9f94fb29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5bb530dc-a15c-449f-9792-f99a9f94fb29" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:to="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2791865-fb31-4251-a0ab-84123d660f07" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ec1649c2-2fd6-46bf-bd64-15f18cd3b829" xlink:to="loc_srt_ProductsAndServicesDomain_e2791865-fb31-4251-a0ab-84123d660f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_07051289-bf39-404e-bcaa-717216a26caa" xlink:href="dnli-20190630.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2791865-fb31-4251-a0ab-84123d660f07" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_07051289-bf39-404e-bcaa-717216a26caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b0e335a3-dde8-456c-af1a-373c19d3d266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b0e335a3-dde8-456c-af1a-373c19d3d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4af6a28c-c25f-4d06-8d4f-1c6e882bdd2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb247c6c-f88c-4d77-abf2-b5225e9aeb3f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4af6a28c-c25f-4d06-8d4f-1c6e882bdd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3589ffbf-ae2e-4fa7-8c79-f6f0b4f811a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4af6a28c-c25f-4d06-8d4f-1c6e882bdd2f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3589ffbf-ae2e-4fa7-8c79-f6f0b4f811a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34fb22ed-59e7-48ec-83ce-fc6b439d41f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34fb22ed-59e7-48ec-83ce-fc6b439d41f9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84c21d9b-38bc-4651-837a-6400e21d3781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e4a2919-4646-42fc-b262-702399beaf6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84c21d9b-38bc-4651-837a-6400e21d3781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_45b9d996-17c1-4436-bc1e-b4f7311b6b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84c21d9b-38bc-4651-837a-6400e21d3781" xlink:to="loc_us-gaap_CollaborativeArrangementMember_45b9d996-17c1-4436-bc1e-b4f7311b6b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64116949-fb04-469f-8c4c-0dc3a9191e76" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f9fec2d-8118-4081-85e5-8499713b028d" xlink:to="loc_srt_RangeMember_64116949-fb04-469f-8c4c-0dc3a9191e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_451023d2-3a7b-44ab-a896-807aaf9e911b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64116949-fb04-469f-8c4c-0dc3a9191e76" xlink:to="loc_srt_MaximumMember_451023d2-3a7b-44ab-a896-807aaf9e911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8b5b174-7379-4bd6-affb-6565b184d90b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_74886e0d-ea5d-4d8f-afd0-494591097a0a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8b5b174-7379-4bd6-affb-6565b184d90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharePurchaseAgreementMember_dbeddf4b-3c89-4946-9abc-36f834ad3449" xlink:href="dnli-20190630.xsd#dnli_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8b5b174-7379-4bd6-affb-6565b184d90b" xlink:to="loc_dnli_SharePurchaseAgreementMember_dbeddf4b-3c89-4946-9abc-36f834ad3449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d19874a2-adce-4707-902d-feacef11f962" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5afaa2f7-b8e7-4cc9-b57e-6c13311eb5b7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d19874a2-adce-4707-902d-feacef11f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_0d20199a-d881-4fc2-8c24-488962fe12c8" xlink:href="dnli-20190630.xsd#dnli_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d19874a2-adce-4707-902d-feacef11f962" xlink:to="loc_dnli_TakedaPharmaceuticalCompanyLimitedMember_0d20199a-d881-4fc2-8c24-488962fe12c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a12b2957-c094-40a5-a087-6c9575073a50" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_27c7f543-cd3c-4280-8a16-5a9709d8befe" xlink:to="loc_srt_ProductsAndServicesDomain_a12b2957-c094-40a5-a087-6c9575073a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a8fba550-11f4-496b-bfc9-140d5648a284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a12b2957-c094-40a5-a087-6c9575073a50" xlink:to="loc_us-gaap_ProductMember_a8fba550-11f4-496b-bfc9-140d5648a284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7797286f-4fed-4499-ad89-ba26f1dbaad2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontPayments_1f35c909-8631-4804-9ec1-f64c16cb3b4f" xlink:href="dnli-20190630.xsd#dnli_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_UpfrontPayments_1f35c909-8631-4804-9ec1-f64c16cb3b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentPerProgram_bd6011f3-2265-43c5-868a-bab7ef9187a6" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentPerProgram"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_PreclinicalMilestonePaymentPerProgram_bd6011f3-2265-43c5-868a-bab7ef9187a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfPrograms_379dd01e-b2db-4637-9b69-cf6f22af0a38" xlink:href="dnli-20190630.xsd#dnli_NumberOfPrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_NumberOfPrograms_379dd01e-b2db-4637-9b69-cf6f22af0a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregatePreclinicalMilestonePayment_871ae8a7-5b79-459d-8e1e-47190efa04dd" xlink:href="dnli-20190630.xsd#dnli_AggregatePreclinicalMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregatePreclinicalMilestonePayment_871ae8a7-5b79-459d-8e1e-47190efa04dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentReceived_b45703b4-82fd-4f99-a70c-4a9ae6e912ba" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_PreclinicalMilestonePaymentReceived_b45703b4-82fd-4f99-a70c-4a9ae6e912ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NumberOfTargets_09631efd-c3f5-4475-b3e9-beef290d4d95" xlink:href="dnli-20190630.xsd#dnli_NumberOfTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_NumberOfTargets_09631efd-c3f5-4475-b3e9-beef290d4d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TargetOptionPeriod_eb5e836b-668d-431a-ac97-e0b9398507ac" xlink:href="dnli-20190630.xsd#dnli_TargetOptionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_TargetOptionPeriod_eb5e836b-668d-431a-ac97-e0b9398507ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OptionFeesPerProgram_77b26eb8-284a-4364-8764-53cecaea020d" xlink:href="dnli-20190630.xsd#dnli_OptionFeesPerProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_OptionFeesPerProgram_77b26eb8-284a-4364-8764-53cecaea020d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateOptionExerciseFee_5bbb058c-8223-40dc-867b-a8dafa87ca78" xlink:href="dnli-20190630.xsd#dnli_AggregateOptionExerciseFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregateOptionExerciseFee_5bbb058c-8223-40dc-867b-a8dafa87ca78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateDevelopmentMilestonePayment_43396552-a73c-43ee-a977-caf5ea21c3f3" xlink:href="dnli-20190630.xsd#dnli_AggregateDevelopmentMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregateDevelopmentMilestonePayment_43396552-a73c-43ee-a977-caf5ea21c3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_CommercialMilestonesPerProgram_6b9e94dc-35b0-4013-916a-768bcf09ca78" xlink:href="dnli-20190630.xsd#dnli_CommercialMilestonesPerProgram"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_CommercialMilestonesPerProgram_6b9e94dc-35b0-4013-916a-768bcf09ca78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AggregateCommercialMilestones_79d30a18-319e-4e01-88c2-03fb047855f5" xlink:href="dnli-20190630.xsd#dnli_AggregateCommercialMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_AggregateCommercialMilestones_79d30a18-319e-4e01-88c2-03fb047855f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_933cfbb3-250b-4459-936b-78bd66309c31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_933cfbb3-250b-4459-936b-78bd66309c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_870380e5-9a71-4c51-bae4-f79bae2e34e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_870380e5-9a71-4c51-bae4-f79bae2e34e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_80010e7f-e6e5-4860-a2dd-11ef589820af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_80010e7f-e6e5-4860-a2dd-11ef589820af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5d2f8243-7014-402f-a145-80462ddd5ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5d2f8243-7014-402f-a145-80462ddd5ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_ad26b625-0e97-4abb-93e2-1a2c38bcb9c9" xlink:href="dnli-20190630.xsd#dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction_ad26b625-0e97-4abb-93e2-1a2c38bcb9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_VariableConsiderationFutureConsideration_4c6e65da-79f0-4d27-9a93-564fcbebf56d" xlink:href="dnli-20190630.xsd#dnli_VariableConsiderationFutureConsideration"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_VariableConsiderationFutureConsideration_4c6e65da-79f0-4d27-9a93-564fcbebf56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_f17fe5db-23e3-4eb2-b71d-54df3f77ca72" xlink:href="dnli-20190630.xsd#dnli_PreclinicalMilestonePaymentEarnedNotYetReceived"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived_f17fe5db-23e3-4eb2-b71d-54df3f77ca72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ConstrainedVariableConsideration_51021dc0-23da-4418-8ade-bf895becbaef" xlink:href="dnli-20190630.xsd#dnli_ConstrainedVariableConsideration"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_ConstrainedVariableConsideration_51021dc0-23da-4418-8ade-bf895becbaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RevenueNumberOfPerformanceObligations_ef79afc2-4f5f-482b-b990-bdf0f2a8353e" xlink:href="dnli-20190630.xsd#dnli_RevenueNumberOfPerformanceObligations"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_dnli_RevenueNumberOfPerformanceObligations_ef79afc2-4f5f-482b-b990-bdf0f2a8353e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cfd01858-43ec-404c-a2a7-69f512cb4c72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cfd01858-43ec-404c-a2a7-69f512cb4c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_216a2df5-8e0f-4a5f-8b49-7813384d2008" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_216a2df5-8e0f-4a5f-8b49-7813384d2008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_6b6b9bf6-5bc2-4288-ba0c-25d37256b55e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_6b6b9bf6-5bc2-4288-ba0c-25d37256b55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eff90f7f-b71d-4aa2-ba15-3bd3e415bc5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e878cb37-b8e4-4d22-8cf2-af80af258a35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eff90f7f-b71d-4aa2-ba15-3bd3e415bc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CollaborationAgreementsSummaryofCollaborationRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91328d09-b4cb-4a9c-a4ee-abdda871297c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91328d09-b4cb-4a9c-a4ee-abdda871297c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72890ce4-6213-4808-a7cb-103489d00c1c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TakedaCollaborationAgreementMember_b1cd6dae-9575-42b5-b665-d3c4e9bf6a47" xlink:href="dnli-20190630.xsd#dnli_TakedaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:to="loc_dnli_TakedaCollaborationAgreementMember_b1cd6dae-9575-42b5-b665-d3c4e9bf6a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SanofiCollaborationAgreementMember_3d1fc980-5641-45ce-9ee4-e2159284d7bc" xlink:href="dnli-20190630.xsd#dnli_SanofiCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd437880-24fb-4a7a-a8f4-fd45d9b70b84" xlink:to="loc_dnli_SanofiCollaborationAgreementMember_3d1fc980-5641-45ce-9ee4-e2159284d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:to="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b86acbc9-0a7d-44c1-af28-407c9f4e8dc9" xlink:to="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_AlzheimersDiseaseServicesMember_d28fb278-8d8d-4f9b-8cb7-001eb1a1e7ef" xlink:href="dnli-20190630.xsd#dnli_AlzheimersDiseaseServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:to="loc_dnli_AlzheimersDiseaseServicesMember_d28fb278-8d8d-4f9b-8cb7-001eb1a1e7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RetainedActivitiesMember_45a22f00-001c-4dd7-a48d-481eaf4ed6db" xlink:href="dnli-20190630.xsd#dnli_RetainedActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9fac6ed1-e54b-418b-b511-674f8ea0cf10" xlink:to="loc_dnli_RetainedActivitiesMember_45a22f00-001c-4dd7-a48d-481eaf4ed6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_40a5bfd2-ff20-4744-8c18-8b6839cb72cb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298e83b-1376-4917-b210-52b3c21daa68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298e83b-1376-4917-b210-52b3c21daa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_0faabda5-9310-45cf-859b-7541a10fd41d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c81921da-7058-4a0f-a7b3-e5b2baa683cf" xlink:to="loc_us-gaap_DeferredRevenue_0faabda5-9310-45cf-859b-7541a10fd41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="simple" xlink:href="dnli-20190630.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efa061dd-1f7b-4bb8-9ef5-d44d9da62b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementTextBlock_7874adff-b0b8-4743-bee8-1ce0a0d88568" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efa061dd-1f7b-4bb8-9ef5-d44d9da62b8d" xlink:to="loc_dnli_LicenseAgreementTextBlock_7874adff-b0b8-4743-bee8-1ce0a0d88568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07fa8bf0-db09-48cb-bcaf-3a68aa29db0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07fa8bf0-db09-48cb-bcaf-3a68aa29db0e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bc7020-82d7-46c2-9918-5e5335b3368a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c68c97d-5316-48b4-9e80-d2c4d1994701" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bc7020-82d7-46c2-9918-5e5335b3368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMember_849e936c-184e-4f0e-8676-562926e072b1" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bc7020-82d7-46c2-9918-5e5335b3368a" xlink:to="loc_dnli_LicenseAgreementMember_849e936c-184e-4f0e-8676-562926e072b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57c6332f-70a2-4584-b6ae-8c4752a67554" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_56d4888b-ed62-48f4-861e-858f49ee2c05" xlink:to="loc_srt_RangeMember_57c6332f-70a2-4584-b6ae-8c4752a67554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_39b88773-76b6-4808-809e-69cf416831c2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57c6332f-70a2-4584-b6ae-8c4752a67554" xlink:to="loc_srt_MaximumMember_39b88773-76b6-4808-809e-69cf416831c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69acdff6-1382-4dbc-b008-00b5dd39baeb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_38d6f790-ee51-48da-9ce6-42cfa6dedfb9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69acdff6-1382-4dbc-b008-00b5dd39baeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_GenentechIncMember_854e99dd-8b4e-46f4-8000-648951fbf071" xlink:href="dnli-20190630.xsd#dnli_GenentechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69acdff6-1382-4dbc-b008-00b5dd39baeb" xlink:to="loc_dnli_GenentechIncMember_854e99dd-8b4e-46f4-8000-648951fbf071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c9b94ccb-8f7e-4dcb-a635-dbdc316171e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a02a5f36-42bb-4dde-8030-de97ca3711ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c9b94ccb-8f7e-4dcb-a635-dbdc316171e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f3dc1e6-c8c9-4a35-8e40-dd6805d368c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c9b94ccb-8f7e-4dcb-a635-dbdc316171e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f3dc1e6-c8c9-4a35-8e40-dd6805d368c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc005afb-0f3f-4a4f-b031-9a16cb187941" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_812cd8b7-ab19-47ad-92ed-457329619607" xlink:href="dnli-20190630.xsd#dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:to="loc_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones_812cd8b7-ab19-47ad-92ed-457329619607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_UpfrontFeesPaid_13d2b0cd-c088-438b-8a02-3c8c7a3ff8d1" xlink:href="dnli-20190630.xsd#dnli_UpfrontFeesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0f53c2e8-3419-49f0-81c7-5c242015e2d3" xlink:to="loc_dnli_UpfrontFeesPaid_13d2b0cd-c088-438b-8a02-3c8c7a3ff8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c346b67-5f2d-4594-8759-18b8abe3f3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a847059c-8882-4f51-b36d-1891b7788705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c346b67-5f2d-4594-8759-18b8abe3f3a0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a847059c-8882-4f51-b36d-1891b7788705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_297dd2c3-e3d9-4caf-bf05-7a38d80787d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d5b7dc9c-f1d4-41b7-82f1-9430bf4051fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_297dd2c3-e3d9-4caf-bf05-7a38d80787d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d5b7dc9c-f1d4-41b7-82f1-9430bf4051fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_f21d9baa-92b4-4b52-9f32-a24de4d2d184" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_297dd2c3-e3d9-4caf-bf05-7a38d80787d5" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_f21d9baa-92b4-4b52-9f32-a24de4d2d184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e2474b5-e06a-45ac-88ab-17ca5f006cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e2474b5-e06a-45ac-88ab-17ca5f006cc3" xlink:to="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1274fd8-785e-44bc-bdb3-2e301a95b6ba" xlink:to="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d7e27f79-c34e-4004-ad49-b57d50a58fc8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:to="loc_srt_MinimumMember_d7e27f79-c34e-4004-ad49-b57d50a58fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a59f359c-7f55-4378-873c-307ecdb24e40" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efb6f44b-0e73-4687-91f9-a9b68c686225" xlink:to="loc_srt_MaximumMember_a59f359c-7f55-4378-873c-307ecdb24e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_677997cb-3d8d-419b-a8a3-01f9d3fdc1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d776e7d1-70a1-4dab-a0a0-6c0beef1e294" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_677997cb-3d8d-419b-a8a3-01f9d3fdc1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_DMSAMember_d9f24cb0-1059-4685-983d-bb6e2a120fd9" xlink:href="dnli-20190630.xsd#dnli_DMSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_677997cb-3d8d-419b-a8a3-01f9d3fdc1b1" xlink:to="loc_dnli_DMSAMember_d9f24cb0-1059-4685-983d-bb6e2a120fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_286b152f-c0b2-4a2f-9448-4880a6435ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_1ba29a80-f76d-4173-887d-22a3b60590a1" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_286b152f-c0b2-4a2f-9448-4880a6435ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LandlordFundedTenantImprovementsMember_1333a3e9-2520-4bf1-8263-d3e1e6856b0c" xlink:href="dnli-20190630.xsd#dnli_LandlordFundedTenantImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_286b152f-c0b2-4a2f-9448-4880a6435ab5" xlink:to="loc_dnli_LandlordFundedTenantImprovementsMember_1333a3e9-2520-4bf1-8263-d3e1e6856b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4b900d06-23c4-468a-800e-35109d05e986" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_HeadquartersLeaseMember_a97c47ab-a20e-41bb-a607-354aa4d03954" xlink:href="dnli-20190630.xsd#dnli_HeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:to="loc_dnli_HeadquartersLeaseMember_a97c47ab-a20e-41bb-a607-354aa4d03954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_NewPremisesSubleaseAgreementMember_35e0dfe6-b32b-481e-b252-2503fa03d95b" xlink:href="dnli-20190630.xsd#dnli_NewPremisesSubleaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_d3b24075-154d-4783-ab9f-9f0ce9d23ce1" xlink:to="loc_dnli_NewPremisesSubleaseAgreementMember_35e0dfe6-b32b-481e-b252-2503fa03d95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_87d3d76b-94c7-45bb-b979-e99360b10cff" xlink:to="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesAreaUnderLease_a07e454e-6f15-4867-9688-ebde7833de2b" xlink:href="dnli-20190630.xsd#dnli_OperatingLeasesAreaUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_OperatingLeasesAreaUnderLease_a07e454e-6f15-4867-9688-ebde7833de2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f25356cb-0129-4316-8ea9-188746a253dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f25356cb-0129-4316-8ea9-188746a253dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TenantImprovementAllowanceRepayableAsRent_e2c29d13-9ffe-4a9a-8fa7-ab3c5748d6b1" xlink:href="dnli-20190630.xsd#dnli_TenantImprovementAllowanceRepayableAsRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_TenantImprovementAllowanceRepayableAsRent_e2c29d13-9ffe-4a9a-8fa7-ab3c5748d6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad9aed2b-321c-45b9-b4cb-853bd28e2c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad9aed2b-321c-45b9-b4cb-853bd28e2c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_ba6e52b0-3cff-4545-8184-864094a40f20" xlink:href="dnli-20190630.xsd#dnli_LesseeOperatingLeaseRenewalNoticePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_LesseeOperatingLeaseRenewalNoticePeriod_ba6e52b0-3cff-4545-8184-864094a40f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_3e92fa3b-3fb9-40f7-a6f2-d8debf58bdd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_3e92fa3b-3fb9-40f7-a6f2-d8debf58bdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f3d289c-fe01-4e0f-afaf-518b5b5ef7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f3d289c-fe01-4e0f-afaf-518b5b5ef7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6e8fefdb-1ce8-40ed-8217-f0255d9e74b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6e8fefdb-1ce8-40ed-8217-f0255d9e74b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ece280ae-8e42-4a7b-903a-ccd0e7f45133" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ece280ae-8e42-4a7b-903a-ccd0e7f45133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_6871e4ed-882d-400f-884c-a68cd6684b51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_6871e4ed-882d-400f-884c-a68cd6684b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c92505be-b64f-4d22-9f16-90c2ecdd15f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LeaseCost_c92505be-b64f-4d22-9f16-90c2ecdd15f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_5c881f1d-b836-486d-8e18-f410d1ce396f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_5c881f1d-b836-486d-8e18-f410d1ce396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a778a61b-11fa-446c-9cf5-d03785a09891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a778a61b-11fa-446c-9cf5-d03785a09891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9953753e-b793-4791-af5b-c49f1ca82db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9953753e-b793-4791-af5b-c49f1ca82db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3579cb3b-50d3-4efe-a284-a23019556469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeasePayments_3579cb3b-50d3-4efe-a284-a23019556469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_OperatingLeasesSubleaseNetRentableArea_5acb64f6-f6f9-4d9a-8c81-3d5b95788b9e" xlink:href="dnli-20190630.xsd#dnli_OperatingLeasesSubleaseNetRentableArea"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_OperatingLeasesSubleaseNetRentableArea_5acb64f6-f6f9-4d9a-8c81-3d5b95788b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_d6cbae31-8fbd-428d-b8dd-9337659359c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_d6cbae31-8fbd-428d-b8dd-9337659359c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_e28ca5cc-1d58-4072-8406-26551f4d124e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_e28ca5cc-1d58-4072-8406-26551f4d124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PurchaseOrderExecuted_0b9aab6e-b42b-4725-8e4b-603ee4905da5" xlink:href="dnli-20190630.xsd#dnli_PurchaseOrderExecuted"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_PurchaseOrderExecuted_0b9aab6e-b42b-4725-8e4b-603ee4905da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsIncurredDevelopmentCosts_9e2a7106-d4eb-45ff-8b49-08904cdd89e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsIncurredDevelopmentCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_CostsIncurredDevelopmentCosts_9e2a7106-d4eb-45ff-8b49-08904cdd89e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PaymentsForManufacturingCost_a867e539-5da8-4fec-9156-6881cc088e74" xlink:href="dnli-20190630.xsd#dnli_PaymentsForManufacturingCost"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_dnli_PaymentsForManufacturingCost_a867e539-5da8-4fec-9156-6881cc088e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_075bcbc4-a440-4540-8d6d-6fe452ef2271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_de57726f-92bc-44b6-8b4a-f5e79d11a2ad" xlink:to="loc_us-gaap_PurchaseObligation_075bcbc4-a440-4540-8d6d-6fe452ef2271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_acca1665-d1b0-491f-8f94-e6b567b47b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_acca1665-d1b0-491f-8f94-e6b567b47b9c" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c9fb3652-5aa7-4c21-b2f8-d506a728c995" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c9fb3652-5aa7-4c21-b2f8-d506a728c995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_42c783e5-8c1e-4de3-b57e-2d03afebcae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_42c783e5-8c1e-4de3-b57e-2d03afebcae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_642449ff-787c-4617-93f0-8dc2678ea7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_642449ff-787c-4617-93f0-8dc2678ea7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_b0e7a6b7-2af1-4b51-bc29-7cdd37b63a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_b0e7a6b7-2af1-4b51-bc29-7cdd37b63a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_69c87327-4ef8-4ed6-9e26-d5e7f9053f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_69c87327-4ef8-4ed6-9e26-d5e7f9053f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_480fb78a-1b22-4408-ad66-30f6bd20d02c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_480fb78a-1b22-4408-ad66-30f6bd20d02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7fd48db0-7f29-4058-a9eb-b260ffae6a15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7fd48db0-7f29-4058-a9eb-b260ffae6a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33fc747f-192b-4c60-b176-cbad8a4b6a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33fc747f-192b-4c60-b176-cbad8a4b6a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2709d93-853f-4d12-837a-70bf3783fb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_991ed01f-de5e-4ae4-b4ce-65032bdb4dd2" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2709d93-853f-4d12-837a-70bf3783fb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_57dd5180-a800-43c6-86bb-d32e65f3c9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_57dd5180-a800-43c6-86bb-d32e65f3c9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_9dda6c14-3c36-488b-a0cd-a19444bcc026" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_9dda6c14-3c36-488b-a0cd-a19444bcc026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_60afe795-9753-41fe-8502-b3965ebb7a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_60afe795-9753-41fe-8502-b3965ebb7a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_9bd531c1-1bda-4bd1-ab97-4c879474e06f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_9bd531c1-1bda-4bd1-ab97-4c879474e06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_c6b0cdee-8914-4d31-aed6-6930ff239278" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_c6b0cdee-8914-4d31-aed6-6930ff239278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_11bb2c63-8b27-44a6-a72d-4dac9b60813a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_11bb2c63-8b27-44a6-a72d-4dac9b60813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_de91c4e5-b389-4b05-957b-1801826dd6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60fafad9-b8cb-4c28-9259-eb0fe15c4df3" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_de91c4e5-b389-4b05-957b-1801826dd6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwards"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a41052af-a2fc-422d-ae28-2b8daa330a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5ae5b5ec-5bb1-4ae6-8cfa-0d1fc851977a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a41052af-a2fc-422d-ae28-2b8daa330a2a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5ae5b5ec-5bb1-4ae6-8cfa-0d1fc851977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be4bd585-6ccf-40ce-b922-4ca0845cadc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f8d66ff3-0f1a-48f0-909f-9882f125557a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be4bd585-6ccf-40ce-b922-4ca0845cadc1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f8d66ff3-0f1a-48f0-909f-9882f125557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_27b17e2e-1fd2-47f7-92bc-3c863ade16b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be4bd585-6ccf-40ce-b922-4ca0845cadc1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_27b17e2e-1fd2-47f7-92bc-3c863ade16b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_200c0fa5-882e-44ee-9521-7e871ac21292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be4bd585-6ccf-40ce-b922-4ca0845cadc1" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_200c0fa5-882e-44ee-9521-7e871ac21292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f3bbd696-ab94-4147-9f52-188561c2dc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be4bd585-6ccf-40ce-b922-4ca0845cadc1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f3bbd696-ab94-4147-9f52-188561c2dc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77baea48-1bc4-44ce-81de-a3bb170dbda8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77baea48-1bc4-44ce-81de-a3bb170dbda8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a13adce-7da4-4968-aed3-1c68213850d4" xlink:to="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ceeb65fc-52a0-4f00-a216-c97acb1b10c9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:to="loc_srt_MaximumMember_ceeb65fc-52a0-4f00-a216-c97acb1b10c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bee1caf5-91cb-4c2d-85e2-836f282fe253" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_236315ef-34c7-467a-929d-836b9f3f40e9" xlink:to="loc_srt_MinimumMember_bee1caf5-91cb-4c2d-85e2-836f282fe253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_be08a7b6-be09-4639-9f3a-e588bc55d157" xlink:to="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandSeventeenEquityIncentivePlanMember_20bd38b2-29d6-458b-8196-88e51d1e485a" xlink:href="dnli-20190630.xsd#dnli_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:to="loc_dnli_TwoThousandSeventeenEquityIncentivePlanMember_20bd38b2-29d6-458b-8196-88e51d1e485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandFifteenEquityIncentivePlanMember_dde7fbf2-e2d4-4c0f-a3ff-fdcbfd757e3b" xlink:href="dnli-20190630.xsd#dnli_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:to="loc_dnli_TwoThousandFifteenEquityIncentivePlanMember_dde7fbf2-e2d4-4c0f-a3ff-fdcbfd757e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_61cd0454-1bff-4618-8e5a-7565273f48df" xlink:href="dnli-20190630.xsd#dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a6157cd3-9235-484a-9d7a-81eafbd97684" xlink:to="loc_dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember_61cd0454-1bff-4618-8e5a-7565273f48df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d613d0d5-4f4f-46e0-b082-fa38b4990782" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketContingentStockOptionsMember_de90fd3a-cc2d-4c76-bfc9-b44700bd50d5" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketContingentStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_dnli_PerformanceAndMarketContingentStockOptionsMember_de90fd3a-cc2d-4c76-bfc9-b44700bd50d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5897ceb5-0e6d-4a09-813e-f7a2b63d1f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_us-gaap_RestrictedStockMember_5897ceb5-0e6d-4a09-813e-f7a2b63d1f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_0ab823a8-4a30-45bd-b02f-53f52c33c8d3" xlink:href="dnli-20190630.xsd#dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember_0ab823a8-4a30-45bd-b02f-53f52c33c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_837ead91-30b3-4144-aaf7-26cee85ce962" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d2a7fa5-1f84-4525-9e2a-ccfa96f9198e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_837ead91-30b3-4144-aaf7-26cee85ce962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d78ddc23-76a2-471f-95e9-8113ca9b3faf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1a10882-5c30-49ce-8439-f106936bd9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1a10882-5c30-49ce-8439-f106936bd9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22927e27-264b-41fb-9cc2-ff5975480762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6258408c-9adf-450b-b8e7-355d3ed00586" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22927e27-264b-41fb-9cc2-ff5975480762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0485737-6d94-4200-b8c2-5c0c0b78bd11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59a66254-79ed-44fb-b4f8-32b29cb0109a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59a66254-79ed-44fb-b4f8-32b29cb0109a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_9279994b-2aa8-486b-919c-203e065b5f0b" xlink:href="dnli-20190630.xsd#dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_9279994b-2aa8-486b-919c-203e065b5f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5ab4f27d-acbf-404c-ae94-2a87f9056b90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5ab4f27d-acbf-404c-ae94-2a87f9056b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_934d42ea-8349-4147-997c-7a07df474520" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_934d42ea-8349-4147-997c-7a07df474520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1a624c18-9c75-41c4-8de4-241ed8538668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1a624c18-9c75-41c4-8de4-241ed8538668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58d9d783-e9ed-4b69-977d-57d45db2345a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58d9d783-e9ed-4b69-977d-57d45db2345a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aa60979c-2f46-4c4b-bc1e-27715f3170fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aa60979c-2f46-4c4b-bc1e-27715f3170fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7e745ee1-6222-4fde-92f8-3ad6b760d7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7e745ee1-6222-4fde-92f8-3ad6b760d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56131511-6161-457d-ac0d-c7df7c7cb8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56131511-6161-457d-ac0d-c7df7c7cb8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_139d234e-9361-498d-b1fb-487f64a92724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_139d234e-9361-498d-b1fb-487f64a92724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3aacb410-b4af-4e1f-8a73-50e3943f5ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3aacb410-b4af-4e1f-8a73-50e3943f5ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8f501f98-5032-4c88-90bf-691a10c3bbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_Dividends_8f501f98-5032-4c88-90bf-691a10c3bbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_843acc93-916b-4b98-88e5-87c9b64845b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_843acc93-916b-4b98-88e5-87c9b64845b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_7c980e2c-0c7a-4ad5-ba77-8b936277ea79" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays_7c980e2c-0c7a-4ad5-ba77-8b936277ea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_e746d41d-63af-4136-8faa-419d4129c24f" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering_e746d41d-63af-4136-8faa-419d4129c24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensation_1bc0c203-ec51-41fb-9f7b-c5780e1ae8b0" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_PerformanceAndMarketShareBasedCompensation_1bc0c203-ec51-41fb-9f7b-c5780e1ae8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_ae6f895e-9760-4f70-bc06-828eb11a003d" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized_ae6f895e-9760-4f70-bc06-828eb11a003d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_70433745-9a35-4af3-8690-2e70a6ea35d3" xlink:href="dnli-20190630.xsd#dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition_70433745-9a35-4af3-8690-2e70a6ea35d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2d19b80-687a-4137-87f5-e851345b8560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2d19b80-687a-4137-87f5-e851345b8560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_916190fd-723b-432c-85df-376e2e273161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_916190fd-723b-432c-85df-376e2e273161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac51164d-2145-4374-978d-3796887986ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac51164d-2145-4374-978d-3796887986ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_04a4d228-8b88-4879-a704-8cef3e51374d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_04a4d228-8b88-4879-a704-8cef3e51374d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ee7fe7d3-94ff-4c8d-a7f0-8bb64515592e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ee7fe7d3-94ff-4c8d-a7f0-8bb64515592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6aa9ec1f-b7fb-43ee-ba88-1b60aab4b6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3a7480b-1409-4c6f-8ded-a838cb8b0450" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6aa9ec1f-b7fb-43ee-ba88-1b60aab4b6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2665caf3-2ce7-4f81-ab26-b62e73d2c2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2665caf3-2ce7-4f81-ab26-b62e73d2c2aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f23ebafd-0375-4527-9768-54e22bba82bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f23ebafd-0375-4527-9768-54e22bba82bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbadbf0f-18c3-4576-88e5-1b920f085028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbadbf0f-18c3-4576-88e5-1b920f085028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_44d53404-cdcf-44c8-b077-42fb48fca9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_44d53404-cdcf-44c8-b077-42fb48fca9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4ec58975-4235-433e-969b-af3ae7b441a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4ec58975-4235-433e-969b-af3ae7b441a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4be9f949-d414-4dcb-8b50-14a75745f210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4be9f949-d414-4dcb-8b50-14a75745f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4c3f54c1-5406-406c-a116-214f14ef8b22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4c3f54c1-5406-406c-a116-214f14ef8b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_88663b60-ab24-45fc-a639-1138e3e95d76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_37f6afe9-3e31-4673-a56f-74d8c954f2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_88663b60-ab24-45fc-a639-1138e3e95d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2665caf3-2ce7-4f81-ab26-b62e73d2c2aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c0ecc292-2330-49a9-b607-d3a20c608574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c0ecc292-2330-49a9-b607-d3a20c608574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_82f54245-ee48-402d-8bba-f4d4c50fc046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_82f54245-ee48-402d-8bba-f4d4c50fc046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_00bcc75d-584b-4ab3-adf4-a624f55d40ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_00bcc75d-584b-4ab3-adf4-a624f55d40ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0b6d9c1b-7ad1-478d-8b85-2c2c9fee7d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0b6d9c1b-7ad1-478d-8b85-2c2c9fee7d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3182f14-0030-42ae-bb20-9e464b247420" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3182f14-0030-42ae-bb20-9e464b247420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0059f500-4071-4207-be5a-83c54c96784a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0059f500-4071-4207-be5a-83c54c96784a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_936414f3-1ad8-484f-ac12-3c0b2fc0e922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d386a486-196e-4ad0-87e8-8d3098cda90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_936414f3-1ad8-484f-ac12-3c0b2fc0e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2665caf3-2ce7-4f81-ab26-b62e73d2c2aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_78039345-9896-4532-affb-b136f582a18c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_78039345-9896-4532-affb-b136f582a18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_31c74653-9023-46ad-8aa0-63d470fd6e08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_31c74653-9023-46ad-8aa0-63d470fd6e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_76a823e5-5d01-4b10-bf2f-39a63ea47e27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_76a823e5-5d01-4b10-bf2f-39a63ea47e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07afe112-68d1-43cc-bf5e-f0b502b4b546" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07afe112-68d1-43cc-bf5e-f0b502b4b546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_365f96ab-f80d-4680-9fce-c1e956aa07a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_365f96ab-f80d-4680-9fce-c1e956aa07a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4b629824-8e60-42f8-b41d-9724fea26910" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4b629824-8e60-42f8-b41d-9724fea26910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3f1d88c5-5488-4215-8b6a-74c219d456e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4c1ab70b-6e91-4132-839a-50453658a793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3f1d88c5-5488-4215-8b6a-74c219d456e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a76c2ef2-6c5a-4855-af50-dd6165a09a98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a76c2ef2-6c5a-4855-af50-dd6165a09a98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:to="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_173defec-0f2c-4da0-abe4-52785c183b27" xlink:to="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f791fe99-13b5-431a-9724-2252a7109642" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:to="loc_srt_MinimumMember_f791fe99-13b5-431a-9724-2252a7109642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be5041ac-c73d-48db-a44a-a74e0f36707d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c24fae44-4202-45b8-8872-dda97d451f44" xlink:to="loc_srt_MaximumMember_be5041ac-c73d-48db-a44a-a74e0f36707d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0798221e-a4f4-4e6f-b9c9-4550545fc53b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cc774088-941a-4ed4-a0b2-b4451562ce89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cc774088-941a-4ed4-a0b2-b4451562ce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_789e30aa-30d0-4818-8747-a5f5071deead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_789e30aa-30d0-4818-8747-a5f5071deead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_cb9d9e26-f15e-4f39-990e-15fa1adbe971" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_cb9d9e26-f15e-4f39-990e-15fa1adbe971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1c31113d-67ec-4706-846c-682ffa2b68bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1c31113d-67ec-4706-846c-682ffa2b68bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f9b4f57-0e2a-42a3-8d0e-8dc4792b42cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f9b4f57-0e2a-42a3-8d0e-8dc4792b42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_83ee204f-124d-4e84-a7a7-9d6865498b71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f029cff7-eb22-41a4-b9ad-5523f50f724b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_83ee204f-124d-4e84-a7a7-9d6865498b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21da9a7a-8956-4dc7-b2e6-d8670eedbdab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21da9a7a-8956-4dc7-b2e6-d8670eedbdab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:to="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741f4c7b-112d-449a-8cbe-700180db899c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_69e6bd5a-f4c3-49b1-85f4-3311cce0b4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741f4c7b-112d-449a-8cbe-700180db899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_032c7fc7-7f05-4de5-91ac-95ab66ab8f79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_741f4c7b-112d-449a-8cbe-700180db899c" xlink:to="loc_us-gaap_RestrictedStockMember_032c7fc7-7f05-4de5-91ac-95ab66ab8f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549edf06-e0f9-4248-b8a8-b3e18aee6f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ee53bfa-1197-46c5-9d0a-b1ad003948ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ee53bfa-1197-46c5-9d0a-b1ad003948ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bcab891f-4c04-4997-b097-fd2c40b90677" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bcab891f-4c04-4997-b097-fd2c40b90677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37d6a1d4-bcab-4e53-89d2-60a7c8f413b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37d6a1d4-bcab-4e53-89d2-60a7c8f413b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a7be8c8c-be94-4c5d-8809-a266f9a54ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a7be8c8c-be94-4c5d-8809-a266f9a54ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ebd9f5d-5d18-4ea1-9dae-05ac54c93f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ebd9f5d-5d18-4ea1-9dae-05ac54c93f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_45bc5e01-92ab-4ae3-867b-7fdfe2d0cfb3" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_be50700c-891a-4286-a680-4c119094f250" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_45bc5e01-92ab-4ae3-867b-7fdfe2d0cfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8b1f7e1-8546-4440-b3ae-922de0443c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_18ffb016-c6c3-4972-aafa-358a01b39ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_18ffb016-c6c3-4972-aafa-358a01b39ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0f04b189-dd73-478e-8832-7888421f8b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0f04b189-dd73-478e-8832-7888421f8b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cc72346f-75e0-42d4-8df7-056d59b7eea0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cc72346f-75e0-42d4-8df7-056d59b7eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4d5133ce-8aac-4d01-9ef6-01931db5e833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4d5133ce-8aac-4d01-9ef6-01931db5e833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_62916209-c804-45da-9404-6fcb67c48229" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_62916209-c804-45da-9404-6fcb67c48229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_85f96926-8412-4e44-be8d-d1cdbfe0992e" xlink:href="dnli-20190630.xsd#dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c441fd60-3351-4b7a-b256-d6591f597f1e" xlink:to="loc_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest_85f96926-8412-4e44-be8d-d1cdbfe0992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract_2f899c31-4734-4ec6-84ae-e70aaa6a5c36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensationAbstract_2f899c31-4734-4ec6-84ae-e70aaa6a5c36" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4491c206-078a-4da2-983f-9324a2e4bb6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8916a70-2f35-4710-9dc9-e78d570d3c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8916a70-2f35-4710-9dc9-e78d570d3c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd34958e-a35f-408b-82f3-1586cef2158e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dbccbfd5-7bf1-4561-b502-03e88f91c87d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd34958e-a35f-408b-82f3-1586cef2158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a919b3b7-8eda-42f6-ac91-aa434a2e7ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6999f051-d351-4eed-a228-8b4db900be4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a919b3b7-8eda-42f6-ac91-aa434a2e7ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ebef931c-13a2-408d-a9c5-ebf017628e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a919b3b7-8eda-42f6-ac91-aa434a2e7ab4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ebef931c-13a2-408d-a9c5-ebf017628e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fec1705b-0995-4e83-8888-18e886bcf364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_658e2fd5-4138-4fa1-9137-1707d23f933e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fec1705b-0995-4e83-8888-18e886bcf364" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_658e2fd5-4138-4fa1-9137-1707d23f933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b909888a-e38a-4821-b5fc-15d3b4213caa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9c01026a-0e20-498f-8948-292f1c4884ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b909888a-e38a-4821-b5fc-15d3b4213caa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9c01026a-0e20-498f-8948-292f1c4884ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="simple" xlink:href="dnli-20190630.xsd#NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_95411075-6965-41e5-868a-e900d4e8f3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_95411075-6965-41e5-868a-e900d4e8f3e2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e81331c-d5b2-43b4-96a7-211a72382875" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_d0b79613-f160-4b95-a504-15bd33851930" xlink:href="dnli-20190630.xsd#dnli_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:to="loc_dnli_EmployeeAndNonEmployeeStockOptionMember_d0b79613-f160-4b95-a504-15bd33851930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_0b079081-16d5-4828-9a50-2ff643a9ef18" xlink:href="dnli-20190630.xsd#dnli_RestrictedSharesSubjectToFutureVestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:to="loc_dnli_RestrictedSharesSubjectToFutureVestingMember_0b079081-16d5-4828-9a50-2ff643a9ef18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_624ea6a5-c509-4df0-a7af-c42153c10399" xlink:href="dnli-20190630.xsd#dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48271d81-f615-497f-9e91-c9b21872f5d3" xlink:to="loc_dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember_624ea6a5-c509-4df0-a7af-c42153c10399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d2cdd01-aed3-412f-8f01-479c6e838da0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_388daeee-18b1-412b-bbc3-e1fd0e9a901b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d2cdd01-aed3-412f-8f01-479c6e838da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_951d4da7-bb32-4b65-8227-0c2028b670d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d2cdd01-aed3-412f-8f01-479c6e838da0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_951d4da7-bb32-4b65-8227-0c2028b670d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>dnli-20190630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:dnli="http://www.denalitherapeutics.com/20190630"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dnli-20190630.xsd" xlink:type="simple"/>
    <context id="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie6858c183ded4c66a5c4cae5464a8c49_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="if15afa2e1e5d465bbf364f085370272d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2735e2fbf77f4227a366ac2442ba6c00_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="icb687f8433d24be0ac5335c8c79c0494_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4b8beed483e6423490b503483915e4f2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5344b99e882d4934943a39b1eb4887b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie51bc7132b78422f88cfdae7c0aacebd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4817dca31d74448380859ba79c4b0707_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i722034f7c8044775b8f4e39ab11f9044_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i48efc218d04b44c5bd998761d74d0369_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i023b35c87938433a989302ec87e7ab6c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7b99abb30444402e9dd33c0c70fe40f9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i42701eeb1e1c4a17b979e71633036f02_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if166a88ab9ee4dda853e8603cb29e805_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie35e501f47d4427fbd9b62dc2c00e2dc_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i71648051f8714218b99562e835fa904b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3db11cdb9fdc4fda8887c70798fe0bb4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id8b1265cc2294fccb8fee9c3f57ef5ad_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9d14f1d11c174d03b34f14d15c06d0e4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idf0c5c2b81f14b2ba8bf900712c881a8_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i59e066377dcf4dd1909aa3b352723c01_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic3fbad4386a8427d8c6f6a3d5a7374ac_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9f9d4a6b28cc473c805fb4ad62ae184b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i412e26418ded47729bc5c01e358338bc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i654d7777e96c48528ad08a99690746d9_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ie023db07ba2245d89a07be32e19c8699_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ie57571f426694fe089fe9cb5f12584ce_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if00aa4b8cda04136b378e14fb7af25df_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ib3637006edc4480da3b4668dd1f931c1_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ib7131d5c68734000965acd7cf27ca3a6_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i4b047174d458400c8d2c9e6554f436c6_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i7de42ac379c3456094525bb4ad42c025_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i25146bfdcf2a47919d391a395b32bece_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="if624bfc7618444aaaee3b88445cdcd15_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ib41e9af92e2b4bce9bf0ea68da08021d_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="iae5650d2914b4b4a8c62050aaaa3c4a7_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ib74065ebcb8745068d2741baeaf0b579_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i9f972032aeb2409db70c5438d495f50e_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ie61e2d55e75b47bf9f99395f341b50b6_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i73b1ab5fa47f47a3a75b2baeb7eb3662_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i823adbb4c4d94559b833efb563159c96_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i6abc0c7c5a6f4e6ea981285f7ae4c287_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="ie0b119c34dd944daa20fa4eaaa3d2ced_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifc8c6e58df014428922e55023f630ade_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i534bf8602525455db76397bb865e573f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i351b20a5b439409598aa2bedf197448c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9d35607870c64688827351e700854bef_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i77531d54e5404598a5078438c8677b65_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i564db519a26f4cb8a0fb1d4e669911f2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i039ece834d1c4019baf20e251e2da235_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7db3561ea15848dab72e9c69da84ebf7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i394557b4e90043e2a2085e2207e5f704_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia647cd1b2d9a45278c18b341c2434e5f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ied7a9a68ed1e4b98bf5fcf82a0334cc8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i646027daed3e4e16b08888af3c67909c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iac821d5ca4ca49dc813f6db1babf4665_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib7fb855d6104424da5e93287267c6ac0_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie3f2152514a74f9691322d7bb19989c8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2188c27fed024d2d9d5cec962236ec1c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if01b372be06641fcb73d69acee794292_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iee33812b6d5f432a938b1e20a417c276_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i32984200dcc845b2a45fea17a3812a06_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id738d34d6e8e4df2b2e0892ca8583817_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie81ed0dc4a654555b4dfaf4dcc554425_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia36129c3c0fb4ec89ee0b9be9bbc5bff_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i748d5ac449c24510a0986355b63cb280_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib33f0957ce474dd592ca5b6c23e5ef19_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i16a6c38d032f484a9b67307311107bd7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8323e729c3744b6984ff8264d437b124_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i76f0f26e09b64eacb441ec24cd77394c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id3042590e499441eac62f97939bd16f4_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7cc97570e5b24fa1a75addc5f860af72_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if168f11e35b14d38bce3e5890ebba5d9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iad1069dc0cad4a3ea5572938e4106e4c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8389b77f46614b0baac4260fdedf92b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i75c93d80020f42b0ba67cdc0e3a25b2a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2aee8333029a4f6c8e7f1247f704004a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if5c9e6e09b474edc8ac0da0e91d2dd01_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i57c0452366984f519dbceb86cfc31faf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie776c9afea3243b2848d752347f688f4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia9c75b127ec34f38865969acc6d34c86_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i220e6c77c75d4bfa83017f0736091135_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i79715623139e4d188ee2ddfaff3f8843_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3d8717aa8b6241c5a643413d64130b63_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i993e3d3eb54f4a728171781129ded3bc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i334c9164544d47ed90f823053546feae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i58cd710ca1ca48d0bc2fb6d628a11664_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic48ac7d1c4324712a1e1298222a87945_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9ae0df8b808c43f280dc28bec5cb444d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id73851e2673146dcb0a9e092ab545074_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2699ac9a6b4a4f988e31180fb9faa2e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ife73f39b1eae47ee85a5a9584ee232ae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i27601e3031d1415087e9519936e0588a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4803624bc1af45deb9ea98f47e4bef89_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i46e4decf7be84439945e9ce2850dc451_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id1d2b210ee09411c9fa11bbd2deba373_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i66b7162b4cdf45099ea769306a7bc7ba_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6e221499c55d4599a35ccd9f1aba1e74_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iadb76427e3334f2b8e9ec593be008827_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3a911ac92d6942418c24d25c2c06cc32_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i74b8017f6aa641f5a8ba1117e78c4395_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i30bc951a4ed74f0ea630f8070210ce78_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i080696e2011c4cebb6a89ccdbaa3ee8d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7fdf1cc314e547498192214867642863_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie41ba916828a4459913741d70d7bc3fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i372598dc17214865814f1254ebfb5161_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7640f25a11a54310893f0d59b851a625_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie6ac2039e8dc42bead781da7dcf42fd1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i497df5ae51894ba7a5a6422af04376bf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibe03351931fd4b02bcbdf4d454a976b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iec24689629b54d34951dd76fb613749b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia035bfff287e4ca591f2a341c56b6b2d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i49c31645a10044e59139a51722cc253f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3a14322869be4b658cd4cde6e287c652_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ica751d3b16db4f8ea312582a7139852b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6c65238201f2438099ea08259947cf04_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="idbdfa55cc0574d5b9693592150a1b134_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iae5e02b2d6aa49058387f1cea12b93b3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id2e2a799afac4657bf2990fa9faac6e4_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic132aa6373a64c79b5f996854ca9bc8c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2c25e606153542d88af272a7ffac8a0e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1434d14831d0404caa8e13694f7f25be_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if0a0f1d286ed4f01b14d389eca094eda_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idc1014a17a2a46eba10d842ec1fccd9b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44b6982078fb47e882b2de8e34ef5adb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2e891a3823f24de4a4f4b99b41087154_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6d9124e0422c4ff1b46cd042394237b5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dnli:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia14c2927959544239a3d263ec3dda43e_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i48082d8a3fa74a8c95c2264e9a347d42_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardEurosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i234d3a677c614b128ac23ca5c79da8dc_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardBritishPoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id1232cc1f5524033b330344d942beb81_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dnli:ForeignExchangeForwardSwissFrancsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8674d4a62e2a492fa95fdbeefacd0bad_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib9f18818b52f4aeabfbf7dbbb4aba705_D20160801-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i55d1fcfacd0d4b0db994f652d3301667_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i647555a3917440f38eef6a6989f68269_D20160824-20160824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">dnli:ExerciseOfBuyoutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-24</startDate>
            <endDate>2016-08-24</endDate>
        </period>
    </context>
    <context id="i2148ac99ab3d4a618499bc77ee8d8c62_D20180530-20180530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">dnli:ExerciseOfBuyoutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-30</startDate>
            <endDate>2018-05-30</endDate>
        </period>
    </context>
    <context id="i958b3c7abe6a45a592e44305c54c7fb4_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i51ca5f46b88d4457b2266e87e2008a2a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib98115cad708471ebe459199e2f80f46_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6f5e0ab57a754c6a92c0fdd5ab774b2d_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i02c7d3db28004ce59eb812568e573405_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i975bd76e0cd24e4c801c23d18da1297b_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ib519012f763b4591aa20a39b32e7dd07_D20160824-20160824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dnli:CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-24</startDate>
            <endDate>2016-08-24</endDate>
        </period>
    </context>
    <context id="iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-20</startDate>
            <endDate>2018-11-20</endDate>
        </period>
    </context>
    <context id="i5c733524c4364bb1abc239f59033a6be_I20181120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-20</instant>
        </period>
    </context>
    <context id="i9cac8973f2034a84af0e4eb2891e8341_I20181120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:CNSProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-20</instant>
        </period>
    </context>
    <context id="iaec92903cf114ddf965cde15c398dded_I20181120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:PeripheralProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-20</instant>
        </period>
    </context>
    <context id="i507009778f314351bad25199f392e188_I20181029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-29</instant>
        </period>
    </context>
    <context id="i06e6fd6fd17d48a7a5c80813484b128b_I20181029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:DenaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-29</instant>
        </period>
    </context>
    <context id="i3cb8f5ce74fd4b1b890b44970091705b_D20181001-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2052c42ed02b4803ac262cf9409d6d92_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain xsi:nil="true"/>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if02f20c18d7e4a85a122b3bb744dc9bb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain xsi:nil="true"/>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8c76dce5aed14afdbce822ee27041a9f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iba03e85f7755476dbbc016d142e2579a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i41156f6db385494f9b24bd04dcc38e24_D20181001-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieb617794c10c4d4ba7d9d482b9cd58bc_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-23</startDate>
            <endDate>2018-02-23</endDate>
        </period>
    </context>
    <context id="ic542e2b47d374ba59c6ab567374c8c94_D20180103-20180103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-03</startDate>
            <endDate>2018-01-03</endDate>
        </period>
    </context>
    <context id="ia22967129e234978a541856d93c716a7_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="ia53bec4ac3404ce2b6767a4da564148f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3f1aebd881a6473d8f034dc7cd3ba883_D20180103-20180103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-03</startDate>
            <endDate>2018-01-03</endDate>
        </period>
    </context>
    <context id="ibc5ea44d386548708e70442d3abb3e3c_I20180103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-03</instant>
        </period>
    </context>
    <context id="id111363c81ee4dffbaa484859d2e9554_I20180103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-03</instant>
        </period>
    </context>
    <context id="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-23</startDate>
            <endDate>2018-02-23</endDate>
        </period>
    </context>
    <context id="ifadb9641e1d64862836bde0c518e5c56_I20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dnli:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-23</instant>
        </period>
    </context>
    <context id="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-23</instant>
        </period>
    </context>
    <context id="i506ba94099c0474082d55a807783f8de_D20180101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2b83a26513784d7ba644b0159e2fcac2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i327284cdcb314428b0f05baf0584c173_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7c2bdbc9872a42678f000e70d3eb04e1_D20180101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i121aa99f2d3f4692bdd510f9652ac846_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2ece0b562fb24861a00cc1837d3ba44d_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="idb48aaf3a1cf4e36903d0037ad367e4c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4ec13fd38f514239afa935809142d525_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:TakedaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i93f1e0b6d51d423fab44d10992a22439_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie0a29ec79a2640e5a067988c35bbf456_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ieaa172b849b9451881f587516f825b58_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8b6d26112ff24d9ab029f080a339e130_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:AlzheimersDiseaseServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i973a1b238c6743cf8760ffc6932c3a7e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1affd54d523b488da0673a88c0036970_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i50e589b4bde248369e6e024a7f4abb85_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3f7fab35ed3247c4a11fd24731d5db87_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dnli:RetainedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i86c1aab124cf41eab4654a55ce7d0456_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3ff05dbaad9645c284a3cedd8231323a_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i02d0ffc88019497f86735d349075b74c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib97dc1f800de421eb8179a2c93529853_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if131cb24360a4f85bb336dd0ab7af8b9_D20160617-20160617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-17</startDate>
            <endDate>2016-06-17</endDate>
        </period>
    </context>
    <context id="ief7842b7854c410c9c6bb0e061d46cec_D20160601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i38c69c189be94bfc9380598800c85b4c_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ia9fe92c33d98463bba6b004929024cfa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6ff9d49b979f434281543ef489df6e3c_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i0036869090d6435dba566fa93d050600_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dnli:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dnli:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0dd82aee18cf4b4d91431b4b49ef0bdb_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="i0de68e60891642eca083500a43ec45ec_I20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-02</instant>
        </period>
    </context>
    <context id="id56b451693a4495eaac87af0665021d3_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="i2634280b279f4601af826b4c8125dd23_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="ic2c4f0ef14eb44cd94cfc60e492db814_I20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-02</instant>
        </period>
    </context>
    <context id="i9f8dc4dba49b4160b31e6e823e1ae788_D20180502-20180502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:HeadquartersLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">dnli:LandlordFundedTenantImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="i6adb2eb42e59415094e9c0d4ffb38967_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dnli:NewPremisesSubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i293b5b178de44724a3a09c4a2268ccae_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifcee909d65844bdd8691aaef6db01445_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i195078f2e63c4ec69a1f3aed2a49cca6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i65a3e9667de048f9be4f3e9b194a89da_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i380397739fb3409c84068db1cde52240_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if3fd410c4ab04f2a98010ca624256620_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">dnli:DMSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i7d1a63d9fd9048e9b346a1bb1e5b53be_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie3d6c473afb5460780db3507a8b37630_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0427708156c3454cb4eb96e9b7ea3878_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i1fc1cd06135f47ebb307c315c07c68a8_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iecff526c59e7452aafbe14147f3cc250_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i32a76c5b5b6e4f3f9cd6493d2dba156f_I20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="i5e0e4017eafa4b21a497bff216646578_D20150501-20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="iedf7537799d4426a9667a6f97c5239eb_D20150501-20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="i82d03abee79c4854acb028d0eef7bf6b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ieea49b8c39144a13b75a300520691ead_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if52074d4e46047fdb42400ddf9179e83_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dnli:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifceb656364a74a0da5c6b45c4e52919b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3f3fe6755fa445a7b223008c32301c1a_D20150801-20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="if4cc341fdaab4fb1baca8e685795587f_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id498dc8dfd914e4ca6892bfb92be83bd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8ef8038c831e4d59a9459cb27f4f1ec8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifb1c8f46d9a3426091ee2103297afede_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib89660bd12204c74b680b13055456d71_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:PerformanceAndMarketContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4b8980df381840e981e39e869a8ad187_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia6a1246830c7445e9ce63b86b50115b5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i33146e3241854f64a4965054ea62ee6c_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i71431700ff4c41c698876f5248f1b209_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i33aae1a9291846d08a77fafcbb0fd48f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic58d3dfd7fcb4f99a54807dfac3b6669_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if1f6b3468396492fb70d28ad0e7f8b98_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ie1b4ec6e313c422fb982eb70ccc6089b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dnli:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8d2e60ed90c84ab2b33750989f3caf7b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i81c40a2236074822a36030b30b61a38c_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i1b68413bf0b9461591e8c59a2ccb9464_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i362003e4d15e477299173e68bb66528d_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ib0f2e8ea17014067925b92520d7e19bf_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id4633b220bff4b1ea513d03256f027b0_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i05bfa152469e4c2a8509fcde1cfa0f93_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieffd6c376be94ea4a96216622c548e7f_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if979d5313f0948369e6c21ef7aec9f23_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if14c6b440b8f48a9838c5d9fcdb9c515_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5c6b993b5bde429e9a7fba5ab9832fca_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i3d126a8dcd56440998101048ca785846_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i275b58f10ba74daeae1286217a8a4e5d_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i24c9b655a8e8443a87f7a3e134f345ba_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia04b255ecd884d8e9200605be79d6280_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="iedf8f1f2f33e4108b9baf4e4d8091e2a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i237c5ee93e0b4218a0aca4f2977365cf_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i1b682f4a3a5c487695cf4824ecff6284_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8afd96134f0548538b390aa584b11fbd_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0fd6c4f1d91440f7aab878612276cb59_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i7f9cdfc6602e4cbcbb2d61b338e5e9d1_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i000b38f6d8874a1ba6da55900807e8e1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie3c2ef2c49884bb4b4428fbe8e81d56e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id8b5ff74e3d147f392767ecdbd341aa2_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i7196f17f798b440fb5034d6f6a84eb2e_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:RestrictedSharesSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ie5d5f8a792ce41f6b36480b7307d2e65_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id99aa73c5353433e959eff9dba13f059_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i97e55800d90541c4b977630444bbdbd0_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="iecd2245025b2447a92a8217ee5cde65c_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dnli:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dnli:Segment</measure>
    </unit>
    <unit id="contract">
        <measure>dnli:contract</measure>
    </unit>
    <unit id="derivative_instrument">
        <measure>dnli:derivative_instrument</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="program">
        <measure>dnli:program</measure>
    </unit>
    <unit id="targets">
        <measure>dnli:targets</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGFibGU6OWQ0ODVlN2QzNDAwNGNmMGEwOWU5YmYxMWM0YmNhZWMvdGFibGVyYW5nZTo5ZDQ4NWU3ZDM0MDA0Y2YwYTA5ZTliZjExYzRiY2FlY18xMi0xLTEtMS0w_336e435f-db69-4db2-8604-0514e189f9b0">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGFibGU6OWQ0ODVlN2QzNDAwNGNmMGEwOWU5YmYxMWM0YmNhZWMvdGFibGVyYW5nZTo5ZDQ4NWU3ZDM0MDA0Y2YwYTA5ZTliZjExYzRiY2FlY18xMy0xLTEtMS0w_163b6021-5c25-4210-91f6-a49c9547bf4e">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGFibGU6OWQ0ODVlN2QzNDAwNGNmMGEwOWU5YmYxMWM0YmNhZWMvdGFibGVyYW5nZTo5ZDQ4NWU3ZDM0MDA0Y2YwYTA5ZTliZjExYzRiY2FlY18xNC0xLTEtMS0w_00fdc4e4-c9f6-4593-8815-72c12a1828fd">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGV4dHJlZ2lvbjo1MGZmY2Q5MjcxMGU0MzQzOTQ0NmY1M2IzZWJhZmFhOF85Ng_f5574897-b88b-41d6-9e71-90393f994eef">0001714899</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80L2ZyYWc6NTBmZmNkOTI3MTBlNDM0Mzk0NDZmNTNiM2ViYWZhYTgvdGV4dHJlZ2lvbjo1MGZmY2Q5MjcxMGU0MzQzOTQ0NmY1M2IzZWJhZmFhOF85NQ_1ccadd3f-30cd-412b-9f94-e332eacdaf58">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMi0xLTEtMS0w_5a1ce9c6-dc94-4455-9bf0-ee23b0b7bc8c"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMi0zLTEtMS0w_c186d26e-087d-4c62-a266-e0b88424358d"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMy0xLTEtMS0w_42c3d512-30fa-4a4b-8f3d-602075e6a65b"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMy0zLTEtMS0w_490c43af-b32f-4b83-a8f8-dd01f470062e"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNC0xLTEtMS0w_7c97def0-a7c3-4c3e-91fc-292e9e6f0791"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNC0zLTEtMS0w_5f79195b-67ef-4937-8eaa-15310d07ed94"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNS0xLTEtMS0w_814db2ca-436b-4004-a1de-64edaac49f87"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfNS0zLTEtMS0w_fbdf2eb4-f453-486f-b966-79bca5a6e213"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOC0xLTEtMS0w_13a687e3-5ac9-433d-9ecb-2127e3fa2a07"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOC0zLTEtMS0w_2909b5c4-31eb-4f81-9d64-1da26a04256b"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOS0xLTEtMS0w_79453393-0a0e-461a-9ee8-d59870a3ca3d"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfOS0zLTEtMS0w_4839c7a1-94e3-435a-acb8-96d32440c3c1"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTAtMS0xLTEtMA_2ec4c31b-795d-429a-a7d5-57cead3a3512"
      unitRef="shares">95656896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTAtMy0xLTEtMA_37c9cbfe-9f00-4512-b5ea-82b3cefd0a75"
      unitRef="shares">94662435</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTEtMS0xLTEtMA_b199afbb-3b0d-4d14-b277-50546066c114"
      unitRef="shares">95656896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xOS9mcmFnOmE5YmFmODc2YmJmYzQ3NjE5NGUzOGY0MzgzN2Q2M2M4L3RhYmxlOjhhY2RhZTQwNjA4ZjRmZThiMGJlMTQ0OTJjY2JkZjQ3L3RhYmxlcmFuZ2U6OGFjZGFlNDA2MDhmNGZlOGIwYmUxNDQ5MmNjYmRmNDdfMTEtMy0xLTEtMA_4d78b9fc-81ca-4f09-8e92-928e2234d407"
      unitRef="shares">94662435</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iecff526c59e7452aafbe14147f3cc250_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTIzMQ_89106c99-db8f-42c3-9be0-ac8e95402417">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iedf7537799d4426a9667a6f97c5239eb_D20150501-20150531"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjIwNQ_7426f688-b493-4e9a-8e34-f30a5275909d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dnli:PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition
      contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjE5Ng_40ff6178-4587-42fe-8169-938e295fadf9">P1Y</dnli:PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS0xLTEtMS0w_297fdf1e-71ba-4856-a7b3-1a3f4759e826"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS0zLTEtMS0w_83a7f4cc-1b0f-4d45-9caf-d1a84c726398"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS01LTEtMS0w_a010da65-4a88-4fde-a8d2-eff822b11732"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjBmNzcyMDFlM2RiYjQ5YTI4M2M3YzVmZGVkMDQ0NzcxL3RhYmxlcmFuZ2U6MGY3NzIwMWUzZGJiNDlhMjgzYzdjNWZkZWQwNDQ3NzFfNS03LTEtMS0w_35a114dd-6e1a-48e5-ad1f-393db1012916"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if14c6b440b8f48a9838c5d9fcdb9c515_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy0xLTEtMS01NjQw_fe6fdb89-8d97-4e81-a92a-21e3ff764c97">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5c6b993b5bde429e9a7fba5ab9832fca_D20180401-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy0zLTEtMS01NjQz_ca6563a6-e8d3-4a39-9ba6-d24aa1c87551">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3d126a8dcd56440998101048ca785846_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy01LTEtMS0w_ae4869de-aa71-4954-86e9-8e62fb0431e6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i275b58f10ba74daeae1286217a8a4e5d_D20180101-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMy03LTEtMS01NjA4_6a601b13-b269-4a07-a50b-1412c1e749a9">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i24c9b655a8e8443a87f7a3e134f345ba_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC0xLTEtMS01NjQw_f33c7499-9aa5-434e-a3bf-8a80b1f843d5">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia04b255ecd884d8e9200605be79d6280_D20180401-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC0zLTEtMS01NjQ0_7c603eed-a4c8-41a1-a4a3-1ce9e8692da6">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iedf8f1f2f33e4108b9baf4e4d8091e2a_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC01LTEtMS0w_93765f45-0df3-47d7-8ef0-087e0d3edaa8">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i237c5ee93e0b4218a0aca4f2977365cf_D20180101-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNC03LTEtMS01NjA4_89708f6b-1053-46f9-9b0a-215d2dc30032">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi0xLTEtMS0w_61abcd29-f79a-4d77-97d0-dce00846224d"
      unitRef="number">0.669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi0zLTEtMS0w_bdbc3cd0-c0c8-4ffd-ae86-8b902dc40e69"
      unitRef="number">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi01LTEtMS0w_a39c1e78-e633-4922-aa23-028663ebaf99"
      unitRef="number">0.669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNi03LTEtMS0w_7c8a9080-b766-448b-aa15-4bc9f3ee5db0"
      unitRef="number">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy0xLTEtMS0w_3094245f-57fd-4404-9fe2-b4e30e791fda"
      unitRef="number">0.778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy0zLTEtMS0w_c4a02566-f0d9-45c2-8ad2-d9f24686e7ec"
      unitRef="number">0.856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy01LTEtMS0w_13fb03ee-9cb7-4fab-82ed-b1440da45acd"
      unitRef="number">0.778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfNy03LTEtMS0w_db6f9e12-a033-444a-bcdb-f7465dd50786"
      unitRef="number">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS0xLTEtMS0w_be5f0c57-c9a0-4cc0-8ab4-adbc1427cde4"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS0zLTEtMS0w_3f94851e-59ac-44d0-b090-14a92218b135"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS01LTEtMS0w_607ffe03-8214-42a8-9fc1-e2b6ff34aa9c"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfOS03LTEtMS0w_af59f524-1bff-4cac-9658-4ddf1a086cca"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtMS0xLTEtMA_deffeca3-9045-4263-a254-caa1c97b1858"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtMy0xLTEtMA_98d145e4-35a3-4385-b1c1-d4f2018611c2"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtNS0xLTEtMA_7ba3d8f9-8477-4481-b4b1-4ad676c1ff65"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82Ny9mcmFnOmY5OWQ1Mzc5NjQ0MzQxNmRiMzE4M2RlMTJlZmVkZGEzL3RhYmxlOjA2ZjJkMTcxYmNkOTQ0YjU5MDBjOTE0NjZkMDg4YjIyL3RhYmxlcmFuZ2U6MDZmMmQxNzFiY2Q5NDRiNTkwMGM5MTQ2NmQwODhiMjJfMTAtNy0xLTEtMA_9b6461ce-7304-4281-b81f-538c5aa6ead0"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <dei:DocumentType
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV84Nw_b34ef696-0eb9-4909-b41b-a0d6d8d02130">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MmU0ZjA5MTU0NGFkNDQwMjhlZTZkMjU1NWViZDQ3MWEvdGFibGVyYW5nZToyZTRmMDkxNTQ0YWQ0NDAyOGVlNmQyNTU1ZWJkNDcxYV8wLTAtMS0xLTU3NDI_a1b279fa-7e57-4331-a322-6c8602c60c9c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8xMzc_d7d92a4e-8f5d-47f7-b2f4-47bfcf2cb487">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6ODM1YTQ5ZWNmNjg3NDQ1MDhiN2MxY2ZkNDZjNzlkMDMvdGFibGVyYW5nZTo4MzVhNDllY2Y2ODc0NDUwOGI3YzFjZmQ0NmM3OWQwM18wLTAtMS0xLTU3NDY_8d031b4f-7a66-481a-9bf3-aec96c564f15">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNDg1_fe496df3-b887-43fc-b744-405d47348fbb">001-38311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNTk_b4c08ccb-b281-4f1b-8b07-47f0f0ae04f9">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8wLTAtMS0xLTU3NTI_fc6b6bd1-1faa-4618-9fcf-6b5e1216700a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8wLTItMS0xLTU3NTI_65b8ad7b-6523-4938-a0a5-fad5d86c442f">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTE5_2e5d63c2-3608-42e8-bc18-bfdff28485c1">161 Oyster Point Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTM0_67ebe106-60b2-41de-95b6-3f09ec136181">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTM4_cc159594-544a-4023-abff-0d28dd2b371e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6NGE1ZjQwYjBjZDg2NGNmNjhiNzQ1MTNiOTBhNDZmMWIvdGFibGVyYW5nZTo0YTVmNDBiMGNkODY0Y2Y2OGI3NDUxM2I5MGE0NmYxYl8zLTAtMS0xLTU3NTYvdGV4dHJlZ2lvbjpmYmFiN2ZjOWMyOWM0NGFhODgyZmQ1ZTQ0MzUzZWNiOV8yNzQ4Nzc5MDY5NTQ1_13282dc9-8aa4-4edc-947e-d8a74ace74f3">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNDkw_a7f77db4-85b4-4cc3-b193-5fabd94a6213">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTAw_7134be4d-b439-4267-a019-1eab1cb7540d">866-8548</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MjQ0NWM0ZmFhNDlhNDE5Y2ExODU4NmY5ZGM4MDE5ZGIvdGFibGVyYW5nZToyNDQ1YzRmYWE0OWE0MTljYTE4NTg2ZjlkYzgwMTlkYl8xLTAtMS0xLTgxNDc_f7c6feaf-22c8-4ae2-b71a-6ee73616b9c1">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MjQ0NWM0ZmFhNDlhNDE5Y2ExODU4NmY5ZGM4MDE5ZGIvdGFibGVyYW5nZToyNDQ1YzRmYWE0OWE0MTljYTE4NTg2ZjlkYzgwMTlkYl8xLTEtMS0xLTgxNDc_f740d099-c4a1-4307-baff-ba421ce9ae62">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6MjQ0NWM0ZmFhNDlhNDE5Y2ExODU4NmY5ZGM4MDE5ZGIvdGFibGVyYW5nZToyNDQ1YzRmYWE0OWE0MTljYTE4NTg2ZjlkYzgwMTlkYl8xLTItMS0xLTgxNDk_0945c449-901e-4c6e-acd0-4f7e9cedc72c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTA1_7a600c8a-befb-42b3-a53b-85ad91944690">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTEw_2b5443a4-d05f-42b7-9ea0-0fc62c0bbb7a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6YjNjM2M1M2YzNGExNDZjZjhhMjc4NDcyZDM4NTI5ZmQvdGFibGVyYW5nZTpiM2MzYzUzZjM0YTE0NmNmOGEyNzg0NzJkMzg1MjlmZF8xLTItMS0xLTU3NzE_7b7244d0-17f6-4ec2-9978-1695a4791b36">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6YjNjM2M1M2YzNGExNDZjZjhhMjc4NDcyZDM4NTI5ZmQvdGFibGVyYW5nZTpiM2MzYzUzZjM0YTE0NmNmOGEyNzg0NzJkMzg1MjlmZF8zLTMtMS0xLTU3NzU_ecc9d675-1325-437d-8aab-def464097365">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGFibGU6YjNjM2M1M2YzNGExNDZjZjhhMjc4NDcyZDM4NTI5ZmQvdGFibGVyYW5nZTpiM2MzYzUzZjM0YTE0NmNmOGEyNzg0NzJkMzg1MjlmZF81LTMtMS0xLTU3Nzg_f539ee58-e650-4b9a-84cb-3ed32fbd0a24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTE3_c18a04c0-f655-43c3-b86f-eb606ad719a2">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yNzQ4Nzc5MDcxNTE2_e9773661-af34-4f23-941f-81f0164a80fa">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie6858c183ded4c66a5c4cae5464a8c49_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xL2ZyYWc6YmFlZTZlYzQyOWJkNDczODk1MDM5MTA2ZmNiNzExZDUvdGV4dHJlZ2lvbjpiYWVlNmVjNDI5YmQ0NzM4OTUwMzkxMDZmY2I3MTFkNV8yMDA5_1a1fd019-00e4-4e7f-bdd5-1adf737a83fb"
      unitRef="shares">95841615</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMy0xLTEtMS0w_3305bfd3-00e7-43ef-9a81-0e77f6c5f393"
      unitRef="usd">62936000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMy0zLTEtMS0w_ffb51c88-1758-4ed8-b0a6-99fa3fe9d5e0"
      unitRef="usd">77123000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNC0xLTEtMS0w_c0571dc6-6abf-44e4-bf80-1f4b3e95a67d"
      unitRef="usd">415667000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNC0zLTEtMS0w_8dc6ee09-ad46-4b72-a2f1-73433efa7d52"
      unitRef="usd">387174000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNS0xLTEtMS0w_fa9e7369-062b-4649-b8f7-1e45658eb108"
      unitRef="usd">17378000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNS0zLTEtMS0w_a5f01c3e-74ff-4d2d-97c7-eb105d409378"
      unitRef="usd">16539000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNi0xLTEtMS0w_b19eb6cd-1483-4dfa-a7ed-cbc5324ce68e"
      unitRef="usd">495981000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNi0zLTEtMS0w_196c5a16-7798-47f0-b2c7-bb71cb920d00"
      unitRef="usd">480836000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNy0xLTEtMS0w_e3288a77-b370-4fab-97e5-7122da38dffd"
      unitRef="usd">55832000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfNy0zLTEtMS0w_e4c6c50d-89f9-44f3-be09-3dea5b956c42"
      unitRef="usd">147881000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfOC0xLTEtMS0w_62b5e0cd-de1b-4350-a05b-a982a8048938"
      unitRef="usd">47195000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfOC0zLTEtMS0w_26b95d29-f54a-4d55-891d-7b9054972855"
      unitRef="usd">25162000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfOS0xLTEtMS0w_46583d91-add1-4556-85e1-0364012f2b0b"
      unitRef="usd">34647000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTAtMS0xLTEtMA_50dfc09d-57f0-4036-a8ac-f40ff1d76730"
      unitRef="usd">3949000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTAtMy0xLTEtMA_f8fff112-95bc-40b0-88dc-eab55afc5131"
      unitRef="usd">8105000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTEtMS0xLTEtMA_8d39813b-476f-4db1-a4da-a02b16357b98"
      unitRef="usd">637604000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTEtMy0xLTEtMA_eeea7464-50c0-4cd6-a2e1-568a4a8678e8"
      unitRef="usd">661984000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTQtMS0xLTEtMA_13d3dcf7-a498-4ea6-8a8f-e9ec6b5846b5"
      unitRef="usd">3931000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTQtMy0xLTEtMA_5c0013d8-8589-48a6-8158-5d18d21dabf1"
      unitRef="usd">1891000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTUtMS0xLTEtMA_df155444-e355-4d51-80e1-9142c15eceab"
      unitRef="usd">13793000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTUtMy0xLTEtMA_ca110a27-3168-485b-9de3-2ef8afd6efca"
      unitRef="usd">8520000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTYtMS0xLTEtMA_e47725e6-9185-44f4-9693-f0bb7c92be62"
      unitRef="usd">4092000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTYtMy0xLTEtMA_a3d4054c-4422-431c-bf78-4b2d09b4a810"
      unitRef="usd">9952000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTctMS0xLTEtMA_70cf551b-1910-4a8a-afd9-cfcb180c41b0"
      unitRef="usd">22598000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTctMy0xLTEtMA_a0970aaf-9e55-46ab-ac3a-1f2b4367c7fa"
      unitRef="usd">11427000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTgtMS0xLTEtMA_b8f4bec9-7fe7-484c-a3cb-4f529efc7851"
      unitRef="usd">2135000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTgtMy0xLTEtMA_7afeb8bd-f8cb-4b79-90bb-8d602096883d"
      unitRef="usd">996000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTktMS0xLTEtMA_404657f6-bb01-47b2-9409-4fc907cec0f2"
      unitRef="usd">46549000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMTktMy0xLTEtMA_386e1993-539b-4310-92fe-be70b03e4aab"
      unitRef="usd">32786000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjAtMS0xLTEtMA_1b8a11eb-734f-4c1d-a9ec-92abec07d44a"
      unitRef="usd">44563000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjAtMy0xLTEtMA_3e618d55-1a99-4bb0-82de-ff365d8d3b53"
      unitRef="usd">57350000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjEtMS0xLTEtMA_1c011e58-55ac-4d32-9b04-3bf3900f2406"
      unitRef="usd">70911000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjItMy0xLTEtMA_eb87e274-2654-4a62-8bb4-8dfd577fa0f5"
      unitRef="usd">24532000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjMtMS0xLTEtMA_cf43ff41-bda1-44e9-92d0-34d0d30b2c16"
      unitRef="usd">408000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjMtMy0xLTEtMA_40f1f356-afe5-4155-95ea-e722249a7c0c"
      unitRef="usd">471000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjQtMS0xLTEtMA_1577e81d-26c2-4228-8d27-0ff983664266"
      unitRef="usd">162431000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjQtMy0xLTEtMA_3dea6c5f-3f68-486f-83c9-1de0cd60ccb7"
      unitRef="usd">115139000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjUtMS0xLTEtMA_6e71afaa-5d61-4f86-8b4e-c1118321442b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjUtMy0xLTEtMA_b9519d55-4f53-49a9-90bd-444506df9631"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjctMS0xLTEtMA_c54496f0-4e3b-40df-a9b9-7f59282865dc"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjctMy0xLTEtMA_801d8fed-7804-49ab-83b8-e68d274de15e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjgtMS0xLTEtMA_4851548c-7440-4ff1-b2e2-fb2ca2a57fb2"
      unitRef="usd">1283000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjgtMy0xLTEtMA_65f7da44-53e0-430d-943e-5f7e363bb30c"
      unitRef="usd">1273000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjktMS0xLTEtMA_3230e611-fafb-4459-b5cd-0b9f7733355c"
      unitRef="usd">798277000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMjktMy0xLTEtMA_9b78af62-736f-4408-bd6d-5e83fb5f5f87"
      unitRef="usd">774158000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzAtMS0xLTEtMA_267be9c0-db92-45af-a52b-a3724c17e922"
      unitRef="usd">879000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzAtMy0xLTEtMA_8be65cd1-c39a-4777-96d6-32e7a297e237"
      unitRef="usd">-649000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzEtMS0xLTEtMA_2b5ef3dd-7175-4b98-9a4e-04b9a48a00fd"
      unitRef="usd">-325266000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzEtMy0xLTEtMA_abc2a8c6-72ad-40a3-8e35-752646cbab38"
      unitRef="usd">-227937000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzItMS0xLTEtMA_c86ec445-1ff1-43a1-85d4-d0936dbea966"
      unitRef="usd">475173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzItMy0xLTEtMA_21a73f65-e8c8-4f73-8a65-cf664727d706"
      unitRef="usd">546845000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzMtMS0xLTEtMA_1c550a1e-91d9-4545-9f20-92d1c62e6673"
      unitRef="usd">637604000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8xNi9mcmFnOjg4YjZhMzlhOGMyMDRhNTJiMDRhZTc3OGNhMWViN2Y0L3RhYmxlOjExMzU5OTBhNGFhMjRkMjJhYmMxN2MwNjM2NDAwNTJjL3RhYmxlcmFuZ2U6MTEzNTk5MGE0YWEyNGQyMmFiYzE3YzA2MzY0MDA1MmNfMzMtMy0xLTEtMA_59a24f0f-66b5-440a-9db9-b194d5df5420"
      unitRef="usd">661984000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi0xLTEtMS0w_8b9bb41d-98f8-4be7-bbef-b777ae33fa04"
      unitRef="usd">4197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi0zLTEtMS0w_22ee099a-2d90-4f01-bd17-2e056cab51f3"
      unitRef="usd">1648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi01LTEtMS01NA_f6a37be5-b1a4-49cc-8bdf-46c34b949efe"
      unitRef="usd">8402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMi03LTEtMS01NA_d86c1410-04e6-4af2-8706-157c23ebdb72"
      unitRef="usd">2289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC0xLTEtMS0w_d649e410-9fbf-40c2-bb34-120619240d69"
      unitRef="usd">51884000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC0zLTEtMS0w_a18ada1d-24e8-4fd9-a910-969d4fcad063"
      unitRef="usd">52134000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC01LTEtMS01NA_9271cc1c-ab79-4dd8-8b7c-687379e1c630"
      unitRef="usd">89287000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNC03LTEtMS01NA_b223e69c-c33b-4898-bbdb-057a2482f68a"
      unitRef="usd">72953000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS0xLTEtMS0w_69ecd225-97fc-47e1-9be1-b2bd4d333100"
      unitRef="usd">15076000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS0zLTEtMS0w_d28edafb-4932-42b9-8099-b60988c11b9e"
      unitRef="usd">6896000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS01LTEtMS01NA_5653b2fa-af96-4f87-987c-29aecb0bd17a"
      unitRef="usd">24386000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNS03LTEtMS01NA_79dd060a-cfd3-4267-a4c2-39b1678fd18b"
      unitRef="usd">12466000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi0xLTEtMS0w_5e8b9637-5ea3-42d5-9411-5832f9381a24"
      unitRef="usd">66960000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi0zLTEtMS0w_b96ae723-752a-4895-befc-b3b367d3fcc6"
      unitRef="usd">59030000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi01LTEtMS01NA_958bc10b-40e9-48b2-8b91-85e55b55b875"
      unitRef="usd">113673000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNi03LTEtMS01NA_cec6feea-6f66-4e80-8443-4be0769d15fa"
      unitRef="usd">85419000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy0xLTEtMS0w_e2637aed-395a-46c2-aad5-e5648a555aca"
      unitRef="usd">-62763000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy0zLTEtMS0w_44fcf69f-0a72-45a9-a0bf-6784f30469c9"
      unitRef="usd">-57382000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy01LTEtMS01NA_b3cf2a9f-218b-4bc1-bc36-5b94ca1950dd"
      unitRef="usd">-105271000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfNy03LTEtMS01NA_aad1777d-0f97-4f99-aced-157ddae02914"
      unitRef="usd">-83130000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC0xLTEtMS0w_c9373382-e04f-4aee-a53c-ef2cc6086431"
      unitRef="usd">4113000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC0zLTEtMS0w_c3bf5460-2086-4880-b772-43a3c4404d7f"
      unitRef="usd">2658000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC01LTEtMS01NA_63e75ff5-003f-46ee-aae9-5f7af9fe5bba"
      unitRef="usd">7629000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOC03LTEtMS01NA_808de4e8-0afc-4763-be49-430923e9a609"
      unitRef="usd">4728000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0xLTEtMS0zMTg3_fed2c989-03de-414d-b943-169413cd58f6"
      unitRef="usd">-58650000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0zLTEtMS0zMTg3_92388a9b-b582-411f-8fac-3906bfce73f6"
      unitRef="usd">-54724000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS01LTEtMS0zMTkw_891d6720-c523-4e5a-ae61-7cb4b36187fc"
      unitRef="usd">-97642000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS03LTEtMS0zMTkw_27c3cede-c5d4-4631-8a7b-5b03636b5dd1"
      unitRef="usd">-78402000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtMS0xLTEtMzE4Nw_d1260926-c033-45f0-9ff3-3d2b0cac744f"
      unitRef="usd">-313000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtMy0xLTEtMzE4Nw_79a160e5-9dba-46bb-970e-c572cdeeb42b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtNS0xLTEtMzE5MA_2c5b2db6-3dcb-4fee-ae13-744369dccbe0"
      unitRef="usd">-313000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTAtNy0xLTEtMzE5MA_c5003aef-bd09-477a-875a-6841dd939d88"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0xLTEtMS0w_314b9cb2-1928-44f5-97c7-9aae23fdc0e3"
      unitRef="usd">-58337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS0zLTEtMS0w_46a325a9-3e0d-413e-b664-d78eac4a699a"
      unitRef="usd">-54724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS01LTEtMS01NA_0692f8d7-fe81-40bd-a9ba-ccbc0f4f12f3"
      unitRef="usd">-97329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfOS03LTEtMS01NA_96070413-0bb0-4dd4-bc7e-80218673d2d5"
      unitRef="usd">-78402000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtMS0xLTEtMA_5d2c245c-f9e3-4eab-8d86-3f47aadc29b0"
      unitRef="usd">547000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtMy0xLTEtMA_00ef8c60-9779-4df1-b572-f366223435f5"
      unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtNS0xLTEtNTg_5bcee414-620e-4c10-afcc-56ac007848f3"
      unitRef="usd">1528000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTEtNy0xLTEtNTg_096ae999-90a5-42a9-9899-860e462414cc"
      unitRef="usd">-1125000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItMS0xLTEtMA_c7a4282b-5ebf-4944-970e-be9d0c02ca3f"
      unitRef="usd">-57790000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItMy0xLTEtMA_0d160463-bfc8-40ac-accb-9610838525a9"
      unitRef="usd">-54930000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItNS0xLTEtNTg_47555f4f-f5fe-4743-9e61-12ff82d33588"
      unitRef="usd">-95801000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTItNy0xLTEtNTg_ca90e85c-c314-4287-8201-37fb710003aa"
      unitRef="usd">-79527000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtMS0xLTEtMA_260d8d33-c26d-46e4-be8a-d772d3576dff"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtMy0xLTEtMA_67a4be54-963a-471b-82fc-7ddcd3d28b59"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtNS0xLTEtNjE_ba581149-7780-4123-a85f-05a53accf75a"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTMtNy0xLTEtNjE_5f05a402-5206-41fc-8a18-2d37e27bf9a9"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtMS0xLTEtMA_cc47e454-3ce5-4ffe-af63-93e7b3e7cc23"
      unitRef="shares">95495497</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtMy0xLTEtMA_caecf6f6-3681-460c-b921-651245282aac"
      unitRef="shares">92899524</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtNS0xLTEtNjE_a7568623-8385-44c8-9a7b-4925d7bd774f"
      unitRef="shares">95241412</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yMi9mcmFnOjM2ZTA0Y2VlYTcyZTQyOGE4YjIwOTg5NmM3ZGFjZjYxL3RhYmxlOjA1OWZmMzFhZDQ2YzQ4ZjZiYzg1MjZlNjA2NTBkMmU2L3RhYmxlcmFuZ2U6MDU5ZmYzMWFkNDZjNDhmNmJjODUyNmU2MDY1MGQyZTZfMTQtNy0xLTEtNjE_004fd99f-6e7d-4cab-ac36-e9a077e8498c"
      unitRef="shares">91239274</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icb687f8433d24be0ac5335c8c79c0494_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi02LTEtMS0w_53fcdfbc-92d9-43e5-89c1-1515bd3bc53e"
      unitRef="shares">94662435</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icb687f8433d24be0ac5335c8c79c0494_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi04LTEtMS0w_4b40a88e-147e-45d1-9b88-93403d08c0b9"
      unitRef="usd">1273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b8beed483e6423490b503483915e4f2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xMC0xLTEtMA_3a38288a-61d3-47e0-a7a8-74c40c09c8db"
      unitRef="usd">774158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5344b99e882d4934943a39b1eb4887b1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xMi0xLTEtMA_8d2c2616-2307-49dc-8d85-36a776f93b6f"
      unitRef="usd">-649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie51bc7132b78422f88cfdae7c0aacebd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xNC0xLTEtMA_024083c8-4b39-4a29-978a-22f125b9cb8a"
      unitRef="usd">-227937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMi0xNi0xLTEtMA_1595041f-f2b2-43f4-b2d2-e0c53949fbaf"
      unitRef="usd">546845000</us-gaap:StockholdersEquity>
    <dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy02LTEtMS0w_ab377028-3aa8-4220-b039-43f2c4954cdc"
      unitRef="shares">547124</dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy04LTEtMS0w_6fb3a5ac-27c7-4605-ab6f-0790aae31310"
      unitRef="usd">5000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy0xMC0xLTEtMA_cb04d341-19b6-4cdf-8d29-0dbf480555aa"
      unitRef="usd">3472000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMy0xNi0xLTEtMA_aabb7c48-5244-47d1-aaf0-02fa13309c59"
      unitRef="usd">3477000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC02LTEtMS0w_c35a6748-9844-408f-8671-ec9e4ce127ce"
      unitRef="shares">93752</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC04LTEtMS0w_d8ec19e4-26c5-4c3c-a1f9-e5e75c27f4df"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC0xMC0xLTEtMA_97939740-9471-4e5a-886d-4e46b41f8a85"
      unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNC0xNi0xLTEtMA_73666f97-e815-4be4-a378-b988991fc711"
      unitRef="usd">64000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS02LTEtMS0w_ddcb0f80-a762-4071-9d6d-30bd8e542f45"
      unitRef="shares">353585</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS04LTEtMS0w_8455c64f-1c75-43ea-9504-a6d22661c897"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS0xMC0xLTEtMA_4fbd9801-2451-4159-9fac-7302a91ca87a"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNS0xNi0xLTEtMA_20233681-ff03-4792-a9f0-2ca7abff133b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i234def2e9b514a7b927e5fb45fcecd4d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNi0xMC0xLTEtMA_4f328b3d-717e-41e1-9497-0e7d9b15ca6e"
      unitRef="usd">20588000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNi0xNi0xLTEtMA_214797e0-d957-408e-a173-3f281891548b"
      unitRef="usd">20588000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i722034f7c8044775b8f4e39ab11f9044_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNy0xNC0xLTEtMA_7204f9d9-9522-4081-a2a4-f6e78be3841b"
      unitRef="usd">-97329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfNy0xNi0xLTEtMA_1e799865-4bfd-405f-afa8-2782899d014e"
      unitRef="usd">-97329000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i48efc218d04b44c5bd998761d74d0369_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOC0xMi0xLTEtMA_4ff0ae6f-2edc-4351-bb32-1dbc8ffb48e5"
      unitRef="usd">1528000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOC0xNi0xLTEtMA_4d69ab8f-9a1b-4856-8d44-f6f03be295a4"
      unitRef="usd">1528000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS02LTEtMS0w_8c85d5dd-da6c-4692-8497-fb74fb3d1f07"
      unitRef="shares">95656896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS04LTEtMS0w_2c2cd7cd-d151-42be-b056-64f4d98b6910"
      unitRef="usd">1283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i023b35c87938433a989302ec87e7ab6c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xMC0xLTEtMA_46089924-0e8c-4f08-bafe-5b6445b34465"
      unitRef="usd">798277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b99abb30444402e9dd33c0c70fe40f9_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xMi0xLTEtMA_a21306e5-1c5a-4f11-9632-bfc9b81b91c0"
      unitRef="usd">879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42701eeb1e1c4a17b979e71633036f02_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xNC0xLTEtMA_42b1c9e0-9e9a-4e7d-b61d-9badc9e0321f"
      unitRef="usd">-325266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfOS0xNi0xLTEtMA_2dd3b588-ecb4-4c7d-b889-b213c9e6d48b"
      unitRef="usd">475173000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if166a88ab9ee4dda853e8603cb29e805_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtNi0xLTEtNzgzNw_c387f304-c638-452d-9ea5-0cadf6507fa3"
      unitRef="shares">95257705</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if166a88ab9ee4dda853e8603cb29e805_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtOC0xLTEtNzgzNw_3d669640-b2a2-4dda-9e72-a522b1a8b655"
      unitRef="usd">1279000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie35e501f47d4427fbd9b62dc2c00e2dc_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTAtMS0xLTc4Mzc_2c4169b1-45f3-4c26-8606-1139912b9889"
      unitRef="usd">781966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71648051f8714218b99562e835fa904b_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTItMS0xLTc4Mzc_ed0d70fe-3d77-446e-a11a-c8f3a02bb7ca"
      unitRef="usd">332000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3db11cdb9fdc4fda8887c70798fe0bb4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTQtMS0xLTc4Mzc_d38a0c2b-6318-4129-bb8a-df36ca190d4d"
      unitRef="usd">-266929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8b1265cc2294fccb8fee9c3f57ef5ad_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTEtMTYtMS0xLTc4Mzc_3611e6d5-c085-433a-ab1d-65e87be74838"
      unitRef="usd">516648000</us-gaap:StockholdersEquity>
    <dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan
      contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItNi0xLTEtNzgzNw_c4b955f3-3ba8-4abd-b67a-849527043436"
      unitRef="shares">347621</dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItOC0xLTEtNzgzNw_fdd31940-b03b-4259-8f29-30d9972c8e65"
      unitRef="usd">3000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTAtMS0xLTc4Mzc_a019ceda-e440-4d8a-a3fd-b520185a94d9"
      unitRef="usd">2566000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTYtMS0xLTc4Mzc_95a4da91-815e-462a-9a10-b33b1f543d51"
      unitRef="usd">2569000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtNi0xLTEtNzgzNw_1f44bf61-35ad-4ad2-98b0-1c61bd289fbc"
      unitRef="shares">46878</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtOC0xLTEtNzgzNw_226429c1-14e7-4fa0-bb0b-4833fe7a42a4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTAtMS0xLTc4Mzc_05b72dbe-05de-4433-b855-9913f5a72ba6"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTYtMS0xLTc4Mzc_beff51ab-f54e-418b-b13a-aee06d064fa0"
      unitRef="usd">32000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i95fa40cae0834a4cbc7fa6d94cfa2954_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtNi0xLTEtNzgzNw_928ea822-0919-489f-9d79-885adb0abe8f"
      unitRef="shares">4692</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtMTYtMS0xLTc4Mzc_59b8bee0-8a71-4329-8c87-862a7fbab070"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica12d7a626e14445996baa73fcba2e6a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTAtMS0xLTc4Mzc_e19c3d59-d7e7-4fc7-93c3-11f3f1f802f4"
      unitRef="usd">13714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTYtMS0xLTc4Mzc_eca3b06a-830c-4d24-b723-9843de17c2f5"
      unitRef="usd">13714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i9d14f1d11c174d03b34f14d15c06d0e4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTQtMS0xLTc4Mzc_d5f59e65-1026-4c43-9d80-084378e1caa1"
      unitRef="usd">-58337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTYtMS0xLTc4Mzc_9e687c0b-0813-49db-9f78-cf365fc3ae32"
      unitRef="usd">-58337000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idf0c5c2b81f14b2ba8bf900712c881a8_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTItMS0xLTc4Mzc_e7ad3196-d244-411d-9518-4ab723275689"
      unitRef="usd">547000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTYtMS0xLTc4Mzc_c28ffc93-447e-47df-8c94-eb82cadf30e5"
      unitRef="usd">547000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtNi0xLTEtNzgzNw_c4a076a0-16b3-4e7c-bab0-3098ec821cff"
      unitRef="shares">95656896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i071d1d6ff9c345db8cc1134ce55ea87e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtOC0xLTEtNzgzNw_08dd6800-e56c-41b0-af8f-fbd28caaa7b8"
      unitRef="usd">1283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i023b35c87938433a989302ec87e7ab6c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTAtMS0xLTc4Mzc_1205b920-292f-4c36-859e-a02fbdeb1fdd"
      unitRef="usd">798277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b99abb30444402e9dd33c0c70fe40f9_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTItMS0xLTc4Mzc_579388e9-fd69-4b2a-be0b-1235fe932ed3"
      unitRef="usd">879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42701eeb1e1c4a17b979e71633036f02_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTQtMS0xLTc4Mzc_04f52711-76d0-4a31-8df9-0ccf7ca6c2fe"
      unitRef="usd">-325266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTYtMS0xLTc4Mzc_d2a3f9bc-ac9e-4eb2-ae04-02d2c32f5e9c"
      unitRef="usd">475173000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i59e066377dcf4dd1909aa3b352723c01_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItNi0xLTEtMA_54dec306-bf34-481b-9f37-d6588a7254b4"
      unitRef="shares">87480362</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i59e066377dcf4dd1909aa3b352723c01_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItOC0xLTEtMA_8609d59f-6ede-4c87-9396-1d0d7110a6d7"
      unitRef="usd">1201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3fbad4386a8427d8c6f6a3d5a7374ac_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTAtMS0xLTA_79041e73-b67a-45c7-9774-e582850d3c4e"
      unitRef="usd">656660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f9d4a6b28cc473c805fb4ad62ae184b_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTItMS0xLTA_2ca7f922-196a-456f-89e0-584a440e9de9"
      unitRef="usd">-368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i412e26418ded47729bc5c01e358338bc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTQtMS0xLTA_21327445-4769-4e7d-b5d5-48b2b8bd23f4"
      unitRef="usd">-191697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i654d7777e96c48528ad08a99690746d9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTItMTYtMS0xLTA_dec55c54-aa0b-452f-9099-b78da868c1f2"
      unitRef="usd">465796000</us-gaap:StockholdersEquity>
    <dnli:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtNi0xLTEtMA_e6e2f601-b7d1-47dc-8727-939f7c3fc9bf"
      unitRef="shares">4214559</dnli:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <dnli:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtOC0xLTEtMA_41a6227e-8684-4c72-959b-42949f7b9fc4"
      unitRef="usd">42000</dnli:StockIssuedDuringPeriodValueCollaborationAgreement>
    <dnli:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTAtMS0xLTA_59dd25a3-8c3b-4b65-b48c-de589fef479a"
      unitRef="usd">94364000</dnli:StockIssuedDuringPeriodValueCollaborationAgreement>
    <dnli:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTMtMTYtMS0xLTA_4c3cd2a5-745e-4018-a1f0-1bfdcb0e63ee"
      unitRef="usd">94406000</dnli:StockIssuedDuringPeriodValueCollaborationAgreement>
    <dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtNi0xLTEtMA_092c9a87-c4f1-46e1-aab5-1df8a5cdb6e3"
      unitRef="shares">360409</dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtOC0xLTEtMA_820a498c-cc32-4fce-a45e-a6bcd1a1d75f"
      unitRef="usd">3000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtMTAtMS0xLTA_4a257fec-9184-4c9e-8cfa-6a043415b6cc"
      unitRef="usd">1649000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTQtMTYtMS0xLTA_bb414279-3eee-4b9c-a8c0-f6dfb0d390f5"
      unitRef="usd">1652000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtNi0xLTEtMA_d1b97f09-326b-4759-8723-10d04d47e9ff"
      unitRef="shares">140624</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtOC0xLTEtMA_87b7258e-8f8d-4e5f-b375-97e2cc5da1d1"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTAtMS0xLTA_02ff7927-7f5b-4f6e-9cc9-e19b1fb22e1b"
      unitRef="usd">308000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTUtMTYtMS0xLTA_97692523-18de-471c-b94f-a3293dd44b05"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtNi0xLTEtMA_f23a9da6-c5c4-4d50-b098-ffdb38fd3149"
      unitRef="shares">1125791</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtOC0xLTEtMA_fb8508ee-5266-477d-80f9-d5acebeed487"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTAtMS0xLTA_9eed5fe0-37b4-46b4-81a1-d6b9ae5fb335"
      unitRef="usd">-11000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTYtMTYtMS0xLTA_965a09bb-4733-4bc9-ab0e-4c59810256fb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib8d93e87ccdd4eeebda02b5ebb6fd0e5_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTAtMS0xLTA_0deb8909-ae5d-4463-a487-2f009b6136fe"
      unitRef="usd">7635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTctMTYtMS0xLTA_14590d30-3bbb-4aa3-8407-e26adaa7de43"
      unitRef="usd">7635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ie023db07ba2245d89a07be32e19c8699_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTQtMS0xLTA_768b22ca-8405-4856-9082-e0949af852dc"
      unitRef="usd">-78402000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTgtMTYtMS0xLTA_7f525d33-bf48-4cf1-95cc-c021a86573da"
      unitRef="usd">-78402000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie57571f426694fe089fe9cb5f12584ce_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTktMTItMS0xLTA_546b2915-5a8e-4a3a-a00a-36ff31a9f688"
      unitRef="usd">-1125000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMTktMTYtMS0xLTA_f788536a-5621-4d90-b7a2-7a5f038acb3b"
      unitRef="usd">-1125000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtNi0xLTEtMA_7449d8b0-38e5-4c82-9e05-203cfb556ec9"
      unitRef="shares">93321745</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtOC0xLTEtMA_001d3137-884e-4463-984b-b2a2ef98fa47"
      unitRef="usd">1259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3637006edc4480da3b4668dd1f931c1_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTAtMS0xLTA_ea468d46-8946-450e-9b0b-3ea0c9372370"
      unitRef="usd">760605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7131d5c68734000965acd7cf27ca3a6_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTItMS0xLTA_3916ecf6-eb7b-44fb-9df9-608a08c41cff"
      unitRef="usd">-1493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b047174d458400c8d2c9e6554f436c6_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTQtMS0xLTA_b576f69b-fc7f-4d0d-99da-cac314f6beec"
      unitRef="usd">-270099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMjAtMTYtMS0xLTA_86cc0f97-531f-4e1d-a757-e7c76910265f"
      unitRef="usd">490272000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i25146bfdcf2a47919d391a395b32bece_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtNi0xLTEtNzgxNw_72e6902d-3c63-47f8-82d3-a210b7cde209"
      unitRef="shares">92588989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i25146bfdcf2a47919d391a395b32bece_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtOC0xLTEtNzgxNw_28be50a8-d4c7-4f90-84d3-ab51640051b1"
      unitRef="usd">1252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if624bfc7618444aaaee3b88445cdcd15_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTAtMS0xLTc4MTc_57681dc5-2482-4c7b-865d-a176bf386f9b"
      unitRef="usd">754438000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib41e9af92e2b4bce9bf0ea68da08021d_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTItMS0xLTc4MTc_7322f7cd-f768-4104-96c1-dfdbea390319"
      unitRef="usd">-1287000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae5650d2914b4b4a8c62050aaaa3c4a7_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTQtMS0xLTc4MTc_ee343899-ad9d-4c99-a57f-ad9a972b4f8a"
      unitRef="usd">-215375000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib74065ebcb8745068d2741baeaf0b579_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzAtMTYtMS0xLTc4MTc_374a0338-2be7-42b6-af16-b9dc47d4dc55"
      unitRef="usd">539028000</us-gaap:StockholdersEquity>
    <dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan
      contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItNi0xLTEtNzgxNw_f9f3ebc2-014e-4f1a-b31b-97c214fe9626"
      unitRef="shares">278674</dnli:StockIssuedDuringPeriodSharesEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItOC0xLTEtNzgxNw_7f145a28-be85-4bd9-9a4b-7cf1b51df799"
      unitRef="usd">2000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItMTAtMS0xLTc4MTc_27852d7e-f99b-453f-8e0d-4aa8b94aa54f"
      unitRef="usd">1431000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <dnli:StockIssuedDuringPeriodValueEquityIncentivePlan
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzItMTYtMS0xLTc4MTc_0a13e13c-0302-4339-bd0e-f4c2b8c11629"
      unitRef="usd">1433000</dnli:StockIssuedDuringPeriodValueEquityIncentivePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtNi0xLTEtNzgxNw_c8054765-69c7-40fd-ac5f-56d650b06872"
      unitRef="shares">46875</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtOC0xLTEtNzgxNw_339f8dd3-168f-4f02-8746-07bad05d38e7"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtMTAtMS0xLTc4MTc_401b6d00-e01d-4ee3-89c7-f2c111736052"
      unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzMtMTYtMS0xLTc4MTc_9c35d411-f882-495f-a124-f03f58ee77f2"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtNi0xLTEtNzgxNw_7c09e638-32cb-4f7c-b141-a5350643b062"
      unitRef="shares">407207</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i49a99c043c2c4f27baeeb4de868bc2b0_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtOC0xLTEtNzgxNw_32ffd2d0-5755-4b10-962d-cf9ff38ee3d5"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtMTAtMS0xLTc4MTc_7ba218fd-e7d3-465f-9356-9ddf4f25a3fa"
      unitRef="usd">-4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzQtMTYtMS0xLTc4MTc_f94b8604-09cf-444d-9058-4bac6fb076e8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5632639d8ea64b1c875d53ce395fcdc9_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzUtMTAtMS0xLTc4MTc_96e7c83b-a7c0-4110-b3b0-d99e22dbc483"
      unitRef="usd">4710000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzUtMTYtMS0xLTc4MTc_a1348dad-a8ee-4f5c-ad93-0a24205a7406"
      unitRef="usd">4710000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i9f972032aeb2409db70c5438d495f50e_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzYtMTQtMS0xLTc4MTc_af697b1d-64d7-4062-b02b-1d2d002f44d2"
      unitRef="usd">-54724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzYtMTYtMS0xLTc4MTc_561fda68-b1a4-4cc5-b19f-60a6ca6eaec0"
      unitRef="usd">-54724000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie61e2d55e75b47bf9f99395f341b50b6_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzctMTItMS0xLTc4MTc_b9a541dc-1977-40cf-8c6e-92a57d19a3de"
      unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzctMTYtMS0xLTc4MTc_ed7005f0-f5d8-445a-b6d4-c19b21c24fae"
      unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtNi0xLTEtNzgxNw_fb9d1aca-3326-488c-9026-0c5df49b3bb6"
      unitRef="shares">93321745</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if00aa4b8cda04136b378e14fb7af25df_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtOC0xLTEtNzgxNw_2c23a0b4-2bf3-47cb-8fd0-6dadf19151f3"
      unitRef="usd">1259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3637006edc4480da3b4668dd1f931c1_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTAtMS0xLTc4MTc_ca975660-c7ea-4868-99c3-521cd0f47465"
      unitRef="usd">760605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7131d5c68734000965acd7cf27ca3a6_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTItMS0xLTc4MTc_9a526d6c-9068-483b-b4a4-f1034b2c2a0c"
      unitRef="usd">-1493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b047174d458400c8d2c9e6554f436c6_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTQtMS0xLTc4MTc_76f74828-1e8d-4e2f-a46d-03230a9d4111"
      unitRef="usd">-270099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yNS9mcmFnOjdiMDU4Y2I4NjhlYzQ0NDNhYWE2NmIwMjViZTYyOGRhL3RhYmxlOjBlNDY4NzAwYjAzYTRjY2NiMjJmOWVkNjZlY2M0OWI4L3RhYmxlcmFuZ2U6MGU0Njg3MDBiMDNhNGNjY2IyMmY5ZWQ2NmVjYzQ5YjhfMzgtMTYtMS0xLTc4MTc_76680dc0-2ed6-4680-979d-126b0a03af1a"
      unitRef="usd">490272000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMy0xLTEtMS0w_33eabb43-1aad-4d9c-a2a4-84d3081d648f"
      unitRef="usd">-97329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMy0zLTEtMS0w_38dd63ea-d47c-47e6-989f-0a44cc2440f9"
      unitRef="usd">-78402000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNS0xLTEtMS0w_1f2f2bd0-d497-40bd-8245-3f83dd07e8d5"
      unitRef="usd">4046000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNS0zLTEtMS0w_c37b254e-0d71-4269-8346-652eede5e69c"
      unitRef="usd">2709000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNi0xLTEtMS0w_0e24879b-a7fe-4f5e-a303-7c8d9e9f6913"
      unitRef="usd">20588000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNi0zLTEtMS0w_8781c333-814c-4b12-8de2-dcd8bbcfa206"
      unitRef="usd">7635000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNy0xLTEtMS0w_05e6f91d-2d25-4903-aa0b-e3d98b12e055"
      unitRef="usd">2734000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfNy0zLTEtMS0w_2fdc7409-fe14-43de-bdbf-3979fe096550"
      unitRef="usd">1092000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOC0xLTEtMS0w_b32f5a59-df6e-4193-aa18-367f2b2acd5a"
      unitRef="usd">1740000</dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <dnli:IncreaseDecreaseInDeferredRent
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOC0zLTEtMS0w_d34ac394-11d0-4510-8249-312a77a1a022"
      unitRef="usd">-1339000</dnli:IncreaseDecreaseInDeferredRent>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOS0xLTEtMS0w_18c42e0a-57dc-4bb4-80c8-f4dd3c99399e"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfOS0zLTEtMS0w_afee10db-ceab-41bc-b387-7812e4e6c425"
      unitRef="usd">36000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTAtMS0xLTEtNDY2OA_1e29a7a7-bbbd-4916-b8c0-bffff70a34e7"
      unitRef="usd">313000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTAtMy0xLTEtNDY3Mg_bd0da5ff-7e15-4244-a9b6-53b3865e873d"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTEtMS0xLTEtMA_edd3e313-d68c-4a01-85a0-018e0371b56c"
      unitRef="usd">-2704000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTEtMy0xLTEtMA_5277198f-1878-4355-8f61-3dcb3bbeff4f"
      unitRef="usd">1718000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTItMS0xLTEtMA_7f736d54-8ef7-4d8f-93f2-b1588d711bff"
      unitRef="usd">1303000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTItMy0xLTEtMA_3b06fd68-5df9-47ab-a2af-913d2a790b26"
      unitRef="usd">7094000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTMtMS0xLTEtMA_885afb3c-9859-4a71-9d7a-088b35a66c1b"
      unitRef="usd">-1887000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTMtMy0xLTEtMA_a750d148-d477-4924-a761-edaad97df562"
      unitRef="usd">-1403000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTQtMS0xLTEtMA_4b4829ad-6fb3-447f-8a84-209cd7b2fb06"
      unitRef="usd">-1616000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTQtMy0xLTEtMA_feae9243-f41e-471c-bf13-d9679072798d"
      unitRef="usd">58305000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTYtMS0xLTEtMA_d96e6a6d-ff60-4fe4-8271-534dc66cd41c"
      unitRef="usd">-73498000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTYtMy0xLTEtMA_435ed359-1e9e-497c-8036-bb0665a3e8e7"
      unitRef="usd">-8247000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTgtMS0xLTEtMA_cde55b87-d118-4c3f-93ec-aebf7a28cb39"
      unitRef="usd">144029000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTgtMy0xLTEtMA_effaa207-dffa-4429-b292-d4cb828359d3"
      unitRef="usd">361686000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTktMS0xLTEtMA_3620a007-6a71-47e0-945b-a711f851b292"
      unitRef="usd">12299000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMTktMy0xLTEtMA_f08cffe2-2cb4-4997-bf80-7d3f9e0651eb"
      unitRef="usd">1109000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjAtMS0xLTEtMA_ed8454c8-6062-4a93-ac78-4747e451bcab"
      unitRef="usd">212162000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjAtMy0xLTEtMA_b2a40168-4a99-4d26-b613-6996da7d1e41"
      unitRef="usd">92049000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjEtMS0xLTEtMA_ad88ea95-b33d-4001-873a-24e74e1f8e94"
      unitRef="usd">55834000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjEtMy0xLTEtMA_c11e8831-35e0-4170-bd91-e813a9d6b5b2"
      unitRef="usd">-270746000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4817dca31d74448380859ba79c4b0707_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjMtMS0xLTEtMA_0a6c6517-5552-4cad-adff-76ebd5519d49"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i65e55f5e38ba49289a1ffdea44904d9f_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjMtMy0xLTEtMA_08009e53-dd58-442f-b991-42bea9e858b5"
      unitRef="usd">1342000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i73b1ab5fa47f47a3a75b2baeb7eb3662_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjQtMS0xLTEtMA_8afaff86-08f4-4693-827f-c94c67e33bd6"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i823adbb4c4d94559b833efb563159c96_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjQtMy0xLTEtMA_d48616dc-d199-4b42-a8cd-29923c982a46"
      unitRef="usd">44000</us-gaap:PaymentsOfStockIssuanceCosts>
    <dnli:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjUtMS0xLTEtMA_65292da5-71a1-4e31-95fb-27d306d59b65"
      unitRef="usd">0</dnli:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement>
    <dnli:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjUtMy0xLTEtMA_8a82676f-caa8-4248-8341-2fa27b9447be"
      unitRef="usd">94406000</dnli:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjYtMS0xLTEtMA_86434ca0-f0a4-4777-a788-551d8054b8fd"
      unitRef="usd">3477000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjYtMy0xLTEtMA_e5a9d3ee-4c30-497b-86e0-ed9e18ae7703"
      unitRef="usd">1651000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjctMS0xLTEtMA_edfa5338-a141-4c58-9d30-7adbc043940c"
      unitRef="usd">3477000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjctMy0xLTEtMA_a818ce25-741c-4f00-813e-e2a948dd724f"
      unitRef="usd">94671000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjgtMS0xLTEtMA_87b4029d-0fd6-430d-9926-922cbb5efbcc"
      unitRef="usd">-14187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjgtMy0xLTEtMA_22826eaf-1b4a-4de2-ada3-4156c4bb153e"
      unitRef="usd">-184322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjktMS0xLTEtMA_d3ca9950-3e15-4105-8678-0cd816672fae"
      unitRef="usd">78623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i654d7777e96c48528ad08a99690746d9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMjktMy0xLTEtMA_b2e48a13-c070-4701-8b5c-431b0ec78c3a"
      unitRef="usd">218910000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzAtMS0xLTEtMA_25c340ef-5e32-4d2e-bf33-373a3c3f6169"
      unitRef="usd">64436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzAtMy0xLTEtMA_e01bf782-2ae5-4d73-912f-a03d086eee36"
      unitRef="usd">34588000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <dnli:NoncashTenantImprovementsPaidByLandlord
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzItMS0xLTEtMA_e335d120-938c-45be-a26a-245dff41f494"
      unitRef="usd">11341000</dnli:NoncashTenantImprovementsPaidByLandlord>
    <dnli:NoncashTenantImprovementsPaidByLandlord
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzItMy0xLTEtMA_e4d13842-f2db-42d3-bf6c-85c11828a125"
      unitRef="usd">0</dnli:NoncashTenantImprovementsPaidByLandlord>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzMtMS0xLTEtMA_17292027-4d4f-4b8c-bf62-9f76d1e93887"
      unitRef="usd">2162000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8yOC9mcmFnOmMyNTJiN2FjZTI1NTRhOWM5MTU2YWM0NmMwNzU1Njg2L3RhYmxlOjExZjA5YTI3OWVlMzQ1ZWRhMTdiM2NlNWIwMzE3YWNlL3RhYmxlcmFuZ2U6MTFmMDlhMjc5ZWUzNDVlZGExN2IzY2U1YjAzMTdhY2VfMzMtMy0xLTEtMA_e63a62d2-3164-4b73-8905-80afd6b4461d"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4Njk_252abbeb-2d28-4bab-8e08-3f68bee854a2">Significant Accounting Policies&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Denali Therapeutics Inc. ("Denali" or the &#x201c;Company&#x201d;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2018&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;as filed with the Securities and Exchange Commission on March&#160;12, 2019 (the "2018 Annual Report on Form 10-K"). The condensed consolidated Balance Sheet as of December 31, 2018 was derived from the audited annual consolidated financial statements as of the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended&#160;June 30, 2019, except as discussed below in the sections titled Leases and Recently Adopted Accounting Standards, there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2018 Annual Report on Form 10-K. For further information with regard to the Company&#x2019;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#x2019;s Consolidated Financial Statements included in the 2018 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated on consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the condensed consolidated financial position and statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of June 30, 2019 and December 31, 2018, the Company had&#160;no&#160;off-balance&#160;sheet&#160;concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s restricted cash consists of the letter of credit for the Company&#x2019;s headquarters building lease, and is included&#160;within other&#160;non-current&#160;assets&#160;on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for its derivative instruments as either assets or liabilities on the condensed consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through Interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted Accounting Standards Update ("ASU") No. 2016-02, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; as of January 1, 2019. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#x201c;ROU&#x201d;) asset an&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;d operating lease liability is recognized for identified operating leases in the condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;ROU assets represent the Company&#x2019;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate (&#x201c;IBR&#x201d;) on the date of lease commencement, or the rate implicit in the lease, if known.  The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;License and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#x201c;ASC&#160;808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company's consolidated balance sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Intraperiod tax allocation rules require allocation of the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. A related tax benefit is then recorded in continuing operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which supersedes the guidance in former ASC 840, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;. The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, C&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;odification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; and ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, in December 2018 through ASU 2018-20, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842): Narrow-Scope Improvements for Lessors&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; and in March 2019 through ASU 2019-01 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and is required to be adopted using a modified retrospective approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has adopted this standard as of January 1, 2019, applying the optional transition method such that it is not required to adjust prior period presentations. ASU 2016-02 has impacted the Company&#x2019;s condensed consolidated balance sheet as the Company has certain operating lease arrangements for which the Company is the lessee and one operating lease arrangement for which the Company is the lessor. The Company has no financing leases. Management has elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The impact of adoption of the standard is that the Company as of January 1, 2019 recognized a ROU asset of $46.1 million and operating lease liability of $71.3 million. The standard did not have a material impact on the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss and stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NjY_837b6815-66b9-4e77-9187-ac0e83b6c157">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Denali Therapeutics Inc. ("Denali" or the &#x201c;Company&#x201d;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.&lt;/span&gt;&lt;/div&gt;</dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzQ_06749192-ef3f-48a0-84a5-e2968d625936">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2018&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;as filed with the Securities and Exchange Commission on March&#160;12, 2019 (the "2018 Annual Report on Form 10-K"). The condensed consolidated Balance Sheet as of December 31, 2018 was derived from the audited annual consolidated financial statements as of the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended&#160;June 30, 2019, except as discussed below in the sections titled Leases and Recently Adopted Accounting Standards, there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2018 Annual Report on Form 10-K. For further information with regard to the Company&#x2019;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#x2019;s Consolidated Financial Statements included in the 2018 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzM_9a10fb82-f676-438a-8056-b3b22eeff7c4">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated on consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4Njc_98068d7c-d651-4126-9c15-339c74f06714">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the condensed consolidated financial position and statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzA_85965ae2-cb4b-43e5-90b0-872cdec7a7f2">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of June 30, 2019 and December 31, 2018, the Company had&#160;no&#160;off-balance&#160;sheet&#160;concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzU_c8ab617b-907b-42bc-a292-5fa75e5ff44d">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfNjU4MA_f5f688f5-45bf-41c1-8bcf-3aca200ed2d5"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzY_96c287e7-fabf-4506-8179-04acc9bf738b">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s restricted cash consists of the letter of credit for the Company&#x2019;s headquarters building lease, and is included&#160;within other&#160;non-current&#160;assets&#160;on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4Njg_05ecce1c-09df-4062-9708-9f824f846847">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for its derivative instruments as either assets or liabilities on the condensed consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through Interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzE_98561fa4-2fd5-4026-9304-cae58307d1ff">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted Accounting Standards Update ("ASU") No. 2016-02, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; as of January 1, 2019. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#x201c;ROU&#x201d;) asset an&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;d operating lease liability is recognized for identified operating leases in the condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;ROU assets represent the Company&#x2019;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate (&#x201c;IBR&#x201d;) on the date of lease commencement, or the rate implicit in the lease, if known.  The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.&lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NjM_6910dc6f-f07c-4a17-b5c0-a8070871b43c">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;License and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#x201c;ASC&#160;808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company's consolidated balance sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTIwOTQ2Mjc5MjcwNDg_9976302a-c686-4e2d-aaa2-f0eab2940407">Income TaxesIntraperiod tax allocation rules require allocation of the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. A related tax benefit is then recorded in continuing operations.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NjQ_b742684c-7a39-4287-bede-345e6145f58e">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc4NzI_94303327-3d14-4524-8288-375caf1bfb8a">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which supersedes the guidance in former ASC 840, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;. The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, C&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;odification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; and ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, in December 2018 through ASU 2018-20, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842): Narrow-Scope Improvements for Lessors&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; and in March 2019 through ASU 2019-01 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and is required to be adopted using a modified retrospective approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has adopted this standard as of January 1, 2019, applying the optional transition method such that it is not required to adjust prior period presentations. ASU 2016-02 has impacted the Company&#x2019;s condensed consolidated balance sheet as the Company has certain operating lease arrangements for which the Company is the lessee and one operating lease arrangement for which the Company is the lessor. The Company has no financing leases. Management has elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The impact of adoption of the standard is that the Company as of January 1, 2019 recognized a ROU asset of $46.1 million and operating lease liability of $71.3 million. The standard did not have a material impact on the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss and stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <dnli:LesseeFinanceLeaseNumberOfContracts
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTczMDM_3f7e1464-ad2a-44d3-beb2-55719ebe77c1"
      unitRef="contract">0</dnli:LesseeFinanceLeaseNumberOfContracts>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6abc0c7c5a6f4e6ea981285f7ae4c287_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc2MzA_3c5a73d7-13ab-437c-b06c-f7121c05e350"
      unitRef="usd">46100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6abc0c7c5a6f4e6ea981285f7ae4c287_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNC9mcmFnOmVjNmQzMDJjYTkyMDQ5ZDNhNzRiMjRlZDRlNGU0ZTljL3RleHRyZWdpb246ZWM2ZDMwMmNhOTIwNDlkM2E3NGIyNGVkNGU0ZTRlOWNfMTc2ODA_c124cf4b-5578-4c6e-b403-b64379596330"
      unitRef="usd">71300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RleHRyZWdpb246YmI0NzZiMDI4ZTEyNDY3MWFhNTQ0OTNhOGJiNWFkNTlfNjg2_478d56de-c847-4b84-bae2-49e0c6915d12">Fair Value Measurements&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.314103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.378205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.262821%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;507,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.153846%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.980769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;380,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;208,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;588,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;There were no transfers of assets or liabilities between the fair value measurement levels during the three and six months ended June 30, 2019 or 2018.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RleHRyZWdpb246YmI0NzZiMDI4ZTEyNDY3MWFhNTQ0OTNhOGJiNWFkNTlfNjg3_f912d882-82a0-44b1-acb7-680e72536a3f">&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.314103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.378205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.262821%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;507,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.153846%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.980769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;380,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;208,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;588,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0b119c34dd944daa20fa4eaaa3d2ced_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC0xLTEtMS0w_42b2622c-1a08-4b4b-9071-9f0e6844e024"
      unitRef="usd">36180000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifc8c6e58df014428922e55023f630ade_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC0zLTEtMS0w_32cff8b4-6970-40c4-b35b-86a514b44e57"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i534bf8602525455db76397bb865e573f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC01LTEtMS0w_f9ad521d-0b92-4a80-93b7-359e2a288d4d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i351b20a5b439409598aa2bedf197448c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfNC03LTEtMS0w_7611959d-8519-4d4f-9bcf-8801f9463464"
      unitRef="usd">36180000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d35607870c64688827351e700854bef_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC0xLTEtMS0w_85ee162c-36a6-47a0-ab4c-6b8ae3c3d678"
      unitRef="usd">273103000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77531d54e5404598a5078438c8677b65_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC0zLTEtMS0w_9eea64e4-dd3f-46dd-91b0-8aa93e1ffff5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i564db519a26f4cb8a0fb1d4e669911f2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC01LTEtMS0w_423cae1a-c32b-426b-94cb-98ad46db7941"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i039ece834d1c4019baf20e251e2da235_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOC03LTEtMS0w_e6dbbf79-c887-4882-8ec1-e1070bf98364"
      unitRef="usd">273103000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7db3561ea15848dab72e9c69da84ebf7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS0xLTEtMS0w_f5a4ce68-4c5d-4df3-be76-2b63d4870206"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i394557b4e90043e2a2085e2207e5f704_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS0zLTEtMS0w_0a7ad614-ec40-477e-baac-b41d657bbe59"
      unitRef="usd">28957000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia647cd1b2d9a45278c18b341c2434e5f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS01LTEtMS0w_8a83c990-0b59-4c38-8842-ab03d5f1e4f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied7a9a68ed1e4b98bf5fcf82a0334cc8_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfOS03LTEtMS0w_43da67bc-355f-439d-834e-026ca7b50cbc"
      unitRef="usd">28957000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i646027daed3e4e16b08888af3c67909c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtMS0xLTEtMA_01e0ddf7-4f29-4cd3-b907-6d0c56ef8b5c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac821d5ca4ca49dc813f6db1babf4665_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtMy0xLTEtMA_e53ef57e-f224-4468-91a6-2e1c10a69076"
      unitRef="usd">78950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7fb855d6104424da5e93287267c6ac0_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtNS0xLTEtMA_ad2bf43e-104b-4eec-8efe-3d5e0a79ddfc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3f2152514a74f9691322d7bb19989c8_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTAtNy0xLTEtMA_6115aba5-1068-4504-87f9-a02f3841d0e8"
      unitRef="usd">78950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2188c27fed024d2d9d5cec962236ec1c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtMS0xLTEtMA_a5bc72f1-f4a7-492c-827a-6ea1d159985c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if01b372be06641fcb73d69acee794292_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtMy0xLTEtMA_866593a4-cfec-4963-856c-ef876419c1cc"
      unitRef="usd">34657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee33812b6d5f432a938b1e20a417c276_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtNS0xLTEtMA_59c6c5b3-9e89-4b29-be9a-018739074e10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32984200dcc845b2a45fea17a3812a06_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTEtNy0xLTEtMA_a4b20b7a-3eaf-489f-b554-35ee1a099557"
      unitRef="usd">34657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id738d34d6e8e4df2b2e0892ca8583817_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtMS0xLTEtMA_b00fa0da-3a2e-44bd-bace-b04b0b7de9fd"
      unitRef="usd">45794000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie81ed0dc4a654555b4dfaf4dcc554425_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtMy0xLTEtMA_09ae61d1-82f3-4718-9639-f296c24b806b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia36129c3c0fb4ec89ee0b9be9bbc5bff_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtNS0xLTEtMA_5efac356-7cea-438e-8171-d37983e34ef5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i748d5ac449c24510a0986355b63cb280_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTMtNy0xLTEtMA_cd1d7653-2abf-4e23-8154-5966dc382460"
      unitRef="usd">45794000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib33f0957ce474dd592ca5b6c23e5ef19_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtMS0xLTEtMA_f25521ce-8f50-4d51-a14c-9eeb90a06076"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16a6c38d032f484a9b67307311107bd7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtMy0xLTEtMA_cb7e218b-3c25-4716-ac59-d9b41de6589c"
      unitRef="usd">10038000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8323e729c3744b6984ff8264d437b124_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtNS0xLTEtMA_64c94e64-c77f-44b7-9c13-9b61dad335b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76f0f26e09b64eacb441ec24cd77394c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTUtNy0xLTEtMA_35891614-c4d3-425d-adc4-47a262fc0003"
      unitRef="usd">10038000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtMS0xLTEtMA_901d9f98-b6d6-464f-b17d-de2b6b3a2632"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id3042590e499441eac62f97939bd16f4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtMy0xLTEtMA_9c91d948-5704-4fd9-8351-04328f165bff"
      unitRef="usd">16000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtNS0xLTEtMA_2559d510-fa25-4bb4-adcb-09312d621603"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTYtNy0xLTEtMA_c81c3a7a-0bba-4240-a800-f167ff808c3a"
      unitRef="usd">16000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctMS0xLTEtMA_3578c665-4430-417e-8f58-0410459f56d7"
      unitRef="usd">355077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id3042590e499441eac62f97939bd16f4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctMy0xLTEtMA_8dbe41d7-bfa2-453e-ad36-406bde9b05ff"
      unitRef="usd">152618000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctNS0xLTEtMA_2bb3e8ee-e5f7-419d-ac55-25bfdf2a8087"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTctNy0xLTEtMA_152ee7a8-cbb9-428c-ab97-97f13e1fcb87"
      unitRef="usd">507695000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktMS0xLTEtMA_dc9309bc-0bf7-4495-aeb4-7247b90fbdbf"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id3042590e499441eac62f97939bd16f4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktMy0xLTEtMA_0ab1fdd1-2f28-4139-9580-6c129646b31d"
      unitRef="usd">155000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktNS0xLTEtMA_e4722ea9-eb3f-4ed4-8784-4dea7a0f8fda"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMTktNy0xLTEtMA_7bbefe50-76f6-4a55-a236-20fc4940ac4d"
      unitRef="usd">155000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7924e1aa1d154d5488bb5593b58aa7fc_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtMS0xLTEtMA_46a99f9f-15f3-47be-9150-7b241a7edcbb"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id3042590e499441eac62f97939bd16f4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtMy0xLTEtMA_23066985-a1d9-43ad-8b9c-8d0c552ee3cc"
      unitRef="usd">155000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7cc97570e5b24fa1a75addc5f860af72_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtNS0xLTEtMA_5ef5c911-045b-42bc-95f3-f7515c875ff1"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmIzYWJjZGRiYWIxZjQwZjNiZTNhNzBkNTA4YTVlNDNkL3RhYmxlcmFuZ2U6YjNhYmNkZGJhYjFmNDBmM2JlM2E3MGQ1MDhhNWU0M2RfMjAtNy0xLTEtMA_465c2db3-580a-4e35-8abc-6e71aa82e669"
      unitRef="usd">155000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if168f11e35b14d38bce3e5890ebba5d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC0xLTEtMS0w_6638b284-f1db-47e6-8410-1128c98ea9a3"
      unitRef="usd">42225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iad1069dc0cad4a3ea5572938e4106e4c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC0zLTEtMS0w_f0245fa7-a690-41f6-b23f-42ec15a3b692"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8389b77f46614b0baac4260fdedf92b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC01LTEtMS0w_59fe913a-bb84-4db3-847c-bf5f5347a025"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75c93d80020f42b0ba67cdc0e3a25b2a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNC03LTEtMS0w_03083b38-c66d-443c-bc90-b52e8bcce3fd"
      unitRef="usd">42225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2aee8333029a4f6c8e7f1247f704004a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS0xLTEtMS0w_9ff0231c-8786-4f61-a664-8cb84d299fe9"
      unitRef="usd">1499000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if5c9e6e09b474edc8ac0da0e91d2dd01_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS0zLTEtMS0w_94321488-227d-4190-8f68-fe2dc275cf59"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i57c0452366984f519dbceb86cfc31faf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS01LTEtMS0w_12c1111b-04e7-4b1c-a6e1-95b81ed73737"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie776c9afea3243b2848d752347f688f4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNS03LTEtMS0w_912556e2-ec4b-46b1-aad9-d8085dd0263d"
      unitRef="usd">1499000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9c75b127ec34f38865969acc6d34c86_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi0xLTEtMS0w_64c7a9bc-6086-4ba9-89eb-7aeab5568c0f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i220e6c77c75d4bfa83017f0736091135_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi0zLTEtMS0w_1d0770b2-db37-4677-b60d-7016a8a6a2b1"
      unitRef="usd">9979000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i79715623139e4d188ee2ddfaff3f8843_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi01LTEtMS0w_60a30b56-5db4-4be8-b85a-5f50370c85e0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3d8717aa8b6241c5a643413d64130b63_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfNi03LTEtMS0w_74f78568-97c5-47ea-9555-1564773f7534"
      unitRef="usd">9979000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i993e3d3eb54f4a728171781129ded3bc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC0xLTEtMS0w_5c414e1f-0d67-40dd-b22e-f00326d5a39d"
      unitRef="usd">219754000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i334c9164544d47ed90f823053546feae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC0zLTEtMS0w_45f20235-e041-430a-b166-0558cbd8ac7f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58cd710ca1ca48d0bc2fb6d628a11664_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC01LTEtMS0w_d57555b2-2d10-4bb2-be94-1e9aba3a01e5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic48ac7d1c4324712a1e1298222a87945_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOC03LTEtMS0w_f8020ae6-a46f-4db3-aeb4-12dc4909c30e"
      unitRef="usd">219754000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ae0df8b808c43f280dc28bec5cb444d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS0xLTEtMS0w_819fc9c1-232a-4a9c-8ea8-b9029ed5a070"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id73851e2673146dcb0a9e092ab545074_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS0zLTEtMS0w_c7ab6f04-6893-4b4f-9aff-9a606961ac51"
      unitRef="usd">73151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2699ac9a6b4a4f988e31180fb9faa2e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS01LTEtMS0w_49d392b4-fd79-4e6d-be5b-3c0e78569aba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife73f39b1eae47ee85a5a9584ee232ae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfOS03LTEtMS0w_3bc2bc40-bbef-4803-a105-3aa1aee21c90"
      unitRef="usd">73151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27601e3031d1415087e9519936e0588a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtMS0xLTEtMA_a15508da-3cb6-480e-ba17-b2bbdf946c96"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4803624bc1af45deb9ea98f47e4bef89_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtMy0xLTEtMA_831b04e2-9619-444a-aa64-2eff0543111c"
      unitRef="usd">71675000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46e4decf7be84439945e9ce2850dc451_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtNS0xLTEtMA_ace7c7af-86cb-4b19-b467-bd7fc7b5d107"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1d2b210ee09411c9fa11bbd2deba373_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTAtNy0xLTEtMA_c09eba34-8ec6-490c-87f1-6685d950958f"
      unitRef="usd">71675000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66b7162b4cdf45099ea769306a7bc7ba_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtMS0xLTEtMA_213ae9ec-acfb-418c-a357-ce984b4e603f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e221499c55d4599a35ccd9f1aba1e74_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtMy0xLTEtMA_99566290-a696-443b-809a-f1b05c5c67de"
      unitRef="usd">22594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadb76427e3334f2b8e9ec593be008827_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtNS0xLTEtMA_4c304aff-6b5e-4b0c-919a-4e2ab1823565"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a911ac92d6942418c24d25c2c06cc32_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTEtNy0xLTEtMA_c880149b-35ea-4e8f-8644-c03804251c11"
      unitRef="usd">22594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74b8017f6aa641f5a8ba1117e78c4395_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtMS0xLTEtMA_73aaa875-2ffa-4ba2-952a-9fe06c502311"
      unitRef="usd">117131000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30bc951a4ed74f0ea630f8070210ce78_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtMy0xLTEtMA_b820bc4e-b68c-44ac-8808-6cf45284b134"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i080696e2011c4cebb6a89ccdbaa3ee8d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtNS0xLTEtMA_aec31140-51c7-46d6-b28f-23c353b2236c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fdf1cc314e547498192214867642863_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTMtNy0xLTEtMA_92c07288-ec13-4697-a165-713e3a9a7c9e"
      unitRef="usd">117131000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie41ba916828a4459913741d70d7bc3fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtMS0xLTEtMA_c3f7336e-c9c4-40b5-ab15-01e6757d159a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i372598dc17214865814f1254ebfb5161_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtMy0xLTEtMA_01e2a380-5c8e-4636-95a5-cc916cab5d68"
      unitRef="usd">1977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7640f25a11a54310893f0d59b851a625_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtNS0xLTEtMA_8e16b19e-17fa-4ca9-bf9c-bab34ce84d32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6ac2039e8dc42bead781da7dcf42fd1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTQtNy0xLTEtMA_b07c60bf-2eda-479b-9f00-3c5d1fc461a8"
      unitRef="usd">1977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i497df5ae51894ba7a5a6422af04376bf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtMS0xLTEtMA_d561aa08-e639-4fe9-9c09-3934bb940d1f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe03351931fd4b02bcbdf4d454a976b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtMy0xLTEtMA_3bb3aa95-c64f-49dd-ada4-343c3c15a0f2"
      unitRef="usd">28773000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec24689629b54d34951dd76fb613749b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtNS0xLTEtMA_dda71645-3211-417d-b4fa-8f14db98f3fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia035bfff287e4ca591f2a341c56b6b2d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTUtNy0xLTEtMA_ba81ec8d-800b-468a-bf2a-d64942907783"
      unitRef="usd">28773000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i49c31645a10044e59139a51722cc253f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtMS0xLTEtMA_ab7b3aac-7d2c-4843-86f5-a19c6a5cc6c0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtMy0xLTEtMA_1a40207c-c749-4399-b6ca-b91a4e7c6b9c"
      unitRef="usd">14000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtNS0xLTEtMA_0f2f58a7-2eb3-42c0-a13d-b0d03ef07e0f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTYtNy0xLTEtMA_495ba125-a099-435d-9958-7c47188ce21b"
      unitRef="usd">14000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i49c31645a10044e59139a51722cc253f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctMS0xLTEtMA_7130af0a-e40d-444b-bce6-03484eb6ea36"
      unitRef="usd">380609000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctMy0xLTEtMA_bad90b94-ec2a-4a83-ac12-5463c85de5a4"
      unitRef="usd">208163000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctNS0xLTEtMA_cfbe38a8-5c14-44c6-be1f-745c4c64ce45"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTctNy0xLTEtMA_16635dbe-8153-4e08-8d81-3446029699a0"
      unitRef="usd">588772000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i49c31645a10044e59139a51722cc253f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktMS0xLTEtMA_9599ecbc-c101-45b7-a791-2d1ca1f29a67"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktMy0xLTEtMA_1705b66f-30be-4a6d-82dc-5b7eae6178a2"
      unitRef="usd">182000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktNS0xLTEtMA_bc3fea6e-285f-4b74-9ede-116cdd87fb98"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMTktNy0xLTEtMA_c0e62fc7-636f-4acc-8d76-31e973da5bc5"
      unitRef="usd">182000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i49c31645a10044e59139a51722cc253f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtMS0xLTEtMA_cf9bde24-acdd-43c0-ac7d-a48995e3c989"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3a14322869be4b658cd4cde6e287c652_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtMy0xLTEtMA_8344757b-99e3-4fb7-bafe-ff9987ec406d"
      unitRef="usd">182000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ica751d3b16db4f8ea312582a7139852b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtNS0xLTEtMA_f663514d-a7f3-4d8c-950b-35e7739f9923"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF8zNy9mcmFnOmJiNDc2YjAyOGUxMjQ2NzFhYTU0NDkzYThiYjVhZDU5L3RhYmxlOmU2MWUwOGY3YTEzMTRmYmM5OGFiYWFjMzhlZmNiNzQ1L3RhYmxlcmFuZ2U6ZTYxZTA4ZjdhMTMxNGZiYzk4YWJhYWMzOGVmY2I3NDVfMjAtNy0xLTEtMA_9839a812-8f29-43c5-82b7-011f158d332b"
      unitRef="usd">182000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5NQ_6c6682d2-6fc3-42b5-9652-a9aaf75fd3ce">Cash and Marketable Securities&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.852564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.621795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Restricted cash included within other non-current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;All marketable securities were considered&#160;available-for-sale&#160;at June 30, 2019 and December 31, 2018. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as discussed in Note 2, "Fair Value Measurements". The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.153846%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.980769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;415,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;470,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;471,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.314103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;387,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;387,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,019)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2019, some of the Company&#x2019;s marketable securities were in an unrealized loss position. At each balance sheet date, the Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the three and six months ended June 30, 2019 and 2018. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than twelve months or the loss is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded unrealized gains on marketable securities in other comprehensive income during the three and six months ended June 30, 2019. There were no unrealized gains in other comprehensive income during the three and six months ended June 30, 2018. As a result, the Company recorded a tax benefit of $0.3 million for the three and six months ended June 30, 2019 on the condensed consolidated statements of operations and a corresponding tax charge in other comprehensive income of $0.3 million. There was no tax benefit recorded for the three and six months ended June 30, 2018 on the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;All of the Company&#x2019;s marketable securities have an effective maturity of less than two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5Nw_cc66dac2-541f-4c45-9543-72b75030cf24">&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.852564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.621795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Restricted cash included within other non-current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5Ng_254dd8b8-1125-489b-b7c7-13b57bd1378d">&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.852564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.621795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Restricted cash included within other non-current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMS0xLTEtMS0w_55fbdcaa-9444-469a-aefb-9a595d5a4db5"
      unitRef="usd">62936000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMS0zLTEtMS0w_bf7fa7de-70a8-45ff-bb00-b5faee8da6c1"
      unitRef="usd">77123000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMS01LTEtMS0w_8b2d8b90-63a3-4fa2-a7dc-b8207d2e4a02"
      unitRef="usd">33088000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMi0xLTEtMS0w_7dd882ba-16e4-4974-ac4e-1df098dff063"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMi0zLTEtMS0w_51003b71-2a1b-4394-bb18-d6f863c6a1b3"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMi01LTEtMS0w_b1471517-6410-404d-97c4-65e52f3a85ea"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMy0xLTEtMS0w_30255582-61ba-4b27-a2d0-3c2b7428101a"
      unitRef="usd">64436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMy0zLTEtMS0w_e8731619-87b4-4092-b7d5-2901136ff016"
      unitRef="usd">78623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjIwNjk5Y2Q3ZDYzYzRlNDViODFmNWNlZThiNDBmNzFmL3RhYmxlcmFuZ2U6MjA2OTljZDdkNjNjNGU0NWI4MWY1Y2VlOGI0MGY3MWZfMy01LTEtMS0w_4bb240c3-754d-4b82-aa12-ef4acd8571d7"
      unitRef="usd">34588000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMjc0ODc3OTA3NDg5MQ_82784743-0ae3-4fc2-a044-0a3a83767c3a">The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.153846%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.980769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;415,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;470,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;471,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.314103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;387,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;387,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,019)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;535,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c65238201f2438099ea08259947cf04_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy0xLTEtMS0w_85db90ef-2bf7-4320-bb7d-00f18f008d7e"
      unitRef="usd">272540000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c65238201f2438099ea08259947cf04_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy0zLTEtMS0w_f9685af6-97e1-4eee-8d9e-5db887073232"
      unitRef="usd">568000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c65238201f2438099ea08259947cf04_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy01LTEtMS0w_54b4219a-379e-42c7-9f0a-bf237199fc0b"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c65238201f2438099ea08259947cf04_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMy03LTEtMS0w_a80cba2b-3ff6-4770-9d54-334b00c3a0f0"
      unitRef="usd">273103000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC0xLTEtMS0w_7f736c2b-d7d2-402b-80ba-e2e9be7f8c63"
      unitRef="usd">28960000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC0zLTEtMS0w_f13b4653-cfb2-4b15-810e-d59fdc56237e"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC01LTEtMS0w_79f6b965-2d37-49bf-9904-98219d97536b"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbdfa55cc0574d5b9693592150a1b134_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNC03LTEtMS0w_7596fc7a-88bd-4515-81ac-ffd5f8cc4e29"
      unitRef="usd">28957000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS0xLTEtMS0w_4b50f338-3337-4017-a094-644e5b919bbe"
      unitRef="usd">78842000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS0zLTEtMS0w_aaa8e2da-cd8a-46d6-809e-4a414daf0fe7"
      unitRef="usd">122000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS01LTEtMS0w_36b65eb6-7565-47f2-b46b-9d2296adc951"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae5e02b2d6aa49058387f1cea12b93b3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNS03LTEtMS0w_805dc90c-750d-447d-80b9-74c18c6184b6"
      unitRef="usd">78950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi0xLTEtMS0w_00848fe8-9ff8-49f6-b6ea-87de151b1fd0"
      unitRef="usd">34657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi0zLTEtMS0w_2dc87873-428c-4f56-ad3c-656fcb760ecc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi01LTEtMS0w_b7fd316d-ec51-41a8-996d-006274b68fa6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2e2a799afac4657bf2990fa9faac6e4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNi03LTEtMS0w_6051a8d8-4b5c-479e-a45d-7c82f320a219"
      unitRef="usd">34657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy0xLTEtMS0w_221d3e04-c0e5-4a94-8263-34e654be211b"
      unitRef="usd">414999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy0zLTEtMS0w_41dab404-63b4-480f-854a-7254ed8ca62a"
      unitRef="usd">697000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy01LTEtMS0w_29a0b9bb-30ee-47c7-87ab-5bf6ead4fafe"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic132aa6373a64c79b5f996854ca9bc8c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfNy03LTEtMS0w_f98f1fab-b155-4bd7-ba5a-a4afbde5bb90"
      unitRef="usd">415667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS0xLTEtMS0w_bfdb8322-65e8-497e-b4a5-4e563d9d7a66"
      unitRef="usd">45339000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS0zLTEtMS0w_b814ec1a-4c9d-40bc-86a8-b3ba0c815d9b"
      unitRef="usd">455000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS01LTEtMS0w_0349810d-a79b-4d6c-9bf9-21d8025c7bde"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c25e606153542d88af272a7ffac8a0e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfOS03LTEtMS0w_83dca02a-cca6-45d1-a2c8-629efc55565b"
      unitRef="usd">45794000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtMS0xLTEtMA_c50beee0-5018-4f0c-914b-1527422a2673"
      unitRef="usd">9968000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtMy0xLTEtMA_9b2ec697-841b-402a-83e9-3fbcc9b63673"
      unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtNS0xLTEtMA_77a665b3-2c2d-4d38-a552-310f7f05a2cc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6540ea35ebd841c6ab0a0d303ab2ed63_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTAtNy0xLTEtMA_472bf4fd-1457-40b6-8cae-bbdbe815978c"
      unitRef="usd">10038000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtMS0xLTEtMA_a10cee99-6c60-4fd1-9e46-444bae133d4d"
      unitRef="usd">55307000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtMy0xLTEtMA_898ac515-278a-413c-91d0-67c75ed6b586"
      unitRef="usd">525000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtNS0xLTEtMA_6835c06c-3052-4e74-ad55-019c4f10af29"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d9d46cd84f74d6592f546a80eee0cbb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTEtNy0xLTEtMA_abfaf3f2-69fa-42a0-ab00-b2ed6c2b1fb3"
      unitRef="usd">55832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItMS0xLTEtMA_67e6a76e-84ea-4e54-a74d-f17c32171f84"
      unitRef="usd">470306000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItMy0xLTEtMA_513e659b-932f-4890-ac29-a797ff485eee"
      unitRef="usd">1222000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItNS0xLTEtMA_31306ff7-f73b-4008-a8d0-87b156c690f4"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOmNhMzU1Y2MwNjJkNTQyNDliY2ViMzRlNDU2OTljODUwL3RhYmxlcmFuZ2U6Y2EzNTVjYzA2MmQ1NDI0OWJjZWIzNGU0NTY5OWM4NTBfMTItNy0xLTEtMA_3fc46cbe-e0c3-44f7-acf0-30c8d1441705"
      unitRef="usd">471499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy0xLTEtMS0w_113dabca-8692-4623-a161-efbe70c34f18"
      unitRef="usd">220081000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy0zLTEtMS0w_e8c33ac9-869d-497c-b68a-1c5c0af0f3ec"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy01LTEtMS0w_acf91c91-dac6-4c46-9989-600efc752890"
      unitRef="usd">356000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1434d14831d0404caa8e13694f7f25be_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMy03LTEtMS0w_372287c8-962a-4b17-b0b6-4cbd69dbefad"
      unitRef="usd">219754000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC0xLTEtMS0w_a9c55985-41d4-48f8-bac8-ce115991d7ff"
      unitRef="usd">73373000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC0zLTEtMS0w_53acf7db-ac14-417a-aa68-af2bfb208c9c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC01LTEtMS0w_001b249e-6e8d-4278-875a-eec77698bfa8"
      unitRef="usd">222000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0a0f1d286ed4f01b14d389eca094eda_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNC03LTEtMS0w_9552ff0f-0587-4882-87a2-ee57be150297"
      unitRef="usd">73151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS0xLTEtMS0w_6e39d1ad-45d2-4b4f-8f52-3d8bf2333e69"
      unitRef="usd">71940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS0zLTEtMS0w_ec3ef4e1-a5bf-44c4-a860-d240fca37d86"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS01LTEtMS0w_35546ae6-37f8-48cc-bcad-3ba6328e23e9"
      unitRef="usd">266000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5d67d58a6ea4d398cf29d8bb4296ab6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNS03LTEtMS0w_a30a66ad-fc53-45b7-848b-8ef1a264e715"
      unitRef="usd">71675000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi0xLTEtMS0w_710f046c-364b-464b-8457-7f0a65c4ade7"
      unitRef="usd">22594000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi0zLTEtMS0w_ab467d0d-adaa-47a2-bc2e-2341c1e50895"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi01LTEtMS0w_d07ddf8b-1ff2-4cf3-aa10-73b5d43e32f0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f7cb9a3cae8477c98ec6b9d0ecf9b4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNi03LTEtMS0w_46d97af2-2fd1-47d7-9776-65d74603c016"
      unitRef="usd">22594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy0xLTEtMS0w_a4249bc9-9113-4e17-9082-c497d62d95de"
      unitRef="usd">387988000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy0zLTEtMS0w_8fb593a0-8d99-4bbf-81ed-54f089435d24"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy01LTEtMS0w_8b361888-a340-437e-94d2-132cc4ac75ed"
      unitRef="usd">844000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i411305bb7ce54bd5ba077969cb6dc8c6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfNy03LTEtMS0w_ec0d4851-d63e-409e-8604-5ab1eb6752b3"
      unitRef="usd">387174000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS0xLTEtMS0w_6a77baff-da5d-47a6-97d9-11b44d7ccc4f"
      unitRef="usd">116878000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS0zLTEtMS0w_141be4b2-3111-457e-becb-112825e14358"
      unitRef="usd">329000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS01LTEtMS0w_fb3b94a4-cb79-4a9c-a976-f4c243908744"
      unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc1014a17a2a46eba10d842ec1fccd9b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfOS03LTEtMS0w_f389601a-0915-492e-bcf6-94b0d9c79282"
      unitRef="usd">117131000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtMS0xLTEtMA_8fc9d451-a49a-456b-9077-7852afabc217"
      unitRef="usd">1975000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtMy0xLTEtMA_b902396c-fd97-4ee7-beb2-8636ccbc6a65"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtNS0xLTEtMA_2713e8bd-01ee-4085-b3d7-18ce79ceaa75"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44b6982078fb47e882b2de8e34ef5adb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTAtNy0xLTEtMA_25b24000-2936-418f-b1f9-8426639553fa"
      unitRef="usd">1977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtMS0xLTEtMA_8592e77e-4f27-48ba-95cf-287f77b8b772"
      unitRef="usd">28864000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtMy0xLTEtMA_2830f588-d6d9-4c78-9a6d-4577a1eaba0a"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtNS0xLTEtMA_e71665bb-bcd2-4b50-9cb2-e4b1f83fd0ed"
      unitRef="usd">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e891a3823f24de4a4f4b99b41087154_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTEtNy0xLTEtMA_b571e5ee-41ca-4ac3-a056-e14bcce631c5"
      unitRef="usd">28773000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItMS0xLTEtMA_77aa674a-332d-43bc-a14c-79376a7633f3"
      unitRef="usd">147717000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItMy0xLTEtMA_47e39a8a-2ae2-4304-aeec-5bf2f2b65828"
      unitRef="usd">339000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItNS0xLTEtMA_b6acd21f-1a4a-4188-968e-eb6c2afdceef"
      unitRef="usd">175000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d9124e0422c4ff1b46cd042394237b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTItNy0xLTEtMA_99f1085d-9c1f-483e-98c2-3c44883acd10"
      unitRef="usd">147881000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtMS0xLTEtMA_de7d4fed-96dc-4f7c-b00a-3ef5a0831f77"
      unitRef="usd">535705000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtMy0xLTEtMA_1e392147-e5ac-48a6-ac6b-eb66f8dda299"
      unitRef="usd">369000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtNS0xLTEtMA_f66855d5-a4c8-4738-ae91-b50da47392c4"
      unitRef="usd">1019000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RhYmxlOjJkNWY0NWQ4MzFmZTQwZjFhNmNiNDIzMjA4MmQ4OTYzL3RhYmxlcmFuZ2U6MmQ1ZjQ1ZDgzMWZlNDBmMWE2Y2I0MjMyMDgyZDg5NjNfMTMtNy0xLTEtMA_503963c2-9150-4a31-a6fb-386e1052fa51"
      unitRef="usd">535055000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_6cb0046b-5e16-4325-89f3-4c0760131782"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_a77e2d74-abbd-47da-a8a0-8f3d65a29511"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_cd53ba3e-83d1-430a-9fe3-4ab2a6f07573"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfOTY5_e5f6ee0c-9023-4a51-afd0-6132dc853ce7"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_6cb0046b-5e16-4325-89f3-4c0760131782"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_a77e2d74-abbd-47da-a8a0-8f3d65a29511"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_cd53ba3e-83d1-430a-9fe3-4ab2a6f07573"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MTAxOQ_e5f6ee0c-9023-4a51-afd0-6132dc853ce7"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MDk5Nw_9b73fb63-8bb9-4900-bc7d-19e0920f1352"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfNjU5NzA2OTc3MDk5Nw_c3057153-9fe7-428f-bab1-a00f15d2aebd"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTA5OTUxMTYzMzI1OQ_487a0c86-cf37-404d-acd3-9ccf39e017bc"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTA5OTUxMTYzMzI1OQ_fcba34b5-6bae-4fb2-ae0f-c9fb9979a6ff"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTY0OTI2NzQ0NjIxNw_79a160e5-9dba-46bb-970e-c572cdeeb42b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80MC9mcmFnOjgwNjdiOTM4MmM3YjQxOTU5YmY0YTI4NTRiMzI0NjNiL3RleHRyZWdpb246ODA2N2I5MzgyYzdiNDE5NTliZjRhMjg1NGIzMjQ2M2JfMTI5Mw_8929dda8-b836-4a11-a7a1-708881106903">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTg2Nw_fd9b7a07-77fe-410c-8e49-bd4cdc7b5cb5">Derivative Financial Instruments&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"&gt;Foreign Currency Exchange Rate Exposure&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#x2019;s forecasted cash flows being denominated in currencies other than the U.S. dollar, primarily the Euro, British Pound, and Swiss Franc. The derivative instruments the Company uses to hedge this exposure are not designated as cash flow hedges, and as a result, changes in their fair value are recorded in Interest and other income, net, on the Company's condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates and take into consideration the current creditworthiness of the counterparties. Information regarding the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations is provided below. The Company did not have foreign currency exchange contracts prior to June 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s forward foreign currency exchange contracts outstanding as of June 30, 2019 (notional amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.868379%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602568%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.385233%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602568%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.916533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602568%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.422151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Aggregate Notional&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Amount in Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Euros &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Jul. 2019 - May 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;British Pounds &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Jul. 2019 - May 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Swiss Francs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Jul. 2019 - Feb 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;margin-top:4pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1) &#160;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;"&gt;The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The derivative liability balance of $0.2 million is recorded in Other current liabilities on the condensed consolidated balance sheet as of both June 30, 2019 and December 31, 2018. The derivative asset balance of $15,682 and $13,669 is recorded in Prepaid assets and other current assets on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. The net loss associated with the Company's derivative instruments of $7,320 and gain of $11,967 is recognized in Interest and other income, net on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2019, respectively, and a net loss of $31,952 was recognized in Interest and other income, net on the condensed consolidated statement of operations and comprehensive loss for both the three and six months ended June 30, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="ia14c2927959544239a3d263ec3dda43e_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA2Mg_ef2f572c-fc25-4f63-af35-353765884a5f"
      unitRef="derivative_instrument">0</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTg2OA_03fc62b6-e012-4ce5-b678-db56a2f1dd31">&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s forward foreign currency exchange contracts outstanding as of June 30, 2019 (notional amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.868379%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602568%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.385233%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602568%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.916533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602568%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.422151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Aggregate Notional&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Amount in Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Euros &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Jul. 2019 - May 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;British Pounds &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Jul. 2019 - May 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Swiss Francs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Jul. 2019 - Feb 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;(1) &#160;The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i48082d8a3fa74a8c95c2264e9a347d42_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMS0yLTEtMS0w_a9d30404-3eb5-4a83-94f9-a3f416c4b6c1"
      unitRef="derivative_instrument">19</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <invest:DerivativeNotionalAmount
      contextRef="i48082d8a3fa74a8c95c2264e9a347d42_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMS00LTEtMS0w_ecc41a39-7db9-490e-b7b1-94fd329433bf"
      unitRef="eur">2776000</invest:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i234d3a677c614b128ac23ca5c79da8dc_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMi0yLTEtMS0w_8cfce1b8-c434-4600-af81-1148bdb261f9"
      unitRef="derivative_instrument">21</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <invest:DerivativeNotionalAmount
      contextRef="i234d3a677c614b128ac23ca5c79da8dc_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMi00LTEtMS0w_67f875f3-386b-4879-8e36-a15e75f17d6b"
      unitRef="gbp">3181000</invest:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="id1232cc1f5524033b330344d942beb81_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMy0yLTEtMS0w_c3bba764-d384-4042-b771-3947349218ef"
      unitRef="derivative_instrument">18</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <invest:DerivativeNotionalAmount
      contextRef="id1232cc1f5524033b330344d942beb81_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfMy00LTEtMS0w_2f4465b9-729b-4b35-8e34-66dd10540249"
      unitRef="chf">703000</invest:DerivativeNotionalAmount>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i8674d4a62e2a492fa95fdbeefacd0bad_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RhYmxlOmUyNDkyOTAwYjAwNTQ2ZTNiNGY4ZjIxNmJlM2JhNjQwL3RhYmxlcmFuZ2U6ZTI0OTI5MDBiMDA1NDZlM2I0ZjhmMjE2YmUzYmE2NDBfNC0yLTEtMS0w_fa623cdf-4773-483a-b57d-da5f5b88e960"
      unitRef="derivative_instrument">58</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeLiabilities
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTkzNg_0df75e44-8631-4159-b29f-0325ce722992"
      unitRef="usd">200000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTkzNg_936bc926-3f3f-4fd3-8803-45f9cd1349d2"
      unitRef="usd">200000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTU3Mw_b8691318-1f84-4637-94b2-5dcf078275b3"
      unitRef="usd">15682</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTk2MQ_887c3c42-3d0b-4f04-8bef-72b4b119671e"
      unitRef="usd">13669</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTY2Mw_55eaedaf-a949-44b2-811e-a03558fdd400"
      unitRef="usd">-7320</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTc1NA_4b0522f2-eb6f-4cdf-8432-b02f08a74e7d"
      unitRef="usd">11967</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTY3Nw_6563f497-489c-4048-94c5-bc7047a2cb40"
      unitRef="usd">-31952</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80My9mcmFnOjExODk2ODExNzE1MjQ1ZGNhMDFhYjg0ZWEwYjA5OTE3L3RleHRyZWdpb246MTE4OTY4MTE3MTUyNDVkY2EwMWFiODRlYTBiMDk5MTdfMTA5OTUxMTYyOTY3Nw_6b8754e1-ea3a-40fc-bc3f-c3641b56ca4d"
      unitRef="usd">-31952</us-gaap:DerivativeGainLossOnDerivativeNet>
    <dnli:AssetAcquisitionTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfNDIzNg_820a83ed-1eef-4133-b6b7-c5c54dc65645">Acquisition&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2016, the Company entered into a License and Collaboration Agreement (&#x201c;F-star Collaboration Agreement&#x201d;) with&#160;F-star&#160;Gamma Limited (&#x201c;F-star Gamma&#x201d;),&#160;F-star&#160;Biotechnologische Forschungs-Und Entwicklungsges M.B.H ("F-star GmbH") and&#160;F-star&#160;Biotechnology Limited ("F-star Ltd") (collectively,&#160;&#x201c;F-star&#x201d;) to leverage&#160;F-star&#x2019;s&#160;modular antibody technology and the Company&#x2019;s expertise in the development of therapies for neurodegenerative diseases. Under the F-star Collaboration Agreement, the Company has made payments to F-star totaling $11.5&#160;million. In connection with the entry into the F-star Collaboration Agreement, the Company also purchased an option for an upfront option fee of $0.5 million (the&#160;&#x201c;buy-out-option&#x201d;),&#160;to acquire all of the outstanding shares of&#160;F-star&#160;Gamma pursuant to a&#160;pre-negotiated&#160;buy-out&#160;option agreement (the &#x201c;Option Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, the Company exercised the Option Agreement and entered into a Share Purchase Agreement (the &#x201c;Purchase&#160;Agreement&#x201d;) with the shareholders of&#160;F-star&#160;Gamma and Shareholder Representative Services LLC, pursuant to which the Company acquired all of the outstanding shares of&#160;F-star&#160;Gamma (the &#x201c;Acquisition&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the Acquisition,&#160;F-star&#160;Gamma became a wholly-owned subsidiary of the Company and the Company changed the entity&#x2019;s name to Denali BBB Holding Limited. In addition, the Company became a direct licensee of certain intellectual property of&#160;F-star&#160;Ltd by way of the Company&#x2019;s assumption of&#160;F-star&#160;Gamma&#x2019;s license agreement with&#160;F-star&#160;Ltd, dated August&#160;24, 2016, (the&#160;&#x201c;F-star&#160;Gamma License&#x201d;). The Company made initial exercise payments under the&#160;Purchase Agreement and the&#160;F-star&#160;Gamma License, in the aggregate, of $17.8 million. In addition, the Company is required to make future contingent payments, to F-star Ltd and the former shareholders of F-star Gamma, up to a maximum amount of $447.0 million in the aggregate upon the achievement of certain defined preclinical, clinical, regulatory and commercial milestones. The amount of the contingent payments will vary based on whether&#160;F-star&#160;delivers an Fcab&#160;(constant&#160;Fc-domains&#160;with antigen-binding activity) that meets&#160;pre-defined&#160;criteria and whether the Fcab has been identified solely by the Company or solely by&#160;F-star&#160;or jointly by the Company and&#160;F-star. In June 2019, the Company made a payment of $1.5 million to F-star Ltd upon the achievement of a specified preclinical milestone in the Company's ETV:IDS program.&lt;/span&gt;&lt;/div&gt;The Company concluded that the assets acquired and liabilities assumed upon the exercise of the Option Agreement did not meet the accounting definition of a business, and as such, the acquisition was accounted for as an asset purchase. The Company recognized $1.5 million of contingent consideration as research and development expense during the three and six months ended June 30, 2019 and $18.3&#160;million of upfront consideration as research and development expense in the three and six months ended June 30, 2018. As the transaction was accounted for as an asset purchase rather than a business combination, the Company did not recognize any contingent consideration on the acquisition date. Further future contingent consideration is expected to be recognized in research and development expense as incurred.Under the F-star Collaboration Agreement, the Company is responsible for certain research costs incurred by F-star Ltd in conducting activities under an agreed development plan for each Fcab, for up to 24 months after the target Fcab is accepted. The Company's responsibility for research costs under the first development plan related to an Fcab that targets the transferrin receptor was completed during the year ended December 31, 2018. The responsibility for costs under the second development plan related to an undisclosed Fcab target commenced in February 2019. The Company recognized $0.3 million and $0.5&#160;million in research and development expense related to the funding of&#160;F-star&#160;Ltd activities under these development plans during the three and six months ended June 30, 2019, respectively, and $0.2 million and $0.5 million for the three and six months ended June 30, 2018, respectively.</dnli:AssetAcquisitionTextBlock>
    <dnli:CollaborativeArrangementPayment
      contextRef="ib9f18818b52f4aeabfbf7dbbb4aba705_D20160801-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfODI0NjMzNzIyMDQ1NA_ded3bbb8-feee-4400-b1e1-41a98fa46083"
      unitRef="usd">11500000</dnli:CollaborativeArrangementPayment>
    <dnli:UpfrontOptionFee
      contextRef="i55d1fcfacd0d4b0db994f652d3301667_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfNTk5_c3530b3b-64db-40b3-9261-48b09696f3cf"
      unitRef="usd">500000</dnli:UpfrontOptionFee>
    <dnli:InitialOptionExercisePayments
      contextRef="i647555a3917440f38eef6a6989f68269_D20160824-20160824"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzg0ODI5MDcwMjQ1NA_5a1bf3c6-1e88-40e1-b098-bf725d8e026b"
      unitRef="usd">17800000</dnli:InitialOptionExercisePayments>
    <dnli:ContingentPaymentsUponAchievementOfMilestones
      contextRef="i2148ac99ab3d4a618499bc77ee8d8c62_D20180530-20180530"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTg0Mw_a1e1416b-2c03-46d8-adea-cbe5fe016750"
      unitRef="usd">447000000.0</dnli:ContingentPaymentsUponAchievementOfMilestones>
    <dnli:ContingentConsiderationPayment
      contextRef="i958b3c7abe6a45a592e44305c54c7fb4_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTY0OTI2NzQ1NDkwNQ_085fc884-a623-4920-b32b-c5c9a937c959"
      unitRef="usd">1500000</dnli:ContingentConsiderationPayment>
    <dnli:AssetAcquisitionContingentConsiderationAmountRecognized
      contextRef="i51ca5f46b88d4457b2266e87e2008a2a_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfODI0NjMzNzIyMDQzNg_c30088e8-4cce-4dac-9c5b-3ed0b8a83fd8"
      unitRef="usd">1500000</dnli:AssetAcquisitionContingentConsiderationAmountRecognized>
    <dnli:AssetAcquisitionContingentConsiderationAmountRecognized
      contextRef="ib98115cad708471ebe459199e2f80f46_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfODI0NjMzNzIyMDQzNg_fdb36b95-3b11-4f3d-80ad-b2ed6daa4ce0"
      unitRef="usd">1500000</dnli:AssetAcquisitionContingentConsiderationAmountRecognized>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6f5e0ab57a754c6a92c0fdd5ab774b2d_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzM2Nw_20144f92-503b-44d9-a648-d3bda18339fe"
      unitRef="usd">18300000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i02c7d3db28004ce59eb812568e573405_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzM2Nw_246e4455-701c-421d-86ca-deffae94a9d1"
      unitRef="usd">18300000</us-gaap:ResearchAndDevelopmentInProcess>
    <dnli:AssetAcquisitionContingentConsiderationAmountRecognized
      contextRef="i975bd76e0cd24e4c801c23d18da1297b_D20180531-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzU2MA_12b6b431-6e28-4011-a6fc-cd071fda48eb"
      unitRef="usd">0</dnli:AssetAcquisitionContingentConsiderationAmountRecognized>
    <dnli:MaximumDevelopmentPlanPeriodForResearchCosts
      contextRef="ib519012f763b4591aa20a39b32e7dd07_D20160824-20160824"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMzkxNQ_4ce3ba4f-86ec-4fdc-9db7-f6106091b3ad">P24M</dnli:MaximumDevelopmentPlanPeriodForResearchCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i51ca5f46b88d4457b2266e87e2008a2a_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfNDA3NA_2bea5fa9-ca95-4ef3-bab6-7cc3e9759329"
      unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib98115cad708471ebe459199e2f80f46_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTA5OTUxMTYzMjM1Mw_95e91d73-80e9-43fc-9b06-38e8471e28ce"
      unitRef="usd">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02c7d3db28004ce59eb812568e573405_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTA5OTUxMTYzMjM4Mg_17955c7d-ec2d-45f3-8dfb-a50f3c7e2cf7"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6f5e0ab57a754c6a92c0fdd5ab774b2d_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80Ni9mcmFnOmI1NjUxZTZmZDEzMDRjMGNhMTMzZjUxNzQ0YjE0NGE4L3RleHRyZWdpb246YjU2NTFlNmZkMTMwNGMwY2ExMzNmNTE3NDRiMTQ0YThfMTA5OTUxMTYzMjQyOQ_1a5e6788-e1c8-49f8-9732-4070b2239299"
      unitRef="usd">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE2MDE_6cb709a9-1933-4233-ab92-a44baec8a0eb">Collaboration Agreements&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sanofi &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi") pursuant to which certain small molecule RIPK1 inhibitors contributed by Sanofi and by Denali will be developed and commercialized. The Sanofi Collaboration Agreement became effective in November 2018, at which time Sanofi paid the Company an upfront payment of $125.0 million. Under the Sanofi Collaboration Agreement, Denali is eligible to receive milestone payments from Sanofi up to approximately $1.1 billion upon achievement of certain clinical, regulatory and sales milestone events. Such milestone payments include $600.0 million in clinical and regulatory milestone payments for CNS Products and $495.0 million in clinical, regulatory and commercial milestone payments for Peripheral Products, as defined in the Sanofi Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Denali will share profits and losses equally with Sanofi for CNS Products sold in the United States and China, and receive variable royalties on net sales for CNS Products sold outside of the United States and China and for Peripheral Products sold worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Denali and Sanofi will jointly develop CNS Products pursuant to a global development plan. The Company will be responsible, at its own cost, for conducting Phase 1 and Phase 2 trials for CNS Products in Alzheimer&#x2019;s disease and any activities required to support such clinical trials and specific for Alzheimer&#x2019;s disease. Denali is conducting, at Sanofi&#x2019;s cost, a Phase 1b trial for the lead CNS penetrant RIPK1 inhibitor, DNL747, in ALS. Sanofi is responsible, at its cost, for all other Phase 1 and Phase 2 trials for CNS Products, including for multiple sclerosis. Sanofi will lead the conduct of all Phase 3 and later stage development trials for CNS Products, with Sanofi and Denali funding 70% and 30% of such costs, respectively. Sanofi will also lead the commercialization activities globally for CNS Products, subject to certain options that Denali has to conduct co-commercialization activities with respect to each CNS Product in the United States and China. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Sanofi will be responsible, at its cost, for conducting activities relating to the development and commercialization of all Peripheral Products. Denali will be entitled to receive tiered royalties in the low- to mid- teen percentages on net sales of Peripheral Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company identified the following distinct performance obligations associated with the Sanofi Collaboration Agreement upon inception: the CNS program license, the Peripheral program license, the Phase 1 and Phase 2 trials for CNS Products for Alzheimer&#x2019;s disease ("Alzheimer's Disease Services"), and the Phase 1b trial for DNL747 for ALS and associated activities ("Retained Activities"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that the Sanofi Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements. The Company also believes that Sanofi meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for three of the performance obligations identified at inception, but does not meet the definition of a customer for the Alzheimer's Disease Services. Further, Sanofi does not meet the definition of a customer for all Phase 3 and later stage development trials for CNS Products led by Sanofi for which Denali will fund 30% of total costs. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the Alzheimer's Disease Services, the guidance in ASC 606 should be analogized for the recognition, measurement and reporting of this performance obligation, and for the cost sharing provisions, the Company determined that the guidance in ASC 730, Research and Development should be applied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The transaction price at inception included upfront fixed consideration of $125.0 million. All potential future milestones and other payments were considered constrained at the inception of the Sanofi Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. The transaction price increased by $9.1 million from inception through June 30, 2019 as amounts due for costs incurred related to the Retained Activities were no longer constrained. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The respective standalone value for each of the performance obligations has been determined by applying the SSP method and the transaction price allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery or the provision of services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company used an adjusted market assessment approach to estimate the selling price for the program licenses, and an expected cost plus margin approach for estimating the Alzheimer&#x2019;s Disease Services and the Retained Activities. The program licenses and existing know-how were delivered on the effective date of the Sanofi Collaboration Agreement. The Alzheimer&#x2019;s Disease Services and the Retained Activities are expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, revenue will be recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Sanofi. For the Retained Activities, revenue will be recognized over time using the output method, based on amounts invoiced to Sanofi, since this is believed to directly correlate to the value of the services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A contract liability of $3.7 million and $3.9&#160;million was recorded on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. These contract liabilities relate to the portion of the Alzheimer's Disease Services performance obligation yet to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. There was a receivable of $3.4 million and $2.3 million at June 30, 2019 and December 31, 2018, respectively, associated with the Sanofi Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In assessing the Sanofi Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Managem&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;ent applies judgment in determining the separate performance obligations, in estimating the selling price, in determining when control was transferred to Sanofi for the licenses, and in estimating total future costs when using the input method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Through June 30, 2019, Denali has not recognized any milestones and has not recorded any product sales recorded under the Sanofi Collaboration Agreement. In July 2019, Sanofi received regulatory approval for the commencement of a DNL758 Phase 1 clinical trial in healthy volunteers. The trial commenced and triggered a milestone payment of $10.0 million, which the Company expects to receive in August 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Takeda &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company granted Takeda an option to develop and commercialize, jointly with the Company, certain biologic products that are enabled by Denali's blood-brain barrier ("BBB") delivery technology and intended for the treatment of neurodegenerative disorders. The programs were Denali&#x2019;s ATV:BACE1/Tau and ATV:TREM2 programs, as well as a third identified discovery stage program.&#160;The Takeda Collaboration Agreement became effective in February 2018, at which time Takeda paid the Company an upfront payment of $40.0 million. Takeda may pay up to an aggregate of $25.0 million with respect to each of the three programs directed to a target and based upon the achievement of certain preclinical milestone events, up to $75.0 million in total, $5.0 million of which was paid upon the Takeda Collaboration Agreement becoming effective. In February 2019, the agreement was amended to replace ATV:BACE1/Tau with ATV:Tau. The amendment did not have a material impact to the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Takeda Collaboration Agreement and unless otherwise agreed jointly between both parties, Denali will be responsible, at its cost, for conducting activities relating to&#160;pre-IND&#160;development of biologic products directed to the three identified targets and enabled by its BBB delivery technology targeting TfR during the applicable research period. The period through which the option can be exercised continues for each target until the first biologic product directed to the relevant target is&#160;IND-ready&#160;or approximately five years after selection of the target, whichever is earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;If Takeda exercises its option with respect to a particular target, then Takeda will have the right to develop and commercialize, jointly with the Company, a specified number of biologic products enabled by its BBB delivery technology that were developed during the research period and which are directed to the relevant target. The Company will grant to Takeda a&#160;co-exclusive&#160;license under the intellectual property the Company controls related to those biologic products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Takeda is obligated to pay Denali a $5.0 million option fee for each target for which Takeda exercises its option, up to $15.0 million in total.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, Takeda may be obligated to pay Denali up to an aggregate of $707.5 million upon achievement of certain clinical and regulatory milestone events if Takeda exercises its option for all three collaboration programs. Takeda may also be obligated to pay Denali up to $75.0 million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $225.0 million if one biologic product from each program achieves this milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;If Takeda exercises its option for a particular target, Denali and Takeda will share equally the development and commercialization costs, and, if applicable, the profits, for each collaboration program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the Takeda Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with Takeda on January&#160;3, 2018, pursuant to which Takeda purchased 4,214,559 shares of Denali&#x2019;s common stock (the "Shares") for an aggregate purchase price of $110.0 million. The sale of the Shares closed on February&#160;23, 2018. The fair market value of the common stock sold to Takeda was $94.4 million, based on the closing stock price of $22.40 on the date of issuance, resulting in&#160;a $15.6 million premium paid to the Company above the fair value of the Company's common stock which was credited to contract liability in the Company's condensed consolidated balance sheet.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that the Takeda Collaboration Agreement is a collaboration arrangement as defined in ASC&#160;808,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;.&#160;Further, during the research period, the Company believes that the arrangement is a contract with a customer as defined in ASC 606,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue From Contracts With Customers.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; The Takeda Collaboration Agreement and the Stock Purchase Agreement are being accounted for as one arrangement because they were entered into at the same time with interrelated financial terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company identified performance obligations during the research period consisting of the license, the development options, and joint steering committee ("JSC") participation together with the research services for each collaboration program. The license rights, JSC involvement, option and research services are considered to be a single performance obligation for each program since the research services are highly interrelated with the option and JSC involvement and will significantly modify the license. The performance obligations under each of the three programs are separate since the activities and risks under the programs are distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has determined that all other goods or services which are contingent upon Takeda exercising its option for each program are not considered performance obligations at the inception of the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The transaction price at inception included fixed consideration consisting of the upfront fee of $40.0 million, the $15.6 million premium on the sale of common stock, and the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;first preclinical milestone payment of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;$5.0 million. It also included variable consideration of $26.0 million relating to future milestones that were not constrained. The amount of variable consideration was estimated using the most likely amount method. A total of $15.0 million in preclinical milestone payments has been received under the Takeda Collaboration Agreement from inception through June 30, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The remaining $44.0 million of preclinical milestones were considered constrained at the inception of the Takeda Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. Additionally, cost and profit sharing income, and the development and commercial milestones as outlined above, have not been considered given Takeda has not exercised its options for the development and commercial phases for any program. There was no change in the transaction price from inception through June 30, 2019. This will be reassessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The transaction price has been ascribed in its entirety to the three performance obligations identified in the research term of the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue is recognized when, or as, the Company satisfies its performance obligations by transferring the promised services to Takeda. Revenue will be recognized over time using the input method, based on costs incurred to perform the research services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda. There were no material changes in estimates during the three and six months ended June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A contract liability of $63.5 million and $64.9 million was recorded on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. These contract liabilities relate to the three performance obligations identified, with such amounts to be recognized over the estimated period of the pre-IND research services, which is expected to be several years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue recognized relating to future milestone payments of $1.5&#160;million, which the Company concluded is probable that a significant reversal in the amount recognized will not occur, is presented net in the contract liability on the condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In assessing the Takeda Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Management applies judgment in determining the separate performance obligations in the research period, estimating variable consideration, and estimating total future costs when using the input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Through June 30, 2019, Denali has recognized $15.0 million in milestones from Takeda and has not recorded any product sales under the Takeda Collaboration Agreement. There was no receivable as of June 30, 2019, and a receivable of $5.0 million as of December 31, 2018, related to the Takeda Collaboration Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441026%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441026%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Takeda Collaboration Agreement&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;Alzheimer's Disease Services&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Retained Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Sanofi Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;(1)Amounts for the three and six months ended June 30, 2019 and the three months ended June 30, 2018 represent revenue recognized during the period that was included in the contract liability balance at the beginning of the period. There was no deferred revenue at the beginning of the period for the six months ended June 30, 2018.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dnli:UpfrontPayments
      contextRef="iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNTMx_c648fa77-7948-4a09-82ca-9c27f1825d64"
      unitRef="usd">125000000.0</dnli:UpfrontPayments>
    <dnli:AggregateClinicalRegulatoryAndSalesMilestonePayment
      contextRef="i5c733524c4364bb1abc239f59033a6be_I20181120"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNjU4_5e89ab33-6f54-418e-b332-90dceff470a1"
      unitRef="usd">1100000000</dnli:AggregateClinicalRegulatoryAndSalesMilestonePayment>
    <dnli:ClinicalAndRegulatoryMilestonePayment
      contextRef="i9cac8973f2034a84af0e4eb2891e8341_I20181120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzcw_e8321d3f-e472-4089-8275-888cb13cda42"
      unitRef="usd">600000000.0</dnli:ClinicalAndRegulatoryMilestonePayment>
    <dnli:ClinicalRegulatoryAndCommercialMilestonePayment
      contextRef="iaec92903cf114ddf965cde15c398dded_I20181120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODQw_40000986-4494-41ee-bc47-0c635db2acac"
      unitRef="usd">495000000.0</dnli:ClinicalRegulatoryAndCommercialMilestonePayment>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="i507009778f314351bad25199f392e188_I20181029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE2MQ_2341193e-37d2-496b-8ec3-9826f81909c4"
      unitRef="number">0.70</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="i06e6fd6fd17d48a7a5c80813484b128b_I20181029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE2OA_c37c691d-1a64-475f-a806-6025d070bb45"
      unitRef="number">0.30</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:CollaborativeAgreementFundedPercentage
      contextRef="i06e6fd6fd17d48a7a5c80813484b128b_I20181029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNTI5Nw_c37c691d-1a64-475f-a806-6025d070bb45"
      unitRef="number">0.30</dnli:CollaborativeAgreementFundedPercentage>
    <dnli:UpfrontPayments
      contextRef="iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNTg5Mw_c648fa77-7948-4a09-82ca-9c27f1825d64"
      unitRef="usd">125000000.0</dnli:UpfrontPayments>
    <dnli:CollaborationAgreementTransactionPriceIncrease
      contextRef="i3cb8f5ce74fd4b1b890b44970091705b_D20181001-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNjE4Nw_2bbbc986-e217-40a1-80c7-ebe5421f9d1e"
      unitRef="usd">9100000</dnli:CollaborationAgreementTransactionPriceIncrease>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2052c42ed02b4803ac262cf9409d6d92_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzU3NA_b79c32ba-2758-4543-9490-74e16c032a45"
      unitRef="usd">3700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if02f20c18d7e4a85a122b3bb744dc9bb_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzU4MQ_89cc6c33-8c99-4415-9d75-2a3b388643ba"
      unitRef="usd">3900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNet
      contextRef="i8c76dce5aed14afdbce822ee27041a9f_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzkyMw_ac2f949a-8c8b-47ee-b466-03b71969665e"
      unitRef="usd">3400000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="iba03e85f7755476dbbc016d142e2579a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzkzMA_e59fc8af-449a-446a-b419-a85dfd7851b4"
      unitRef="usd">2300000</us-gaap:AccountsReceivableNet>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="i3cb8f5ce74fd4b1b890b44970091705b_D20181001-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODQzNw_b376c583-eb21-465b-8305-28e43a9c52a5"
      unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41156f6db385494f9b24bd04dcc38e24_D20181001-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODQ3Mw_1e19a44c-2028-44a5-b898-4b1e15cf3fde"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dnli:ClinicalMilestonePayment
      contextRef="ieb617794c10c4d4ba7d9d482b9cd58bc_D20190801-20190831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODI0NjMzNzI1NzA2MA_98724453-bf0b-4763-bb9e-9cdc37f3121e"
      unitRef="usd">10000000.0</dnli:ClinicalMilestonePayment>
    <dnli:UpfrontPayments
      contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzE0NjgyNTYyOTIwMw_03267a27-182b-4a47-bf83-a7e5570b67a9"
      unitRef="usd">40000000.0</dnli:UpfrontPayments>
    <dnli:PreclinicalMilestonePaymentPerProgram
      contextRef="ic542e2b47d374ba59c6ab567374c8c94_D20180103-20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzE0NjgyNTYyOTIxOQ_e3518499-ef16-43a9-84fb-420feb86903f"
      unitRef="usd">25000000.0</dnli:PreclinicalMilestonePaymentPerProgram>
    <dnli:NumberOfPrograms
      contextRef="ia22967129e234978a541856d93c716a7_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5OTUxMTY3NzQzNA_82cd259e-c3c1-46f0-b3b3-a9e9d2e9c7b7"
      unitRef="program">3</dnli:NumberOfPrograms>
    <dnli:AggregatePreclinicalMilestonePayment
      contextRef="ic542e2b47d374ba59c6ab567374c8c94_D20180103-20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfNzE0NjgyNTYyOTI0NA_6d11f1be-b810-49f0-b956-06dd795592d3"
      unitRef="usd">75000000.0</dnli:AggregatePreclinicalMilestonePayment>
    <dnli:PreclinicalMilestonePaymentReceived
      contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfODI0NjMzNzI1NzAzOQ_f74b12ed-669a-4a0d-b0e9-1d3d18b4663f"
      unitRef="usd">5000000.0</dnli:PreclinicalMilestonePaymentReceived>
    <dnli:NumberOfTargets
      contextRef="ia53bec4ac3404ce2b6767a4da564148f_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY0OTI2NzQ5MTUzNg_2339a6ed-29e6-4457-9266-a5bec7c0bdd0"
      unitRef="targets">3</dnli:NumberOfTargets>
    <dnli:TargetOptionPeriod
      contextRef="i3f1aebd881a6473d8f034dc7cd3ba883_D20180103-20180103"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfOTk2Mw_a4ab649a-ff67-49d6-91a3-42e8b1fea5db">P5Y</dnli:TargetOptionPeriod>
    <dnli:OptionFeesPerProgram
      contextRef="ibc5ea44d386548708e70442d3abb3e3c_I20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5MjE_449e6191-3452-49d8-ac97-ce3647454216"
      unitRef="usd">5000000.0</dnli:OptionFeesPerProgram>
    <dnli:AggregateOptionExerciseFee
      contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5OTY_f600644f-cbf9-442a-bc1a-f9bd6779904f"
      unitRef="usd">15000000.0</dnli:AggregateOptionExerciseFee>
    <dnli:AggregateDevelopmentMilestonePayment
      contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTEwODM_2cc5af8a-b835-4f06-8975-5cc3f346cdcb"
      unitRef="usd">707500000</dnli:AggregateDevelopmentMilestonePayment>
    <dnli:CommercialMilestonesPerProgram
      contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTEyNzM_e0c7b16c-e148-4fdf-a5fe-936b3d640499"
      unitRef="usd">75000000.0</dnli:CommercialMilestonesPerProgram>
    <dnli:AggregateCommercialMilestones
      contextRef="id111363c81ee4dffbaa484859d2e9554_I20180103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTEzNjk_14d30069-e998-4491-8646-55273821aab7"
      unitRef="usd">225000000.0</dnli:AggregateCommercialMilestones>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTYyNTQ_cca28b4f-54e6-40c4-b2ee-a4fbe082a924"
      unitRef="shares">4214559</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTYzMzk_58157af3-93ec-4320-a19f-9a32e382ccb7"
      unitRef="usd">110000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="ifadb9641e1d64862836bde0c518e5c56_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY0NDE_0c5e3a19-9d23-46ec-b22c-7c6845127148"
      unitRef="usd">94400000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifadb9641e1d64862836bde0c518e5c56_I20180223"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY0ODE_f818e3ff-07a8-4938-8ade-0bfd4a692e8e"
      unitRef="usdPerShare">22.40</us-gaap:SaleOfStockPricePerShare>
    <dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction
      contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTY1MjQ_dd38fcf9-5f72-4a42-90dd-91e32e71b4eb"
      unitRef="usd">15600000</dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction>
    <dnli:RevenueNumberOfPerformanceObligations
      contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTA5OTUxMTY3NjgwNg_30208087-7157-43c2-9b95-a8539f91bfa3"
      unitRef="program">3</dnli:RevenueNumberOfPerformanceObligations>
    <dnli:UpfrontPayments
      contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgxNjU_03267a27-182b-4a47-bf83-a7e5570b67a9"
      unitRef="usd">40000000.0</dnli:UpfrontPayments>
    <dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction
      contextRef="id44a4dbe47504c68958abf0ab5820ebe_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgxNzM_dd38fcf9-5f72-4a42-90dd-91e32e71b4eb"
      unitRef="usd">15600000</dnli:SaleOfStockConsiderationPremiumReceivedOnTransaction>
    <dnli:PreclinicalMilestonePaymentReceived
      contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgyNjA_f74b12ed-669a-4a0d-b0e9-1d3d18b4663f"
      unitRef="usd">5000000.0</dnli:PreclinicalMilestonePaymentReceived>
    <dnli:VariableConsiderationFutureConsideration
      contextRef="ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTgzMDc_d515446c-46fd-49eb-9bdd-a91ded60c8bc"
      unitRef="usd">26000000.0</dnli:VariableConsiderationFutureConsideration>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="i506ba94099c0474082d55a807783f8de_D20180101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMzg0ODI5MDc0MzMxMw_a21c2a14-208b-4dc8-8624-7c561fb579bb"
      unitRef="usd">15000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <dnli:ConstrainedVariableConsideration
      contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTg3ODM_8d939eed-dca4-4871-a0b9-15cd42203d4f"
      unitRef="usd">44000000.0</dnli:ConstrainedVariableConsideration>
    <dnli:RevenueNumberOfPerformanceObligations
      contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTk0NDE_30208087-7157-43c2-9b95-a8539f91bfa3"
      unitRef="program">3</dnli:RevenueNumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia53bec4ac3404ce2b6767a4da564148f_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTk5ODc_304b722c-d9ff-41d9-b734-c9d99107e8f1"
      unitRef="usd">63500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2b83a26513784d7ba644b0159e2fcac2_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMTk5OTQ_41777996-1b4b-46bf-ae55-71893a020ce7"
      unitRef="usd">64900000</us-gaap:ContractWithCustomerLiability>
    <dnli:RevenueNumberOfPerformanceObligations
      contextRef="ic3628a04bd5a4cfbb9ee6914f99d28c9_I20180223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjAxMDQ_30208087-7157-43c2-9b95-a8539f91bfa3"
      unitRef="program">3</dnli:RevenueNumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i327284cdcb314428b0f05baf0584c173_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjAzNTM_0f8f1087-3c37-46cc-aa32-5efe7b3172f1"
      unitRef="usd">-1500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="i506ba94099c0474082d55a807783f8de_D20180101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjA5NTE_a21c2a14-208b-4dc8-8624-7c561fb579bb"
      unitRef="usd">15000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2bdbc9872a42678f000e70d3eb04e1_D20180101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjA5ODg_66605543-a4f1-4311-b1b5-b44de59bcaa5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dnli:PreclinicalMilestonePaymentEarnedNotYetReceived
      contextRef="ia53bec4ac3404ce2b6767a4da564148f_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjEwNzE_a09f062e-8ba1-440b-9f0d-320c6bfdfe63"
      unitRef="usd">0</dnli:PreclinicalMilestonePaymentEarnedNotYetReceived>
    <dnli:PreclinicalMilestonePaymentEarnedNotYetReceived
      contextRef="i2b83a26513784d7ba644b0159e2fcac2_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjExMTU_048676c5-9b94-44c5-9457-16f7c69536de"
      unitRef="usd">5000000.0</dnli:PreclinicalMilestonePaymentEarnedNotYetReceived>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE1OTk_32f0a767-458b-4a15-94c5-127107043f05">&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441026%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441026%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Takeda Collaboration Agreement&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;Alzheimer's Disease Services&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Retained Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Sanofi Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;"&gt;_________________________________________________&lt;/span&gt;&lt;/div&gt;(1)Amounts for the three and six months ended June 30, 2019 and the three months ended June 30, 2018 represent revenue recognized during the period that was included in the contract liability balance at the beginning of the period. There was no deferred revenue at the beginning of the period for the six months ended June 30, 2018.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i121aa99f2d3f4692bdd510f9652ac846_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi0xLTEtMS0w_8133c67e-ee5d-43a2-8314-390089ae5c92"
      unitRef="usd">740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ece0b562fb24861a00cc1837d3ba44d_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi0zLTEtMS0w_c25c6b3b-e2ca-482b-bbe5-51ff497efa21"
      unitRef="usd">1648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb48aaf3a1cf4e36903d0037ad367e4c_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi01LTEtMS0zODY_d3c10636-78c3-4af7-9e87-37bfe3252d81"
      unitRef="usd">1422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ec13fd38f514239afa935809142d525_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfMi03LTEtMS0zOTc_e7221c16-ec89-4fc8-b40a-69b976344547"
      unitRef="usd">2289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93f1e0b6d51d423fab44d10992a22439_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC0xLTEtMS0w_01e4d623-51bf-4352-ab63-d8cda9babb91"
      unitRef="usd">99000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0a29ec79a2640e5a067988c35bbf456_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC0zLTEtMS0w_5fe3f542-ba43-4433-a82e-e18d36dcb294"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaa172b849b9451881f587516f825b58_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC01LTEtMS0zODY_02c74b21-3b20-4bb1-bdc7-17e490b25fe6"
      unitRef="usd">193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b6d26112ff24d9ab029f080a339e130_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNC03LTEtMS0zOTk_5b12acf0-03bd-45d3-b874-fa00d79b41c4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i973a1b238c6743cf8760ffc6932c3a7e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS0xLTEtMS0w_efcfe2c2-6062-4365-afeb-0e55d37d1b8d"
      unitRef="usd">3358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1affd54d523b488da0673a88c0036970_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS0zLTEtMS0w_28d76d70-91ac-4250-8aed-f8acc11ba5c8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50e589b4bde248369e6e024a7f4abb85_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS01LTEtMS0zODY_933e14df-a691-4f61-b492-ed7523e88084"
      unitRef="usd">6787000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f7fab35ed3247c4a11fd24731d5db87_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNS03LTEtMS0zOTk_51488a8c-d4dd-4bc8-804d-1c3cc17af43d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86c1aab124cf41eab4654a55ce7d0456_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi0xLTEtMS0w_ec7b9f48-1251-4a4b-a293-8089561e5a73"
      unitRef="usd">3457000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ff05dbaad9645c284a3cedd8231323a_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi0zLTEtMS0w_3a4ae0d3-c3a6-4165-9f8f-14cab86bc253"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02d0ffc88019497f86735d349075b74c_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi01LTEtMS0zODY_fee72fc6-58d6-49db-86ee-baf96da31b93"
      unitRef="usd">6980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib97dc1f800de421eb8179a2c93529853_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNi03LTEtMS0zOTk_87e61061-98f9-409c-998c-b2190c95b255"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy0xLTEtMS0w_4859ce9e-8303-4563-ae6b-b5ebae365c84"
      unitRef="usd">4197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy0zLTEtMS0w_d39c0fae-d99d-43c3-9ebf-f7e62f9195a4"
      unitRef="usd">1648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy01LTEtMS0zODY_fbcd3fe4-799f-4855-8989-1e6b64fcf838"
      unitRef="usd">8402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RhYmxlOmRlN2UyMzU5MzlhYzQ2YTlhNjNkNzkxN2JjNmJkZGVkL3RhYmxlcmFuZ2U6ZGU3ZTIzNTkzOWFjNDZhOWE2M2Q3OTE3YmM2YmRkZWRfNy03LTEtMS0zOTk_a8c62f15-cb3a-4af9-9962-d7890298f721"
      unitRef="usd">2289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="i7de42ac379c3456094525bb4ad42c025_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF80OS9mcmFnOjMyM2RhNzJkMmU4ODQ1YjdhOWNhYWI4YzRkYWNjMmZhL3RleHRyZWdpb246MzIzZGE3MmQyZTg4NDViN2E5Y2FhYjhjNGRhY2MyZmFfMjE1MzM_4d73bdd9-fc0d-4c8b-8b7f-90d4d920de01"
      unitRef="usd">0</us-gaap:DeferredRevenue>
    <dnli:LicenseAgreementTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMzc3Nw_6aaaa30b-ba97-401d-944a-255217ea31e6">License Agreements&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Genentech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (&#x201c;Genentech&#x201d;). The agreement gives the Company access to Genentech&#x2019;s LRRK2 inhibitor small molecule program for Parkinson&#x2019;s disease. Under the agreement, Genentech granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under Genentech&#x2019;s rights to certain patents and patent applications directed to small molecule compounds which bind to and inhibit LRRK2 and (ii)&#160;a&#160;non-exclusive,&#160;worldwide, sublicensable license to certain related&#160;know-how,&#160;in each case, to develop and commercialize certain compounds and licensed products incorporating any such compound. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may owe Genentech milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $315.0 million in the aggregate, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages.&lt;/span&gt;&lt;/div&gt;To date, the Company has paid Genentech an upfront fee, a technology transfer fee and a clinical milestone payment totaling $12.5&#160;million in the aggregate, all of which were recorded as research and development expense as incurred. No amounts were recorded in the three and six months ended June 30, 2019 and 2018.</dnli:LicenseAgreementTextBlock>
    <dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones
      contextRef="if131cb24360a4f85bb336dd0ab7af8b9_D20160617-20160617"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTMwNQ_7eea2c35-af63-4012-b847-304cbcc7a5fb"
      unitRef="usd">315000000.0</dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones>
    <dnli:UpfrontFeesPaid
      contextRef="ief7842b7854c410c9c6bb0e061d46cec_D20160601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfNjU5NzA2OTc3ODY4NA_d926a2cc-1b42-4ccb-bf40-1fe5dcd2115a"
      unitRef="usd">12500000</dnli:UpfrontFeesPaid>
    <dnli:UpfrontFeesPaid
      contextRef="i38c69c189be94bfc9380598800c85b4c_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_0f6e007f-f2c1-474a-a54f-417889d7a9e6"
      unitRef="usd">0</dnli:UpfrontFeesPaid>
    <dnli:UpfrontFeesPaid
      contextRef="ia9fe92c33d98463bba6b004929024cfa_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_6f1b321f-48db-46eb-aa17-9564b4f382d5"
      unitRef="usd">0</dnli:UpfrontFeesPaid>
    <dnli:UpfrontFeesPaid
      contextRef="i6ff9d49b979f434281543ef489df6e3c_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_bfc06eb7-4ce3-4ace-85f3-4e9547eb37b0"
      unitRef="usd">0</dnli:UpfrontFeesPaid>
    <dnli:UpfrontFeesPaid
      contextRef="i0036869090d6435dba566fa93d050600_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81NS9mcmFnOmM0MDNlN2M2YTE5YjQ4ZDRiNmZkNDY1NTJlMmVlZDIzL3RleHRyZWdpb246YzQwM2U3YzZhMTliNDhkNGI2ZmQ0NjU1MmUyZWVkMjNfMTY0OTI2NzQ1Mzc0NQ_c8c7fa00-4cec-4223-9096-34f98c16cb32"
      unitRef="usd">0</dnli:UpfrontFeesPaid>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0NA_a43be5f1-8ada-4f53-8a3c-c9cc425b775b">Commitments and Contingencies &lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"&gt;In May 2018, the Company entered into an amendment to its operating lease for its former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand its headquarters to 148,020 rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of ten years from the legal commencement date, which was April&#160;1, 2019 when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which the Company was deemed to have obtained control over the property. The Company has an option to extend the lease term for a period of ten years by giving the landlord written notice of the election to exercise the option at least nine months, but not more than twelve months, prior to the expiration of the Headquarters Lease Amendment lease term. The Company did not believe this renewal was reasonably certain at lease inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"&gt;The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $25.9 million, which was fully utilized, of which $4.4 million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the condensed consolidated balance sheet as of June 30, 2019. The Company is also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"&gt;As of June 30, 2019, the carrying value of the ROU asset was $34.6 million. The related current and non-current liabilities as of June 30, 2019 were $2.0&#160;million and $70.9 million, respectively. The current and non-current lease liabilities are included in Other current liabilities and Operating lease liability, less current portion, respectively, in the Condensed Consolidated Balance Sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"&gt;Management was required to exercise judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for the Headquarters Lease Amendment, the discount rate used to determine the measurement of the lease liability. The discount rate used was 9.0%, which was management&#x2019;s estimate of the Company&#x2019;s incremental borrowing rate since the rate implicit in the lease was not known. To estimate the Company&#x2019;s incremental borrowing rate, management considered observable debt yields of comparable market instruments, as well as benchmarks within the Headquarters Lease Amendment that may be indicative of the rate implicit in the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Total operating lease costs, including variable and short term lease costs, were $2.5 million and $4.8 million for the three and six months ended June 30, 2019, respectively. Rent expense excluding amortization of leasehold improvements was $0.6 million and $1.3 million for the three and six months ended June 30, 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2019, the weighted average remaining lease term is 9.8 years and the weighted average discount rate used to determine the operating lease liability was 9.0%. Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2019 was $1.9 million and was included in Net cash used in operating activities in our condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of June 30, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.967949%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.262821%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.769231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38,217)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") to sublease approximately 36,835 rentable square feet of space in its New Premises. The Sublease Agreement has a term of five years from the commencement date of April&#160;12, 2019 and provides for the Company to receive monthly base rent amounts escalating over the term of the lease. The Company  also passes through a portion of the operating expenses for the New Premises to the sublessee, such as taxes and insurance, which are treated as variable sublease income. Total sublease income for the three and six months ended June 30, 2019, including rent and variable costs, was $0.8 million. There was no sublease income for the three and six months ended June 30, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table details the future undiscounted cash inflows relating to the Company's sublease as of June 30, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.967949%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.262821%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.769231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted sublease receipts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company&#x2019;s balance sheet, statements of comprehensive loss, or statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (&#x201c;DMSA&#x201d;) with Lonza Sales AG (&#x201c;Lonza&#x201d;) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated, the DMSA will expire on September&#160;6, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2019 and December 31, 2018, the Company had non-cancellable purchase orders for biological product development and manufacturing costs totaling $25.1 million and $24.7 million respectively. The activities under these purchase orders are expected to be completed by November 2024. As of June 30, 2019 and December 31, 2018, the Company had total non-refundable purchase commitments of $10.3 million and $14.0 million, respectively, under the DMSA.&lt;/span&gt;&lt;/div&gt;During the three months ended June 30, 2019 and 2018, the Company incurred costs of $3.1&#160;million and $1.1&#160;million, respectively, and made payments of $3.9&#160;million and $0.6 million, respectively, for the development and manufacturing services rendered under the DMSA. During the six months ended June 30, 2019 and 2018, the Company incurred costs of $6.7 million and $1.2 million, respectively, and made payments of $6.5 million and $0.7 million, respectively, for the development and manufacturing services rendered under the DMSA.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <dnli:OperatingLeasesAreaUnderLease
      contextRef="i0dd82aee18cf4b4d91431b4b49ef0bdb_D20180502-20180502"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfODIx_b04841d4-06b9-4f9f-9775-c197cb252719"
      unitRef="sqft">148020</dnli:OperatingLeasesAreaUnderLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i0de68e60891642eca083500a43ec45ec_I20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfOTc1_d3763b39-d513-4a22-b7a2-23d5792ea6c7">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i0de68e60891642eca083500a43ec45ec_I20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTI4OQ_c0251af7-7f68-43fa-80a0-b1235689fa81">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dnli:LesseeOperatingLeaseRenewalNoticePeriod
      contextRef="id56b451693a4495eaac87af0665021d3_D20180502-20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTM3OA_e205a88d-c96f-4683-ac46-c129ce6111d3">P9M</dnli:LesseeOperatingLeaseRenewalNoticePeriod>
    <dnli:LesseeOperatingLeaseRenewalNoticePeriod
      contextRef="i2634280b279f4601af826b4c8125dd23_D20180502-20180502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0NQ_73b8dc20-be01-430f-8de3-253b7fe1d64f">P12M</dnli:LesseeOperatingLeaseRenewalNoticePeriod>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="ic2c4f0ef14eb44cd94cfc60e492db814_I20180502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTc0Mg_d26c0308-2e15-4607-9d44-c2e92921f0bc"
      unitRef="usd">25900000</us-gaap:LeaseholdImprovementsGross>
    <dnli:TenantImprovementAllowanceRepayableAsRent
      contextRef="i9f8dc4dba49b4160b31e6e823e1ae788_D20180502-20180502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ1NzA1Ng_9c663e27-9e58-4c86-8878-28709c86bcf2"
      unitRef="usd">4400000</dnli:TenantImprovementAllowanceRepayableAsRent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjMwMA_9a39f4aa-20ef-4b5b-920d-259930d5ac50"
      unitRef="usd">34600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjQzNg_5cff89d4-fd61-4fc6-8bb1-31a98d92b414"
      unitRef="usd">2000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjQ0Mw_cfe68fff-591d-4185-a7f5-bd4d75c4c554"
      unitRef="usd">70900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMjkwMw_01a46361-d304-4629-9c0b-f7c4bee99216"
      unitRef="number">0.090</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCost
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTI2Nw_9071b409-5500-4d2d-9f18-740199e30dfe"
      unitRef="usd">2500000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTI4MQ_0dce60a8-0131-4c6b-8eda-60223ef2ab95"
      unitRef="usd">4800000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwOTk0OQ_1540082f-d0fb-4334-b3cd-978c86c42d89"
      unitRef="usd">600000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwOTk1Mg_35cc9f37-616c-4333-90cd-092f51d733c4"
      unitRef="usd">1300000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNDMzMw_114bcaec-6a18-4d81-a9ad-84ddb6025664">P9Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNDQzMw_0771cdc4-a62a-4a7d-a90e-3830961d5f79"
      unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNDUyNg_821ee9c2-2d4f-426d-959f-ba9eaa4e091f"
      unitRef="usd">1900000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0Mg_4aae8a02-c918-42b4-a775-ec512b4995ee">&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of June 30, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.967949%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.262821%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.769231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(38,217)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfMS0yLTEtMS0w_20042649-e513-41fd-9bbd-2f8bc49b8fd2"
      unitRef="usd">3642000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfMi0yLTEtMS0w_f1e267c4-3157-4980-9047-50ec4a6ad0ac"
      unitRef="usd">9767000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfMy0yLTEtMS0w_81925417-c227-4c07-b5f1-aac58adfcc2c"
      unitRef="usd">10386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNC0yLTEtMS0w_ee7beed2-f521-4237-a29c-79bbf5b0f6b3"
      unitRef="usd">10726000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNS0yLTEtMS0w_76f94952-bfb6-49a6-ae43-e3a84b073099"
      unitRef="usd">11078000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNi0yLTEtMS0w_e5026d8c-5f04-45db-8598-4460652b1717"
      unitRef="usd">65494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfNy0yLTEtMS0w_f0902c93-648c-40eb-9683-baaad2b9a5f3"
      unitRef="usd">111093000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfOC0yLTEtMS0w_6d8939a7-99f6-4149-8152-a9212d9ac7fb"
      unitRef="usd">38217000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOjc3YzJiZTAzMjVlNjQ5NDM5MTQ0ODU4ZmE2YmNkNGQyL3RhYmxlcmFuZ2U6NzdjMmJlMDMyNWU2NDk0MzkxNDQ4NThmYTZiY2Q0ZDJfOS0yLTEtMS0w_4a90f0b4-6561-4c0c-accc-a6e5a7c1772f"
      unitRef="usd">72876000</us-gaap:OperatingLeaseLiability>
    <dnli:OperatingLeasesSubleaseNetRentableArea
      contextRef="i6adb2eb42e59415094e9c0d4ffb38967_I20181031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzIzNQ_d5ceb8be-fb3c-436f-b540-3ad2a2f5b421"
      unitRef="sqft">36835</dnli:OperatingLeasesSubleaseNetRentableArea>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="i6adb2eb42e59415094e9c0d4ffb38967_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzMyNg_68f8c5ba-e6db-48d5-bef8-80ab7ef591f4">P5Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY4Mw_6c41cd73-d4de-478d-a2c5-a57296d1ae83"
      unitRef="usd">800000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY4Mw_c529a086-d12f-4f00-98f0-432273934959"
      unitRef="usd">800000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY5Nw_21cb2e11-bbc2-459b-9ae8-a461857b635d"
      unitRef="usd">0</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcwNzY5Nw_7085be2a-c427-46f1-adbd-b34312e9bb75"
      unitRef="usd">0</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzI0Mw_843bfcad-13e5-43f2-89b8-13aebcdd64ca">&lt;div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table details the future undiscounted cash inflows relating to the Company's sublease as of June 30, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.967949%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.262821%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.769231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted sublease receipts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfMS0yLTEtMS0w_1236afea-048d-4076-b20c-15c81a5d7fd5"
      unitRef="usd">1392000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfMi0yLTEtMS0w_50315afd-6f51-4598-a7e3-ad13a788790d"
      unitRef="usd">2842000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfMy0yLTEtMS0w_4ff8a602-5735-47eb-b4e9-545288a643bf"
      unitRef="usd">2925000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNC0yLTEtMS0w_62a3af84-d5d7-49f2-8060-55345a0804d1"
      unitRef="usd">3009000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNS0yLTEtMS0w_89a8e176-44fc-4447-8f39-bf3409d2f8ee"
      unitRef="usd">3096000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNi0yLTEtMS0w_377ee13d-f603-47f8-b243-860039c40efe"
      unitRef="usd">876000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RhYmxlOmVkNTYwODIzYTQyNjRmZmI4ZGM0NDU0NzhmMWQwZDg0L3RhYmxlcmFuZ2U6ZWQ1NjA4MjNhNDI2NGZmYjhkYzQ0NTQ3OGYxZDBkODRfNy0yLTEtMS0w_834583c5-fedd-4448-8e4b-0640a451f991"
      unitRef="usd">14140000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <dnli:PurchaseOrderExecuted
      contextRef="i293b5b178de44724a3a09c4a2268ccae_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjgwNQ_475423fc-65ad-4f6c-8646-d5a2f8a9242f"
      unitRef="usd">25100000</dnli:PurchaseOrderExecuted>
    <dnli:PurchaseOrderExecuted
      contextRef="ifcee909d65844bdd8691aaef6db01445_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjgxMg_c0280fcf-6edf-4a68-a87c-c56186fc99da"
      unitRef="usd">24700000</dnli:PurchaseOrderExecuted>
    <us-gaap:PurchaseObligation
      contextRef="i293b5b178de44724a3a09c4a2268ccae_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcxNzc4Ng_d5111879-3331-4845-840c-d3a0bdd49f4d"
      unitRef="usd">10300000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation
      contextRef="ifcee909d65844bdd8691aaef6db01445_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMzg0ODI5MDcxNzc5Mw_39b5e633-fa33-4f17-9b52-6b1ed71e333a"
      unitRef="usd">14000000.0</us-gaap:PurchaseObligation>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="i195078f2e63c4ec69a1f3aed2a49cca6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjk3Ng_ff020f9e-960c-4b9c-904e-6f3b88b21315"
      unitRef="usd">3100000</us-gaap:CostsIncurredDevelopmentCosts>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="i65a3e9667de048f9be4f3e9b194a89da_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNjk4Mw_48f4537a-f48f-44c7-bd44-ce276db312bd"
      unitRef="usd">1100000</us-gaap:CostsIncurredDevelopmentCosts>
    <dnli:PaymentsForManufacturingCost
      contextRef="i195078f2e63c4ec69a1f3aed2a49cca6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzAyMg_19f74934-3af1-4a63-9237-52607aed7a00"
      unitRef="usd">3900000</dnli:PaymentsForManufacturingCost>
    <dnli:PaymentsForManufacturingCost
      contextRef="i65a3e9667de048f9be4f3e9b194a89da_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfNzAyOQ_0462bcd2-3946-4393-9b23-c9680507ac5e"
      unitRef="usd">600000</dnli:PaymentsForManufacturingCost>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="i380397739fb3409c84068db1cde52240_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTY5OQ_ee1e81d3-b780-4360-a8af-1ed57a1ea871"
      unitRef="usd">6700000</us-gaap:CostsIncurredDevelopmentCosts>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="if3fd410c4ab04f2a98010ca624256620_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTcwNg_6d62319b-827d-47e4-8c4f-efc5a2bd7484"
      unitRef="usd">1200000</us-gaap:CostsIncurredDevelopmentCosts>
    <dnli:PaymentsForManufacturingCost
      contextRef="i380397739fb3409c84068db1cde52240_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTc0Nw_ef14397a-7b06-4326-82b4-644061a62812"
      unitRef="usd">6500000</dnli:PaymentsForManufacturingCost>
    <dnli:PaymentsForManufacturingCost
      contextRef="if3fd410c4ab04f2a98010ca624256620_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF81OC9mcmFnOmYxZjhjY2JiMDQyZjQ4YzliYTU3NDlkNTNlY2VlYjNjL3RleHRyZWdpb246ZjFmOGNjYmIwNDJmNDhjOWJhNTc0OWQ1M2VjZWViM2NfMTY0OTI2NzQ0OTc1NA_2f0ca506-5390-43ba-8904-0b76a441a0c9"
      unitRef="usd">700000</dnli:PaymentsForManufacturingCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNTE_70d6d941-9c73-4831-98bc-c6530a37380c">Stock-Based Awards&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2017, the Company adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;), which initially reserved approximately 6.4&#160;million shares of common stock for the issuance of stock options,&#160;restricted stock and other stock awards, to employees,&#160;non-employee&#160;directors, and consultants under terms and provisions established by the Board of Directors and approved by the stockholders. The 2017 Plan provides that the number of shares reserved and available for issuance under the 2017 Plan will automatically increase each January 1, beginning on January 1, 2019, by the least of (i) 10.0 million shares, (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the administrator of the 2017 Plan. In January 2019, common stock available for issuance under the 2017 Plan was increased by approximately 4.8 million shares as a result of this automatic increase provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Awards granted under the 2017 Plan expire no later than&#160;ten years from the date of grant. For stock options, the option price shall not be less than&#160;100%&#160;of the estimated fair value of the Company's common stock on the day of grant. Options granted typically vest over a&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTIzMQ_89106c99-db8f-42c3-9be0-ac8e95402417"&gt;four&lt;/span&gt;-year period but may be granted with different vesting terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2015 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;In May 2015, the Company adopted the 2015 Stock Incentive Plan (the &#x201c;2015 Plan&#x201d;), which as amended, reserved approximately 8.3 million shares of common stock for the issuance of stock options, restricted stock and other stock awards, to employees,&#160;non-employee&#160;directors, and consultants under terms and provisions established by the Board of Directors and approved by the stockholders. Awards granted under the 2015 Plan expire no later than&#160;ten years from the date of grant. For stock options, the option price shall not b&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;e less than&#160;100%&#160;of the estimated fair value of the Company's common stock on the day of grant. Options granted typically vest over a&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjIwNQ_7426f688-b493-4e9a-8e34-f30a5275909d"&gt;four&lt;/span&gt;-year period but may be granted with different vesting terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon adoption of the 2017 Plan, no new awards or grants are permitted under the 2015 Plan, and the approximately 0.2 million shares that were then unissued and available for future award under the 2015 Plan became available under the 2017 Plan. The 2015 Plan will continue to govern restricted stock awards and option awards previously granted thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2019 there were approximately 3.7&#160;million shares available for the Company to grant under the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes option award activity under the 2017 Plan and the 2015 Plan:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;margin-bottom:10pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.391026%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Number&#160;of&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted- &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted- &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;remaining&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;contractual&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Aggregate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Intrinsic&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,612,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,296,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(465,281)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(447,374)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,996,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options vested and expected to vest at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,251,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,228,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Aggregate intrinsic value represents the difference between the Company&#x2019;s estimated fair value of its common stock and the exercise price of outstanding options. The total intrinsic value of options exercised was $5.1&#160;million and $8.4&#160;million for the three and six months ended June 30, 2019, respectively, and $3.5 million and $4.7&#160;million for the three and six months ended June 30, 2018, respectively. During the three and six months ended June 30, 2019, the weighted-average grant date fair value of the vested options was $9.35 and $10.80 per share, respectively. During the three and six months ended June 30, 2018, the weighted-average grant-date fair value of the vested options was $2.83 and $2.87 per share, respectively. The weighted-average grant date fair value of all options granted during the three and six months ended June 30, 2019 was $13.16 and $11.92 per share, respectively. The weighted-average grant date fair value of all options granted during the three and six months ended June 30, 2018 was $13.37 and $15.90 per share, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Options Granted to Employees with Service-Based Vesting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.365385%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;5.50 - 6.08 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;66.9% - 77.8% &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.0% - 85.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.9% - 77.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.0% - 87.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;2.0% - 2.3% &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7% - 2.9%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0% - 2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6% - 2.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Term:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the&#160;mid-point&#160;between the vesting date and the end of the contractual term).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.  The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-Free Interest Rate:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Dividend:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Performance and Market Contingent Stock Options Granted to Employees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August and November 2015, the Board of Directors granted approximately 1.6 million and 0.1 million shares of performance- and market- contingent awards to members of the senior management team, respectively. These awards have an exercise price of $0.68 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;These awards have two separate market triggers for vesting based upon either (i)&#160;the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company&#x2019;s initial public offering for its common stock, or (ii)&#160;stepped target prices for a change in control transaction. In the event that neither of these market triggers are achieved by the specified timelines, such awards will terminate with respect to that portion of the shares. The expense recognized associated with these performance- and market- contingent awards is $4.8 million and $0.4 million of general and administrative and research and development expense, respectively, for the three and six months ended June 30, 2019. The remaining expense to be recognized for these awards, using the accelerated attribution method, is $0.8&#160;million which will be recognized over the remaining derived service period of approximately &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjE5Ng_40ff6178-4587-42fe-8169-938e295fadf9"&gt;one&lt;/span&gt; year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company used a lattice model with a Monte Carlo simulation to value these stock options. This valuation methodology utilized the estimated fair value of the Company&#x2019;s common stock on grant date and several key assumptions, including expected volatility of the Company&#x2019;s stock price based on comparable public companies, risk-free rates of return and expected dividend yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Options Granted to&#160;Non-Employees&#160;with Service-Based Vesting Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation related to stock options granted to&#160;non-employees&#160;is recognized as the stock options are earned. Prior to the adoption of ASU 2018-07 during the third quarter of 2018, the unvested options granted to non-employees were revalued using the Company's estimate of fair value on each reporting date. Subsequent to the adoption of ASU 2018-07, existing stock options granted to non-employees are no longer revalued, and the estimated fair value of new stock options granted to non-employees is calculated on the date of grant and not remeasured, similar to stock options granted to employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the 2017 Plan, the Company may grant restricted stock awards ("RSAs"), which represent restricted shares of issued common stock for which the recipient's rights in the stock are restricted until the shares are vested, and restricted stock units ("RSUs"), which represent a commitment to issue shares of common stock in the future upon vesting. The fair value of restricted stock underlying the RSAs and RSUs is determined based on the closing market price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Aggregated information regarding RSAs and RSUs granted under the Plan for the six months ended June 30, 2019 is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:62.903846%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.147436%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.147436%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share Awards &amp;amp; Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;503,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;494,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(353,585)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,639)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;610,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected to vest - June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;610,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2017, the Company adopted the 2017 Employee Stock Purchase Plan (the &#x201c;2017 ESPP&#x201d;), which initially reserved &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;1.0 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; shares of common stock for employee purchases under terms and provisions established by the Board of Directors. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2017 ESPP provides that the number of shares reserved and available for issuance under the 2017 ESPP will automatically increase each January 1, beginning on January 1, 2019, by the least of (i) 2.0 million shares, (ii) 1% of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the administrator of the 2017 Plan. In January 2019, common stock available for issuance under the 2017 ESPP was increased by approximately 1.0 million shares as a result of this automatic increase provision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the 2017 ESPP, employees may purchase common stock through payroll deductions at a price equal to&#160;85%&#160;of the lower of the fair market value of common stock on the first trading day of each offering period or on the exercise date. The 2017 ESPP provides for consecutive, overlapping 12-month offering periods. The offering periods are scheduled to start on the first trading day on or after May 31 or November 30 of each year. Contributions under the 2017 ESPP are limited to a maximum of&#160;15%&#160;of an employee's eligible compensation. During the three and six months ended June 30, 2019 and 2018, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;0.1 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; shares of common stock were issued under the 2017 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s results of operations include expenses relating to stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.185897%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2019, total unamortized stock-based compensation expense related to employee and non-employee awards was $86.7 million. The weighted-average periods over which such stock-based compensation expense will be recognized is approximately 3.0 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7d1a63d9fd9048e9b346a1bb1e5b53be_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTgy_884b149c-683f-4115-93a9-0833272889ca"
      unitRef="shares">6400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i7d1a63d9fd9048e9b346a1bb1e5b53be_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjIz_077cef6d-78c8-43c2-a698-1f29a569613e"
      unitRef="shares">10000000.0</dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ie3d6c473afb5460780db3507a8b37630_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjM5_bf5b492a-1fd2-47d8-ae57-26f670e47ac2"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i0427708156c3454cb4eb96e9b7ea3878_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTE1_f6dbec31-ba38-48ac-aa1d-d58f799b38e9"
      unitRef="shares">4800000</dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i1fc1cd06135f47ebb307c315c07c68a8_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAyNQ_a9d2494f-6fec-4dfa-ac5a-74e015496c4a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="iecff526c59e7452aafbe14147f3cc250_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTExMQ_b2a7ee17-4b57-47ae-b0f4-a8657c6825de"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i32a76c5b5b6e4f3f9cd6493d2dba156f_I20150531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTQ0Nw_7e575ea1-b637-4ba8-9d92-6042e6a10564"
      unitRef="shares">8300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i5e0e4017eafa4b21a497bff216646578_D20150501-20150531"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTc1OA_d6d6e1be-e245-4052-b4bf-991a25c198b6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="iedf7537799d4426a9667a6f97c5239eb_D20150501-20150531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTg0NA_a758c259-d307-4b2e-b739-aad17cfb1f37"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i82d03abee79c4854acb028d0eef7bf6b_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjMwMw_3b1b4eaf-ffec-4f7d-bbb6-8facbc261dec"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ieea49b8c39144a13b75a300520691ead_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjM4NA_abdd4c6f-9ec6-4460-97ed-f6fcc9410685"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if52074d4e46047fdb42400ddf9179e83_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjY1Mg_5b95be6a-4df9-4dc9-aa17-633b4b26353e"
      unitRef="shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNDg_9fe7ad69-cb40-45bc-b48d-e1c8a6fe28e5">&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes option award activity under the 2017 Plan and the 2015 Plan:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;margin-bottom:10pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.391026%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.301282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Number&#160;of&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted- &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted- &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;remaining&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;contractual&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Aggregate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Intrinsic&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;"&gt;Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,612,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,296,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(465,281)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(447,374)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,996,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options vested and expected to vest at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,251,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercisable at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,228,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS0xLTEtMS0w_7c3784cd-58d8-484a-8700-3d372a330bf8"
      unitRef="shares">9612652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS0zLTEtMS0w_e08e24a7-5ad6-4bfc-9d17-4735e7ac184a"
      unitRef="usdPerShare">10.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifceb656364a74a0da5c6b45c4e52919b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS01LTEtMS0w_7ebf941d-e42c-42c7-97c6-1420a7f6573a">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2735e2fbf77f4227a366ac2442ba6c00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMS03LTEtMS0w_69a7cec8-05b9-492b-bcbf-965d84c7c4ca"
      unitRef="usd">97804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMi0xLTEtMS0w_14883dbc-a5ea-4dbc-ba8e-283ccdc160b2"
      unitRef="shares">3296335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMi0zLTEtMS0w_654fd219-6d42-4095-88d2-e0a9cc898afc"
      unitRef="usdPerShare">18.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMy0xLTEtMS0w_3aafd493-3b60-410d-bceb-2f0cc92573f2"
      unitRef="shares">465281</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfMy0zLTEtMS0w_37f7de7a-776c-4a07-9504-7f5ceb7337fd"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNC0xLTEtMS0w_ab9a1fa3-ef04-4d05-aba2-925755d6599f"
      unitRef="shares">447374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNC0zLTEtMS0w_036a2aff-304e-4b59-a5cb-4836ca0f933b"
      unitRef="usdPerShare">16.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS0xLTEtMS0w_7e997376-60fd-411d-a8bd-8733d468f2da"
      unitRef="shares">11996332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS0zLTEtMS0w_88113b04-5a79-4e9a-bce7-0153aab96c5b"
      unitRef="usdPerShare">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS01LTEtMS0w_c9364d05-2b47-423e-8e30-4663d316b52f">P8Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNS03LTEtMS0w_7c0d041c-1088-4974-a68c-9acc9b73d34f"
      unitRef="usd">96434000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi0xLTEtMS0w_5841f7f9-01c4-4ec8-9257-ee4593dae3a7"
      unitRef="shares">10251600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi0zLTEtMS0w_09950949-dee9-48f4-8cf0-02f418e733de"
      unitRef="usdPerShare">14.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi01LTEtMS0w_9402cf51-ebbb-472f-921a-c7d9d5925d2d">P8Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNi03LTEtMS0w_11773d0f-29f8-4c1f-ad7b-67a58e6dcbcc"
      unitRef="usd">61400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy0xLTEtMS0w_33f53774-5ad3-404d-988d-2215158e45e2"
      unitRef="shares">3228421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy0zLTEtMS0w_bf6f293f-1b51-42d1-b528-14c334f79af5"
      unitRef="usdPerShare">10.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy01LTEtMS0w_414f45fb-936a-48a0-bb40-1652c533b942">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if15afa2e1e5d465bbf364f085370272d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjdjNjVjMjMyYWUzNDRlNDBiNjkxZmQ4ZTU2MGYwMDhiL3RhYmxlcmFuZ2U6N2M2NWMyMzJhZTM0NGU0MGI2OTFmZDhlNTYwZjAwOGJfNy03LTEtMS0w_4e3853da-8874-4d3a-82ef-766cbc9402f7"
      unitRef="usd">34173000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzA1MQ_28603328-e006-4a2e-9343-a5fc36175140"
      unitRef="usd">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MjkzMA_2047fc0e-5d12-4fd3-9b96-51f9a4148bf3"
      unitRef="usd">8400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1Mjg5Ng_fce5317f-f0e4-49bf-b82a-ed1b21d3be05"
      unitRef="usd">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MjkzNQ_aa61c1c9-d9d3-442c-8cfb-edb0cd7f7873"
      unitRef="usd">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzE5Mg_222bf54c-fb74-44a7-99f4-62ef5eb07932"
      unitRef="usdPerShare">9.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzAyNw_6269b98d-fb69-40b4-a1e7-9e40508fe8cc"
      unitRef="usdPerShare">10.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzE5OQ_8ad91e25-b808-41c7-bec0-71c6b47bb288"
      unitRef="usdPerShare">2.83</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzIwMQ_e3cdca82-7359-450b-a449-e8cf3ac6807a"
      unitRef="usdPerShare">2.87</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzMyMQ_1f5371d5-3cd0-446b-b276-58a62cff3946"
      unitRef="usdPerShare">13.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzI5OA_18d25557-f70d-403c-bcd3-b20bc3d7191e"
      unitRef="usdPerShare">11.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzMyOA_c34532ca-bed3-42e0-8ea7-8475203e4859"
      unitRef="usdPerShare">13.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTY0OTI2NzQ1MzQ1NA_b888b5dd-d573-4ed3-a366-e7c179409fc3"
      unitRef="usdPerShare">15.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjc0ODc3OTA5MTQxMw_b5cf856f-3df1-4483-8d8d-2417198e074a">&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.365385%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.307692%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;5.50 - 6.08 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.50 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;66.9% - 77.8% &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.0% - 85.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.9% - 77.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.0% - 87.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;2.0% - 2.3% &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7% - 2.9%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0% - 2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6% - 2.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS0xLTEtMS0w_297fdf1e-71ba-4856-a7b3-1a3f4759e826"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS0zLTEtMS0w_83a7f4cc-1b0f-4d45-9caf-d1a84c726398"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS01LTEtMS0w_a010da65-4a88-4fde-a8d2-eff822b11732"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjA3NTUzOGIxZGZkYzRjMDk5ZjdjNWViOWY5ZDUyYjk4L3RhYmxlcmFuZ2U6MDc1NTM4YjFkZmRjNGMwOTlmN2M1ZWI5ZjlkNTJiOThfNS03LTEtMS0w_35a114dd-6e1a-48e5-ad1f-393db1012916"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:Dividends
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjA0NQ_e8caf010-8815-4798-a507-44668a47b51e"
      unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDY4NQ_9bfe8627-604f-44d7-b085-54f7d18409c9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3f3fe6755fa445a7b223008c32301c1a_D20150801-20150831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDgzMw_f7e6acf8-24d2-40e3-a6a1-4cad74d3c26a"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if4cc341fdaab4fb1baca8e685795587f_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDg0MA_58c2c22a-11e2-4b58-9072-4ee8a86458a3"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if4cc341fdaab4fb1baca8e685795587f_D20151101-20151130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDk5MQ_d9313f18-60a1-4824-90d9-43ad9bb894ce"
      unitRef="usdPerShare">0.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3f3fe6755fa445a7b223008c32301c1a_D20150801-20150831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNDk5MQ_fdd3aee5-f324-4636-a065-2a80d39d79c7"
      unitRef="usdPerShare">0.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays
      contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNTE4NQ_e0db0834-7abd-469e-b7d7-46d6adba9bb7">P90D</dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays>
    <dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering
      contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNTIyNA_9fb7ce13-4ad2-4ae2-a0ae-cb750b32fc74">P180D</dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering>
    <dnli:PerformanceAndMarketShareBasedCompensation
      contextRef="id498dc8dfd914e4ca6892bfb92be83bd_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA2NA_6cc0e06b-c277-4ead-a599-d68fbcf31303"
      unitRef="usd">4800000</dnli:PerformanceAndMarketShareBasedCompensation>
    <dnli:PerformanceAndMarketShareBasedCompensation
      contextRef="i8ef8038c831e4d59a9459cb27f4f1ec8_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA2NA_7226a640-7a8c-469f-9522-7941d1a03aea"
      unitRef="usd">4800000</dnli:PerformanceAndMarketShareBasedCompensation>
    <dnli:PerformanceAndMarketShareBasedCompensation
      contextRef="ifb1c8f46d9a3426091ee2103297afede_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA3MQ_6359bcc5-4039-455f-a270-4b1820aaded2"
      unitRef="usd">400000</dnli:PerformanceAndMarketShareBasedCompensation>
    <dnli:PerformanceAndMarketShareBasedCompensation
      contextRef="ib89660bd12204c74b680b13055456d71_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfNjA3MQ_cd3fef4d-058e-4246-b8b1-b49f7d9eb1bd"
      unitRef="usd">400000</dnli:PerformanceAndMarketShareBasedCompensation>
    <dnli:PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized
      contextRef="i421f99d073834ccf9c51e24b07c5efb5_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMzg0ODI5MDcxODQyNQ_f3d7ca2c-d77a-4285-85ce-4ff23315b8ef"
      unitRef="usd">800000</dnli:PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNTQ_82a0c2d0-d73b-413e-835a-3c5752381fda">&lt;div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Aggregated information regarding RSAs and RSUs granted under the Plan for the six months ended June 30, 2019 is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:62.903846%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.147436%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.147436%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share Awards &amp;amp; Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;503,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;494,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(353,585)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,639)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;610,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected to vest - June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;610,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4b8980df381840e981e39e869a8ad187_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMS0xLTEtMS0w_20171844-ec07-4657-92e6-bfdedd01ed7b"
      unitRef="shares">503243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4b8980df381840e981e39e869a8ad187_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMS0zLTEtMS0w_08bc4c46-e217-4ab9-8599-47012e84ea85"
      unitRef="usdPerShare">4.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMi0xLTEtMS0w_134ff4c5-1ba9-481a-8b2c-f489e88fd674"
      unitRef="shares">494984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMi0zLTEtMS0w_4f5c815c-ca46-4cd1-b3a2-f30e6b94d403"
      unitRef="usdPerShare">19.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMy0xLTEtMS0w_08a07453-67e2-4110-b9c3-067906695f1f"
      unitRef="shares">353585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfMy0zLTEtMS0w_6952e719-b9f6-4892-b7bb-17e74447a1a2"
      unitRef="usdPerShare">0.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNC0xLTEtMS0w_197c3ca3-654b-448b-ac50-ba721fb635ab"
      unitRef="shares">34639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNC0zLTEtMS0w_f3bc8b0b-6c2a-4b63-b3d4-6461709fa01b"
      unitRef="usdPerShare">21.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia6a1246830c7445e9ce63b86b50115b5_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNS0xLTEtMS0w_e0680112-7dea-40d0-9584-c139145f54cc"
      unitRef="shares">610003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia6a1246830c7445e9ce63b86b50115b5_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNS0zLTEtMS0w_e433a932-4a69-479b-84cf-566b4eead36a"
      unitRef="usdPerShare">18.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia6a1246830c7445e9ce63b86b50115b5_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNi0xLTEtMS0w_a8b40d66-63ec-4a63-b62a-efbc5cd5667d"
      unitRef="shares">610003</dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest
      contextRef="icfb128f16f1e4575885da6b03e58be47_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOjE3NTAzM2U5ZTM4MDQ3OGE4YWE1MGQxNTU5YTQ2MjQyL3RhYmxlcmFuZ2U6MTc1MDMzZTllMzgwNDc4YThhYTUwZDE1NTlhNDYyNDJfNi0zLTEtMS0w_566059a8-5f32-4ca6-b1f9-20aaf039f97f"
      unitRef="usdPerShare">18.44</dnli:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfODQ2Mg_84ab336c-ae42-43d9-85fd-52bfd7a20219"
      unitRef="shares">1000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfODc1NQ_38a964f0-83f1-40fe-9873-e97daa8e36b4"
      unitRef="shares">2000000.0</dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i33146e3241854f64a4965054ea62ee6c_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfODc3MQ_95d8dcd3-1633-4280-a464-fc6f5a67ea6e"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i71431700ff4c41c698876f5248f1b209_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTA0Nw_22115274-508d-43b9-8f6f-26ed7abd9ac2"
      unitRef="shares">1000000.0</dnli:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="i33146e3241854f64a4965054ea62ee6c_D20171201-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTIxMg_361022d3-91d7-48d7-9c63-9790183fad72"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i6558b77a528e4e5ea7f03fe9eaba3494_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTYwMg_92940351-4eec-4ac0-be08-2ef7ae11b86a"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i33aae1a9291846d08a77fafcbb0fd48f_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_3f1556f6-5b2f-4bc6-9a56-4c870d3d8a40"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ic58d3dfd7fcb4f99a54807dfac3b6669_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_516950ab-64af-40d3-a40e-bb2f4b6df0bc"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="if1f6b3468396492fb70d28ad0e7f8b98_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_d6348119-a570-403b-bb08-abce88936cba"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie1b4ec6e313c422fb982eb70ccc6089b_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfOTY3MA_e02da434-aa7a-41fd-a3a5-80d8e3613b9e"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNTI_b25fd2e4-ed78-4ed4-8285-baaf38400d7c">&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s results of operations include expenses relating to stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.185897%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102564%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d2e60ed90c84ab2b33750989f3caf7b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi0xLTEtMS0w_8b39bf0c-a2d0-4f84-bdf3-6b50594c4ed5"
      unitRef="usd">5295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81c40a2236074822a36030b30b61a38c_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi0zLTEtMS0w_986c9305-24e6-466c-98e0-718eb15edb8c"
      unitRef="usd">2586000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b68413bf0b9461591e8c59a2ccb9464_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi01LTEtMS0w_0260f2a8-3d49-4b24-bfe1-0be253ffcd51"
      unitRef="usd">9277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i362003e4d15e477299173e68bb66528d_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMi03LTEtMS0w_66ad1103-694b-446d-8ad8-60bff4366ec7"
      unitRef="usd">4272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0f2e8ea17014067925b92520d7e19bf_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy0xLTEtMS0w_4a514d0f-e856-40da-aac0-aae77bb4efea"
      unitRef="usd">8419000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4633b220bff4b1ea513d03256f027b0_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy0zLTEtMS0w_afd287f3-31b3-4f3e-8777-7b9b4deb702c"
      unitRef="usd">2124000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i05bfa152469e4c2a8509fcde1cfa0f93_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy01LTEtMS0w_bcc40aff-3f01-48c4-9904-b734bec35e25"
      unitRef="usd">11311000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieffd6c376be94ea4a96216622c548e7f_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfMy03LTEtMS0w_c11aa3ff-8711-41bb-8ad2-4655991ed2c2"
      unitRef="usd">3363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC0xLTEtMS0w_41aa2eea-86e4-4c5f-b594-3747da3e0e53"
      unitRef="usd">13714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC0zLTEtMS0w_ba9375c1-c73a-4474-9dc0-d6ab518a15c4"
      unitRef="usd">4710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC01LTEtMS0w_a27e5403-befa-4299-9a64-35f23717fcbb"
      unitRef="usd">20588000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RhYmxlOmFlZWViMzljN2UyNzQwODk4ODM0MDJjNzQ2MjgyMzQ2L3RhYmxlcmFuZ2U6YWVlZWIzOWM3ZTI3NDA4OTg4MzQwMmM3NDYyODIzNDZfNC03LTEtMS0w_fd173296-2e3e-4811-82e8-7fa4eb8baafd"
      unitRef="usd">7635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if979d5313f0948369e6c21ef7aec9f23_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAwMjc_380a9527-f636-4a90-a54d-58d5e98d378b"
      unitRef="usd">86700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTAxNDU_724ef4fc-3a05-4884-9e08-d89b7782fecd">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RleHRyZWdpb246MGU2OGFmNGE2NWJhNDZjOWFhZmY2ZmYyY2FjNjI0NDVfNDI5_96bae61e-4a1f-4553-8e46-76e681cf002a">Net Loss Per Share&lt;div style="text-indent:27pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.288462%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.596154%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.314103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three and Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options issued and outstanding and ESPP shares issuable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,214,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,264,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;610,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,167,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Early exercised common stock subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;229,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,865,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,661,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RleHRyZWdpb246MGU2OGFmNGE2NWJhNDZjOWFhZmY2ZmYyY2FjNjI0NDVfNDI4_77b32f8b-700f-4dd4-a039-3912c35bb299">&lt;div style="text-indent:27pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.288462%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.596154%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.314103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three and Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options issued and outstanding and ESPP shares issuable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,214,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,264,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;610,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,167,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Early exercised common stock subject to future vesting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;229,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,865,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,661,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1b682f4a3a5c487695cf4824ecff6284_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0xLTEtMS0w_b81a9781-4bc6-4a90-af19-a038b4780aa6"
      unitRef="shares">12214029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8afd96134f0548538b390aa584b11fbd_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0xLTEtMS0w_eaca3301-d01b-446e-a53a-90dea4263b76"
      unitRef="shares">12214029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0fd6c4f1d91440f7aab878612276cb59_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0zLTEtMS0w_2af62eb3-289b-4c21-8c0f-ce0b24628e45"
      unitRef="shares">9264644</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7f9cdfc6602e4cbcbb2d61b338e5e9d1_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMi0zLTEtMS0w_da5c08fb-5e7d-44a6-be32-50d0ae7cd3b4"
      unitRef="shares">9264644</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i000b38f6d8874a1ba6da55900807e8e1_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0xLTEtMS0w_ce1dfcd7-66d9-40a6-b643-590f17fafa66"
      unitRef="shares">610003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie3c2ef2c49884bb4b4428fbe8e81d56e_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0xLTEtMS0w_d1e3cb74-5289-462e-820e-5c0d161b1dc7"
      unitRef="shares">610003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id8b5ff74e3d147f392767ecdbd341aa2_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0zLTEtMS0w_03fa2ecc-8971-4dc9-9824-f0e2e2395d89"
      unitRef="shares">1167997</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7196f17f798b440fb5034d6f6a84eb2e_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfMy0zLTEtMS0w_f2431c5d-5573-41da-af24-518a50515fab"
      unitRef="shares">1167997</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie5d5f8a792ce41f6b36480b7307d2e65_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0xLTEtMS0w_62afc513-0d35-41f7-abd5-482184dbf17f"
      unitRef="shares">41672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id99aa73c5353433e959eff9dba13f059_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0xLTEtMS0w_c28e12f2-28a7-4af3-a639-dfdbf68764f4"
      unitRef="shares">41672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i97e55800d90541c4b977630444bbdbd0_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0zLTEtMS0w_9b4bec7d-3fe5-4a32-b1c5-03420ed3a40c"
      unitRef="shares">229172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iecd2245025b2447a92a8217ee5cde65c_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNC0zLTEtMS0w_c3204cb0-b050-482c-ba35-2104481a6909"
      unitRef="shares">229172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0xLTEtMS0w_3594d1a8-156d-47ce-8658-6319fb509aee"
      unitRef="shares">12865704</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0xLTEtMS0w_74e2b293-7813-4452-909b-b28b553dad2d"
      unitRef="shares">12865704</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61ffb198559e4ff6a7d74c809ac45631_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0zLTEtMS0w_84c41f15-c526-4fb1-bf10-1913030f5e8e"
      unitRef="shares">10661813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7237cc24c0454eeb9a3ce72bef947b56_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF83MC9mcmFnOjBlNjhhZjRhNjViYTQ2YzlhYWZmNmZmMmNhYzYyNDQ1L3RhYmxlOmUzMjI1YzU2ODljNTQ4NmQ5ODJlYjJlZjg4M2FjMjEwL3RhYmxlcmFuZ2U6ZTMyMjVjNTY4OWM1NDg2ZDk4MmViMmVmODgzYWMyMTBfNS0zLTEtMS0w_8f206f25-8721-44a5-a56a-a865a011c3c6"
      unitRef="shares">10661813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6879548192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,841,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6880799856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,936<span></span>
</td>
<td class="nump">$ 77,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">415,667<span></span>
</td>
<td class="nump">387,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,378<span></span>
</td>
<td class="nump">16,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">495,981<span></span>
</td>
<td class="nump">480,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">55,832<span></span>
</td>
<td class="nump">147,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">47,195<span></span>
</td>
<td class="nump">25,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">34,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">3,949<span></span>
</td>
<td class="nump">8,105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">637,604<span></span>
</td>
<td class="nump">661,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,793<span></span>
</td>
<td class="nump">8,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,092<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">22,598<span></span>
</td>
<td class="nump">11,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,135<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">46,549<span></span>
</td>
<td class="nump">32,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, less current portion</a></td>
<td class="nump">44,563<span></span>
</td>
<td class="nump">57,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="nump">70,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">162,431<span></span>
</td>
<td class="nump">115,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 95,656,896 shares and 94,662,435 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">798,277<span></span>
</td>
<td class="nump">774,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">879<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(325,266)<span></span>
</td>
<td class="num">(227,937)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">475,173<span></span>
</td>
<td class="nump">546,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 637,604<span></span>
</td>
<td class="nump">$ 661,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6771320512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">95,656,896<span></span>
</td>
<td class="nump">94,662,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">95,656,896<span></span>
</td>
<td class="nump">94,662,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6879756368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 4,197<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">$ 8,402<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">51,884<span></span>
</td>
<td class="nump">52,134<span></span>
</td>
<td class="nump">89,287<span></span>
</td>
<td class="nump">72,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,076<span></span>
</td>
<td class="nump">6,896<span></span>
</td>
<td class="nump">24,386<span></span>
</td>
<td class="nump">12,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">66,960<span></span>
</td>
<td class="nump">59,030<span></span>
</td>
<td class="nump">113,673<span></span>
</td>
<td class="nump">85,419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(62,763)<span></span>
</td>
<td class="num">(57,382)<span></span>
</td>
<td class="num">(105,271)<span></span>
</td>
<td class="num">(83,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">4,113<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
<td class="nump">7,629<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(58,650)<span></span>
</td>
<td class="num">(54,724)<span></span>
</td>
<td class="num">(97,642)<span></span>
</td>
<td class="num">(78,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,337)<span></span>
</td>
<td class="num">(54,724)<span></span>
</td>
<td class="num">(97,329)<span></span>
</td>
<td class="num">(78,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized income (loss) on marketable securities, net of tax</a></td>
<td class="nump">547<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
<td class="num">(1,125)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (57,790)<span></span>
</td>
<td class="num">$ (54,930)<span></span>
</td>
<td class="num">$ (95,801)<span></span>
</td>
<td class="num">$ (79,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (usd per share)</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">95,495,497<span></span>
</td>
<td class="nump">92,899,524<span></span>
</td>
<td class="nump">95,241,412<span></span>
</td>
<td class="nump">91,239,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6880294432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,480,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 465,796<span></span>
</td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="nump">$ 656,660<span></span>
</td>
<td class="num">$ (368)<span></span>
</td>
<td class="num">$ (191,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan', window );">Issuances under equity incentive plans</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of early exercised common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of early exercised common stock</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with Takeda Collaboration Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with the Takeda Collaboration Agreement</a></td>
<td class="nump">94,406<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">94,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,321,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">490,272<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">760,605<span></span>
</td>
<td class="num">(1,493)<span></span>
</td>
<td class="num">(270,099)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,588,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">539,028<span></span>
</td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="nump">754,438<span></span>
</td>
<td class="num">(1,287)<span></span>
</td>
<td class="num">(215,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan', window );">Issuances under equity incentive plans</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of early exercised common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of early exercised common stock</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,321,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">$ 490,272<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">760,605<span></span>
</td>
<td class="num">(1,493)<span></span>
</td>
<td class="num">(270,099)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">94,662,435<span></span>
</td>
<td class="nump">94,662,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 546,845<span></span>
</td>
<td class="nump">$ 1,273<span></span>
</td>
<td class="nump">774,158<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="num">(227,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan', window );">Issuances under equity incentive plans</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">3,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of early exercised common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of early exercised common stock</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(97,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 1,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">95,656,896<span></span>
</td>
<td class="nump">95,656,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 475,173<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
<td class="nump">798,277<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="num">(325,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,257,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">516,648<span></span>
</td>
<td class="nump">$ 1,279<span></span>
</td>
<td class="nump">781,966<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="num">(266,929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan', window );">Issuances under equity incentive plans</a></td>
<td class="nump">2,569<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of early exercised common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of early exercised common stock</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">95,656,896<span></span>
</td>
<td class="nump">95,656,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 475,173<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
<td class="nump">$ 798,277<span></span>
</td>
<td class="nump">$ 879<span></span>
</td>
<td class="num">$ (325,266)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_StockIssuedDuringPeriodSharesCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_StockIssuedDuringPeriodSharesCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_StockIssuedDuringPeriodValueCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_StockIssuedDuringPeriodValueCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_StockIssuedDuringPeriodValueEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_StockIssuedDuringPeriodValueEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6783257120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,329)<span></span>
</td>
<td class="num">$ (78,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock&#8211;based compensation expense</a></td>
<td class="nump">20,588<span></span>
</td>
<td class="nump">7,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization of discounts on marketable securities</a></td>
<td class="num">(2,734)<span></span>
</td>
<td class="num">(1,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense', window );">Non-cash rent expense</a></td>
<td class="nump">1,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_IncreaseDecreaseInDeferredRent', window );">Non-cash rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="num">(313)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="num">(1,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">7,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(1,887)<span></span>
</td>
<td class="num">(1,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(1,616)<span></span>
</td>
<td class="nump">58,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(73,498)<span></span>
</td>
<td class="num">(8,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(144,029)<span></span>
</td>
<td class="num">(361,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(12,299)<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">212,162<span></span>
</td>
<td class="nump">92,049<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">55,834<span></span>
</td>
<td class="num">(270,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement', window );">Issuance of common stock in connection with the Takeda Collaboration Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">94,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of awards under equity incentive plans</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">94,671<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(14,187)<span></span>
</td>
<td class="num">(184,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">78,623<span></span>
</td>
<td class="nump">218,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">64,436<span></span>
</td>
<td class="nump">34,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NoncashTenantImprovementsPaidByLandlord', window );">Tenant improvements provided by the landlord</a></td>
<td class="nump">11,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases accrued but not yet paid</a></td>
<td class="nump">2,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of issuance costs related to issuance of stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,342)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of issuance costs related to issuance of stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Non-Cash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NoncashTenantImprovementsPaidByLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Tenant Improvements Paid By Landlord</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NoncashTenantImprovementsPaidByLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869808496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Organization and Description of Business</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali Therapeutics Inc. ("Denali" or the &#8220;Company&#8221;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">as filed with the Securities and Exchange Commission on March&#160;12, 2019 (the "2018 Annual Report on Form 10-K"). The condensed consolidated Balance Sheet as of December 31, 2018 was derived from the audited annual consolidated financial statements as of the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended&#160;June 30, 2019, except as discussed below in the sections titled Leases and Recently Adopted Accounting Standards, there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2018 Annual Report on Form 10-K. For further information with regard to the Company&#8217;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#8217;s Consolidated Financial Statements included in the 2018 Annual Report on Form 10-K.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated on consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the condensed consolidated financial position and statements of operations and comprehensive loss.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of June 30, 2019 and December 31, 2018, the Company had&#160;no&#160;off-balance&#160;sheet&#160;concentrations of credit risk.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s restricted cash consists of the letter of credit for the Company&#8217;s headquarters building lease, and is included&#160;within other&#160;non-current&#160;assets&#160;on the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Derivatives and Hedging Activities</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its derivative instruments as either assets or liabilities on the condensed consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through Interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company adopted Accounting Standards Update ("ASU") No. 2016-02, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> as of January 1, 2019. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#8220;ROU&#8221;) asset an</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">d operating lease liability is recognized for identified operating leases in the condensed consolidated balance sheet. </span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent the Company&#8217;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate (&#8220;IBR&#8221;) on the date of lease commencement, or the rate implicit in the lease, if known.  The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License and Collaboration Revenue</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#8220;ASC&#160;808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &#160;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company's consolidated balance sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span></div><div style="margin-top:18pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Intraperiod tax allocation rules require allocation of the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. A related tax benefit is then recorded in continuing operations. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss per Share</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which supersedes the guidance in former ASC 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, C</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">odification Improvements to Topic 842, Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, in December 2018 through ASU 2018-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Narrow-Scope Improvements for Lessors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and in March 2019 through ASU 2019-01 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Codification Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and is required to be adopted using a modified retrospective approach.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has adopted this standard as of January 1, 2019, applying the optional transition method such that it is not required to adjust prior period presentations. ASU 2016-02 has impacted the Company&#8217;s condensed consolidated balance sheet as the Company has certain operating lease arrangements for which the Company is the lessee and one operating lease arrangement for which the Company is the lessor. The Company has no financing leases. Management has elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The impact of adoption of the standard is that the Company as of January 1, 2019 recognized a ROU asset of $46.1 million and operating lease liability of $71.3 million. The standard did not have a material impact on the Company&#8217;s condensed consolidated statements of operations and comprehensive loss and stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6867475264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.314103%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.378205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.262821%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,180&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,180&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">273,103&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">273,103&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,957&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,957&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,950&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,950&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,794&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,794&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,038&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,038&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">355,077&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">152,618&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">507,695&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.153846%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.980769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">42,225&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">42,225&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,499&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,499&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,979&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,979&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">219,754&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">219,754&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,151&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,151&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,675&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,675&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">117,131&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">117,131&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,773&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,773&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">380,609&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">208,163&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">588,772&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div>There were no transfers of assets or liabilities between the fair value measurement levels during the three and six months ended June 30, 2019 or 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869810960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Marketable Securities</a></td>
<td class="text">Cash and Marketable Securities<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Cash, cash equivalents and restricted cash</span></div><div><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:55.852564%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.461538%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461538%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.621795%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">62,936&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,123&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">33,088&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted cash included within other non-current assets</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">64,436&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,623&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,588&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Marketable securities</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">All marketable securities were considered&#160;available-for-sale&#160;at June 30, 2019 and December 31, 2018. On a recurring basis, the Company records its marketable securities at fair value using Level 1 or Level 2 inputs as discussed in Note 2, "Fair Value Measurements". The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.153846%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.980769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">272,540&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">568&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">273,103&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,960&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,957&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,842&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">122&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(14)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,950&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Commercial paper</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total short-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">414,999&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">697&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">415,667&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,339&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,794&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,968&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,038&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total long-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55,307&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">525&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55,832&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">470,306&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,222&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">471,499&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.314103%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">220,081&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">29&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(356)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">219,754&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,373&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(222)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,151&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,940&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(266)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,675&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Commercial paper</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total short-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">387,988&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(844)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">387,174&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">116,878&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">329&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(76)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">117,131&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,975&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,864&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(99)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,773&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total long-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">147,717&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">339&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(175)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">147,881&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">535,705&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">369&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,019)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">535,055&#160;</span></td></tr></table></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, some of the Company&#8217;s marketable securities were in an unrealized loss position. At each balance sheet date, the Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the three and six months ended June 30, 2019 and 2018. All marketable securities with unrealized losses as of each balance sheet date have been in a loss position for less than twelve months or the loss is not material.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company recorded unrealized gains on marketable securities in other comprehensive income during the three and six months ended June 30, 2019. There were no unrealized gains in other comprehensive income during the three and six months ended June 30, 2018. As a result, the Company recorded a tax benefit of $0.3 million for the three and six months ended June 30, 2019 on the condensed consolidated statements of operations and a corresponding tax charge in other comprehensive income of $0.3 million. There was no tax benefit recorded for the three and six months ended June 30, 2018 on the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">All of the Company&#8217;s marketable securities have an effective maturity of less than two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6618394880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Exchange Rate Exposure</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company&#8217;s forecasted cash flows being denominated in currencies other than the U.S. dollar, primarily the Euro, British Pound, and Swiss Franc. The derivative instruments the Company uses to hedge this exposure are not designated as cash flow hedges, and as a result, changes in their fair value are recorded in Interest and other income, net, on the Company's condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates and take into consideration the current creditworthiness of the counterparties. Information regarding the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations is provided below. The Company did not have foreign currency exchange contracts prior to June 2018.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s forward foreign currency exchange contracts outstanding as of June 30, 2019 (notional amounts in thousands):</span></div><div style="margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"/><td style="width:31.868379%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.385233%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.916533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.422151%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Aggregate Notional</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Amount in Foreign Currency</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Euros </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,776&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - May 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">British Pounds </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,181&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - May 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Swiss Francs </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">703&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - Feb 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">_________________________________________________</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:4pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1) &#160;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The derivative liability balance of $0.2 million is recorded in Other current liabilities on the condensed consolidated balance sheet as of both June 30, 2019 and December 31, 2018. The derivative asset balance of $15,682 and $13,669 is recorded in Prepaid assets and other current assets on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. The net loss associated with the Company's derivative instruments of $7,320 and gain of $11,967 is recognized in Interest and other income, net on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2019, respectively, and a net loss of $31,952 was recognized in Interest and other income, net on the condensed consolidated statement of operations and comprehensive loss for both the three and six months ended June 30, 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869713584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AssetAcquisitionTextBlock', window );">Acquisition</a></td>
<td class="text">Acquisition<div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August 2016, the Company entered into a License and Collaboration Agreement (&#8220;F-star Collaboration Agreement&#8221;) with&#160;F-star&#160;Gamma Limited (&#8220;F-star Gamma&#8221;),&#160;F-star&#160;Biotechnologische Forschungs-Und Entwicklungsges M.B.H ("F-star GmbH") and&#160;F-star&#160;Biotechnology Limited ("F-star Ltd") (collectively,&#160;&#8220;F-star&#8221;) to leverage&#160;F-star&#8217;s&#160;modular antibody technology and the Company&#8217;s expertise in the development of therapies for neurodegenerative diseases. Under the F-star Collaboration Agreement, the Company has made payments to F-star totaling $11.5&#160;million. In connection with the entry into the F-star Collaboration Agreement, the Company also purchased an option for an upfront option fee of $0.5 million (the&#160;&#8220;buy-out-option&#8221;),&#160;to acquire all of the outstanding shares of&#160;F-star&#160;Gamma pursuant to a&#160;pre-negotiated&#160;buy-out&#160;option agreement (the &#8220;Option Agreement&#8221;).</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company exercised the Option Agreement and entered into a Share Purchase Agreement (the &#8220;Purchase&#160;Agreement&#8221;) with the shareholders of&#160;F-star&#160;Gamma and Shareholder Representative Services LLC, pursuant to which the Company acquired all of the outstanding shares of&#160;F-star&#160;Gamma (the &#8220;Acquisition&#8221;).</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As a result of the Acquisition,&#160;F-star&#160;Gamma became a wholly-owned subsidiary of the Company and the Company changed the entity&#8217;s name to Denali BBB Holding Limited. In addition, the Company became a direct licensee of certain intellectual property of&#160;F-star&#160;Ltd by way of the Company&#8217;s assumption of&#160;F-star&#160;Gamma&#8217;s license agreement with&#160;F-star&#160;Ltd, dated August&#160;24, 2016, (the&#160;&#8220;F-star&#160;Gamma License&#8221;). The Company made initial exercise payments under the&#160;Purchase Agreement and the&#160;F-star&#160;Gamma License, in the aggregate, of $17.8 million. In addition, the Company is required to make future contingent payments, to F-star Ltd and the former shareholders of F-star Gamma, up to a maximum amount of $447.0 million in the aggregate upon the achievement of certain defined preclinical, clinical, regulatory and commercial milestones. The amount of the contingent payments will vary based on whether&#160;F-star&#160;delivers an Fcab&#160;(constant&#160;Fc-domains&#160;with antigen-binding activity) that meets&#160;pre-defined&#160;criteria and whether the Fcab has been identified solely by the Company or solely by&#160;F-star&#160;or jointly by the Company and&#160;F-star. In June 2019, the Company made a payment of $1.5 million to F-star Ltd upon the achievement of a specified preclinical milestone in the Company's ETV:IDS program.</span></div>The Company concluded that the assets acquired and liabilities assumed upon the exercise of the Option Agreement did not meet the accounting definition of a business, and as such, the acquisition was accounted for as an asset purchase. The Company recognized $1.5 million of contingent consideration as research and development expense during the three and six months ended June 30, 2019 and $18.3&#160;million of upfront consideration as research and development expense in the three and six months ended June 30, 2018. As the transaction was accounted for as an asset purchase rather than a business combination, the Company did not recognize any contingent consideration on the acquisition date. Further future contingent consideration is expected to be recognized in research and development expense as incurred.Under the F-star Collaboration Agreement, the Company is responsible for certain research costs incurred by F-star Ltd in conducting activities under an agreed development plan for each Fcab, for up to 24 months after the target Fcab is accepted. The Company's responsibility for research costs under the first development plan related to an Fcab that targets the transferrin receptor was completed during the year ended December 31, 2018. The responsibility for costs under the second development plan related to an undisclosed Fcab target commenced in February 2019. The Company recognized $0.3 million and $0.5&#160;million in research and development expense related to the funding of&#160;F-star&#160;Ltd activities under these development plans during the three and six months ended June 30, 2019, respectively, and $0.2 million and $0.5 million for the three and six months ended June 30, 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6867486176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into a Collaboration and License Agreement ("Sanofi Collaboration Agreement") with Genzyme Corporation, a wholly owned subsidiary of Sanofi S.A. ("Sanofi") pursuant to which certain small molecule RIPK1 inhibitors contributed by Sanofi and by Denali will be developed and commercialized. The Sanofi Collaboration Agreement became effective in November 2018, at which time Sanofi paid the Company an upfront payment of $125.0 million. Under the Sanofi Collaboration Agreement, Denali is eligible to receive milestone payments from Sanofi up to approximately $1.1 billion upon achievement of certain clinical, regulatory and sales milestone events. Such milestone payments include $600.0 million in clinical and regulatory milestone payments for CNS Products and $495.0 million in clinical, regulatory and commercial milestone payments for Peripheral Products, as defined in the Sanofi Collaboration Agreement. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali will share profits and losses equally with Sanofi for CNS Products sold in the United States and China, and receive variable royalties on net sales for CNS Products sold outside of the United States and China and for Peripheral Products sold worldwide.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali and Sanofi will jointly develop CNS Products pursuant to a global development plan. The Company will be responsible, at its own cost, for conducting Phase 1 and Phase 2 trials for CNS Products in Alzheimer&#8217;s disease and any activities required to support such clinical trials and specific for Alzheimer&#8217;s disease. Denali is conducting, at Sanofi&#8217;s cost, a Phase 1b trial for the lead CNS penetrant RIPK1 inhibitor, DNL747, in ALS. Sanofi is responsible, at its cost, for all other Phase 1 and Phase 2 trials for CNS Products, including for multiple sclerosis. Sanofi will lead the conduct of all Phase 3 and later stage development trials for CNS Products, with Sanofi and Denali funding 70% and 30% of such costs, respectively. Sanofi will also lead the commercialization activities globally for CNS Products, subject to certain options that Denali has to conduct co-commercialization activities with respect to each CNS Product in the United States and China. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Sanofi will be responsible, at its cost, for conducting activities relating to the development and commercialization of all Peripheral Products. Denali will be entitled to receive tiered royalties in the low- to mid- teen percentages on net sales of Peripheral Products.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company identified the following distinct performance obligations associated with the Sanofi Collaboration Agreement upon inception: the CNS program license, the Peripheral program license, the Phase 1 and Phase 2 trials for CNS Products for Alzheimer&#8217;s disease ("Alzheimer's Disease Services"), and the Phase 1b trial for DNL747 for ALS and associated activities ("Retained Activities"). </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company believes that the Sanofi Collaboration Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements. The Company also believes that Sanofi meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for three of the performance obligations identified at inception, but does not meet the definition of a customer for the Alzheimer's Disease Services. Further, Sanofi does not meet the definition of a customer for all Phase 3 and later stage development trials for CNS Products led by Sanofi for which Denali will fund 30% of total costs. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literature for guidance where the performance obligation does not fall under ASC 606, and determined that for the Alzheimer's Disease Services, the guidance in ASC 606 should be analogized for the recognition, measurement and reporting of this performance obligation, and for the cost sharing provisions, the Company determined that the guidance in ASC 730, Research and Development should be applied. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The transaction price at inception included upfront fixed consideration of $125.0 million. All potential future milestones and other payments were considered constrained at the inception of the Sanofi Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. The transaction price increased by $9.1 million from inception through June 30, 2019 as amounts due for costs incurred related to the Retained Activities were no longer constrained. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The respective standalone value for each of the performance obligations has been determined by applying the SSP method and the transaction price allocated based on the relative SSP method with revenue recognition timing to be determined either by delivery or the provision of services.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company used an adjusted market assessment approach to estimate the selling price for the program licenses, and an expected cost plus margin approach for estimating the Alzheimer&#8217;s Disease Services and the Retained Activities. The program licenses and existing know-how were delivered on the effective date of the Sanofi Collaboration Agreement. The Alzheimer&#8217;s Disease Services and the Retained Activities are expected to be delivered over time as the services are performed. For the Alzheimer's Disease Services, revenue will be recognized over time using the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best reflect the transfer of services to Sanofi. For the Retained Activities, revenue will be recognized over time using the output method, based on amounts invoiced to Sanofi, since this is believed to directly correlate to the value of the services performed.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A contract liability of $3.7 million and $3.9&#160;million was recorded on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. These contract liabilities relate to the portion of the Alzheimer's Disease Services performance obligation yet to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> be satisfied, with such amounts to be recognized over the estimated period of the services, which is expected to be several years. There was a receivable of $3.4 million and $2.3 million at June 30, 2019 and December 31, 2018, respectively, associated with the Sanofi Collaboration Agreement. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In assessing the Sanofi Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Managem</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">ent applies judgment in determining the separate performance obligations, in estimating the selling price, in determining when control was transferred to Sanofi for the licenses, and in estimating total future costs when using the input method.  </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Through June 30, 2019, Denali has not recognized any milestones and has not recorded any product sales recorded under the Sanofi Collaboration Agreement. In July 2019, Sanofi received regulatory approval for the commencement of a DNL758 Phase 1 clinical trial in healthy volunteers. The trial commenced and triggered a milestone payment of $10.0 million, which the Company expects to receive in August 2019.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Takeda </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2018, the Company entered into a Collaboration and Option Agreement ("Takeda Collaboration Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company granted Takeda an option to develop and commercialize, jointly with the Company, certain biologic products that are enabled by Denali's blood-brain barrier ("BBB") delivery technology and intended for the treatment of neurodegenerative disorders. The programs were Denali&#8217;s ATV:BACE1/Tau and ATV:TREM2 programs, as well as a third identified discovery stage program.&#160;The Takeda Collaboration Agreement became effective in February 2018, at which time Takeda paid the Company an upfront payment of $40.0 million. Takeda may pay up to an aggregate of $25.0 million with respect to each of the three programs directed to a target and based upon the achievement of certain preclinical milestone events, up to $75.0 million in total, $5.0 million of which was paid upon the Takeda Collaboration Agreement becoming effective. In February 2019, the agreement was amended to replace ATV:BACE1/Tau with ATV:Tau. The amendment did not have a material impact to the condensed consolidated financial statements.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the Takeda Collaboration Agreement and unless otherwise agreed jointly between both parties, Denali will be responsible, at its cost, for conducting activities relating to&#160;pre-IND&#160;development of biologic products directed to the three identified targets and enabled by its BBB delivery technology targeting TfR during the applicable research period. The period through which the option can be exercised continues for each target until the first biologic product directed to the relevant target is&#160;IND-ready&#160;or approximately five years after selection of the target, whichever is earlier.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If Takeda exercises its option with respect to a particular target, then Takeda will have the right to develop and commercialize, jointly with the Company, a specified number of biologic products enabled by its BBB delivery technology that were developed during the research period and which are directed to the relevant target. The Company will grant to Takeda a&#160;co-exclusive&#160;license under the intellectual property the Company controls related to those biologic products.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Takeda is obligated to pay Denali a $5.0 million option fee for each target for which Takeda exercises its option, up to $15.0 million in total.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, Takeda may be obligated to pay Denali up to an aggregate of $707.5 million upon achievement of certain clinical and regulatory milestone events if Takeda exercises its option for all three collaboration programs. Takeda may also be obligated to pay Denali up to $75.0 million per biologic product upon achievement of a certain sales-based milestone, or an aggregate of $225.0 million if one biologic product from each program achieves this milestone.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If Takeda exercises its option for a particular target, Denali and Takeda will share equally the development and commercialization costs, and, if applicable, the profits, for each collaboration program.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Takeda Collaboration Agreement, the Company entered into a common stock purchase agreement (the "Stock Purchase Agreement") with Takeda on January&#160;3, 2018, pursuant to which Takeda purchased 4,214,559 shares of Denali&#8217;s common stock (the "Shares") for an aggregate purchase price of $110.0 million. The sale of the Shares closed on February&#160;23, 2018. The fair market value of the common stock sold to Takeda was $94.4 million, based on the closing stock price of $22.40 on the date of issuance, resulting in&#160;a $15.6 million premium paid to the Company above the fair value of the Company's common stock which was credited to contract liability in the Company's condensed consolidated balance sheet.&#160; </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company believes that the Takeda Collaboration Agreement is a collaboration arrangement as defined in ASC&#160;808,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;Further, during the research period, the Company believes that the arrangement is a contract with a customer as defined in ASC 606,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue From Contracts With Customers.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> The Takeda Collaboration Agreement and the Stock Purchase Agreement are being accounted for as one arrangement because they were entered into at the same time with interrelated financial terms.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company identified performance obligations during the research period consisting of the license, the development options, and joint steering committee ("JSC") participation together with the research services for each collaboration program. The license rights, JSC involvement, option and research services are considered to be a single performance obligation for each program since the research services are highly interrelated with the option and JSC involvement and will significantly modify the license. The performance obligations under each of the three programs are separate since the activities and risks under the programs are distinct. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has determined that all other goods or services which are contingent upon Takeda exercising its option for each program are not considered performance obligations at the inception of the Takeda Collaboration Agreement.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The transaction price at inception included fixed consideration consisting of the upfront fee of $40.0 million, the $15.6 million premium on the sale of common stock, and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">first preclinical milestone payment of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">$5.0 million. It also included variable consideration of $26.0 million relating to future milestones that were not constrained. The amount of variable consideration was estimated using the most likely amount method. A total of $15.0 million in preclinical milestone payments has been received under the Takeda Collaboration Agreement from inception through June 30, 2019.  </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The remaining $44.0 million of preclinical milestones were considered constrained at the inception of the Takeda Collaboration Agreement since the Company could not conclude it is probable that a significant reversal in the amount recognized will not occur. Additionally, cost and profit sharing income, and the development and commercial milestones as outlined above, have not been considered given Takeda has not exercised its options for the development and commercial phases for any program. There was no change in the transaction price from inception through June 30, 2019. This will be reassessed at each reporting period. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The transaction price has been ascribed in its entirety to the three performance obligations identified in the research term of the Takeda Collaboration Agreement.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue is recognized when, or as, the Company satisfies its performance obligations by transferring the promised services to Takeda. Revenue will be recognized over time using the input method, based on costs incurred to perform the research services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda. There were no material changes in estimates during the three and six months ended June 30, 2019.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A contract liability of $63.5 million and $64.9 million was recorded on the condensed consolidated balance sheet as of June 30, 2019 and December 31, 2018, respectively. These contract liabilities relate to the three performance obligations identified, with such amounts to be recognized over the estimated period of the pre-IND research services, which is expected to be several years. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue recognized relating to future milestone payments of $1.5&#160;million, which the Company concluded is probable that a significant reversal in the amount recognized will not occur, is presented net in the contract liability on the condensed consolidated balance sheet. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In assessing the Takeda Collaboration Agreement, management is required to exercise considerable judgment in estimating revenue to be recognized. Management applies judgment in determining the separate performance obligations in the research period, estimating variable consideration, and estimating total future costs when using the input method.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Through June 30, 2019, Denali has recognized $15.0 million in milestones from Takeda and has not recorded any product sales under the Takeda Collaboration Agreement. There was no receivable as of June 30, 2019, and a receivable of $5.0 million as of December 31, 2018, related to the Takeda Collaboration Agreement.  </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Revenue</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:37.583333%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441026%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441026%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Takeda Collaboration Agreement</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">740&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,648&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,422&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,289&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Alzheimer's Disease Services</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">99&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">193&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Retained Activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,358&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,787&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Sanofi Collaboration Revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,457&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,980&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Collaboration Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,197&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,648&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,402&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,289&#160;</span></td></tr></table></div><div style="margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">_________________________________________________</span></div>(1)Amounts for the three and six months ended June 30, 2019 and the three months ended June 30, 2018 represent revenue recognized during the period that was included in the contract liability balance at the beginning of the period. There was no deferred revenue at the beginning of the period for the six months ended June 30, 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6606482432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Genentech</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Company entered into an Exclusive License Agreement with Genentech, Inc. (&#8220;Genentech&#8221;). The agreement gives the Company access to Genentech&#8217;s LRRK2 inhibitor small molecule program for Parkinson&#8217;s disease. Under the agreement, Genentech granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under Genentech&#8217;s rights to certain patents and patent applications directed to small molecule compounds which bind to and inhibit LRRK2 and (ii)&#160;a&#160;non-exclusive,&#160;worldwide, sublicensable license to certain related&#160;know-how,&#160;in each case, to develop and commercialize certain compounds and licensed products incorporating any such compound. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company may owe Genentech milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $315.0 million in the aggregate, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages.</span></div>To date, the Company has paid Genentech an upfront fee, a technology transfer fee and a clinical milestone payment totaling $12.5&#160;million in the aggregate, all of which were recorded as research and development expense as incurred. No amounts were recorded in the three and six months ended June 30, 2019 and 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6673615536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lease Obligations</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In May 2018, the Company entered into an amendment to its operating lease for its former corporate headquarters in South San Francisco (the "Headquarters Lease Amendment") to relocate and expand its headquarters to 148,020 rentable square feet in a building in South San Francisco, California (the "New Premises"). The Headquarters Lease Amendment has a contractual term of ten years from the legal commencement date, which was April&#160;1, 2019 when the building was ready for occupancy. For accounting purposes, the lease commencement date was determined to be August&#160;1, 2018, which was the date at which the Company was deemed to have obtained control over the property. The Company has an option to extend the lease term for a period of ten years by giving the landlord written notice of the election to exercise the option at least nine months, but not more than twelve months, prior to the expiration of the Headquarters Lease Amendment lease term. The Company did not believe this renewal was reasonably certain at lease inception.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The Headquarters Lease Amendment provides for monthly base rent amounts escalating over the term of the lease. In addition, the Headquarters Lease Amendment provided a tenant improvement allowance ("TIA") of up to $25.9 million, which was fully utilized, of which $4.4 million will be repaid to the landlord in the form of additional monthly rent. This is recorded as leasehold improvement assets and an offset to the lease ROU asset on the condensed consolidated balance sheet as of June 30, 2019. The Company is also required to pay the operating expenses for the New Premises, such as taxes and insurance, which are treated as variable lease payments.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As of June 30, 2019, the carrying value of the ROU asset was $34.6 million. The related current and non-current liabilities as of June 30, 2019 were $2.0&#160;million and $70.9 million, respectively. The current and non-current lease liabilities are included in Other current liabilities and Operating lease liability, less current portion, respectively, in the Condensed Consolidated Balance Sheet.  </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Management was required to exercise judgment in applying the requirements of ASC 842, including the determination as to whether certain contracts contain a lease and for the Headquarters Lease Amendment, the discount rate used to determine the measurement of the lease liability. The discount rate used was 9.0%, which was management&#8217;s estimate of the Company&#8217;s incremental borrowing rate since the rate implicit in the lease was not known. To estimate the Company&#8217;s incremental borrowing rate, management considered observable debt yields of comparable market instruments, as well as benchmarks within the Headquarters Lease Amendment that may be indicative of the rate implicit in the lease. </span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Total operating lease costs, including variable and short term lease costs, were $2.5 million and $4.8 million for the three and six months ended June 30, 2019, respectively. Rent expense excluding amortization of leasehold improvements was $0.6 million and $1.3 million for the three and six months ended June 30, 2018, respectively.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2019, the weighted average remaining lease term is 9.8 years and the weighted average discount rate used to determine the operating lease liability was 9.0%. Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2019 was $1.9 million and was included in Net cash used in operating activities in our condensed consolidated statements of cash flows.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of June 30, 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.967949%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.262821%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:28.769231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (six months)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,642&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,767&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,386&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,726&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,078&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and later</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">65,494&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">111,093&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(38,217)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">72,876&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company entered into a sublease agreement ("Sublease Agreement") to sublease approximately 36,835 rentable square feet of space in its New Premises. The Sublease Agreement has a term of five years from the commencement date of April&#160;12, 2019 and provides for the Company to receive monthly base rent amounts escalating over the term of the lease. The Company  also passes through a portion of the operating expenses for the New Premises to the sublessee, such as taxes and insurance, which are treated as variable sublease income. Total sublease income for the three and six months ended June 30, 2019, including rent and variable costs, was $0.8 million. There was no sublease income for the three and six months ended June 30, 2018.</span></div><div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table details the future undiscounted cash inflows relating to the Company's sublease as of June 30, 2019 (in thousands):</span></div><div style="margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.967949%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.262821%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:28.769231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (six months)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,392&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,842&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,925&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,009&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,096&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and later</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">876&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted sublease receipts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14,140&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnification</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company&#8217;s balance sheet, statements of comprehensive loss, or statements of cash flows.</span></div><div style="margin-top:18pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commitments</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Effective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (&#8220;DMSA&#8221;) with Lonza Sales AG (&#8220;Lonza&#8221;) for the development and manufacture of biologic products. Under the DMSA, the Company will execute purchase orders based on project plans authorizing Lonza to provide development and manufacturing services with respect to certain of the Company's antibody and enzyme products, and will pay for the services provided and batches delivered in accordance with the DMSA and project plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the DMSA will expire on September&#160;6, 2022.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 and December 31, 2018, the Company had non-cancellable purchase orders for biological product development and manufacturing costs totaling $25.1 million and $24.7 million respectively. The activities under these purchase orders are expected to be completed by November 2024. As of June 30, 2019 and December 31, 2018, the Company had total non-refundable purchase commitments of $10.3 million and $14.0 million, respectively, under the DMSA.</span></div>During the three months ended June 30, 2019 and 2018, the Company incurred costs of $3.1&#160;million and $1.1&#160;million, respectively, and made payments of $3.9&#160;million and $0.6 million, respectively, for the development and manufacturing services rendered under the DMSA. During the six months ended June 30, 2019 and 2018, the Company incurred costs of $6.7 million and $1.2 million, respectively, and made payments of $6.5 million and $0.7 million, respectively, for the development and manufacturing services rendered under the DMSA.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869762832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Awards</a></td>
<td class="text">Stock-Based Awards<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2017 Equity Incentive Plan</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which initially reserved approximately 6.4&#160;million shares of common stock for the issuance of stock options,&#160;restricted stock and other stock awards, to employees,&#160;non-employee&#160;directors, and consultants under terms and provisions established by the Board of Directors and approved by the stockholders. The 2017 Plan provides that the number of shares reserved and available for issuance under the 2017 Plan will automatically increase each January 1, beginning on January 1, 2019, by the least of (i) 10.0 million shares, (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the administrator of the 2017 Plan. In January 2019, common stock available for issuance under the 2017 Plan was increased by approximately 4.8 million shares as a result of this automatic increase provision.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Awards granted under the 2017 Plan expire no later than&#160;ten years from the date of grant. For stock options, the option price shall not be less than&#160;100%&#160;of the estimated fair value of the Company's common stock on the day of grant. Options granted typically vest over a&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTIzMQ_89106c99-db8f-42c3-9be0-ac8e95402417">four</span>-year period but may be granted with different vesting terms. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2015 Stock Incentive Plan</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;In May 2015, the Company adopted the 2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;), which as amended, reserved approximately 8.3 million shares of common stock for the issuance of stock options, restricted stock and other stock awards, to employees,&#160;non-employee&#160;directors, and consultants under terms and provisions established by the Board of Directors and approved by the stockholders. Awards granted under the 2015 Plan expire no later than&#160;ten years from the date of grant. For stock options, the option price shall not b</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">e less than&#160;100%&#160;of the estimated fair value of the Company's common stock on the day of grant. Options granted typically vest over a&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMjIwNQ_7426f688-b493-4e9a-8e34-f30a5275909d">four</span>-year period but may be granted with different vesting terms. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon adoption of the 2017 Plan, no new awards or grants are permitted under the 2015 Plan, and the approximately 0.2 million shares that were then unissued and available for future award under the 2015 Plan became available under the 2017 Plan. The 2015 Plan will continue to govern restricted stock awards and option awards previously granted thereunder.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 there were approximately 3.7&#160;million shares available for the Company to grant under the 2017 Plan. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes option award activity under the 2017 Plan and the 2015 Plan:&#160;</span></div><div style="margin-top:10pt;margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:42.391026%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Weighted- </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Average</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Exercise&#160;Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Weighted- </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Average</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">remaining</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">contractual</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">life (years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Aggregate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Intrinsic</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,612,652&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.49&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.20</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">97,804&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,296,335&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18.58&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(465,281)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.62&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(447,374)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16.30&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,996,332&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12.72&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.23</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">96,434&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,251,600&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14.77&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.58</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">61,400&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,228,421&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.17&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7.70</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,173&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Aggregate intrinsic value represents the difference between the Company&#8217;s estimated fair value of its common stock and the exercise price of outstanding options. The total intrinsic value of options exercised was $5.1&#160;million and $8.4&#160;million for the three and six months ended June 30, 2019, respectively, and $3.5 million and $4.7&#160;million for the three and six months ended June 30, 2018, respectively. During the three and six months ended June 30, 2019, the weighted-average grant date fair value of the vested options was $9.35 and $10.80 per share, respectively. During the three and six months ended June 30, 2018, the weighted-average grant-date fair value of the vested options was $2.83 and $2.87 per share, respectively. The weighted-average grant date fair value of all options granted during the three and six months ended June 30, 2019 was $13.16 and $11.92 per share, respectively. The weighted-average grant date fair value of all options granted during the three and six months ended June 30, 2018 was $13.37 and $15.90 per share, respectively. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options Granted to Employees with Service-Based Vesting</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:26.365385%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;5.50 - 6.08 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Volatility</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;66.9% - 77.8% </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">80.0% - 85.6%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">66.9% - 77.8%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">80.0% - 87.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2.0% - 2.3% </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.7% - 2.9%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0% - 2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.6% - 2.9%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Dividend yield</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the&#160;mid-point&#160;between the vesting date and the end of the contractual term).</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.  The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:25pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividend:</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div><div style="margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Performance and Market Contingent Stock Options Granted to Employees</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August and November 2015, the Board of Directors granted approximately 1.6 million and 0.1 million shares of performance- and market- contingent awards to members of the senior management team, respectively. These awards have an exercise price of $0.68 per share.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These awards have two separate market triggers for vesting based upon either (i)&#160;the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company&#8217;s initial public offering for its common stock, or (ii)&#160;stepped target prices for a change in control transaction. In the event that neither of these market triggers are achieved by the specified timelines, such awards will terminate with respect to that portion of the shares. The expense recognized associated with these performance- and market- contingent awards is $4.8 million and $0.4 million of general and administrative and research and development expense, respectively, for the three and six months ended June 30, 2019. The remaining expense to be recognized for these awards, using the accelerated attribution method, is $0.8&#160;million which will be recognized over the remaining derived service period of approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBhNjFlYjczMDQ3OTQ4YTU4NzdjZmI5MGEyNjQ0ZDcwL3NlYzowYTYxZWI3MzA0Nzk0OGE1ODc3Y2ZiOTBhMjY0NGQ3MF82NC9mcmFnOmJmYWE2YjlhMTEyNzRlOTBhYzE2MmE1MmM4YTM2MTk1L3RleHRyZWdpb246YmZhYTZiOWExMTI3NGU5MGFjMTYyYTUyYzhhMzYxOTVfMTA5OTUxMTY0NjE5Ng_40ff6178-4587-42fe-8169-938e295fadf9">one</span> year.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company used a lattice model with a Monte Carlo simulation to value these stock options. This valuation methodology utilized the estimated fair value of the Company&#8217;s common stock on grant date and several key assumptions, including expected volatility of the Company&#8217;s stock price based on comparable public companies, risk-free rates of return and expected dividend yield.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options Granted to&#160;Non-Employees&#160;with Service-Based Vesting Valuation Assumptions</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation related to stock options granted to&#160;non-employees&#160;is recognized as the stock options are earned. Prior to the adoption of ASU 2018-07 during the third quarter of 2018, the unvested options granted to non-employees were revalued using the Company's estimate of fair value on each reporting date. Subsequent to the adoption of ASU 2018-07, existing stock options granted to non-employees are no longer revalued, and the estimated fair value of new stock options granted to non-employees is calculated on the date of grant and not remeasured, similar to stock options granted to employees. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Activity</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the 2017 Plan, the Company may grant restricted stock awards ("RSAs"), which represent restricted shares of issued common stock for which the recipient's rights in the stock are restricted until the shares are vested, and restricted stock units ("RSUs"), which represent a commitment to issue shares of common stock in the future upon vesting. The fair value of restricted stock underlying the RSAs and RSUs is determined based on the closing market price of the Company's common stock on the date of grant.</span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Aggregated information regarding RSAs and RSUs granted under the Plan for the six months ended June 30, 2019 is summarized below:</span></div><div style="margin-top:10pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:62.903846%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.147436%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.147436%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Share Awards &amp; Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value at Date of Grant per Share</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">503,243&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.86&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">494,984&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">19.09&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and released</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(353,585)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">0.17&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,639)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">21.31&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">610,003&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18.44&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected to vest - June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">610,003&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18.44&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company adopted the 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;), which initially reserved </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">1.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> shares of common stock for employee purchases under terms and provisions established by the Board of Directors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The 2017 ESPP provides that the number of shares reserved and available for issuance under the 2017 ESPP will automatically increase each January 1, beginning on January 1, 2019, by the least of (i) 2.0 million shares, (ii) 1% of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the administrator of the 2017 Plan. In January 2019, common stock available for issuance under the 2017 ESPP was increased by approximately 1.0 million shares as a result of this automatic increase provision.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Under the 2017 ESPP, employees may purchase common stock through payroll deductions at a price equal to&#160;85%&#160;of the lower of the fair market value of common stock on the first trading day of each offering period or on the exercise date. The 2017 ESPP provides for consecutive, overlapping 12-month offering periods. The offering periods are scheduled to start on the first trading day on or after May 31 or November 30 of each year. Contributions under the 2017 ESPP are limited to a maximum of&#160;15%&#160;of an employee's eligible compensation. During the three and six months ended June 30, 2019 and 2018, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">0.1 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> shares of common stock were issued under the 2017 ESPP.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s results of operations include expenses relating to stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:39.185897%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,295&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,586&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,277&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,272&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,419&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,124&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,311&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,363&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,714&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,710&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,588&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,635&#160;</span></td></tr></table></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, total unamortized stock-based compensation expense related to employee and non-employee awards was $86.7 million. The weighted-average periods over which such stock-based compensation expense will be recognized is approximately 3.0 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869835680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. </span></div><div style="text-indent:25pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:53.288462%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.596154%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.314103%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three and Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options issued and outstanding and ESPP shares issuable</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,214,029&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,264,644&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted shares subject to future vesting</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">610,003&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,167,997&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Early exercised common stock subject to future vesting</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">41,672&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">229,172&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,865,704&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,661,813&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6879900496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Organization and Description of Business</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Denali Therapeutics Inc. ("Denali" or the &#8220;Company&#8221;) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases. The Company is headquartered in South San Francisco, California.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of SEC Regulation S-X for interim financial information. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">as filed with the Securities and Exchange Commission on March&#160;12, 2019 (the "2018 Annual Report on Form 10-K"). The condensed consolidated Balance Sheet as of December 31, 2018 was derived from the audited annual consolidated financial statements as of the period then ended. Certain information and footnote disclosures typically included in the Company's annual consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All such adjustments are of a normal recurring nature except for the impacts of adopting new accounting standards discussed below. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended&#160;June 30, 2019, except as discussed below in the sections titled Leases and Recently Adopted Accounting Standards, there were no material changes to the Company's significant accounting and financial reporting policies from those reflected in the 2018 Annual Report on Form 10-K. For further information with regard to the Company&#8217;s Significant Accounting Policies, please refer to Note 1, "Significant Accounting Policies," to the Company&#8217;s Consolidated Financial Statements included in the 2018 Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated on consolidation.&#160;For the Company and its subsidiary, the functional currency has been determined to be U.S. dollars. Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction gains and losses resulting from remeasurement are recognized in interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the condensed consolidated financial position and statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of June 30, 2019 and December 31, 2018, the Company had&#160;no&#160;off-balance&#160;sheet&#160;concentrations of credit risk.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Cash</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s restricted cash consists of the letter of credit for the Company&#8217;s headquarters building lease, and is included&#160;within other&#160;non-current&#160;assets&#160;on the accompanying condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives and Hedging Activities</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Derivatives and Hedging Activities</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its derivative instruments as either assets or liabilities on the condensed consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through Interest and other income, net in the condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company adopted Accounting Standards Update ("ASU") No. 2016-02, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> as of January 1, 2019. A determination is made as to whether an arrangement is a lease at inception. A right-of-use (&#8220;ROU&#8221;) asset an</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">d operating lease liability is recognized for identified operating leases in the condensed consolidated balance sheet. </span></div><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent the Company&#8217;s right to use the underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments due over the lease term, with the ROU assets adjusted for lease incentives received. When determining the present value of lease payments, the Company uses its incremental borrowing rate (&#8220;IBR&#8221;) on the date of lease commencement, or the rate implicit in the lease, if known.  The Company does not assume renewals in its determination of the lease term unless the renewals are deemed by management to be reasonably certain at lease inception.</span></div>Leases with an initial term of 12 months or less are not recorded on the balance sheet, unless they include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes lease expenses on a straight-line basis over the lease term. The Company has leases with lease and non-lease components, which the Company has elected to account for as a single lease component.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License and Collaboration Revenue</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC&#160;808,&#160;Collaborative Arrangements&#160;(&#8220;ASC&#160;808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;&#160;For collaboration arrangements within the scope of ASC&#160;808&#160;that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC&#160;808&#160;and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC&#160;808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&#160;The accounting treatment pursuant to Topic 606 is outlined below. &#160;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The terms of licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenue, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenue. The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. </span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company's consolidated balance sheets. If the Company expects to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company considers the terms of the contract to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices ("SSP").&#160;The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, the Company uses its best estimate of the SSP for the deliverable. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesIntraperiod tax allocation rules require allocation of the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. A related tax benefit is then recorded in continuing operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss per Share</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which supersedes the guidance in former ASC 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, C</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">odification Improvements to Topic 842, Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, in December 2018 through ASU 2018-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Narrow-Scope Improvements for Lessors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and in March 2019 through ASU 2019-01 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842): Codification Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and is required to be adopted using a modified retrospective approach.</span></div><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has adopted this standard as of January 1, 2019, applying the optional transition method such that it is not required to adjust prior period presentations. ASU 2016-02 has impacted the Company&#8217;s condensed consolidated balance sheet as the Company has certain operating lease arrangements for which the Company is the lessee and one operating lease arrangement for which the Company is the lessor. The Company has no financing leases. Management has elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows us to carryforward the historical lease classification. The impact of adoption of the standard is that the Company as of January 1, 2019 recognized a ROU asset of $46.1 million and operating lease liability of $71.3 million. The standard did not have a material impact on the Company&#8217;s condensed consolidated statements of operations and comprehensive loss and stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business, policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6618191792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets Measured at Fair Value</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value at each balance sheet date are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.314103%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.378205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.262821%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,180&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,180&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">273,103&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">273,103&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,957&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,957&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,950&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,950&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,794&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,794&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,038&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,038&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">355,077&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">152,618&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">507,695&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.153846%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.980769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">42,225&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">42,225&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,499&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,499&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,979&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,979&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">219,754&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">219,754&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,151&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,151&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,675&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,675&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government treasuries</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">117,131&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">117,131&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,773&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,773&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">380,609&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">208,163&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">588,772&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency derivative contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6651347488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:55.852564%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.461538%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461538%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.621795%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">62,936&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,123&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">33,088&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted cash included within other non-current assets</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">64,436&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,623&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,588&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:55.852564%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.461538%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461538%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.621795%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">62,936&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,123&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">33,088&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted cash included within other non-current assets</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">64,436&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,623&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,588&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available for Sale Securities</a></td>
<td class="text">The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.153846%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.980769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">272,540&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">568&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">273,103&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,960&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,957&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,842&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">122&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(14)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">78,950&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Commercial paper</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,657&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total short-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">414,999&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">697&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">415,667&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,339&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">45,794&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,968&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,038&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total long-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55,307&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">525&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55,832&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">470,306&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,222&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">471,499&#160;</span></td></tr></table><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.314103%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Short-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">220,081&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">29&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(356)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">219,754&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,373&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(222)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73,151&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,940&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(266)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,675&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Commercial paper</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,594&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total short-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">387,988&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(844)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">387,174&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Long-term marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government treasuries</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">116,878&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">329&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(76)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">117,131&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">U.S. government agency securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,975&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,977&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Corporate debt securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,864&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(99)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">28,773&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total long-term marketable securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">147,717&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">339&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(175)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">147,881&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">535,705&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">369&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,019)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">535,055&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6642609056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Forward Foreign Currency Exchange Purchase Contracts Outstanding</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s forward foreign currency exchange contracts outstanding as of June 30, 2019 (notional amounts in thousands):</span></div><div style="margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839744%;"><tr><td style="width:1.0%;"/><td style="width:31.868379%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.385233%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.916533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602568%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.422151%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Aggregate Notional</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Amount in Foreign Currency</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Euros </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,776&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - May 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">British Pounds </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,181&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - May 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Swiss Francs </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">703&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Jul. 2019 - Feb 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">_________________________________________________</span></div>(1) &#160;The notional amount represents the net amount of foreign currency that will be received upon maturity of the forward contracts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869810960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Collaboration Revenue</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:37.583333%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441026%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441026%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583333%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Takeda Collaboration Agreement</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">740&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,648&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,422&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,289&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#ee2724;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Alzheimer's Disease Services</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">99&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">193&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Retained Activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,358&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,787&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Sanofi Collaboration Revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,457&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,980&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Collaboration Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,197&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,648&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,402&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,289&#160;</span></td></tr></table></div><div style="margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6pt;font-weight:400;line-height:120%;">_________________________________________________</span></div>(1)Amounts for the three and six months ended June 30, 2019 and the three months ended June 30, 2018 represent revenue recognized during the period that was included in the contract liability balance at the beginning of the period. There was no deferred revenue at the beginning of the period for the six months ended June 30, 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6618191792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity, Payments</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of June 30, 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.967949%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.262821%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:28.769231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (six months)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,642&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,767&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,386&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,726&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,078&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and later</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">65,494&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">111,093&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(38,217)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">72,876&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Operating Lease Maturity, Receivable</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:4pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table details the future undiscounted cash inflows relating to the Company's sublease as of June 30, 2019 (in thousands):</span></div><div style="margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.967949%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.262821%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:28.769231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (six months)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,392&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,842&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,925&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,009&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,096&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and later</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">876&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted sublease receipts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14,140&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6617698896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes option award activity under the 2017 Plan and the 2015 Plan:&#160;</span></div><div style="margin-top:10pt;margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:42.391026%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.301282%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Weighted- </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Average</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Exercise&#160;Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Weighted- </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Average</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">remaining</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">contractual</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">life (years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Aggregate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Intrinsic</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:100%;">Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,612,652&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.49&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.20</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">97,804&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,296,335&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18.58&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(465,281)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.62&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(447,374)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16.30&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,996,332&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12.72&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.23</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">96,434&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,251,600&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14.77&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.58</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">61,400&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,228,421&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.17&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7.70</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">34,173&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Granted</a></td>
<td class="text"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of stock options granted to employees were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:26.365385%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.307692%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;5.50 - 6.08 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 - 6.08</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Volatility</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;66.9% - 77.8% </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">80.0% - 85.6%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">66.9% - 77.8%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">80.0% - 87.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;2.0% - 2.3% </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.7% - 2.9%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0% - 2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.6% - 2.9%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Dividend yield</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Activity</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:10pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Aggregated information regarding RSAs and RSUs granted under the Plan for the six months ended June 30, 2019 is summarized below:</span></div><div style="margin-top:10pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:62.903846%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.147436%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.147436%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Share Awards &amp; Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Fair Value at Date of Grant per Share</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">503,243&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.86&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">494,984&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">19.09&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and released</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(353,585)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">0.17&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,639)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">21.31&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">610,003&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18.44&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected to vest - June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">610,003&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18.44&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s results of operations include expenses relating to stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:39.185897%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102564%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,295&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,586&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,277&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,272&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,419&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,124&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,311&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,363&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:13pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,714&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,710&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,588&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,635&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6651347488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations</a></td>
<td class="text"><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:53.288462%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.596154%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.314103%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three and Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options issued and outstanding and ESPP shares issuable</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,214,029&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,264,644&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Restricted shares subject to future vesting</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">610,003&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,167,997&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Early exercised common stock subject to future vesting</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">41,672&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">229,172&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,865,704&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,661,813&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6871216336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>contract </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LesseeFinanceLeaseNumberOfContracts', window );">Number of financing leases | contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 34,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net operating lease liabilities</a></td>
<td class="nump">$ 72,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LesseeFinanceLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LesseeFinanceLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6883234688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 471,499,000<span></span>
</td>
<td class="nump">$ 535,055,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">15,682<span></span>
</td>
<td class="nump">13,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total asset fair value measurements</a></td>
<td class="nump">507,695,000<span></span>
</td>
<td class="nump">588,772,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability - foreign currency derivative contracts</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liability fair value measurements</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">36,180,000<span></span>
</td>
<td class="nump">42,225,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,979,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">273,103,000<span></span>
</td>
<td class="nump">219,754,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">28,957,000<span></span>
</td>
<td class="nump">73,151,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">78,950,000<span></span>
</td>
<td class="nump">71,675,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term marketable securities: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">34,657,000<span></span>
</td>
<td class="nump">22,594,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember', window );">Long-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">45,794,000<span></span>
</td>
<td class="nump">117,131,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember', window );">Long-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember', window );">Long-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">10,038,000<span></span>
</td>
<td class="nump">28,773,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total asset fair value measurements</a></td>
<td class="nump">355,077,000<span></span>
</td>
<td class="nump">380,609,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability - foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liability fair value measurements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">36,180,000<span></span>
</td>
<td class="nump">42,225,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">273,103,000<span></span>
</td>
<td class="nump">219,754,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term marketable securities: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Long-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">45,794,000<span></span>
</td>
<td class="nump">117,131,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Long-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Long-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total asset fair value measurements</a></td>
<td class="nump">152,618,000<span></span>
</td>
<td class="nump">208,163,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability - foreign currency derivative contracts</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liability fair value measurements</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,979,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">28,957,000<span></span>
</td>
<td class="nump">73,151,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">78,950,000<span></span>
</td>
<td class="nump">71,675,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term marketable securities: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">34,657,000<span></span>
</td>
<td class="nump">22,594,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">10,038,000<span></span>
</td>
<td class="nump">28,773,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total asset fair value measurements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability - foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liability fair value measurements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term marketable securities: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Long-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Long-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Long-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dnli_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6617299920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Schedule of Restricted Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,936<span></span>
</td>
<td class="nump">$ 77,123<span></span>
</td>
<td class="nump">$ 33,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included within other non-current assets</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 64,436<span></span>
</td>
<td class="nump">$ 78,623<span></span>
</td>
<td class="nump">$ 34,588<span></span>
</td>
<td class="nump">$ 218,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6881142192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Summary of Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 470,306<span></span>
</td>
<td class="nump">$ 535,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(1,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">471,499<span></span>
</td>
<td class="nump">535,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">414,999<span></span>
</td>
<td class="nump">387,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">415,667<span></span>
</td>
<td class="nump">387,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">272,540<span></span>
</td>
<td class="nump">220,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">273,103<span></span>
</td>
<td class="nump">219,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,960<span></span>
</td>
<td class="nump">73,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">28,957<span></span>
</td>
<td class="nump">73,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">78,842<span></span>
</td>
<td class="nump">71,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">78,950<span></span>
</td>
<td class="nump">71,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">34,657<span></span>
</td>
<td class="nump">22,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">34,657<span></span>
</td>
<td class="nump">22,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">55,307<span></span>
</td>
<td class="nump">147,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">55,832<span></span>
</td>
<td class="nump">147,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities: | U.S. government treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">45,339<span></span>
</td>
<td class="nump">116,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">45,794<span></span>
</td>
<td class="nump">117,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,968<span></span>
</td>
<td class="nump">28,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holding Gains</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 10,038<span></span>
</td>
<td class="nump">$ 28,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dnli_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dnli_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6871217520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax charge in other comprehensive income</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Effective maturity (less than)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6883329648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)<br> &#8364; in Thousands, &#163; in Thousands, SFr in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>GBP (&#163;) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>CHF (SFr) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>EUR (&#8364;) </div>
<div>derivative_instrument</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>derivative_instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset - foreign currency derivative contracts | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net gain (loss) on derivative instruments | $</a></td>
<td class="num">$ (7,320)<span></span>
</td>
<td class="num">$ (31,952)<span></span>
</td>
<td class="nump">$ 11,967<span></span>
</td>
<td class="num">$ (31,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardEurosMember', window );">Euros | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate Notional Amount in Foreign Currency | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardBritishPoundsMember', window );">British Pounds | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate Notional Amount in Foreign Currency | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 3,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardSwissFrancsMember', window );">Swiss Francs | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate Notional Amount in Foreign Currency | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardEurosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardEurosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardBritishPoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardBritishPoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardSwissFrancsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dnli_ForeignExchangeForwardSwissFrancsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6881633568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">22 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>May 30, 2018</div></th>
<th class="th"><div>Aug. 24, 2016</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,884<span></span>
</td>
<td class="nump">$ 52,134<span></span>
</td>
<td class="nump">$ 89,287<span></span>
</td>
<td class="nump">$ 72,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember', window );">Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeArrangementPayment', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontOptionFee', window );">Upfront option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ContingentConsiderationPayment', window );">Contingent consideration payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AssetAcquisitionContingentConsiderationAmountRecognized', window );">Contingent consideration recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_MaximumDevelopmentPlanPeriodForResearchCosts', window );">Maximum development plan period for research costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember', window );">Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma | Exercise of buy-out option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_InitialOptionExercisePayments', window );">Initial option exercise payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember', window );">Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma | Maximum | Exercise of buy-out option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ContingentPaymentsUponAchievementOfMilestones', window );">Contingent payments upon the achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AssetAcquisitionContingentConsiderationAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Amount Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AssetAcquisitionContingentConsiderationAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeArrangementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeArrangementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ContingentConsiderationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ContingentConsiderationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ContingentPaymentsUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon the achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ContingentPaymentsUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_InitialOptionExercisePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial option exercise payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_InitialOptionExercisePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_MaximumDevelopmentPlanPeriodForResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum development plan period for research costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_MaximumDevelopmentPlanPeriodForResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront option fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=dnli_ExerciseOfBuyoutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=dnli_ExerciseOfBuyoutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6882936896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Sanofi (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2018</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,197<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">$ 8,402<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment', window );">Milestone payments upon achievement of certain clinical, regulatory and sales milestone events</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementFundedPercentage', window );">Funded percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborationAgreementTransactionPriceIncrease', window );">Increase in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sanofi | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ClinicalMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sanofi | CNS Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ClinicalAndRegulatoryMilestonePayment', window );">Clinical and regulatory milestone payments</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sanofi | Peripheral Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ClinicalRegulatoryAndCommercialMilestonePayment', window );">Clinical, regulatory and commercial milestone payments</a></td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sanofi | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Denali</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CollaborativeAgreementFundedPercentage', window );">Funded percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Clinical Regulatory And Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ClinicalAndRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical And Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ClinicalAndRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ClinicalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ClinicalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ClinicalRegulatoryAndCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical, Regulatory, and Commercial Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ClinicalRegulatoryAndCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborationAgreementTransactionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Transaction Price, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborationAgreementTransactionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CollaborativeAgreementFundedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funded Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CollaborativeAgreementFundedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_CNSProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_CNSProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_PeripheralProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_PeripheralProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_DenaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_DenaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6617975600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Sanofi Performance Obligation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember', window );">Alzheimer's Disease Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=None">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=None</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6880380272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 23, 2018 </div>
<div>USD ($) </div>
<div>program </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>targets</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>targets</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>targets</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>program</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,197<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">$ 8,402<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentReceived', window );">Preclinical milestone payment received</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_NumberOfTargets', window );">Number of targets | targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_TargetOptionPeriod', window );">Target option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OptionFeesPerProgram', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_VariableConsiderationFutureConsideration', window );">Variable consideration relating to future milestones</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived', window );">Preclinical milestone payment earned not yet received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ConstrainedVariableConsideration', window );">Remaining preclinical milestones, cost and profit sharing income, and the development and commercial milestones</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_RevenueNumberOfPerformanceObligations', window );">Number of performance obligations | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,500<span></span>
</td>
<td class="nump">$ 64,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Share Purchase Agreement | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock (in shares) | shares</a></td>
<td class="nump">4,214,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase price</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Fair market value of common stock</a></td>
<td class="nump">$ 94,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Closing stock price (usd per share) | $ / shares</a></td>
<td class="nump">$ 22.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction', window );">Premium on sale of common stock</a></td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Maximum | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PreclinicalMilestonePaymentPerProgram', window );">Preclinical milestone payments per program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregatePreclinicalMilestonePayment', window );">Total aggregate payments due upon achievement of certain preclinical milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateOptionExerciseFee', window );">Aggregated option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateDevelopmentMilestonePayment', window );">Total aggregate payments due upon achievement of certain clinical and regulatory milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_CommercialMilestonesPerProgram', window );">Milestone payments per biologic product upon achievement of a certain sales-based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_AggregateCommercialMilestones', window );">Milestone payments upon achievement of biologic product from each program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate commercial milestones if one biologic product from each program achieves the milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregateOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate option exercise fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregateOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_AggregatePreclinicalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total aggregate payments due upon achievement of certain preclinical milestone events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_AggregatePreclinicalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_CommercialMilestonesPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestones per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_CommercialMilestonesPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ConstrainedVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Constrained variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ConstrainedVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OptionFeesPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fees per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OptionFeesPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PreclinicalMilestonePaymentEarnedNotYetReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical Milestone Payment Earned Not Yet Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PreclinicalMilestonePaymentEarnedNotYetReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PreclinicalMilestonePaymentPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments due upon achievement of certain preclinical milestone events per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PreclinicalMilestonePaymentPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PreclinicalMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PreclinicalMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_RevenueNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_RevenueNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration premium received on transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_TargetOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Target Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_TargetOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_VariableConsiderationFutureConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration relating to future milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_VariableConsiderationFutureConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dnli_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dnli_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6880674448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Collaboration Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 4,197<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">$ 8,402<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_TakedaCollaborationAgreementMember', window );">Takeda Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember', window );">Sanofi Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">3,457<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember', window );">Sanofi Collaboration Agreement | Alzheimer's Disease Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember', window );">Sanofi Collaboration Agreement | Retained Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 3,358<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,787<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_TakedaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_TakedaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_SanofiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_AlzheimersDiseaseServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dnli_RetainedActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dnli_RetainedActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6882901680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details) - Genentech Inc - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 17, 2016</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones', window );">Milestone payments upon achievement of specified clinical and regulatory milestones</a></td>
<td class="nump">$ 315.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dnli_LicenseAgreementMember', window );">License Agreement | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_UpfrontFeesPaid', window );">Upfront fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payment upon achievement of clinical and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_UpfrontFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_UpfrontFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dnli_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dnli_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dnli_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dnli_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6881965888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=dnli_HeadquartersLeaseMember', window );">Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OperatingLeasesAreaUnderLease', window );">Area under lease | ft&#178;</a></td>
<td class="nump">148,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal option term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=dnli_NewPremisesSubleaseAgreementMember', window );">New Premises Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_OperatingLeasesSubleaseNetRentableArea', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Sublease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=dnli_LandlordFundedTenantImprovementsMember', window );">Landlord Funded Tenant Improvements | Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_TenantImprovementAllowanceRepayableAsRent', window );">Tenant improvement allowance repayable in rent</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=dnli_DMSAMember', window );">DMSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PurchaseOrderExecuted', window );">Purchase order executed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsIncurredDevelopmentCosts', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PaymentsForManufacturingCost', window );">Payments for development and manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Non-refundable purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LesseeOperatingLeaseRenewalNoticePeriod', window );">Lease renewal notice period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">$ 25,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_LesseeOperatingLeaseRenewalNoticePeriod', window );">Lease renewal notice period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_LesseeOperatingLeaseRenewalNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Renewal Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_LesseeOperatingLeaseRenewalNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OperatingLeasesAreaUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases area under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OperatingLeasesAreaUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_OperatingLeasesSubleaseNetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Sublease, Net Rentable Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_OperatingLeasesSubleaseNetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PaymentsForManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for manufacturing cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PaymentsForManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PurchaseOrderExecuted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase order executed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PurchaseOrderExecuted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_TenantImprovementAllowanceRepayableAsRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of tenant improvement allowance repayable to landlord in future rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_TenantImprovementAllowanceRepayableAsRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsIncurredDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=68064819&amp;loc=d3e62014-109447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsIncurredDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=dnli_HeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=dnli_HeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=dnli_NewPremisesSubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=dnli_NewPremisesSubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=dnli_LandlordFundedTenantImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=dnli_LandlordFundedTenantImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=dnli_DMSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=dnli_DMSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6880105296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (six months)</a></td>
<td class="nump">$ 3,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2020</a></td>
<td class="nump">9,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2021</a></td>
<td class="nump">10,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2022</a></td>
<td class="nump">10,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2023</a></td>
<td class="nump">11,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2024 and later</a></td>
<td class="nump">65,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">111,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(38,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net operating lease liabilities</a></td>
<td class="nump">$ 72,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869714384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">2019 (six months)</a></td>
<td class="nump">$ 1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2020</a></td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2021</a></td>
<td class="nump">2,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2022</a></td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2023</a></td>
<td class="nump">3,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">2024 and later</a></td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted sublease receipts</a></td>
<td class="nump">$ 14,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in fifth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor after fifth fiscal year following latest statement of financial position date for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6882686944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated fair value of option (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.16<span></span>
</td>
<td class="nump">$ 13.37<span></span>
</td>
<td class="nump">$ 11.92<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.35<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,714<span></span>
</td>
<td class="nump">$ 4,710<span></span>
</td>
<td class="nump">$ 20,588<span></span>
</td>
<td class="nump">$ 7,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,419<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
<td class="nump">$ 11,311<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
<td class="nump">$ 2,586<span></span>
</td>
<td class="nump">$ 9,277<span></span>
</td>
<td class="nump">$ 4,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dnli_PerformanceAndMarketContingentStockOptionsMember', window );">Performance and Market Contingent Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays', window );">Vesting trigger, number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering', window );">Vesting trigger, number of days after IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized', window );">Share based compensation cost not recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition', window );">Period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dnli_PerformanceAndMarketContingentStockOptionsMember', window );">Performance and Market Contingent Stock Options | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PerformanceAndMarketShareBasedCompensation', window );">Performance and market-contingent awards expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dnli_PerformanceAndMarketContingentStockOptionsMember', window );">Performance and Market Contingent Stock Options | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_PerformanceAndMarketShareBasedCompensation', window );">Performance and market-contingent awards expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Common stock purchase discounted rate for employees</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee contribution to ESPP, percent of base compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding and ESPP Shares Issuable and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized stock- based compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dnli_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dnli_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember', window );">Shares Transferred As Available For Issuance From 2015 Plan to 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of option price of estimated fair value on grant date</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of option price of estimated fair value on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PerformanceAndMarketShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance And Market Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PerformanceAndMarketShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance and market share based compensation cost not yet recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Days After Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dnli_PerformanceAndMarketContingentStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dnli_PerformanceAndMarketContingentStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dnli_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dnli_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dnli_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dnli_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6868761104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance (in shares)</a></td>
<td class="nump">9,612,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted (in shares)</a></td>
<td class="nump">3,296,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised (in shares)</a></td>
<td class="num">(465,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited (in shares)</a></td>
<td class="num">(447,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance (in shares)</a></td>
<td class="nump">11,996,332<span></span>
</td>
<td class="nump">9,612,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest (in shares)</a></td>
<td class="nump">10,251,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">3,228,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise&#160;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (usd per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (usd per share)</a></td>
<td class="nump">18.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (usd per share)</a></td>
<td class="nump">4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (usd per share)</a></td>
<td class="nump">16.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (usd per share)</a></td>
<td class="nump">12.72<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (usd per share)</a></td>
<td class="nump">14.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (usd per share)</a></td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Option Activity, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 2 months 23 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and expected to vest</a></td>
<td class="text">8 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning balance</a></td>
<td class="nump">$ 97,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending balance</a></td>
<td class="nump">96,434<span></span>
</td>
<td class="nump">$ 97,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">61,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 34,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6869013552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">77.80%<span></span>
</td>
<td class="nump">85.60%<span></span>
</td>
<td class="nump">77.80%<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6799148128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Restricted Stock Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share Awards &amp; Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">503,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, granted (in shares) | shares</a></td>
<td class="nump">494,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, vested (in shares) | shares</a></td>
<td class="num">(353,585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, forfeited (in shares) | shares</a></td>
<td class="num">(34,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, unvested, ending balance (in shares) | shares</a></td>
<td class="nump">610,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, vested and expected to vest (in shares) | shares</a></td>
<td class="nump">610,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value at Date of Grant per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, unvested, beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 4.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, granted (usd per share) | $ / shares</a></td>
<td class="nump">19.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, vested (usd per share) | $ / shares</a></td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, forfeited (usd per share) | $ / shares</a></td>
<td class="nump">21.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, unvested, ending balance (usd per share) | $ / shares</a></td>
<td class="nump">18.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest', window );">Weighted-average fair value at date of grant per share, vested and expected to vest (usd per share) | $ / shares</a></td>
<td class="nump">$ 18.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dnli_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6672172240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 13,714<span></span>
</td>
<td class="nump">$ 4,710<span></span>
</td>
<td class="nump">$ 20,588<span></span>
</td>
<td class="nump">$ 7,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">5,295<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">9,277<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 8,419<span></span>
</td>
<td class="nump">$ 2,124<span></span>
</td>
<td class="nump">$ 11,311<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6782990352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">12,865,704<span></span>
</td>
<td class="nump">10,661,813<span></span>
</td>
<td class="nump">12,865,704<span></span>
</td>
<td class="nump">10,661,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EmployeeAndNonEmployeeStockOptionMember', window );">Options issued and outstanding and ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">12,214,029<span></span>
</td>
<td class="nump">9,264,644<span></span>
</td>
<td class="nump">12,214,029<span></span>
</td>
<td class="nump">9,264,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_RestrictedSharesSubjectToFutureVestingMember', window );">Restricted shares subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">610,003<span></span>
</td>
<td class="nump">1,167,997<span></span>
</td>
<td class="nump">610,003<span></span>
</td>
<td class="nump">1,167,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember', window );">Early exercised common stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">41,672<span></span>
</td>
<td class="nump">229,172<span></span>
</td>
<td class="nump">41,672<span></span>
</td>
<td class="nump">229,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_RestrictedSharesSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_RestrictedSharesSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_J[#UVNS-/S:^"'8M_+J+[@M02P,$%     @ PX8&3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M!K1,J60P[S%JC*L- XUQ[ 3&((=I82YEU$)7-=*M<>@$  XX 8""3@#@M!,
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M1!UKXP,1J-R,#KT 8!X2V ,:?_DB23ID1ZIRG9J0'\Q# CP4ZQ>A+9Y68L6
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M#TH%(B_CY\Q)EY0!N#Z_L3_$VGTM%V'A'M6SK%R;TP,E%=1B4.X)QT>8Z_E
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MAW"VXYB-AL=N^D%L_L;%+U!+ P04    " ##A@9/D5R._[8!  #2 P  &0
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M:?XUHH<@97,35J@-#VQV%-0^FG?!MN.:C8[';GI!;'[&Q2]02P,$%     @
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M'VPQ%-0N'#_XLYG&;#(<]O,/8LLW+GX#4$L#!!0    ( ,.&!D^J#7H]6@(
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MD[PRT7L1Q<>,W*W0@KG,F&B#"5<$,>JK1>2SN$3_T",__>#-\.#HART]^(_
MT2MP= +'OTJ,=R7Z,(G?)/::Q!Z!=&?BPYS\)HG7)/$(O-N9>#!)X#=)O2:I
M1R#<F?@P^W]"-E>0@VQ<\RE4BK%WC;^)KOW]&+DK_ <^/PY?J&RZ7J&;T*81
MW'6MA=!@4@D>S*FVYCU:%PQJ;:>F?Y"<NW)>:#$L#PY97[WB-U!+ P04
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M[']MC =,);G"$6KQ@RV&@MJ'XRV>[31FD^%-/_\@MGSCX@]02P,$%     @
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MI@6#@[;3S,SET$"'A1;=^#A$TPM5_ 502P,$%     @ PX8&3TBT1P$*"
M<C@  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULE5OM;ALW$'P500\0
M<?G-P#90I2A:H 6"%&U_*_8Y%B+I7.ELIV_?.WT8OMM9FOP36_(<-61NEK/'
MT=5+N_]^>&B:;O9CN]D=KN</7??X<;$XW#XTV]7A0_O8[/J_W+?[[:KK7^Z_
M+0Z/^V9U=[QHNUEHI?QBNUKOYC=7Q_<^[V^NVJ=NL]XUG_>SP]-VN]K_MVPV
M[<OUG.:7-[ZLOSUTPQN+FZO'U;?FSZ;[Z_'SOG^U>!WE;KUM=H=UNYOMF_OK
M^4_T\1-9-UQQA/R];EX.;WZ?#7/YVK;?AQ>_W5W/U4"IV32WW3#&JO_QW'QJ
M-IMAJ)[(O^=1YZ\?.ESX]O?+Z+\<9]_/YNOJT'QJ-_^L[[J'ZWF<S^Z:^]73
MIOO2OOS:G&?DYK/S]']OGIM-#Q^8])]QVVX.QW]GMT^'KMV>1^FI;%<_3C_7
MN^//E_/XE\OP!?I\@7Z]@&SV G.^P$PN6)R8':?Z\ZI;W5SMVY?9_O3?];@:
M[@KZ:/K%O!W>/*[=\6_]; _]N\\W.MBKQ?,PT!FS/&'T6\P8\8DC7'J%+'H"
MKRPT9*&/UYL1"X<','  <QS C@;PDVF<,/Z(V1TQ-I!-22DUF0Y'.N.4<V^1
M(U(6DK* 5)B0.F'<FX\BY^-T?0'*>"\LL8-D'" 3)V0<^QBG@D^.KQ! QAB"
M%E?(0U(>D$H34AZL$& $8%&F$R"=P.G$R><L0QD= ,O0B9!.!'0(#Y#@ *E<
M5J1P>5" @Y[6!\4F:SQ%Q5<%(*W66A86"56+ "TC#(%+#E74',)%AT#58=(]
M@T9WPJ3HC#\+UQ("Q21:80A< <A5S!CKE8!@^8RY%%,*F1EC,1)2HT07"XAB
MQ8RQA"@5["QGT-L9ZV!(&:   *44G!671V-E:J1,+PR!5:2I?'FTL''K@N4Y
M@T9SCLD%OCH V:^C(WEQL#(U4F80AL""T[9B<;#@--ISV>+PK33$XY;+%@<@
MR0>Y>&HL8HU$'(4AL#9UJ%@<K$T-=C>^.)'O+-;#.X<C^WTE962%]:Z!WJ-@
MM Q6IE$5;A8KTX#]C?M9XINI"^,IG_TL1Q(%,K*N#):[ 7)/TA""4S<5JX.E
M:9"Q]M,Y \^<0I!GC#5L@(:38,(,UIOQ%3/&>C-@+^3W _"<2ID([@>.[,MC
M,/+B8 T;H.&DA2&PWDR%1[58;Q;LA+S/XLYSNBI9R)@(5JU%JIWV6)9KT?0-
M1  U#4&C\DJV4A;+UJ)=>MIG6;[W,D(YR)@(%K]%^_*TP[+<,3,B.<B8B-":
M@Q*2A ;"XLI@*^RTQ97!%MCII>5V6NBN #+?75E<;2RH-DGH-2RN#+;">5M<
M&2S:B=F#$6ZGL]V5PR7$@1*2!+H.B]]5F&F'9>J 3-F,7;$&'=:@ QI,0N/@
ML'I<A3=VPN.H$F_LN..5^BH$S?=5#FO2 4TFH75P6#^NPAT[K!]7XHX=][QL
M67*0,1&L0@=4F(1FP6-Q^0H_[+&X?(D?]GR[9 \)<Y Q$2Q1CPRPT!YXK#]?
M88 ]UI\O,,!+SPTP6XX<9$P$J]AS%1OQ";#P"+C"'7NL-U_BCCWWO$*W!)#O
M=$L>B]AS$1LE] X>R\]7V.. Y1>0/9YV2Z'8^P:LT, 5:I30"@2LK5#Q1#9@
M;862<Z#POK_,0L9$L$(#5ZA1@K\,6%NAPE\&K*V SE>FG5$ )R<>'&@ F+RY
M!N& !2EUVB$%=,2B3Y9W2@HTLBJ2ESO9@*4:T'X[[9 "WTSQV0_ Y<ZBL/0#
M\K_L- KX7T@)X'+G4;B41%Y*C!(:@XCK1*RPR1'7B5A@DY?Q_6XV"QD3P=4F
M\FICE#077"=BA9..N$Y$X*19UQ"Y/9;FBDM)Y*7$**%KB%C\L<(61^%$%!V)
MLKER^67/GR+67^3Z,TIH!!+62ZIPO@GK)94XW_2^\\U"QD2PZA)7G5%"(Y"P
M7E*%\TU8+ZG$^29N:X7S)H#,GS<EK,&$?+#0%B0LL%3A@Q,66"KQP8EOF<)Y
M$T)FSYL2%FT"-IBD(80@0U6208HR%!CAY055<.2$H/DS)U)"G$$!]TQ"IT!*
M"#2HFD2#$B(-JL1!7U"Y@I/'3,@(F0<%7#0)304I(?6@:F(/2L@]*.2DITW4
M!55\YD1*B#XHKF1#4KY%">$'59-^4$+\017E'Q2PE_CH"4'S9T\D19- -LF0
M%(D1@T05?I2D*!&A\Y5IGW5!9463Q4S(" I&J2368Q&()7$RY0J64DLHML3Z
MJ@LJ3Z;X615)^2="3GG:45U0>3+%=IJD)!6(4O7.0QI$J!-48:E)"DE1@:E>
M7E#Y92E^VDQ2W KDK0P)?08)T2C2%;Z;A' 4:90Q9%DW7>RK28A0$<A0&1(:
M#1("3Z0KO#4)D2?2*&3(IURN1"$812 994AH)DB(,9&N<,PD!)E(EWCF"RI[
M\V<Q$S*"$D$FRI#01I 08")=XY6%"!.9(J]LW@]5Y#$3,H(201K*:'$0066F
M*N\K!7Z+W+$IV%NSF D90:T@!F6TU#0(\28R->Y8"#B1*7#'RPLJORPYS(2,
MH&B0E3)::AJ$8!.9&N\L1)O(%'EGPPTQ7Y8<9A(?%Q0-4E)&2RV%$' B6^.6
MA3 2P302ZZ7*LT8DA(T(I(V,EAH$(2A$MN()+0E1(;(E:8<+RN?NA"SF1&;Q
MYKM?P[?Q_ECMOZUWA]G7MNO:[?7P9:_[MNV:?CSUH1_NH5G=O;[8-/?=\.MP
M^K0_?0GN]*)K'Z]/W_!;O'[-\.9_4$L#!!0    ( ,.&!D]+^M>$&@(  "T&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;(V5X:Z;(!B&;\5X 0<%
ML?;$FNRT7;9D2YJS;/M-6UK-07% Z]G=#Y :*V[KGPKXO"_O]ZDT[[AXDR6E
M*GBO62-78:E4^PR /)2T)O*)M[31=TY<U$3IJ3@#V0I*CE94,P"C* 4UJ9JP
MR.W:3A0YORA6-70G GFI:R)^OU#&NU48A[>%U^I<*K, BKPE9_J-JN_M3N@9
M&%R.54T;6?$F$/2T"C_$SUML> O\J&@G1^/ 5++G_,U,/A]7860"448/RC@0
M?;G2-67,&.D8OYQG.&QIA./QS?VCK5W7LB>2KCG[61U5N0JS,#C2$[DP]<J[
M3]35@\/ %?^%7BG3N$FB]SAP)NUO<+A(Q6OGHJ/4Y+V_5HV]=L[_)IL70">
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M;&VZ 9TH%2"M>P_R+ OYZ/4+ B>AIJF<,]/ZS4+0IGO54/^TKO\#4$L#!!0
M   ( ,.&!D]UH\F+<@,  *$/   9    >&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;)6776_:,!2&_TJ4^S6Q\XT J4 IM)M4==IVG8*!J$G,$E.V?S_'<=/$
M'%/OIDG,\YX/^_C4'I]I]5H?"&'6GR(OZXE]8.PX<IQZ<R!%6M_0(RGY+SM:
M%2GCG]7>J8\52;="5.0.=MW0*=*LM*=C,?943<?TQ/*L)$^559^*(JW^SDA.
MSQ,;V>\#S]G^P)H!9SH^IGORG; ?QZ>*?SF=E6U6D++.:&E59#>Q;]'H$0N!
M('YFY%SWWJTFE1=*7YN/]79BNTU$)"<;UIA(^>.-S$F>-Y9X'+^E4;OSV0C[
M[^_6ER)YGLQ+6I,YS7]E6W:8V+%M;<DN/>7LF9Y71"84V);,_BMY(SG'FTBX
MCPW-:_'7VIQJ1@MIA8=2I'_:9U:*YUG:?Y?! BP%N!.TDZ,5>%+@F0I\*?!-
M!8$4!*:"4 K"3N#CJX)("B)302P%\8? ORI(I" Q]8#<]Y5S3=-&W6)_K+87
MB$)LJT24W2)EZ71<T;-5M3OGF#8;%(VXBAMO1D4ABQ]YZ=5\]&WJ^6CLO#66
M)#-K&=QCD.L-F07 =(3#0^CBP& <,WRA]WP\]#&'&#4. SMW!G:6$.,/F7N(
M"8;,"F+"(;.&F&C(/$!,/&0>(2:!5\&#J\$3%KR^A<"%+?BP!5]8\ <6E'JZ
M;YE0,&5;*T'@NJZ2,H#%N(\-X@G@> (@'J4>[@,@GC!6J > \L)0,[\A'$T(
M1*-4WBR\\/,E\K R.7. \E"BIK:XQ!!*0J6X[CXU-L@M@G.+@-Q\V$(,6XC-
MJR^!+21 #,J.7+9,T)^21"F(SY'5Y\CZ*C+(IFG\8'-V@7S4[B&AN.<'1U&H
M\:3[-X  3Y'&!MS";Q$V7S^D:4#(,UA!"?5G%JL]QH!9&3#KZ\PP)TU+1%!/
MC-6<6BCI^?%0K/.D:78(ZG:ZFM.T*!3^QRIJ6@&">L'%*D:7^R-65_%S9F7
MK*\SPYPTS0G%ESF%KAI+"S5;LG,4]<Y*0T^:)H: +A;J3E.:SH%=\U7$FIZ
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MO-UL*66$:X(;WL8]__KH!P79,O&*^'O37<&[ :.U^KP(^F^<^5]02P,$%
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MORG)7JAE*M>L'0?;C:!--^H&_;R]_ =02P,$%     @ PX8&3X#W%700 @
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M6KW5C2J-%TVES/[TQWS7'0_]/UP8,VQ C0$]&E!VUH 9 _9A$)\UB(Q!]&%
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M/\NS?H8I84TFKBAK*?6XP%)*HNL?# 1+('$U,.*6[MP;T&FN1/<R]26,%8X
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M]9L3%PU5>BC.2'8"Z-$&-0SA($A10^O6+PL[]R+*@E\4JUMX$9Z\- T5_W;
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M,0T8G)3I$MT7PW$Y#!3OQJL 3?=1^1]02P,$%     @ PX8&3_NM#+K^ 0
MOP4  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL=93;CILP$(9?!?$
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M%I58;/W$E9E58/:XK;+?6SN$_X"Q/6A\@Y(0S QG+2@(H/DKMJ  "  PS+7
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MK/[*$17<<2":)0:A8)/!8<VSI!<]!_6<SL05NB/@B--B8;-PL+AA7.-#GAQ
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M9$'[FFJ/245[(I/8*$W/J,[4O7<0O3D0>2"%&R[+!C@4G7A@42N>ACT10&M
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M)MOF:IFU\7>O8(TV&XFQM63C#'K3A%Z=)KHQ9R0EGGMG '-KJC5>;#HQX1&
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M8!/=RSWV4@%[M*,>M;0;78:#+W4BMHHM1@L!"GO^=27=@X3%2MRY#$"Z-^"
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MVK^ D',<C\1J>3K[/6[7.YOH* P@5_>8WGDX+RI,J27/'"&+&PN"EF4+MXO
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M +%#_:4^ONPR9^C='SM.;I)AZ&'Q\G&4 1S\]#[9F#,![!BNP8.ENXEISEK
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M0N58#E+JT\U#!<_@]X?R*/Q[K;1LN,Z&J9PK1C'$TJI,M)DJ=F,FR6$?.G>
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MW@Q;'(WCP6RD=B>SN\.TK%;)?)6MUVE)QCX#A1:RNK21149"T]*2G$A7]-&
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M\E0<[0QN!%;T(+<<$ (@2D^.O?FDK4L/4^^U791K=T_K%.78 M1%B2O'O.&
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M >#\KHY4D5;#4VLP] 8'655C(VSS>H4+-;>&K<RW='87B/ C\8^4K2#>;E/
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MD#?ZQJ]M'6:IQ/'4@7.EABWOQFP\ 0^H]/,PNQMV!9'"Y6OQB!=4N6NEMNG
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MZ6Q+]>98''=6Y ).*YI1"XK5,Z699#V3I3[8B([R6>!70@M\$*."IWIE^>Y
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M'M864+,AB'IA;E(;4R9*#,(ML^19IJ#!&8!J>UB;"0(.=!&#WLW4@J%F,5\
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M3;YN,"TCZ'CW90JR1>,*C(*'ZC@IN%*Y%.]=+D4KA?B946":LF!7TL+?3&(
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MOUJ@&(Y9&"=')1)N'RF'1<-(22P^QO;)B9B1XH(Q=![WZ:B*I#YHL:E:A$J
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ME["XOP19WACF?S9+LL6Q7RZ9-U*>X[YOZDI#^X72U[']]/OA-U!+ P04
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MY/N#/#UHU!\TH@>-^X/&]*!)?]"$'C3M#YK2@V;]03-ZD R!C$-^$L*:K[4
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M<R\N<F5L<U!+ 0(4 Q0    ( ,.&!D\GZ(<.@@   +$    0
M  "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ PX8&3PJX["GO
M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ PX8&3YE<G",0!@  G"<  !,              ( !MP(  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ##A@9/=A9T<CL#  "@#P
M&               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ PX8&3]M9*6$5!   [!(  !@              ( !:0P  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,.&!D^RK;XN/ (
M +('   8              "  ;00  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " ##A@9/.$ ?;-X#  !]$   &               @ $F
M$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ PX8&3^7M
M0-6U!@  ]B4  !@              ( !.A<  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( ,.&!D^P\03.9@0  /\4   8
M  "  24>  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " ##
MA@9/&A[_@;0!  #2 P  &               @ '!(@  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ PX8&3W!D=PRS 0  T@,  !@
M         ( !JR0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( ,.&!D_VMV0XM $  -(#   8              "  90F  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " ##A@9/D5R._[8!  #2 P
M&0              @ %^*   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( ,.&!D^%P.OUL $  -(#   9              "  6LJ  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ PX8&3^=RC"RP
M 0  T@,  !D              ( !4BP  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " ##A@9/WR ]_+ !  #2 P  &0
M@ $Y+@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,.&
M!D\GB1 (M@$  -(#   9              "  2 P  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ PX8&3R"F)+JS 0  T@,  !D
M         ( !#3(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " ##A@9/,E2,([0!  #2 P  &0              @ 'W,P  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,.&!D^J#7H]6@(  *0(
M   9              "  >(U  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ PX8&3RSO_;2W 0  T@,  !D              ( !<S@
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " ##A@9/!#30
M?]0!  "<!   &0              @ %A.@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( ,.&!D],>IK"N $  -(#   9
M  "  6P\  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MPX8&3WJT_P:T 0  T@,  !D              ( !6SX  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " ##A@9/0L8N'\8!   W!   &0
M            @ %&0   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( ,.&!D_;TM*ZWP$   $%   9              "  4-"  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ PX8&3W3%E>^V 0
MT@,  !D              ( !640  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " ##A@9/ VRN=C,"  "M!@  &0              @ %&
M1@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,.&!D](
MM$<!"@@  '(X   9              "  ;!(  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ PX8&3TOZUX0: @  +08  !D
M     ( !\5   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,.&!D\B^?FG*P,  ),.   9              "
M 0]B  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ PX8&
M3U4]<(*X 0  $P0  !D              ( !<64  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " ##A@9/P><H*?H#   +%   &0
M        @ %@9P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( ,.&!D]B79D>X (  'L+   9              "  9%K  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ PX8&3X#W%700 @  KP8
M !D              ( !J&X  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " ##A@9/7Q#@3QL$   %%0  &0              @ 'O<
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,.&!D]0AYG/
M)P(  )L&   9              "  4%U  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ PX8&3_NM#+K^ 0  OP4  !D
M ( !GW<  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " ##
MA@9/%<PKD?0%  !*(@  &0              @ '4>0  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,.&!D_GKXL"4 ,  +0-   9
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M970T-2YX;6Q02P$"% ,4    " ##A@9/I%*UX_-V  "0ZP$ %
M    @ '&C@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " ##A@9/
M=:+A(7<"  !T#0  #0              @ 'K!0$ >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( ,.&!D^4X>#'U@,  'X>   /              "  8T( 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ##A@9/9VT:EL !  "\&P  &@
M            @ &0# $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " ##A@9/-QE]R+@!  #;&P  $P              @ &(#@$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     -@ V *P.  !Q$ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>281</ContextCount>
  <ElementCount>370</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Cash and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CashandMarketableSecurities</Role>
      <ShortName>Cash and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Stock-Based Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwards</Role>
      <ShortName>Stock-Based Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Cash and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables</Role>
      <ShortName>Cash and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/CashandMarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/CollaborationAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Stock-Based Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsTables</Role>
      <ShortName>Stock-Based Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/StockBasedAwards</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/NetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Cash and Marketable Securities - Schedule of Restricted Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails</Role>
      <ShortName>Cash and Marketable Securities - Schedule of Restricted Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Cash and Marketable Securities - Summary of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash and Marketable Securities - Summary of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Cash and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/AcquisitionDetails</Role>
      <ShortName>Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/Acquisition</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Collaboration Agreements - Sanofi (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails</Role>
      <ShortName>Collaboration Agreements - Sanofi (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Collaboration Agreements - Sanofi Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails</Role>
      <ShortName>Collaboration Agreements - Sanofi Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Collaboration Agreements - Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Collaboration Agreements - Summary of Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails</Role>
      <ShortName>Collaboration Agreements - Summary of Collaboration Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.denalitherapeutics.com/role/LicenseAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Stock-Based Awards - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails</Role>
      <ShortName>Stock-Based Awards - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Stock-Based Awards - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dnli-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="dnli-20190630.htm">dnli-20190630.htm</File>
    <File>dnli-20190630.xsd</File>
    <File>dnli-20190630_cal.xml</File>
    <File>dnli-20190630_def.xml</File>
    <File>dnli-20190630_lab.xml</File>
    <File>dnli-20190630_pre.xml</File>
    <File>exhibit311q22019.htm</File>
    <File>exhibit312q22019.htm</File>
    <File>exhibit321q22019.htm</File>
    <File>exhibit322q22019.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dnli-20190630.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 281,
   "dts": {
    "calculationLink": {
     "local": [
      "dnli-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dnli-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "dnli-20190630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20190630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dnli-20190630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 463,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 46,
    "http://www.denalitherapeutics.com/20190630": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 52
   },
   "keyCustom": 58,
   "keyStandard": 312,
   "memberCustom": 32,
   "memberStandard": 28,
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.denalitherapeutics.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Acquisition",
     "role": "http://www.denalitherapeutics.com/role/Acquisition",
     "shortName": "Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Collaboration Agreements",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - License Agreements",
     "role": "http://www.denalitherapeutics.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Stock-Based Awards",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwards",
     "shortName": "Stock-Based Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Net Loss Per Share",
     "role": "http://www.denalitherapeutics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dnli:OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.denalitherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Cash and Marketable Securities (Tables)",
     "role": "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables",
     "shortName": "Cash and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Stock-Based Awards (Tables)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsTables",
     "shortName": "Stock-Based Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.denalitherapeutics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Cash and Marketable Securities - Schedule of Restricted Cash and Cash Equivalents (Details)",
     "role": "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails",
     "shortName": "Cash and Marketable Securities - Schedule of Restricted Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i7de42ac379c3456094525bb4ad42c025_I20180630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Cash and Marketable Securities - Summary of Available for Sale Securities (Details)",
     "role": "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
     "shortName": "Cash and Marketable Securities - Summary of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Cash and Marketable Securities - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails",
     "shortName": "Cash and Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)",
     "role": "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails",
     "shortName": "Derivative Financial Instruments - Summary of Forward Foreign Currency Exchange Contracts Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Acquisition (Details)",
     "role": "http://www.denalitherapeutics.com/role/AcquisitionDetails",
     "shortName": "Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "ib9f18818b52f4aeabfbf7dbbb4aba705_D20160801-20180531",
      "decimals": "-5",
      "lang": null,
      "name": "dnli:CollaborativeArrangementPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Collaboration Agreements - Sanofi (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
     "shortName": "Collaboration Agreements - Sanofi (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "iabb5304c2e4d451cb6981615044d5ec3_D20181120-20181120",
      "decimals": "-5",
      "lang": null,
      "name": "dnli:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i2052c42ed02b4803ac262cf9409d6d92_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Collaboration Agreements - Sanofi Performance Obligation (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
     "shortName": "Collaboration Agreements - Sanofi Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i2052c42ed02b4803ac262cf9409d6d92_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Collaboration Agreements - Takeda (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
     "shortName": "Collaboration Agreements - Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "ib4ede48c196e4720b4b3ebb7d6802602_D20180223-20180223",
      "decimals": "-5",
      "lang": null,
      "name": "dnli:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Collaboration Agreements - Summary of Collaboration Revenue (Details)",
     "role": "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
     "shortName": "Collaboration Agreements - Summary of Collaboration Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i121aa99f2d3f4692bdd510f9652ac846_D20190401-20190630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if131cb24360a4f85bb336dd0ab7af8b9_D20160617-20160617",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - License Agreements (Details)",
     "role": "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if131cb24360a4f85bb336dd0ab7af8b9_D20160617-20160617",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "dnli:LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Company's Future Minimum Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)",
     "role": "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails",
     "shortName": "Commitments and Contingencies - Summary of Company's Future Minimum Lease Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "if15afa2e1e5d465bbf364f085370272d_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Stock-Based Awards - Narrative (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
     "shortName": "Stock-Based Awards - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i2735e2fbf77f4227a366ac2442ba6c00_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Stock-Based Awards - Summary of Stock Option Activity (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
     "shortName": "Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i4b8980df381840e981e39e869a8ad187_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i4b8980df381840e981e39e869a8ad187_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "role": "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails",
     "shortName": "Net Loss Per Share - Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i78b6a20891674247a4682df2ae9eff4f_D20190401-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i59e066377dcf4dd1909aa3b352723c01_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i59e066377dcf4dd1909aa3b352723c01_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Significant Accounting Policies",
     "role": "http://www.denalitherapeutics.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Fair Value Measurements",
     "role": "http://www.denalitherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Cash and Marketable Securities",
     "role": "http://www.denalitherapeutics.com/role/CashandMarketableSecurities",
     "shortName": "Cash and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20190630.htm",
      "contextRef": "i0afe1a5ac8f54bdd9e6713d674e4b177_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dnli_AggregateClinicalRegulatoryAndSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate Clinical Regulatory And Sales Milestone Payment",
        "label": "Aggregate Clinical Regulatory And Sales Milestone Payment",
        "terseLabel": "Milestone payments upon achievement of certain clinical, regulatory and sales milestone events"
       }
      }
     },
     "localname": "AggregateClinicalRegulatoryAndSalesMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate commercial milestones if one biologic product from each program achieves the milestone.",
        "label": "Aggregate Commercial Milestones",
        "terseLabel": "Milestone payments upon achievement of biologic product from each program"
       }
      }
     },
     "localname": "AggregateCommercialMilestones",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate development milestone payment.",
        "label": "Aggregate Development Milestone Payment",
        "terseLabel": "Total aggregate payments due upon achievement of certain clinical and regulatory milestone events"
       }
      }
     },
     "localname": "AggregateDevelopmentMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregateOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate option exercise fee.",
        "label": "Aggregate Option Exercise Fee",
        "terseLabel": "Aggregated option exercise fee"
       }
      }
     },
     "localname": "AggregateOptionExerciseFee",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AggregatePreclinicalMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total aggregate payments due upon achievement of certain preclinical milestone events.",
        "label": "Aggregate Preclinical Milestone Payment",
        "terseLabel": "Total aggregate payments due upon achievement of certain preclinical milestone events"
       }
      }
     },
     "localname": "AggregatePreclinicalMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AlzheimersDiseaseServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alzheimer's Disease Services",
        "label": "Alzheimer's Disease Services [Member]",
        "terseLabel": "Alzheimer's Disease Services"
       }
      }
     },
     "localname": "AlzheimersDiseaseServicesMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_AssetAcquisitionContingentConsiderationAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration, Amount Recognized",
        "label": "Asset Acquisition, Contingent Consideration, Amount Recognized",
        "terseLabel": "Contingent consideration recognized"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationAmountRecognized",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_AssetAcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition [Text Block]",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Acquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dnli_CNSProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CNS Product",
        "label": "CNS Product [Member]",
        "terseLabel": "CNS Product"
       }
      }
     },
     "localname": "CNSProductMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ClinicalAndRegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical And Regulatory Milestone Payment",
        "label": "Clinical And Regulatory Milestone Payment",
        "terseLabel": "Clinical and regulatory milestone payments"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ClinicalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Milestone Payment",
        "label": "Clinical Milestone Payment",
        "verboseLabel": "Milestone payment"
       }
      }
     },
     "localname": "ClinicalMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ClinicalRegulatoryAndCommercialMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical, Regulatory, and Commercial Milestone Payment",
        "label": "Clinical, Regulatory, and Commercial Milestone Payment",
        "terseLabel": "Clinical, regulatory and commercial milestone payments"
       }
      }
     },
     "localname": "ClinicalRegulatoryAndCommercialMilestonePayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborationAgreementTransactionPriceIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Transaction Price, Increase",
        "label": "Collaboration Agreement, Transaction Price, Increase",
        "terseLabel": "Increase in transaction price"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceIncrease",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeAgreementFundedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Funded Percentage",
        "label": "Collaborative Agreement, Funded Percentage",
        "terseLabel": "Funded percentage"
       }
      }
     },
     "localname": "CollaborativeAgreementFundedPercentage",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dnli_CollaborativeArrangementPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Payment",
        "label": "Collaborative Arrangement, Payment",
        "terseLabel": "Amount paid"
       }
      }
     },
     "localname": "CollaborativeArrangementPayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma [Member]",
        "label": "Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma [Member]",
        "terseLabel": "Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma"
       }
      }
     },
     "localname": "CollaborativeArrangementWithFStarAndAcquisitionOfFStarGammaMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_CommercialMilestonesPerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial milestones per program.",
        "label": "Commercial Milestones Per Program",
        "terseLabel": "Milestone payments per biologic product upon achievement of a certain sales-based milestone"
       }
      }
     },
     "localname": "CommercialMilestonesPerProgram",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ConstrainedVariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Constrained variable consideration.",
        "label": "Constrained Variable Consideration",
        "terseLabel": "Remaining preclinical milestones, cost and profit sharing income, and the development and commercial milestones"
       }
      }
     },
     "localname": "ConstrainedVariableConsideration",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ContingentConsiderationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration Payment",
        "label": "Contingent Consideration Payment",
        "terseLabel": "Contingent consideration payment"
       }
      }
     },
     "localname": "ContingentConsiderationPayment",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ContingentPaymentsUponAchievementOfMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent payments upon the achievement of milestones.",
        "label": "Contingent payments upon achievement of milestones",
        "terseLabel": "Contingent payments upon the achievement of milestones"
       }
      }
     },
     "localname": "ContingentPaymentsUponAchievementOfMilestones",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_DMSAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DMSA.",
        "label": "DMSA [Member]",
        "terseLabel": "DMSA"
       }
      }
     },
     "localname": "DMSAMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_DenaliMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denali [Member]",
        "label": "Denali [Member]",
        "terseLabel": "Denali"
       }
      }
     },
     "localname": "DenaliMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_EarlyExercisedCommonStockSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early exercised common stock subject to future vesting.",
        "label": "Early exercised common stock subject to future vesting [Member]",
        "terseLabel": "Early exercised common stock subject to future vesting"
       }
      }
     },
     "localname": "EarlyExercisedCommonStockSubjectToFutureVestingMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_EmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Non Employee Stock Option [Member]",
        "label": "Employee And Non Employee Stock Option [Member]",
        "terseLabel": "Options issued and outstanding and ESPP shares issuable"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ExerciseOfBuyoutOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise of buy-out option.",
        "label": "Exercise of buy-out option [Member]",
        "terseLabel": "Exercise of buy-out option"
       }
      }
     },
     "localname": "ExerciseOfBuyoutOptionMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ForeignExchangeForwardBritishPoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Exchange Forward - British Pounds [Member]",
        "label": "Foreign Exchange Forward - British Pounds [Member]",
        "terseLabel": "British Pounds"
       }
      }
     },
     "localname": "ForeignExchangeForwardBritishPoundsMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ForeignExchangeForwardEurosMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Exchange Forward - Euros [Member]",
        "label": "Foreign Exchange Forward - Euros [Member]",
        "terseLabel": "Euros"
       }
      }
     },
     "localname": "ForeignExchangeForwardEurosMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ForeignExchangeForwardSwissFrancsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Exchange Forward - Swiss Francs [Member]",
        "label": "Foreign Exchange Forward - Swiss Francs [Member]",
        "terseLabel": "Swiss Francs"
       }
      }
     },
     "localname": "ForeignExchangeForwardSwissFrancsMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_GenentechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Genentech Inc.",
        "label": "Genentech Inc [Member]",
        "terseLabel": "Genentech Inc"
       }
      }
     },
     "localname": "GenentechIncMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_HeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Headquarters lease.",
        "label": "Headquarters Lease [Member]",
        "terseLabel": "Headquarters Lease"
       }
      }
     },
     "localname": "HeadquartersLeaseMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of deferred rent.",
        "label": "Increase Decrease In Deferred Rent",
        "terseLabel": "Non-cash rent expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_IncreaseDecreaseInNonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Non-Cash Operating Lease Expense",
        "label": "Increase (Decrease) In Non-Cash Operating Lease Expense",
        "terseLabel": "Non-cash rent expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashOperatingLeaseExpense",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_InitialOptionExercisePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial option exercise payments.",
        "label": "Initial option exercise payments",
        "terseLabel": "Initial option exercise payments"
       }
      }
     },
     "localname": "InitialOptionExercisePayments",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_LandlordFundedTenantImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Landlord funded tenant improvements.",
        "label": "Landlord Funded Tenant Improvements [Member]",
        "terseLabel": "Landlord Funded Tenant Improvements"
       }
      }
     },
     "localname": "LandlordFundedTenantImprovementsMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_LesseeFinanceLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Finance Lease, Number Of Contracts",
        "label": "Lessee, Finance Lease, Number Of Contracts",
        "terseLabel": "Number of financing leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseNumberOfContracts",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_LesseeOperatingLeaseRenewalNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Renewal Notice Period",
        "label": "Lessee, Operating Lease, Renewal Notice Period",
        "terseLabel": "Lease renewal notice period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalNoticePeriod",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement milestone payment upon achievement of clinical and regulatory milestones.",
        "label": "License Agreement Milestone Payment Upon Achievement Of Clinical And Regulatory Milestones",
        "terseLabel": "Milestone payments upon achievement of specified clinical and regulatory milestones"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentUponAchievementOfClinicalAndRegulatoryMilestones",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement",
        "label": "License Agreement [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dnli_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term investments.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term marketable securities:"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term marketable securities:"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_MaximumDevelopmentPlanPeriodForResearchCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum development plan period for research costs.",
        "label": "Maximum development plan period for research costs",
        "terseLabel": "Maximum development plan period for research costs"
       }
      }
     },
     "localname": "MaximumDevelopmentPlanPeriodForResearchCosts",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_NewPremisesSubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Premises Sublease Agreement [Member]",
        "label": "New Premises Sublease Agreement [Member]",
        "terseLabel": "New Premises Sublease Agreement"
       }
      }
     },
     "localname": "NewPremisesSubleaseAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_NoncashTenantImprovementsPaidByLandlord": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Tenant Improvements Paid By Landlord",
        "label": "Noncash Tenant Improvements Paid By Landlord",
        "terseLabel": "Tenant improvements provided by the landlord"
       }
      }
     },
     "localname": "NoncashTenantImprovementsPaidByLandlord",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Programs",
        "label": "Number Of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_NumberOfTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Targets",
        "label": "Number Of Targets",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "NumberOfTargets",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_OperatingLeasesAreaUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating leases area under lease.",
        "label": "Operating Leases Area Under Lease",
        "terseLabel": "Area under lease"
       }
      }
     },
     "localname": "OperatingLeasesAreaUnderLease",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "dnli_OperatingLeasesSubleaseNetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Sublease, Net Rentable Area",
        "label": "Operating Leases, Sublease, Net Rentable Area",
        "terseLabel": "Rentable square feet"
       }
      }
     },
     "localname": "OperatingLeasesSubleaseNetRentableArea",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "dnli_OptionFeesPerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option fees per program.",
        "label": "Option Fees Per Program",
        "terseLabel": "Option fee"
       }
      }
     },
     "localname": "OptionFeesPerProgram",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and description of business, policy.",
        "label": "Organization and Description of Business, Policy [Policy Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessPolicyPolicyTextBlock",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dnli_PaymentsForManufacturingCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for manufacturing cost.",
        "label": "Payments for Manufacturing Cost",
        "terseLabel": "Payments for development and manufacturing services"
       }
      }
     },
     "localname": "PaymentsForManufacturingCost",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PerformanceAndMarketContingentStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance and market contingent stock options.",
        "label": "Performance And Market Contingent Stock Options [Member]",
        "terseLabel": "Performance and Market Contingent Stock Options"
       }
      }
     },
     "localname": "PerformanceAndMarketContingentStockOptionsMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_PerformanceAndMarketShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance And Market Share Based Compensation",
        "label": "Performance And Market Share Based Compensation",
        "terseLabel": "Performance and market-contingent awards expense"
       }
      }
     },
     "localname": "PerformanceAndMarketShareBasedCompensation",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance and market share based compensation cost not yet recognized.",
        "label": "Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized",
        "terseLabel": "Share based compensation cost not recognized"
       }
      }
     },
     "localname": "PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognized",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized Period Of Recognition",
        "label": "Performance And Market Share Based Compensation Compensation Cost Not Yet Recognized Period Of Recognition",
        "terseLabel": "Period of recognition"
       }
      }
     },
     "localname": "PerformanceAndMarketShareBasedCompensationCompensationCostNotYetRecognizedPeriodOfRecognition",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_PeripheralProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Peripheral Product",
        "label": "Peripheral Product [Member]",
        "terseLabel": "Peripheral Product"
       }
      }
     },
     "localname": "PeripheralProductMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_PreclinicalMilestonePaymentEarnedNotYetReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preclinical Milestone Payment Earned Not Yet Received",
        "label": "Preclinical Milestone Payment Earned Not Yet Received",
        "terseLabel": "Preclinical milestone payment earned not yet received"
       }
      }
     },
     "localname": "PreclinicalMilestonePaymentEarnedNotYetReceived",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PreclinicalMilestonePaymentPerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments due upon achievement of certain preclinical milestone events per program.",
        "label": "Preclinical Milestone Payment Per Program",
        "terseLabel": "Preclinical milestone payments per program"
       }
      }
     },
     "localname": "PreclinicalMilestonePaymentPerProgram",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PreclinicalMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preclinical milestone payment received.",
        "label": "Preclinical Milestone Payment Received",
        "terseLabel": "Preclinical milestone payment received"
       }
      }
     },
     "localname": "PreclinicalMilestonePaymentReceived",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement",
        "label": "Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with the Takeda Collaboration Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_PurchaseOrderExecuted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase order executed.",
        "label": "Purchase Order Executed",
        "terseLabel": "Purchase order executed"
       }
      }
     },
     "localname": "PurchaseOrderExecuted",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_RestrictedSharesSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted shares subject to future vesting.",
        "label": "Restricted shares subject to future vesting [Member]",
        "terseLabel": "Restricted shares subject to future vesting"
       }
      }
     },
     "localname": "RestrictedSharesSubjectToFutureVestingMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_RetainedActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Retained Activities",
        "label": "Retained Activities [Member]",
        "terseLabel": "Retained Activities"
       }
      }
     },
     "localname": "RetainedActivitiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_RevenueNumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Number Of Performance Obligations",
        "label": "Revenue, Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "RevenueNumberOfPerformanceObligations",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dnli_SaleOfStockConsiderationPremiumReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of stock consideration premium received on transaction.",
        "label": "Sale Of Stock Consideration Premium Received On Transaction",
        "terseLabel": "Premium on sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationPremiumReceivedOnTransaction",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_SanofiCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement",
        "label": "Sanofi Collaboration Agreement [Member]",
        "terseLabel": "Sanofi Collaboration Agreement"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi [Member]",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award, Threshold Consecutive Trading Days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award, Threshold Consecutive Trading Days",
        "terseLabel": "Vesting trigger, number of consecutive trading days"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardThresholdConsecutiveTradingDays",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Days After Initial Public Offering",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Days After Initial Public Offering",
        "terseLabel": "Vesting trigger, number of days after IPO"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDaysAfterInitialPublicOffering",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value expected to vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Expected To Vest",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested and expected to vest (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueExpectedToVest",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dnli_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Shares, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dnli_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares allowable under the plan (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dnli_SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares transferred as available for issuance from the 2015 plan to the 2017 plan.",
        "label": "Shares Transferred As Available For Issuance From Two Thousand Fifteen Plan to Two Thousand Seventeen Plan [Member]",
        "terseLabel": "Shares Transferred As Available For Issuance From 2015 Plan to 2017 Plan"
       }
      }
     },
     "localname": "SharesTransferredAsAvailableForIssuanceFromTwoThousandFifteenPlanToTwoThousandSeventeenPlanMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short term marketable securities.",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-term marketable securities:"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dnli_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dnli_StockIssuedDuringPeriodSharesCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Collaboration Agreement",
        "label": "Stock Issued During Period, Shares, Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with Takeda Collaboration Agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCollaborationAgreement",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dnli_StockIssuedDuringPeriodSharesEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Equity Incentive Plan",
        "label": "Stock Issued During Period, Shares, Equity Incentive Plan",
        "terseLabel": "Issuances under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEquityIncentivePlan",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dnli_StockIssuedDuringPeriodValueCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Collaboration Agreement",
        "label": "Stock Issued During Period, Value, Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with the Takeda Collaboration Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCollaborationAgreement",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_StockIssuedDuringPeriodValueEquityIncentivePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Equity Incentive Plan",
        "label": "Stock Issued During Period, Value, Equity Incentive Plan",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquityIncentivePlan",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_TakedaCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Takeda Collaboration Agreement",
        "label": "Takeda Collaboration Agreement [Member]",
        "terseLabel": "Takeda Collaboration Agreement"
       }
      }
     },
     "localname": "TakedaCollaborationAgreementMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Takeda pharmaceutical company limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TargetOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Target Option Period",
        "label": "Target Option Period",
        "terseLabel": "Target option period"
       }
      }
     },
     "localname": "TargetOptionPeriod",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dnli_TenantImprovementAllowanceRepayableAsRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of tenant improvement allowance repayable to landlord in future rent.",
        "label": "Tenant Improvement Allowance Repayable As Rent",
        "terseLabel": "Tenant improvement allowance repayable in rent"
       }
      }
     },
     "localname": "TenantImprovementAllowanceRepayableAsRent",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2017 employee stock purchase plan.",
        "label": "Two Thousand And Seventeen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand seventeen equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dnli_UpfrontFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront fees paid.",
        "label": "Upfront Fees Paid",
        "terseLabel": "Upfront fee paid"
       }
      }
     },
     "localname": "UpfrontFeesPaid",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_UpfrontOptionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront option fee.",
        "label": "Upfront Option Fee",
        "terseLabel": "Upfront option fee"
       }
      }
     },
     "localname": "UpfrontOptionFee",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dnli_VariableConsiderationFutureConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable consideration relating to future milestones.",
        "label": "Variable Consideration Future Consideration",
        "terseLabel": "Variable consideration relating to future milestones"
       }
      }
     },
     "localname": "VariableConsiderationFutureConsideration",
     "nsuri": "http://www.denalitherapeutics.com/20190630",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "invest_DerivativeNotionalAmount": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate Notional Amount in Foreign Currency"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r101",
      "r143",
      "r146",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r126",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r15",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r47",
      "r48",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r150",
      "r152",
      "r185",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r152",
      "r179",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation cost recognized",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r269",
      "r278"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r37"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total asset fair value measurements"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r106",
      "r116"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r103",
      "r107",
      "r116"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r154",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases accrued but not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r24",
      "r70"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r71",
      "r76",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r8",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r70",
      "r75"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r237"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r147",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r125",
      "r273",
      "r284"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, shares outstanding ending balance (in shares)",
        "periodStartLabel": "Common stock, shares outstanding beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 95,656,896 shares and 94,662,435 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r16",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "terseLabel": "Fair market value of common stock"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r92",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r204",
      "r207",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r138",
      "r139",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r138",
      "r139",
      "r144"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r138",
      "r139",
      "r144"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r147",
      "r149",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsIncurredDevelopmentCosts": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.",
        "label": "Costs Incurred, Development Costs",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "CostsIncurredDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Effective maturity (less than)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r34",
      "r239"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, less current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r68",
      "r98"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r38",
      "r39",
      "r234"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative asset",
        "verboseLabel": "Asset - foreign currency derivative contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Net gain (loss) on derivative instruments"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r215",
      "r217",
      "r219",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r38",
      "r39",
      "r234"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Liability - foreign currency derivative contracts",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r210",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of Contracts"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r81",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r218",
      "r219",
      "r223",
      "r225",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r82",
      "r209",
      "r211",
      "r213",
      "r214",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Collaboration Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r137",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends paid"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized stock- based compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options Issued and Outstanding and ESPP Shares Issuable and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r229",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r229",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r229",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r229",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r147",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r213",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsSummaryofForwardForeignCurrencyExchangeContractsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r79",
      "r99",
      "r196"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r76",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization of discounts on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r5",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate (as a percentage)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity, Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "2024 and later"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019 (six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal option term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total undiscounted sublease receipts"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in fifth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity, Receivable"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year",
        "terseLabel": "2019 (six months)"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor after fifth fiscal year following latest statement of financial position date for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Thereafter",
        "terseLabel": "2024 and later"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Sublease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r271",
      "r282"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liability fair value measurements"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r1",
      "r29"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r49",
      "r52",
      "r56",
      "r69",
      "r87",
      "r274",
      "r285"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Net operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesSummaryofCompanysFutureMinimumLeaseCommitmentsDetails",
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r245",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate (as a percentage)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r250",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax",
        "terseLabel": "Net unrealized income (loss) on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r50",
      "r53",
      "r202",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r42",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Tax charge in other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r30"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairment"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of issuance costs related to issuance of stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r154",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r63",
      "r182"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of awards under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r122",
      "r283"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Domain]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r12",
      "r270",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r12",
      "r270",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Non-refundable purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RegistrationPaymentArrangementArrangementDomain": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies and describes the contingent obligation arising from a commitment made to the recipient of the entity's financial instruments to endeavor (a) to file a registration statement for the resale of those financial instrument (demand or \"piggyback\" rights granted to the recipient) or for the resale of equity shares that are issuable upon exercise or conversion of those financial instruments and (b) for the registration statement to be declared effective by the Securities and Exchange Commission within a specified grace period.",
        "label": "Registration Payment Arrangement, Arrangement [Domain]",
        "terseLabel": "Registration Payment Arrangement, Arrangement [Domain]"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementArrangementDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RegistrationPaymentArrangementByArrangementAxis": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertinent to describing and quantifying a commitment or performance under a commitment to a recipient of an entity's shares (such as to shareholders of an acquired entity) to register the recipient's holdings of such shares, by payment arrangement.",
        "label": "Registration Payment Arrangement by Arrangement [Axis]",
        "terseLabel": "Registration Payment Arrangement by Arrangement [Axis]"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementByArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r188",
      "r295"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r4",
      "r11",
      "r70",
      "r75",
      "r293"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included within other non-current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesScheduleofRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r137",
      "r281"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones.",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "terseLabel": "Milestones recognized"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Closing stock price (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareScheduleofDilutiveSecuritiesNotIncludedinDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Dilutive Securities Not Included in Diluted Per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/AcquisitionDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r81",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r218",
      "r219",
      "r223",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Forward Foreign Currency Exchange Purchase Contracts Outstanding"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r152",
      "r178",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r8",
      "r75",
      "r268",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r154",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r158",
      "r168",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock\u2013based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Common stock purchase discounted rate for employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Shares, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Shares, unvested, ending balance (in shares)",
        "periodStartLabel": "Shares, unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average fair value at date of grant per share, unvested, ending balance (usd per share)",
        "periodStartLabel": "Weighted-average fair value at date of grant per share, unvested, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value at Date of Grant per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Shares, vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee contribution to ESPP, percent of base compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Share Awards &amp; Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Option Activity, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated fair value of option (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending balance",
        "periodStartLabel": "Aggregate intrinsic value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r160",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "periodStartLabel": "Number of options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance (usd per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise\u00a0Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and expected to vest (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percent of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Stock issued during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r151",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price (usd per share)",
        "verboseLabel": "Weighted average exercise price, exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails",
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r175",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofAssumptionsUsedforEstimatingtheFairValueofStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options vested (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of option price of estimated fair value on grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term marketable securities:"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r13",
      "r14",
      "r136",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r136",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Vesting of early exercised common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r136",
      "r137",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/StockBasedAwardsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r137",
      "r153",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Vesting of early exercised common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r102"
     ],
     "calculation": {
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSanofiDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsSummaryofCollaborationRevenueDetails",
      "http://www.denalitherapeutics.com/role/CollaborationAgreementsTakedaDetails",
      "http://www.denalitherapeutics.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r147",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r147",
      "r149",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CashandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesDetails",
      "http://www.denalitherapeutics.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r90",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average number of shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16242-108621"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919396-209981"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62014-109447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r296": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r297": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r298": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r299": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r301": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r302": {
   "Article": "12",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "13",
   "Sentence": "Column B"
  },
  "r303": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001714899-19-000043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-19-000043-xbrl.zip
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M"Y&0IX->;]!?^+O3@L7Z1?8A-5KO2#<&4V#]P5Y,H!0;1@'_RO)#X>8P#++
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M KTUFS9[X3JEF)84QVP;P#E3RX&1#ABE+.SAP=T3[LVKU=E+%3R5I*3/ B)
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MEU*P2FE+22ZHX-31TNO1L)[Q$EE,<ZHVYP6=1<BHZ_;4PEJ0)46GLPV8B%P
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MC.P"6*\\0@V>2.U 9B>RBTF7V )$M(SNS3(KH>5@U4Z9X'.2;J*TC)=0I#)
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MX!,[?MG'""HP'6C!UCUSCI1V3\V&XE(,J!.2!^=2\)1L#%E0*B'"PLC<N;#
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M84&(2B($%TM1TEJPQIV8 1;0R9B^CY*:7R,P0<'U1O17@/D1(Y"+,]JY$#*
MLEA#7FA+<,DH'2@N '-S1JB5@/$J"XV1R(4$W@"F*)3/@JBPIK&Q!;-'\V@"
MIC=S1%3G^GW200*@U-$9U$(8)6R0A+F5@9+)#D&CC2'V1X6&0\K+HXMS\"]&
MHP-D63T;#GI_E&6]W\;@*MK6HN *4W7A( .!%4S1<P0%0N1<@G2!O&[[N)NE
M#SZ].=MHC=46T &*C";53,H$9%20(7X5?;Z-(7BCH=VI>17L29!UQC!G!8,N
M*L4*BS48_R.3Q%,.XL\XB)]?U;7\&8?YJY21T^W/JGY:[N<U''ZDR>9H7:8,
M_?&;\2!]7-^O*P5N.B.(28"_/E_PTQ%N@90TR)(1(Y0H(R;T9+UQP1CORHEP
MY>F@X _SJ\#F7+CRNB-W<NITZJ@K6?>9$TY[S7(N(1E)"J)@]X%*;$.1ME8(
M=R:3J1F"S\GG4E?:$"2T/JA8(O_%?"/F%F6W7&MI5ET3-L0]EO1R[K$#-QJ?
M;$ASO<59=P9HMY]KXZEXH7UBNTZ03<  )J2H7($B*;6A,/8":&W0:$P_DB]@
M<T -R@KVATE)H55P6"A3BX!VH\*=+MSOPY+7RU7*?+!6Q"R5$I <1.M%9%YK
M#!B;G6R1X5S ;'[-)C#.O,A%>^E!4/"2="!O WK,TKOY3Q'_"ET7)#D>=M.8
M\@1,+4D&3VQ=E"_2,F<!XXSW)M=:.9J,CP2NO<;EUN0R>]6-%J4"Z[5@O0V&
M0B*KH[?1""E--/,?99V#,36]B*HU/':<0Z,\ 1E"5X0N% @C,[@ \S^7<94!
MO1#U7KX8^.[M[PV.B"8".DO_;=$,A=82+&D%TALH%A""-<( H55$-K4@GVB^
MI3;[_!]72ZXX(4JIQ3B3#=X[6XP"MGM1B3#_B:#S*=D;20G5&I$D!A68']HL
M/#I7L*081<DLL9:[(;.7VNQ=@&1\UKEDQU*%$@(:\,+E@DE':VUHT2JU%HAX
M)JO5BBRVKG7Q.E@(JD0GLF('3Y"KI;%]BY8TM4/$M[^TB62LJX=)2YU L8B#
M5\1R3BG5\EBQO9[C/(IX-ILU9D564 XB><"HHM;.B.!#T0F+BRVRQ8M@W)4"
ME@D$*J6M<."50OZ@1>3_K43MVU3F>^X%/!,[+*/U('4L(@:PT@1)/IFZ^4BJ
M/T"+E/3<"W@V&\59)80FR-(0.*="D$Z3]9&9M%$^MXAHS;V 9T*SV.U5Y FE
M$Q+J5N[*1/ZC1'8D0VR3/WP+:0:MM,(9K-91*1%+@2@)C=19:&5L$<K%-FP^
MVR(1SV9G-Q,+2J/ !H*DT#.-+BF33 5%"?JNV>&9C^+;M\142K9).UNWS"$$
M#+8N8%0J&?!TFC)\ARSQS$?Q#'9\"RYDHZ4N(ISN[IR4I.*04BBJ!:M9_F2>
M]5)4XR0-IB5SK45"7:X"(OH"'H-GK]7DJEMC3>LV+:!',UN).1.R4U<7A4DM
MS[H99J" KD0T&%ETJJ0VE*B;F<!F4W@N2V71YY2-Y7$6@F<3)L G=-YXL"V@
M+K,<8;=/1)0ST?@B140'&0E)*L]<Q*%'(-.&D, L1]CMTPH%*41K#'KR !J]
M8T:A26HH&DQLPV9U,RL_,1,;A@*B,H92]AZRIZ"$L.SB$=-#JWP;'/:9"6PF
M-HQR88585-&:0 H?0\0"Q+*KJRD4MM2&W=8(FX$-TW4M)@5-(H*2'@4FA*)J
M!5QK4AN<Z5F.L-NW876B295:E=\D\,X&%A)X!;5<&ZM$:($-._>1^0ZYNW=0
M@QEO*!T,N^,NC4[JV%*NQ3J>#GK[!^-)3&2]K.*PW^UOCU[2<%+OX]>CJV]P
M(;?@S-U>[N?.H'\KSO?LC:;'DH.MI$88\$;[J(- 9!<B2EG.%^;.LPZ^5PBY
M?:4O:@ 5BJPKMT$P!\;HG;=2*6=3-*W*"[SS")D)CW.U=F-)U@I%D&**464K
MH]:>#(4L6T +[A5"9K'QL(C:%\N>F0.4$6U&8X(07CCRU*I5K#>.D O+JR:5
MRL[W"GMV,#X8TCL^S'>\BV2$=%)45(+ 'GRLV_&"\B4R0KS,QK9J3?V]@<D,
MBLGX:$IQ0#I/*DP'9B*.4HY9@T14"WLS;S"9S2X?,M@B77'!UZG($HW0D&VQ
MZ(&BH@5QG4.8S" *:;(I'EU0B6"R0,:"%]%IX6JB?:OJCMT\>\7AWM'J(0U3
M=T2Y;AHTZ$^XZSVR/B$@.IV,-AJTIF "E1)JU7I=Q*D_O."R<XJ7VR>UP9$Q
M7H@<A &9( 97-S "8(;+E*5-^XC=-[S,9@5?RDJ!$<I$!> P*/1*.B*3,INC
M-JW^N8=XN6'^\JA[^)C9V>!@F&AT\G6',$\:G[N?GOS"?YW Z(/X4 LG?/EU
M-#[:JPB@[O;.^#&8_?'/G[MYO/-8"O'___S@TDD]'&YW^\UXL/\8^#P^.-K'
M_I-?XO 1W_+D\_F=3PZ>71HQ?=P>#@[ZN4F#O<'P\7 [_E,9\]/9GR7Q4/SW
MSR?'_L&X$Z7\7/C]FH*][M[1X_^]/.SBWO\^^6W4/29N(+=A\O7S:>.%^'FO
MVZ?F]&6DXC>H'=1D2H/A!$Z/E^I6Z<-Z6FT_SG7[EG:&5/[UX!]5:N[!DXU:
MBGYI4)9J*31&W^B71_A5O_]!KI/;XUYWN_^X5CNGX<^G0HR#\7C0>ZS^5H[?
M>*?QI)&7 ;-'9?P8#\:#LTN&D_>?_!('0W[?VNE[N#^BQV<??K[PO'K]R?=N
MO^J?Q[5G<W>TOX='C[O]29].GGL*W1 >AE!E- 'PF$?!.)\UZ13<#T^./1KG
M/QX,_J$0YY=?><JEZQ]-GG#R%&Y^[;]_/= /OAI:FMM\391]_>J?:#CN)MP[
M_>VDP\]ZKHY&N3]>&@WVNGGI'R<M/SMX*IL_'M_'7/?Y/!$-'S[_X40T\D28
M7U[OT:1_OP46M5WV"[K^=*#]HTS^NSBTN'U_,[3\5T/+736T'CQYVWFQL;JR
M]&9C>6/US3<@^^_:_+?*86IO\&;UZ=O7+S9>K+Y96NZL+*W^S]-_+W>>KRX]
M75];>_'FS8OUSA1?Z[M$H:[W(N]QM,/X&@_Z/RVM/'SZ<$DQ[PU76(T[H$"T
M?.A 2QNNJ4"^[>;BH9':6GDC-__&EL](]7V#]IJ)3KY2[<YOJV_'&%2-]Z?D
M8R;FX=GZZ[6E7Y@L]P?]SD&/R75:.N74KROQZ@HL)-%@\L5 S#F0=5)GZX @
M2G=EP<VE/E:7*E/W\<H@'527H:[A>7 :)M+OCN+*X-/OZO6G3;UVD'=7/VT]
M#[OKN[_N=':?[6WNIN.UE5=Z?>,5;&Z\A<YQWMWJO3!KSU>/.KNOQ-9*^OR[
M[NQM'@\^;VYL'FZ]?Z'7CI=%Y_BC6'^^*M=7DMY46]WUC5]WUG8W1>?Y*[WV
MS!_^KK:.-M\GN]E[MK>UL<77OSI:?__;Q\Y*.EY?^2C75M;,VL:RVNIUNIWC
MU<.ME;>?\O-WD/_]V]Z6VOL4=_>[F^_?[75Z[W8[*R_,9N\5/W,-UC?>?EX[
M_GBXMK+5VU3<EHUG'SOO/'0^?X@:J-A@&T$Q-!!$:"+(V*#(-OLLU&0?#BF:
M5Q.'Y8L,KO(E%E9A817:;A7^R-3GM\D_;!)N0*V'ZVGU?]9ZX4OK??KO[_9E
M;9M\6?'P+P<]2*/%7YSQ-Y?_E9\,#^N:LC EM7"&L#I,U/[A.>+.R<+AE"#.
M#[@FOB]"^&\".U=!]S*XK]EX?NRT&<FDEOZ8K^9N&5'B,3[8B[BW-QC'P>%5
MA.75 0YY5.P=O:;]P7#<2N[RK!N?O[5KO;=B:W>9C[_E^S$W67GU>6UWI][G
MX]KN6]EY_ZZ[Q6U>>[]Z>LT[?I;I;VT,CK8V7O?65CX>=C9>B<WWS'=6EH_6
MGU<.].JHL_%6;IVTX7#SG?_\^\;R>.V-./Q]XZUF?O0!950N%&P<&=> UK)!
MK51CD[=")2M22 ^>_-<_@@/[\Y_RGS_7^^T9+%?%!Z8X6%Z]77Z]L?KZ]\VE
MUZLOUU]O++U\^_K-V^7.QM+&^M*;U:<;+]8[2U(OK;]>DN:?^;^7UI\M;?Q[
M=>E+8.6__B&M^/D\LK+\=*.>(X.&2W+X <_GIOR<:QK$9X/ATGB'EOYS-JJ7
M3N81EH@M4)Z^ W1!W3S.M2P%WW$GX]$1X9#Z5^F;EY/VK)[,=K12VWRWIW2X
M=IP^9)>#0J"&NSDWX(IKHBK GV))1:4(WCUX\MM!GY:T^&FI=O77.F-IQG'
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M3QJ87WW]0)W@G%F. A8Q [-"!BQ&.'I)/7;.*5N ^1$!<T(?V^BF\4/#>I^
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M@Q$:P>"X<5S5"I^XL&<.5?YP,5C2!,Z#1#7<0M:+7>V<R?#\7.QTDUL :0%
MVGTQPZD\%HH$+Y&T+B+.@2,7-48D<L? ""M5:+8Y$2TIU3))U6JW]L6.ZT,Q
MBATOS8[/B85.-@R #;()?A%WBB)+(T&*<98V2E8%09MMIA.S4'Q=S.+1N*C>
M#."S[80&?/N<\R8F%7KZU6$O?\'M^E 4XVZ;G<V&IA50C*E<7TW$FO9!U0&^
M2<BH0-0=(.K=#-6(UH!BTB LJ4-<<H.<C@H1X$(*#8[@G#*L6DSI#7'?%'.N
M-=,HYKQT<SYG'%9$3#P#I'A,.X=  S+**Y3M. $T-LF,DSG+EF!F\UP9K%YV
MM=\?V>Z*N,5BVYXEA/+KCE0K(!X%D^Z,29T9BN&( 2=]0(1KEC I6F05)%5P
M7C#*/4@-S38WHF4T*=Z,IVW6*R @Q:SO8=;G5(,8Z84E$BEE-.(J8N1HHAK.
M*>*=H3A471TU;NGY(K\U<V[4RH+^Z.<G7WG09+$MT!. IS5%5';[/5_P:G&\
MFDU4 4:UMBH!5)(5XM&ZM#4"@12A-%BF0XRAV4YJH1DMGHZG;>9K"K@4,[^K
MF9_3$N ^\1(<D#;1(,XC0RZ'8%@ *YP1TE<UO+AJZ?EV&_5R@=3+I-X,^I_3
MF$^J4$M."OY\G)2WU>C!J!Z.D!K/7;U8QZDDWW1M;[35"Z].A;D+!8P6 :.]
MV40.29T [ ,*0!SB3&!DL7#(&DVMQEP;IM,>2;6($<7S\>CM>"71E6+'R[+C
M<U)!96(.@1H4!;>(!R$2O2 !*6>PX$91+42S346+R+GV#L75<;,][27]M:,T
MED87[! :U8A0/Z)Q^J4*LM3#VU'C*:P7M3@3Z!]9GF_S ^_%OX90^6$+)BV"
M2;.9&TE:F@5#4%([@K@0$FD!!.$D0$QHI Z[9IOQEN1+S1%]=/Z,&AOR__=?
MFA+Z2]F5+K:"5#E_2=U1'6/S-9ZXFJT;YWE!Q3%VMU-.^UMYK9BL&5L?! [1
M8Q.0R,$ZGA8*9+7U*'(<(PE*JB2M-FL9/E=N4-F,;K0%KV S6BQX*19\<F;!
M42<U)80B(YQ/%NPPTCIX!-:)A,=>D"2MMFX1/)<[J6Q#?Y3<=SUQ6-G\+!9J
M>^*GQ^>:K/4K5KU(U@2="R8OA,FO9EF5#LQHPASB2N:4:Y=VY#Q89#%U1#*A
MG-'-MF2J)?%<A[QJL!$O %< [I%PT )P=P.X<]() %9QR9' /FT;?4C;QK0F
M(2&UY59+I2$#G"0MH]=VBG5MOJLE5\+\HV-=IUME U5)%<-1WW\Z['>3X0__
MITJQ&)TT'GX;/@,U+$%-Z(]SPND#5LK<J**"2YN=L@'[<:G,[KE%W*U>YD85
M8=V@[Z\9C->K&,&6]U4C@,9G>Y*3/)?I0K@?5CXZ$GTWY^WZ5:1FCH"IPKZ9
MZ&LY'G47WOSGK&. L,""CPI9G@](@95(6QT1&/#2"<W3/U6XA6W*J<<"6@6T
MZK6Y+Z"U%- ZW^R+))@$7!IIH0WB.H,6$1J)0'2@)%@72;--6MJL[?#$HRE8
ME;1W,(8PN\,IJ8V;1IJR!&><-@6"[@)!?\WRII $)SCG")@0.=F:((V!($,X
M]42 !^L2!+&6,G.5XUWW/KF8\0;0B&+&RS'C<R;A+2'84H48D6G[HX5#)@!#
M%**V,4B(WN9<%4'Q!@8-ZLDD?/\X5U6K&@27;->-HA*OCC]W^R< ;W/?\H)%
M]\:B@UE* 5PI*D F#J%%/A3.D9&&H8B=4]Y0!Y(VV[R%S5)+/Y3,UUI:\PH8
M1;'FI5OS.;.P+' LN$^&3"GBC'B49)DXAJ,!&\>M)KC9-BTC-O$P9KV8Q8MT
MJSQWQ4FQL<SB5(3_=$:'+\;#-'<P. 6DDP)'=X$C/TLN%/91".(0,02CA#X6
MI?V-03YZ1S3VG+@$1Y2VA"DEM!^_1:^B'UBQZ >PZ!F"@8W"UD9D('L@I77(
M>F81B=1Q)I57T3;;A+0XG>MH=?%=_/"TKK^:[54<&!M%,RHYEHW./7'HXRRS
M<#IR!]X@%7-O59VV/)9YAW@4U$#T2@N2F$6+L%(]ZO';\-V)13'4!S'4<\*@
M; 2G74!19_-TRB"#G4,Z2$RQD5JST&P;LX%UL&O=<Z-V3HDG4!MW!52B@-,]
MP>G3+(O@.(E)18F<PP1QY2@R')O$(KS!RH/',0<_9$LLM^['H_-// 'C7H'S
MHACW_8W[G'DP+8$8PY!@)E>8)1@9&@$Y4-AA!MSF9"E&6TJOC7P\EKIBU\5"
M6HTN#(=GA.1S?U!R+S:.;]SJ3RV5B^Z&4T<7:H\1IRTAX'+OXXBX)P%9 SZ!
ME76)@:C N4TDA+>$7&I29_%EU-*HUQTD*49]=Z.>(1\@B<[%L(DU:3_A<CDR
M&@#%!-$BZ,"<8,VV4"TFUI;C^5B.PU\NBWW*04Y6RT">8D1WY36R"TS=%Z8N
M5.@B'B?JD0^Q">L1#XPBXS!'+ G28!PIQ[+95KAER%)/XCXZ!TB-S;E4RK[+
MK+V$" E>0F-0M6TJ6]FE:E[9H]1/6O7:HYS:W]MD<"_2_SNCLN+?<<7?OE"R
MSFD%5'%$I>"(6TF1=HXC'6(029P6Q]ROA[?$?+T^R\9DD6X+M8O*UGCV5K(-
MN3W_HT#.'2%G9W:3X2-G,7*"7+ $<0X&&1HP8CS@P+"CGJ1-!L<E!?SQ6^I#
M96H52[V[I9[,Y$-$$IF0R$80B!,AD!%@$2A**3=6>>QS4\[2'7@IN5JUR^A^
M FD<J\W1*F"T$!A=+!*8MB.@24@[%4]16BQTVJ10A7",1J=E@U.9: .1M,4W
MIDQ@,>O:\8IBUJLPZYG(:( D$1$1BU7Q&QF19MX@$G([<(F]=RJ?(!,MPN9*
MNBP>B-ORLHZ/.Z/<Y'I2,S_;3!H9]'RNHO_3;G\$#?WSPV^PEH! #[/$?QMV
MGO<ZW?]MC@9CN)HG<39[6[WP8G;NBMW/8?<7:M=)4"2)Q2(1)$$\:HFTXX \
M(40S2C)4YY7RDL'7>=>_24:QR )9C.)AC>)\,71&$)/3A'@4#*4==G4Z*B#.
MN< R1"-SU\(;C*)LL&]>^-Y=TQSF;CTR-JK]R@9]_X;0MM#Y<CJDZK:=7DC0
M]QP1.O.)ZA:4/3/ZJLK/J;(7]?PZ2[C==KJ='J##R>\$X_^>).573YX[\'P>
MG.8S5&V36HU_I6\EC<]VT/ABNV/XI<%Q*WUS_ML8'MI!;K(T'AWV!^D+0\,.
M&_W8^'W<@P;#K4;F3Q6?? D>CAT,&HQ4K^I?&F<?[PR'N?!BOJP_'@U'Z8><
MHS?WK<ZL-8F@.-_KX_OZ#H-^L,/#R\3@S:F*5=C[=]:JLD]>B!I<J)WD!>=&
MYF[DD#MHXA"1-2X7/!"&:JJE"/XLQ:9$SAZ]\2['PU6,]P&-]YS7:TR"CA"0
MTIAG7N^09DXCD-F%S0,0 0L9[X9P_8UF2\?'_=XM]&A)_,B(EA2RI8T\NT^Z
MT/"6K"(98EGTJ=5(=_D,2:.^0/?D8<G44\R!7,GARZR2!9'OB,@7"D9Q+8C@
MVB/%>>)4,1+D*% 4'?666J'2#[E[#]7ED.7C-]Z5'+(LQGL_XSVG4U)$%2SG
M2#!(QLMP0(8S0.EE8)(YQW)>4C)>-9?QULSU5*^BDUMI('GB;#?1GTY(%*[A
M[>?.R'9+QO)&L8=S0;Y)<MSNO9A(L>#00CATH5X4HPR#)"3I2W2(<V&0$SX@
M[$Q:21AC0B0<4D8G))JK_&WQR6RT%:^B 5>QXN58\3F;,$YI&R5%BLF8K!AK
MY((,2(!FT8DHHE;)BA5O$3'7F82:.6=JQB>\'Q^/JUXOC?ZDH'7_^/, #J$W
M['R!1J>7?H?&3]W^<#A/)E+9XZSX4-2, *M3%R]FQ;==2>^/)+M=&.W%??NM
M(-,BR/3]0BDH*I4#XS$*SE#$D_R0%=0ARQ3EGB@PE#;;6BVU&&5Q4:S.?']:
M";D8ILE(/Q5#7K$AS\1_',BT,2#(,V,15THA(X-$C(*RU"B@+%$,>4U5V9^+
MI^(NS") [/C.J+@HE@A =R<09P T]S;G+8QLIP?AE1WTTDP-9V3[<B+: D<+
MP=&%,D_4"8@L!*2($H@[HY&Q'!!./UJN+<8QY%*X25?DU5JX*S@?4%P6FT0K
MBE6OT:IG>G$Y3ZWV$BEJ ^+8,J2!":0$E5QZ9QW3N;N>:AEVU1OY\$3C[AN+
M6G;6&%Z34EX/?\43.-^Y@GC)[)&!5Y5T"S@M!$[;%])7M03/N4 DIUIP9@G2
M270H8,-D<&!-/KW-E6B1^8*V3]:=\02L>P5QE&+=][?N<^I!B54L2H% >XUX
M5(EZV/2KCU)R1550N6ZLX+*E^5P-^&KFZ*B5(5TI%E,E?,[2D2J16/UR RE9
MV1S>BE33-Z??QM+[H3_.1Y-NA+)US?>_;EQW:&UZ*LT]F^M7WWJQO)DJ'EN]
M4%:%>ZX*.Q>KB0N!+0%D2#"(B\3^3*2Y[5(@7E*04K%F6S+5DIAO2'I, <\"
MGIL!GJLM@53 <RG@>4ZIA;$TK7412>E$SDJRR 1GD".&!Q&BX!0G\)2D9?1<
MX%E1ZG^/;%+LTW,_EX]G34S&0]*BP2_'=O"QTYN8##U7^?9_W.#?[8OGA^YR
MGP<\X47PJ1%6W_$\)\AU_.V'OFAUZ.L=0,/ZG)!D>R?Y>%6O/TK\>M1/AF;'
MH9-#B\G( O2&DY\J(*DBCK'3LSW?J1R#Z86J(,JSJ]-4F<$'_"$G;LPS>]==
M];D_K'( GP^@:_-YKE^^=L+H<')R;?I @J<YF'FY>?T=K$M/,![!+U/PPS=_
MYMJQK4R2M\N-73K/-O/OX>!\F?D(R W ?D(VIO$_M]VO]F289_AP<.%1;YW#
M^S[TZ]=+>>A*' F7^[D;3I)DTM $O/FR/$Y;Z_$U#@=YB?JO; @J;6@S)N5C
MC+EZ4+:;__S;MJ^3:-VT45VOC2^AET;6V#^$@?T,XT1'AHWMGK\&#>8!3;EB
MS+S]V5Z<H=^+6?1[=X9Y68[3'DWI@LHU<2&QJ)%SBA:8B?H\^D]_G:X!/V_F
M^+=[C=%A?SQ,,AFV&O#-0Z;"^7AQ):8DM-/?CM, 1\.KCWD_"C!=8Z8*73&1
MT\],KZBV*W8\ZI]^9,*XJU>F+#W-3-=^'L+STQ^N[*=F3YKGJ0F=X>>N/7G>
MZ5634GWO%-:->69,GN(*W*?^QNF0IL#_;/+>I?W?Y$TNGU&FB#(W7W+KYV]_
M$S]CS"C.[_AY_(S<]J;$A&IZQX^7@6_TP'_@79\3HQ[>D7XMTUCF;OHFWX2Y
MEV_BA],UA<6'CSRH)4<>$F^#QDZZX>&P\2HA;#BK/#&'G^X4A],^%7X01EW@
MTC4H:U&7.8LN=KZM35D*Q/T XNX73+V?SJXLA6')"IVC37</2]Q'Q98P8T4#
MEJ,!>CT:4(1<S+PL,T]%_ZX#F9(3=5MCBV[7NJFON3& +] ;0ST3GTIH_@Z3
MM7X-6R#RKK23EF)MB%2<<F6YU#1$:L&D>>'QP\LJ;8EC@NZ=O_1VHNJO!_WC
M'#W)H_NG,SI\,1ZFN87!JV^^.\XSN#4<0OHOU.@@[\G.651^A[[?W\(']._N
MP;X_>;__YTGZ'#\XVOZZM_]1[![OL/>_O3YZ?W3P[3PJOT7V_GE_O//]]>'[
MEW_2@^]_\O='[SL'WS^2G:/WW=VC+;J[_^NGG>._Z)6H_,N_Q/OC@^\[_[S^
MM/OR_='NR\/CW>/?C_9>_G6RFZ[?>7E =G[[,XWC?=SI3"/R[_#7#]H9YS@)
MR.BH$7>@D',0D5-*66 L6LR;;=XB9E.J_11(+)"X$DBD3'E/N<=<< !G+/.@
M:#(>PY43LH)$?0J)ND!BO2'Q^QDD4@J C;&(!I/KJ.+<UIDH1 $+Z:T3)+)<
MBE'R36GG7""Q0.(J(!';",0*ZW44W(5@0"K"0J*,P!U1:LH226&)&P&)9 J)
M9'?K0Y26*0<".6)SN7_OD78A(BX]X\[PM V 9ENW.*8U!\7U&%'9MQ=$7@,B
M2Q*C(T8+88#'9,0J*.XU-M9S(1F9DE122.I&(#*;0>2@I2><8(0Y2,1MI$@K
M+!$1RE,&+CA%FVW:HGIM/88?2ZO%:?)G[V,#OGW.J:+#TFBQ?'\MOK^VL;'R
M]$_AZ6L6P#.U6C;>PA#LP!]6J>@AL:-N_W,^4%!*.&YJ8&HBSZU>>'DNS5<3
M2E"H[ )4=O?%3 @J2)XV)XG(FN@BXMA3Y!SCB% LB:$<!VF:;4%:>KY3H35P
MN!:+WI2X2K'HI5GT>03%$FV#)0%1#KEV4C#(FFS@T@0>O0U):,FB:8NP8M&/
MWZ)7&Q8H%KTTBYX- !BJB/?$(^N403P$C;13'DFMF#) ?)9:6YL6U77/%*E%
M!*  RJ9XM0N@+ U09OW7CE(&TGCD&7.(:Z,3[0\.8:$LY9I&J6VSK6C+B+6U
MO+R'TZ9>KHC?H <#VZT\$38<=WJ=X6A0%5JI1WWGQX%+JW1&3"6:8&GK@CP+
M,MT!F=[-N".D 1\H%<BHZ!%70)!QD'MIN\ #8XS@1'2(:&%UM9%$J>K\Z&QZ
MA>Z(8M-+M>ESAT2@&D+5T-8PBCAU!B6V:)"3V&CM"7$&FFW9TJ:8].,WZ57Z
M(XI)+]6D9ST20@KF:+3(1B,1CUHAHY5'U%CP#N><[;2!H+S%=-VMN@:1W((I
M&^.2*)BR5$R9=4HH$P*6V"(? TM$02IDN:>(&9?V=#H&HETB_[3%K^DB5_L#
MSDS5RKPF71_Z5Y+KZN$J?0)-:5;IKSC+H9RBU+# U"(P-7MF5X!V1C*%!-@,
M4D$@PPE!0C,:#=/$4I[K:+>,Q#4/Q103?T3NBV+B]S3Q<X=%LF^;Q,1RITN;
M@R,")9%YY)AC4@46O<_=ITP+LV+B3]S$5^G.*"9^3Q._D%(AM/,$.\0QF&3D
MCJ*TL.<NDB"$2_]I)=)F@["67&X#R9)342"FMMZ- C'WA)A9?X8'+R. 13)*
MB3AHC#3G+!?ZP4J:0$2TS;86+4[**<%[VE/N M&(@_[QJ4NCWWLP5\;3Z*_[
MTVI]&<,T9>FGNV#5=L_WCR%K0$&K1=#J9,:M 50R92$@9H3-A24HLC8(!$)R
M;85(##=AE:0M):^RH9_K$LHIEO[@EGY_ET:Q]#58^KEW@_/HHS018:LHXL(:
M9+&+2"K-(\-<&I]/?*D6TU>KR11+?S*6O@3/1K'T-5CZK)/#,9](6+)U2K1+
M^PY/D/-,(N$,]Y88@4-HM@E.6J)(?8W]*6=H/ 6H68*'HT#-&J!FUMF1=@MI
M45 !X6@4XM$D6N'3?H((%8(%3 WAS;9F+7)-T.3G&N=MU,NLMG-_ AB.JL,D
M_=$A#!J=2G];C1Z4XA8;FI^QV^_U+\)122=;')'V9@M;>,,42UL8!)A'Q"T
MLH)Y!)%Z+[&6G)&JMCJI>W2G&/-F96(48UZ2,9_[+#QS:1,J<1*.EHAKC7./
M!(HX2W+D'/.@8BZW*,6F5 4OQKP9.1?%F)=DS+-N"<E B1@%PICE*M9Y;4ZT
M"HFH;#01A'/Y]'E+TKGBHB7SHF#))B17%"Q9$I;,^ATTU@%RI:NT*N03XY(A
M!]PD:H -96"LQ";S?$7GH@8EQ^('.1:),O<','4Z-$;VV\,=&2F.TEKD69S[
M1[=&HT''C4?6=6&__\8.H#<JV+4(=IW7NOB^L_^1?8@0J#?:(,P"($YX0,YP
MAH@TG# ?A(XYU5RGG<V/O*8E/E-@YS$E?13862;L?+\ .XD9:6V-0TYHFF"'
M1*2C]8BE)</%)%M6P4YF35=KA-8&=HKA/\H<D&+XRS1\<F[XG[Y^2,PQ28]B
MY 5EB(.PR((D2'G''9-$J^B;;:-:DM<X^:OPC<<-.VO)!RFPLTS881=@ARJ?
M&&/:X7@1..))A$A;Y9!PF$DFG0B!--OJ^@Z&)3ED_N204Z=,PT$/8J<DA-0K
M(>0,E:Z#GGW[;>H/_G4BO((YBS3HV]_*>#-QKWQ_Q7>_?@B$2FRH1!ZS1'9$
MS%U.(D,L4(>]]8KSV&RSVB> E"!3+2=H;=DGWV'0#W9X6&#D@6#DY *,*&,3
M&H! )KA\-,XY9!3.7$91'Y(X.77-!!F:$OI+S:&D6',MTD\*#WA0 ]X]YP%B
M9^L#]<+1X&1:^+U#/.9T$R ,I?6?21.\=X WEP=LJMOC*4+'DK--"A%X8!PY
MN8 C7F#,+$3D C:(*V615L(BJ3E)RP S0>N%B$!)-KG9JG9AU.CFA).:NUWK
M/(>U3RU)0BZG[^Z;2?+U R/<&>\H(H9JQ'G,_5.\0L9:H"P&CX%5622,76T/
M5YNH3DT-_#'9^#KR.(J-+R%MX^L'+BVCN5@' QP0)PR0DY*CH#0D]FBE,;:D
M;!0;7TO*1K'Q)61HY&QV+ V-.B@401/$L0O(&F>1]\[CQ,((C:S*SV#7'(VI
MC94_+D=%P9A:Y&<4C%E".D95^5ABA1.!0-@YG)M)<^2\ J0Q)5HJ%F@0)1GC
MW@:U5Q7G2 K[>0"'T!MVOIR=FODI.S9^?EX7OW+Y_O+]3_[[-\07&SI?3H=4
MW;;3"] ;/4>$SGRBN@4USXR^BG]SXM=%T+L.%F\'TFZG!^AP\CO!^+^G'MUQ
M;P#IJ;]#N(B%C40XCNW@$U1)EXTA^/&@,^K L"IKU.C'G-1VAI=I$M9-\VJ\
M\*S6Z7NIJ%I>]%[,KGDS:;5?;*>;Q?NZ/WB7R-N[,R%OA:/Q<'2<%/G7ZG3I
M6_!=.QQV8IKW_ CG[P^3$NW%??NM$,"%8EFOSG/CMCZ(0#WEPJ-H(!\"L [I
MH"5B,6F #9X:A[,KZ:JON%Z-.PL"U,PG7+!@0[#@Y P+,(:HO<3(*&729C 2
MY(2B*#(I*66<B9@V@Q1?;;A9&V]3@8%:Y+3-7WBUX$)-<>$T;VYW_^,'X=)&
MBQ..),6 N"<8V>@]$M)ZC)7F.GNB24O,5U>E>*,+.FV8P[G@5&UQZN0<IW!N
MUFF,009;@3BUZ2>=?M42 Y<T(9CW&:<(%<69?6=CO6 &55[>97Q;V2PM%F!;
MUX3]ZT;\I[5KC[A^]:I]HN(URT!![SNA]_:L)\HGZ5%-'1+@(N*&\\G1*@<F
M8(^IMRQ6O8B465;YJP>,7Q0(+!"X<3Z[ H'K@, 9!UQ(>V6>JY9&KQ''UB/K
MO4-&$JR9%CGGL\KK-#_LFU(@L$#@4X' M:2Y%@A<'@3.^AJY$D(DZHZBB("X
MX@R97)6,T!@3MV=,Y(-U1K0T7E:7NL=S^K3LPPL"/QF?;$'@)2+PC!?56X-!
M"X\\(QRE/;E".DD-,16=(CB?>\X=.4Q+T!^=(-R01+KU'FK^#(/&\- .H-5P
M=MCQ53N_T.F.1Q"6B>@+3=P,2+$$4J$_SKEX3P?2[WS0XY;96K_.W8KI;V#P
M+JOA<GVL],:<H%=VT$O3,CS]WE^S\F_UPLN)ZI]A."X8/@>&[\SZ4JG$02>N
MC#R5(3=5XLB!MB@HE2BT4#+$V&SC9[+&C9X+Y!7(6Q?DW<^G6B!O99!W[CN5
M:6%R(#@RDEG$%7&)M4:/5 @^L$"U$R9#GJCQ6=D">07RU@1Y]_2A%LA;%>2=
M^4J/7GUP5FA"N$%*:8PXH0Q9+2+"P@IFO8]*I)TZ>?;#L[M//B.S(&Y!W!4C
M[CU]I@5Q5X:X)^>(*V+"5HXI$A3+A+B)8&I+-$J[:@54N6ALQ3+UC\[(;$B"
MZ08?,?ZG^@U"PZ8)L!^AT1L?.QCD\\.5MW78Z(]'PY'MY6>XS?7Z(">,[QPR
MN@8'I^].OV^>9:4^R'DC<$YDM%Q?)%X@NG2J/EL3[=FME&<O5HBZ=ZXX!5SO
M ZY_7D@ ]5P!3SMXYD&@M"0"LE$R9!@HE_YZ3UD5^>?5WZ6>2'YTY?4+8BS%
ME5<0HWZ(<>[S\Q9\E%$B)G.%/(D]<H82) 6A7%!-K<T=#&E+FQRMOEH+LR#&
M4A#C\<#%/=U@!2YJ!Q>S_C*KA-22,I23J1%/NVUD<NM!;J@(R@6E<A.PQ"XH
M)RU.KGK-EHH7JTHR5)MQF+F@U<)H=4\74D&K^J'5C*\)8QZ#,1%)4 %Q;QVR
MGDD$QF*E0'.C,[LA+<I,BZJYV$WE=OIW55CMU+-Q@XN'/Q-)U6>LT:=78?#+
ML1U\[/0FV:OTW%+:_W&#?[<O^DR6<^<']"2=1QFJ[WC>&:4!^=N=2[1R+KT#
M:%B?"WK:WDG2^T:O/X)A8]1/%FO'H9/]3LE40^ZX4_U49?G:_'+L]&S/IY&D
M!TLO5*?_G\TU<52M>%9NGX-+ZO7#D5^5^ ]TIT*,#_@#%<V;[K_([1[#YZY<
M];D_[&1C?SZ KAUUOL O7SMA=#AQ@D[E)7B:_9F7F]??P;JDI FU?YDNF_CF
MS]SX3#502W[)<3OS[^'@G*%\!.0&8#\A&]/XG]ON5WLRS#-\.+CPJ+?.X7T?
M^O7KI3QT)8ZT</<'55F1YPF$$OW)E^5QVEJ/KW$XR%SFO[*AJV9[OZKYV8^-
M%YGH)&C\S[]M^SJ)WDL;3\.0]](_=;W^O81>&DMC_S 1I<\P3MQUV-CN^1]
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M-5+<<^RQ\3JX9ELIWB)BJ2TF"\P5F*L7S"U2=ETPSITQH#4-/!$"PY,A&4?
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MB/#Y\ ?,4ZU@\<8ZB4QO]WS_&/Y(C+KL Q?:!QY<[:DCHC @!2*82L0]3UO
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M SQ&:550W&MLK.=",E*6T$U:0L\]G]PS'Z@52'$!B"?1H;3'P8BX&+S#(!E
MM81RO#;'YSTB**Q6]G;JLQPF2PLP:$#EN<\=S9(:Y]YFG[NV-RRG.\KICHWQ
M0DZ"3]NG&OPF*7!Q02Z$QW_.NB"QH=Y8K9#GD2 N@2!KG4 D1&V%#TX"R\D^
M..%QW>M'%4/?) ?D;89<B-5\ACQ[%(+B)##MD?>,(AX]()L9EI7.!V))4"(F
M0RXF_.A-N!;.QV+=][?N6<\CMU2H"!X94@47#"#MHT728LXX$4YZGT\Z25Y6
MZ0TU\?N[LHJTBK2*M!Z#X[$LG\M8/L^]CLYQPJDRB"5"A+@S'EGM,8HR1(<#
M,SB*:OD4<X7G:Y9M62^GX]\P'*61Y#Q)L(/N20.^P<!WAA NY$T6KV.) =7$
MZW@AR?TFQV/U[Z\VJ7'N10J]8144*K['A5#YKUG?8R#.J(@3*%/I$%?"Y/1'
MA@@.2;9<@<E][0C'+4E+.L5C,_<']#W^P)XKAO4#<RXD:SYSGO5 *J>HT(!T
MU %Q$!$YI@0R"JCW(E@22+-=TA\?OR$OP0-9#'G%ACSK;,0T1F6H0BJ*M#!'
M"<AX;Q 0XTATE )QS3;#5RL %%O>"%LN67-%6D5::U\GE^!J+.ODRM?)<Z^B
M4=)0D7>L.I<?5,0C9WA$EE'#$O7A#HNT3I*Y"GF51,;Y?(J#]..@XT<0IN>O
M[5<[""6)L41V-LJ=^/9,C:O+MK(2[\)H+[[N#R)T1N-J\,6YN  X'\PZ%R-E
MU@0KD1>>(QX$1@X;C9*X'=,Q,,)-CO@0FFML;$IYV&+^&^)>7,B\"_>:S[QG
MG(W1:8$U !)4RD2]5$ :1X."L!X<0. Z5WXN=KVA=KU(V;XEN!MOJRQ:+'QU
M%C[KA33)BD4$C)AR:067Z1]-+$%!.F-!1,>8N-;$:U?-KUAW29XKTBK2JATC
M7FZJXW<8](,='I95=.VKZ(R/4@J+C<OY-8PA[KQ!UN'<+$4833 5,KHS$R^Y
MC_<TODJ)D;/39,<S-WOQ3C[-8% )W15I%6FMG>BLXDCD*=O9"D?CX2C7B1GN
M][?29.7!V>X;VPG;O1?V<V=DNU4(P%V.Q;[-Y3F&G1&\@\&7CH<)37H+OO^Q
M5]VE8DR%#2W$AOS%S*8 3AN<.!"(@#B7#%FN%:(1)Y(D"9,1FFW5DDR4W*;-
MA(4"XD5:15IK7W)7<8RR++FU77+/'1"$"X,#PXBY[(6PN7HJQPH!E3;8I!;
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M<PO5#U.$D2"\U(JE8>!<,L,'Y2-5WC(K;P:ZQ1V-!?&6@'CG01YF2-JD1HG
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M6'N#*53."&@9)=*EC68,^JL4=E[:LXQD^L783@[\'Y%1%S?P2F[@NQ.G8^G
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MTNFY!C:QCCIYQ78GX[1>=7"UQ"F^8]_&\@CC9_/=I^_PR^T/R&.EA1; &.,
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M4@6I4^$F4J1%J:]#J5?,'$H(E6<$.,=D*LX*P*C(S"DVT7'WDDG#<H\_6DY
MOE42<CAM6NS>+ ]YC)D400S2A@5-1:!"$RVB^VFT-\(;PCDN/*1OD+7634/J
MH$.0'$ 9**!<D;3#,P"KJ.7"$V(<OQ$>4A*C_>0A$A/MC*$VD@[*HDLA"?'!
MI)@A4U;Q*Q]/6#3W.C5W138<E1QQ9X%#*=-I* 9:6@>P4IA8);&F47/IR51
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MR>O%D8X>Z+?!N0-A(DA*+8(1V B=EK'3)4M@!5J@/,< I91.$4D=]P'\!FS
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M^_N\4EU3*>8UZ2)=NUP[%7RCT^Y&=%3_33#^/[DW<MNZ=F>A#W(UOOO;:6D
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M^KS+@;]ZG,?R]F"'[>\>BKUW7S15FBO.$+95\VT/0(8YAS^9U4Q)Y9E=[%3
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M!$?&*Z25=4BX)*,-/-F46WN=M^\EYV&M57VU27T)6-R-GK-&YRN=2 +%=D0
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M97/0M2#/4DO^W>ODI\T)?-D^O^TVK'._/8"W=BNP_ROVV[W03#]Y;B(/=EG
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MK7C%%@5[[^!5SNWC\"_;._AXMK_[WV^?Z*O3O;]?M]_NON]\.OB]G;VRO8,
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MSAH(,0?4JC&#9S)]IOH[@_K>MAG];4PTW*O=;R4+/[[;SJB^Z)3;P@?>@.6
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M$^)7%O1.6Z0^IM]VD=Q<T#UUY_ PQX6&L;4_IAV3Y1^,3NYQ>&*+7F> "PL
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M)%4TN^^7Y/RH(L')<=XMB!V<E/T/U5>0+1!'$L;PZ7^K>T9W"1 7&\SLJNV
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M6<44+,UA41EJA3W9&WP#4"PI^%I\UOGRD=.Z@@[?0S''70Q@?-4G=5S65&Q
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M?H5CM :RZHO)=OJCHF<SA9=F!+2T9IMXFG-,P%KE:FQP1G(2"=!I+:D&9AV
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M[>SM'G_:^_TU_7#R!N]]?$=@%\&U?W]J?]Q+[2O/]BX.I87_,>R0LT8ACDE
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MW,8V(V)K,3(["U"WD(U:'(]@58X 1D#2 ,8BP!O\M]^[M-U<*JH%5Y[&86L
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M3#6+W@3B2J%=HX/F7+#$A4]*R/G3MJEU*!IE9B5:=SAYNWD LP,V E-OG9'
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M'K_%'@R-]!P:?:?$;I438N3.R,?-870RDNLQC*K]S;C:@=6#Y3NYR[CXR/A
M>OZ**J;@]>G8PAW7"9R__^P=,WW,%FVK=]Z_SGR9&7?GM-J1!0X^VTZWXJC#
MZX+\MEHKCQNJ&<WG+?!V8+0L?;E\ '1=4,TZYO626)H<!78]FOQ3CW*G&N3;
MT1C'(:KDA<'*WF[["JQM0KCS-GHD+5!8'C1!UMB - _! ;L14O)L;>N%&+L2
M>3>NC+D@!;?QX,Q;4)-BEU_+04/7DIII/\V?52&5E^NNV=M]DP4(*T5\\!Q9
M27/-9A5 @'!$3#-L) DB*;/"7;/5^M4.CJLJ*240MP[AF2^&.N?H6X3F6]6W
M-.MSX*]H:<_*75V0Z>5&Y>SMOKO<.SK4E,1H/$4TY&(65 +7%2;EXI'16AZQ
M(2D3G=5'& 6@YBOL IW,!=F.*UCJG$X!4?[ZYTJJ\N?G_54!$(,A_&?L,B]W
M2]W>Q?VJ*BV)-F@RI&_.D"9-AO1+R)!>FBUZ8_;G?'HK!X9@=<*2.+!@D_$!
M4YFBQ@(LZ.C&E3<>*V]YV0'0^/BZ;8?G??AOF9.7G+P,5BZW-FJ+*?(F4U/J
M@&/DI+SH!8%?3*ZJ/Y^,_.QBN29E+%,O!UT6PZ]LB!S-=^ISY;?";6!8-?O,
MFFBL;L;<)W7Z@R'\^SE.,_/JH&+>+*TNJ./^5I'PK +G2XO<-1BP]4.Y0>]\
M *,:_/C3>N?OV_]=9U?.9'"74@CV?-@;K6O5QJ9\4O>]\;F5\MD@_C3Z8:$Q
MT;2,Y+6".3[KVLN?.J=EE<IS:QU@S)8Q><V+)JA;6-=#JK7$5O6WN49*U1^I
MVC)2&6Y67W+M]Z_](U-;5%)@2X]Q<ZJWE#24W?;FC]'BV_L8OX<6W^]AY[5>
M%=MD-_J8[=@6(S_=J0'9(\S)DWC^-V\1O[J?UA/NXE;![,0"_O'%-@AMVL,M
MGX]O+Z./'T&Z3G>W:XGXR -3.8H!#O;3;YWLC'E?7,U/H\G;79EYU>3M(]SS
MZH_.AX.=J_;'O[LP#K&WVQ;M@S=X?_<=_W#RBKX_V?L$S[J<;_*6Q]\^^:/;
MWFU?[OWSCN[M?L+MW!AN]PW?.S@^>7_PH?.>YO?Z([7_PI?COL<48TXE-RB6
M4@@D!62<"X@F[3R8;SH%NK'--B6_5:_.[XIJ/+A"F*H<]Q3T^J.NT7/MO?K\
M$''W/+X^?0L&%5R1P?#@HM?@X3IXV)G"PT0BE<ISQ(A0B!N-D<%<(8&CYU;:
M@*W?V#:;2JIOA8>/0 F_%1Z2I\:)'V^-&CS\9GB8(VH:1%P'$2^G$%$30P4G
M"GE*<XELK)#+%2RM]4+;D+RG@(@$;S*]&.;64,1U(9$V%/&)+])W (F_]<X;
MFWD=1-S[=0H18U0NQD!1$I0@3IE"EAJ/%%C.23B<I&,%$17]9HCX'9%$UI#$
M)[Y(WP,B=CXW''$M1)SV(BJ9##>"(I><!*O92F0C9R@RJ[G#BF&3R_623:P6
M$W(:CK@N(O*J$:D=QG[#%I_X<CU/;-S) 7D-/-X#'J>=BE%@*H/V2*2<02^"
M0UH8C3B76 KJB")J8UN*36X6BY,UA'&M_5:E@L\$9\VFZ#1L\MF&5#Q/+&UP
M<QW<G'8])FPP]88AR0$\.8X.F5Q/VEEK W7&BI0-[<PKS6)J9<,KU]I<?\YD
M-MKP\7Q0F@@U#/.)+]P/SP@6WTWIY5=?/%RZ4W+,&HQ< R/WIYV1P"L-,U8A
M8Q*8WH0;I E8XM900H.Q7I6>]WJ3DL43ZQ\;6GG+398SU*X)S']JI/()A.;6
M?ZD?Q>"/H7>>LP:6L\P7'A-ZWWG\]COD:6FA%?JGT3/KZ)EI%R^W!B?L.)(B
M5Z[UV"/K/?PCH[#*$Z5HVMA6=%.KVQ]Z_:OD\TRGYDYWIKQS&="IO#+^U"N<
MO#YM[?MA+^>=W-1TL37(^[[4[CSJQRK]_H>-OT8?[HP^K%HC3BX^.^OWOI2R
MA]W+M3HA2AL<C8[3* PG AL>C<>!I^28-E)5#3 (9F1ZG^([]C\<O0BHVK=U
M_[[<$O'%-D*<KC.T=_7Z:N_-81 ^.NTB@@7(=89D0DYPC!B8PY8F 4M%@.S)
M3<V6%+M;VA6QEUJP$WRN0E,Z9TY7^*_*M2X*6-WB\#9M#=<1H?5ZM/7Z35O#
M%;+2SJ4:I$[:"V=1E,$AKH- +B:=^[8Y%9,P)/&-[4E^ZNHNAXL=!G--XJF^
MAG2J?_U,5Z!I+"O=6GWLC'I!W:=9T'0GBZJ/Q5ENI9 3<P'%CXYS"\&J+/7H
MB[?L:3'*P2W@F>W8>S6Y&$-PYQ3F,(^[.*?G/KY#(<))2=-QZ>_Q0T=E3)]-
M;97ING(CK"D*H#L@+[;>RNR&?L_;8.E[3GQ0# 4>(N)*!V2I%\@*18T,Q$;-
MUJ+A7[.(:;/D=UER+ZBQ6$L4"$T(3"2,C$X8-#^EBAG&C2CU)1>#*J[O/-*/
MUQ?T>NRRDT6]@[RL4.^-L*PK+&+OXI 2#U2+$.2<IX@+XY !3$" Y$0+Y203
M82U\>-B2L\V:/\*:*ZR%B]0BSW-POLQQ^<$%Y!AGA$;CG!(;VZ>]6^##/5F)
MGJNS]?@U>^8-@-&1ZT'O%Y"5PC1#4[YG5+[GXE!SYI*W 1$61>[A3)$V3L.O
M-CH?@N3>WK5\SY-WLRPKZ!/BT':Z536?= Z"LJRH3^>T*NM3%7?+W^U-FS7_
M-9ARM-RASLY<#9VYR6O*[#1E=IHR.TV9G6]]EO>$#V:;,CM-F9VFS,ZZ 3JW
MX<[?<:6=D[_A\_<78$Q=O3]X ^-X>P)CXA]^;^.]W7?P[..3]C]O+C[L'N'Y
M ]0/0*[W/N[P]L>]X[W=UW3O]P\G[S\>?WI_]0;O'<![_@[CV?WET_[NV]E*
M.X0R"8:/19CK@#A6$CF*/2+":["&@DH!3#6RR4Q3::>IM//]ART^3U \N.AE
M&!PT.+@.#DXGPPC,\G(&)),@V4VID561(1L(LTIK97" +;RIOUW%L>\E:+&I
ML/,,%NF9XF#V"C=(N#823J>W\)2TE9@BH9A 7$6''(\&"2ZHAK]D?VU&0D,7
M@WD:1M@4UFD8X5- PEQ+IP'"=8%PIJ".I);9I#D*8 8C;O+)%)88"<&XL%AC
M'G)8XR;&BWV%&DK8U--I*.&3 $+XIP'"M8%PVD>HC=61*(DX3Q[^X0KIQ R"
M5>78!)ITC 4(35-JL2FCTW##!X;$NYK"L1]+![L&^-8!OFFG(%,J1L("2A(S
M,(631HYRAK3$F!G/<4P ?.NDEC7\[[;E<<;Q2R4]X^SI5<AY @$033)SD\S\
M]!EXHW_6T3\S1<X9%YIY@5(,(1-OC73D#F')L>6")&/(QC;AFX0O]LV^6W;S
MM8V(ISMCZK.F[_#M@GRG?+Q-W^&7UG?XQC["\WV':5")6^N333QQG?L<4&H3
M5M(:(\/&31ORVN4?:<R[B7FYZT\=H&H=OQ"6N[2(0(@GIYT$JCA/R'K=7%?&
M]S_N.]Y8%J&D[?:!$-C^):S=>7]0A,.=#^#RP6"V4L*)O1RE'K<ZL[-1HO(_
MPTUR]#ZPWK,JFR6G%9=\W\_Q-/3Z<+]N4;/PP^@1K3/;'Y[&\E'/]D/KI$0N
MPZ^]!'<O/^5;]6 D_7)Q[M%[T1D> Y<>G$4_S/>'ZX:V<PI#' [+5\;9N_E)
MP]9I;]CJ=DXZF8L/>S",7DEEMOW.H.1!GY<D_0Q8_KBDZY>$Y%$N/MQO$/N?
M833E95P<34-HN<OI*=ILG<8CP.V<R0WS"L/L=M-YMW62+8'3<.Z'HUSI\1<^
M=WK=R11V[<7"+>$^)4V\ QNVVX47/@?K @8 5&5XF7,G^O *5>*X[]H.3/B)
MA14JM^G A-9SMM6"]<[D+S]L=F%SJ8&9,AASJSLU$]7,AP[8,<->W7!Y-/FC
M!2L?QI.S;N\REGQQ.RPS 0OVO^>=G,<]_7KVI)=7H"PO#/CT*$O=9 AE,DY@
M!/"$P7#\K.F&S>4!63CS<I87AW4<C//2.UDKV>'Y(,]DO8XYCV3\$A-1RU>,
M![[5VNL!FSS)624P19_ASC&>5I-[?M8[G<^\7[$U*C!>E*BR/X[/JST&DY(3
MW$][HR4L[S3]@ Y,ZT6^IKP4_!%V:S=4X[)9[F.&@59,*6^)V=']W__0E*B?
M![,]JS?+M-3+"G?U<'$_'L?30:X?D'=(D;VYB\9-N+=NRK,9X_@W3EI:%^AA
MT@ H9NO8KE,.ISSY22=JO2I"DE?YKW@VK#)%P(!2UQ;&V8V?8[=W=C(JAM"V
MI^<)V/EYAA^X48V/DP(FN7[)297$^$.60(I_WFW_M5-^)#__6"')OWNG5[;U
ME\T=WW=^'U]8/AY?.4J3#'-#.!D/H=): *6]HX[/.S%C+>S@=V7OY>_F1\^^
M7X&D^"5Z(.6ML_.^/\X.FF(\#TK9C)"W$=SK8]Y19[!SX(7.A\>]?N<JOW(U
M]*F-OWIX12N.9FB5[IK5#/^58738<;UP6>'IZ148H^-7J_"CO,(9(-]HAL8/
M&2NH?)FS0W\,'X;8A46OUK1E?6YS7^"@C&@T2:,*(^.WWFJ-ML$W8RKO3C-O
M:$4+I#:O)] *H"R@S#<GPZZ7\RPK&%BWL617EJ/,N8*4K@:MY[VC=Y:D1>9U
MG$H$VUQ2^^K8!M YI\AG,>AVBVTPOQ.R:(UV5D4\"H^Y7MA+@100[@RZ\.LZ
M15*H84XXHG2(G"O*+;/8>&XIE=I[&U?X>FY3**-4Q/JS?K_]_'JOJNT?7FR^
M^]['HXN]-X=<"4Y9\D@*&Q!/TB,MN41!6)JT-93GRG-4;)&512^*%*RST,G'
M:+ )4FB>4]2U-,3:F&1PF' NZK)5=+;R6;/0=U[H+^VC0X^IQLDG)&-(B%NI
MD=7*(R\DT3)Y8X*%A>9;BX5LQPM=ZRY0)=W+JDY4ON)S1<;/1QIWL @EF;[F
MTE"^,L.R(95)9S<.*TMJK_=Y1$9@!*U[@%I!G@)M_9A@2+/(YB<,+S_AB:#3
MR!,]EEL'EF0Q(5ZLT$Y5X_BR=^7YWM%A$(00K0QBC!'$-1=(<^Q1@(4 $.$F
M\9 ;PVTM%JM_BDC5+/I-BR[:%X?,.!$E8T"4X!^>B$+P"472D1@4B2 +-A\=
M;"T>'(P6?7,&MC8G.%78XQPOO/;<X'DSQ16.W1L=M;L5L9M4JUE=.Z_LKT5<
M[ISZ\WXV/BIRN";P$B.PTHF"&'@>O326)&9CH)8; %[YD+7S?LT#?%T/=\KN
M+9^_V'VY]_$3 P!."5.<3$1& NQR9WSNWAZ13,QI[2AA1&QLLR5,L;+$[@K"
MP$Q9-%*J$#'7R;C($WS@B.%6 VM9KU)6(P!W$H!<, \FGPNF+ *<  K)O4(N
M<(Y\I HT(B/490U\DP#, W)E1(9)$ZFGB!"585$/\+=>?\8)EJ7CY0K'U<XE
MV!?$),4-XXC91+)]P9#)S7L%E5C!8BB+<4:'54D&3QD=FL6_;O'WWQQB+JGS
M@2)FN$2<&5A\1QGR1FH,F]-Z$7,IS<4(PU4L[6;/[XQKM9_92*88<^RN-<5>
MKJ_[^RC<A6G,C%+,))=CS#T8+%('1WR(@E*.'[((;*.ZEMH4!^_Q_L%KNG?U
M!O[[7H"PQDBB)H$AIW2N]BHQLMHF!!:%4)9$JQ79V);7.4+6MB-9"IQ@SZW#
M/%%K<C%7T$R44R$EQ>L5>&WDX+YRX"]R#?<@P7 W#FFJ0LX0YDA[GE!,7EB@
M,HIKGNG,8J6$5:!U;R;S-?"B46:WE!&\=W$8$P%M!I17.9P5&Y4@+;E/"X>5
M(;"!-:$9*Y8TA'C*6-'(P"UE@.SM'-($TR]@^04S65\XBS18$P@[)2WGQ&)?
MZH2OUA>/1&X6O56MQ5/.LGJ'^%#R96&NTRXM5'Q:,^'V"UZNVT3G/8)+:T7
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M2B?P<-=L"CQ#8Q#7N?0R?L6C(4QXSP*,MD:S1"+!.*977((S6%8ZG:*)#OL
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MQSQP7=4-H-AI6CUY"Q"'+\'$&A=.S!(JYD5))X,)?* TLK+=]R<DB.' #_+
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M9*H+PKG%!E:1IA^]28?]A\:U2DM/.E25E)3[.4."&"OG%O=\]-7BU9C3@N[
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MKQ8P;UV0*X#O9VZ-Z W&$+JV+3@Q)3;&!-(0_+8\ALE;(?]@WAK.7BP]S[%
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MG9,A"(=_ND(^1M5+G3 !2"(E-6QKE[:"&ISQ7F=A$L(,R\<-E\RDL>.G4[1
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MHCJ\<EK7U9XD55.*OCC$2?18QU"HPICN8!:NVG7<H>>G\J69<+V,VQ.4T7/
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MH+ NYZ9U[;$?[+C066#\J!/X-[/C.FM#&9Z"@I?\#<??P,Y&3MC/P-!F&,4
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MEB/*"8.DJ!TA<?,RQUDQIKN5L7X9IN_S2\XHN(^)@OM^1L'-*+@31,$9O\2
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MZ]=YC"^GMXL ,F<+[+&3@7.;G2^DL_+AS!N3SQ,GCVC.(J,.H-HX>?%]RBG
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MP$J"ID]$-]XHZD:G@&VN$&:(V$&5J: .O58PC@U>IW56B)PBCWW6.4/!J$*
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M*=+8.?C?=AX'/8-WW'0-59PPGE>:@;$JR?RFS^5-F^:C]A!G.9,S>]=&2%?
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MJ6M+2$;P>9J#O16"QH9 0(Y#"W8/+BY19]5"G=8 0=43C(+\%YES"AQPZA]
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MB#5"RT4*C;_N!N/X;5GWLY;SRWIX9.MAAIW#  =%I%Q$."VI9OSF91D\]&5
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MG8HS9"X?*E3DE7\TMS\TW=$1K5SE(..*Z2SN[L391OF<9BR1<";,CO"Y4_+
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ME<KN$GELKH@1ZL\U@O?P*COH?>>>7B;YZ+OFLHP>^C*:GX3>-VO!XJREZU8
M%0;ZV2TY>2?6BK:UATO3=R!6(1A#DL$8@=,@]A 9B5&R#XK59I+G'M!>\I)>
M^]-<Q60OB_3Q+5*FO?1A\UN@(K$E 8-2:R2(CU"570SYCD"66)= "2P"]32D
M"R3-+6I@PUXH5F_;[O8),,!W2S"?;A[H+,&50M!U 3(\]F7]UAVYC:QUS2H+
M2<<CWI7 06=9J5JWP[I^$RI@<?F+UQ!]!.C:#*V[O<%E$3WT193TP% L2VE
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M#2?"?SK-8MZ&<,9NEU[PPO(0?&,DM? #I/1B#S.-QK5DI6KS<B6U<VD1Z"?
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M;U^^<=E:7_RRL(P<S8^:9/FS,8 GCH=76([5;1[#(V>WEI<MVJIA>V,7L\4
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MOG;CK7-MXE8JD@KA0RLHMOC]!Y*X\<=(T,.L'$UDZA>3# E1<TD^;8OSC,F
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M.>J0VP% L6XGQ0W-Q;8L2'<F038)W@S.E+K/^.38UL\334SBK*X%2)QN0YF
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M<V6A<<HJ(BR..7S%K!6J4F[0QCTEWCQY-N13$[MHFE6I22$,D0$4/: YA;*
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M'G1?:_H_ON&_,G2AAEGVQTY>I03NQ'W*N86Z621!9,+\#$^#*SJ@P$<W!4O
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M>T/L.]^;CC%QQ>@8A2,PE00\;MF>J0IDXQ;H?1XDJGMCWF)H!:!^HM[X*9R
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MY\YT_M\Y!(S$9V.5->Y"D@#C9]E\XM)Q@6!&L"7XU(DOM?\=1.DC4!(WR73
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MIX!F&M&54W@XRKT4#'6:3!+!:1::3)OWX!J3G:S+D9H*J9E7>;W\U$7I*66
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M<=-6$V75&S:WUA%ZGOSR4EA)!3>2LT242CBH2]%VAW(ADFFO$C"@O,F^[J8
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M,^&\9,4$;5!<T9.H?7)9XH>\236=70&/Z8SB>)BXKV8?EH<OY\?]1$D7N!=
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MUK0!2O-HM2A"<5VB]0)X(:UH*3+0KP:ND-PM:2-E;VG;#K2!!Q>81FFD<C0
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M!^T$:K"6-](G)3:BZM-0V);\<@\1#M?>N)7HC\:+DHPJP#U!2K1^*DX&@-/
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MM .MA>"1*  J1Z9#+&0)H&510N+:!<"0^L_;JN&GLM[#@DBTUQ2R1(+)A<6
M6::<DE1M#P%>]96W]3O.JB;>3,8?AR3VGS__.47:6I<)D:/WS])L^)$(4,_P
M1_2+:_K=UVS)9W$ZFT":#6JRN"\H6!)(!AE:FD7:DD%FL)[[)FEB$WNW'_@G
MD>6U"Z<VW!,?6XL-S.K;M]U%H]-H"JOW![36%P)CZN8<BO#:)D&;\Q,,+W@,
M5=X;=;"+'EK8U3=C:FI S"@-+_ 6Q#_&'27V53K@DN/<L110,^VD8=Y&,B94
M,:BS=%XT"95N,9BSI.BCLZ*!)_ +DH>2AG,IT?<7.-?B*#^[K.$7_[.(%*=_
MEK*5@F7NR%PMA2R?*#G#1)80JB#Y>B92/\SM N[X3'Q\&HP;Z[!%XNSF'(1H
M(J3H(TO:%4+%#0LI>68A2Q5],D:VB90^D121D^-2#WIJL$J]''W$A9@6<B$!
MW23WZ_++<)K&UZ,9L?[-!"^'UY>#PH6T64GRRCA)@0"RD$$S*[2"7&NE^"9E
M+O; ^IUWS37<=S+OW4"EW\>C*K O GI5?_WKISJ'< !22T%6*W/"T_R)23#P
M@C.%UI'K5418SPC9$L2UVWO/F%BMM=1CNN\6J+]@P<D$\]MYQ&LBEPB,8&@D
M$#2R8(,IF7&3 T 0W/.T)X%NON<[87K30H/\W+^30*M 7H_>P06^+B02$L+L
M<\U5G]]Z7\T#%3D07RTJYH54-7V.:(STHZI%%2VD8*UJL?-U@W?&%&NHQP8)
MNO,K+%HO$TEF(:G5.HDJAJ"B8Q%*8EKEQ$(--@5!=F(2*B$T213;BN@[IWK2
M5H-LVKM+ZA<1+._2OXP_Y.*U2&30X7QY5;X&,7N6$AHE>#(1F\0P=8=XEN=>
MC338HTF^'2GY"E<PS*M=?#DGR(F8SY=GTRG.I@/,4:ED S-%U#J,+M5[^<0P
MZV)<X&B@R472?G!/(2NC'P(\R+/>M=?@9.LNZF=I[JE.W\#G>82R+27I5!,G
M@R698/58C4)&-J37RH((\4C+VAJR,V+2(3II<J"U >#D&O.K(<3AQ<(L6-+\
MJZ_Z]6\#)(<T^N*9C<$R'00P7QS9"[R8E(SV)*NC<6H'X.=%N58:/<K66>V)
M*I;_',X^/"=CETS*R0KPYX%S2@6!@:58>[$H0@I8. NT]*8498FQB9.Y(\XS
MXEM_^FI0RJZ[&3LH2MOL:"O/IKJ]X.?A*)H5&6)V4J=DFZ0R=H=XEEY (PT>
MCVN+*X;NPC*\B%*T8U(0630'P6(RP!S2'WA&:4.3:-A^X#_5\+*66FS@'9"]
MN2K-D_[[>CC!WV#R#YQ7LWB'Z7JRF# F.>MDJ <SGN9E2H(%\ET8IJB#S,XX
MT<1#Z(3N9%:[IJH?M];;,<AUZR"9K,VO9\E9H0P^I[KRTY(LK69 (F"H0&(@
MZ]+G)H&-W2%^IUE_&FS@L1*PA)BG+TB,]=:"L/T&LSH1/K\N&R>'5N"Y(9%$
M-+3X>X,L>F48<J^<UKR :9*2MC/2\V1>4WTV<%"[RXS,W%BL-IF@"?)U/!0&
M*I(K;3ABC 9MLRCNCA#/DG*--'@\#^+%< 2CU%U8.I=<C*HYYZ:.0G(6I4_,
MQIHF)!2:T.2,I!_X3]6#:*G%%AOOTD1X7;[4K*I] 9^/I[/I %R00GG%E()(
MTY%K%ES0#-%Q\$(4M)O[F?9DUFT"=3)K6U-%;S'D#M92CV["/*+IYCZ_0O6Z
MW*AN,#\X'&&JLI@?'6ZN?J:D!VM"9N RT!BB9K3M>Y80O <91)9KX;1; M!Z
M G16+'LT339V)+X.8U$\[L\1O>-+"Q8R23>'HU?G:$H?N[BN9>;F8W]]-9?R
MH'92C*$ *_/&ERDJ%D4Q]"/-LABCIL&W=CIZ']59<?WT>'(\9V:#? <@@590
MIUGD]3"=%[*%R.]B@GXTQ9<2VC3TZ0[Q+.G92(,-G)D*L_Z_'B5])$^?K)2O
M[0[J'VC^W/[%C4\NRJ*N7S;^^FDYI^B;#S!ZCV_)</^U%-I[!M)ALBYXEI,.
M3.N<6/3D)EI-QH^)2NHV>3?''>8W[QR=,"L:K+<'C7:@0PQ&TSZ1(#JFT=>N
M@1Y9M *"K5T#99/SI(-0GS=#=]+9J2VZ ZN#DY)V#.E-8=I9SR*J0/S(SJOZ
M-]6FDE]_A-LC1?CZZFI151<N5H5Z7H[*>'*Y<&!6NS8M(-;0#LVR-&&Q:WO,
MG%EN3-#<19';]"_OAN^;GW<M]-!C>LK<%UXF.OR!9&W-7EY>D16VJ/%4B_3]
M_/D5C/+%N-:'SY$+E(7E8"33,J9JA#G&M>*U530G870ZM>CXPD=0?@MMC1N+
MND4YU$5LW3Q$/"\:=I%]<EW#QG^^GOT^GOU?G%7$ P/"2/3 3'*UI9P&FAJ:
MLZ2,P&*M<<ZW65N[ 7Q:%&JJG@:G4VO%Q=&0=\9Y8+4?9JW]9VKW!V YRV"L
MY#&VZC=P(F7Y#]I(]I?EMU&67T9'EEJP3!9-PHE!L(!D<GJ2# \Z"A&:1*I^
M"V7Y=]+V3F7Y=Y'ZT<JO=P'UO2S_KMKK5(=]']$?KUU#+EP &)8XAYK2RQGX
M LSG0,LJZI3;=.[X5LKR]T^'721^E++\VB4GDD0F8C6,E2&+QF;!@"P90"^,
M@38&YZF6Y=])0P^6Y=]%O WJA[Z9+)-3;V+*(KAZA<""\(YIDS(#*)E)Y91U
MQE@7VX1E; #S%+1^L)"W3O1&1;3?#=^/AF68:A#O(O.TMI@;7PQ3O2^[!:I;
M >W[']AK\>P=L*\5SD89L<1< OBLM8[1B&B=P!@LV.SM "//+NC$C$E8 V&0
M>6,X4RKZ')5!Q^7-P301?S,U/((Z.JG%"9N,]%)Y*W3RTGM=K.>H? I"F3C@
MBCO.K656*4UJJ9&]+I+/#9*7I)%[B,W5\CM,ZOWL1_REULR_Z%\]=UYP/#7=
M/[8U=7D 80K$[&H6B4A@42"0 K,/D0M+"Y_/(F9:.@,*IFMQH*"DI!V/UXOK
M@!)@S_+SB]Z8]PWEZ]% \#3=L[),U)07[3,RL#(2B7CFT1270WE(83N\[^"0
MB^NZ:[PN7Q(6WRV."*8#I6V$)"1S2*,A^IO:X"&S5"O_VQR,P#9ANML0'6_+
M;J7O.]$2O0B_1_-M/O!7.)TB+D(V<%X)<(5SE4M-#HJ@,181"5#.3*/)S,=(
MFU?0/#@#B1?7B>4=7O9T]-Y$O V\M=MU(-\.WW^8O2Y_3G%>6F9 *RD'LEMJ
MD3]::(M0-?>EGD5K,C%%**HTN?>_%]73(4G_2FAP(7 ;W-=Z"E8XDU/0S&DM
M:T!+(5C1,H+CB_?.&=6DFO\6/$^=%?L)ON^JO_<.>W'NK101$TL-V"B1Z&IK
MKVJL)8;0I414=J);I=^'W]7Z6N@HFT3/(CV5BZ,;]2%?C">_XU\W!C<9C^C;
MM+A%GY^"&HX\*O*&N=55>K3:^7EO<RXU]]QD$$W.BW9">>R+I2;TV-[2HV<U
M-3!6_J#/O2[/\G@>P[X\!>N"J>7%TR90CW/OU%"7XT:*.!9)BLS29&]8B(DF
M!H3 @D;+.-<2O5/)MHG)/AXY'KB$>F1N["+_-FUBEX-]-X-1ADF>_GE5FR.2
MVBR72Y J()9 -I6+G%PQ55-B4 $3' $YQNQ,DWNJ3NB.?XMQN"+O=H?M60M;
MST,:W6J\@.'D/^#B&G\CD_QZLI@Q^YS3;GY0K^>Q';"NG;O*#"X9(:5"T"9J
MSX-!840P-IID]"#Q[ IPQ0!JTUYCJO*39CX7'[G1V13=QS'Y1NAS6Z<_82\?
MUU[DFW"O"UX2JX,@(1JIBS(!R.?/Q0*B+"K+09(^J6024R!KV3H3603-&2@K
MK3;<"6@G^ .N(^Y]7GO1=[ELX,8: U$:E8OV07@2N=<I842O9+ #4)SL:V%J
MR4C-=(Y ] ^UZSTXY8T6M7K\8=O3%_"+@L[/1C=KIBX'E%^/WM92-).:6C?*
MOX]'D]6//\-T>,,3S1*E)@TP:X%FJ=7D&&3O6<C! BW02L<FAW:]CJ*/]!-Z
MP5J&QA>(M9D2.<.$: #&HLDI,4?6#=DZ1;*8@F&)EKZ8<E3!-&D,WQGA\7?^
MQ^/CIA2H_M78( KFV4=::>I*3]9UK2;UM6S4+QAG-XI(624U(0*&NL9[Y9+)
MO-&%A4 ; !?)8",CLR/ <V9;$R4V<&=^P0E-A7GF_Z(#@',B0O")D0E.Y(=Z
M)*S0,T.F7(+ 2VA3!6<=R#F3YR"E-+BW6:#8M%0*A=F+:!BY:P3,(+$W9,%X
MB<A])CNG33N&K8C.F3;]J*E!QOA7/M\LTJ^]*&BL9TEXR[0&&FJ4R*RA4=K"
MC6I3J'<CFG/FS>'J:9#T?0/*)D8K \H'J9B3JM8!434E/7#FR?/RF)PRIDE!
M\?MAG3.+>E18@W:/?<AI<44F38V5@,BPA,)TO3WW8+!6%DA!<AE!-ZDGT-L(
MCI4!>3K4?!SEG\KU^9?1__SYR[?_/L0)(?OP^15^Q(OY18W+45LA"S.BEK(3
ML= $K<6)N8U2!NW!-S'\N\%[K$S,1Z+.-@+WI\(&ON3&@].[>)<Y+%W MKQL
MWPGMX]S"MU#[-F8UT]FC$ZV$(*0-@5F9$M.Y.L\I:V9R<9GG4+QMXF>< ,$>
MN,D_.7[MHJJ6O'HYNKJ>3><2$,N[9!L$&*TC,V1I,!T2L!"2909$+EA$2*5)
M?8)[,#VBM]&_-K?QYD!5-#B?WP1M%7&0N/.VFJ4Y"U&[=2460U1,!$MN=(S1
M89,^'?=@.C>6[*.*(ZTE:D5@F^CE. ]^R$QKE5BHL==2.VUH?74Q- DANP?3
MN;%D'U4TZ5U;^W7,*[W0OYCOMD73&N:S8R(E3;LM<.9U#"P7 H9&@\M-JES<
MA7+>/M>!JFE.EN<PP_?CR?!_X&9,70>$+9VJAR$^CB=UJ#+OY49OFFC24?U!
MI#P:HX3SK&8/DCD5:QT)51A:L 8L%EI;GQ)7'G"*CD^57130@"+O/HPGLS]P
M<OD5ZG2U.QIG34Z<Q5IN6@NA:M<H8!QR]B(5'7.3@*;MD!ZC!W6_"EROS]:/
M]'M/YQZ/WF]&A2)JZVO+8^WGO=4C"]EG5C(O.6GCHUI;+K8E<6][Q9/1<8^2
M;%+E=5- W'S!2V =*8N<:\]IP3/:,(C9,YY3CKIXKW2SO@.;(9VW+=J3JAJ$
M=MPI:;Z&<?-O5RYZ!^PMK=5#P#^.'=L7$<:/K,4&R]E!8Y#*B82&5F&I GVA
M71:<@CI-3:J%T9QO4IOX]!CX@'5\B@3<17D-B/?;>(2?%UU^7UR/\@H53R!0
M0&;9"%KE-5<L8 ZL2#+;A+(VM+E/WPSG^#;5\50Z[ET?#6X-_GSWQV1N+GS^
M&OR]1.:C3CK1Z$JM!JY3=,PK61B0M1"MDR7%)E[6=DAGQ):>]-*H^BT9JD.X
M> -DL:Z<AIR%L86S$I4DIX'4&IQ"%I-23J9Y3G43TWP3FC/BR>'::' BO.R0
M!Q<O1R26Z^I<SK=B5)X6.$=*K#5===&<$-%H99:NUA5ULHTYLP7/>3MO?2BI
M08#U'Q,830M.JEC>X>3CL'9:?%TVH)W60Y'IYC\MK^>ZC*5IY90>!_-(L5Y]
ML&2]?L9CJ[A%398^Q^2B< F]8;S4+CPTR5F$+!G0-@\@A8Z^B>5U^G1]*'+L
MU-FZBV8;L/0>JS)Z;C.")5I ;>9B.?/"1>8*24=8Z7V;'L2G9.T_GJJ[6_^[
MZ*F)O_CW\4><C.93ZSV.TIW4X25.T$%PFT0-QTQDD/#(0$-@*ACM79:1MRFL
MVA7@6;.K@0Z;>)J3J_$$9K@1G(@)G)\7E)9D\4K0+' D@22G-'(9K&M2G?5>
M5&?,JOZTU< CW>PFRZ!BC#;72^S(=*Z5J8OGS%AEA7%% ;;IP7L:AQ8G1)U#
MM;/U"K%1F;1ZD .CO#C.K:[XC?(BMR!UJR)UW^-Z+2+5&?=:#2GCL4B=<XH!
MM><\IB!++CY8=. B#"0O!;-PI*):OXL^2-_QS(K((01TTOE>VK[<,X#]RZ<]
M_-!C*:%#*37@SDD;,&4N-7H)(B4E YA0=+9*#BRWQG*MF/!8VZ(KS[S.P*(L
MI#1,M''SQJIXESY@OK[ <;E], IWCD /*+W6Z_N/I> #);/&A2B#]T$'P'J+
M&3AH4U %2");C9 'GNO(:S%+H2VMH=(B\SP%1I_U7&EOE,767+B^O(3)YW'Y
M4GNHW*T]U(0$W5]\-.WO*8OU;D_%:IX#%N6=%EF'Q,%@<:BP9&7TP&N7E*+=
M-SN:_1JL9='4-LLQ2)>CD$;( ROZK8C\NFRO*?7J1NWXXK@MEJDL:OLI89A/
M0,:"C9EV#4L#:9+LN!/*OBNDW3:$GUV.)[/A_]!T'T]G\S/\0<!H@DV&&:'J
MH;W1-8!7,LS1"J55R;:)"[,KT$?H5]Z,70]51.M5:4<HP[>&-Z7KR^L+\L+R
MWR?CZ?3/T01IH:(!_)W$_G-=;O /^#0(/#C:)PS+7I-GC^3C!S+126PQ19]R
M4JY)/ZQ>T)\Q'1NHMT4Q\CT'\8I^^CH(+":64CC9+N3UZ4P6+22HQ_<Y>4G;
MGLMMBKCU@?X[1_M4;XOB@5TK82I%SJ\U-(-4K)6I8V1 0B-;2@BCD]0:RC%H
M>#KE3!^/:;THJ4DEP5LS8 WU(E9#6QF448(9&6I3*T^NF"*)\-JTM<@0>6FR
MY7; =JS26\<C3M\*.96B61NR (5'90HMG%[HVG3;:185B2EZE4*-+4VZ":].
M)S&[=V4_G'*]B] ?)WVV"\+O*=>[*W/W/-I]-/$XG"D9O0Y<LL*](:32LL"U
M93:)(*00,HDFQ82^G93KQE3910$]4F31AF^5\;OIX'(5?)*SE2K0LNEK6_+L
M!0.,Y&9JB<!1%9O6"+*M\^7#+SO)=-N=%#1N*-U6B=7WP$NF>%&T9U;7:!!(
MY+#YQ&G)3:(8E$&+CFVR'WS7T])]S[)M415J2]RD%9%S3)D5G67UT6MU6V>)
MD5E9J;UPT"2KX\0"]EL;F'V(O\$12:_Q(5W&\CT4?Y]0_)U8TC*X>1\5GWHH
M/A<QH 5D2=%.K+4%%@7-<C16@S&^R#8F\>G3=<]0_)-AZRZ:/6XH/L<2R= H
M))@<F+8DIU!#)Y6D/QBC $J3:^$G&XJ_DZJ[A^+OHJ?'#,4O.3I74P:25[4\
MLJD'J<8RJ;/0%DM0J4G:Y9F$XA_&K@8Z/'HHON0>C"J<.0^1Z8C(@HG$!T6>
MD?!&Y]@H^?OIAN(?PJK^M-4^%/_W\>SE*%U<9\S_.9Q]N#=17B=5#$T#EDH*
M]:*X,%\[!8M0T%H?A<Q-<HKVAWS6)#R*GD\H\O]WF$SF_<K:Q+/>>?RQHE;O
M']=:;*J'[,#3IE1#DCDXCT*# P!G$N?>$J<R\8@VL7D_47( '(-:/-O);*(+
M8)Q,?80D?VT?MXG@^^CF@2?VJHY=T*\G"'@.$B/)VP8M; FQ.,?1.R-DC,(,
M:$BA:)]8SM(Q#347RV5DAL?DLG B:M=> _NG:W1Z[A&UT2%I ZW+.MF<.+D,
M249O%03N!<]1ZQ#-("27.)('0;-$,RU1LP@J,TDKK9=)%Q2AO4Z^Q*>_&$_^
M@DFF_^#P_>CY]61"MNGG7S\E6B/>X_/Q:#:!-)N^OIY-9[1JT!9SP)K7'-,1
MN="W!-=XE!"5\4"T$5Y+30SRL407K>369TX\0D P13)5LF Z*%F;XF2&'GDI
M6:)R[L#(_YM].5>Q.LI'4VO-,EYJ":.Z;0<R#ABW4&),6H!MXF)NP-)?5]C?
MKZLU\KK<4.^_XT4>6*6+RZ%6:8J9:1,]BT%*%FWP6AL5O&D4R?4 LN-;FX=R
M87O/USZ$W^.ARW!^/W@3W[A*%BZ>78ZO1[,!6)/('B:3U49>,VX\"R$&<M*%
MLCQ*D=*&IO?3E0JFF/[Y_?CC3XO75$JHY?>5#.H&&1X \NU2H$\)-S@!V=R-
MV$;#Y?S@3Q0::,R.>4M?3,BA7NGZQ)MXI"?2++K=]-]7R T.+.ZTO3=)D]$&
M@?S1I)A.Q3"HA=>U<L$G\,3%)ITIUH$\)7WO(=HF<=PK/#6?IN8KO![=6)!P
M-@@\>JEDI-$6M[33E3,L&/"F1 Y>-=[[MR![2F3H0_@-2A-^!;,(^0C:T@ %
M9SY6BF+(S#M:EZ1VW F7ZU%(6RX<-7J_G;YW%^>IQ.-_'<-7._7M</J/^56W
M$5:",202)20M9DXQ#\#K21=))KD8<I/8@?M /5X(U0'*WDJ< X7>U$Q<N?CU
ME'UYG-X%6\L8J/O /4Y,4W^JW,J1GO1P;*ZD#$E;61O[>%7[A!H6H:9'!B[)
M^K6*MZF5?'R./!!(]#@4V47\?4?B+\\,5V>%RY/$7Z\GXR\MN'2I)_R:+!]:
M0G7*R(*3@3E?;\Q2"A[6&B%M"<5^\%6/:58>JI9Q,YGV'7V_&=W/]?IM^N'-
M^$:[B 31*!$D,T822I3D"QM !M&)6D@O6!T/T/R&5SYM!APJX^/,_7=_#:?3
M%Q,8I2^Y(K*@BN3[:*]Y#3<G+PA0L%1*,D&IVG+\ ![<>>'39L%A\FUPYK0&
M<R6!)3A7(!?!)5,>"*&,M/\E\KHLFLRS"3'[)H<0]Z)Z @SI7_H-SJC^'?/[
M^6WAE"#.\Y,6)<Y3M-K4;O*N.E3.2!9DB#1>SV6R5DK<< %Q."<VPWD*;F8/
M@FZP,MQ%M6J$T %72^=R&[#'<2S[4-Z#?#A \@W<R>WXP!2+"9G!:ME"IKU,
M6L-$T%ZJ()+23<H<'Y<1#[B11R7$#@)O<JZP (3YV72)\:OKO-S$LBFN>#1,
M62]H8?26_!X7&2;KHHWT%1O=83V([?B&1#^*O'.\T*\6MOJ<C0)=GZ7_OAY.
MYP_<)ZCKYC_O-?YJ*ZZU4"EELO!%:)DMZA)L*)BRA"*DJE7Q8&"3=$GQS.C7
MM3$H1 8UD@0*-XHG 2'V4B?Y!N #@N0V/*656#L%HI521$@IU@M;9\B0$E*4
MX#PMIEK$,A"BWOX(SR#/IXZQM,1ZSH*.]#\M"H_VP$"TY^,+^NUX$9O\;#*I
MMOH\4&C1,"UM^?,\0I[,>1KIC6I3U5\(*"--\'GK\R@(JH^,*Q[)V=-%&MXF
MMZ"_01QT\K -R!OX7/\S*&"+ B>9$YQV2F/)E-8J,'1"!D4S2JU'/6PY<7C@
M1<=?_A^-1[=.)OJ4?]_GDW]>D=1&L]=7=; OD/PJAZ E]RRK;!9]*WTRBHFH
MZ$_.6A-$)S*L/_E<M7^0A/L^A'Q990X7"S"_?JI9/%-<\G ZD!C112V9F9>I
M 5]8%"8SY8(.BO[G"N^D^WM?<ZY$Z$_V/1X^+!>HT8R,V*]+TO3/*])'^C#$
MCW-)O"Z_#2]P.AN/:D5.KVP09-!Z7LBZ\M&P*$U@(*4242MCBNFX7>SPVG-E
M33O=]'B"N8:4OIL.Z8ESAVNURW'A@C&V,,LU28"72"!U8MZ214XDYQZ[%9FZ
M_SW?>7*P]!L$V+W%*=(#:V+H+\3;B_%51?5R]&8R3C@EWA;NI"^%B53348U6
MA PEF4"^=D!)WMHF-OH#N,Z03"TT=I=0YJ"59AY2?,.MW<+]17K!6TSC]Z-:
MI7S ?10J [FJ.2_K#H.AQ1*-C09!%M[QBGU/ &=(IZ/IZR['[$$<^PT^#2^O
M+V]P_\T%C-[@9#BNJ7^KZ5&[AY#Q9K* G&B?+<@)J"(9N91IL06,HH:?\-2)
M6+N\]5S9U$PS=RGDVNQ[OWZZPM$4!QPL%[6AGG%A&9@4,\P/B3TDR='R<+Q=
M;XGJ#&G5O[;N4LD?2J6O)?9[D-?B#MU'[8+EAJ%V2-Z"(+]!69B;AQ&%<"8U
M[MW5UU".E2EQ,E1]9#:<2I;&<[@:SA8]:.;K_>ORY^AJ,OZ(F>S4*YS4+,-?
M/RV*T[P@;2Z[?LW-C9\_+S_S^?6$OOLO3(LZAC7;R&"A/4+5/&1'ID?,-?/%
M%;0)A4E9MI@5#<;R6,$ZC\W.]8)%C\R2!I$ 2RBKF,8.8%I&"-U"\SAA08^N
MXW'?"FK.FH+2AR(=R[P6;%6A,- <&.::;RE%,:G)0G<$MCP0,G3:9-E%+WU?
M$&U;KVMEMQ?O9C"A=?N&)_^ZS'_Y=[B\A%53%.NU)/N%$=9YB;?(@$?%4$4I
MO W:I:[7 P=".;XG<X >NUP8MU%"CU?*T\EL\+:BG<\(SH/Q9.,R#\4P'8IF
M@ *9I6^=30XD=$ETHX?>6%OHI_5UY=9;S]SDV5\#/5XJ?@&Q*J?< <8.YDEW
M0CR&07* !M9U>(#X>MP7UN%DXZ4--7X!<R$XV;%@:NADS-D+E;6+79+?3T.+
M6PR%_I6XB]1Z5M[RP/0KD"R]ULSE>NI@%*TJ"0MS4O-00K8Q=$DGZ:2^6V\^
MWG9\D.S'?0BN05'XM_A^.)W=NM6]L7O\_/G&#W/2%J^,"H;@!L*LK?(L0@TH
M$2DJSHW@"EM8]SOB///]^AC:;9"J=C_<&]\NP^V[P&UY0+$CWL<YPFC*@9WX
MUH\"&QQ@[ S;.I_1)194IBE9 ^J@.,Z"C9X<<_ B-\FG/0F^/7 (<M)TVT%O
M?1^!K$(S7Y>?KS^/KY>1NZM:$MGKXI!6]FC(E!!%L8!6,QED2+7T<US/N-MR
MNG'?6XY_<-%4/^,6PCUVTM0-*X$4\7Z""QMAGX2?;8_JM^I_%[SK%?Z%2L6+
M5))Q.@?O2Q)1Q""DM\F8,O R98LF,2<$*4B"9>!H =0@(C<E16MT'XE56\#O
M7UC^_@<>0_ =2LF#"(4\":1%EBQ(I2!9XY0O$+,O1>>!J'UBLY=,SI,*74@L
M&AM8<31!G-/<!=%0_.]@-"[#0UI@='GN,91QSTC6=%)BUH:6GLQUT,9Y* )(
M0QBYRY"5' 29%'<@6$FU!H6>IQEKSHKR7CCI4S+IE++AM,ZI.$<<RN0H:14+
M^<(R,AO0*2M0<IU:6$0GDPVWS,?YDGCA:;;5C8>9VI%92U^8!ZX9V;+5GA5@
M''3:T=<>_(W'4>W"DTWY3GO)M^_LMF?O:<J_AQD^IS\/$UR0G7-]4?_%Y]I$
M"6A%_I(\L8J4ER;K'$-F7-=$')XYBTI[QB6Y\%S1SUIVXL,>+S]7SK364^^W
MI$N8!.XKTCL(77;%T8[.'.C$-"JRECQMUXHGYVQ0SJ5NM?PZO>Y<N=._+GI/
MK]M$ZJ]-U.Y@Y2"LC46R; *0HTUN%F1O:Z9%R$$E3Y;&3KSI^.)S9U +_?2?
M9'=3)"N#]L5U-5G?$%[Z =[C (U(REK'5-2UJ:A'%I$<!Q.LAY!E!.QFU'1[
MW]DRIW]M])A\MP[QA@=T0PYO)L.$+T>I]D+&07:)RRP]2:%^\=PQ$&2\2702
M?%% #-F5.!W>^YU O6NGQZ2[E<R>I50SM*9O,>'P8SW0J+T;#.=*%EH.G<R9
M#'RM631&DUWF.:"P!7.3+):-:,Z02/UII^\<NM7&>F<'-;7 $-2^K]%JII..
M=9B9U8+?"5(4WG:L.+/E#6=(@_XDWB0/[B..KG&9VSD_\E\A_ UG'\;Y]@=J
M\B=MF8 Q*^9-#DSK6N#3<LL<^NB,,L&9)K4-=X=ZAF0[DEX;I-$M =6H[E7U
MWWG7ZFL"30;_(NI[.'I?<Y;I?_D/^#0(D<?(,["8@JI5-<A^4P*9DL9&":5@
M;-(+;@^LW[G83+-WR1A.,*?3&.63P,2\<YQ&),E$-!B8-%$GSHL3ODGKJN\Y
MG0<3^)'9<"HYG;74^^NR'GVBBA!DL!3&(\U/G45-E@7%HO1*: N.RR9=<S:B
M>4)!BSLQ9-RWIAJ$B-T5!FP>_S+HI O<EJ&).^)]G-#$'C2][JT>04TGP"X?
M2@83"LLED-]%]@2+ 3E#:[T"Z:)9/T][0JQZ( #Q\4FUBW8:D&G;(KX*AP,O
M'(!E0FE!DK# 0-K ,$BE; 0L>-3"Q8\5G-A4J^NE OI32<]YE<_KX1Y.KF R
M^_P[7"XRDY107.60F+- SG12F46A$BNU<3IA)->F2PIWIV2>30#.W!#J12]]
M)U[BU?4D?8#IUPNI=8C+(-XN('M/R^R*[OA)FX<K<GPL+?2=W=D9;"J$563'
MD,^K/KK 0HZ9B530"1W1NBXG8=\"5>[)#'TDINPB_+XCGA81LRM;G+0%25AF
M0^VC!Y$S;V)D7'IC8^')Q6[1!3>?>N3TT#92'_<ALKZC('^9!TBOC*-H"V@G
M6$&9B*8<F0]$6%.T"QE<4-"MO>3-ISXYW>TMLIY7YC>3<;Y.L]>3=SCY.$R+
ME<9:Z8JQDF$-8]/.%C:O^1V##H@1H@J]&7V; 'PW^@[72X]Q83?PU/$O$4V7
M4Z +J+Z-O*UHCF_4':ZHNUKO2<IMEHH-X+@0(6J;&29/EHGRD05:S\@?3D5I
M8VWR72H!G*+J[S'2CJ3Y783;>QCZ[^^6P%8[%0^QR)(85QB9YLXS4-P2(JB]
MA(0H)7?:W->??-P-OB=IC_L25=\&6:U5?57SU2YN8Y(\6.Y381 R[491"L(D
M@'E1/$AE0&*WWDM;7O#-:[$/P;4IJW@#C(5H?" ^Y52;S'/OF4\:&)D467EC
MH%%5Y2>CZL/%VO.1VKL9S.8&Y+M$?L%D.)[O)5)E*Z(EAQ]"'5HAER[4CEXB
M03(FD[O76QVLC0B^V^$]:*;'>/LYH"6./T?3*TS#,L2\G E=0/5MB&]%<WQ#
MO =-C5N)N6=+?#LX&WA.6AH6HB%(,6D65026A19.Z 20RC>J^WLL\6.I?A?I
M-E+YB_$$$TQ7>Y9&39:'04;[G*IUP-0BO##YI#P(!=%WB6'>2=^W(1S7#NA)
M-QNT?8!@3Z12S.(XF"S8,IY<PBCAZW@Q?+_H2=ZHI,:]+SM>G8WN8UXKOB$+
MD(T(3@<+VJA8FQMF9R38$+G1:2!C3J: 9P80R9V7Y,X[E9A-,0K/HRJQ'%A\
MXTL >Z7Q</1^XV!JBY@TP_S'\)(^\KJ\H]].R\+">?4U-A2*!>D32[*6-\KD
M;?JL:P<UB][36++LLOKOG]%P\!!Z2P.Y#\E D9U?2',,4))6"SBR]%U@Q18>
M=?%"=*H;W49.CU&;ZU$8N#75HS?=-2F2>J"L%NY(BE*[1+9)\20LG1VY(S7A
M.QHIR2T!I)7E)&?J40/GOR5B]JOSQPZ5WWJ^C4E8'9)DLF3+M*6)&+/53)@B
M?,JTA<HNX:;?W-7@8W#@H>O 771QM+N@+J#.[3IP)T5UNA3:1\K'HX!T]<[+
ML$(N$R.?3##@$)G7HOKDEA?>)4/L%%6_ZW5@ \WO(-R^KP.?7?S/!R1A3*:_
M#*>U7L0*VZJ/A.-&2!]8++4I#-?((CG>S DG!6V_EG[H=+WTP(M.Y>YA)UV,
M&PGR%(W<VBUH]@O,<-FX"I4RH%A>]#6@[:]6N62*/&D1LLIRO1C#B1B[MX9Q
MAI;'"?!AZT7;<<_6_H!_8(;^C]%N/_<X98*WCF3]<"S7(L&AA&*U3A8@@TY>
M&)Z=CXFG ?C )23#G%:::>!U<RN<64D;'0:T0IE3JDR+WOD4E6/1(^'-4C*?
M: I \1R*-!Z4:;$.G6QE6E&428$'YFW=OSS7+)#%PDCA9+>0J*(NG?;KIU69
M=A>>W%N9=A?Y]AX"-,%TL;E6#RW?9-.\G\#E@(Q1+FH9?"G)C-&*)K.W'EB$
MZ+"0<>.@6YVD3J\[5U[TKXN^+?O?KZL<7Y<EENE N9 S%V1WRAQK+P['0K2!
MI6*+E% X*-^)&.M//E<.'"3AO@O&?BF'? \S!]X)0 ^.F>C("3&UCE)M2J<=
MZ1@+<)V[Q7IV>=NYTJ)W3?1=#_8>7(LZ@)@'41O':3-C7I;,= F!@>/D90#Y
M%1:#D!W3M3J\[%R)TK<>^BX#NUK?_H#)>R3;AP>R>6JWZJ1J2TOM#(L* XN(
M10:>=0[=NC2O/?A<]7^(?'NLU#K'LL"PZ*Q4(Z;'>8#1H%<V,FL]4:_&1D,*
M\[RXH((WW$'JI.Z[SSY7C1\HY;YKK2Z O$"<WK!9G8O28O1,>@T$R-+:X^B+
M40D3('#)N]D(FYY^KHH_6-(]UE>];:0LD*U:K!'"@8DQ<N,3;3FRQLEE^LZZ
MR,!G*.!= M?-3]C^CG.E04]2[['$Z6U8O^!'O!A?S8O7K%NL6JE@C:%1UF@Y
MK1 9!.=8@F(0I*!-2^U&BWO>=O8$Z4L3/18@71:?O]/BXN:29F/ H(F[RL2:
M<",4"\("<];'5'CHO';<_YYSI4>/TM]PW-17WZP-( <N9,5!>*9$("\7N6#>
M)\FX*I%KYXTIW7R'>U]SKKSH3_8;:'%PJF/MQ?6ZO)N-TS]6+L^[#S#!Z<OI
M]!KSR]$-:0R"4JG$J)@T/-;>B(&%:AX['[,E)H2DF@3R[@+R#&G67)<;B+?W
M@>@&L,]) D-Z[/SJ='6Z\OH66N^X\AP-"^ $T\D(%H$$5%R(-3)9:6QRE[@3
MRN_4:Z#-#=S;^X3UJ]@N+VN4!*&=OARMRLCG/-<67+R!(4V6YW UG,'%P',N
M.+K"T!)B[2UG4%NO"('%^. E":?--79WD&?,O&:ZW$"\O8]L-TR3>2,HL@_G
M*_3 9%F\U(HY+D@"7!8&0AOFN;8$,!O(OO'Z=@O0&1.J%QUM(,]A9\#;%M@W
M$[P<7E]N7F<A2QNM-(QC<+5(7:0]'B43(),BMR.&C@U+]WG[&5+H.)K:P*W#
MCIK_ R;#&K1X"^Z+Z]GUY/:O!CI9M":3TQH*KS)QM(,'Q8S5)46,Q=ANQ\]=
MWWBN'&JBD0V\.>R<^IX[TE]A,D(2V.S_XM?[TB)<09,CDPH5^;I1LNA$9D;G
MHHJKQZC=.G'O^.)S95%+_6P@TV'GW)77LPD)%_-&]@^,X%+DQ D=\5UKX9F'
MC"P6'TS$5(NU=SR^O/]-YTJ77C6P@1^''6XO@^*_Q'5MBHFGP9,+"25)IDO-
M._6RM@H(?!XH721X952W:KB=7G>N3.E?%QLB[@Y.J]G4-.X5T7IX,9Q]'J22
MN?"FMM[%5'-^$KF"X)@-Q0B9HD[KFU%?;OT]J,Z04/UK:P.7>NCL<@^ZNSTQ
MYUECN9!OB)RH#\1_'W5@S@NE/ F&\R;N_&XPO[.MA3XWT._@P_(]VK*2.QE#
M+):96)=@Z3V+P!.3)BM7NV$:TZ5(\/Y9@.?2;O<0&C;6ZP8J'GQVOD]75BPE
M\.+*PIW0 .18@#!,Q:Q0"QJ):5E^Y8SZ[?9 QF::W<#&PP_4^R]=ZEQPTMM2
M&XWEVL\Z,,@U-QRD+2)'@-S$,/S></?PH_O'9<-C5Q&ZOP]C0 TR$/6TU98V
MCI)8E%8RQZ4*(2*4]</;[PUW>V=(IX:[NVCJ!%JB=H'[O>'NX9H^L#?J/FHZ
M 79YG:3((;)Z#4;8C6!>.6!6<X[T%T4^V)-EU5X-=X])JEVT<_R&N]K$D$.P
M3+@D:&E6EL544X!U<4J(ZDEUJ8S56P6*;Z;A[BY:W:WA[BXJZ;GA[ML*9=$U
MJ(2"26;FA?"U]02-SZ!AGC9O)U3DTO?6Z>'+6\_<Y-E? WWWTZT@5CU(.L#H
MO6/NU_<?OU[BGAI8U^$!XNN[U>U-.%H(&W1@-72>EJU0:D>9Q'A."FA#%.BZ
M%#X[#2W>4_JP9R7N(+6>E?<;?!I>7E]^V1H$62A9,@6N1J1#3;"CG<)S!U "
M!MH>^E+?K3<?N=OIOK(?]R&X)N4+IT@/_$"[R(W,N!L;R.HT\8_Q\J;XQ7CR
MNE91F_[\N9JP<RH[[;U%GAF"H3TE^\*@U.9?09L@>'# FW39Z@7]F>_MC\>$
M'LNO]#"(.H1EK=(N@VAY*-++*![GJ.016-0?CP^D0 ,?N9_!)!]-%$XSIVI-
MI)@M#:9$9HVEWWN= ^^R.3\E'C]P./-4:+R+YONNDS=/O'BSWAQ^:?;DB#D7
M'9F:MZ(,NC9[C8DI6[S2D!5M7MVR&^YYRV.TASFZUL8M1-[SZ<WS\?5HAI,K
MF,P^_PZ7B]EAH #(,K\L=$RG1':*<<AL$DH)@22#WDK?;P)PYG9?+WKIN6'G
M6[Q:)^\ZQ.44Z0*R]\.?KNB.?S1TN"+'Q])"WV=(G<%F$;S3(&EJI%H/DCL6
MN,RL("0L0I1@N\2&? M4N>?\Z9&8LHOP^S9$%F7<W]#>>$DOJZ7?X>+Y^/(*
M1I]?#2^',\RK5A*YJC( R]X+6DM3#5^1FI$91_ *"IFZ%=GI^L8C'UZUT=:X
MM:A[-D8V-I^1+KEBM&(IU])/TG/F05AF(#@>LH]8ND3<?G.]ND[(&#E8+SV6
M[KR_ETT74.?6MVLG177JWK2/E(_6MPN$C#(8QQ(/M9X & ;<.]HQZ9>&.P6&
M?Z.JW[5O5_^:WT6X#0[=EL"6.Q7X$L$8SFC;(S#!1A8+&4A"\VRL]B [M0W?
M^?#L%HI3Z>*UDV;&?8EUJP%PY*;AUY>7,/D\+K?^OHR\;] VO,OKCM(X?.=Q
MKW5'PA2]USQZ6BBT]B(H5X(H!6S0X'D9Y!!E*2ZP'!79#<(K%DJR+$6R/Y/(
MW,&AK<-[C7-/- 8I:N4&7M,::S<G<%$Q-%&2?6.]2HW*2CU^=Z1#,DZD#!Z]
MBDPH9VG2"_(XI>#,R*AJU%H5W?=<HF,SM(]<HETTVR",X1>R,2837*7<#7@!
MB)EVIZ (A#:I,&]"9,YH 8*7K$63?(DU'&=,HD,TTL"F:^#G5NLGEBQ9*9)&
MY+1F/M6R&I$$$U)T,C6Y5?V>:W8P.1^9#:>=:^:D#SRA9E8*53OQ>1)LHI6=
M*^U#YCR)U(+73SW7;">&=,HUVT53)Y -U 7N]URSPS5]8%K0/FHZ 7;%K)7S
MGC.I2Z3]P $#7S0CR\*0?^G(_6QR3G,2K-HKU^R8I-I%.VWN_S8?;JS@B91M
M!F3U&(MI&0V+UAJ65=)8*W: 7HM%N??F[[YWG7X&V4ZZNGO[UYN@>_03E\5=
M1^,RO!>>RJ*D0$,W5HOJI1!0I!F"4I@@O<XN=FO-]O"[GC />A9TFTN=VY<8
MT5M(,=$"#ZY>6B;!H,B:EN-2*!I]7J^V_/W^MT<[MQ>]])QKN/T6I NH<[O_
MW4E1G6X!]Y'RT>Y_0X%D,0N&1L=Z8Q%9-$(PZW3Q"#P5<2[WO_UK?A?A]FTL
M/KOXGP](PIA,?QE.$::XPK:*HI:^1.EH.<M^WC<XTNH6'>-<8!0@T'6L9/S
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M%DXM9,-" +)FH:8JJ&2<]MEVC [J_,IOG@,-)=QCG,A]3"5<^!=<5,(.( ?
M3-:1DC7_TL3 HJX^C5$Q2U_OWYO$$SZ ZYMG20OY]WBCN0APVX[M]S'9A/@&
M)\-Q'D2P:&3D3*52"*,F1U3X&JBA>="@>9&\TR+1\87?O/*;2;?!^?(<UX?Q
M1;ZQF$W_/B&!#!0&68!\*%6(E@2$5BU;),L^8RS&QYR[M%K;8VW8!NF;9T;/
M4N^Q=\D*V1IAA^\_S%Z7/Z=8RS;/YF=2TH?$"I+>--;RJ04*,Z(V'S187&QR
M/'@OJB?#BOYD?Y<8ME]BO!I"'%X,9Y^?7T\FU<ZQZ N6')E(6*NX8&9>"L<*
ME\;D@$X?@QGKL)XH-0Z2_EUNN$;<J/>W2X"84'I> P-1RUH5+K+ %;"4,D=7
MM!&J2>& !Y$]=8;LJ8.[)/$M7)%?AM-48T+>P@P'UCN!NE+7RTPDI@7.>YUH
M^_,I6^MU-$U2,A\"]F0HTJL&[C(D]&*+/A]/9X,4I.$F(HM6DU&<I23_65CB
M:Y*8<A:FM#,]*X(GI/-]9+KA1.K@H\NU<]6W7R\\?R?KQB3O11&915^OWKTE
M$J+PK&C!,^UJ*M@FS7'N1?5D6-"?[#<PX^# A-OH_A.KX8OYV4?Z[7ORF:O@
M;IZRB@$XY\&*6-N  8G")A92,2QSY;P!'GQHLE/L"O2)\J=G#6V@U,'GGO<"
MOKGGO<%)JL91"$8YHVAU=$$Q[4*M1VDB2YH6R02T'\8FL5&[ CT/2AVJH0V4
MVONL=#/@936HZ4 9%U)4D1F>"1869+4+(7U1I'%CK+9=<H4.),X*SA.EQU[2
MWD""O8]+-]T,O[N.%_4;VD+KACJ_])D@# RD:F)95FP)9&C5*Y_D28'9Q&"<
M]S$\&/VQP_N^>96WDNT&_1]\/%I=J/'DWIO?;%,$5(+Y$G/M;%OMJIQ94,I9
M$Y0)J4N1Y[W<V/NA??-,::2%#43I^;CTIL6]HO:<UQ=3,4#I$YB4F,AF7@!;
M,J^Y9=(:(XK.0NHN7>1[='W6(3X9XC32R@8"[7VF.E\-WRPSIU[7I_WZ"=,U
MV48#'@- M&0!:1G) I+SB.#(+%>(.M301M-I8]GX^&]>R3U);H,R#S[[K <P
MTY>+D]B;$=_SWP\"2G""N)4U$CI32ATL35D?N$XY^X!-&MS>B^J;IT/_LM_
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M:CI\GC\%]WO:.9F+,-: 3.U%D),(C.P(WCJK/.?&6 9<V>@IZN&B;5I>[)"
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MC5;6:03]DP'2S1'&J'A=KBJZ66OOEX<64+EVJM4V_:7 ][Q^P/T%4EMEEG0
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M>_4/?^O2VMJ=]?%); 4B_3M?,E7:-J)!RF$FK395VC:!J1?$,,)I$*:)G^#
M*+?V[(AS>[<W9ME0]7QT%>UC&.N]\%:1<\P!.Z6RUP!N1S<K@5U4T#Z#C9L*
MVL<&?:$*VF<P.%Y!^]R%8Y/Y[N_+HCU'E-8&7:Z4Q_2:L5R9(GAY@W/VOGB-
M'_(&+Q=1X)$4"0ZIG]&NE#9! 8:8^*'G!83%GE9JS)C!YT8]K3/J'E>_\Z8/
MC)8O$6T5ZDJ8F";\&<R#'B>Y0M<Q/75B=Y5+:E4JJ9<<;$0'2G:U&^NEMYD=
M:(Z9W5Q!@_$GSAPT1^9Y'N&(>XS(*EP7HNQV5$,0UCO.%XF((HX(@?(YE!06
M!1DD7IQ"G @/R5_C,(FTL_N.CS,WMEI+RGH'UB:H6'#->ISGH#W-2A8!<TQ
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M-[S*'[$JO?VQ5$/AY?6]ZK&P"(4DZ38(.@X2:9U%3-(V%I *%K 88\2YUE'
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M*'U009'Z1@EPM.>"866G$9.D9Z(ZAM[Y&M#)K-X#4!;'X09?O[31HT[R&2_
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MINM=S;3S>.D>YG+,'6Y8+A#N)7<GEV-Z9BMB88"1Z\(F17HHI;?=\NO]3A6
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M&8:0I"B&7A2G88AB/]8+MS0?>FZT,,@WKEZ?/N)Z1HP;'!WSQE[O@[KM5]6
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MSJ'K.NF^K^O55K?:("%9Z&$"D;0/(4I9I@[1,0P3/\F"6,3"-^K-;E6ZN:T
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MS>BQI\ZK23Z:\..:]V//R=%6870!'+8='\1"T6V3D$<BE%%)4[7!8$3]D><
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MCR'68>@I2&,D(2,)MHQ%[QUM:E]_(VS02ANTXAKFB)M!;$8%WH ;F!3.8C;
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M*6 )15BD@J:26G6ALI5@:BS=,5I;,;7/K-$AT$H K47G]VY-K:RGRHRG!YV
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M:P70;E6N,>H&CQRU<J@NJ:)\@UUKL0DLUD/-_R06=N_*_3F,@*'FU)O!,)B
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M$<<40!DB0%+. $=<9"B))(EC&_XT&G5J+-D('9"%8LD]L>W8T@QR,T[T#N3
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M,\$RS,T,LPOC3,T8T]%WNTC&>76^-&^$M0YH/(>MY=?OCMAH#%")>!-LA1R
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MHT_1[N0MYU7=;3*OKBOKU"QE,?ZFV['=/PHM]RQ&7*0IQ@!%*0<P15PG]>6
M<A1F,B8R@\Q\RSV*S%-;C&KA]8D.V8J_C=9L%0@V57_$]:.H/^A?BD5SC6$G
MRS%?"A.?P.2F>OH^X=V+LE.^OKX,MNH'E?Z! B#0"$SOY;#Q=4SN)1G+7S*Q
ME\72_S+JM/7[<,81940_T*C8[ON2QAW:S1_UCI1%J8;:=W:]UG_NPD1RF%.<
M1A@P"AF (A* L"P#.).(Q7&*8DELG%5FPT[-\JBDUA31U'HFYEV=+/$V\W;Y
M1W'@17T+X$[DF]JK_1K\;/X[2!2.'5(^O6F&(X_J:K-#X] /9WFW2T_#E6#J
M=P4C\U^+N2C7RT7;[%IM_+ZME@\K\C0+TSC-XT0 ',)0AQ(J.I))!@A$%.=(
M1A":>^>,AIP:'W6$#IY:J8/GMFW\LS)5GFO);5K/&8%OL&7Q#NG Y-1%<ROP
MUDS4G3V^#02F33\^WZ".U5>O?2GY1NW-GY5I3MAC(5YJTURM"$RLUD1MTI]/
MOM/JPH,WVI<CS@K0_CYX1D\:L9^=C6;[?>FL[K0C^'*UGOU@8D%6Q?*WA<Z!
M+60A^(?EDYK]F1 1$@F*09S$"8 0<8!8*-0_4YPF*<P%-"J]V3O*U&B\%51W
MK]B*&ORLA36,G.B'M9^MO8$UM$NHD?$R-,848*1ZCSFH[N^8@NI?AV9@_P"C
MD(&1CNWW;W:Q:W6:4\'9WQ6_K H=^7;Z][5=.8N2%*5QS@%)%!_ 3(;*T(,0
M2"D%Q)RA++$*E[A&F*D1R$[J*K?!MN#,%;-BMD\="^N!^>=L LE-<# #9ZX:
M8Z?K VN_A6>ND&?D"C/7(W=<2L;#,UU/,\O[%5F44NCJP[?E[0LIYMI[^&FY
MTK4U=-5(7;WF_E_+^\?EIE2O[*="KH58:+?B_;+S\Q^5^=W\IDE4%3+,TYP)
MD*4)!1 E&% :0:!VY9!E(J8P,:I%.(ZX4V/LYF"AHW%P6P9;G0.E=-!J'6BU
M==68M#IT"-9+_8_<Z;AJT%?"]!AS*A,]Q@FFU1PKU8)6MZ!1>COG>[_<:E[_
MVB47??#7P?;@<BJOQ9AGEF6P[KP>I S(]O70L4=%^WI436=U,$-% \_-*]'\
M(*]^X,LA,MI<7#Z('%2*D<\@QT#T^/AQE%'=V\\N5_O-'%LOX?WRG:C+*@O^
M*UGK!DRO!XGK.60\8H0"BH0$D,8,()PAP".19V$B4"RM6JM=)\[4[(N#%JE!
M*_5-X%I@_<KI,MLHCC<) Z_]M2(G6M5N_>"*OJD(6H5NMC,T:#$"/_CZ;F%[
MA42C][*]'KU336T]/-6Q\\2V3;4::Q=OHEO4?%XT=5!/Q[%\UPVARF(M?HC5
M2\%$'9&KA%T^+*JGU+4IU0Z1"4D$B*-< )CC#)!85_]+$8MB1).46Y6L'UK@
MJ1%Y5:6QB5AC'6TLNV,,/<UF]#ZER1MX ;C]]OG]S>EXPUT V(UN\K6J%NBJ
M?<>R7 <=G3SV\!@)>*_M0(:6>=S.(B/-P%&3DK'&=5Q_RE+H1#L64T$B!+!D
M2*T280@02I5%3Y*<)3 )><1GZZ62U7"5J!YKQ>7;AP_'"?=Z#+7)U[)9\G<-
MDR'+6BL_-!?V:VS/9GL*>N6<^LGC,L.>-D??[_YO';^RSK[_!YF+74_C#X*N
M=_^:2?5_6/(,1$)  "/]"498?8PAQQD,69)'1@5!; >>FM7U*UG]4ZRK?5BY
M%=+RDS7%W/"C'@#)@3][+5BGF_G-SO4-E+4#2M+C@K#G!$M\O+*&Z=CC\HHE
M(D?,8WN_SZ"0JFU-3 05BHE 2&$,H,PYH+$(@<200,)#":5=DXNS0TV-?WI*
M53JU%#H+L1GY^ %N8+IQQLQ3B,5PG7O.CC:!\(C^/CH7[W _.A!BWV6V;:'6
M^LX^;,3GQ??E7#WGX3\$67TJ7L2,AA)%F9 @S]0> T*: B)9! 3-1!3G><I#
MZU,#)TFFQCAQ&"?V!P)NDV!^%C XM",< PAQXAA@J\CN1. F4,H$Q2)HU FT
M/H%6R*___RI,?;O^W809W>M_%6:G'/[7/="--9MV9$UT1A0R&H<$ XHY!3")
M(D!RH?O'\XPA3H245FT=]YX^-7;;-O^SBJD_#9P9>SG#,3 C&2-AS2TG-?;)
M%_L#C,H!)W4[_*Y/7^3XK:I)^ZJFL<G?"(D4*:4$"!(C'?R> 1S&$(B(4BSB
M$&&[X/?]QT_N:]7A35H\U^]U'SS##]89DJ&_6',T[+_9DTI[_6CW1QCWJSVI
MW=%G>_HJAZ#KOXN%CI%BCY\7;-M^*L$8LAQD:9KI(I\($)8G "(609%D4.U'
MC*.DCY\_M2]W*Z$^V+0(1CV!7/]7ZP&/@3_;/2A< G1/8&(147L=-B.%P.YA
MY"M^];SFO0&G)VX;+T+TO,Q[(9T]ESGV,M'1)76CU0^;E2[E4!WR5B>[NR25
MZJJZ,HU8W\E/RY44Q7JST@=&B8Q(0A% G%7YN@(0R#%@).8TS,,TRJW">ZX5
M:&J$^+N26>_EEU+7D6Q3Q*HVQ@'1"MAV=[IVPLR,H3&G86 >KH1LF@D'M3)!
MK<VVTW G>:^^NBT))JK*!!V]//8-\82PU[8@U\HT;M</3P@>-?7P]5S7;LHO
M8J%'TM9H/;I<KIYTJ/X=G1</]=J?"Q&Q)*( ,:)X5ZB](*))!(2(<9K2&%-J
MQ;M&HTZ-7#M"!LNME+;]E$W@-F--[R .3(V-O)H &XF#+J0[F6^"VR==Z\EG
M;V4+J/QV5S89>.3^RA98''=8MKEYV..V6ZF^^L/#GI 1$C-!  M%#F &<T!I
MIK;!<9*'DJ6Y2*P.\:\19FH$%H<QK(ZLYT0--\SQV\E)\7L"=RW4DSN$(UJA
M*9S#]2'[%D=Q)^69Y&E<'W*N!W*]S[3T%XIB]J%QLGPJ2D;F;45[MM'AT%G"
M)<J 1%Q;=P(K.R^. .0PXAABAF*C!J"]HTR-#%M!@UK29I,65+(:NLUZ0;W@
M4/0%U<!DYH22N0/-!(4=\90M\Y2"_?5A^?)OZOZ:=-1?#KFF_]GC^-I,U-MZ
MW(PN=O_L[]6M,QHG^J/.@)"Z'3J,"< Y12!,810ACF*4&M55/GSP9#]N+9S]
MUUQA9?X!VR(PUC?;J[S31]K5U,-W63UN]$^QJ\2IKV_O]XZ.[FV'\&[K5;$N
M;Q>\7>H+4?ZJEO[-2O"[Q7<=WZR]/U6UXX-D]I#"*,Y1"$*60GV6EP#*>0XD
MSG@F2<R3!%IYO7U*-[5/O]8D:(4/R+K3K-G2^^UU%@U=X6\U-T/[Q1N]*@_W
M=CYN@F:Z]*ZTH]YN^I:+8*MA4-=S'[)BP2#P>W6:>Q5P7 _Z$-@>N=,'&<3>
M[/JX6*O=W"WGZB,JORW+-9G__\7S^R47,\%2$2=Y###,-)VG"%!,.. $B8R@
M$*4I-37"S@\S-5ZN)0T:475Q2BULH*0-M+CF1EH/LI=--C]X#<R5KE!9F727
MD;C"P.MY^&CFWF4%N\:?P=6N)'!/_OC,E5U9-7K6_O&ZX<XL82P,LY2 %),,
MP$@F (N$ DFC-$DE2:/4+%CKTD@3I0(E;; O;M,5RY8+S@%L2@<>8!N'$>P1
M<Z"$"VA<S0KGGC\R,5Q0\Y@;+MW@ME/\O&#+)_%C3=95B99;6JY7A*T-=PMG
M[I[0FUM+&&Q%#'ZV0GJTVB_ X-/^/C?4J);T!7T/;>)+ESOG]_#--DU%<H@2
MAC! F%  == QB7$$9)QF$64LAW:E'/:>/K4%K!'..JVG@Y?9]^V,PL!?=2/7
MY3ACE[2>8XT]I_5T!A@[K>=8MQ-I/2<N<K4]/R_4]Z"^]>)%?"!K\EYM=14#
MS%@D91PF&$":J:\UC/77FG. 0TXEY *FAGD"%P::VH?;V%$=80,M;="(:VMX
MGD'7U.Z\'K-QS$YKN!RLSGXLKC8ZSSQ^9)NS7\ECD_/"]0XY0W7LP:=BH2.V
MJLB#MOOK^^6BL@K*61IG-(P4):2QWI>F. .4TQPD.8D9@PF-N5$(E>F 4R.)
M76MF68FM/<]S+;EI7( IT!=X8@#X!N:+-O2ID;<-?&H O9/!5FC/2%ID*GE&
M=*34)0_(VJ4U6<#4F^=D\ISQ$I\LM-K+A+*YS]D/4%5F_2#J_WY>W#*VVHCN
MH<7M@M^M'T6G>//N=[.<Y7$6YA"DH4Z-PD( I+O5ACR!/(\@$9%5B/ZU DV-
MU1OIJY/&I18Z8/5R&LQW0MOMZ*Z>,V,GSV@S,;PWJ*X__$NKS%]T"9IV;KHG
MP'J>*I6Z@;0&,^7B//("KV<OTW4RC>V.\H+@";^5G^<ZE@I<KIZ7ZJ%BOP!A
MX\ A+"(APPC B*H_,)$Z)2I4?$MR&H4BCU*CUK%&HTV-3+?"!EQ7W70M6MJ/
ML!D[>L-M8.K;0790J'0 )YH1)EZ+!O8..&[=0!/=CTH'&MWD1B.MI;AEJ!_B
MH0KQG\4L#,-()$#&D@!($PJPE!00B B5@M$86IEL9T>:&GWL=MC+[=I>-K+:
M,<AY<,W8PPMD S/'#JV=)?3C$EK6G'$1"9]\<7ZP4;GBHLZ'/''Y!C>.^*T4
M=_)CN2Z>% <I8J RC06"@"8R C!.8X!DF  4$@A)FF01L0KXW7_\U-A 2:=?
M[JU\=@QP )W99^\.R,#?^B$6XS1Q/@V'SP_^8(11O_+3VAU^VF>NNB:JXY[\
M\?$/W>!$O!,+(8OU#(4Y3Z-(  JI!#!-)* 9#8&(($Q1'.,<DME"/"@1N+&;
MYM1(1J\TKE_I[GB#!X*LR1\!K66T=K:<A-38A^(,TZB!,CK$JY$Q^*61\B^^
M(V7.XN _4N9XJ#>(E#FK[^E(F?.7N['!-A+]W>OVK_]>* MBQ1Y?OX@7A8 N
MCD]%@I-<(I"DE&FW @6(JE4_95F,<LK"+#1*P[4;=FK6P"XY)-@*6SD#O][^
M[M2.P!!],Q[QC^G M'(-G-;L8H>.3[(Q''E4[K%#XY"*+.^^IA]:&[<24YHP
MJ1/_A8X*@@(I.T6$($YS+$D,<8Z1?5LTEU"@T;JCM6= [EW2S()^KH9D8)JH
MY;KQ%]G3J[#_'FJC!O3TZG:ZH]IUH3M&E4/.=,(FF,18< 9"&>F2F8P"G*<"
M2*:-BAA*+*P*[SO(,#43XWRW\K;ZBL?:2%<W*!\0[(%)Q:02TFA]R!UA'*WL
MT50ZCCOB9%7D:)#>XO\N^(,:Z8,HBX=%%8[5%.3/$>0R%1C$,LD 5(0(,&<0
M8('R/&513F*K)DSG!IH:S35R!AU!'3L<G(76C,5\ #8P53EA9<U#EX#P239G
MQQJ542YI?$@;%Z]W#>6HH_3^4:P?WV_*]?))K+9L]%6ITACQ893$<1J&@&+&
M <P$!(3A#*0IPT@F,HT2JQ-9PW&GQARMV-W0N)M@KBA]NV%Z7J[LJ]^:3H,9
MK0P [L LL\7U7TKDH)5YSQ[:R>TS',0**+^!(69#CQPB8H7'<;"(W>T.:1J_
M/2NI%^N[9_V-?1)BQG(89SR-0(AC 6",$D"C# $,><((H9"9I5>>?/K4Z*>1
M+UA6 @92F%8'.0E=/YE<#<C0!\(-%K5LP:?KL+#(D[@&DY&2(H[?$U]-7<XI
MWYOJ<'33>'D-Y^3=2V(X>Y&C,VIG&[0^4)PE,>,Y 6%&"8!1%@+$U'8K0H1G
M.4RC5$(;!_+Q$-/V(CMG$IS TM!!=!5"0_M_NM:C=\_R>=6]^FR.1QG7)7-6
MRR./R_DKW3YPW?YI1>:W"W[+GXI%H:M&Z%34YFQ\%M)4$(YTP2(=ODI2"2B/
M0Z#V2"3,DXPB(FPV2Q?&FYJ5THA;'::2/8'MOOU+,)L1@4?P!F:%+F[[LK:!
M+_XXPA 5GX1Q:<A1V<-0_T,J,;W-)0&]8/H1MP\K416CV9V(0 3#D$0<X#P,
M <SS') X3=4^!Z:4LBQ-I%D5^MYAIL8BC:#!5E*KU.BS8!IL>KQ -+@%<8!.
M\-/D@,@&*9O4<1^(C94P?HB<K[SP2QCT9X.?O7O$'/!+&NQG?E^\VK%ZEIKH
M1U)VNWXQPF0,90IRF'$ &8& IIR",$$H"E$.<685]7\\Q-3([^MR =3KLEGP
MZNSWN1$X8,NGIV+M<!)_ E4S\^DZK 9FP5:X3HLTCP6WSFKNM>K6\2CCEMXZ
MJ^51_:WS5SJ8.[</BC@>JL3"%S%?/NMW^M=B+LKU<B&::),93R5+< (!8UFN
M"T)S0"*BS)\<I1+"*$DC<\O'9,2I\4#M12&MY,%S$X83\(T(-L_+14#88Z'T
MJ4R I0R86*U)L0B8$JA@S69"W;R9Z[?]-7AJ%0YTOSHKF\IHQ@S,*]_S,##'
M;,4-.O(&6X';R"C?0%I87[X!'<D0VP'+.\#N7M#F7??EN;9!J==4,WK0>%:;
MC5Y[!IS5C?9E%K\L=:>F1_6LIN@TS&3&),1 $*;(/$(,8!(+@-(PAS)1%$^-
MK+A3#Y\:;U?R!96 UJ6[CX"[P*E7PC'T1M4<":OBB.=4OJ(@XM$C1RN">$Z9
M;N'#L]=<?4AUNZB[:#\NY^K^\N-_;8KUZXPQ(I 4$K!,;[HB093MI;[9).11
ME E(,6&.1U8G!YSF 5;GX*HRI<J.W/_K?Z XRO\6B$I^YW.MT_!;GW)=#>IX
M9UX5DA_[4;OFU*L7BH'.P$Z/^58G8KT(])R/]=_GF$K%>:$M2<5>I."?%^_)
M<Z$^K5DJ0D(9U VIPQA HK,Z)0E!BGE,<<1T:54;K\Z9<:9F&NS$5!9NP8'>
MK-626B99G8'5C#@\@#7TOFN'DQ915\-[?P$G^QRL?A2\9F.=&6K<O*Q^?8\R
MM"Y<[EI[_?WRZ6FYJ(CFQR-1+\W=9EVNU:)0+!YF),X$YS &$BMN@)AG +,L
M BB)$RJ3,!>,VU5@[QMN:NS0%!:O10XJF6^"6NJ@(W;P2UG]['P!!!?H+V\T
M_ (Z,(,88NFS6+L),E>7;.\=9.3"[28*'Y=O-[K+L<&L?MX[4@JN!M&'\I47
MZW:U4F]&Y25]][J[I/%RW/Z+K/B78B$^K\53.2,A3GC,"(@BH@R3&&- ]1])
MP@0E692%U"HQ]'J1IL92E;B :GF#KDY!1ZF O@;=ZQK%@DJSX*?6+:B4LTRY
M\C#!9B;2N-,V,!>.-&/V;66]@>RUE^SU4HW;0-8;BD==8_T]V>&0\ =9+&71
M5+W%0J2<IA"@%.7*,,0$$!A#D!.)"4QY3@V[0AX^>7+L6LEF<:"T!Y/!"9RK
M\D-S5"76Y:J_%P"P.#ES!6*D$S)30.P.PDXIW7O@M7?#> =;I^3<.\ Z>8&C
MU=BV *P]7IKKE@M]/EY5P(IB"4-*8[4NZNP-H?Z&$Y2!E*$,I0G%E%O%'_6.
M-C4VJF4,=D(ZU1KK!]C0(/,%V]#[3EO$[*TF$R2\&D2] XYKZYCH?F3&&-WD
MF$)/RD?]/_WH%S*OGKK@OY+5/\5:1^_MJJ;O8FMIKDP7[=6B&$8 1B0#B#((
MH%0_QSQ*D] J0\1!AJGQC!:_.AC:2=WI!6"93N\P)68<-##0 S.3EOPFJ)#N
M*'!S'G:SJ'+[O'MW%+WFX#N(,6X^OCM.1[GY5SQJ9$]<S=&?%^5Z55G99=7'
MYOZ1+.H,W?+OZA'K\O/BFU@52SX+&4EEQ 2 ,,L C$.U,<1<@HB&*8USD6!B
M51YV+,&GQL"U*_8F>-!2"A[\4BP"JV.&T6=^8$?>@/,Y=7??31.?$72T;[J.
MK97^3=4%];+4$.C3V1J$";@&':=M$@Y$6]G_'&Y&QQGQYHQT'7]J"]^GY4J*
M8KU15/$/43P\*I:^?1$K\B J!3ZH3<ZV)/*,R41$7$*0<JS61L%"0*F.XA.A
M$"A!(4^R:2R+-FI-;=%L!0:DECB0NJ[X2U57G*P#KN/;E[)>4X-G19_5BGH3
MR%IGO<QN2K[[S6266JMW[:T7XJ'>H/]GEND.0#=!"U'08%0OXKJ#O0AV9?'_
M#"NYR[S_.=9Y*\W^'[$"7&9S/!O!23I'"X(]"KZ9BSMY6M8J<J812X]7ZUB6
MFZ?Z9P<EM05'F8")!(F,=/4IM5IAED<@97D:\DR0'!$K2\"K>%-;T7]LGI[(
MZE6OVAV9@]\T^:I5NVU!IJ/PU!O2(4Q]1Z5ZS:?B_%YHC$DW7)+?;"J'7EH;
MQ:I).;]\UO.U72:W*NY-_9 5V(>9 *]KG%\)QUVK!D'W:,T99A3'= L]XKVZ
MMSI9E3"+0Y(0D(2IIOZ0 R3"%&3J X(YH3JQWBK)HOOTJ3%W':BFI7,ZH]Y'
MSHP_G?$8F/[,H;!/FCBELM=4B;T!QDV0.*7;45K$R8OLOM9RM9Y]%VU=EVT1
MG??+C3(<5L]DM7[]JJ:WZ28 HR1":2J /AD&,,MT SR8 Q2C'$<XQU@8N7*L
M1IW:U]V5,M!B6O9LL(.\__,?#,BA#X#M,33F!R=,>GA#/:_#&>I?AWQA-^ H
M/.*$0<LO;C<[5ME:Z0;SZ]<?&_J?@JWOEW>KVQ=2S+4EHC:Z^^UIFD]"4@PA
M5V:$E"D'$,<48$D3D*=IBB *U0XSL2K#92_#U#BI52%H= C62S4-P5:-:L-X
MV%7+K=6,RXR9V3 #S\/ E#;,%-A7"W,'T6LY,0<QQJTWYH[344&R*Q[ED(S0
MML!3C_Z5+#:2,-VK:_'P?EFN9S3G,8]1"F*J^Y=CF0&:4@0@IU$>A33&L5%
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MG1>-:]D(+ XM$?<R>KB:"(LP\RL(&2F<W)P8NX#Q <O/!H8?/C-> /@ VKU
M[Z'?.$C2@U K__7[ER^KY=?:1].A&W_HF,%/X@OYIL.&;JM/^J(KS?,8ES$$
M+$-JP8WR!!"LG"610($$*6%:FM=M,>YV:C+6 (_F.^01Z:!'JPZ[OO)F7B7
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M>P71%I5X77IYK2*]5S!RIG[O-:VZ.=K*IU]V%3[?*_?^1;07A&>H+%*HYD0
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M=F3YO7]EV/?(M['L&#F^FV7YO,.FP=TOGV^[*U<ISG&>*0=1QG6:& RH3 A
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M/7:YW.W(IR_&/!P?PI@_:J=(U6H]^V6^F+]L7MK;.PAGF)2P "R%%$!:9H!
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MS--QRF7WIMP/_):K_:WR;H?\8?FCOA(KYE\%?Z?^H7?)JUDNRCP3.068)@)
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M-2/'TEA>^W()KH-Q<M]\C5&!=I0?UO#^[/D =I(V>@36Y:GO6,@\B@A>UOD
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ML#%/E;O1!K@6D"^V)&X#"%VSQIBKS^">0U8:C3>9_+HFA:\#Z9OVX:^):]U
M,1TX2D^Q]>ISF)_5 _OGY>I]N#VF[E7^7Q?K;6N4'[ L5_@.TUE8K^=EGG9*
MOO[Y38VF=.0ZZEH?7 LU5:H=[UG68(WRW@BF(FMS+?Y<'$Y\,=H"GP?L@>G
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M:&OI -YD#L%:%]!QK4/KJ7K]5E,?I-VO5E,?(NH.L')WY/(E#YE[FYBRX.N
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M$G<Q1HM-NBD^0=.TK:"F1=@Q:ND48?)JLYA$Q**$$'2M+Y4)?'U[$<HJ3>>
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M9UJ4/1\<EJ/KI@.$_?'^]]7V)/GROIX;ET?+EA,755*)I%'J(#R5H@4G18%
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MJV6^2)LWJ_>X^CQ/.XMHC+!%&P&(TH"RIL V SOZ^I@70Y1^-$=E'P$OKN7
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MC, *1:E1$G.CB"'0+IT&NL7TPNV)IS2?[I1CJM'0T8!F')-"%,([=#("E]:
M\MQ"%)PB&!%E'9I<J9Q2IG@:U8X' :N'1/$A4FX R*]VK]V1.F,EA)B#!B]I
MT117%W":7!:K%?DJC$)WWF5>]<$@W5O'&751/@6 ITBG-W -5H/P,_E:BWOC
MC8ZJ+/CV(3W7"SRSRJ:J &J/6L/K#>)2)Q['Z,!CT9"5RCX'(V*G:?/3J@+8
MN-S[4GI/<OF!/OUC9NMLK%P*1$;L(!='UAZ:#GA"%EAV3N]ONX^$+H^^XAPR
M[(<@YZM8IQ_&3]!8G5 -]>BSAC9=[=<Q,5N"BX5!CLQ37)PHYDZA@*2-,@3A
MZ<>#E 6?:QU328SI4"*P(FLIN:KJ*#GX4(=Y<&>]&J91T[_JF$Y$]PO4,1T"
MC@9BE4>J'Y)QR=L,6G(*N%RL VL<L5@DE;GWRK)!$/Y]U#$=!)%N=4P'R*L!
MT!V<]+8Q6288.)$M*),$>,\=:-12ZB@E:?J_ZIA.1\:I=4P'B&GLK,R^&[<C
MP2F/7IH$W"D$51C6ALL&M!%>&&161'Y48-,"0@:5YU/QRQ','7LP>V7+=JBX
MR<HY%P&S$:1 1=&B.:U<T[<>4236I;]AM\'KMV\]NTJ28[:\X^70 GAVF-=D
M@*44!2P+M&SM%$03:-E)62V"L5IW*<'M#I^QJP&.E-B^S(]@W\A2_R7\/;^Z
MN;JMI?/1.6LE6!/-MG[8,8]@?"J*&R=YZM+DH)/<OWKSR)(_1F[+/I@XLO3_
ML;Q9T).(2]>?WX2KK09(ETVQG@&BKG,_<P"?D"@1J023,9?86T'B0PLXN]3Z
ML=O(R=(9>T?!/V]6Z6.XYU/MD[2KKS$^I%R* 2X=*5Z.B3A$>L-8U#G+VKBW
MRQV[;OM-UU6-9Y-.%_QR:"F,'0G]$Q=$"*://RW2K:.N%7J?<^V008ZZJ3LW
M8PR,<E[S$@NSW:*@;Y\]XO8TC/26_;&R@9,96OCR"N].67^N?U!E4]4F,!%T
MD55/8JR%=K2=,\D@H[<I2,MY&.3Z[A-K&G<*:R,;7-^R:Q>&._U,/GJ54@17
M+.E4IN^"D1IRS$ERPRU'\X) ''./ZUWVW3!UA" :0-5;D@DMX",IY;UA6#_^
M_6<]K-K9:U]D3K1L2"YY4D!9&T8I8E8VCNDLC>L4MQU14/CLVII$V#%(^*8B
ML%^Q-("T7HO=6-$R"70@%4%'U8[*CB<+.@E%:-(HLAP"DB]>Y#U8EZ3&-NK1
MT#%VJ/%-7F"OA?/O?Q(>2)9D!>H_25R7VU[/Q)BW^.'FLC[\\[UQ8(Z+E%VT
M$&(EWH8,7F &I:T4WG!O6+>KYGVO[(R*O0\"V)-9H)>4]MA0__U/$LOB>C,8
M.,SSC,LL(DL9$G.U?:JCK9(<,Y"TH=D@2W&Y6TB]]^ S*NH^&FBG\+K](LDZ
M_6A^O>%J6.1Z9V).;%RD.1[9->[QQ_7>%:[CRGNJEKSWOHN]][V:K]/E<GVS
MPKNZ,9&D,M$0OHJH-L37(=W: W?1T;-ED:'+5>XCW*H#5MG'3+1G7_:EO#@X
M99GV"9QSFV;C'*(TF7CB>;36.=LIV3T,3QJI#1\.90_-/1M(>),V>QL/O&_C
MMWOHRYG AZ@8QQ!ZFS/A%%!FVG=K[6PL3 -ME2X[9IW-XRE]7X;PYWJ9$'_]
M<S.\8_'AY]I4X*Y;^"_A^F9%_]V(Y(M"91UM3J10A6<%BI0(G"@4XRG)8E%,
M\S+(S9\CUCHIDW@ WO9-XM!B;.#LJ)*X7'U-XBYB6K]?_H"WLXT>H;8(GGT,
M@4*C2-1&+< 7*2 (E5%ED?DP/?].6_;88<Q+XO>%A#OI+?Y-K4RM4>-)_;&[
M/_[EMOVG*1O% ; HE"4P 3(3R$<-U84,$;A-01?&3$H#'3"_I .P7*^_];]F
MI*PR6Q-I-TB6:(]ULI+U@-Y+PR)GJ0S20>7AY4QI&S\$-=^8P=.%,79%UEV9
M:^3"JI(=6*<1E*K5(CE*$"@9#UY'$[M<3AF@0'PPH/0AO@>+O _A90L V&4G
ML413:+7 T$I0QEGPO'@(/AJ7C#-"]'M'8/1:JN,D]DB1]R'L&[O(>[ZX5Y^<
MR0;:0@A/LA9W,:8@9.4A:G(!6="NI"[=A[H5>=]_<QM%W@?);=D'$\>6_E?5
MZ4&3[UW/VVS1&FI;7G!6)I#,8LI1*%2]]0(]O,1_D+Y^O4C_:"8V$)S_MBLA
M_>(JW36L^GFY^$ ONOKRT<9 9FL-VLSK30@.*I.'%%A@8!*+B(6C\(/$XP>O
M=-P0O$>7XF5D-34PWM8V6^M]'60@-YU3N2<279 $H.*S+#GQ_0NN(\"QA8K*
M@=%S"E:/$.78Y1"O?GEW<;O?^R)4B@PXT[[N&QJ\DQEB-"@"%ZSDO4M1CU1"
M?'GFA)!RC.R6IS.R!6NU6OZ)J^O/[V[B_\-T_7[YZ^KB4YA?5CO_>O],=*-0
M/ ;A@V-0K*E,(C?#T88 0@09#1%->C:(K3ITI>/>LQMBZQQ45E,#XTYGA3.1
M:U& [+D %>@[KY0#Y1P+1DD=XB!YTB/6.K)!'!8]IV#U"%&.O77^'!;YDD3V
M^J8F!M[C(BRN?[KZ<[7<EDW>-NO@4LH@T8/0M>MT+!R<,!*R1(ZT-YC(NDW,
MZ?:^"2'L&)DOAQ5  Q9PJWSW:C+I[S:ZJ*)G+#,#0B95W8I0;RPB2,V9STRC
M=X/<KGIL0>/>\1M@<^V%\XTB:*=K64:AF-7 M2)[;IV$$#TI7&$)?2;Z<!#/
M[?$EC9PPZ47D'7!T!/_'WM_^+X;\7S=A51^W(>GV9)#B(V5K$"V((8K'>J6,
M66*-"D%E)OU^YYQ'-K1'7M >(HX1WK)G3HZ-AC?XUV\KO)JO<4V;^R6&;]N(
M28TL%S00I8B;,2\0:<^E?9?)$IC,7G>;F_/\NT8^$QT (SWSMX5M:'^'_OGN
M1DE&;:TPI99+I9J<-+4-0X"BT?K,>1!AF +.1Y<T[CW((9R9?K@_MMGY.F)8
M7ZPP_$[>_FKSSUE@%I56"*9P31IA+'CC'&#,2*HG,XIN%N?)US16TW&D()>#
M<+4%._- Z?%[7%W52\7;.3:S(K34)D4R"<*#JAU7'89ZV<-990)]FE^L8/SK
MI366W#L-6P-)9&P;],W)PL7EY?*OL$CX%O\,GZNIOEB_I9_/4"1!S)&TW1=R
MZ(*GJ*&$>B]6)FV5RZ9CE]K.KVSLA+L'VS0,MQNU4T0'_A4NJW+,0O8!,WEV
M4M1YB3IZB*IV[M R9N%J6\Y!FFD_LZ[&CGF&LU#'RF)L\_0$+6^6U_.$O^%J
MOLRS& QJ$1E(<AN))J7!<5=[ORKF55"L"-;).'5\86,N=0^F:0A.-V&8B(Z/
MR\M\__#\GRMBX$RB%R5(TH-"*D +)^MJBH#L,L:B7<S9#F.3'EM2)U29B:"J
M9PDT@*4]Y9A_^'C]:_E]C75JY/6F6Y1P]<8?DLP5UO& )130W$4=-18;!VGB
M]>2J.B'*3@Q1_<FA.5#=72O]Q\VJ<GAFT!4L.=9A:W6Z/69P@ELH3&B=/5KU
M$JC:7U8G6+E)P^HD2;2+J]H@9T<0)A2.U?[HJ&INVD;P3 9(*3.T16DN![F!
M]^S*.J'+GP>ZCI1' P![R&&L-_9J>^.WX1IGQEF.JJJ)JUU(&!EBYU2B+=ZE
M;(Q340^4CWUZ8=V./-G$\-6K.)J UZ:Z=7T]2UYHIB-"-(HBCBSJ_7-N2#F2
MP)0SUV4X/[VNH!M@IG)(?AJ#&T#&W@'_6[SKV_J&W#^=G..%9XBN=A]VA@"/
MW$%1G&7:NJ4W@]RM?G)5W1 TM:/P_@31'*K^ VM4@?GB$_WT [[%F@"_?]S/
M9\%:%PPG?Y"70)PS"7RJ@Y:9M$X'YIT?9'L[=*'=L#>58_07$5?K<+R_K_^&
MJU2]1^^UM%J2$;=>@K*>4]BK(R1%MCP%VO/C(!64ARZT&QRG=N8^J+B:@^-M
M\Z"9U-:G*"-HEHD*6AL$X11]D806K8TR769-G0BZV^5T@]943N5[9/W869P]
M1^&V!HR\A.HS;+*>*PPS'5+U0 T44SSYH37GF1P)/^OHM74N^F?[+QWPOFYP
MF<IQ^U",;L#X/-2_;*_D(IL4 TH.KD0*;H6K;F?.X*6T1OMZV7^0OKK/+ZT;
MRJ9V!-^S2!H V>/!S*T6;53H<LUG*%P*.B7@6=>38"O J5I.;[3F164N% Z_
MZSVUQ&Z@F_8!?6\B&GMWO+W*_6L5RX]_8[HAUW'&H@\A&G(052V(MF(S?":"
M81)1>:9ST)TVPP<?WPT@4SEC[XF-#5BA>AZW_FF;$K@_F&CS\YE'$2PG&&>%
M1(PNI?*&3(7S3*6<G<<NK9\.-CQ/KJI;E>?4CM/[$\3HYF47,;Q>KGX)BYM"
M>_/-BKBU.?H-SEC4T@/I =G)@@D\UP:,<SS5219HN]UW>NHMW1 RE?/S?IG:
M@,VY,YSQ<OYA(Y89LSJFF"B:5(K5(B\&+IL,IJ#2 HL0^[-8^VW8\V4IW; S
MM9/S$UD^Z2[+[VZNKL+J\Y(BA:L_P^+S^O4-Z0[N^O/MLE)W?SU,*^;CUO!R
M_9I[X-$H39U#2H$;HR'S2"#VG/;%XA6@B=K8J&ST:1@'Y06;.C]<R3&O<Z"V
MF\*KFR\<\9YC9L0',A>UCA]5+;9&,)I)$7-4.;]@_=;#BYQ2 ^A#$-:M!*<'
MP36PB3\YH^*6OFU>C,3Y:WE-K V7_XEA-4N^1&FT !V"!94$ARB*@ZR9"98"
M:>\':3%T_)+'!>QP,#ID[DA_,IT*>HFM/RW>+B_I(1\JD>__6LZ42-9)I* ^
M\3H"&&5MX8L@,I.A8$QAJ)X?QRUXW"N1;2'W5'E.%K<$1)P9)93RI8!UEL('
MPRUX6:=/YB2,=1AL:@BY=<GC7L=L'+L'RW2JZ'V]O%G-(D,;3+0@0N%U)!!M
M+TEXL"EG::.10;_\D+*G5CSN1<^VL7NP1"<+W?DGTE&?G)7"UI()1U^R 8_"
MD&>$MGBF91FF-?K1*Q[WJFGCT#U4HA."[D6A=^[3JAPKT;H / H!2C$'(1L#
MDA43LV"9B4$.6$Y9]+BW6IL#\,ERG1"&9[9DY7)D8$MMA<(TT>4Q4C!J6"D!
M3>#CG2W0 L>]']L<-@^2U_$X7%Z'R^%Q^/LB[PIO,?_X=Z)?O;BJ_YI)69)5
MM@#WM28@&0:16P,IANR"BB;(EP?E8ZL=]ZIM&PCM19*'P]5OX;K #^%Z][L#
MW<J=%6&9SU[6)BSU"A87X*0-8%DLTCI9HAZD/\XCZQGW!NZ+@:X/:9Q[+G8[
M''@S-GZT7.P#:V@J%_L<CT;)Q=*&'4K('J)+U38*!UYH#QA90:Z3RN4,!NQV
M'&W]<)9$VYPU=PR"8PR43 :<B1&R%&ATD<FG09*S)ZUZ2MG:0S!X[-3RTT7;
M2$#5A=CW?RTK>>N9SSF8Q!7(M+E=Z^K<KY0A<*_J0-3$Q$ #$PY;Z+@)K_;0
M>I0 IP30F@C94FA8*&B]!F^U!,4+DC_%!$3IC<88;>"#]7P\;*GC9K8:!.EQ
M0IP03&O.8Z>',6O)$P<><P 5,Z]-[6O-A+->685LF'X1!Z]TW!16>R ]3H13
MPBA]V1*8ZABGC*1ZGC8,E2416-,<QDM6BI!>V$'N?1R\TG%S50UB]"@13@BC
M[RF:QE S&C/.8Q3)2'"QYN)4,!!L[3250_+1,,?ER-O][5+'34BUA](CA3@A
MF,XR>IX4:O);G*<M@I%#HVT$BA"Y$R9G$P?+^G=9X+AYJ/8@>9# >DM$#78$
M^^YZF?[X@6C-%W^%53[J"/6;9_1\!/KT&GLZPOP"IU\WYZFX6&\6_18O:XYE
M<[ORW4<";:P+N47&E^I_Q9D6H4 0)8$29)D"$OY$=#D$*5D0@^PQIRW[5"O7
M^>T_W'_[>Q+9#_28/V8Z8&U\G$#'R&N*Q(!+)0#+O"2GN;=V7*X]O.YQ#SI?
M$*G[1O(EY=U^^FK?+FW&A_5B07=/&MB./K3>-JQI1(J5M=-@4BJ@6$*(OI8?
MI<"<TBGD84K0Q[6F[])'S#>7].XO.G1_%1OY_?IG_79]D:[GG^;7GS<R_*)@
MQ65C2I' "@^@7&'@61V$Z)PH7&BMAS&HIR]]TC;U$+SNV]07EGH#L=%#%.]8
MNC%,]RG^]W!YLT7!>GUSM?W9'O7"1FY1(/"2B>6VV.W%=YF<D2$C-W&0,ZA^
MR1@W'=48_E\(#>WI0MS7_K=(+)XGDL&&#Q0$[_WD]\7\^C&[0 M.%!+KVE@=
M02E$"E4%!XO.\I $%WZ0*H(AB1HW(]:.GHR'E*:TYD=RKY>?$=_AZM,\X<-;
M:)UEF#;?_5K>8EI^6,S_FZ2S&1NV$=F]K53&F(TW-4^C0'%%YJ-H42=D:L.3
MR$D,DG0;C*)QDW--Z,N8&)E>%/LFK.H1Z"<\H:CRV6<.'-D^34,;,:ZU,6!0
M#GCMK:1J9;#C&2$0NKAE.>8PB-O:=HQ[08);?-B.XOOA\\,>X79,.S+EM)46
M3*Y:2)I3C_T%Z$1;6;0N9C[(&4%O%$PZXCT$O8=&O,-@8$2W9;VZGKVM)%W\
M/5_/1. 4B!##; ZT:&]<3;A+X,DXP:73+'?)^-%#[X&6_K4/V*_>.B[81I+X
M\E3VMX"97_ JXFHFI)%<8P&ID@5E;*"XUF=PTD1?9%$,NPPTZ(Z:[7O'P<T)
M$MN7^1'L&UGJOX2_Z_V-W<(38C2Z)- B,%"% !\$-Y"\#2GRR%GJ3>Y?O7ED
MR1\CMV4?3!Q;^MO;.[N%1T2>0M'@^;:B@2C76"]]F2*<*"ATEZLRW:1__\WC
M'$?V)OVCF=C X<9OEV'Q)EQM;5]$YH*-!N@;3QR0GF)-&0"U<S%IG;D>9,3@
M_46,>S0]KN]PLE : M2K9;V/- N&EI=H__1":E!.D5)ETBS',928O35ND(JS
MKY<QKD-ZO#@?P<41O!V[_?K[OY;O/RYOZK72=_B)F(:X^/&_;N;7GW]:U$E@
M\T]8J;LUQ2QFZ:( LK\&E':1B/(&G$/-,T=2K;W,\B/]V ]Z;1LH.4:XRQ?A
M=$,8>CTO3].5,]H2BP 4F<QO8@6"+ 5*3K%DJRW*>"B"GGOIN%O7 /CIE<MC
MHV>S6:_?T_Z]WK[\8GWQ*<POZV[]>KGZ:;V^"43B:V+LMRRH-+]?/J1:][AA
M>,I,:04\$@^4X0Y(BP)8;;2PY$"Z7#IA;O"ECIO7[ NI;4FT =]KZW[2+V\\
MC6RXS"P32TN=9VV0/%#F!)0@ZY06SZP;)"'_U2K&15H;[OSQ8FD 4\<S[@O9
MB[RG\B:+8&L% "^.N*F%KKT* Z14@C?%<^\&&1TW!#'C>HTG8&L_43*VH,=V
M$'[#55FNKNJ6083\$E9_X/7=):#K^Y5AM]X/>E:RK-34NV')4E!7DH>HE&7D
M5VN21*?]_M WCYQ?&1THRY>26@/V=Z^N:D>$=MXFC!H8&B(B,$_NDD0H-HAH
M9"8N#E)Z_>!J1CZR:P6._4EL;$MXSRN^N'^*<%O:5,FZG=UUSUMF(3HAZZRW
M(.OLKIAI]Q$%M"Q:)"F3R[*3/3SN_2.[FJW \*4DV(!M_(J<K97?$>*DQ9 ]
MV2\6:[\6I2"$8D&8A.AT0F\&B7T>7=&XE9'-@+-?R34 P9\6:7E%9(3K#1]_
MWI5U;KUQZW).0H(UH=X.X 6\QFKWN4S!1UG"(.6]3ZQI9!@V$8[W);)VT7>K
MH$([Q5P"'S)%@YI%8A):D%IGB9DQ[09ICO?DJL:-77J3?3=,'2&(!E#U3US@
M*ER2Q;_(5_/%O%9AUH/_W93YVT(''CASKNI<]15\+<I4TD/AS'AI8O:=:L0.
M1E>GU36)LF/0L!Q:- W@C0(FI 5\)*KNC1C_FB0AO+ HJA^@8FW %\%3  ^E
M:&^U<LP.X]!U6-NXX>]P6.M;+ T@[5FWXS&OX^>[>==%!DMT1>"JUF\D4\!E
MS!"<="FZR(C)HQQ=/[OT<;O2M>'[O3  &H!\;6JUN]?_C_#G_#I<;M.F5;M7
MF_Z1JVTG]]MTZ4S[8,AN*+">R%**=#JJXD"**'R*C#,_R-GBP2MM_!B\9R@M
M7U*N8Y] /GSK^%OFQGWFOKFI^]*OY2+G>?V36[;4&Y=_5?/Q>^V1_O[CYM1K
M1IN7]YYV+A'JH9<SM'UQGPBA$IG141?6K4KH9=;;^$'[,(!O%0\-V/:C)?(;
MKFHQ5_A V_&O-]?KZ[#(\\6';;YB>YEAI@-9!V%)."G6Z] J04#:<$5PFWF"
M)OJV')T.1#6>(AAVQV@&+:UHSC'VA,*?^6KSR]O;^C,O558" SBI_.Y^OK<)
M;& V%V65%L.I21\4-)Z9> &=>'$<3%D![K*&JWG:WN:^=4-W9F+&@Q$J<0<^
M64V<2*K*@TR!XIB=ELZ885ID#4;2R)'S1%6D7Z2THC/'"&)7@/1/^L7K]4\[
MB_$?./_P\1KSQ2=<T=:Z^?!5N,;78;ZJK<<H8'/99^LDX"9@B\:#M[3%:IN5
MSE%(-<PTQ!>F<]P^]"UH5Z.8FK+*;;[\.ZYK'>"6-WP6@F'>UG"N*$-RHC@O
M)HX@K.6Z2&Y9R4WITP-$C-LA?ZK*<BH:IJP)MR<@NW./>Q=D-N9A9I%\4T0.
M1M1F9R4C>%&/!4,VT1J6;1QD0.90!(T[*7JJ&M(G2J:L+;MM]<>_R46=K_%N
M9WU?9V3\M+A>S1?K>=KMI89+KCGQA!L.2F]./UB&1 &?399DE0>I@'@)XL8=
M?3U5+1H*/:UHU#%AX&TW9=I]L8.#RJ7/Y(62>9&5+=YEB+6L0#E;C I>6#%(
MPX@7HJ];SI*=LV(U!J)6=*NW(/"?J^5Z/9,AI*@X@ZA" 86<Q!2L!,U0>B6+
MSCFUN#D]0$LWG3G71/_8X&A /U[-/\TS+O)ZYHIFO'A'*Y6U,[-SX%DL8'PM
M>4PRQC((JN]6T V+YY:#/TT0#2#H^)JSQURZO4WH]O/-8??,*1E2\A(\-[3K
M1.)3;:@#SM;QD<HI'0=II/:R9';3A>\VG3X>I)JHWCKZG*Z.75]_7%[6"9QK
M3#>UOOW]*M22@U?A\WI&!#N&(@%+-H *64,,UH*+Y.T):S'8O;#[J:*MH9;9
M33G.+:_>F/BGK0B[ ^M*]44=2_S38GX]#Y>_W<3+>?JU$#GTZ0RM,EGQ#$96
M7XY+ ZX$X@SW]&/ADU '=)T:=K'=E.+<,NE-0F%LU7BH;\?#/)KQF%@23 (F
MS7>73(J-D+0E2\ #$ML[(;S[.[L!]=R2TD,*9CIX^_K[]?6;Y?5_XO67,3VS
M@*8XKQ&\-;7!MZ4X.C'2->$P<AYHZ;EG/#ZWIFYX/;>\\)B"/1\\;X./NT%4
M&\VV3$EIE08?:D_&4"0XXQD(M"P8I!]V;.4RZ#*[H?[<<KV-B;^!TYW=.#7,
M#W-@=V5U%D3F/CH&QM7(@4L*&FS1@$YS2?&STV:04NUNR^L&YG--N0X@P@:
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M*:<"2B4'D5G:Y$6)RI44?!YD/L#A2YUHW[X! 3^LM _'L]_B>8$?JE/9Q"9
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MF=PD03<HDXAK*^(YL0FU;]\TS]I/3YY(&4Q<JQ*>0;L990Q(HR)Y;%N-D^4
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M=W3WBN;)FYL##62.JW0F:*=PQ7S&;<_>,[]74C=<O3\!4$L! A0#%     @
MPX8&3Z#PW>LK$ , :^@> !$              ( !     &1N;&DM,C Q.3 V
M,S N:'1M4$L! A0#%     @ PX8&3]E5')Q_$0  F;D  !$
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M &1N;&DM,C Q.3 V,S!?<')E+GAM;%!+ 0(4 Q0    ( ,.&!D][W5:7-P@
M #LM   4              "  =[S! !E>&AI8FET,S$Q<3(R,#$Y+FAT;5!+
M 0(4 Q0    ( ,.&!D^9NWGO,0@  &,M   4              "  4?\! !E
M>&AI8FET,S$R<3(R,#$Y+FAT;5!+ 0(4 Q0    ( ,.&!D],^YXV104  +(:
M   4              "  :H$!0!E>&AI8FET,S(Q<3(R,#$Y+FAT;5!+ 0(4
M Q0    ( ,.&!D^!S'A/4 4  #P;   4              "  2$*!0!E>&AI
F8FET,S(R<3(R,#$Y+FAT;5!+!08     "@ * )("  "C#P4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
